data_2mob_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mob _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.49 ' O ' ' C ' ' A' ' 37' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.495 1.777 0 CA-C-O 121.099 0.476 . . . . 0.0 110.695 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.49 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -29.87 132.96 0.06 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.403 0.621 . . . . 0.0 111.846 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.505 HG21 ' N ' ' A' ' 39' ' ' VAL . 1.7 p -142.48 149.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.515 179.489 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 79' ' ' LYS . 11.1 p -127.68 150.05 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.78 -1.2 . . . . 0.0 111.707 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.53 ' CD1' HG13 ' A' ' 86' ' ' ILE . 23.5 tp -112.36 132.05 55.21 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.631 HG12 ' CE2' ' A' ' 77' ' ' TRP . 2.6 t -127.28 124.87 64.95 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 111.603 -177.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.511 ' CB ' ' HB3' ' A' ' 76' ' ' TRP . 0.9 OUTLIER -119.53 -174.18 2.68 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.002 -1.061 . . . . 0.0 110.605 179.189 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.528 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.8 ptp -117.66 21.58 12.88 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.937 . . . . 0.0 110.642 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.62 ' O ' ' CB ' ' A' ' 45' ' ' SER . 3.6 mmtt -88.95 -93.14 0.11 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.456 -0.778 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.62 ' CB ' ' O ' ' A' ' 44' ' ' LYS . 1.3 p 89.36 178.01 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 45' ' ' SER . 0.1 OUTLIER 62.93 -87.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 109.663 -179.242 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.51 ' O ' HD11 ' A' ' 51' ' ' ILE . 1.2 mt-10 -52.16 -24.95 7.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.44 -0.787 . . . . 0.0 111.895 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.771 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -73.48 -62.37 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.709 -178.082 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.545 ' C ' ' O ' ' A' ' 48' ' ' ILE . 85.4 m-20 -37.83 -32.57 0.06 Allowed 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.316 -0.954 . . . . 0.0 108.782 179.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.27 -55.98 5.06 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.771 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -71.3 -48.69 52.66 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.165 0 O-C-N 120.679 -1.263 . . . . 0.0 109.29 178.922 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.568 ' HA ' HG21 ' A' ' 55' ' ' ILE . 45.8 mm -46.01 -41.23 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 119.871 -1.768 . . . . 0.0 108.604 177.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.687 ' HA ' ' HB2' ' A' ' 57' ' ' LEU . 2.1 tm-20 -64.73 -60.89 2.58 Favored 'General case' 0 C--N 1.292 -1.91 0 O-C-N 121.206 -0.933 . . . . 0.0 110.143 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -77.62 -12.59 59.98 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 120.868 -1.145 . . . . 0.0 111.488 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.67 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 tp -107.43 -34.96 2.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 O-C-N 121.59 -0.694 . . . . 0.0 111.499 -178.197 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.551 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.5 t -117.18 -37.89 2.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.655 -0.653 . . . . 0.0 112.632 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.687 ' HB2' ' HA ' ' A' ' 53' ' ' GLU . 1.4 tm? -37.51 -55.49 1.08 Allowed 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 122.272 1.034 . . . . 0.0 109.947 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.31 -48.97 12.2 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.487 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -50.82 -47.39 47.31 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.503 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -78.03 7.07 46.11 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.406 ' HD2' HD12 ' A' ' 57' ' ' LEU . 0.2 OUTLIER -106.77 -8.56 16.75 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.972 -1.311 . . . . 0.0 110.891 -179.768 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.5 -82.63 0.22 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.945 -1.097 . . . . 0.0 109.93 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.403 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -79.56 -30.3 41.64 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 122.432 1.111 . . . . 0.0 108.158 178.678 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.503 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 8.5 m-20 -74.65 127.03 87.96 Favored Pre-proline 0 C--N 1.295 -1.801 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.478 ' O ' ' HB2' ' A' ' 66' ' ' SER . 43.5 Cg_endo -62.86 -47.7 8.21 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 121.77 1.646 . . . . 0.0 110.822 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 65' ' ' PRO . 1.7 t 179.96 111.86 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.958 1.361 . . . . 0.0 109.339 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.631 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.292 1.3 mp -104.37 134.77 44.77 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.508 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.551 -176.823 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.56 ' CG1' ' HB3' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -92.03 162.73 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 109.374 178.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.482 ' HA ' HD13 ' A' ' 78' ' ' ILE . 24.3 t -136.28 106.51 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.045 -1.034 . . . . 0.0 110.31 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.559 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.7 mm-40 -102.05 145.42 29.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.841 . . . . 0.0 110.421 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . 0.428 ' CG ' ' OD2' ' A' ' 49' ' ' ASP . 11.6 p-10 -136.96 119.72 16.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.451 -0.78 . . . . 0.0 108.965 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.567 ' CB ' ' HB2' ' A' ' 75' ' ' PHE . 27.0 mttm -125.49 83.28 2.15 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.019 -1.051 . . . . 0.0 111.506 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.558 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 18.64 73.66 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.237 0 CA-C-O 121.231 0.539 . . . . 0.0 111.949 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 43' ' ' MET . . . 103.54 11.18 33.86 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.567 ' HB2' ' CB ' ' A' ' 72' ' ' LYS . 20.4 m-85 -138.26 101.03 4.28 Favored 'General case' 0 C--N 1.286 -2.165 0 O-C-N 121.837 -0.802 . . . . 0.0 110.587 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.707 ' CD2' HG22 ' A' ' 48' ' ' ILE . 17.5 t90 -89.39 87.53 7.13 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.518 -0.738 . . . . 0.0 109.494 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.631 ' CE2' HG12 ' A' ' 41' ' ' VAL . 11.7 m0 -98.06 111.59 23.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.08 -1.012 . . . . 0.0 110.427 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.505 HG12 ' NE1' ' A' ' 76' ' ' TRP . 0.3 OUTLIER -114.65 148.17 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.737 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.56 ' HB3' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -130.28 125.46 34.83 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.921 -1.112 . . . . 0.0 110.16 179.81 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.518 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -125.44 173.97 8.52 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.478 -0.764 . . . . 0.0 110.031 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.97 52.51 1.27 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 110.046 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -169.59 -105.94 0.19 Allowed Glycine 0 C--N 1.302 -1.337 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -133.08 115.5 15.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.505 -0.997 . . . . 0.0 110.316 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.475 HG21 ' O ' ' A' ' 124' ' ' ILE . 8.1 tp -105.49 148.36 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 110.261 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -103.99 159.29 15.79 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.157 -0.965 . . . . 0.0 111.392 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.671 ' CG2' ' CD2' ' A' ' 122' ' ' PHE . 0.3 OUTLIER -162.32 149.82 4.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 O-C-N 121.442 -0.787 . . . . 0.0 110.438 179.772 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.582 ' N ' HD11 ' A' ' 86' ' ' ILE . 1.4 m-20 -135.31 -176.13 4.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.011 -1.056 . . . . 0.0 111.455 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.602 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -138.41 -9.31 1.46 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.813 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.43 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -43.71 -48.34 7.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.474 -1.392 . . . . 0.0 110.269 179.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.525 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 10.1 tt0 -49.36 -47.63 47.3 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.455 -0.778 . . . . 0.0 109.892 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 94' ' ' LEU . . . -56.81 -26.46 58.04 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.067 -1.021 . . . . 0.0 109.649 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.699 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -73.97 -48.84 14.82 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 0.0 OUTLIER -58.23 -19.3 32.79 Favored 'General case' 0 C--N 1.289 -2.052 0 O-C-N 121.104 -1.233 . . . . 0.0 107.951 178.56 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.565 ' CD2' HD21 ' A' ' 95' ' ' LEU . 11.4 tp -82.11 -68.0 0.73 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.826 -0.546 . . . . 0.0 109.613 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.565 HD21 ' CD2' ' A' ' 94' ' ' LEU . 0.2 OUTLIER -100.96 -29.66 12.07 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.082 -1.011 . . . . 0.0 109.135 178.587 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 69.44 43.96 66.98 Favored Glycine 0 N--CA 1.498 2.768 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.833 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.687 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 8.2 mmmt -138.23 -124.17 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.672 0 O-C-N 121.091 -1.241 . . . . 0.0 109.724 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.687 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 45.9 Cg_endo -71.14 -4.96 15.94 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 121.172 1.454 . . . . 0.0 108.724 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.76 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.8 p90 -23.66 -44.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.076 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.76 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -49.14 -52.48 25.96 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 123.348 1.547 . . . . 0.0 107.734 -179.125 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.57 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 67.5 t -99.04 -53.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.807 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.486 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 0.5 OUTLIER -44.42 -30.02 0.79 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.773 -1.204 . . . . 0.0 108.434 179.364 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.564 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.8 t70 -83.11 -45.94 13.37 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.614 ' HB2' ' CE2' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -60.9 -41.16 95.55 Favored 'General case' 0 C--O 1.202 -1.425 0 C-N-CA 117.928 -1.509 . . . . 0.0 109.144 179.168 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.564 ' CD1' HG11 ' A' ' 101' ' ' VAL . 28.0 mt -61.58 -46.47 89.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.725 -1.235 . . . . 0.0 111.341 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -73.94 -33.07 35.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 110.464 -178.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.534 ' O ' ' O ' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -90.42 -40.71 11.89 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.121 -0.987 . . . . 0.0 110.143 -179.954 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.618 ' O ' ' N ' ' A' ' 111' ' ' THR . 1.6 p -65.86 1.66 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.647 -1.283 . . . . 0.0 111.32 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.509 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.42 -33.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.997 -1.064 . . . . 0.0 110.872 -179.699 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.551 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . 1.9 p -88.02 39.16 0.88 Allowed 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 108' ' ' VAL . 8.9 t -60.63 -10.93 5.9 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.377 -0.827 . . . . 0.0 111.698 -178.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.57 ' C ' ' O ' ' A' ' 111' ' ' THR . 0.6 OUTLIER 16.56 -84.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 CA-C-O 121.094 0.473 . . . . 0.0 112.081 -179.839 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.537 ' O ' ' O ' ' A' ' 114' ' ' ARG . . . -83.54 52.99 4.81 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.537 ' O ' ' O ' ' A' ' 113' ' ' GLY . 10.6 ttt85 43.49 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 O-C-N 121.539 -0.977 . . . . 0.0 111.544 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.476 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -142.41 107.83 5.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.748 -1.22 . . . . 0.0 110.346 -179.128 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 33.3 t80 -69.43 118.39 12.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.105 -0.997 . . . . 0.0 109.247 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.532 ' HA ' ' HB3' ' A' ' 122' ' ' PHE . 7.4 t -83.84 158.09 21.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.146 -0.971 . . . . 0.0 111.301 -178.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.555 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -135.1 54.72 1.92 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.662 -0.649 . . . . 0.0 110.388 -179.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.3 -57.72 0.07 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.555 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -114.4 -23.75 9.21 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.844 -0.798 . . . . 0.0 111.24 -178.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.539 ' O ' ' CB ' ' A' ' 118' ' ' LEU . 5.5 tttt -138.72 147.27 42.51 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.904 -1.122 . . . . 0.0 110.796 -179.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.671 ' CD2' ' CG2' ' A' ' 86' ' ' ILE . 0.1 OUTLIER -116.02 -177.96 3.29 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.086 -1.009 . . . . 0.0 109.136 178.326 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.476 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.9 OUTLIER -156.42 141.23 17.06 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 110.342 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.536 ' N ' ' CD1' ' A' ' 124' ' ' ILE . 3.1 mp -111.28 129.65 66.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 110.34 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.429 ' OG1' ' N ' ' A' ' 126' ' ' SER . 1.7 t -145.15 -169.1 3.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.184 -0.947 . . . . 0.0 110.399 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.429 ' N ' ' OG1' ' A' ' 125' ' ' THR . 3.8 t . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.848 . . . . 0.0 110.595 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.488 ' HB2' ' HB2' ' A' ' 126' ' ' SER . 77.9 m-20 . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.467 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.41 146.38 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.656 -0.653 . . . . 0.0 110.474 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.468 ' CG2' ' C ' ' A' ' 125' ' ' THR . 1.9 t -136.56 120.95 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.843 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.402 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 9.6 p -97.64 134.79 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.581 ' HA ' ' OG ' ' A' ' 110' ' ' SER . 9.2 tp -106.98 147.96 29.25 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.637 ' HB ' ' HB3' ' A' ' 110' ' ' SER . 50.6 t -149.07 126.58 2.65 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 120.576 -1.328 . . . . 0.0 110.322 -178.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.62 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 12.4 tp -135.73 178.71 6.83 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.526 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 8.6 ptp -78.61 178.5 7.77 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.725 -1.235 . . . . 0.0 110.79 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.463 ' HD3' ' N ' ' A' ' 74' ' ' GLY . 4.4 mtmt -64.09 95.9 0.13 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.539 -0.726 . . . . 0.0 112.127 -178.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.515 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 0.2 OUTLIER -73.85 -0.96 17.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 0.0 109.712 178.224 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 45' ' ' SER . 8.0 t0 74.82 -58.96 0.56 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.501 -0.75 . . . . 0.0 112.297 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.498 ' O ' HG12 ' A' ' 51' ' ' ILE . 1.4 mt-10 -95.06 23.68 5.47 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.809 -1.182 . . . . 0.0 111.781 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.791 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -63.23 -71.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 120.823 -1.173 . . . . 0.0 111.674 -179.494 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.566 ' C ' ' O ' ' A' ' 48' ' ' ILE . 15.6 t0 -36.8 -34.2 0.07 Allowed 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.051 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.516 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -77.65 -54.83 5.92 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.791 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.24 -50.8 33.75 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 O-C-N 120.757 -1.214 . . . . 0.0 109.324 178.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.583 ' HA ' HG21 ' A' ' 55' ' ' ILE . 36.4 mm -46.13 -39.33 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 119.798 -1.814 . . . . 0.0 108.506 177.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.573 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 3.8 tm-20 -64.39 -61.5 2.19 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.185 -0.947 . . . . 0.0 110.333 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -80.69 -10.83 59.7 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.254 -0.904 . . . . 0.0 111.258 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.685 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.8 tp -106.18 -33.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 CA-C-O 121.644 0.735 . . . . 0.0 110.467 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.577 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.4 t -117.39 -45.31 3.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.3 -177.448 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.573 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -58.61 -39.15 79.61 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.096 -1.628 . . . . 0.0 108.492 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.516 ' N ' HD21 ' A' ' 57' ' ' LEU . 1.3 tttt -100.02 -41.04 7.34 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 55' ' ' ILE . . . -67.32 -49.02 55.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.491 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -81.39 23.64 4.63 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 120.926 -1.338 . . . . 0.0 110.366 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -107.54 -9.27 15.96 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.854 -1.38 . . . . 0.0 110.76 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.47 -84.8 0.31 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 120.95 -1.094 . . . . 0.0 110.109 -179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.417 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 4.7 ptpt -70.0 -35.82 74.67 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.491 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.6 OUTLIER -69.36 122.68 86.34 Favored Pre-proline 0 C--N 1.298 -1.668 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.811 179.138 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.422 ' HG2' ' HB3' ' A' ' 81' ' ' ASP . 43.7 Cg_endo -63.26 -45.6 11.78 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 121.733 1.622 . . . . 0.0 110.924 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.457 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 0.6 OUTLIER 179.37 111.57 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 CA-C-O 122.92 1.343 . . . . 0.0 109.653 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.628 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.297 1.3 mp -106.68 133.97 49.67 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.403 0 CA-C-N 114.012 -1.449 . . . . 0.0 111.728 -176.799 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.562 ' HB ' ' CG ' ' A' ' 79' ' ' LYS . 1.0 OUTLIER -91.81 139.28 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.555 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.567 ' CG2' ' CG2' ' A' ' 52' ' ' ILE . 72.9 t -104.76 89.3 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.178 -0.952 . . . . 0.0 110.328 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.721 ' HB3' ' HB2' ' A' ' 77' ' ' TRP . 0.3 OUTLIER -82.04 50.55 1.59 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -0.795 . . . . 0.0 110.231 179.928 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . 0.478 ' OD2' ' HB2' ' A' ' 49' ' ' ASP . 3.5 t70 -77.66 109.38 11.59 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.036 -1.04 . . . . 0.0 110.095 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.8 tttt -129.21 142.06 50.97 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.027 -1.046 . . . . 0.0 109.711 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.81 86.78 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.881 . . . . 0.0 109.633 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 158.72 -49.26 0.41 Allowed Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.548 ' HB3' ' CD1' ' A' ' 77' ' ' TRP . 5.1 m-85 -143.62 145.13 32.24 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.814 -0.815 . . . . 0.0 110.418 -179.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.719 ' CG ' HG22 ' A' ' 48' ' ' ILE . 17.8 t90 -94.25 80.14 3.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.613 -0.679 . . . . 0.0 109.989 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.721 ' HB2' ' HB3' ' A' ' 70' ' ' GLU . 7.9 m95 -87.83 128.27 35.34 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 109.039 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -131.95 137.41 54.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.794 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.562 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 5.5 tttp -118.09 143.36 46.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.506 -1.371 . . . . 0.0 110.818 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.485 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -134.28 134.78 42.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.578 -0.701 . . . . 0.0 110.028 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.422 ' HB3' ' HG2' ' A' ' 65' ' ' PRO . 1.1 t0 -86.27 51.29 2.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.207 -0.933 . . . . 0.0 110.267 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.82 -120.37 0.54 Allowed Glycine 0 C--N 1.3 -1.419 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -113.8 164.29 13.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.367 -1.078 . . . . 0.0 109.372 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.468 HG21 ' O ' ' A' ' 124' ' ' ILE . 4.2 tp -147.83 144.07 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.952 -1.093 . . . . 0.0 110.56 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -122.34 150.45 42.38 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.401 -0.812 . . . . 0.0 110.178 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.695 HG21 ' CG ' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -161.42 169.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.459 -0.776 . . . . 0.0 109.651 -179.158 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' A' ' 86' ' ' ILE . 77.7 m-20 -139.63 -173.13 3.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.09 -1.006 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.593 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -131.56 -19.26 2.72 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.092 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.417 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -40.67 -46.15 2.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.076 -1.015 . . . . 0.0 110.537 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -48.63 -54.31 15.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.333 -0.854 . . . . 0.0 109.674 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.532 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -52.67 -28.3 21.09 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.462 -0.774 . . . . 0.0 109.701 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.745 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -70.84 -31.15 67.44 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -69.77 -24.08 63.46 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.549 ' HB3' ' CD2' ' A' ' 95' ' ' LEU . 0.4 OUTLIER -78.69 -59.16 2.89 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.613 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.549 ' CD2' ' HB3' ' A' ' 94' ' ' LEU . 0.2 OUTLIER -110.07 -29.34 8.26 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.178 -0.951 . . . . 0.0 110.897 179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 68.56 42.65 80.24 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.663 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 33.2 mttt -133.05 -134.41 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.403 0 O-C-N 121.261 -1.141 . . . . 0.0 109.947 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.663 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.4 Cg_endo -71.78 -4.3 14.82 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 N-CA-C 108.683 -1.314 . . . . 0.0 108.683 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.75 ' CD1' ' N ' ' A' ' 100' ' ' SER . 4.1 p90 -26.56 -42.29 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.88 0.848 . . . . 0.0 111.72 178.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.3 OUTLIER -52.34 -53.09 49.12 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-O 122.593 1.187 . . . . 0.0 108.779 -177.493 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.584 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 59.7 t -102.63 -46.22 10.79 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.463 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 64.7 t80 -52.05 -32.17 33.36 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 117.559 -1.656 . . . . 0.0 107.588 179.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 3.1 t70 -79.63 -50.7 10.27 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.479 -0.888 . . . . 0.0 108.906 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.602 ' O ' ' CG1' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -55.05 -42.74 73.09 Favored 'General case' 0 C--O 1.204 -1.296 0 C-N-CA 116.913 -1.915 . . . . 0.0 108.515 179.398 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.543 HD13 ' CG1' ' A' ' 101' ' ' VAL . 52.6 mt -59.07 -29.4 67.3 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.871 -1.143 . . . . 0.0 111.352 179.506 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.439 HD11 ' O ' ' A' ' 102' ' ' TYR . 1.1 mt -92.05 -41.23 12.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 120.939 -1.101 . . . . 0.0 110.879 -178.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.534 ' O ' ' O ' ' A' ' 41' ' ' VAL . 0.1 OUTLIER -90.99 -17.24 26.64 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.903 -1.123 . . . . 0.0 110.967 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.602 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 9.1 p -69.48 -3.58 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.089 -1.632 . . . . 0.0 110.093 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -35.1 -27.96 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.667 -0.646 . . . . 0.0 111.35 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.637 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -66.68 8.34 0.26 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 111.399 178.987 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.547 ' OG1' ' CB ' ' A' ' 115' ' ' ALA . 1.4 t -86.14 38.55 0.77 Allowed 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 117.922 -1.511 . . . . 0.0 110.633 -178.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 19.4 m -55.59 -21.48 9.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 O-C-N 121.42 -0.8 . . . . 0.0 110.861 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -105.72 -71.26 0.8 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -143.83 158.14 43.89 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.377 -1.072 . . . . 0.0 110.105 -179.733 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.549 ' HA ' HD13 ' A' ' 124' ' ' ILE . . . -160.67 83.79 0.68 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.168 -0.957 . . . . 0.0 111.201 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.448 ' HB2' HG23 ' A' ' 123' ' ' THR . 1.3 m-85 -80.26 117.59 21.17 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.225 -0.922 . . . . 0.0 108.811 178.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.482 ' O ' HG21 ' A' ' 117' ' ' THR . 4.3 t -84.86 131.98 34.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.146 -0.971 . . . . 0.0 110.406 -179.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.589 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -102.01 38.37 1.66 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 110.396 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.95 -59.64 0.14 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 118' ' ' LEU . 62.3 m -107.5 -13.79 14.99 Favored 'General case' 0 C--N 1.291 -1.935 0 O-C-N 121.941 -0.741 . . . . 0.0 110.059 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.523 ' HB2' ' CB ' ' A' ' 118' ' ' LEU . 1.0 OUTLIER -125.96 165.85 18.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.078 -1.014 . . . . 0.0 111.507 -179.397 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.695 ' CG ' HG21 ' A' ' 86' ' ' ILE 0.255 0.0 OUTLIER -124.9 145.26 49.91 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.896 . . . . . . . . 4 4 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.464 ' C ' HD13 ' A' ' 124' ' ' ILE . 0.7 OUTLIER -144.42 110.15 5.31 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.252 -1.53 . . . . 0.0 110.247 -178.18 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.642 HD11 ' CE1' ' A' ' 122' ' ' PHE . 1.5 mp -113.02 153.7 14.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' A' ' 38' ' ' VAL . 10.2 t -159.52 -176.86 6.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.542 -1.349 . . . . 0.0 111.721 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.488 ' HB2' ' HB2' ' A' ' 36' ' ' ASN . 80.6 p . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.616 -0.677 . . . . 0.0 110.299 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.475 ' O ' ' OG ' ' A' ' 126' ' ' SER . 5.7 m120 . . . . . 0 N--CA 1.502 2.155 0 CA-C-O 120.937 0.398 . . . . 0.0 110.995 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -40.35 116.03 0.63 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.138 -0.976 . . . . 0.0 110.97 -179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.534 ' CG2' ' CB ' ' A' ' 126' ' ' SER . 3.2 t -121.86 148.96 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.384 -0.823 . . . . 0.0 109.729 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.505 ' O ' ' HB2' ' A' ' 110' ' ' SER . 9.4 p -127.92 139.07 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 111.299 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.543 ' CD2' HD12 ' A' ' 84' ' ' ILE . 9.3 tp -117.25 128.67 55.31 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.68 HG12 ' CD1' ' A' ' 77' ' ' TRP . 39.9 t -130.35 150.94 35.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 O-C-N 120.776 -1.203 . . . . 0.0 112.013 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.539 ' CB ' ' CE3' ' A' ' 76' ' ' TRP . 0.1 OUTLIER -143.09 176.91 8.75 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 177.544 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.501 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 6.5 ptt? -110.55 36.34 3.13 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.697 -1.252 . . . . 0.0 110.218 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.529 ' HB3' ' CD1' ' A' ' 48' ' ' ILE . 5.1 mmtt -88.51 -81.27 0.26 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.482 -0.761 . . . . 0.0 112.409 -178.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.535 ' H ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER 67.99 92.97 0.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.197 -178.692 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.48 ' HB2' ' O ' ' A' ' 45' ' ' SER . 3.5 t70 170.96 -80.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.416 -0.803 . . . . 0.0 110.029 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.553 ' HB3' HD11 ' A' ' 51' ' ' ILE . 13.4 mt-10 -91.9 -10.3 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.891 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.809 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -60.65 -64.76 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.341 -0.849 . . . . 0.0 111.526 -178.933 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 2.1 t70 -41.11 -36.88 0.78 Allowed 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 118.769 -1.172 . . . . 0.0 108.961 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.475 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -76.19 -52.97 8.97 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.545 -0.722 . . . . 0.0 110.094 178.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.809 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.3 OUTLIER -70.6 -50.03 47.84 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.06 0 O-C-N 120.6 -1.312 . . . . 0.0 108.943 179.104 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.605 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 48.1 mm -43.41 -39.87 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.302 -1.498 . . . . 0.0 108.263 177.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.585 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 24.8 tt0 -65.86 -63.93 0.97 Allowed 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.437 179.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -77.79 -9.79 59.21 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.196 -0.94 . . . . 0.0 111.299 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.69 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.6 tp -106.61 -34.96 2.99 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-O 121.753 0.787 . . . . 0.0 110.359 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.605 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.2 t -117.24 -46.31 3.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.961 -0.696 . . . . 0.0 112.202 -177.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.585 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.3 OUTLIER -56.53 -39.1 72.78 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.274 -1.516 . . . . 0.0 109.502 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.9 tttp -93.58 -49.74 5.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.0 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.94 -42.38 9.69 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.574 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.46 -54.12 14.26 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.591 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 15.0 ttpt -67.6 12.57 0.09 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.624 -0.927 . . . . 0.0 112.552 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.89 -64.04 0.94 Allowed 'General case' 0 C--N 1.305 -1.33 0 O-C-N 120.56 -1.338 . . . . 0.0 108.351 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.2 mtmt -97.87 -22.06 16.56 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.591 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -69.25 128.98 92.25 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.179 179.779 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.74 -44.32 13.96 Favored 'Trans proline' 0 C--N 1.302 -1.905 0 C-N-CA 122.038 1.826 . . . . 0.0 111.603 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.431 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.44 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.331 0 CA-C-O 123.097 1.427 . . . . 0.0 109.567 -179.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.674 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.305 1.2 mp -97.8 140.87 16.98 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.538 0 CA-C-N 113.741 -1.572 . . . . 0.0 111.563 -176.898 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.542 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 3.1 t -83.23 137.0 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.454 -0.779 . . . . 0.0 110.01 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.545 HG21 ' CG2' ' A' ' 52' ' ' ILE . 27.6 t -119.99 81.77 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.133 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.633 ' HB2' ' CB ' ' A' ' 77' ' ' TRP . 1.9 mm-40 -78.91 141.13 37.87 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.364 -0.835 . . . . 0.0 110.289 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -145.7 127.88 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.286 -0.884 . . . . 0.0 109.614 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.517 ' O ' ' C ' ' A' ' 73' ' ' ALA . 3.7 ttpt -157.91 -176.9 6.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.021 -1.049 . . . . 0.0 111.326 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.517 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -25.99 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.343 0.592 . . . . 0.0 111.819 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 41.33 44.51 3.95 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.501 ' HA ' ' HA ' ' A' ' 43' ' ' MET . 0.1 OUTLIER -137.25 90.91 2.56 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 121.554 0.692 . . . . 0.0 110.044 179.86 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.701 ' CE2' HG23 ' A' ' 48' ' ' ILE . 8.8 t90 -83.0 82.28 8.3 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.436 -0.79 . . . . 0.0 109.547 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.68 ' CD1' HG12 ' A' ' 41' ' ' VAL . 13.6 m95 -89.59 131.27 35.69 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.141 -0.975 . . . . 0.0 110.975 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.557 ' CG1' ' NE1' ' A' ' 76' ' ' TRP . 21.3 mm -134.66 153.09 34.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.366 -0.834 . . . . 0.0 109.876 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.542 ' HG2' ' HB ' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -143.55 135.46 26.59 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.947 -179.378 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.555 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -136.43 140.23 42.99 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.597 -0.689 . . . . 0.0 110.03 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -84.46 51.15 2.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.012 . . . . 0.0 110.287 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.77 -148.38 5.97 Favored Glycine 0 N--CA 1.477 1.398 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -88.18 144.77 26.27 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.277 -1.131 . . . . 0.0 109.8 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.543 HD12 ' CD2' ' A' ' 40' ' ' LEU . 9.8 tt -142.46 172.85 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.962 . . . . 0.0 110.67 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.495 ' N ' ' CG1' ' A' ' 84' ' ' ILE . 15.4 mt-10 -131.71 176.41 8.35 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.955 -1.091 . . . . 0.0 112.017 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.613 ' CG2' ' CB ' ' A' ' 122' ' ' PHE . 0.0 OUTLIER -160.94 154.46 3.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.58 ' N ' ' CD1' ' A' ' 86' ' ' ILE . 4.8 m-20 -137.1 -178.7 5.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.796 -1.19 . . . . 0.0 111.903 -178.378 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.633 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -150.35 -29.9 0.21 Allowed 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.103 177.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.429 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -39.29 -47.03 1.64 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.062 -1.024 . . . . 0.0 110.663 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 93' ' ' GLU . 2.7 mm-40 -50.92 -63.34 1.16 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 121.871 0.843 . . . . 0.0 109.41 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.489 ' O ' HD13 ' A' ' 95' ' ' LEU . . . -38.61 -38.08 0.37 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.464 179.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.68 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -64.18 -42.49 97.95 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.044 -1.623 . . . . 0.0 109.044 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' N ' ' O ' ' A' ' 90' ' ' GLU . 14.0 mt-10 -60.14 -24.65 64.88 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.525 HD21 ' N ' ' A' ' 95' ' ' LEU . 8.7 tt -79.73 -60.38 2.37 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.523 -0.735 . . . . 0.0 110.469 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.542 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -109.95 -20.46 12.73 Favored 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.97 -179.456 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 63.05 90.4 0.03 OUTLIER Glycine 0 N--CA 1.497 2.71 0 C-N-CA 118.786 -1.674 . . . . 0.0 109.604 179.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.679 ' HB3' ' HD2' ' A' ' 98' ' ' PRO 0.261 0.2 OUTLIER -175.99 -151.69 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.192 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 -178.744 . . . . . . . . 4 4 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.679 ' HD2' ' HB3' ' A' ' 97' ' ' LYS . 43.1 Cg_endo -67.8 -1.99 7.79 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 N-CA-C 108.841 -1.253 . . . . 0.0 108.841 176.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.778 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.3 p90 -21.3 -44.58 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.641 0.734 . . . . 0.0 112.427 179.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.778 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -54.47 -53.78 49.65 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 122.868 1.318 . . . . 0.0 108.95 -177.104 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.56 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 48.3 t -98.44 -47.05 12.44 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.343 0 CA-C-N 115.147 -0.933 . . . . 0.0 113.267 -178.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.56 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 5.9 t80 -51.06 -29.22 12.24 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 117.512 -1.675 . . . . 0.0 107.843 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 8.8 t70 -80.9 -44.45 18.3 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.597 ' O ' ' CG1' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -59.55 -45.23 92.4 Favored 'General case' 0 C--O 1.201 -1.476 0 C-N-CA 117.833 -1.547 . . . . 0.0 109.102 178.861 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.537 HD13 ' CG1' ' A' ' 101' ' ' VAL . 2.5 mt -64.21 -27.29 68.96 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 119.893 -1.755 . . . . 0.0 111.062 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -95.18 -12.73 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 109.937 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.515 ' ND2' ' HA ' ' A' ' 104' ' ' LEU . 0.0 OUTLIER -118.86 -36.11 3.52 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.507 -0.745 . . . . 0.0 110.289 -179.196 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.597 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 1.8 p -62.69 -4.86 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.207 -0.933 . . . . 0.0 111.603 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.88 -27.22 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.399 -0.813 . . . . 0.0 111.81 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.583 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 90.6 p -82.24 28.84 0.43 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.877 -1.14 . . . . 0.0 109.791 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.463 ' HB ' HG23 ' A' ' 108' ' ' VAL . 5.4 t -89.49 42.89 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.945 -1.097 . . . . 0.0 109.38 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 96.7 t -57.95 -47.29 86.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.762 -0.586 . . . . 0.0 111.364 -179.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -78.01 -75.19 0.97 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.511 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -152.95 -176.98 6.0 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.238 -1.154 . . . . 0.0 110.538 -179.14 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.437 ' HB3' HG13 ' A' ' 124' ' ' ILE . . . -170.36 73.77 0.07 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.368 -0.833 . . . . 0.0 110.317 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.451 ' HB3' HG23 ' A' ' 123' ' ' THR . 17.5 t80 -72.69 140.67 48.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 18.8 m -89.3 117.55 28.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 110.532 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.667 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -86.64 39.61 0.85 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.431 -0.793 . . . . 0.0 110.728 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 59.6 -62.01 0.01 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.311 -1.115 . . . . 0.0 110.311 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.667 ' N ' ' O ' ' A' ' 118' ' ' LEU . 38.3 p -88.44 -28.62 20.77 Favored 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.928 -0.748 . . . . 0.0 109.979 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.526 ' O ' ' N ' ' A' ' 118' ' ' LEU . 3.6 ptmt -146.1 -167.76 2.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.129 -0.982 . . . . 0.0 110.665 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.613 ' CB ' ' CG2' ' A' ' 86' ' ' ILE . 5.8 m-85 -116.77 165.07 13.72 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.321 -0.862 . . . . 0.0 110.85 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.498 ' O ' ' CG2' ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.22 105.1 5.61 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.659 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.512 HD11 ' CG2' ' A' ' 86' ' ' ILE . 1.8 mp -108.2 141.57 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -0.952 . . . . 0.0 109.623 -179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 13.4 t -149.94 -170.76 3.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.06 -1.025 . . . . 0.0 111.11 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.534 ' CB ' ' CG2' ' A' ' 38' ' ' VAL . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.44 -0.787 . . . . 0.0 110.537 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.508 ' O ' ' C ' ' A' ' 37' ' ' ALA . 31.5 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.508 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -27.25 127.28 0.06 Allowed 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.347 0.594 . . . . 0.0 111.997 -179.303 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.485 HG11 ' O ' ' A' ' 36' ' ' ASN . 14.5 m -111.76 174.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.502 ' O ' ' HB3' ' A' ' 110' ' ' SER . 13.2 p -144.78 125.1 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.139 -0.975 . . . . 0.0 110.783 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.533 HD12 ' CG1' ' A' ' 86' ' ' ILE . 20.6 tp -92.85 162.85 13.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.596 HG12 ' CE2' ' A' ' 77' ' ' TRP . 5.6 t -149.65 123.47 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 O-C-N 120.106 -1.621 . . . . 0.0 111.833 -178.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.592 HD11 ' CZ3' ' A' ' 76' ' ' TRP . 0.2 OUTLIER -126.36 156.35 40.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.127 -0.983 . . . . 0.0 109.853 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.505 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.6 ptm -96.98 31.38 2.41 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.921 -1.112 . . . . 0.0 110.183 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.517 ' O ' ' HA2' ' A' ' 74' ' ' GLY . 2.3 mmtt -87.74 -86.59 0.16 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.482 -0.761 . . . . 0.0 110.956 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.525 ' CA ' HD12 ' A' ' 48' ' ' ILE . 0.2 OUTLIER 73.37 113.26 0.06 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.36 -0.838 . . . . 0.0 110.746 -179.834 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.523 ' N ' HD12 ' A' ' 48' ' ' ILE . 0.3 OUTLIER 164.73 -83.95 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.665 -0.647 . . . . 0.0 109.438 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.465 ' O ' HG12 ' A' ' 51' ' ' ILE . 5.1 mt-10 -95.52 1.1 53.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.866 . . . . 0.0 110.045 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.796 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -61.93 -66.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.103 -0.998 . . . . 0.0 111.046 -178.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.528 ' C ' ' O ' ' A' ' 48' ' ' ILE . 5.3 t0 -40.09 -33.58 0.24 Allowed 'General case' 0 C--N 1.292 -1.932 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.68 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.484 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -78.71 -55.5 5.13 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.717 -0.614 . . . . 0.0 109.835 178.235 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.796 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -68.31 -48.43 73.31 Favored 'Isoleucine or valine' 0 C--O 1.185 -2.316 0 C-N-CA 118.301 -1.36 . . . . 0.0 108.232 178.642 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.596 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 46.3 mm -43.32 -41.19 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.004 -1.685 . . . . 0.0 108.42 176.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.556 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 16.2 tt0 -64.84 -62.91 1.28 Allowed 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.895 -1.128 . . . . 0.0 110.025 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -77.41 -11.78 59.88 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.323 -0.86 . . . . 0.0 111.584 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.703 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.5 tp -107.23 -33.47 2.66 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.531 0.682 . . . . 0.0 111.039 -178.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.596 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.8 t -117.22 -45.17 3.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.598 -0.689 . . . . 0.0 112.153 -177.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.556 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -54.58 -30.08 53.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 119.758 -1.839 . . . . 0.0 108.959 -179.798 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.533 ' N ' HD21 ' A' ' 57' ' ' LEU . 13.4 mmtt -85.99 -47.49 9.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.473 -0.767 . . . . 0.0 110.483 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.44 -45.09 5.37 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.58 ' N ' ' O ' ' A' ' 56' ' ' VAL . . . -68.97 -73.04 0.76 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.574 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 22.4 ttpt -65.72 9.84 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.403 -1.057 . . . . 0.0 112.557 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.63 -63.47 1.13 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.555 -1.341 . . . . 0.0 108.454 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.0 mtmt -97.97 -20.34 17.48 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 177.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.574 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.8 OUTLIER -68.68 141.1 92.43 Favored Pre-proline 0 N--CA 1.489 1.503 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.393 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.438 ' O ' ' OG ' ' A' ' 66' ' ' SER . 42.9 Cg_endo -62.38 -46.38 12.35 Favored 'Trans proline' 0 C--N 1.298 -2.107 0 C-N-CA 122.228 1.952 . . . . 0.0 112.002 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 65' ' ' PRO . 0.9 OUTLIER 178.81 112.99 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 123.158 1.456 . . . . 0.0 110.66 -179.691 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.69 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.306 1.0 OUTLIER -89.99 147.67 5.06 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.684 0 CA-C-N 113.573 -1.649 . . . . 0.0 110.86 -178.185 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.562 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -102.05 138.21 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.133 -0.98 . . . . 0.0 110.695 -179.581 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.518 ' HA ' HD11 ' A' ' 78' ' ' ILE . 5.5 t -116.82 90.97 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.372 -0.83 . . . . 0.0 109.073 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.567 ' CB ' ' HB2' ' A' ' 77' ' ' TRP . 13.2 mm-40 -79.61 76.51 6.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.487 -0.758 . . . . 0.0 110.655 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -89.04 113.62 24.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.973 -1.079 . . . . 0.0 109.485 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.471 ' O ' ' OG ' ' A' ' 45' ' ' SER . 13.0 mttp -145.47 -162.02 1.42 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.032 -1.042 . . . . 0.0 111.059 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.574 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -39.76 96.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.335 -0.853 . . . . 0.0 111.243 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.517 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 37.73 50.1 1.93 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.574 ' CD2' ' O ' ' A' ' 73' ' ' ALA . 8.6 m-85 -146.59 87.14 1.69 Allowed 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.875 -0.779 . . . . 0.0 109.761 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.726 ' CE2' HG23 ' A' ' 48' ' ' ILE . 4.5 t90 -82.13 74.16 9.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.516 -0.74 . . . . 0.0 110.033 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.596 ' CE2' HG12 ' A' ' 41' ' ' VAL . 8.9 m95 -82.0 123.33 28.81 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.581 ' CG1' ' NE1' ' A' ' 76' ' ' TRP . 5.5 mm -116.38 141.01 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.003 -1.061 . . . . 0.0 110.159 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.562 ' HG2' ' HB ' ' A' ' 68' ' ' VAL . 0.4 OUTLIER -123.61 130.52 52.79 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.612 -0.68 . . . . 0.0 109.598 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.5 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -130.28 165.89 21.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.222 -0.924 . . . . 0.0 110.289 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -118.35 50.32 1.18 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.341 -0.849 . . . . 0.0 110.304 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -119.77 0.52 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -112.22 152.67 28.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -1.115 . . . . 0.0 109.717 179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.531 ' CG2' HG23 ' A' ' 124' ' ' ILE . 8.1 tt -152.41 175.19 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.474 ' N ' ' CG1' ' A' ' 84' ' ' ILE . 56.2 mt-10 -148.16 172.47 14.27 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.007 -1.058 . . . . 0.0 111.315 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.691 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -124.48 167.62 18.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 121.601 -0.687 . . . . 0.0 109.552 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.417 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 26.0 m-20 -154.98 138.97 16.37 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.015 -1.053 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.574 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -151.73 -37.52 0.12 Allowed 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.379 -1.328 . . . . 0.0 111.0 177.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.477 ' O ' ' HG2' ' A' ' 93' ' ' GLU . . . -39.89 -40.27 0.97 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.501 -0.75 . . . . 0.0 110.567 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.52 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 3.2 mt-10 -72.06 -43.97 64.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.317 -0.864 . . . . 0.0 109.408 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.567 ' HB2' ' CE1' ' A' ' 99' ' ' PHE . . . -60.35 -49.84 75.99 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 108.955 179.206 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.53 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -53.53 -57.43 15.66 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.52 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 7.1 pt-20 -59.98 -13.24 10.38 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.332 -1.099 . . . . 0.0 110.038 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.545 HD22 ' N ' ' A' ' 95' ' ' LEU . 0.5 OUTLIER -92.22 -43.75 9.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.317 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.609 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -97.64 -41.31 8.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.795 -1.191 . . . . 0.0 109.247 179.464 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.565 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -145.33 -74.7 0.02 OUTLIER Glycine 0 N--CA 1.483 1.805 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.565 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.3 OUTLIER 161.61 -55.77 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.858 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.737 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.528 ' HD2' ' N ' ' A' ' 97' ' ' LYS . 52.2 Cg_endo -74.66 -23.54 14.49 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.856 1.45 . . . . 0.0 110.251 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.609 ' CG ' HD12 ' A' ' 95' ' ' LEU . 2.6 t80 -47.28 -49.42 23.71 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.223 -0.923 . . . . 0.0 109.996 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.574 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 29.5 p -31.97 -64.12 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.889 0.852 . . . . 0.0 110.429 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.586 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 13.8 t -72.69 -60.78 2.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 O-C-N 121.034 -1.041 . . . . 0.0 112.572 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 101' ' ' VAL . 1.7 t80 -44.94 -30.48 1.02 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.532 -1.355 . . . . 0.0 109.332 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 6.4 t0 -77.08 -31.52 56.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.598 -0.689 . . . . 0.0 109.287 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.627 ' O ' ' CG1' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -74.81 -19.49 60.17 Favored 'General case' 0 C--O 1.2 -1.51 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.24 179.739 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.546 HD13 ' CG1' ' A' ' 101' ' ' VAL . 1.4 mt -91.27 -26.12 19.14 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.345 -1.472 . . . . 0.0 111.226 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -97.22 -13.58 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.015 -1.053 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.551 ' O ' ' O ' ' A' ' 41' ' ' VAL . 0.1 OUTLIER -105.57 -42.9 5.08 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.509 -0.745 . . . . 0.0 110.012 179.766 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.627 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 3.5 p -57.32 -2.86 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 120.879 -1.138 . . . . 0.0 112.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.504 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -25.22 -39.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.77 -0.581 . . . . 0.0 112.365 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.576 ' N ' ' O ' ' A' ' 108' ' ' VAL . 1.9 m -80.27 43.14 0.61 Allowed 'General case' 0 C--N 1.287 -2.137 0 C-N-CA 118.43 -1.308 . . . . 0.0 108.79 178.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.543 ' CG2' HG12 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -63.33 2.02 0.44 Allowed 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.267 -0.896 . . . . 0.0 112.45 -179.146 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.454 ' C ' ' O ' ' A' ' 111' ' ' THR . 9.6 p -38.16 -27.24 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 120.808 -1.183 . . . . 0.0 111.17 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.535 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -97.64 50.22 1.41 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.535 ' C ' ' O ' ' A' ' 113' ' ' GLY . 1.5 ttm-85 19.86 100.36 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.356 0.598 . . . . 0.0 111.982 179.165 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.583 ' HB2' ' CE2' ' A' ' 122' ' ' PHE . . . -85.09 93.69 8.68 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.266 -0.896 . . . . 0.0 111.47 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 123' ' ' THR . 0.1 OUTLIER -74.44 143.91 44.5 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.189 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 4.0 m -79.51 160.21 26.62 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.79 -1.194 . . . . 0.0 111.309 -178.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.9 OUTLIER -130.62 35.33 4.03 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.665 -0.647 . . . . 0.0 109.891 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.49 -59.76 0.29 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.502 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -115.42 -9.24 12.15 Favored 'General case' 0 C--N 1.292 -1.908 0 O-C-N 122.013 -0.698 . . . . 0.0 110.186 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HB2' ' HB3' ' A' ' 118' ' ' LEU . 20.8 mttt -137.68 -162.26 1.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.151 -0.968 . . . . 0.0 111.195 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.691 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.263 0.1 OUTLIER -132.15 160.66 35.4 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.068 -179.235 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.516 ' N ' ' O ' ' A' ' 116' ' ' TYR . 0.9 OUTLIER -138.3 104.14 5.1 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.034 -1.041 . . . . 0.0 110.598 178.697 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.531 HG23 ' CG2' ' A' ' 84' ' ' ILE . 3.4 mp -98.44 146.78 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.201 -0.937 . . . . 0.0 108.59 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.41 ' N ' HG21 ' A' ' 124' ' ' ILE . 12.5 t -149.4 166.75 28.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.782 -1.199 . . . . 0.0 111.108 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.472 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 2.4 t . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 121.555 0.693 . . . . 0.0 109.533 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.466 ' O ' ' HB3' ' A' ' 126' ' ' SER . 4.0 m-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.147 0.498 . . . . 0.0 110.276 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -31.87 141.32 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.569 0.699 . . . . 0.0 111.904 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.417 HG11 ' O ' ' A' ' 37' ' ' ALA . 24.2 m -141.42 176.17 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.472 -0.767 . . . . 0.0 109.709 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.486 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 5.5 p -136.46 130.5 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.953 -1.092 . . . . 0.0 111.097 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.599 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 12.4 tp -98.1 160.66 14.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 177.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.599 ' CG2' ' O ' ' A' ' 40' ' ' LEU . 2.9 t -166.31 116.4 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 O-C-N 120.871 -1.143 . . . . 0.0 110.093 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.6 ' CB ' ' CE3' ' A' ' 76' ' ' TRP . 2.5 mm? -135.38 -171.68 2.89 Favored 'General case' 0 C--N 1.289 -2.056 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.404 ' O ' ' N ' ' A' ' 45' ' ' SER . 20.9 ptm -104.09 161.43 14.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.161 -0.962 . . . . 0.0 109.813 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -44.75 96.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.3 -0.875 . . . . 0.0 111.263 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 4.5 m -82.11 11.81 4.86 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.165 -0.959 . . . . 0.0 110.265 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' SER . 13.3 t0 78.41 -62.51 0.34 Allowed 'General case' 0 N--CA 1.503 2.18 0 O-C-N 121.569 -0.707 . . . . 0.0 112.421 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.536 ' O ' HG12 ' A' ' 51' ' ' ILE . 3.5 mt-10 -93.31 26.56 2.88 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.776 -1.203 . . . . 0.0 112.195 -177.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.756 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.61 -75.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 120.932 -1.105 . . . . 0.0 111.092 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.3 t70 -37.63 -32.22 0.05 Allowed 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.45 -56.13 4.91 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 177.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.756 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -71.28 -52.14 29.02 Favored 'Isoleucine or valine' 0 C--O 1.193 -1.88 0 O-C-N 120.977 -1.077 . . . . 0.0 109.869 179.075 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.6 ' HA ' HG21 ' A' ' 55' ' ' ILE . 47.2 mm -48.22 -38.73 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 119.89 -1.756 . . . . 0.0 108.121 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.624 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.7 tt0 -63.07 -61.12 2.59 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.183 -0.948 . . . . 0.0 110.352 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -81.06 -12.0 59.4 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 111.405 -178.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.636 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.3 tp -105.88 -32.99 2.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-O 121.645 0.736 . . . . 0.0 110.365 -178.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.57 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.5 t -117.89 -45.08 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.869 -0.732 . . . . 0.0 112.694 -177.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.624 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -49.31 -42.75 42.34 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.011 -1.681 . . . . 0.0 109.037 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.528 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 14.3 mttt -85.08 -44.22 13.2 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.574 0.702 . . . . 0.0 109.51 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -65.54 -51.36 48.67 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.54 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -69.43 -8.36 59.38 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' A' ' 57' ' ' LEU . 2.1 tptm -107.36 -9.02 16.13 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.129 -1.218 . . . . 0.0 110.954 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.17 -79.05 0.24 Allowed 'General case' 0 C--N 1.308 -1.197 0 O-C-N 120.886 -1.134 . . . . 0.0 110.69 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.9 mtmt -87.45 -29.38 21.47 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.54 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.9 m-80 -69.18 124.99 91.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.113 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 66' ' ' SER . 42.9 Cg_endo -62.56 -42.87 24.34 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.781 1.654 . . . . 0.0 110.671 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.483 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 0.4 OUTLIER 179.4 110.0 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 123.008 1.385 . . . . 0.0 109.64 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.651 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.297 1.1 mp -105.37 149.99 8.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 113.839 -1.528 . . . . 0.0 110.496 -177.205 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.489 HG11 ' HB3' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -103.44 130.36 53.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.322 -0.861 . . . . 0.0 110.013 179.725 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.523 ' CG1' HG22 ' A' ' 52' ' ' ILE . 55.5 t -113.95 100.29 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.168 -0.957 . . . . 0.0 109.889 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.565 ' N ' ' O ' ' A' ' 77' ' ' TRP . 0.7 OUTLIER -89.81 79.55 6.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.385 -0.822 . . . . 0.0 110.681 -179.487 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -80.47 91.02 5.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.073 -1.017 . . . . 0.0 109.396 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.433 ' HB2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -89.78 154.45 19.9 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.159 -0.963 . . . . 0.0 110.482 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -59.63 -12.65 7.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.818 . . . . 0.0 110.548 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.452 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . -147.29 22.92 1.56 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.456 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.452 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 5.8 m-85 -160.77 108.8 1.57 Allowed 'General case' 0 C--N 1.289 -2.051 0 O-C-N 121.76 -0.847 . . . . 0.0 109.887 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.755 ' CE2' HG21 ' A' ' 48' ' ' ILE . 13.1 t90 -89.8 77.84 6.97 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.599 -0.688 . . . . 0.0 109.379 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.598 ' CE2' HG12 ' A' ' 41' ' ' VAL . 12.4 m0 -102.77 134.6 45.89 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.506 -0.746 . . . . 0.0 112.433 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.522 ' O ' ' N ' ' A' ' 40' ' ' LEU . 1.2 mp -138.65 152.39 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.489 ' HB3' HG11 ' A' ' 68' ' ' VAL . 0.4 OUTLIER -127.83 152.74 47.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.831 -1.168 . . . . 0.0 110.041 -179.728 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.484 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -139.42 178.86 6.9 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.299 -0.875 . . . . 0.0 110.603 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.418 ' HA ' ' HA ' ' A' ' 37' ' ' ALA . 41.6 m-20 -122.54 50.49 1.49 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.364 -0.835 . . . . 0.0 110.138 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.55 -126.66 0.88 Allowed Glycine 0 C--N 1.301 -1.386 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -99.8 143.93 29.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -1.22 . . . . 0.0 109.925 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.548 ' CD1' ' HB2' ' A' ' 40' ' ' LEU . 4.8 tp -125.85 161.99 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.145 -0.972 . . . . 0.0 110.012 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.526 ' N ' HG13 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.88 164.96 23.02 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.137 -0.977 . . . . 0.0 111.717 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.594 ' CG2' ' HB3' ' A' ' 122' ' ' PHE 0.26 0.3 OUTLIER -139.91 175.02 7.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.363 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.555 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 74.9 m-20 -149.55 173.37 13.69 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.861 -1.149 . . . . 0.0 111.308 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.637 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -150.96 -48.77 0.12 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.97 0.891 . . . . 0.0 109.759 177.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.414 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -41.37 -45.4 3.05 Favored 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.351 -0.843 . . . . 0.0 110.643 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.566 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 1.1 tt0 -49.81 -38.55 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 122.138 0.971 . . . . 0.0 108.483 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.577 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -63.45 -42.59 98.64 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.396 -0.815 . . . . 0.0 109.191 178.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.719 ' N ' ' CD2' ' A' ' 99' ' ' PHE . . . -63.15 -65.37 3.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.566 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 5.2 pt-20 -38.21 -31.56 0.05 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.818 -0.813 . . . . 0.0 108.94 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.548 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 0.1 OUTLIER -73.6 -71.16 0.33 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.68 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.577 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 0.1 OUTLIER -86.97 -55.17 3.95 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.972 -1.08 . . . . 0.0 108.847 178.599 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 88.18 50.14 3.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.696 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 15.2 mttt -150.74 -110.7 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 121.288 -1.125 . . . . 0.0 110.646 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.696 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 58.6 Cg_endo -85.5 12.98 2.89 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 CA-C-N 120.926 1.366 . . . . 0.0 109.67 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.729 ' O ' ' N ' ' A' ' 101' ' ' VAL . 29.3 p90 -49.85 -146.0 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 122.009 0.909 . . . . 0.0 110.474 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.696 ' N ' ' CD2' ' A' ' 99' ' ' PHE . 2.1 p 32.73 -77.59 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 122.269 1.033 . . . . 0.0 111.323 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.729 ' N ' ' O ' ' A' ' 99' ' ' PHE . 38.0 t -66.02 -64.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.582 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.491 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 16.0 t80 -59.89 -39.9 86.9 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 119.99 -1.694 . . . . 0.0 106.69 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.581 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 0.3 OUTLIER -63.42 -38.96 93.16 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.847 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.631 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 3.2 pp -83.75 -38.89 20.78 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 117.957 -1.497 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.59 ' N ' ' CD1' ' A' ' 104' ' ' LEU . 66.7 mt -49.82 -22.19 1.37 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 120.802 -1.186 . . . . 0.0 109.602 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -107.83 -33.4 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.288 -0.882 . . . . 0.0 110.15 179.768 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.581 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.7 p30 -96.7 -3.65 42.19 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.968 -1.082 . . . . 0.0 110.027 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.653 ' CG2' ' CE2' ' A' ' 122' ' ' PHE . 9.8 p -83.11 -7.7 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 110.804 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 108' ' ' VAL . 8.5 t -42.02 -22.91 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.193 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.595 ' CB ' ' N ' ' A' ' 41' ' ' VAL . 82.8 p -53.22 -4.31 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.313 -0.867 . . . . 0.0 112.641 179.283 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.533 ' CG2' HG12 ' A' ' 124' ' ' ILE . 45.1 p -71.76 -73.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.428 0 O-C-N 119.923 -1.736 . . . . 0.0 110.868 -178.105 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.5 ' HB ' ' O ' ' A' ' 111' ' ' THR . 47.9 t 61.78 11.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.517 -0.74 . . . . 0.0 110.575 -179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -161.2 -68.94 0.02 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.533 ' HB3' ' CG2' ' A' ' 125' ' ' THR . 0.1 OUTLIER -136.58 165.86 24.88 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.305 -1.114 . . . . 0.0 110.497 -179.38 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -156.25 68.79 0.62 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.318 -0.864 . . . . 0.0 110.185 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.542 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 7.1 t80 -69.69 132.15 45.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.246 -0.908 . . . . 0.0 109.657 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.4 m -88.57 138.87 31.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.147 -0.971 . . . . 0.0 110.305 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -108.73 37.19 2.6 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.381 -0.824 . . . . 0.0 110.197 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.21 -58.47 0.25 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.553 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.8 OUTLIER -113.38 -23.35 9.92 Favored 'General case' 0 C--N 1.293 -1.871 0 O-C-N 121.95 -0.735 . . . . 0.0 110.067 -179.873 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -116.69 -168.22 1.42 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.653 ' CE2' ' CG2' ' A' ' 108' ' ' VAL . 14.5 t80 -138.03 161.71 36.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.782 . . . . 0.0 109.159 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' A' ' 116' ' ' TYR . 0.8 OUTLIER -145.24 139.26 27.03 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 120.569 -1.332 . . . . 0.0 110.337 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.589 ' CD1' ' CD2' ' A' ' 122' ' ' PHE . 2.1 mp -134.91 154.39 36.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.467 -0.77 . . . . 0.0 110.18 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 114' ' ' ARG . 1.9 t -152.34 -175.04 5.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.186 -0.946 . . . . 0.0 110.34 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.466 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 90.4 p . . . . . 0 N--CA 1.492 1.656 0 O-C-N 121.364 -0.835 . . . . 0.0 110.538 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.526 ' O ' ' C ' ' A' ' 37' ' ' ALA . 5.5 m-80 . . . . . 0 N--CA 1.496 1.851 0 CA-C-O 120.735 0.302 . . . . 0.0 110.636 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.526 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -26.38 139.43 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.353 0.596 . . . . 0.0 111.496 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.452 HG13 ' OG ' ' A' ' 126' ' ' SER . 8.7 p -102.08 136.3 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.474 ' O ' ' HB2' ' A' ' 110' ' ' SER . 8.4 p -80.65 135.44 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.041 -1.037 . . . . 0.0 110.273 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.548 ' HB2' HG12 ' A' ' 84' ' ' ILE . 14.7 tp -110.42 134.48 52.29 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.635 HG12 ' CE2' ' A' ' 77' ' ' TRP . 10.1 t -130.63 121.24 50.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 O-C-N 120.86 -1.15 . . . . 0.0 110.942 -177.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.649 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 0.4 OUTLIER -120.54 -171.63 2.21 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.633 -0.667 . . . . 0.0 109.475 179.245 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.98 159.48 15.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.154 -0.967 . . . . 0.0 109.965 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.64 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.189 -0.945 . . . . 0.0 110.6 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.482 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 1.8 t -86.53 11.25 13.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 110.144 179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 45' ' ' SER . 5.5 m-20 67.71 -62.87 0.33 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.494 -0.754 . . . . 0.0 111.108 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.495 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.0 mt-10 -87.21 30.17 0.79 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.103 -0.998 . . . . 0.0 110.616 -179.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.882 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.36 -75.2 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.969 -1.082 . . . . 0.0 111.393 -178.698 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.527 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -39.47 -31.61 0.1 Allowed 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.305 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -75.4 -53.79 8.12 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.714 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.41 -53.55 19.1 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.76 0 O-C-N 120.997 -1.065 . . . . 0.0 109.992 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.599 ' HA ' HG21 ' A' ' 55' ' ' ILE . 44.8 mm -47.05 -37.15 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 119.962 -1.711 . . . . 0.0 108.106 177.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.603 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 30.2 tt0 -64.39 -63.43 1.14 Allowed 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.386 -0.821 . . . . 0.0 110.282 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.44 -10.03 59.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.354 -0.841 . . . . 0.0 111.295 -178.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.653 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.4 tp -106.68 -33.79 2.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-O 121.62 0.724 . . . . 0.0 110.371 -179.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.567 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.3 t -118.67 -43.22 2.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.08 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.603 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -44.98 -38.47 4.77 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.449 -1.407 . . . . 0.0 109.775 -178.346 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.53 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 0.0 OUTLIER -86.78 -44.61 11.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -56.55 -53.35 44.2 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.525 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -72.19 0.79 37.57 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 2.0 mmtt -106.57 -9.31 16.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.845 -1.385 . . . . 0.0 111.357 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.36 -80.05 0.12 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.888 -1.133 . . . . 0.0 109.852 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.58 -24.75 16.46 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 122.307 1.051 . . . . 0.0 108.411 178.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.525 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.4 m-20 -67.51 116.55 38.39 Favored Pre-proline 0 C--N 1.294 -1.844 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.727 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -62.99 -37.36 53.99 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 124.299 1.684 . . . . 0.0 111.558 -179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.446 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 0.3 OUTLIER 179.36 111.61 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 123.145 1.45 . . . . 0.0 109.908 179.423 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.644 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.298 1.2 mp -104.5 155.01 6.09 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 CA-C-N 113.665 -1.607 . . . . 0.0 111.024 -177.442 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.534 HG12 ' CE ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -110.55 147.04 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.172 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.532 ' HA ' ' CG1' ' A' ' 78' ' ' ILE . 58.1 t -128.5 106.18 14.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.15 -0.968 . . . . 0.0 110.093 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.523 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.3 mm-40 -97.16 84.06 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.779 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . 0.407 ' OD1' ' N ' ' A' ' 71' ' ' ASP . 15.7 p-10 -96.47 128.17 43.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.153 -0.967 . . . . 0.0 110.201 -179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -144.76 143.51 30.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 110.07 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -58.55 81.52 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 109.542 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 159.02 -40.11 0.49 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -139.94 173.81 11.15 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-O 121.835 0.826 . . . . 0.0 110.984 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.882 ' CE2' HG21 ' A' ' 48' ' ' ILE . 13.4 t90 -138.92 83.29 1.95 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.635 ' CE2' HG12 ' A' ' 41' ' ' VAL . 11.3 m95 -104.87 120.55 41.68 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.111 -0.993 . . . . 0.0 112.379 -177.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.564 HD13 ' CD1' ' A' ' 76' ' ' TRP . 1.1 mt -130.61 141.74 45.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.097 -1.002 . . . . 0.0 109.283 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.534 ' CE ' HG12 ' A' ' 68' ' ' VAL . 2.1 ptpt -114.12 134.17 55.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 110.028 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.496 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -120.16 148.91 43.05 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.317 -0.864 . . . . 0.0 109.838 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.485 ' HA ' ' CB ' ' A' ' 37' ' ' ALA . 1.4 m-20 -95.43 53.3 1.47 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.168 -0.958 . . . . 0.0 110.379 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.16 -116.79 0.39 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 125' ' ' THR . . . -121.39 146.61 46.7 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.169 -1.195 . . . . 0.0 110.165 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.548 HG12 ' HB2' ' A' ' 40' ' ' LEU . 5.5 tp -133.53 159.72 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.042 -1.036 . . . . 0.0 110.698 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.479 ' N ' HG13 ' A' ' 84' ' ' ILE . 16.9 mt-10 -137.56 130.32 30.06 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.325 -0.86 . . . . 0.0 110.793 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.592 ' CB ' ' HB3' ' A' ' 122' ' ' PHE . 1.7 mm -86.37 -176.1 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.333 -0.854 . . . . 0.0 109.82 179.699 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -156.54 154.8 30.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 110.869 179.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.576 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -150.13 -25.39 0.25 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.361 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.434 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -39.52 -45.24 1.54 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.936 -1.103 . . . . 0.0 111.032 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.454 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 1.2 tp10 -54.34 -60.6 3.12 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.345 -0.847 . . . . 0.0 109.844 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.502 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -42.28 -31.71 0.42 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.5 -0.75 . . . . 0.0 109.836 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.701 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -72.09 -41.78 53.19 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.454 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 7.7 mt-10 -55.82 -24.74 38.04 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.103 -1.234 . . . . 0.0 108.29 179.105 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.528 ' CD2' HD21 ' A' ' 95' ' ' LEU . 15.4 tp -87.05 -70.95 0.58 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 121.277 0.561 . . . . 0.0 110.01 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.552 ' CD1' ' HB3' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -87.27 -29.82 21.36 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.653 179.821 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 62.5 46.36 93.95 Favored Glycine 0 N--CA 1.499 2.844 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.145 177.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.727 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 0.1 OUTLIER -143.69 -128.58 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.262 0 O-C-N 120.901 -1.352 . . . . 0.0 109.636 178.728 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.727 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.5 Cg_endo -68.9 -3.63 11.8 Favored 'Trans proline' 0 N--CA 1.499 1.852 0 CA-C-N 121.738 1.656 . . . . 0.0 110.034 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.723 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.7 p90 -30.17 -41.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.211 1.005 . . . . 0.0 111.434 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.723 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 4.4 t -53.49 -58.18 8.06 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-O 122.894 1.331 . . . . 0.0 110.082 -177.189 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.611 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 46.9 t -97.9 -37.41 6.63 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.471 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 2.9 t80 -59.6 -33.67 71.77 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 119.741 -1.849 . . . . 0.0 107.674 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.587 ' HB3' ' O ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER -76.04 -42.67 47.07 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 178.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.611 ' CD2' ' HA ' ' A' ' 101' ' ' VAL . 0.9 OUTLIER -68.01 -36.67 80.35 Favored 'General case' 0 C--O 1.209 -1.078 0 C-N-CA 117.38 -1.728 . . . . 0.0 107.563 177.933 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.61 ' CD2' ' CG1' ' A' ' 101' ' ' VAL . 0.3 OUTLIER -46.87 -49.39 20.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.801 178.852 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.45 HG21 HD11 ' A' ' 106' ' ' ILE . 4.6 mm -83.87 -26.37 7.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.598 -0.689 . . . . 0.0 110.355 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.566 ' ND2' ' HA ' ' A' ' 104' ' ' LEU . 1.2 p30 -104.34 18.37 22.28 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.176 -0.953 . . . . 0.0 110.7 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.55 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 8.4 p -121.56 -12.39 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 120.894 -1.129 . . . . 0.0 109.733 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -36.67 -27.31 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.499 -0.751 . . . . 0.0 112.222 -178.969 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.581 ' OG ' ' N ' ' A' ' 41' ' ' VAL . 54.4 p -86.06 34.05 0.61 Allowed 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.619 -1.3 . . . . 0.0 109.254 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.492 ' OG1' ' HB3' ' A' ' 115' ' ' ALA . 9.9 t -107.12 50.05 0.78 Allowed 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.645 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 66.4 t -80.75 -33.32 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.642 -0.661 . . . . 0.0 111.496 -178.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -66.92 -78.97 0.23 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.404 ' HB2' HG21 ' A' ' 125' ' ' THR . 0.4 OUTLIER -135.21 175.8 9.25 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.364 -1.08 . . . . 0.0 109.996 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 122' ' ' PHE . . . -167.39 75.16 0.14 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.905 -1.122 . . . . 0.0 111.226 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.512 ' N ' ' O ' ' A' ' 123' ' ' THR . 0.4 OUTLIER -77.76 116.72 18.5 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.189 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.1 m -79.23 129.02 34.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.063 . . . . 0.0 110.478 -179.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.548 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.4 OUTLIER -104.04 45.62 0.95 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.383 -0.823 . . . . 0.0 110.386 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.37 -58.52 0.11 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.548 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.3 OUTLIER -115.69 -12.72 11.5 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.885 -0.774 . . . . 0.0 110.995 -179.473 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 63.2 mttt -124.2 178.71 5.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.971 -1.081 . . . . 0.0 111.294 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.592 ' HB3' ' CB ' ' A' ' 86' ' ' ILE . 2.5 t80 -126.85 146.61 50.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.589 -0.695 . . . . 0.0 109.194 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.512 ' O ' ' N ' ' A' ' 116' ' ' TYR . 0.9 OUTLIER -134.8 123.03 22.91 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 120.678 -1.264 . . . . 0.0 110.688 -179.701 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.546 HD12 ' CG1' ' A' ' 86' ' ' ILE . 3.4 mp -124.39 168.51 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 83' ' ' ALA . 9.0 t -159.09 154.87 26.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.555 -1.34 . . . . 0.0 111.518 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.627 -0.671 . . . . 0.0 109.986 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.456 ' O ' ' C ' ' A' ' 37' ' ' ALA . 1.5 m-80 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.154 0.502 . . . . 0.0 110.132 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -36.45 127.31 0.81 Allowed 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 121.372 0.606 . . . . 0.0 111.083 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.529 ' CG1' HG23 ' A' ' 124' ' ' ILE . 15.7 t -129.95 141.38 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 109.698 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.536 ' O ' ' HB2' ' A' ' 110' ' ' SER . 4.0 p -107.95 133.13 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 120.945 -1.097 . . . . 0.0 111.205 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.532 ' HB2' HG12 ' A' ' 84' ' ' ILE . 4.8 tp -105.4 143.51 33.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.643 HG12 ' CE2' ' A' ' 77' ' ' TRP . 11.4 t -139.84 129.2 28.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 O-C-N 120.462 -1.399 . . . . 0.0 111.909 -178.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.538 HD11 ' CZ3' ' A' ' 76' ' ' TRP . 11.3 mt -135.42 -172.16 3.01 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.301 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.477 ' O ' ' N ' ' A' ' 45' ' ' SER . 8.0 ptm -100.31 151.96 20.88 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.827 -1.171 . . . . 0.0 110.466 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.451 ' HB2' ' HA2' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -48.14 89.28 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.468 -0.77 . . . . 0.0 111.543 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 43' ' ' MET . 29.6 t -65.1 -88.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.175 -0.953 . . . . 0.0 109.531 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -151.78 -77.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.879 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.485 ' O ' HG12 ' A' ' 51' ' ' ILE . 4.1 mt-10 -96.07 34.28 1.59 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.356 -0.84 . . . . 0.0 110.979 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.761 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.39 -64.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.792 -1.193 . . . . 0.0 111.633 -178.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.48 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -44.58 -38.12 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 118.702 -1.199 . . . . 0.0 108.746 179.354 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.458 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.79 -49.03 19.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.53 -0.732 . . . . 0.0 110.25 178.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.761 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.04 -51.03 28.17 Favored 'Isoleucine or valine' 0 C--O 1.191 -1.995 0 O-C-N 120.703 -1.248 . . . . 0.0 109.313 179.341 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.608 ' HA ' HG21 ' A' ' 55' ' ' ILE . 41.9 mm -45.53 -39.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.097 -1.627 . . . . 0.0 108.155 177.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.561 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 48.1 tt0 -62.72 -63.48 1.2 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -81.62 -8.19 59.68 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.289 -0.882 . . . . 0.0 111.398 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.666 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.7 tp -107.09 -33.72 2.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 CA-C-O 121.776 0.798 . . . . 0.0 110.137 -179.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.582 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 3.0 t -117.88 -44.83 3.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 C-N-CA 120.041 -0.664 . . . . 0.0 112.627 -177.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.561 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -60.69 -36.82 79.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.364 -1.46 . . . . 0.0 109.033 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.8 tmtt? -100.93 -44.67 5.67 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.821 0.819 . . . . 0.0 109.037 178.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -69.2 -52.24 23.75 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.577 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.66 -43.85 73.9 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.822 -1.399 . . . . 0.0 110.155 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.548 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 12.9 ttmt -63.15 9.23 0.05 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.522 -0.987 . . . . 0.0 113.196 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.62 -63.8 1.03 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.225 -1.547 . . . . 0.0 108.854 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.12 -21.43 17.34 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 177.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.578 ' HB3' ' CD1' ' A' ' 67' ' ' ILE . 0.4 OUTLIER -68.61 124.1 89.27 Favored Pre-proline 0 C--N 1.301 -1.514 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.911 -179.648 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.451 ' O ' ' OG ' ' A' ' 66' ' ' SER . 48.7 Cg_endo -65.38 -48.23 3.55 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.093 1.862 . . . . 0.0 111.953 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.476 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 4.8 m -164.49 106.92 0.88 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 123.322 1.534 . . . . 0.0 109.539 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.691 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -100.36 163.69 2.91 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.549 0 CA-C-N 113.358 -1.747 . . . . 0.0 111.384 -176.547 . . . . . . . . 4 4 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.552 ' CG1' ' HG2' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -119.12 160.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.179 -0.951 . . . . 0.0 110.904 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.562 HG21 ' CG2' ' A' ' 52' ' ' ILE . 98.4 t -133.22 107.26 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.448 -0.782 . . . . 0.0 109.59 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.618 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.0 mm-40 -94.41 125.08 38.83 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.344 -0.848 . . . . 0.0 110.543 -179.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -134.45 117.55 16.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.029 -1.044 . . . . 0.0 109.967 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.442 ' O ' ' HG3' ' A' ' 44' ' ' LYS . 0.5 OUTLIER -136.13 161.49 35.56 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.176 -0.953 . . . . 0.0 110.235 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -48.61 106.12 0.09 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 110.11 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.579 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . 71.44 41.73 57.69 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.579 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 49.2 m-85 -160.8 102.52 1.32 Allowed 'General case' 0 C--N 1.29 -2.008 0 O-C-N 121.997 -0.708 . . . . 0.0 110.445 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.704 ' CE2' HG23 ' A' ' 48' ' ' ILE . 12.0 t90 -105.1 73.95 1.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.643 ' CE2' HG12 ' A' ' 41' ' ' VAL . 16.1 m0 -94.44 142.15 27.76 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.525 0.679 . . . . 0.0 111.047 -178.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.61 ' CD1' ' CD1' ' A' ' 76' ' ' TRP . 0.8 OUTLIER -147.25 139.49 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.137 -0.977 . . . . 0.0 109.476 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.552 ' HG2' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -115.97 129.74 56.51 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 110.291 -179.585 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.572 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -110.63 154.64 23.51 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 120.104 -0.638 . . . . 0.0 109.809 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.446 ' HB2' HD13 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -97.94 43.55 1.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.985 -1.072 . . . . 0.0 110.146 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -171.69 -114.89 0.34 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -114.63 165.17 13.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.419 -1.048 . . . . 0.0 109.206 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.532 HG12 ' HB2' ' A' ' 40' ' ' LEU . 4.4 tp -151.05 114.33 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.74 -1.225 . . . . 0.0 111.113 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -74.93 154.64 38.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.378 -0.826 . . . . 0.0 110.232 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.648 HG21 ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -161.01 130.12 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.131 -0.98 . . . . 0.0 110.695 -179.894 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.55 ' N ' HD12 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -128.87 173.61 10.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.888 . . . . 0.0 110.831 -179.964 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.559 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -151.06 -28.86 0.19 Allowed 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.041 178.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.525 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -41.51 -53.51 3.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 0.0 109.722 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.44 -57.41 7.03 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.563 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.45 -30.82 54.03 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.525 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -64.7 -56.2 18.23 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 108.359 -1.897 . . . . 0.0 108.359 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -62.47 -14.37 40.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.478 -1.013 . . . . 0.0 109.469 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.545 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 5.1 tt -75.92 -57.66 3.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.783 . . . . 0.0 109.039 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.631 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -93.72 -35.51 12.76 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.124 179.477 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -160.57 -71.49 0.02 OUTLIER Glycine 0 N--CA 1.491 2.319 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.214 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.561 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 164.95 -59.44 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.552 -0.969 . . . . 0.0 109.848 -179.769 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.0 Cg_endo -68.41 -17.28 44.08 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 124.068 1.562 . . . . 0.0 109.836 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.631 ' CG ' HD12 ' A' ' 95' ' ' LEU . 2.3 t80 -49.14 -50.3 38.2 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.078 -1.049 . . . . 0.0 108.416 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.559 ' HA ' ' CB ' ' A' ' 88' ' ' ALA . 4.5 m -30.23 -57.51 0.19 Allowed 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.703 0.763 . . . . 0.0 111.574 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.641 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 43.7 t -84.07 -54.47 8.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 121.513 -0.742 . . . . 0.0 112.685 -178.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.516 ' HA ' ' HB2' ' A' ' 105' ' ' LEU . 2.0 t80 -51.32 -40.05 58.24 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 119.7 -1.875 . . . . 0.0 107.045 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.541 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 21.6 t70 -57.14 -46.89 82.32 Favored 'General case' 0 N--CA 1.486 1.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.666 178.19 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.641 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 4.2 pp -80.2 -29.3 38.58 Favored 'General case' 0 C--O 1.201 -1.459 0 C-N-CA 117.921 -1.512 . . . . 0.0 108.245 179.109 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.536 ' CD2' HG11 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -49.67 -24.74 2.41 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 120.113 -1.617 . . . . 0.0 109.523 178.49 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.2 mp -103.51 -37.42 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.359 -0.838 . . . . 0.0 110.441 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.535 ' ND2' ' HA ' ' A' ' 104' ' ' LEU . 3.6 p30 -99.52 -13.02 19.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.909 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.576 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 5.2 p -66.7 -8.99 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 109.811 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.9 OUTLIER -39.99 -24.35 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.689 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.56 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 1.2 p -72.92 9.65 1.11 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.138 -0.976 . . . . 0.0 110.51 178.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.518 ' CG2' ' CG2' ' A' ' 108' ' ' VAL . 2.2 p -85.69 26.26 0.98 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.694 -1.254 . . . . 0.0 110.936 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.414 HG11 ' N ' ' A' ' 113' ' ' GLY . 6.9 p -57.05 -18.63 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.968 -1.082 . . . . 0.0 109.375 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.499 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -98.79 50.89 1.21 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.119 -1.592 . . . . 0.0 109.119 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.499 ' C ' ' O ' ' A' ' 113' ' ' GLY . 12.1 ttm180 28.81 95.87 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.494 0.664 . . . . 0.0 111.526 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -74.84 124.85 27.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.41 -0.806 . . . . 0.0 111.147 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' THR . 1.8 t80 -69.72 115.73 9.29 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.3 m -79.0 164.36 24.44 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.081 -1.012 . . . . 0.0 111.553 -178.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.566 ' N ' ' O ' ' A' ' 121' ' ' LYS . 0.2 OUTLIER -144.79 48.88 1.31 Allowed 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.08 -60.6 0.22 Allowed Glycine 0 N--CA 1.483 1.775 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.551 HG21 ' CG ' ' A' ' 121' ' ' LYS . 1.2 t -117.43 -17.87 9.96 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.849 -0.794 . . . . 0.0 111.529 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.566 ' O ' ' N ' ' A' ' 118' ' ' LEU . 13.5 mtmt -122.94 161.4 24.25 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 120.76 -1.212 . . . . 0.0 110.534 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.707 ' CD1' ' N ' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -134.95 162.28 32.87 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.966 -1.084 . . . . 0.0 109.218 178.653 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.492 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.7 OUTLIER -141.8 118.61 11.12 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.915 -1.116 . . . . 0.0 110.599 -178.807 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.53 HD13 ' N ' ' A' ' 124' ' ' ILE . 2.3 mp -87.02 132.84 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.552 -0.718 . . . . 0.0 109.82 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 9.5 t -156.93 159.16 37.84 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.109 -0.995 . . . . 0.0 110.629 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.1 t . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.108 179.911 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 90.5 m-20 . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.03 0.443 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.54 157.94 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.55 -0.719 . . . . 0.0 110.444 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 38' ' ' VAL . 4.5 p -131.56 131.41 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -0.95 . . . . 0.0 110.266 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 110' ' ' SER . 8.9 p -91.29 168.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.298 -0.876 . . . . 0.0 110.495 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.54 ' HB2' HG12 ' A' ' 84' ' ' ILE . 13.7 tp -134.23 134.23 41.78 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.667 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.618 HG23 ' CG ' ' A' ' 77' ' ' TRP . 14.9 t -136.95 127.52 40.32 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 O-C-N 120.462 -1.399 . . . . 0.0 110.707 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.614 ' CB ' ' CE3' ' A' ' 76' ' ' TRP . 1.0 OUTLIER -131.39 -174.03 3.28 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.55 -0.86 . . . . 0.0 108.94 178.923 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.425 ' O ' ' N ' ' A' ' 45' ' ' SER . 3.1 ptm -82.6 157.99 23.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.89 -1.131 . . . . 0.0 110.185 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.498 ' CE ' ' OD1' ' A' ' 46' ' ' ASP . 8.3 ptmt -47.01 94.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 111.259 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.496 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 0.3 OUTLIER -78.08 4.24 12.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.297 -0.877 . . . . 0.0 110.387 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.509 ' N ' HD12 ' A' ' 48' ' ' ILE . 35.1 m-20 64.2 -67.95 0.1 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.52 -0.738 . . . . 0.0 112.681 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.508 ' O ' HD11 ' A' ' 51' ' ' ILE . 1.5 mt-10 -80.33 16.71 1.22 Allowed 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.866 -1.146 . . . . 0.0 112.555 -177.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.784 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -65.41 -68.24 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 120.531 -1.356 . . . . 0.0 111.438 -179.303 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.548 ' C ' ' O ' ' A' ' 48' ' ' ILE . 12.8 t70 -38.5 -31.61 0.06 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 119.048 -1.061 . . . . 0.0 108.635 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.25 -56.57 4.25 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.612 -0.68 . . . . 0.0 109.765 178.051 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.784 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.02 -43.19 67.79 Favored 'Isoleucine or valine' 0 C--O 1.195 -1.786 0 O-C-N 120.903 -1.123 . . . . 0.0 109.873 179.533 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.578 ' HA ' ' CG2' ' A' ' 56' ' ' VAL . 50.3 mm -52.9 -47.69 52.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.804 0 O-C-N 119.668 -1.895 . . . . 0.0 107.226 177.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.699 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.1 tm-20 -57.61 -57.29 13.37 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.37 -0.831 . . . . 0.0 110.389 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -78.3 -20.33 51.74 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.335 -0.853 . . . . 0.0 112.667 -178.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.586 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 mm -106.17 -30.45 2.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 O-C-N 120.983 -1.073 . . . . 0.0 110.903 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.578 ' CG2' ' HA ' ' A' ' 52' ' ' ILE . 17.2 t -115.24 -42.15 3.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.699 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -68.17 -31.12 70.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.517 -1.365 . . . . 0.0 109.152 -179.89 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.516 ' N ' HD11 ' A' ' 57' ' ' LEU . 6.0 mttt -107.58 -43.89 4.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.429 -0.794 . . . . 0.0 109.483 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.69 -43.5 6.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.578 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.61 -64.7 2.84 Favored Glycine 0 N--CA 1.491 2.343 0 O-C-N 121.091 -1.241 . . . . 0.0 110.155 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.57 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.3 OUTLIER -59.73 3.51 0.05 Allowed 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.575 -0.956 . . . . 0.0 112.681 -179.506 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -55.32 -64.25 0.9 Allowed 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.657 -1.277 . . . . 0.0 109.02 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -90.72 -23.29 20.74 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.073 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.578 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 3.0 m-20 -69.0 134.8 89.65 Favored Pre-proline 0 C--N 1.3 -1.587 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.672 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -63.0 -45.32 13.04 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.111 1.874 . . . . 0.0 111.299 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.44 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.2 OUTLIER 179.12 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.307 0 CA-C-O 122.999 1.38 . . . . 0.0 109.916 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.635 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.297 1.2 mp -101.48 140.2 20.77 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.475 0 CA-C-N 113.911 -1.495 . . . . 0.0 111.415 -177.361 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.576 ' CB ' ' HB3' ' A' ' 79' ' ' LYS . 1.2 t -96.73 132.9 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.785 . . . . 0.0 109.814 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.54 ' CG1' HG22 ' A' ' 52' ' ' ILE . 58.3 t -114.23 92.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.184 -0.948 . . . . 0.0 110.341 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.629 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.0 mm-40 -87.39 73.04 9.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.456 -0.777 . . . . 0.0 110.135 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . 0.483 ' OD2' ' HB2' ' A' ' 49' ' ' ASP . 52.8 t0 -81.91 122.44 27.75 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.936 -1.103 . . . . 0.0 110.637 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.1 OUTLIER -132.76 135.86 45.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.733 179.564 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.08 -26.57 0.16 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.145 -0.972 . . . . 0.0 109.964 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . -80.76 -50.23 5.35 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -144.61 157.96 43.98 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.772 -0.84 . . . . 0.0 110.294 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.681 ' CD2' HG22 ' A' ' 48' ' ' ILE . 1.6 t90 -109.81 85.95 2.2 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.629 ' HB2' ' HB2' ' A' ' 70' ' ' GLU . 7.2 m0 -85.15 124.51 31.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.459 -0.776 . . . . 0.0 110.958 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.579 ' CG1' ' NE1' ' A' ' 76' ' ' TRP . 3.0 mm -115.93 160.19 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.014 178.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.576 ' HB3' ' CB ' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -140.69 143.72 35.23 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.899 -1.125 . . . . 0.0 110.359 -178.97 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.469 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.03 139.59 19.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.301 -0.875 . . . . 0.0 109.521 179.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -92.98 58.54 2.98 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.09 -1.006 . . . . 0.0 110.091 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -168.89 -164.69 25.03 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.03 129.84 40.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -1.142 . . . . 0.0 109.889 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.54 HG12 ' HB2' ' A' ' 40' ' ' LEU . 3.8 tp -125.02 159.99 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.383 -0.823 . . . . 0.0 110.177 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.504 ' N ' HG13 ' A' ' 84' ' ' ILE . 12.3 mt-10 -131.29 157.19 43.98 Favored 'General case' 0 C--N 1.307 -1.241 0 O-C-N 121.006 -1.058 . . . . 0.0 111.515 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.702 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -128.97 159.32 41.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.698 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.465 ' OD2' ' CG ' ' A' ' 121' ' ' LYS . 5.3 m-20 -156.05 154.91 31.75 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.645 -1.284 . . . . 0.0 111.594 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.565 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -151.83 -24.28 0.19 Allowed 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.355 -0.938 . . . . 0.0 111.49 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.516 ' HA ' ' OG ' ' A' ' 100' ' ' SER . . . -41.16 -51.83 3.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.009 -1.057 . . . . 0.0 110.303 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 94' ' ' LEU . 8.8 tt0 -48.51 -37.58 17.95 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.893 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.668 ' CB ' ' CE1' ' A' ' 99' ' ' PHE . . . -86.39 -53.18 5.15 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.549 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -50.15 -40.08 35.89 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.505 ' HG3' ' O ' ' A' ' 89' ' ' ALA . 9.6 mt-10 -75.52 -33.38 60.72 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.575 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 1.5 tt -51.27 -66.91 0.3 Allowed 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 177.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.598 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.3 OUTLIER -76.42 -59.2 2.87 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.302 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 112.3 14.7 10.44 Favored Glycine 0 N--CA 1.497 2.715 0 C-N-CA 119.021 -1.561 . . . . 0.0 109.936 178.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.584 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 0.4 OUTLIER -104.57 -166.96 0.11 Allowed Pre-proline 0 C--N 1.294 -1.835 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.343 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.584 ' HD2' ' CB ' ' A' ' 97' ' ' LYS . 38.4 Cg_endo -66.83 -0.96 5.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 N-CA-C 109.458 -1.016 . . . . 0.0 109.458 177.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.668 ' CE1' ' CB ' ' A' ' 91' ' ' ALA . 18.8 t80 -35.54 -65.54 0.24 Allowed 'General case' 0 C--N 1.314 -0.97 0 O-C-N 121.699 -0.626 . . . . 0.0 110.908 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.565 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 0.3 OUTLIER -29.81 -73.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.037 0.922 . . . . 0.0 111.353 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.649 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 29.9 t -77.22 -50.41 20.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.328 -0.857 . . . . 0.0 113.254 -178.145 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.571 ' CD1' ' HB2' ' A' ' 98' ' ' PRO . 3.7 m-85 -51.72 -43.07 62.71 Favored 'General case' 0 C--N 1.292 -1.899 0 O-C-N 119.704 -1.872 . . . . 0.0 108.15 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.569 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 13.8 t70 -60.4 -40.05 89.53 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.592 -0.692 . . . . 0.0 110.421 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.649 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 4.3 pp -82.36 -39.8 22.26 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 117.816 -1.554 . . . . 0.0 109.04 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.567 ' N ' ' CD1' ' A' ' 104' ' ' LEU . 56.3 mt -51.94 -19.71 1.94 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.824 -1.172 . . . . 0.0 110.459 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.405 ' N ' HD11 ' A' ' 106' ' ' ILE . 1.3 mp -102.44 -42.75 8.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.148 -0.97 . . . . 0.0 109.864 -179.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 4.7 p30 -88.03 -13.18 42.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.287 -0.883 . . . . 0.0 110.141 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.577 ' O ' ' N ' ' A' ' 110' ' ' SER . 2.6 t -64.48 -5.88 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.923 -1.11 . . . . 0.0 110.195 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.461 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.49 -28.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.9 -0.5 . . . . 0.0 111.978 -179.567 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.577 ' N ' ' O ' ' A' ' 108' ' ' VAL . 35.1 p -75.3 15.88 0.4 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.77 -1.206 . . . . 0.0 110.581 178.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.547 ' O ' ' N ' ' A' ' 113' ' ' GLY . 0.0 OUTLIER -58.06 -66.61 0.45 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 118.389 -1.325 . . . . 0.0 109.881 -179.032 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 111' ' ' THR . 4.9 t 63.23 -67.32 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.476 -0.765 . . . . 0.0 110.024 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -93.82 51.81 2.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.506 ' CG ' ' N ' ' A' ' 115' ' ' ALA . 0.5 OUTLIER 47.01 176.33 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 O-C-N 121.579 -0.953 . . . . 0.0 111.016 179.162 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.649 ' CB ' ' CE2' ' A' ' 122' ' ' PHE . . . -148.9 115.57 5.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.893 -1.13 . . . . 0.0 111.229 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.406 ' O ' ' HB ' ' A' ' 123' ' ' THR . 0.2 OUTLIER -76.26 112.53 12.84 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.334 -0.854 . . . . 0.0 108.887 178.678 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.3 m -79.49 125.12 29.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.072 -1.017 . . . . 0.0 110.851 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.525 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -92.3 50.34 1.62 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.412 -0.805 . . . . 0.0 110.042 179.38 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.4 -58.73 0.18 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 118' ' ' LEU . 18.4 p -115.72 -8.83 12.0 Favored 'General case' 0 C--N 1.291 -1.94 0 O-C-N 122.009 -0.701 . . . . 0.0 110.613 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.465 ' CG ' ' OD2' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -122.95 -170.53 2.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.048 -1.033 . . . . 0.0 111.836 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.702 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.269 1.8 t80 -139.33 147.16 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.078 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.491 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.9 OUTLIER -139.77 121.66 15.54 Favored 'General case' 0 C--N 1.308 -1.238 0 O-C-N 120.506 -1.371 . . . . 0.0 110.543 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.535 ' HB ' ' CG2' ' A' ' 84' ' ' ILE . 3.9 mp -118.09 142.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 109.939 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 1.8 t -144.93 136.93 25.82 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.083 -1.011 . . . . 0.0 110.421 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.27 -0.894 . . . . 0.0 110.492 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.461 ' O ' ' HB2' ' A' ' 126' ' ' SER . 35.3 m120 . . . . . 0 N--CA 1.492 1.657 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.46 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.29 143.81 0.12 Allowed 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.169 -0.957 . . . . 0.0 110.541 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.542 ' CG2' HG23 ' A' ' 124' ' ' ILE . 3.4 p -108.36 137.26 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.182 -0.949 . . . . 0.0 110.484 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.542 ' CG1' ' HB2' ' A' ' 110' ' ' SER . 5.8 p -112.74 136.2 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.067 -1.021 . . . . 0.0 110.491 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.511 ' CD1' ' CD1' ' A' ' 86' ' ' ILE . 11.0 tp -105.17 141.75 36.17 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.634 HG12 ' CE2' ' A' ' 77' ' ' TRP . 2.3 t -143.19 127.24 14.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 118.248 -1.381 . . . . 0.0 112.072 -177.277 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.639 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 2.7 mm? -129.48 -168.46 1.95 Allowed 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.009 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.48 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -103.33 167.43 9.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.071 179.254 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.03 103.29 0.05 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.277 -0.89 . . . . 0.0 110.812 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.524 ' HB3' ' CD1' ' A' ' 48' ' ' ILE . 18.9 t -87.74 -116.76 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.272 -0.892 . . . . 0.0 109.985 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.401 ' N ' ' OG ' ' A' ' 45' ' ' SER . 9.9 m-20 -142.11 -76.66 0.27 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.618 -1.301 . . . . 0.0 110.83 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.498 ' HB2' HG22 ' A' ' 51' ' ' ILE . 2.3 mt-10 -95.09 35.57 1.27 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.361 -0.837 . . . . 0.0 110.155 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.774 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.77 -66.45 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.251 -0.906 . . . . 0.0 111.274 -179.171 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -41.25 -40.57 1.65 Allowed 'General case' 0 C--N 1.284 -2.271 0 C-N-CA 119.106 -1.038 . . . . 0.0 108.96 179.213 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' N ' ' OD1' ' A' ' 49' ' ' ASP . . . -74.57 -50.35 18.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.592 -0.692 . . . . 0.0 110.401 178.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.774 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -72.12 -49.64 42.27 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.079 0 O-C-N 120.553 -1.342 . . . . 0.0 109.488 179.454 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.611 ' HA ' HG21 ' A' ' 55' ' ' ILE . 40.3 mm -46.59 -38.07 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.028 -1.67 . . . . 0.0 108.246 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.564 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 0.6 OUTLIER -64.3 -62.81 1.37 Allowed 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.105 -0.997 . . . . 0.0 110.082 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -79.75 -11.28 59.85 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.367 -0.833 . . . . 0.0 111.435 -179.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.687 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.2 tp -106.05 -33.38 2.79 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.034 0 CA-C-O 121.631 0.729 . . . . 0.0 110.546 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.597 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 3.8 t -117.65 -44.56 3.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.499 -0.75 . . . . 0.0 112.479 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.564 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.5 OUTLIER -61.77 -40.83 96.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.264 -1.523 . . . . 0.0 108.542 179.964 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.46 ' N ' HD21 ' A' ' 57' ' ' LEU . 2.4 mtpt -92.37 -43.21 9.36 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.521 0.677 . . . . 0.0 109.426 178.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -75.15 -50.78 8.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.28 -59.99 5.43 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.635 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.585 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -64.99 10.31 0.08 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.56 -0.965 . . . . 0.0 112.636 -179.508 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.39 -63.98 0.95 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.453 -1.404 . . . . 0.0 108.661 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -100.35 -17.83 17.06 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.585 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 1.4 m-20 -67.99 136.88 92.03 Favored Pre-proline 0 C--N 1.301 -1.533 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.684 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -62.19 -42.81 26.93 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 122.54 2.16 . . . . 0.0 112.521 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.444 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.33 112.91 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 123.1 1.429 . . . . 0.0 110.125 -179.811 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.649 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.302 1.2 mp -101.65 147.79 8.13 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 CA-C-N 113.766 -1.561 . . . . 0.0 111.577 -177.143 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.564 ' CG1' ' HB3' ' A' ' 79' ' ' LYS . 1.6 p -110.87 153.13 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.41 -0.806 . . . . 0.0 110.275 179.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.518 ' CG2' HG22 ' A' ' 52' ' ' ILE . 89.2 t -118.25 104.82 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.244 -0.91 . . . . 0.0 109.6 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.55 ' N ' ' O ' ' A' ' 77' ' ' TRP . 0.9 OUTLIER -84.05 65.2 8.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.44 -0.787 . . . . 0.0 110.729 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.24 117.24 29.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.97 -1.081 . . . . 0.0 110.249 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 5.4 tttt -146.96 143.49 28.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 110.171 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.04 96.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 109.991 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 151.64 -58.11 0.43 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.47 ' HB2' ' CD1' ' A' ' 77' ' ' TRP . 2.3 p90 -141.08 163.01 34.14 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.926 -0.749 . . . . 0.0 110.457 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.727 ' CE2' HG23 ' A' ' 48' ' ' ILE . 2.5 t90 -118.03 75.63 1.02 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.634 ' CE2' HG12 ' A' ' 41' ' ' VAL . 21.0 m0 -95.82 149.06 21.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.606 -0.684 . . . . 0.0 111.674 -178.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.53 ' CD1' ' NE1' ' A' ' 76' ' ' TRP . 1.2 mp -146.87 130.31 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.563 -0.711 . . . . 0.0 109.151 178.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.564 ' HB3' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -95.89 160.77 14.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.315 -0.866 . . . . 0.0 110.515 -179.123 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.483 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -150.14 141.46 23.25 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.535 -0.728 . . . . 0.0 109.905 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -107.33 50.41 0.77 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.81 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.28 -110.85 0.24 Allowed Glycine 0 C--N 1.301 -1.368 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -123.67 143.41 50.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.315 -1.109 . . . . 0.0 110.02 179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.557 HG13 ' N ' ' A' ' 85' ' ' GLU . 2.8 tp -142.82 160.66 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 109.876 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.557 ' N ' HG13 ' A' ' 84' ' ' ILE . 45.1 mt-10 -129.67 122.69 29.47 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.022 -1.049 . . . . 0.0 111.753 -179.119 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.615 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.6 OUTLIER -79.61 165.4 2.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 121.641 -0.662 . . . . 0.0 109.648 179.484 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 6.2 m-20 -155.89 139.43 15.92 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.763 -1.211 . . . . 0.0 111.549 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.565 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -152.47 -33.09 0.13 Allowed 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.753 177.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.535 ' HA ' ' CB ' ' A' ' 100' ' ' SER . . . -44.09 -52.62 7.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -0.844 . . . . 0.0 110.125 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.492 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 1.3 pt-20 -57.99 -44.5 87.21 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.534 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.13 -34.65 78.54 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.532 -0.73 . . . . 0.0 109.303 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.51 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -69.24 -56.87 8.17 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.492 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.3 pt-20 -54.65 -19.56 6.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.403 -1.057 . . . . 0.0 109.368 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.53 HD21 ' HG ' ' A' ' 95' ' ' LEU . 5.4 tt -78.81 -61.8 1.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.69 -0.631 . . . . 0.0 110.527 -179.441 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.617 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -77.62 -45.1 26.11 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 118.35 -1.34 . . . . 0.0 109.086 179.289 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.481 ' O ' ' HB2' ' A' ' 97' ' ' LYS . . . -145.76 -75.21 0.02 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.555 ' N ' ' HD2' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 166.46 -55.88 0.0 OUTLIER Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.883 -0.775 . . . . 0.0 109.407 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.555 ' HD2' ' N ' ' A' ' 97' ' ' LYS . 46.8 Cg_endo -73.14 -21.19 20.69 Favored 'Trans proline' 0 C--N 1.307 -1.614 0 O-C-N 124.167 1.614 . . . . 0.0 110.515 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.617 ' CG ' HD12 ' A' ' 95' ' ' LEU . 2.8 t80 -50.06 -50.04 49.22 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.009 -1.057 . . . . 0.0 109.626 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.565 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 16.7 p -31.53 -68.76 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-O 121.875 0.845 . . . . 0.0 111.216 -179.241 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.579 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 1.7 t -69.41 -56.16 12.69 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 O-C-N 121.189 -0.945 . . . . 0.0 113.238 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.503 ' N ' HG11 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -50.1 -31.92 14.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.356 -1.465 . . . . 0.0 109.345 -178.865 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.573 ' OD2' ' CE2' ' A' ' 99' ' ' PHE . 5.6 t70 -76.61 -28.83 56.26 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.673 ' HG ' ' N ' ' A' ' 105' ' ' LEU . 0.0 OUTLIER -65.81 -48.74 70.7 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.16 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.673 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 1.4 mt -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.674 -1.266 . . . . 0.0 110.042 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.45 -22.78 5.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.555 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.5 p30 -108.39 -28.76 9.2 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.178 -0.951 . . . . 0.0 110.802 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.583 ' CG2' ' CG2' ' A' ' 111' ' ' THR . 1.6 p -70.75 0.7 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.82 -1.175 . . . . 0.0 110.719 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -36.4 -26.92 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.47 -0.769 . . . . 0.0 112.0 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.575 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . 87.7 p -78.69 32.37 0.2 Allowed 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.758 -1.214 . . . . 0.0 110.595 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.583 ' CG2' ' CG2' ' A' ' 108' ' ' VAL . 25.4 p -94.77 44.42 1.1 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.682 -1.261 . . . . 0.0 109.323 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 28.3 m -60.54 -37.43 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.595 -0.691 . . . . 0.0 110.804 -179.252 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.438 ' HA3' ' O ' ' A' ' 125' ' ' THR . . . -76.17 -75.15 0.89 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.423 ' HB2' HG21 ' A' ' 125' ' ' THR . 3.3 ttt85 -145.13 -170.75 3.5 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.312 -1.111 . . . . 0.0 110.428 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.564 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -165.88 75.0 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.035 -1.041 . . . . 0.0 110.55 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.487 ' O ' ' N ' ' A' ' 123' ' ' THR . 0.1 OUTLIER -81.41 121.5 26.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.282 -0.886 . . . . 0.0 109.644 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.7 m -83.89 156.39 22.42 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.228 -0.92 . . . . 0.0 110.62 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.526 ' O ' ' N ' ' A' ' 120' ' ' THR . 7.3 mp -127.91 38.5 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.357 -0.839 . . . . 0.0 110.257 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.2 -59.5 0.41 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.824 -1.711 . . . . 0.0 108.824 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.526 ' N ' ' O ' ' A' ' 118' ' ' LEU . 58.4 p -115.14 -12.71 11.87 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 122.031 -0.687 . . . . 0.0 109.824 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.483 ' CB ' ' HB2' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -121.59 -167.12 1.47 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.43 -0.794 . . . . 0.0 110.633 -179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.655 ' CD2' ' CD1' ' A' ' 104' ' ' LEU . 16.0 t80 -153.86 164.22 38.74 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.519 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.564 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.6 OUTLIER -150.08 153.06 35.78 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.39 -1.444 . . . . 0.0 110.275 -179.154 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.593 ' N ' ' CD1' ' A' ' 124' ' ' ILE . 2.2 mp -141.38 145.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.51 -0.744 . . . . 0.0 109.181 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.438 ' O ' ' HA3' ' A' ' 113' ' ' GLY . 11.0 t -138.86 174.21 10.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.89 -1.131 . . . . 0.0 110.534 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.461 ' HB2' ' O ' ' A' ' 36' ' ' ASN . 69.2 p . . . . . 0 C--N 1.304 -1.397 0 O-C-N 121.319 -0.863 . . . . 0.0 110.423 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.437 ' O ' ' C ' ' A' ' 37' ' ' ALA . 1.8 m-20 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.222 0.534 . . . . 0.0 110.304 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.437 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.7 143.52 0.15 Allowed 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.518 -0.739 . . . . 0.0 110.774 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.468 HG12 ' O ' ' A' ' 125' ' ' THR . 22.9 m -124.54 -174.71 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.226 -0.922 . . . . 0.0 110.373 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.485 ' HA ' ' HA ' ' A' ' 79' ' ' LYS . 3.0 p -148.34 127.54 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.238 -0.914 . . . . 0.0 110.844 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.499 ' CG ' HG12 ' A' ' 84' ' ' ILE . 0.2 OUTLIER -88.99 127.75 35.68 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 177.817 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.602 HG12 ' CE2' ' A' ' 77' ' ' TRP . 2.7 t -121.43 117.05 51.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.883 -1.127 . . . . 0.0 111.435 -178.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.642 ' HB2' ' CE3' ' A' ' 76' ' ' TRP . 0.6 OUTLIER -119.64 159.35 24.58 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.41 -0.916 . . . . 0.0 109.475 178.254 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.506 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 9.5 ptm -92.8 27.21 2.44 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.82 -1.175 . . . . 0.0 111.381 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.562 ' CB ' HD12 ' A' ' 48' ' ' ILE . 4.1 mmtp -86.81 -90.12 0.11 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.249 -0.907 . . . . 0.0 110.408 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.547 ' HB3' ' N ' ' A' ' 75' ' ' PHE . 1.4 p 77.37 57.96 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 CA-C-O 121.877 0.846 . . . . 0.0 110.978 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.472 ' OD1' ' O ' ' A' ' 45' ' ' SER . 0.2 OUTLIER -161.58 -91.44 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.53 ' O ' HD12 ' A' ' 51' ' ' ILE . 2.1 mt-10 -54.38 -27.41 36.24 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.281 -0.887 . . . . 0.0 111.351 179.109 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.893 ' HA ' ' CD1' ' A' ' 51' ' ' ILE . 0.4 OUTLIER -74.85 -51.38 22.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 118.397 -1.321 . . . . 0.0 112.971 -176.781 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.528 ' C ' ' O ' ' A' ' 48' ' ' ILE . 14.4 t70 -42.96 -29.97 0.38 Allowed 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.366 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.44 -54.89 5.48 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.847 177.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.893 ' CD1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -66.9 -47.82 81.44 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.158 0 C-N-CA 117.844 -1.543 . . . . 0.0 108.226 178.773 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.59 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 45.1 mm -43.05 -40.99 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 120.374 -1.454 . . . . 0.0 107.86 176.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.616 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 2.4 tt0 -62.87 -67.7 0.4 Allowed 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.307 -0.871 . . . . 0.0 110.141 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.422 ' O ' ' OD1' ' A' ' 54' ' ' ASP . 37.0 t0 -75.72 -9.86 58.95 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 121.093 -1.004 . . . . 0.0 111.723 -178.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.684 ' N ' ' O ' ' A' ' 51' ' ' ILE . 3.9 tp -107.54 -34.63 2.81 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 CA-C-O 121.588 0.709 . . . . 0.0 111.224 -178.459 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.59 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 3.5 t -117.19 -42.91 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.553 -0.717 . . . . 0.0 112.45 -177.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.616 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 10.5 tt -42.2 -55.93 3.09 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.827 -1.17 . . . . 0.0 108.943 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.535 ' O ' ' CG ' ' A' ' 61' ' ' LYS . 1.0 OUTLIER -89.73 -49.19 6.79 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.317 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -48.91 -49.91 27.98 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.519 ' HA2' ' HB2' ' A' ' 64' ' ' ASN . . . -83.87 22.38 8.11 Favored Glycine 0 N--CA 1.489 2.215 0 O-C-N 121.181 -1.188 . . . . 0.0 110.185 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.535 ' CG ' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -106.44 -9.4 16.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.697 -1.472 . . . . 0.0 110.769 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.98 -84.66 0.33 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 121.098 -1.001 . . . . 0.0 110.156 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -71.03 -32.25 68.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 122.211 1.005 . . . . 0.0 108.742 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.519 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 0.5 OUTLIER -73.38 118.91 72.79 Favored Pre-proline 0 C--N 1.296 -1.733 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 179.65 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.45 ' HG2' ' HB2' ' A' ' 81' ' ' ASP . 45.6 Cg_endo -63.96 -43.42 15.82 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 124.146 1.603 . . . . 0.0 111.053 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.43 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.1 OUTLIER 178.76 112.09 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 CA-C-O 122.944 1.354 . . . . 0.0 109.751 179.477 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.638 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.292 1.2 mp -102.7 132.12 49.48 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.488 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.208 -177.359 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.55 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -92.11 116.16 32.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.863 179.501 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.517 ' CG2' ' CG2' ' A' ' 52' ' ' ILE . 67.5 t -94.88 96.99 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.146 -0.971 . . . . 0.0 110.012 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.609 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.1 mm-40 -91.51 143.15 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.298 -0.876 . . . . 0.0 110.455 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -139.78 108.91 6.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 109.795 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.71 -166.81 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.266 -0.897 . . . . 0.0 110.795 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.522 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -53.29 107.54 0.25 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 0.0 110.396 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 42.81 44.7 5.63 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.547 ' N ' ' HB3' ' A' ' 45' ' ' SER . 7.3 m-85 -144.45 86.45 1.82 Allowed 'General case' 0 C--N 1.292 -1.895 0 O-C-N 121.871 -0.781 . . . . 0.0 111.378 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.723 ' CE2' ' CG2' ' A' ' 48' ' ' ILE . 1.2 t90 -81.55 88.19 6.21 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.058 -1.026 . . . . 0.0 108.597 178.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.609 ' HB2' ' HB2' ' A' ' 70' ' ' GLU . 8.1 m0 -90.6 124.67 35.23 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.376 -0.828 . . . . 0.0 111.04 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.612 ' CG1' ' NE1' ' A' ' 76' ' ' TRP . 13.8 mm -117.41 141.87 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.042 . . . . 0.0 110.16 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.55 ' HG2' ' HB ' ' A' ' 68' ' ' VAL . 1.1 ttpt -122.58 122.13 38.13 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.581 -0.7 . . . . 0.0 109.675 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -129.32 143.54 50.88 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.336 -0.853 . . . . 0.0 110.036 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.45 ' HB2' ' HG2' ' A' ' 65' ' ' PRO . 67.6 m-20 -88.18 49.81 1.87 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.057 -1.027 . . . . 0.0 109.956 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.35 -162.77 23.25 Favored Glycine 0 C--N 1.302 -1.357 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -72.6 154.36 40.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.183 -1.186 . . . . 0.0 109.791 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.521 HG13 ' N ' ' A' ' 85' ' ' GLU . 3.0 tp -137.11 156.03 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.941 . . . . 0.0 110.235 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.521 ' N ' HG13 ' A' ' 84' ' ' ILE . 91.0 mt-10 -121.89 155.44 35.43 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.182 -0.949 . . . . 0.0 110.99 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.64 ' CG2' ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -161.33 147.15 4.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.573 -0.704 . . . . 0.0 109.792 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.515 ' N ' HD11 ' A' ' 86' ' ' ILE . 3.5 m-20 -124.65 176.53 6.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.095 -1.003 . . . . 0.0 111.544 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.654 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -140.05 -14.28 1.04 Allowed 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.991 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.503 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -48.24 -45.86 34.82 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.664 -1.273 . . . . 0.0 110.971 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.558 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 18.2 tt0 -50.48 -36.15 32.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.551 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.563 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -68.17 -31.22 70.61 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.035 -1.041 . . . . 0.0 108.876 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.741 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -68.74 -61.4 4.7 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 108.599 -1.8 . . . . 0.0 108.599 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.558 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 6.0 pt-20 -45.4 -27.97 0.79 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.226 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.532 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 0.7 OUTLIER -68.59 -70.9 0.24 Allowed 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.341 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.563 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 0.0 OUTLIER -98.86 -46.46 5.63 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.021 -1.05 . . . . 0.0 109.224 178.99 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 93.44 51.84 2.11 Favored Glycine 0 N--CA 1.499 2.861 0 C-N-CA 120.185 -1.007 . . . . 0.0 111.538 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.694 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 30.8 pttt -145.46 -135.6 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 O-C-N 120.914 -1.345 . . . . 0.0 109.37 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.694 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.3 Cg_endo -71.7 0.17 7.42 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 CA-C-N 121.077 1.42 . . . . 0.0 108.989 178.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.796 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.8 p90 -25.62 -41.34 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 CA-C-O 121.823 0.821 . . . . 0.0 111.698 178.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.796 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -55.96 -62.39 1.73 Allowed 'General case' 0 C--N 1.292 -1.895 0 CA-C-O 123.368 1.556 . . . . 0.0 108.62 -177.073 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.567 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 24.2 t -88.26 -42.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 CA-C-N 114.558 -1.201 . . . . 0.0 113.021 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.485 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 5.0 t80 -52.02 -43.11 63.55 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 119.91 -1.744 . . . . 0.0 107.426 178.264 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.579 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 18.5 t70 -61.41 -47.95 83.46 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.687 -0.633 . . . . 0.0 110.065 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 122' ' ' PHE . 4.5 pp -74.27 -41.16 61.68 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 116.655 -2.018 . . . . 0.0 109.738 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.534 HD13 ' CG1' ' A' ' 101' ' ' VAL . 39.2 mt -51.32 -19.23 1.21 Allowed 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.481 -1.387 . . . . 0.0 110.654 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.461 HD12 ' O ' ' A' ' 102' ' ' TYR . 0.6 OUTLIER -93.71 -49.59 12.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.123 -0.985 . . . . 0.0 110.403 -178.826 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.525 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.7 OUTLIER -100.19 -11.28 20.56 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.077 -1.014 . . . . 0.0 111.471 -179.249 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.56 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 5.9 p -65.2 -6.54 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.302 -1.498 . . . . 0.0 109.947 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -33.78 -31.52 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.728 -0.607 . . . . 0.0 112.028 -179.505 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.557 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . 28.8 p -84.69 27.89 0.7 Allowed 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 118.877 -1.129 . . . . 0.0 109.348 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.56 ' N ' ' O ' ' A' ' 108' ' ' VAL . 9.6 t -64.64 -35.9 82.51 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 110.644 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.502 ' N ' HG21 ' A' ' 111' ' ' THR . 61.8 t 52.61 -88.6 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.724 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -86.15 54.97 4.76 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.246 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.535 ' CG ' ' N ' ' A' ' 115' ' ' ALA . 1.8 ttt180 45.54 176.8 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.747 -0.855 . . . . 0.0 111.444 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.535 ' N ' ' CG ' ' A' ' 114' ' ' ARG . . . -130.01 114.11 15.4 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.995 -1.066 . . . . 0.0 110.725 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.454 ' HB2' HG21 ' A' ' 123' ' ' THR . 25.7 m-85 -69.7 121.14 16.58 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.34 -0.85 . . . . 0.0 108.829 178.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 6.2 m -79.3 178.55 8.0 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.192 -0.943 . . . . 0.0 110.734 -178.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.597 ' O ' ' N ' ' A' ' 120' ' ' THR . 1.3 tt -156.9 60.56 0.52 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.448 -0.783 . . . . 0.0 110.431 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.44 -57.44 0.05 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.057 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 118' ' ' LEU . 15.7 p -115.89 -26.97 7.15 Favored 'General case' 0 C--N 1.292 -1.925 0 O-C-N 121.64 -0.917 . . . . 0.0 111.772 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.576 ' O ' ' N ' ' A' ' 118' ' ' LEU . 1.5 pttm -132.07 -169.57 2.24 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.831 -1.168 . . . . 0.0 110.991 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.64 ' CE2' ' CG2' ' A' ' 86' ' ' ILE . 0.5 OUTLIER -149.21 -179.12 6.8 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.264 -0.897 . . . . 0.0 109.12 179.124 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.527 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 1.1 t -155.62 165.67 35.86 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.755 -1.215 . . . . 0.0 110.186 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.597 ' N ' ' CD1' ' A' ' 124' ' ' ILE . 4.0 mp -134.09 144.13 36.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.336 -0.852 . . . . 0.0 110.466 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.468 ' O ' HG12 ' A' ' 38' ' ' VAL . 11.9 t -123.25 -170.09 2.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.325 -0.859 . . . . 0.0 110.201 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.443 ' HB2' HG11 ' A' ' 38' ' ' VAL . 2.8 t . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.179 -0.951 . . . . 0.0 110.473 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.502 ' OD1' ' N ' ' A' ' 36' ' ' ASN . 15.1 p-10 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.444 0.64 . . . . 0.0 110.454 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.462 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.94 106.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.229 0.538 . . . . 0.0 111.284 -179.341 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.5 HG21 ' N ' ' A' ' 39' ' ' VAL . 4.1 p -125.84 149.79 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.317 -0.864 . . . . 0.0 109.504 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.5 ' N ' HG21 ' A' ' 38' ' ' VAL . 13.7 p -105.82 142.44 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.01 -1.056 . . . . 0.0 111.108 -179.421 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.59 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 8.1 tp -100.93 162.07 13.15 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 177.468 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.608 HG12 ' CE2' ' A' ' 77' ' ' TRP . 3.0 t -165.77 132.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 120.658 -1.276 . . . . 0.0 111.665 -178.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.634 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 0.3 OUTLIER -143.06 -171.69 3.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.19 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 7.2 ptt? -98.45 153.29 18.7 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.798 -1.189 . . . . 0.0 109.899 179.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.488 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -53.13 95.65 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 0.0 110.982 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.468 ' HB3' HG22 ' A' ' 48' ' ' ILE . 30.5 t -72.89 -92.1 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.297 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 36.1 t0 -157.95 -70.3 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.157 -0.964 . . . . 0.0 110.401 179.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.479 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.8 mt-10 -96.45 36.13 1.4 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.283 -0.885 . . . . 0.0 110.412 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.771 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -56.02 -64.34 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.997 -1.064 . . . . 0.0 111.624 -178.772 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.473 ' O ' ' HB2' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -45.44 -34.75 3.3 Favored 'General case' 0 C--N 1.285 -2.218 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.768 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.29 -49.88 12.84 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.473 -0.767 . . . . 0.0 110.341 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.771 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -71.66 -48.44 52.08 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.092 0 O-C-N 120.711 -1.243 . . . . 0.0 108.958 179.127 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.6 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 35.1 mm -46.97 -40.89 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.068 -1.645 . . . . 0.0 107.912 177.106 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.545 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 7.5 tt0 -61.69 -62.43 1.81 Allowed 'General case' 0 C--N 1.293 -1.855 0 O-C-N 121.163 -0.961 . . . . 0.0 110.575 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -80.2 -12.6 59.62 Favored 'General case' 0 N--CA 1.502 2.145 0 O-C-N 121.451 -0.781 . . . . 0.0 111.616 -178.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.666 ' N ' ' O ' ' A' ' 51' ' ' ILE . 3.8 tp -106.09 -33.27 2.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 CA-C-O 121.672 0.749 . . . . 0.0 110.659 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.6 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 14.4 t -116.57 -43.91 3.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 C-N-CA 119.91 -0.716 . . . . 0.0 112.439 -177.41 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.545 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -63.35 -35.92 81.99 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.28 -1.513 . . . . 0.0 108.937 179.978 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.528 ' N ' HD21 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -94.77 -47.53 6.43 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.439 -0.788 . . . . 0.0 109.344 179.189 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.49 -45.05 8.19 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.589 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.07 -53.42 18.7 Favored Glycine 0 N--CA 1.49 2.243 0 O-C-N 121.12 -1.224 . . . . 0.0 110.05 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.567 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.9 OUTLIER -62.41 6.58 0.08 Allowed 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.459 -1.024 . . . . 0.0 112.827 -179.421 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.26 -63.84 1.01 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.518 -1.364 . . . . 0.0 108.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -97.2 -19.96 18.26 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 178.046 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.589 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 3.9 m-20 -68.43 125.92 92.17 Favored Pre-proline 0 C--N 1.301 -1.517 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.556 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.435 ' C ' ' OG ' ' A' ' 66' ' ' SER . 46.6 Cg_endo -64.45 -42.26 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 121.96 1.773 . . . . 0.0 111.136 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.495 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 0.0 OUTLIER -177.97 110.88 0.07 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-O 123.065 1.412 . . . . 0.0 109.527 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.667 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.308 1.0 OUTLIER -103.73 145.38 12.79 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 CA-C-N 113.735 -1.575 . . . . 0.0 111.416 -176.556 . . . . . . . . 4 4 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.53 ' CG1' ' HB3' ' A' ' 79' ' ' LYS . 1.9 p -109.41 142.28 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.055 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.549 ' CG2' HG22 ' A' ' 52' ' ' ILE . 32.4 t -108.75 117.17 53.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.239 -0.913 . . . . 0.0 110.001 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.563 ' N ' ' O ' ' A' ' 77' ' ' TRP . 1.0 OUTLIER -98.64 94.67 6.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.578 -0.701 . . . . 0.0 110.482 -179.435 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -91.37 88.91 7.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.802 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -88.72 165.99 14.36 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.331 -0.856 . . . . 0.0 110.689 -179.439 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -38.22 -58.21 1.01 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.589 -0.695 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.584 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -132.03 52.51 0.82 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 74' ' ' GLY . 57.7 m-85 -159.49 103.48 1.58 Allowed 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.913 -0.757 . . . . 0.0 110.057 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.7 ' CE2' HG21 ' A' ' 48' ' ' ILE . 6.4 t90 -90.0 77.73 6.83 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.608 ' CE2' HG12 ' A' ' 41' ' ' VAL . 13.0 m0 -101.28 143.98 30.68 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.512 -0.743 . . . . 0.0 112.308 -177.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.546 ' CG1' ' HA ' ' A' ' 69' ' ' VAL . 1.6 mt -137.49 139.3 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.302 -0.874 . . . . 0.0 109.625 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.53 ' HB3' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -102.19 134.85 44.79 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.467 -0.77 . . . . 0.0 110.06 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.525 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -134.43 143.8 47.77 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 110.054 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -95.15 50.29 1.26 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.068 -1.02 . . . . 0.0 110.106 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.491 ' O ' ' CG1' ' A' ' 38' ' ' VAL . . . -171.03 -169.83 34.5 Favored Glycine 0 C--N 1.3 -1.472 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -71.41 143.79 50.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -1.136 . . . . 0.0 109.682 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.553 HG22 ' CG1' ' A' ' 124' ' ' ILE . 4.2 tp -126.36 159.69 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.243 -0.911 . . . . 0.0 109.89 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.523 ' CA ' HD12 ' A' ' 124' ' ' ILE . 37.0 mt-10 -123.13 151.77 41.77 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 121.01 -1.056 . . . . 0.0 111.813 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.61 HG21 ' CB ' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -121.11 168.18 13.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 121.48 -0.762 . . . . 0.0 109.226 179.259 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 56.8 m-20 -131.54 177.28 7.62 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.08 -1.013 . . . . 0.0 109.961 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.644 ' CA ' ' HA ' ' A' ' 100' ' ' SER . . . -151.46 -49.96 0.12 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.014 178.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.415 ' O ' ' N ' ' A' ' 92' ' ' GLY . . . -48.53 -47.54 39.11 Favored 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.155 -0.966 . . . . 0.0 111.168 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.404 ' C ' ' O ' ' A' ' 89' ' ' ALA . 9.3 mt-10 -48.53 -40.63 27.56 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.561 ' C ' ' HB2' ' A' ' 99' ' ' PHE . . . -53.0 -45.18 67.75 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.923 0.868 . . . . 0.0 108.909 177.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.668 ' N ' ' HB2' ' A' ' 99' ' ' PHE . . . -51.46 -40.4 46.61 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -178.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -64.84 -32.29 73.92 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.476 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -70.79 -64.43 0.9 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.51 -0.744 . . . . 0.0 110.048 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.564 ' CD1' ' HA ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER -107.7 -27.36 10.35 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.191 -0.943 . . . . 0.0 110.575 -179.857 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . 65.26 62.96 4.46 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.167 178.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.619 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 19.3 mttt 163.0 -68.34 0.0 OUTLIER Pre-proline 0 N--CA 1.516 2.844 0 O-C-N 121.312 -1.11 . . . . 0.0 111.009 177.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.619 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 55.9 Cg_endo -86.36 6.59 5.37 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 N-CA-C 107.391 -1.811 . . . . 0.0 107.391 176.8 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.668 ' HB2' ' N ' ' A' ' 92' ' ' GLY . 0.1 OUTLIER -52.87 -132.08 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.014 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.874 -179.448 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.644 ' HA ' ' CA ' ' A' ' 88' ' ' ALA . 40.3 p -6.65 -55.85 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.63 ' N ' ' O ' ' A' ' 99' ' ' PHE . 1.9 t -85.75 -68.78 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -177.34 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.583 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 0.3 OUTLIER -56.83 -30.86 64.17 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 116.929 -1.908 . . . . 0.0 106.21 179.631 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.55 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 38.9 t70 -66.99 -40.86 87.46 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.214 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.602 ' CD1' ' N ' ' A' ' 105' ' ' LEU . 3.0 pp -83.27 -41.48 18.28 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 117.98 -1.488 . . . . 0.0 108.913 179.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.602 ' N ' ' CD1' ' A' ' 104' ' ' LEU . 0.3 OUTLIER -54.04 -16.99 2.24 Favored 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.314 -1.492 . . . . 0.0 110.011 178.673 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.494 HD11 HG22 ' A' ' 106' ' ' ILE . 0.8 OUTLIER -108.74 -27.94 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 179.642 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 0.3 OUTLIER -114.12 -2.67 13.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.083 -1.01 . . . . 0.0 110.744 -179.451 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.575 HG22 ' CZ ' ' A' ' 122' ' ' PHE . 4.1 p -81.93 -10.09 12.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.122 -0.986 . . . . 0.0 110.627 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.4 t -43.55 -20.92 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.031 -1.043 . . . . 0.0 110.345 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.575 ' CB ' ' N ' ' A' ' 41' ' ' VAL . 92.9 p -53.05 -7.81 0.09 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.304 -0.872 . . . . 0.0 112.223 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.56 ' O ' ' CB ' ' A' ' 112' ' ' VAL . 0.2 OUTLIER -110.51 -84.79 0.56 Allowed 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.014 -1.474 . . . . 0.0 111.092 -178.752 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.56 ' CB ' ' O ' ' A' ' 111' ' ' THR . 0.4 OUTLIER 80.06 -14.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.95 -0.468 . . . . 0.0 110.317 -179.239 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -114.95 -75.45 0.63 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.493 ' O ' HG23 ' A' ' 124' ' ' ILE . 11.6 tpt180 -115.24 151.21 34.9 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.353 -1.086 . . . . 0.0 109.531 179.344 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.476 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -165.44 67.99 0.13 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.203 -0.936 . . . . 0.0 110.124 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.511 ' N ' ' O ' ' A' ' 123' ' ' THR . 0.6 OUTLIER -69.21 124.07 22.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.915 . . . . 0.0 109.908 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.41 ' O ' HG21 ' A' ' 117' ' ' THR . 4.3 t -94.68 131.69 40.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 110.356 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.516 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -100.19 45.9 0.97 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.452 -179.98 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.43 -59.2 0.29 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.516 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.6 OUTLIER -115.31 -10.48 12.05 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.947 -0.737 . . . . 0.0 110.3 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -120.38 -168.33 1.61 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.049 -1.032 . . . . 0.0 111.179 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.61 ' CB ' HG21 ' A' ' 86' ' ' ILE . 2.2 t80 -150.51 153.37 35.71 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.515 -0.741 . . . . 0.0 110.442 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.511 ' O ' ' N ' ' A' ' 116' ' ' TYR . 0.8 OUTLIER -142.35 115.38 8.79 Favored 'General case' 0 C--N 1.31 -1.121 0 O-C-N 120.971 -1.081 . . . . 0.0 109.851 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.554 HD13 ' CG1' ' A' ' 86' ' ' ILE . 0.1 OUTLIER -125.03 151.62 30.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.266 -0.896 . . . . 0.0 109.383 179.27 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.427 ' CG2' ' HB3' ' A' ' 114' ' ' ARG . 6.4 t -136.11 -168.23 2.19 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 110.265 -179.412 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 19.1 p . . . . . 0 N--CA 1.488 1.43 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 -179.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.465 ' O ' ' OG ' ' A' ' 126' ' ' SER . 69.4 m-80 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.261 0.553 . . . . 0.0 110.18 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -39.62 145.83 0.12 Allowed 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.464 -0.773 . . . . 0.0 110.415 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.415 HG11 ' O ' ' A' ' 36' ' ' ASN . 3.6 m -122.92 171.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.972 . . . . 0.0 110.237 -179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.536 HG11 ' CG2' ' A' ' 112' ' ' VAL . 10.8 p -131.52 120.53 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -0.88 . . . . 0.0 110.234 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.566 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 5.5 tt -73.1 157.77 36.63 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.575 HG12 ' CE2' ' A' ' 77' ' ' TRP . 24.0 t -160.04 116.48 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 121.097 -1.002 . . . . 0.0 110.592 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.607 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 2.5 mt -138.02 -169.55 2.59 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.455 ' SD ' ' OD2' ' A' ' 103' ' ' ASP . 2.8 ptt? -106.77 151.02 25.72 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.952 -1.093 . . . . 0.0 109.547 178.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.493 ' HB2' ' HA2' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -44.19 103.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.262 -0.899 . . . . 0.0 111.033 -179.034 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.489 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 1.2 m -86.84 19.4 2.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -0.922 . . . . 0.0 110.286 179.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 2.1 m-20 68.3 -57.24 0.49 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.444 -0.785 . . . . 0.0 111.412 179.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.541 ' O ' HG12 ' A' ' 51' ' ' ILE . 1.6 mm-40 -94.05 31.83 1.59 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.923 -1.11 . . . . 0.0 110.948 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.797 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -59.97 -78.26 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.201 -0.937 . . . . 0.0 111.084 -178.844 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.546 ' C ' ' O ' ' A' ' 48' ' ' ILE . 6.8 m-20 -36.79 -32.63 0.04 OUTLIER 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.77 -53.41 7.98 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.766 -0.584 . . . . 0.0 109.551 177.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.714 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.47 -50.67 33.43 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 O-C-N 120.943 -1.098 . . . . 0.0 110.089 179.466 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.603 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 32.4 mm -49.88 -40.78 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 119.829 -1.794 . . . . 0.0 108.281 178.288 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.568 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 18.6 tt0 -62.97 -57.74 9.7 Favored 'General case' 0 C--N 1.29 -1.982 0 O-C-N 120.967 -1.083 . . . . 0.0 110.576 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -81.74 -14.51 56.38 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.296 -0.878 . . . . 0.0 111.489 -178.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.647 ' N ' ' O ' ' A' ' 51' ' ' ILE . 3.7 tp -105.98 -32.35 2.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 CA-C-O 121.563 0.697 . . . . 0.0 110.736 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.603 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 12.0 t -116.34 -43.31 3.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 C-N-CA 119.839 -0.744 . . . . 0.0 112.557 -177.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.568 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.3 OUTLIER -64.32 -41.27 96.89 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.117 -1.614 . . . . 0.0 109.036 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.444 ' N ' HD21 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -85.92 -41.83 14.59 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.61 0.719 . . . . 0.0 109.49 179.323 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.99 -53.0 3.28 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.573 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -70.03 -72.11 0.91 Allowed Glycine 0 N--CA 1.49 2.294 0 O-C-N 120.96 -1.318 . . . . 0.0 110.358 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.573 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -45.33 -8.41 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.597 -0.943 . . . . 0.0 113.518 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 60' ' ' GLY . . . -49.81 -65.34 0.58 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.39 -1.443 . . . . 0.0 108.502 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -89.22 -26.95 20.95 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.573 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 5.3 m-20 -67.6 112.64 10.9 Favored Pre-proline 0 C--N 1.297 -1.676 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.294 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.468 ' O ' ' OG ' ' A' ' 66' ' ' SER . 46.3 Cg_endo -64.59 -41.69 18.64 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.839 1.693 . . . . 0.0 111.355 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.484 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 7.0 m -164.0 104.87 0.9 Allowed 'General case' 0 N--CA 1.484 1.274 0 CA-C-O 123.35 1.548 . . . . 0.0 109.777 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.655 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.312 1.1 mp -106.02 136.42 40.49 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 CA-C-N 113.314 -1.766 . . . . 0.0 110.588 -177.203 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.58 ' CG1' ' HG3' ' A' ' 79' ' ' LYS . 4.4 t -87.42 134.63 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.256 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.581 ' HA ' ' CG1' ' A' ' 78' ' ' ILE . 95.8 t -117.36 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 178.116 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.554 ' N ' ' O ' ' A' ' 77' ' ' TRP . 2.9 mm-40 -86.98 113.3 22.63 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.688 -0.633 . . . . 0.0 110.79 -178.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 71' ' ' ASP . 8.3 p-10 -123.97 112.42 17.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.312 179.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.446 ' O ' ' C ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -152.76 150.23 29.18 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.831 -1.168 . . . . 0.0 111.332 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 35.52 -102.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.818 -0.551 . . . . 0.0 111.036 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.493 ' HA2' ' HB2' ' A' ' 44' ' ' LYS . . . -128.84 37.48 2.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.651 ' CE2' ' CZ2' ' A' ' 77' ' ' TRP . 0.1 OUTLIER -129.77 103.23 6.7 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.698 0.761 . . . . 0.0 109.863 179.54 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.797 ' CE2' HG21 ' A' ' 48' ' ' ILE . 12.5 t90 -96.86 80.95 3.06 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.651 ' CZ2' ' CE2' ' A' ' 75' ' ' PHE . 11.6 m0 -103.6 131.3 50.87 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.317 -0.865 . . . . 0.0 112.68 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.601 HD12 ' CD1' ' A' ' 52' ' ' ILE . 2.1 mt -128.14 130.28 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.104 -0.998 . . . . 0.0 109.437 177.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.58 ' HG3' ' CG1' ' A' ' 68' ' ' VAL . 1.9 mtpt -97.86 136.44 38.17 Favored 'General case' 0 C--N 1.295 -1.798 0 C-N-CA 119.748 -0.781 . . . . 0.0 109.779 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.503 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -140.5 140.81 35.37 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 110.003 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -93.91 50.05 1.39 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.165 -0.959 . . . . 0.0 110.302 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.72 -167.89 31.72 Favored Glycine 0 C--N 1.3 -1.46 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.9 129.65 39.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.152 -1.205 . . . . 0.0 110.13 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.531 ' CG2' ' HB ' ' A' ' 124' ' ' ILE . 8.2 tp -120.67 123.97 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.165 -0.96 . . . . 0.0 110.585 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -87.22 161.67 17.89 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.283 -0.886 . . . . 0.0 111.257 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.654 ' CG2' ' CE2' ' A' ' 122' ' ' PHE . 0.3 OUTLIER -161.46 149.01 4.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 O-C-N 121.254 -0.904 . . . . 0.0 110.704 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.557 ' N ' HD11 ' A' ' 86' ' ' ILE . 2.1 m-20 -152.14 171.1 18.43 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.088 -1.008 . . . . 0.0 111.341 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.544 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -151.24 -37.48 0.13 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.881 -0.728 . . . . 0.0 110.158 177.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.537 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -39.51 -46.87 1.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.622 -0.674 . . . . 0.0 110.312 -179.267 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.542 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 8.9 mt-10 -65.85 -52.06 53.57 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.813 0.816 . . . . 0.0 109.436 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 95' ' ' LEU . . . -54.25 -30.88 51.89 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 110.254 179.686 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.488 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -75.38 -56.43 4.68 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.542 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 3.2 pt-20 -50.14 -20.75 1.08 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.255 -1.144 . . . . 0.0 109.706 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.597 ' CD2' ' N ' ' A' ' 95' ' ' LEU . 1.4 tt -86.44 -65.91 0.96 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.976 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.597 ' N ' ' CD2' ' A' ' 94' ' ' LEU . 3.4 pp -70.06 -44.62 68.77 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.134 -0.979 . . . . 0.0 110.74 -179.566 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.538 ' N ' ' CD1' ' A' ' 95' ' ' LEU . . . -149.14 -76.06 0.02 OUTLIER Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.186 -1.483 . . . . 0.0 109.807 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.579 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 11.7 mttt 164.68 -63.09 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.917 0 O-C-N 121.843 -0.798 . . . . 0.0 109.989 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.3 Cg_endo -71.87 -18.51 28.07 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.764 1.402 . . . . 0.0 108.945 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.591 ' CB ' ' CD1' ' A' ' 95' ' ' LEU . 3.2 t80 -44.17 -52.09 7.62 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.787 0.803 . . . . 0.0 109.434 179.129 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.544 ' HA ' ' CB ' ' A' ' 88' ' ' ALA . 50.6 m -34.16 -58.26 0.46 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.728 0.775 . . . . 0.0 111.856 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.619 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 14.5 t -81.97 -50.43 16.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.453 ' C ' ' O ' ' A' ' 101' ' ' VAL . 4.3 t80 -49.48 -41.22 39.9 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 119.867 -1.77 . . . . 0.0 107.526 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.579 ' OD1' ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -62.73 -43.64 98.27 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 121.602 -0.686 . . . . 0.0 110.146 178.903 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.619 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 4.1 pp -78.6 -38.9 38.87 Favored 'General case' 0 C--O 1.202 -1.4 0 C-N-CA 117.24 -1.784 . . . . 0.0 109.004 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.53 ' N ' HD13 ' A' ' 104' ' ' LEU . 63.2 mt -53.04 -16.29 1.06 Allowed 'General case' 0 C--N 1.29 -1.99 0 O-C-N 119.074 -2.266 . . . . 0.0 109.35 177.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.415 ' N ' ' C ' ' A' ' 104' ' ' LEU . 0.4 OUTLIER -118.06 -26.67 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.22 -0.925 . . . . 0.0 109.169 179.182 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.553 ' OD1' ' CD2' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -113.34 -3.8 13.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.375 -0.828 . . . . 0.0 110.26 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.587 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 12.1 p -60.46 -12.06 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.919 -1.113 . . . . 0.0 109.831 -179.172 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.507 ' O ' ' N ' ' A' ' 111' ' ' THR . 23.5 t -42.59 -22.29 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.429 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 108' ' ' VAL . 6.1 t -44.11 -16.89 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.373 -0.829 . . . . 0.0 110.953 177.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.576 ' CG2' ' CG1' ' A' ' 124' ' ' ILE . 3.0 p -109.22 44.84 1.11 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.648 -1.283 . . . . 0.0 110.677 -178.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.536 ' CG2' HG11 ' A' ' 39' ' ' VAL . 3.6 m -56.13 -25.63 20.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 110.055 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -96.58 -73.4 1.15 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.486 ' O ' ' HB ' ' A' ' 111' ' ' THR . 0.0 OUTLIER -126.55 155.35 42.54 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.383 -1.069 . . . . 0.0 109.804 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.522 ' CB ' ' HB ' ' A' ' 111' ' ' THR . . . -150.81 74.83 1.18 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.026 -1.047 . . . . 0.0 110.981 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -69.1 101.8 1.51 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.083 -1.011 . . . . 0.0 108.367 178.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.49 ' HA ' ' HB3' ' A' ' 122' ' ' PHE . 3.6 m -79.14 162.9 25.49 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.446 -0.784 . . . . 0.0 111.147 -178.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.671 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.9 OUTLIER -147.14 39.34 1.0 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.825 -0.547 . . . . 0.0 109.93 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 59.5 -61.07 0.01 OUTLIER Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 179.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.671 ' N ' ' O ' ' A' ' 118' ' ' LEU . 3.3 m -93.34 -16.23 24.89 Favored 'General case' 0 C--N 1.289 -2.033 0 O-C-N 121.914 -0.757 . . . . 0.0 110.473 -179.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.538 ' CG ' ' OD2' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -159.85 153.86 23.23 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.975 -1.078 . . . . 0.0 111.084 -179.535 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.658 ' CD1' ' N ' ' A' ' 122' ' ' PHE . 0.4 OUTLIER -134.48 166.38 23.0 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.256 -0.902 . . . . 0.0 109.298 178.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.505 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 9.2 t -144.11 157.95 44.01 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.958 -1.089 . . . . 0.0 110.461 -178.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.617 ' N ' ' CD1' ' A' ' 124' ' ' ILE . 3.4 mp -121.15 150.27 24.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.383 -0.823 . . . . 0.0 110.307 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.485 ' O ' ' HB2' ' A' ' 114' ' ' ARG . 5.3 t -160.47 -163.6 1.11 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.383 -0.823 . . . . 0.0 110.402 -179.568 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.63 0 O-C-N 121.49 -0.756 . . . . 0.0 109.96 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 1.6 m-20 . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.53 125.49 0.51 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.771 -0.581 . . . . 0.0 111.159 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 94.1 t -89.87 135.37 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 110.273 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.476 ' O ' ' HB2' ' A' ' 110' ' ' SER . 8.2 p -117.5 130.5 72.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.112 -0.993 . . . . 0.0 110.732 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.595 ' HA ' ' OG ' ' A' ' 110' ' ' SER . 25.3 tp -105.9 141.06 37.94 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.598 ' CB ' ' HB3' ' A' ' 110' ' ' SER . 56.3 t -132.11 134.12 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.316 -1.49 . . . . 0.0 110.909 -178.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.629 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 26.4 mt -140.27 -166.31 2.09 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.551 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 23.5 ptm -101.44 166.59 10.65 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.328 -0.857 . . . . 0.0 110.879 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.496 ' HG2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -65.0 90.57 0.09 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -0.921 . . . . 0.0 111.694 -179.281 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 1.2 t -83.37 8.79 12.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.231 -0.918 . . . . 0.0 109.799 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.546 ' CB ' ' O ' ' A' ' 45' ' ' SER . 3.6 t0 77.16 -71.06 0.12 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.607 -0.683 . . . . 0.0 112.582 178.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.496 ' O ' HG12 ' A' ' 51' ' ' ILE . 3.8 mt-10 -81.74 24.24 0.61 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 120.948 -1.095 . . . . 0.0 111.873 -177.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.775 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.19 -63.09 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.874 -1.142 . . . . 0.0 112.323 -179.062 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -45.85 -35.39 4.44 Favored 'General case' 0 C--N 1.291 -1.946 0 C-N-CA 118.497 -1.281 . . . . 0.0 108.142 178.958 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.463 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.25 -51.69 12.69 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.847 -0.533 . . . . 0.0 110.123 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.775 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.81 -49.51 39.55 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.009 0 O-C-N 120.6 -1.312 . . . . 0.0 109.752 179.656 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.592 ' CG2' ' CG2' ' A' ' 69' ' ' VAL . 42.0 mm -46.73 -39.75 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 119.848 -1.783 . . . . 0.0 107.916 177.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.58 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 56.3 tt0 -62.62 -64.17 1.0 Allowed 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.485 179.242 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -80.02 -9.93 59.73 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.212 -0.93 . . . . 0.0 111.51 -178.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.664 ' N ' ' O ' ' A' ' 51' ' ' ILE . 3.7 tp -106.85 -34.35 2.85 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 121.611 0.719 . . . . 0.0 110.642 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.587 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 9.7 t -116.83 -43.82 3.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 C-N-CA 119.864 -0.734 . . . . 0.0 112.701 -177.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.58 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -55.52 -32.35 62.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.182 -1.574 . . . . 0.0 108.545 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.52 ' N ' HD21 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -93.44 -43.33 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.527 -0.733 . . . . 0.0 109.634 179.329 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -73.56 -47.27 22.05 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.565 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.02 -68.22 1.71 Allowed Glycine 0 N--CA 1.49 2.272 0 O-C-N 121.082 -1.246 . . . . 0.0 110.062 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.499 ' HG3' ' HA ' ' A' ' 66' ' ' SER . 0.0 OUTLIER -60.09 5.92 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.311 -1.111 . . . . 0.0 113.291 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.63 -64.64 0.75 Allowed 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.327 -1.483 . . . . 0.0 108.525 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.6 ptpt -95.44 -24.72 16.55 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.566 1.174 . . . . 0.0 107.92 177.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.565 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 1.2 m-20 -67.31 145.66 98.62 Favored Pre-proline 0 C--N 1.295 -1.78 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.868 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.457 ' O ' ' HE3' ' A' ' 61' ' ' LYS . 41.9 Cg_endo -61.62 -47.03 12.25 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 C-N-CA 122.533 2.156 . . . . 0.0 112.164 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.499 ' HA ' ' HG3' ' A' ' 61' ' ' LYS . 0.6 OUTLIER 179.23 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 123.156 1.455 . . . . 0.0 110.272 -179.793 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.67 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.289 1.1 mp -97.38 155.33 3.62 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.489 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.312 -177.483 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.567 ' CG1' ' HG3' ' A' ' 79' ' ' LYS . 0.2 OUTLIER -128.89 132.14 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.57 -0.707 . . . . 0.0 110.241 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.592 ' CG2' ' CG2' ' A' ' 52' ' ' ILE . 16.5 t -78.62 -178.67 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.601 ' HB3' ' HB2' ' A' ' 77' ' ' TRP . 0.8 OUTLIER -160.53 66.39 0.33 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 120.646 -1.283 . . . . 0.0 110.585 -178.747 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -71.63 120.77 17.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 110.24 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -119.67 148.01 43.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.196 -0.94 . . . . 0.0 109.81 179.764 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -60.31 77.61 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.915 . . . . 0.0 110.549 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 133.54 -20.37 4.15 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.697 -1.239 . . . . 0.0 110.302 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.496 ' O ' ' HG2' ' A' ' 44' ' ' LYS . 6.1 m-85 -131.27 176.75 8.02 Favored 'General case' 0 C--N 1.288 -2.097 0 O-C-N 121.703 -0.88 . . . . 0.0 111.612 -179.204 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.728 ' CE2' HG23 ' A' ' 48' ' ' ILE . 7.4 t90 -141.39 79.11 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.601 ' HB2' ' HB3' ' A' ' 70' ' ' GLU . 11.1 m0 -93.98 162.84 13.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.823 0.82 . . . . 0.0 111.326 -178.622 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.619 HD13 ' CD1' ' A' ' 76' ' ' TRP . 1.2 mp -159.27 138.85 3.48 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.626 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.567 ' HG3' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -106.94 142.14 37.03 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.542 -0.724 . . . . 0.0 110.12 -178.312 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.469 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -138.2 147.26 43.6 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.541 -0.724 . . . . 0.0 110.029 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.29 49.71 0.9 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.024 -1.048 . . . . 0.0 110.218 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 177.99 43.57 Favored Glycine 0 C--N 1.302 -1.356 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.61 123.11 21.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.328 -1.101 . . . . 0.0 109.937 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.458 ' CG1' ' N ' ' A' ' 85' ' ' GLU . 15.8 tt -120.3 171.92 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.188 -0.945 . . . . 0.0 110.766 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.522 ' CG ' ' OG1' ' A' ' 123' ' ' THR . 1.3 mt-10 -133.26 158.91 41.73 Favored 'General case' 0 C--N 1.309 -1.171 0 O-C-N 121.299 -0.876 . . . . 0.0 110.966 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.613 HG21 ' CE2' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -161.51 139.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.589 -0.694 . . . . 0.0 110.502 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.491 ' N ' HD12 ' A' ' 86' ' ' ILE . 2.8 m-20 -130.5 -178.51 4.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.244 -0.91 . . . . 0.0 110.679 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -151.11 -27.66 0.2 Allowed 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.373 -0.931 . . . . 0.0 111.246 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.461 ' HA ' ' HB2' ' A' ' 100' ' ' SER . . . -43.59 -54.13 5.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.909 -1.119 . . . . 0.0 110.217 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.514 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 4.0 mt-10 -53.58 -46.4 70.31 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.624 -0.83 . . . . 0.0 109.109 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.552 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.18 -38.37 87.86 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.436 -0.79 . . . . 0.0 108.99 178.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -66.98 -56.83 10.95 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.517 ' HG3' ' N ' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -57.54 -17.58 14.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.291 -1.123 . . . . 0.0 109.542 179.644 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.527 HD22 ' N ' ' A' ' 95' ' ' LEU . 3.4 tt -80.58 -58.51 3.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.643 -0.661 . . . . 0.0 110.001 -179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.696 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.2 OUTLIER -85.09 -33.26 22.46 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.44 179.48 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.545 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -155.92 -74.59 0.02 OUTLIER Glycine 0 N--CA 1.487 2.055 0 C-N-CA 119.103 -1.522 . . . . 0.0 109.669 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.562 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 2.3 mmtp 162.97 -57.56 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.822 -0.81 . . . . 0.0 108.923 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.562 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 47.7 Cg_endo -75.52 -18.53 17.58 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 124.21 1.637 . . . . 0.0 109.785 179.035 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.696 ' CG ' HD12 ' A' ' 95' ' ' LEU . 1.1 t80 -51.3 -46.31 62.49 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 119.071 -1.052 . . . . 0.0 108.64 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.548 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 1.3 t -31.7 -68.89 0.08 Allowed 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.974 0.892 . . . . 0.0 110.519 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.6 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 1.2 t -72.68 -59.22 3.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.632 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.496 ' N ' ' CG1' ' A' ' 101' ' ' VAL . 0.1 OUTLIER -44.51 -33.05 1.6 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.467 -1.396 . . . . 0.0 108.712 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.534 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 35.2 t70 -64.81 -42.95 94.61 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.6 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 1.6 pp -75.27 -41.38 57.36 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.107 -1.437 . . . . 0.0 109.542 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.457 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 52.3 mt -55.15 -16.17 2.87 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 119.86 -1.775 . . . . 0.0 109.904 178.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -95.23 -46.74 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.325 -0.859 . . . . 0.0 110.196 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.513 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.5 OUTLIER -113.27 -4.21 13.74 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.145 -0.972 . . . . 0.0 112.093 -178.711 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.599 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 5.2 p -65.91 -8.8 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.6 -1.312 . . . . 0.0 109.768 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.96 -27.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.084 0.468 . . . . 0.0 112.024 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.598 ' HB3' ' CB ' ' A' ' 41' ' ' VAL . 1.0 OUTLIER -64.52 5.88 0.25 Allowed 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.135 -0.978 . . . . 0.0 111.949 179.585 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.498 HG21 HG21 ' A' ' 108' ' ' VAL . 32.2 p -61.93 -8.52 5.21 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.402 -1.436 . . . . 0.0 111.573 -177.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.527 ' CG1' ' N ' ' A' ' 113' ' ' GLY . 25.5 t 48.66 -92.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.527 ' N ' ' CG1' ' A' ' 112' ' ' VAL . . . -138.68 -3.8 1.73 Allowed Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.512 -1.327 . . . . 0.0 110.108 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.537 ' HG2' ' CG2' ' A' ' 125' ' ' THR . 1.4 mpt_? -123.95 146.94 48.14 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.046 -1.267 . . . . 0.0 110.661 -179.53 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -169.71 80.06 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.9 m-85 -69.05 89.36 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.258 -0.901 . . . . 0.0 109.06 179.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 14.3 t -79.33 151.21 31.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.388 -0.82 . . . . 0.0 111.306 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -133.74 62.67 1.65 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.83 -60.67 0.13 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.575 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.8 OUTLIER -118.21 -34.94 3.95 Favored 'General case' 0 C--N 1.292 -1.921 0 O-C-N 121.964 -0.727 . . . . 0.0 112.004 -179.243 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.559 ' O ' ' N ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -105.0 149.51 25.7 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 120.994 -1.066 . . . . 0.0 111.003 -178.789 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.654 ' CD1' ' N ' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -136.14 164.08 28.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.027 -1.046 . . . . 0.0 110.408 179.501 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.522 ' OG1' ' CG ' ' A' ' 85' ' ' GLU . 0.8 OUTLIER -138.79 149.93 45.52 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.291 -0.881 . . . . 0.0 109.225 -179.684 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.477 HG23 ' HA ' ' A' ' 111' ' ' THR . 0.0 OUTLIER -125.24 156.82 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.065 -1.022 . . . . 0.0 110.057 -179.419 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.537 ' CG2' ' HG2' ' A' ' 114' ' ' ARG . 6.3 t -160.78 163.53 32.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.131 -0.981 . . . . 0.0 110.625 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.432 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER . . . . . 0 N--CA 1.485 1.302 0 O-C-N 121.281 -0.887 . . . . 0.0 110.222 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.476 ' O ' ' OG ' ' A' ' 126' ' ' SER . 52.1 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.053 0.454 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.466 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.1 117.61 0.54 Allowed 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.518 -0.739 . . . . 0.0 110.717 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.427 HG11 ' O ' ' A' ' 36' ' ' ASN . 21.2 m -102.41 173.56 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.185 -0.947 . . . . 0.0 109.921 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.472 ' O ' ' OG ' ' A' ' 110' ' ' SER . 7.7 p -137.77 145.67 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 111.008 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.545 ' HB2' ' CG1' ' A' ' 84' ' ' ILE . 10.6 tp -111.67 137.31 49.74 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.623 HG12 ' CE2' ' A' ' 77' ' ' TRP . 80.5 t -133.77 124.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 120.664 -1.272 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.627 ' CB ' ' CE3' ' A' ' 76' ' ' TRP . 16.2 mt -132.84 178.84 6.56 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.632 178.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.429 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 2.2 ppp? -88.64 172.21 9.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.139 -0.976 . . . . 0.0 110.142 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.33 83.25 0.25 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.47 ' HB2' HG21 ' A' ' 48' ' ' ILE . 13.7 m -54.17 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.194 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 0.7 OUTLIER -158.64 -83.25 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.407 -0.808 . . . . 0.0 109.964 179.272 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.525 ' HB2' HG22 ' A' ' 51' ' ' ILE . 1.5 mt-10 -96.93 38.34 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.35 -0.844 . . . . 0.0 110.064 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.779 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -45.17 -60.72 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.172 -0.955 . . . . 0.0 111.32 -179.083 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 48' ' ' ILE . 3.2 m-20 -47.31 -44.44 23.53 Favored 'General case' 0 C--N 1.282 -2.363 0 C-N-CA 118.372 -1.331 . . . . 0.0 108.622 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.17 -47.04 60.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.559 -0.713 . . . . 0.0 110.854 179.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.779 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -74.78 -49.76 28.35 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.062 0 O-C-N 120.649 -1.282 . . . . 0.0 110.069 -179.909 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.6 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 40.7 mm -45.0 -37.53 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.056 -1.652 . . . . 0.0 108.23 177.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.555 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 1.2 tt0 -68.66 -63.18 1.11 Allowed 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.296 -0.878 . . . . 0.0 110.256 179.279 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.11 -10.34 59.33 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.283 -0.885 . . . . 0.0 110.933 -179.322 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.679 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 tp -107.58 -35.43 2.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 CA-C-O 121.575 0.702 . . . . 0.0 110.681 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.6 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.1 t -117.75 -44.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.974 -0.69 . . . . 0.0 112.694 -176.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.555 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.9 OUTLIER -56.55 -41.63 77.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.11 -1.619 . . . . 0.0 109.478 -179.363 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -87.78 -43.98 11.46 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.634 -0.667 . . . . 0.0 110.583 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.17 -41.52 6.58 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.056 -178.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.552 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.83 -54.36 15.09 Favored Glycine 0 N--CA 1.492 2.399 0 O-C-N 120.803 -1.41 . . . . 0.0 110.328 -179.143 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.537 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -60.64 8.86 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.45 -1.03 . . . . 0.0 113.248 -179.323 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.55 ' CB ' ' HE3' ' A' ' 63' ' ' LYS . . . -57.19 -67.77 0.29 Allowed 'General case' 0 C--N 1.308 -1.229 0 O-C-N 120.258 -1.526 . . . . 0.0 109.076 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.588 ' N ' ' CE ' ' A' ' 63' ' ' LYS . 5.4 mmpt? -90.19 -19.53 24.11 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.552 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 6.3 m-20 -69.34 121.08 80.86 Favored Pre-proline 0 C--N 1.299 -1.588 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.401 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.472 ' O ' ' OG ' ' A' ' 66' ' ' SER . 44.9 Cg_endo -64.09 -39.24 32.48 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.884 1.723 . . . . 0.0 111.16 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.482 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 2.8 m -177.77 111.2 0.07 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 123.012 1.386 . . . . 0.0 109.193 179.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.615 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.299 1.3 mp -107.06 145.48 14.51 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.465 0 CA-C-N 113.823 -1.535 . . . . 0.0 111.673 -176.533 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.493 HG11 ' CB ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.04 142.66 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.931 179.454 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.533 HG11 ' CG1' ' A' ' 78' ' ' ILE . 66.1 t -115.32 100.38 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.125 -0.984 . . . . 0.0 110.154 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.566 ' N ' ' O ' ' A' ' 77' ' ' TRP . 1.1 mm-40 -83.59 124.51 30.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.489 -0.757 . . . . 0.0 109.869 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -123.25 102.47 7.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.15 -0.969 . . . . 0.0 109.587 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -103.97 144.23 31.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.164 -0.96 . . . . 0.0 109.948 -179.704 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.72 83.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.435 -0.79 . . . . 0.0 110.044 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 132.73 -24.88 3.82 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -125.08 161.63 26.36 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.778 -0.836 . . . . 0.0 110.931 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.692 ' CE2' HG23 ' A' ' 48' ' ' ILE . 11.8 t90 -135.88 79.46 1.77 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.623 ' CE2' HG12 ' A' ' 41' ' ' VAL . 11.2 m0 -98.79 137.72 36.97 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.495 -0.753 . . . . 0.0 112.433 -177.563 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.551 HD13 ' CD1' ' A' ' 76' ' ' TRP . 1.3 mt -138.29 139.15 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.304 -0.873 . . . . 0.0 109.486 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.493 ' CB ' HG11 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -109.01 162.28 14.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.188 -0.945 . . . . 0.0 110.582 -179.387 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.478 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.31 140.64 20.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.97 50.03 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -0.906 . . . . 0.0 109.961 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.53 -138.85 2.6 Favored Glycine 0 C--N 1.301 -1.374 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.29 163.28 23.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -1.179 . . . . 0.0 109.885 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.545 ' CG1' ' HB2' ' A' ' 40' ' ' LEU . 5.7 tp -150.83 161.85 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.099 -1.001 . . . . 0.0 110.307 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.504 ' N ' HG13 ' A' ' 84' ' ' ILE . 2.4 mt-10 -140.18 164.75 29.22 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.229 -0.92 . . . . 0.0 110.384 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.693 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -125.53 165.22 23.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.298 -0.876 . . . . 0.0 109.718 179.62 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.522 ' OD1' ' CG ' ' A' ' 121' ' ' LYS . 9.5 m-20 -149.46 155.29 40.15 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.304 -0.872 . . . . 0.0 110.656 -179.648 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.627 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -146.12 -22.37 0.45 Allowed 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 118.808 -1.157 . . . . 0.0 111.301 177.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -41.57 -46.48 3.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.667 -1.271 . . . . 0.0 110.624 179.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.442 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.2 tt0 -49.36 -57.76 6.31 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.401 -0.812 . . . . 0.0 109.659 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.565 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -45.55 -30.31 1.43 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.687 -0.633 . . . . 0.0 109.727 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -71.17 -37.83 63.51 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.442 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.3 mt-10 -64.69 -20.19 66.17 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.445 HD23 HD21 ' A' ' 95' ' ' LEU . 7.4 tt -84.54 -67.57 0.79 Allowed 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.527 ' CD1' ' HB3' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -100.77 -23.3 14.63 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.115 -0.99 . . . . 0.0 110.112 179.26 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 60.1 45.69 95.53 Favored Glycine 0 N--CA 1.5 2.942 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.278 178.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.689 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 13.7 mttt -138.06 -127.43 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.456 0 O-C-N 121.091 -1.241 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.689 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 42.0 Cg_endo -71.61 -4.91 15.96 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 CA-C-N 120.894 1.355 . . . . 0.0 108.605 178.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.767 ' CD1' ' N ' ' A' ' 100' ' ' SER . 2.8 p90 -24.12 -42.55 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 CA-C-O 121.599 0.714 . . . . 0.0 112.032 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.767 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.2 OUTLIER -57.94 -54.86 42.18 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 122.901 1.334 . . . . 0.0 109.18 -177.64 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.61 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 6.5 t -94.17 -43.88 13.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.672 -178.135 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.46 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 37.4 t80 -53.1 -41.12 64.64 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 120.209 -1.557 . . . . 0.0 107.652 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.587 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.4 t0 -68.5 -43.13 77.53 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.437 -0.79 . . . . 0.0 109.922 179.152 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.61 ' CD2' ' HA ' ' A' ' 101' ' ' VAL . 2.9 pp -75.25 -40.38 58.99 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 116.756 -1.978 . . . . 0.0 109.046 179.252 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.544 ' N ' HD13 ' A' ' 104' ' ' LEU . 23.6 mt -52.82 -20.02 2.93 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.094 -1.629 . . . . 0.0 109.867 178.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -92.09 -44.92 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.267 -0.896 . . . . 0.0 110.629 -179.581 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.488 ' HB2' ' O ' ' A' ' 41' ' ' VAL . 0.6 OUTLIER -114.48 -7.59 12.83 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 112.243 -178.366 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.57 ' CB ' HD11 ' A' ' 104' ' ' LEU . 6.0 p -60.89 -17.64 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.592 -1.317 . . . . 0.0 109.34 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.447 ' N ' HG11 ' A' ' 108' ' ' VAL . 1.0 OUTLIER -39.84 -22.78 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.7 -179.231 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.584 ' HB2' ' HB ' ' A' ' 41' ' ' VAL . 0.1 OUTLIER -73.28 9.52 1.26 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.698 -1.251 . . . . 0.0 110.558 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.537 ' O ' ' HB ' ' A' ' 112' ' ' VAL . 1.1 t -61.53 -10.86 8.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.762 -1.212 . . . . 0.0 110.396 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.537 ' HB ' ' O ' ' A' ' 111' ' ' THR . 2.1 t 66.89 -52.73 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.576 -0.702 . . . . 0.0 110.62 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -173.15 -26.87 0.02 OUTLIER Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.458 ' O ' HG22 ' A' ' 124' ' ' ILE . 18.2 ttt180 -138.81 147.74 42.91 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.063 -1.257 . . . . 0.0 111.023 -179.494 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.484 ' HA ' HG13 ' A' ' 124' ' ' ILE . . . -155.76 93.61 1.48 Allowed 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.38 -0.825 . . . . 0.0 110.285 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.525 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 12.2 t80 -69.72 118.88 13.13 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.49 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.2 m -79.55 117.78 20.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.619 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -79.38 49.62 1.01 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.935 179.404 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.93 -60.14 0.36 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 108.674 -1.77 . . . . 0.0 108.674 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -116.01 -10.15 11.63 Favored 'General case' 0 C--N 1.293 -1.875 0 O-C-N 122.001 -0.705 . . . . 0.0 110.382 179.712 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.522 ' CG ' ' OD1' ' A' ' 87' ' ' ASP . 1.7 tttt -121.07 -161.94 0.93 Allowed 'General case' 0 N--CA 1.493 1.685 0 CA-C-O 122.052 0.929 . . . . 0.0 111.397 -179.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.693 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.26 0.2 OUTLIER -141.22 150.93 43.31 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.97 -179.105 . . . . . . . . 4 4 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.525 ' CG2' ' HB3' ' A' ' 116' ' ' TYR . 0.7 OUTLIER -137.4 110.96 8.03 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.982 -1.074 . . . . 0.0 110.001 178.705 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.487 ' HB ' ' CG2' ' A' ' 84' ' ' ILE . 4.8 mp -113.86 157.28 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 110.174 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.466 ' N ' HG21 ' A' ' 124' ' ' ILE . 15.3 t -146.96 170.24 17.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.293 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.307 -0.87 . . . . 0.0 110.684 -179.527 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.477 ' HA ' ' OG ' ' A' ' 126' ' ' SER . 26.9 p-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.506 0.67 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -39.74 134.0 1.45 Allowed 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.623 -0.673 . . . . 0.0 110.995 -179.502 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 80' ' ' ALA . 7.6 p -141.18 152.45 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.308 -0.87 . . . . 0.0 109.732 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.476 HG11 ' O ' ' A' ' 39' ' ' VAL . 14.5 p -114.87 136.28 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 111.464 -179.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.483 ' N ' ' O ' ' A' ' 78' ' ' ILE . 3.8 tp -100.53 146.11 27.49 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 176.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.618 ' CG2' ' CD2' ' A' ' 77' ' ' TRP . 2.2 t -139.12 121.45 17.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 O-C-N 120.403 -1.436 . . . . 0.0 111.365 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.688 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 3.3 mm? -133.42 153.02 51.96 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.294 -0.879 . . . . 0.0 109.212 178.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 12.7 ptm -75.45 153.68 37.47 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.837 -1.164 . . . . 0.0 109.721 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.535 ' CG ' ' HA2' ' A' ' 74' ' ' GLY . 10.0 ptmt -45.16 123.59 4.06 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.032 -1.042 . . . . 0.0 110.859 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.8 m -100.05 -86.28 0.39 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.592 179.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -158.0 -79.11 0.07 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 110.92 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.486 ' C ' HD12 ' A' ' 51' ' ' ILE . 1.4 mt-10 -96.74 39.06 1.18 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.305 -0.872 . . . . 0.0 110.367 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.771 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.04 -69.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.117 -0.99 . . . . 0.0 111.586 -178.916 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.8 m-20 -41.15 -36.05 0.67 Allowed 'General case' 0 C--N 1.284 -2.267 0 C-N-CA 119.059 -1.057 . . . . 0.0 109.062 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -77.78 -50.22 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.601 -0.687 . . . . 0.0 109.9 178.601 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.771 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.31 -50.93 28.0 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.011 0 O-C-N 120.848 -1.157 . . . . 0.0 109.325 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.598 ' HA ' HG21 ' A' ' 55' ' ' ILE . 44.2 mm -47.19 -40.71 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 119.881 -1.762 . . . . 0.0 108.147 177.569 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.541 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 60.2 tt0 -60.85 -61.58 2.48 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -84.1 -9.15 58.83 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.201 -0.937 . . . . 0.0 111.669 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.675 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.5 tp -106.68 -32.81 2.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 CA-C-O 121.695 0.759 . . . . 0.0 110.098 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.586 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 7.4 t -116.46 -45.05 3.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 C-N-CA 119.942 -0.703 . . . . 0.0 112.188 -177.626 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.541 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -64.81 -37.67 88.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.339 -1.475 . . . . 0.0 108.557 179.798 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.505 ' N ' HD21 ' A' ' 57' ' ' LEU . 6.6 mtpt -96.86 -42.07 8.13 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.524 -0.735 . . . . 0.0 109.221 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -77.54 -49.84 7.0 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.27 -47.86 49.48 Favored Glycine 0 N--CA 1.489 2.178 0 O-C-N 120.973 -1.31 . . . . 0.0 110.136 -179.144 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.557 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 17.6 ttpp -65.17 9.98 0.09 Allowed 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.624 -0.927 . . . . 0.0 113.124 -179.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.67 -62.88 1.35 Allowed 'General case' 0 C--N 1.304 -1.386 0 O-C-N 120.387 -1.446 . . . . 0.0 108.897 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mtmt -101.62 -17.58 16.28 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.576 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 0.5 OUTLIER -67.96 127.27 93.32 Favored Pre-proline 0 C--N 1.3 -1.544 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.229 -179.165 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -66.22 -49.52 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.321 2.014 . . . . 0.0 111.587 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.439 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -166.97 106.23 0.6 Allowed 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 123.211 1.481 . . . . 0.0 109.489 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.678 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -97.1 148.91 5.19 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 CA-C-N 113.47 -1.696 . . . . 0.0 111.836 -176.507 . . . . . . . . 4 4 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.494 HG11 ' CB ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.44 145.44 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.298 -0.876 . . . . 0.0 110.201 179.731 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.543 ' CG2' HG23 ' A' ' 52' ' ' ILE . 99.2 t -121.31 96.7 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.152 -0.968 . . . . 0.0 110.089 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.3 mm-40 -79.36 134.6 36.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.263 -0.898 . . . . 0.0 110.092 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ASP . . . . . 0.469 ' O ' ' OD1' ' A' ' 71' ' ' ASP . 1.1 p30 -143.31 112.24 6.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.179 -0.951 . . . . 0.0 110.017 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.47 ' HG3' ' HB2' ' A' ' 75' ' ' PHE . 0.2 OUTLIER -147.55 -171.45 3.8 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.892 -1.13 . . . . 0.0 111.241 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.465 ' O ' ' C ' ' A' ' 74' ' ' GLY . . . -40.22 110.84 0.16 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.47 -0.769 . . . . 0.0 110.911 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.535 ' HA2' ' CG ' ' A' ' 44' ' ' LYS . . . 36.47 59.62 1.01 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.47 ' HB2' ' HG3' ' A' ' 72' ' ' LYS . 2.5 m-85 -160.75 75.49 0.54 Allowed 'General case' 0 C--N 1.291 -1.961 0 O-C-N 121.849 -0.795 . . . . 0.0 110.039 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.724 ' CE2' HG21 ' A' ' 48' ' ' ILE . 4.1 t90 -82.49 78.34 9.14 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.654 0.74 . . . . 0.0 109.08 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . 0.618 ' CD2' ' CG2' ' A' ' 41' ' ' VAL . 23.2 m0 -98.94 148.27 24.14 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.594 -0.691 . . . . 0.0 111.626 -178.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.555 ' CD1' ' NE1' ' A' ' 76' ' ' TRP . 1.2 mp -146.65 141.58 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.339 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.494 ' CB ' HG11 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -116.74 141.75 47.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.129 -0.982 . . . . 0.0 110.695 -179.022 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.509 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -127.07 163.51 23.62 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.385 -0.822 . . . . 0.0 110.008 179.537 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -106.41 47.44 0.88 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.068 -1.02 . . . . 0.0 110.179 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -108.11 0.21 Allowed Glycine 0 C--N 1.299 -1.482 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -126.22 166.14 17.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.458 -1.025 . . . . 0.0 110.091 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.507 ' CG2' ' HB ' ' A' ' 124' ' ' ILE . 7.9 tp -143.91 158.61 16.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.121 -0.987 . . . . 0.0 110.524 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.46 ' O ' HG12 ' A' ' 86' ' ' ILE . 34.2 tt0 -122.76 173.8 7.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.261 -0.899 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.699 HG22 ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -157.62 149.78 9.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 O-C-N 121.148 -0.97 . . . . 0.0 111.007 -179.58 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' HG21 ' A' ' 86' ' ' ILE . 71.0 m-20 -138.54 152.21 48.0 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.06 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.57 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -151.84 -34.84 0.13 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.335 -1.346 . . . . 0.0 111.585 178.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.533 ' CB ' ' OG1' ' A' ' 120' ' ' THR . . . -40.91 -45.35 2.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.289 -0.882 . . . . 0.0 110.181 -179.235 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.557 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 3.8 tt0 -67.86 -52.02 41.52 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 178.792 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.565 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.8 -41.15 70.23 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 108.965 178.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.53 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -59.49 -55.31 31.35 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.557 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 0.9 OUTLIER -57.02 -16.94 8.16 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.174 -1.192 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.5 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 7.4 tt -86.25 -64.27 1.18 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.501 -0.749 . . . . 0.0 111.014 -179.302 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.631 HD12 ' CD1' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -71.36 -37.2 71.66 Favored 'General case' 0 N--CA 1.502 2.168 0 C-N-CA 118.485 -1.286 . . . . 0.0 109.849 -179.706 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -158.41 -74.43 0.02 OUTLIER Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.545 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 167.53 -63.24 0.0 OUTLIER Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.956 . . . . 0.0 109.52 179.855 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.9 Cg_endo -72.04 -16.22 28.93 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.476 1.25 . . . . 0.0 109.64 178.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.631 ' CD1' HD12 ' A' ' 95' ' ' LEU . 3.1 t80 -48.87 -48.51 42.09 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 121.074 -1.017 . . . . 0.0 109.171 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.57 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 3.8 t -32.36 -61.87 0.24 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.752 0.787 . . . . 0.0 110.764 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.581 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 19.4 t -82.79 -54.41 9.48 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.822 0 O-C-N 121.183 -0.948 . . . . 0.0 112.793 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.419 ' HA ' HD13 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -46.56 -29.98 2.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.67 -1.269 . . . . 0.0 108.917 179.911 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.53 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 29.5 t70 -82.17 -37.18 26.53 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.451 -0.78 . . . . 0.0 109.441 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.583 ' O ' ' HB ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -68.75 -21.78 64.35 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.364 179.523 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.537 ' CD1' HG11 ' A' ' 101' ' ' VAL . 4.6 mt -86.75 -27.72 23.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.819 -1.175 . . . . 0.0 110.373 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.444 HG21 ' N ' ' A' ' 107' ' ' ASN . 0.6 OUTLIER -97.24 -28.52 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 121.134 -0.979 . . . . 0.0 109.956 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.562 ' O ' ' O ' ' A' ' 41' ' ' VAL . 2.5 p30 -87.49 -30.44 20.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.34 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.583 ' HB ' ' O ' ' A' ' 104' ' ' LEU . 9.9 p -66.3 -0.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 120.61 -1.306 . . . . 0.0 110.9 179.407 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -30.05 -34.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.813 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' SER . . . . . 0.57 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . 82.8 p -84.4 33.66 0.51 Allowed 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.533 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' THR . . . . . 0.579 ' HB ' ' CG2' ' A' ' 108' ' ' VAL . 11.5 t -96.46 44.26 1.07 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.26 179.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.573 ' CG1' ' N ' ' A' ' 113' ' ' GLY . 0.5 OUTLIER -61.68 -48.66 87.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.542 -0.724 . . . . 0.0 111.015 -178.687 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.573 ' N ' ' CG1' ' A' ' 112' ' ' VAL . . . -57.21 -77.04 0.18 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.521 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -157.72 -169.04 2.72 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.384 -1.068 . . . . 0.0 110.105 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.412 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -170.7 84.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.478 ' HB3' HG21 ' A' ' 123' ' ' THR . 4.7 t80 -69.84 105.71 2.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.003 -1.061 . . . . 0.0 108.351 178.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 7.6 m -79.03 145.95 33.58 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.299 -0.876 . . . . 0.0 110.915 -178.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . 0.612 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.1 OUTLIER -123.69 50.3 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.587 -0.695 . . . . 0.0 110.282 179.914 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 62.15 -57.26 0.03 OUTLIER Glycine 0 N--CA 1.491 2.326 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 178.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.612 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.8 t -111.7 -15.18 13.49 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.753 -0.851 . . . . 0.0 111.406 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -143.57 150.6 39.08 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.758 -1.214 . . . . 0.0 110.77 -179.614 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.699 ' CE2' HG22 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -124.68 164.17 20.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.877 -1.139 . . . . 0.0 110.769 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.487 ' OG1' ' O ' ' A' ' 84' ' ' ILE . 2.8 t -144.27 131.85 21.09 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.514 -0.741 . . . . 0.0 109.831 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.619 HD12 ' CE1' ' A' ' 122' ' ' PHE . 2.0 mp -101.91 162.66 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 110.674 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' THR . . . . . 0.422 ' N ' ' CG2' ' A' ' 124' ' ' ILE . 3.3 t -152.34 -175.3 5.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -0.872 . . . . 0.0 109.806 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' SER . . . . . 0.477 ' OG ' ' HA ' ' A' ' 36' ' ' ASN . 19.7 t . . . . . 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.086 . . . . 0.0 110.705 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' A' ' 36' ' ' ASN . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.276 0.56 . . . . 0.0 110.367 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 35' ' ' SER . 0.4 OUTLIER 68.96 -57.08 0.52 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.142 -0.974 . . . . 0.0 110.695 179.782 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.49 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -29.87 132.96 0.06 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.403 0.621 . . . . 0.0 111.846 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.505 HG21 ' N ' ' A' ' 39' ' ' VAL . 1.7 p -142.48 149.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.515 179.489 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 79' ' ' LYS . 11.1 p -127.68 150.05 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.78 -1.2 . . . . 0.0 111.707 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.53 ' CD1' HG13 ' A' ' 86' ' ' ILE . 23.5 tp -112.36 132.05 55.21 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.631 HG12 ' CE2' ' A' ' 77' ' ' TRP . 2.6 t -127.28 124.87 64.95 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 111.603 -177.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.511 ' CB ' ' HB3' ' A' ' 76' ' ' TRP . 0.9 OUTLIER -119.53 -174.18 2.68 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.002 -1.061 . . . . 0.0 110.605 179.189 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.528 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.8 ptp -117.66 21.58 12.88 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.937 . . . . 0.0 110.642 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.62 ' O ' ' CB ' ' A' ' 45' ' ' SER . 3.6 mmtt -88.95 -93.14 0.11 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.456 -0.778 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.62 ' CB ' ' O ' ' A' ' 44' ' ' LYS . 1.3 p 89.36 178.01 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 45' ' ' SER . 0.1 OUTLIER 62.93 -87.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 109.663 -179.242 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.51 ' O ' HD11 ' A' ' 51' ' ' ILE . 1.2 mt-10 -52.16 -24.95 7.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.44 -0.787 . . . . 0.0 111.895 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.771 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -73.48 -62.37 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.709 -178.082 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.545 ' C ' ' O ' ' A' ' 48' ' ' ILE . 85.4 m-20 -37.83 -32.57 0.06 Allowed 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.316 -0.954 . . . . 0.0 108.782 179.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.27 -55.98 5.06 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.771 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -71.3 -48.69 52.66 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.165 0 O-C-N 120.679 -1.263 . . . . 0.0 109.29 178.922 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.568 ' HA ' HG21 ' A' ' 55' ' ' ILE . 45.8 mm -46.01 -41.23 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 119.871 -1.768 . . . . 0.0 108.604 177.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.687 ' HA ' ' HB2' ' A' ' 57' ' ' LEU . 2.1 tm-20 -64.73 -60.89 2.58 Favored 'General case' 0 C--N 1.292 -1.91 0 O-C-N 121.206 -0.933 . . . . 0.0 110.143 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -77.62 -12.59 59.98 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 120.868 -1.145 . . . . 0.0 111.488 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.67 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 tp -107.43 -34.96 2.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 O-C-N 121.59 -0.694 . . . . 0.0 111.499 -178.197 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.551 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.5 t -117.18 -37.89 2.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.655 -0.653 . . . . 0.0 112.632 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.687 ' HB2' ' HA ' ' A' ' 53' ' ' GLU . 1.4 tm? -37.51 -55.49 1.08 Allowed 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 122.272 1.034 . . . . 0.0 109.947 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.31 -48.97 12.2 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.487 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -50.82 -47.39 47.31 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.503 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -78.03 7.07 46.11 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.406 ' HD2' HD12 ' A' ' 57' ' ' LEU . 0.2 OUTLIER -106.77 -8.56 16.75 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.972 -1.311 . . . . 0.0 110.891 -179.768 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.5 -82.63 0.22 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.945 -1.097 . . . . 0.0 109.93 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.403 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -79.56 -30.3 41.64 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 122.432 1.111 . . . . 0.0 108.158 178.678 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.503 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 8.5 m-20 -74.65 127.03 87.96 Favored Pre-proline 0 C--N 1.295 -1.801 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.478 ' O ' ' HB2' ' A' ' 66' ' ' SER . 43.5 Cg_endo -62.86 -47.7 8.21 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 121.77 1.646 . . . . 0.0 110.822 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 65' ' ' PRO . 1.7 t 179.96 111.86 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.958 1.361 . . . . 0.0 109.339 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.631 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.292 1.3 mp -104.37 134.77 44.77 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.508 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.551 -176.823 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.56 ' CG1' ' HB3' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -92.03 162.73 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 109.374 178.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.482 ' HA ' HD13 ' A' ' 78' ' ' ILE . 24.3 t -136.28 106.51 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.045 -1.034 . . . . 0.0 110.31 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.559 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.7 mm-40 -102.05 145.42 29.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.841 . . . . 0.0 110.421 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . 0.428 ' CG ' ' OD2' ' A' ' 49' ' ' ASP . 11.6 p-10 -136.96 119.72 16.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.451 -0.78 . . . . 0.0 108.965 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.567 ' CB ' ' HB2' ' A' ' 75' ' ' PHE . 27.0 mttm -125.49 83.28 2.15 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.019 -1.051 . . . . 0.0 111.506 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.558 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 18.64 73.66 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.237 0 CA-C-O 121.231 0.539 . . . . 0.0 111.949 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 43' ' ' MET . . . 103.54 11.18 33.86 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.567 ' HB2' ' CB ' ' A' ' 72' ' ' LYS . 20.4 m-85 -138.26 101.03 4.28 Favored 'General case' 0 C--N 1.286 -2.165 0 O-C-N 121.837 -0.802 . . . . 0.0 110.587 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.707 ' CD2' HG22 ' A' ' 48' ' ' ILE . 17.5 t90 -89.39 87.53 7.13 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.518 -0.738 . . . . 0.0 109.494 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.631 ' CE2' HG12 ' A' ' 41' ' ' VAL . 11.7 m0 -98.06 111.59 23.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.08 -1.012 . . . . 0.0 110.427 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.505 HG12 ' NE1' ' A' ' 76' ' ' TRP . 0.3 OUTLIER -114.65 148.17 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.737 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.56 ' HB3' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -130.28 125.46 34.83 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.921 -1.112 . . . . 0.0 110.16 179.81 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.518 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -125.44 173.97 8.52 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.478 -0.764 . . . . 0.0 110.031 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.97 52.51 1.27 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 110.046 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -169.59 -105.94 0.19 Allowed Glycine 0 C--N 1.302 -1.337 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -133.08 115.5 15.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.505 -0.997 . . . . 0.0 110.316 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.475 HG21 ' O ' ' A' ' 124' ' ' ILE . 8.1 tp -105.49 148.36 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 110.261 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -103.99 159.29 15.79 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.157 -0.965 . . . . 0.0 111.392 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.671 ' CG2' ' CD2' ' A' ' 122' ' ' PHE . 0.3 OUTLIER -162.32 149.82 4.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 O-C-N 121.442 -0.787 . . . . 0.0 110.438 179.772 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.582 ' N ' HD11 ' A' ' 86' ' ' ILE . 1.4 m-20 -135.31 -176.13 4.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.011 -1.056 . . . . 0.0 111.455 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.602 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -138.41 -9.31 1.46 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.813 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.43 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -43.71 -48.34 7.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.474 -1.392 . . . . 0.0 110.269 179.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.525 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 10.1 tt0 -49.36 -47.63 47.3 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.455 -0.778 . . . . 0.0 109.892 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 94' ' ' LEU . . . -56.81 -26.46 58.04 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.067 -1.021 . . . . 0.0 109.649 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.699 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -73.97 -48.84 14.82 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 0.0 OUTLIER -58.23 -19.3 32.79 Favored 'General case' 0 C--N 1.289 -2.052 0 O-C-N 121.104 -1.233 . . . . 0.0 107.951 178.56 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.565 ' CD2' HD21 ' A' ' 95' ' ' LEU . 11.4 tp -82.11 -68.0 0.73 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.826 -0.546 . . . . 0.0 109.613 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.565 HD21 ' CD2' ' A' ' 94' ' ' LEU . 0.2 OUTLIER -100.96 -29.66 12.07 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.082 -1.011 . . . . 0.0 109.135 178.587 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 69.44 43.96 66.98 Favored Glycine 0 N--CA 1.498 2.768 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.833 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.687 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 8.2 mmmt -138.23 -124.17 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.672 0 O-C-N 121.091 -1.241 . . . . 0.0 109.724 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.687 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 45.9 Cg_endo -71.14 -4.96 15.94 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 121.172 1.454 . . . . 0.0 108.724 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.76 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.8 p90 -23.66 -44.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.076 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.76 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -49.14 -52.48 25.96 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 123.348 1.547 . . . . 0.0 107.734 -179.125 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.57 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 67.5 t -99.04 -53.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.807 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.486 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 0.5 OUTLIER -44.42 -30.02 0.79 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.773 -1.204 . . . . 0.0 108.434 179.364 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.564 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.8 t70 -83.11 -45.94 13.37 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.614 ' HB2' ' CE2' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -60.9 -41.16 95.55 Favored 'General case' 0 C--O 1.202 -1.425 0 C-N-CA 117.928 -1.509 . . . . 0.0 109.144 179.168 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.564 ' CD1' HG11 ' A' ' 101' ' ' VAL . 28.0 mt -61.58 -46.47 89.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.725 -1.235 . . . . 0.0 111.341 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -73.94 -33.07 35.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 110.464 -178.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.534 ' O ' ' O ' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -90.42 -40.71 11.89 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.121 -0.987 . . . . 0.0 110.143 -179.954 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.618 ' O ' ' N ' ' A' ' 111' ' ' THR . 1.6 p -65.86 1.66 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.647 -1.283 . . . . 0.0 111.32 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.509 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.42 -33.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.997 -1.064 . . . . 0.0 110.872 -179.699 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.551 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . 1.9 p -88.02 39.16 0.88 Allowed 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 108' ' ' VAL . 8.9 t -60.63 -10.93 5.9 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.377 -0.827 . . . . 0.0 111.698 -178.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.57 ' C ' ' O ' ' A' ' 111' ' ' THR . 0.6 OUTLIER 16.56 -84.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 CA-C-O 121.094 0.473 . . . . 0.0 112.081 -179.839 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.537 ' O ' ' O ' ' A' ' 114' ' ' ARG . . . -83.54 52.99 4.81 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.537 ' O ' ' O ' ' A' ' 113' ' ' GLY . 10.6 ttt85 43.49 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 O-C-N 121.539 -0.977 . . . . 0.0 111.544 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.476 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -142.41 107.83 5.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.748 -1.22 . . . . 0.0 110.346 -179.128 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 33.3 t80 -69.43 118.39 12.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.105 -0.997 . . . . 0.0 109.247 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.532 ' HA ' ' HB3' ' A' ' 122' ' ' PHE . 7.4 t -83.84 158.09 21.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.146 -0.971 . . . . 0.0 111.301 -178.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.555 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -135.1 54.72 1.92 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.662 -0.649 . . . . 0.0 110.388 -179.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.3 -57.72 0.07 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.555 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -114.4 -23.75 9.21 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.844 -0.798 . . . . 0.0 111.24 -178.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.539 ' O ' ' CB ' ' A' ' 118' ' ' LEU . 5.5 tttt -138.72 147.27 42.51 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.904 -1.122 . . . . 0.0 110.796 -179.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.671 ' CD2' ' CG2' ' A' ' 86' ' ' ILE . 0.1 OUTLIER -116.02 -177.96 3.29 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.086 -1.009 . . . . 0.0 109.136 178.326 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.476 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.9 OUTLIER -156.42 141.23 17.06 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 110.342 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.536 ' N ' ' CD1' ' A' ' 124' ' ' ILE . 3.1 mp -111.28 129.65 66.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 110.34 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.429 ' OG1' ' N ' ' A' ' 126' ' ' SER . 1.7 t -145.15 -169.1 3.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.184 -0.947 . . . . 0.0 110.399 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.429 ' N ' ' OG1' ' A' ' 125' ' ' THR . 3.8 t -120.45 -89.25 0.61 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.848 . . . . 0.0 110.595 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' A' ' 128' ' ' LEU . 13.3 mt-10 -52.78 161.6 0.72 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.419 -0.8 . . . . 0.0 110.511 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.475 ' O ' ' O ' ' A' ' 127' ' ' GLU . 29.6 mt . . . . . 0 C--N 1.307 -1.256 0 O-C-N 121.551 -0.718 . . . . 0.0 110.888 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.118 0.485 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.488 ' HB2' ' HB2' ' A' ' 126' ' ' SER . 77.9 m-20 -86.25 109.89 19.25 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.186 -0.946 . . . . 0.0 110.457 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.467 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.41 146.38 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.656 -0.653 . . . . 0.0 110.474 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.468 ' CG2' ' C ' ' A' ' 125' ' ' THR . 1.9 t -136.56 120.95 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.843 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.402 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 9.6 p -97.64 134.79 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.581 ' HA ' ' OG ' ' A' ' 110' ' ' SER . 9.2 tp -106.98 147.96 29.25 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.637 ' HB ' ' HB3' ' A' ' 110' ' ' SER . 50.6 t -149.07 126.58 2.65 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 120.576 -1.328 . . . . 0.0 110.322 -178.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.62 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 12.4 tp -135.73 178.71 6.83 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.526 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 8.6 ptp -78.61 178.5 7.77 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.725 -1.235 . . . . 0.0 110.79 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.463 ' HD3' ' N ' ' A' ' 74' ' ' GLY . 4.4 mtmt -64.09 95.9 0.13 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.539 -0.726 . . . . 0.0 112.127 -178.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.515 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 0.2 OUTLIER -73.85 -0.96 17.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 0.0 109.712 178.224 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 45' ' ' SER . 8.0 t0 74.82 -58.96 0.56 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.501 -0.75 . . . . 0.0 112.297 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.498 ' O ' HG12 ' A' ' 51' ' ' ILE . 1.4 mt-10 -95.06 23.68 5.47 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.809 -1.182 . . . . 0.0 111.781 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.791 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -63.23 -71.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 120.823 -1.173 . . . . 0.0 111.674 -179.494 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.566 ' C ' ' O ' ' A' ' 48' ' ' ILE . 15.6 t0 -36.8 -34.2 0.07 Allowed 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.051 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.516 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -77.65 -54.83 5.92 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.791 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.24 -50.8 33.75 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 O-C-N 120.757 -1.214 . . . . 0.0 109.324 178.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.583 ' HA ' HG21 ' A' ' 55' ' ' ILE . 36.4 mm -46.13 -39.33 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 119.798 -1.814 . . . . 0.0 108.506 177.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.573 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 3.8 tm-20 -64.39 -61.5 2.19 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.185 -0.947 . . . . 0.0 110.333 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -80.69 -10.83 59.7 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.254 -0.904 . . . . 0.0 111.258 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.685 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.8 tp -106.18 -33.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 CA-C-O 121.644 0.735 . . . . 0.0 110.467 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.577 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.4 t -117.39 -45.31 3.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.3 -177.448 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.573 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -58.61 -39.15 79.61 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.096 -1.628 . . . . 0.0 108.492 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.516 ' N ' HD21 ' A' ' 57' ' ' LEU . 1.3 tttt -100.02 -41.04 7.34 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 55' ' ' ILE . . . -67.32 -49.02 55.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.491 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -81.39 23.64 4.63 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 120.926 -1.338 . . . . 0.0 110.366 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -107.54 -9.27 15.96 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.854 -1.38 . . . . 0.0 110.76 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.47 -84.8 0.31 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 120.95 -1.094 . . . . 0.0 110.109 -179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.417 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 4.7 ptpt -70.0 -35.82 74.67 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.491 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.6 OUTLIER -69.36 122.68 86.34 Favored Pre-proline 0 C--N 1.298 -1.668 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.811 179.138 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.422 ' HG2' ' HB3' ' A' ' 81' ' ' ASP . 43.7 Cg_endo -63.26 -45.6 11.78 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 121.733 1.622 . . . . 0.0 110.924 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.457 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 0.6 OUTLIER 179.37 111.57 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 CA-C-O 122.92 1.343 . . . . 0.0 109.653 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.628 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.297 1.3 mp -106.68 133.97 49.67 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.403 0 CA-C-N 114.012 -1.449 . . . . 0.0 111.728 -176.799 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.562 ' HB ' ' CG ' ' A' ' 79' ' ' LYS . 1.0 OUTLIER -91.81 139.28 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.555 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.567 ' CG2' ' CG2' ' A' ' 52' ' ' ILE . 72.9 t -104.76 89.3 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.178 -0.952 . . . . 0.0 110.328 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.721 ' HB3' ' HB2' ' A' ' 77' ' ' TRP . 0.3 OUTLIER -82.04 50.55 1.59 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -0.795 . . . . 0.0 110.231 179.928 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . 0.478 ' OD2' ' HB2' ' A' ' 49' ' ' ASP . 3.5 t70 -77.66 109.38 11.59 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.036 -1.04 . . . . 0.0 110.095 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.8 tttt -129.21 142.06 50.97 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.027 -1.046 . . . . 0.0 109.711 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.81 86.78 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.881 . . . . 0.0 109.633 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 158.72 -49.26 0.41 Allowed Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.548 ' HB3' ' CD1' ' A' ' 77' ' ' TRP . 5.1 m-85 -143.62 145.13 32.24 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.814 -0.815 . . . . 0.0 110.418 -179.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.719 ' CG ' HG22 ' A' ' 48' ' ' ILE . 17.8 t90 -94.25 80.14 3.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.613 -0.679 . . . . 0.0 109.989 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.721 ' HB2' ' HB3' ' A' ' 70' ' ' GLU . 7.9 m95 -87.83 128.27 35.34 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 109.039 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -131.95 137.41 54.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.794 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.562 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 5.5 tttp -118.09 143.36 46.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.506 -1.371 . . . . 0.0 110.818 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.485 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -134.28 134.78 42.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.578 -0.701 . . . . 0.0 110.028 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.422 ' HB3' ' HG2' ' A' ' 65' ' ' PRO . 1.1 t0 -86.27 51.29 2.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.207 -0.933 . . . . 0.0 110.267 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.82 -120.37 0.54 Allowed Glycine 0 C--N 1.3 -1.419 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -113.8 164.29 13.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.367 -1.078 . . . . 0.0 109.372 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.468 HG21 ' O ' ' A' ' 124' ' ' ILE . 4.2 tp -147.83 144.07 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.952 -1.093 . . . . 0.0 110.56 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -122.34 150.45 42.38 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.401 -0.812 . . . . 0.0 110.178 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.695 HG21 ' CG ' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -161.42 169.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.459 -0.776 . . . . 0.0 109.651 -179.158 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' A' ' 86' ' ' ILE . 77.7 m-20 -139.63 -173.13 3.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.09 -1.006 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.593 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -131.56 -19.26 2.72 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.092 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.417 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -40.67 -46.15 2.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.076 -1.015 . . . . 0.0 110.537 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -48.63 -54.31 15.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.333 -0.854 . . . . 0.0 109.674 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.532 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -52.67 -28.3 21.09 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.462 -0.774 . . . . 0.0 109.701 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.745 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -70.84 -31.15 67.44 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -69.77 -24.08 63.46 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.549 ' HB3' ' CD2' ' A' ' 95' ' ' LEU . 0.4 OUTLIER -78.69 -59.16 2.89 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.613 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.549 ' CD2' ' HB3' ' A' ' 94' ' ' LEU . 0.2 OUTLIER -110.07 -29.34 8.26 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.178 -0.951 . . . . 0.0 110.897 179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 68.56 42.65 80.24 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.663 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 33.2 mttt -133.05 -134.41 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.403 0 O-C-N 121.261 -1.141 . . . . 0.0 109.947 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.663 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.4 Cg_endo -71.78 -4.3 14.82 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 N-CA-C 108.683 -1.314 . . . . 0.0 108.683 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.75 ' CD1' ' N ' ' A' ' 100' ' ' SER . 4.1 p90 -26.56 -42.29 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.88 0.848 . . . . 0.0 111.72 178.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.3 OUTLIER -52.34 -53.09 49.12 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-O 122.593 1.187 . . . . 0.0 108.779 -177.493 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.584 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 59.7 t -102.63 -46.22 10.79 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.463 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 64.7 t80 -52.05 -32.17 33.36 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 117.559 -1.656 . . . . 0.0 107.588 179.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 3.1 t70 -79.63 -50.7 10.27 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.479 -0.888 . . . . 0.0 108.906 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.602 ' O ' ' CG1' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -55.05 -42.74 73.09 Favored 'General case' 0 C--O 1.204 -1.296 0 C-N-CA 116.913 -1.915 . . . . 0.0 108.515 179.398 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.543 HD13 ' CG1' ' A' ' 101' ' ' VAL . 52.6 mt -59.07 -29.4 67.3 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.871 -1.143 . . . . 0.0 111.352 179.506 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.439 HD11 ' O ' ' A' ' 102' ' ' TYR . 1.1 mt -92.05 -41.23 12.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 120.939 -1.101 . . . . 0.0 110.879 -178.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.534 ' O ' ' O ' ' A' ' 41' ' ' VAL . 0.1 OUTLIER -90.99 -17.24 26.64 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.903 -1.123 . . . . 0.0 110.967 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.602 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 9.1 p -69.48 -3.58 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.089 -1.632 . . . . 0.0 110.093 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -35.1 -27.96 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.667 -0.646 . . . . 0.0 111.35 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.637 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -66.68 8.34 0.26 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 111.399 178.987 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.547 ' OG1' ' CB ' ' A' ' 115' ' ' ALA . 1.4 t -86.14 38.55 0.77 Allowed 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 117.922 -1.511 . . . . 0.0 110.633 -178.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 19.4 m -55.59 -21.48 9.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 O-C-N 121.42 -0.8 . . . . 0.0 110.861 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -105.72 -71.26 0.8 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -143.83 158.14 43.89 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.377 -1.072 . . . . 0.0 110.105 -179.733 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.549 ' HA ' HD13 ' A' ' 124' ' ' ILE . . . -160.67 83.79 0.68 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.168 -0.957 . . . . 0.0 111.201 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.448 ' HB2' HG23 ' A' ' 123' ' ' THR . 1.3 m-85 -80.26 117.59 21.17 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.225 -0.922 . . . . 0.0 108.811 178.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.482 ' O ' HG21 ' A' ' 117' ' ' THR . 4.3 t -84.86 131.98 34.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.146 -0.971 . . . . 0.0 110.406 -179.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.589 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -102.01 38.37 1.66 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 110.396 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.95 -59.64 0.14 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 118' ' ' LEU . 62.3 m -107.5 -13.79 14.99 Favored 'General case' 0 C--N 1.291 -1.935 0 O-C-N 121.941 -0.741 . . . . 0.0 110.059 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.523 ' HB2' ' CB ' ' A' ' 118' ' ' LEU . 1.0 OUTLIER -125.96 165.85 18.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.078 -1.014 . . . . 0.0 111.507 -179.397 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.695 ' CG ' HG21 ' A' ' 86' ' ' ILE 0.255 0.0 OUTLIER -124.9 145.26 49.91 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.896 . . . . . . . . 4 4 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.464 ' C ' HD13 ' A' ' 124' ' ' ILE . 0.7 OUTLIER -144.42 110.15 5.31 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.252 -1.53 . . . . 0.0 110.247 -178.18 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.642 HD11 ' CE1' ' A' ' 122' ' ' PHE . 1.5 mp -113.02 153.7 14.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' A' ' 38' ' ' VAL . 10.2 t -159.52 -176.86 6.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.542 -1.349 . . . . 0.0 111.721 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.488 ' HB2' ' HB2' ' A' ' 36' ' ' ASN . 80.6 p -86.68 -76.07 0.37 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.616 -0.677 . . . . 0.0 110.299 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 6.0 mt-10 -94.26 -166.82 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.384 -0.823 . . . . 0.0 110.711 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--N 1.307 -1.275 0 O-C-N 121.554 -0.716 . . . . 0.0 111.237 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 36' ' ' ASN . 8.1 p . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 120.987 0.423 . . . . 0.0 110.051 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.546 ' CB ' ' O ' ' A' ' 35' ' ' SER . 5.7 m120 77.31 -13.13 0.98 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.791 -0.568 . . . . 0.0 110.995 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -40.35 116.03 0.63 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.138 -0.976 . . . . 0.0 110.97 -179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.534 ' CG2' ' CB ' ' A' ' 126' ' ' SER . 3.2 t -121.86 148.96 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.384 -0.823 . . . . 0.0 109.729 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.505 ' O ' ' HB2' ' A' ' 110' ' ' SER . 9.4 p -127.92 139.07 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 111.299 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.543 ' CD2' HD12 ' A' ' 84' ' ' ILE . 9.3 tp -117.25 128.67 55.31 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.68 HG12 ' CD1' ' A' ' 77' ' ' TRP . 39.9 t -130.35 150.94 35.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 O-C-N 120.776 -1.203 . . . . 0.0 112.013 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.539 ' CB ' ' CE3' ' A' ' 76' ' ' TRP . 0.1 OUTLIER -143.09 176.91 8.75 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 177.544 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.501 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 6.5 ptt? -110.55 36.34 3.13 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.697 -1.252 . . . . 0.0 110.218 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.529 ' HB3' ' CD1' ' A' ' 48' ' ' ILE . 5.1 mmtt -88.51 -81.27 0.26 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.482 -0.761 . . . . 0.0 112.409 -178.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.535 ' H ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER 67.99 92.97 0.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.197 -178.692 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.48 ' HB2' ' O ' ' A' ' 45' ' ' SER . 3.5 t70 170.96 -80.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.416 -0.803 . . . . 0.0 110.029 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.553 ' HB3' HD11 ' A' ' 51' ' ' ILE . 13.4 mt-10 -91.9 -10.3 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.891 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.809 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -60.65 -64.76 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.341 -0.849 . . . . 0.0 111.526 -178.933 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 2.1 t70 -41.11 -36.88 0.78 Allowed 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 118.769 -1.172 . . . . 0.0 108.961 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.475 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -76.19 -52.97 8.97 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.545 -0.722 . . . . 0.0 110.094 178.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.809 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.3 OUTLIER -70.6 -50.03 47.84 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.06 0 O-C-N 120.6 -1.312 . . . . 0.0 108.943 179.104 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.605 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 48.1 mm -43.41 -39.87 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.302 -1.498 . . . . 0.0 108.263 177.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.585 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 24.8 tt0 -65.86 -63.93 0.97 Allowed 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.437 179.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -77.79 -9.79 59.21 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.196 -0.94 . . . . 0.0 111.299 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.69 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.6 tp -106.61 -34.96 2.99 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-O 121.753 0.787 . . . . 0.0 110.359 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.605 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.2 t -117.24 -46.31 3.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.961 -0.696 . . . . 0.0 112.202 -177.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.585 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.3 OUTLIER -56.53 -39.1 72.78 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.274 -1.516 . . . . 0.0 109.502 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.9 tttp -93.58 -49.74 5.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.0 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.94 -42.38 9.69 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.574 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.46 -54.12 14.26 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.591 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 15.0 ttpt -67.6 12.57 0.09 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.624 -0.927 . . . . 0.0 112.552 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.89 -64.04 0.94 Allowed 'General case' 0 C--N 1.305 -1.33 0 O-C-N 120.56 -1.338 . . . . 0.0 108.351 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.2 mtmt -97.87 -22.06 16.56 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.591 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -69.25 128.98 92.25 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.179 179.779 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.74 -44.32 13.96 Favored 'Trans proline' 0 C--N 1.302 -1.905 0 C-N-CA 122.038 1.826 . . . . 0.0 111.603 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.431 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.44 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.331 0 CA-C-O 123.097 1.427 . . . . 0.0 109.567 -179.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.674 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.305 1.2 mp -97.8 140.87 16.98 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.538 0 CA-C-N 113.741 -1.572 . . . . 0.0 111.563 -176.898 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.542 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 3.1 t -83.23 137.0 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.454 -0.779 . . . . 0.0 110.01 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.545 HG21 ' CG2' ' A' ' 52' ' ' ILE . 27.6 t -119.99 81.77 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.133 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.633 ' HB2' ' CB ' ' A' ' 77' ' ' TRP . 1.9 mm-40 -78.91 141.13 37.87 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.364 -0.835 . . . . 0.0 110.289 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -145.7 127.88 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.286 -0.884 . . . . 0.0 109.614 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.517 ' O ' ' C ' ' A' ' 73' ' ' ALA . 3.7 ttpt -157.91 -176.9 6.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.021 -1.049 . . . . 0.0 111.326 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.517 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -25.99 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.343 0.592 . . . . 0.0 111.819 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 41.33 44.51 3.95 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.501 ' HA ' ' HA ' ' A' ' 43' ' ' MET . 0.1 OUTLIER -137.25 90.91 2.56 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 121.554 0.692 . . . . 0.0 110.044 179.86 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.701 ' CE2' HG23 ' A' ' 48' ' ' ILE . 8.8 t90 -83.0 82.28 8.3 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.436 -0.79 . . . . 0.0 109.547 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.68 ' CD1' HG12 ' A' ' 41' ' ' VAL . 13.6 m95 -89.59 131.27 35.69 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.141 -0.975 . . . . 0.0 110.975 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.557 ' CG1' ' NE1' ' A' ' 76' ' ' TRP . 21.3 mm -134.66 153.09 34.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.366 -0.834 . . . . 0.0 109.876 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.542 ' HG2' ' HB ' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -143.55 135.46 26.59 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.947 -179.378 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.555 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -136.43 140.23 42.99 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.597 -0.689 . . . . 0.0 110.03 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -84.46 51.15 2.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.012 . . . . 0.0 110.287 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.77 -148.38 5.97 Favored Glycine 0 N--CA 1.477 1.398 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -88.18 144.77 26.27 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.277 -1.131 . . . . 0.0 109.8 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.543 HD12 ' CD2' ' A' ' 40' ' ' LEU . 9.8 tt -142.46 172.85 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.962 . . . . 0.0 110.67 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.495 ' N ' ' CG1' ' A' ' 84' ' ' ILE . 15.4 mt-10 -131.71 176.41 8.35 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.955 -1.091 . . . . 0.0 112.017 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.613 ' CG2' ' CB ' ' A' ' 122' ' ' PHE . 0.0 OUTLIER -160.94 154.46 3.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.58 ' N ' ' CD1' ' A' ' 86' ' ' ILE . 4.8 m-20 -137.1 -178.7 5.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.796 -1.19 . . . . 0.0 111.903 -178.378 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.633 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -150.35 -29.9 0.21 Allowed 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.103 177.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.429 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -39.29 -47.03 1.64 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.062 -1.024 . . . . 0.0 110.663 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 93' ' ' GLU . 2.7 mm-40 -50.92 -63.34 1.16 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 121.871 0.843 . . . . 0.0 109.41 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.489 ' O ' HD13 ' A' ' 95' ' ' LEU . . . -38.61 -38.08 0.37 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.464 179.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.68 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -64.18 -42.49 97.95 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.044 -1.623 . . . . 0.0 109.044 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' N ' ' O ' ' A' ' 90' ' ' GLU . 14.0 mt-10 -60.14 -24.65 64.88 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.525 HD21 ' N ' ' A' ' 95' ' ' LEU . 8.7 tt -79.73 -60.38 2.37 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.523 -0.735 . . . . 0.0 110.469 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.542 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -109.95 -20.46 12.73 Favored 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.97 -179.456 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 63.05 90.4 0.03 OUTLIER Glycine 0 N--CA 1.497 2.71 0 C-N-CA 118.786 -1.674 . . . . 0.0 109.604 179.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.679 ' HB3' ' HD2' ' A' ' 98' ' ' PRO 0.261 0.2 OUTLIER -175.99 -151.69 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.192 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 -178.744 . . . . . . . . 4 4 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.679 ' HD2' ' HB3' ' A' ' 97' ' ' LYS . 43.1 Cg_endo -67.8 -1.99 7.79 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 N-CA-C 108.841 -1.253 . . . . 0.0 108.841 176.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.778 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.3 p90 -21.3 -44.58 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.641 0.734 . . . . 0.0 112.427 179.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.778 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -54.47 -53.78 49.65 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 122.868 1.318 . . . . 0.0 108.95 -177.104 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.56 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 48.3 t -98.44 -47.05 12.44 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.343 0 CA-C-N 115.147 -0.933 . . . . 0.0 113.267 -178.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.56 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 5.9 t80 -51.06 -29.22 12.24 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 117.512 -1.675 . . . . 0.0 107.843 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 8.8 t70 -80.9 -44.45 18.3 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.597 ' O ' ' CG1' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -59.55 -45.23 92.4 Favored 'General case' 0 C--O 1.201 -1.476 0 C-N-CA 117.833 -1.547 . . . . 0.0 109.102 178.861 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.537 HD13 ' CG1' ' A' ' 101' ' ' VAL . 2.5 mt -64.21 -27.29 68.96 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 119.893 -1.755 . . . . 0.0 111.062 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -95.18 -12.73 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 109.937 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.515 ' ND2' ' HA ' ' A' ' 104' ' ' LEU . 0.0 OUTLIER -118.86 -36.11 3.52 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.507 -0.745 . . . . 0.0 110.289 -179.196 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.597 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 1.8 p -62.69 -4.86 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.207 -0.933 . . . . 0.0 111.603 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.88 -27.22 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.399 -0.813 . . . . 0.0 111.81 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.583 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 90.6 p -82.24 28.84 0.43 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.877 -1.14 . . . . 0.0 109.791 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.463 ' HB ' HG23 ' A' ' 108' ' ' VAL . 5.4 t -89.49 42.89 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.945 -1.097 . . . . 0.0 109.38 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 96.7 t -57.95 -47.29 86.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.762 -0.586 . . . . 0.0 111.364 -179.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -78.01 -75.19 0.97 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.511 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -152.95 -176.98 6.0 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.238 -1.154 . . . . 0.0 110.538 -179.14 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.437 ' HB3' HG13 ' A' ' 124' ' ' ILE . . . -170.36 73.77 0.07 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.368 -0.833 . . . . 0.0 110.317 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.451 ' HB3' HG23 ' A' ' 123' ' ' THR . 17.5 t80 -72.69 140.67 48.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 18.8 m -89.3 117.55 28.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 110.532 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.667 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -86.64 39.61 0.85 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.431 -0.793 . . . . 0.0 110.728 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 59.6 -62.01 0.01 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.311 -1.115 . . . . 0.0 110.311 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.667 ' N ' ' O ' ' A' ' 118' ' ' LEU . 38.3 p -88.44 -28.62 20.77 Favored 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.928 -0.748 . . . . 0.0 109.979 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.526 ' O ' ' N ' ' A' ' 118' ' ' LEU . 3.6 ptmt -146.1 -167.76 2.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.129 -0.982 . . . . 0.0 110.665 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.613 ' CB ' ' CG2' ' A' ' 86' ' ' ILE . 5.8 m-85 -116.77 165.07 13.72 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.321 -0.862 . . . . 0.0 110.85 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.498 ' O ' ' CG2' ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.22 105.1 5.61 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.659 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.512 HD11 ' CG2' ' A' ' 86' ' ' ILE . 1.8 mp -108.2 141.57 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -0.952 . . . . 0.0 109.623 -179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 13.4 t -149.94 -170.76 3.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.06 -1.025 . . . . 0.0 111.11 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.534 ' CB ' ' CG2' ' A' ' 38' ' ' VAL . 0.4 OUTLIER -96.54 -33.51 11.8 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.44 -0.787 . . . . 0.0 110.537 -179.929 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' A' ' 128' ' ' LEU . 1.7 mm-40 -37.65 105.49 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.65 -0.656 . . . . 0.0 110.68 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.496 ' O ' ' O ' ' A' ' 127' ' ' GLU . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.275 0 O-C-N 121.63 -0.669 . . . . 0.0 110.582 -179.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.147 0.499 . . . . 0.0 109.839 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.508 ' O ' ' C ' ' A' ' 37' ' ' ALA . 31.5 m-20 -129.86 -92.86 0.43 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 110.59 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.508 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -27.25 127.28 0.06 Allowed 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.347 0.594 . . . . 0.0 111.997 -179.303 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.485 HG11 ' O ' ' A' ' 36' ' ' ASN . 14.5 m -111.76 174.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.502 ' O ' ' HB3' ' A' ' 110' ' ' SER . 13.2 p -144.78 125.1 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.139 -0.975 . . . . 0.0 110.783 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.533 HD12 ' CG1' ' A' ' 86' ' ' ILE . 20.6 tp -92.85 162.85 13.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.596 HG12 ' CE2' ' A' ' 77' ' ' TRP . 5.6 t -149.65 123.47 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 O-C-N 120.106 -1.621 . . . . 0.0 111.833 -178.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.592 HD11 ' CZ3' ' A' ' 76' ' ' TRP . 0.2 OUTLIER -126.36 156.35 40.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.127 -0.983 . . . . 0.0 109.853 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.505 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.6 ptm -96.98 31.38 2.41 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.921 -1.112 . . . . 0.0 110.183 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.517 ' O ' ' HA2' ' A' ' 74' ' ' GLY . 2.3 mmtt -87.74 -86.59 0.16 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.482 -0.761 . . . . 0.0 110.956 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.525 ' CA ' HD12 ' A' ' 48' ' ' ILE . 0.2 OUTLIER 73.37 113.26 0.06 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.36 -0.838 . . . . 0.0 110.746 -179.834 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.523 ' N ' HD12 ' A' ' 48' ' ' ILE . 0.3 OUTLIER 164.73 -83.95 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.665 -0.647 . . . . 0.0 109.438 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.465 ' O ' HG12 ' A' ' 51' ' ' ILE . 5.1 mt-10 -95.52 1.1 53.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.866 . . . . 0.0 110.045 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.796 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -61.93 -66.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.103 -0.998 . . . . 0.0 111.046 -178.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.528 ' C ' ' O ' ' A' ' 48' ' ' ILE . 5.3 t0 -40.09 -33.58 0.24 Allowed 'General case' 0 C--N 1.292 -1.932 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.68 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.484 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -78.71 -55.5 5.13 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.717 -0.614 . . . . 0.0 109.835 178.235 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.796 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -68.31 -48.43 73.31 Favored 'Isoleucine or valine' 0 C--O 1.185 -2.316 0 C-N-CA 118.301 -1.36 . . . . 0.0 108.232 178.642 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.596 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 46.3 mm -43.32 -41.19 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.004 -1.685 . . . . 0.0 108.42 176.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.556 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 16.2 tt0 -64.84 -62.91 1.28 Allowed 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.895 -1.128 . . . . 0.0 110.025 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -77.41 -11.78 59.88 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.323 -0.86 . . . . 0.0 111.584 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.703 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.5 tp -107.23 -33.47 2.66 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.531 0.682 . . . . 0.0 111.039 -178.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.596 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.8 t -117.22 -45.17 3.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.598 -0.689 . . . . 0.0 112.153 -177.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.556 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -54.58 -30.08 53.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 119.758 -1.839 . . . . 0.0 108.959 -179.798 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.533 ' N ' HD21 ' A' ' 57' ' ' LEU . 13.4 mmtt -85.99 -47.49 9.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.473 -0.767 . . . . 0.0 110.483 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.44 -45.09 5.37 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.58 ' N ' ' O ' ' A' ' 56' ' ' VAL . . . -68.97 -73.04 0.76 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.574 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 22.4 ttpt -65.72 9.84 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.403 -1.057 . . . . 0.0 112.557 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.63 -63.47 1.13 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.555 -1.341 . . . . 0.0 108.454 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.0 mtmt -97.97 -20.34 17.48 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 177.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.574 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.8 OUTLIER -68.68 141.1 92.43 Favored Pre-proline 0 N--CA 1.489 1.503 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.393 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.438 ' O ' ' OG ' ' A' ' 66' ' ' SER . 42.9 Cg_endo -62.38 -46.38 12.35 Favored 'Trans proline' 0 C--N 1.298 -2.107 0 C-N-CA 122.228 1.952 . . . . 0.0 112.002 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 65' ' ' PRO . 0.9 OUTLIER 178.81 112.99 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 123.158 1.456 . . . . 0.0 110.66 -179.691 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.69 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.306 1.0 OUTLIER -89.99 147.67 5.06 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.684 0 CA-C-N 113.573 -1.649 . . . . 0.0 110.86 -178.185 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.562 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -102.05 138.21 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.133 -0.98 . . . . 0.0 110.695 -179.581 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.518 ' HA ' HD11 ' A' ' 78' ' ' ILE . 5.5 t -116.82 90.97 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.372 -0.83 . . . . 0.0 109.073 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.567 ' CB ' ' HB2' ' A' ' 77' ' ' TRP . 13.2 mm-40 -79.61 76.51 6.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.487 -0.758 . . . . 0.0 110.655 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -89.04 113.62 24.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.973 -1.079 . . . . 0.0 109.485 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.471 ' O ' ' OG ' ' A' ' 45' ' ' SER . 13.0 mttp -145.47 -162.02 1.42 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.032 -1.042 . . . . 0.0 111.059 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.574 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -39.76 96.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.335 -0.853 . . . . 0.0 111.243 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.517 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 37.73 50.1 1.93 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.574 ' CD2' ' O ' ' A' ' 73' ' ' ALA . 8.6 m-85 -146.59 87.14 1.69 Allowed 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.875 -0.779 . . . . 0.0 109.761 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.726 ' CE2' HG23 ' A' ' 48' ' ' ILE . 4.5 t90 -82.13 74.16 9.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.516 -0.74 . . . . 0.0 110.033 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.596 ' CE2' HG12 ' A' ' 41' ' ' VAL . 8.9 m95 -82.0 123.33 28.81 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.581 ' CG1' ' NE1' ' A' ' 76' ' ' TRP . 5.5 mm -116.38 141.01 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.003 -1.061 . . . . 0.0 110.159 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.562 ' HG2' ' HB ' ' A' ' 68' ' ' VAL . 0.4 OUTLIER -123.61 130.52 52.79 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.612 -0.68 . . . . 0.0 109.598 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.5 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -130.28 165.89 21.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.222 -0.924 . . . . 0.0 110.289 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -118.35 50.32 1.18 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.341 -0.849 . . . . 0.0 110.304 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -119.77 0.52 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -112.22 152.67 28.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -1.115 . . . . 0.0 109.717 179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.531 ' CG2' HG23 ' A' ' 124' ' ' ILE . 8.1 tt -152.41 175.19 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.474 ' N ' ' CG1' ' A' ' 84' ' ' ILE . 56.2 mt-10 -148.16 172.47 14.27 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.007 -1.058 . . . . 0.0 111.315 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.691 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -124.48 167.62 18.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 121.601 -0.687 . . . . 0.0 109.552 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.417 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 26.0 m-20 -154.98 138.97 16.37 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.015 -1.053 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.574 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -151.73 -37.52 0.12 Allowed 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.379 -1.328 . . . . 0.0 111.0 177.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.477 ' O ' ' HG2' ' A' ' 93' ' ' GLU . . . -39.89 -40.27 0.97 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.501 -0.75 . . . . 0.0 110.567 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.52 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 3.2 mt-10 -72.06 -43.97 64.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.317 -0.864 . . . . 0.0 109.408 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.567 ' HB2' ' CE1' ' A' ' 99' ' ' PHE . . . -60.35 -49.84 75.99 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 108.955 179.206 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.53 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -53.53 -57.43 15.66 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.52 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 7.1 pt-20 -59.98 -13.24 10.38 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.332 -1.099 . . . . 0.0 110.038 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.545 HD22 ' N ' ' A' ' 95' ' ' LEU . 0.5 OUTLIER -92.22 -43.75 9.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.317 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.609 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -97.64 -41.31 8.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.795 -1.191 . . . . 0.0 109.247 179.464 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.565 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -145.33 -74.7 0.02 OUTLIER Glycine 0 N--CA 1.483 1.805 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.565 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.3 OUTLIER 161.61 -55.77 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.858 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.737 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.528 ' HD2' ' N ' ' A' ' 97' ' ' LYS . 52.2 Cg_endo -74.66 -23.54 14.49 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.856 1.45 . . . . 0.0 110.251 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.609 ' CG ' HD12 ' A' ' 95' ' ' LEU . 2.6 t80 -47.28 -49.42 23.71 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.223 -0.923 . . . . 0.0 109.996 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.574 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 29.5 p -31.97 -64.12 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.889 0.852 . . . . 0.0 110.429 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.586 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 13.8 t -72.69 -60.78 2.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 O-C-N 121.034 -1.041 . . . . 0.0 112.572 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 101' ' ' VAL . 1.7 t80 -44.94 -30.48 1.02 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.532 -1.355 . . . . 0.0 109.332 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 6.4 t0 -77.08 -31.52 56.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.598 -0.689 . . . . 0.0 109.287 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.627 ' O ' ' CG1' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -74.81 -19.49 60.17 Favored 'General case' 0 C--O 1.2 -1.51 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.24 179.739 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.546 HD13 ' CG1' ' A' ' 101' ' ' VAL . 1.4 mt -91.27 -26.12 19.14 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.345 -1.472 . . . . 0.0 111.226 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -97.22 -13.58 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.015 -1.053 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.551 ' O ' ' O ' ' A' ' 41' ' ' VAL . 0.1 OUTLIER -105.57 -42.9 5.08 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.509 -0.745 . . . . 0.0 110.012 179.766 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.627 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 3.5 p -57.32 -2.86 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 120.879 -1.138 . . . . 0.0 112.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.504 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -25.22 -39.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.77 -0.581 . . . . 0.0 112.365 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.576 ' N ' ' O ' ' A' ' 108' ' ' VAL . 1.9 m -80.27 43.14 0.61 Allowed 'General case' 0 C--N 1.287 -2.137 0 C-N-CA 118.43 -1.308 . . . . 0.0 108.79 178.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.543 ' CG2' HG12 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -63.33 2.02 0.44 Allowed 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.267 -0.896 . . . . 0.0 112.45 -179.146 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.454 ' C ' ' O ' ' A' ' 111' ' ' THR . 9.6 p -38.16 -27.24 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 120.808 -1.183 . . . . 0.0 111.17 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.535 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -97.64 50.22 1.41 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.535 ' C ' ' O ' ' A' ' 113' ' ' GLY . 1.5 ttm-85 19.86 100.36 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.356 0.598 . . . . 0.0 111.982 179.165 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.583 ' HB2' ' CE2' ' A' ' 122' ' ' PHE . . . -85.09 93.69 8.68 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.266 -0.896 . . . . 0.0 111.47 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 123' ' ' THR . 0.1 OUTLIER -74.44 143.91 44.5 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.189 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 4.0 m -79.51 160.21 26.62 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.79 -1.194 . . . . 0.0 111.309 -178.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.9 OUTLIER -130.62 35.33 4.03 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.665 -0.647 . . . . 0.0 109.891 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.49 -59.76 0.29 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.502 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -115.42 -9.24 12.15 Favored 'General case' 0 C--N 1.292 -1.908 0 O-C-N 122.013 -0.698 . . . . 0.0 110.186 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HB2' ' HB3' ' A' ' 118' ' ' LEU . 20.8 mttt -137.68 -162.26 1.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.151 -0.968 . . . . 0.0 111.195 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.691 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.263 0.1 OUTLIER -132.15 160.66 35.4 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.068 -179.235 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.516 ' N ' ' O ' ' A' ' 116' ' ' TYR . 0.9 OUTLIER -138.3 104.14 5.1 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.034 -1.041 . . . . 0.0 110.598 178.697 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.531 HG23 ' CG2' ' A' ' 84' ' ' ILE . 3.4 mp -98.44 146.78 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.201 -0.937 . . . . 0.0 108.59 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.41 ' N ' HG21 ' A' ' 124' ' ' ILE . 12.5 t -149.4 166.75 28.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.782 -1.199 . . . . 0.0 111.108 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.476 ' O ' ' O ' ' A' ' 127' ' ' GLU . 2.4 t -94.27 -32.69 13.54 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.555 0.693 . . . . 0.0 109.533 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' A' ' 128' ' ' LEU . 14.4 mm-40 -42.51 167.59 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.746 -0.596 . . . . 0.0 110.452 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.8 OUTLIER . . . . . 0 C--N 1.307 -1.277 0 O-C-N 121.297 -0.877 . . . . 0.0 110.804 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.1 m . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 121.212 0.53 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.466 ' O ' ' HB3' ' A' ' 126' ' ' SER . 4.0 m-20 -110.07 -1.69 17.4 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.374 -0.829 . . . . 0.0 110.276 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -31.87 141.32 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.569 0.699 . . . . 0.0 111.904 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.417 HG11 ' O ' ' A' ' 37' ' ' ALA . 24.2 m -141.42 176.17 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.472 -0.767 . . . . 0.0 109.709 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.486 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 5.5 p -136.46 130.5 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.953 -1.092 . . . . 0.0 111.097 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.599 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 12.4 tp -98.1 160.66 14.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 177.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.599 ' CG2' ' O ' ' A' ' 40' ' ' LEU . 2.9 t -166.31 116.4 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 O-C-N 120.871 -1.143 . . . . 0.0 110.093 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.6 ' CB ' ' CE3' ' A' ' 76' ' ' TRP . 2.5 mm? -135.38 -171.68 2.89 Favored 'General case' 0 C--N 1.289 -2.056 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.404 ' O ' ' N ' ' A' ' 45' ' ' SER . 20.9 ptm -104.09 161.43 14.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.161 -0.962 . . . . 0.0 109.813 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -44.75 96.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.3 -0.875 . . . . 0.0 111.263 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 4.5 m -82.11 11.81 4.86 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.165 -0.959 . . . . 0.0 110.265 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' SER . 13.3 t0 78.41 -62.51 0.34 Allowed 'General case' 0 N--CA 1.503 2.18 0 O-C-N 121.569 -0.707 . . . . 0.0 112.421 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.536 ' O ' HG12 ' A' ' 51' ' ' ILE . 3.5 mt-10 -93.31 26.56 2.88 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.776 -1.203 . . . . 0.0 112.195 -177.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.756 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.61 -75.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 120.932 -1.105 . . . . 0.0 111.092 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.3 t70 -37.63 -32.22 0.05 Allowed 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.45 -56.13 4.91 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 177.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.756 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -71.28 -52.14 29.02 Favored 'Isoleucine or valine' 0 C--O 1.193 -1.88 0 O-C-N 120.977 -1.077 . . . . 0.0 109.869 179.075 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.6 ' HA ' HG21 ' A' ' 55' ' ' ILE . 47.2 mm -48.22 -38.73 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 119.89 -1.756 . . . . 0.0 108.121 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.624 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.7 tt0 -63.07 -61.12 2.59 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.183 -0.948 . . . . 0.0 110.352 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -81.06 -12.0 59.4 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 111.405 -178.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.636 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.3 tp -105.88 -32.99 2.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-O 121.645 0.736 . . . . 0.0 110.365 -178.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.57 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.5 t -117.89 -45.08 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.869 -0.732 . . . . 0.0 112.694 -177.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.624 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -49.31 -42.75 42.34 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.011 -1.681 . . . . 0.0 109.037 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.528 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 14.3 mttt -85.08 -44.22 13.2 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.574 0.702 . . . . 0.0 109.51 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -65.54 -51.36 48.67 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.54 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -69.43 -8.36 59.38 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' A' ' 57' ' ' LEU . 2.1 tptm -107.36 -9.02 16.13 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.129 -1.218 . . . . 0.0 110.954 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.17 -79.05 0.24 Allowed 'General case' 0 C--N 1.308 -1.197 0 O-C-N 120.886 -1.134 . . . . 0.0 110.69 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.9 mtmt -87.45 -29.38 21.47 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.54 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.9 m-80 -69.18 124.99 91.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.113 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 66' ' ' SER . 42.9 Cg_endo -62.56 -42.87 24.34 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.781 1.654 . . . . 0.0 110.671 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.483 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 0.4 OUTLIER 179.4 110.0 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 123.008 1.385 . . . . 0.0 109.64 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.651 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.297 1.1 mp -105.37 149.99 8.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 113.839 -1.528 . . . . 0.0 110.496 -177.205 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.489 HG11 ' HB3' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -103.44 130.36 53.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.322 -0.861 . . . . 0.0 110.013 179.725 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.523 ' CG1' HG22 ' A' ' 52' ' ' ILE . 55.5 t -113.95 100.29 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.168 -0.957 . . . . 0.0 109.889 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.565 ' N ' ' O ' ' A' ' 77' ' ' TRP . 0.7 OUTLIER -89.81 79.55 6.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.385 -0.822 . . . . 0.0 110.681 -179.487 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -80.47 91.02 5.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.073 -1.017 . . . . 0.0 109.396 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.433 ' HB2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -89.78 154.45 19.9 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.159 -0.963 . . . . 0.0 110.482 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -59.63 -12.65 7.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.818 . . . . 0.0 110.548 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.452 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . -147.29 22.92 1.56 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.456 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.452 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 5.8 m-85 -160.77 108.8 1.57 Allowed 'General case' 0 C--N 1.289 -2.051 0 O-C-N 121.76 -0.847 . . . . 0.0 109.887 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.755 ' CE2' HG21 ' A' ' 48' ' ' ILE . 13.1 t90 -89.8 77.84 6.97 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.599 -0.688 . . . . 0.0 109.379 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.598 ' CE2' HG12 ' A' ' 41' ' ' VAL . 12.4 m0 -102.77 134.6 45.89 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.506 -0.746 . . . . 0.0 112.433 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.522 ' O ' ' N ' ' A' ' 40' ' ' LEU . 1.2 mp -138.65 152.39 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.489 ' HB3' HG11 ' A' ' 68' ' ' VAL . 0.4 OUTLIER -127.83 152.74 47.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.831 -1.168 . . . . 0.0 110.041 -179.728 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.484 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -139.42 178.86 6.9 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.299 -0.875 . . . . 0.0 110.603 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.418 ' HA ' ' HA ' ' A' ' 37' ' ' ALA . 41.6 m-20 -122.54 50.49 1.49 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.364 -0.835 . . . . 0.0 110.138 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.55 -126.66 0.88 Allowed Glycine 0 C--N 1.301 -1.386 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -99.8 143.93 29.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -1.22 . . . . 0.0 109.925 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.548 ' CD1' ' HB2' ' A' ' 40' ' ' LEU . 4.8 tp -125.85 161.99 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.145 -0.972 . . . . 0.0 110.012 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.526 ' N ' HG13 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.88 164.96 23.02 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.137 -0.977 . . . . 0.0 111.717 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.594 ' CG2' ' HB3' ' A' ' 122' ' ' PHE 0.26 0.3 OUTLIER -139.91 175.02 7.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.363 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.555 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 74.9 m-20 -149.55 173.37 13.69 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.861 -1.149 . . . . 0.0 111.308 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.637 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -150.96 -48.77 0.12 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.97 0.891 . . . . 0.0 109.759 177.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.414 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -41.37 -45.4 3.05 Favored 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.351 -0.843 . . . . 0.0 110.643 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.566 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 1.1 tt0 -49.81 -38.55 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 122.138 0.971 . . . . 0.0 108.483 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.577 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -63.45 -42.59 98.64 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.396 -0.815 . . . . 0.0 109.191 178.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.719 ' N ' ' CD2' ' A' ' 99' ' ' PHE . . . -63.15 -65.37 3.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.566 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 5.2 pt-20 -38.21 -31.56 0.05 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.818 -0.813 . . . . 0.0 108.94 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.548 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 0.1 OUTLIER -73.6 -71.16 0.33 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.68 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.577 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 0.1 OUTLIER -86.97 -55.17 3.95 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.972 -1.08 . . . . 0.0 108.847 178.599 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 88.18 50.14 3.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.696 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 15.2 mttt -150.74 -110.7 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 121.288 -1.125 . . . . 0.0 110.646 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.696 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 58.6 Cg_endo -85.5 12.98 2.89 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 CA-C-N 120.926 1.366 . . . . 0.0 109.67 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.729 ' O ' ' N ' ' A' ' 101' ' ' VAL . 29.3 p90 -49.85 -146.0 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 122.009 0.909 . . . . 0.0 110.474 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.696 ' N ' ' CD2' ' A' ' 99' ' ' PHE . 2.1 p 32.73 -77.59 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 122.269 1.033 . . . . 0.0 111.323 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.729 ' N ' ' O ' ' A' ' 99' ' ' PHE . 38.0 t -66.02 -64.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.582 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.491 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 16.0 t80 -59.89 -39.9 86.9 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 119.99 -1.694 . . . . 0.0 106.69 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.581 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 0.3 OUTLIER -63.42 -38.96 93.16 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.847 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.631 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 3.2 pp -83.75 -38.89 20.78 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 117.957 -1.497 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.59 ' N ' ' CD1' ' A' ' 104' ' ' LEU . 66.7 mt -49.82 -22.19 1.37 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 120.802 -1.186 . . . . 0.0 109.602 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -107.83 -33.4 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.288 -0.882 . . . . 0.0 110.15 179.768 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.581 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.7 p30 -96.7 -3.65 42.19 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.968 -1.082 . . . . 0.0 110.027 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.653 ' CG2' ' CE2' ' A' ' 122' ' ' PHE . 9.8 p -83.11 -7.7 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 110.804 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 108' ' ' VAL . 8.5 t -42.02 -22.91 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.193 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.595 ' CB ' ' N ' ' A' ' 41' ' ' VAL . 82.8 p -53.22 -4.31 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.313 -0.867 . . . . 0.0 112.641 179.283 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.533 ' CG2' HG12 ' A' ' 124' ' ' ILE . 45.1 p -71.76 -73.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.428 0 O-C-N 119.923 -1.736 . . . . 0.0 110.868 -178.105 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.5 ' HB ' ' O ' ' A' ' 111' ' ' THR . 47.9 t 61.78 11.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.517 -0.74 . . . . 0.0 110.575 -179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -161.2 -68.94 0.02 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.533 ' HB3' ' CG2' ' A' ' 125' ' ' THR . 0.1 OUTLIER -136.58 165.86 24.88 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.305 -1.114 . . . . 0.0 110.497 -179.38 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -156.25 68.79 0.62 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.318 -0.864 . . . . 0.0 110.185 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.542 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 7.1 t80 -69.69 132.15 45.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.246 -0.908 . . . . 0.0 109.657 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.4 m -88.57 138.87 31.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.147 -0.971 . . . . 0.0 110.305 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -108.73 37.19 2.6 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.381 -0.824 . . . . 0.0 110.197 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.21 -58.47 0.25 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.553 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.8 OUTLIER -113.38 -23.35 9.92 Favored 'General case' 0 C--N 1.293 -1.871 0 O-C-N 121.95 -0.735 . . . . 0.0 110.067 -179.873 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -116.69 -168.22 1.42 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.653 ' CE2' ' CG2' ' A' ' 108' ' ' VAL . 14.5 t80 -138.03 161.71 36.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.782 . . . . 0.0 109.159 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' A' ' 116' ' ' TYR . 0.8 OUTLIER -145.24 139.26 27.03 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 120.569 -1.332 . . . . 0.0 110.337 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.589 ' CD1' ' CD2' ' A' ' 122' ' ' PHE . 2.1 mp -134.91 154.39 36.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.467 -0.77 . . . . 0.0 110.18 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 114' ' ' ARG . 1.9 t -152.34 -175.04 5.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.186 -0.946 . . . . 0.0 110.34 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.466 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 90.4 p -89.51 -90.08 0.14 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.364 -0.835 . . . . 0.0 110.538 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.464 ' N ' ' OG ' ' A' ' 126' ' ' SER . 2.6 mt-10 -93.33 122.73 36.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.114 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.461 ' O ' ' O ' ' A' ' 127' ' ' GLU . 1.9 mp . . . . . 0 C--N 1.306 -1.286 0 O-C-N 121.451 -0.781 . . . . 0.0 110.335 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 37' ' ' ALA . 62.0 m . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 120.874 0.368 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.526 ' O ' ' C ' ' A' ' 37' ' ' ALA . 5.5 m-80 62.94 -64.91 0.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.719 . . . . 0.0 110.636 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -26.38 139.43 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.353 0.596 . . . . 0.0 111.496 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.452 HG13 ' OG ' ' A' ' 126' ' ' SER . 8.7 p -102.08 136.3 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.474 ' O ' ' HB2' ' A' ' 110' ' ' SER . 8.4 p -80.65 135.44 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.041 -1.037 . . . . 0.0 110.273 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.548 ' HB2' HG12 ' A' ' 84' ' ' ILE . 14.7 tp -110.42 134.48 52.29 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.635 HG12 ' CE2' ' A' ' 77' ' ' TRP . 10.1 t -130.63 121.24 50.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 O-C-N 120.86 -1.15 . . . . 0.0 110.942 -177.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.649 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 0.4 OUTLIER -120.54 -171.63 2.21 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.633 -0.667 . . . . 0.0 109.475 179.245 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.98 159.48 15.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.154 -0.967 . . . . 0.0 109.965 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.64 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.189 -0.945 . . . . 0.0 110.6 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.482 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 1.8 t -86.53 11.25 13.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 110.144 179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 45' ' ' SER . 5.5 m-20 67.71 -62.87 0.33 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.494 -0.754 . . . . 0.0 111.108 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.495 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.0 mt-10 -87.21 30.17 0.79 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.103 -0.998 . . . . 0.0 110.616 -179.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.882 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.36 -75.2 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.969 -1.082 . . . . 0.0 111.393 -178.698 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.527 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -39.47 -31.61 0.1 Allowed 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.305 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -75.4 -53.79 8.12 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.714 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.41 -53.55 19.1 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.76 0 O-C-N 120.997 -1.065 . . . . 0.0 109.992 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.599 ' HA ' HG21 ' A' ' 55' ' ' ILE . 44.8 mm -47.05 -37.15 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 119.962 -1.711 . . . . 0.0 108.106 177.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.603 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 30.2 tt0 -64.39 -63.43 1.14 Allowed 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.386 -0.821 . . . . 0.0 110.282 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.44 -10.03 59.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.354 -0.841 . . . . 0.0 111.295 -178.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.653 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.4 tp -106.68 -33.79 2.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-O 121.62 0.724 . . . . 0.0 110.371 -179.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.567 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.3 t -118.67 -43.22 2.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.08 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.603 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -44.98 -38.47 4.77 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.449 -1.407 . . . . 0.0 109.775 -178.346 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.53 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 0.0 OUTLIER -86.78 -44.61 11.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -56.55 -53.35 44.2 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.525 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -72.19 0.79 37.57 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 2.0 mmtt -106.57 -9.31 16.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.845 -1.385 . . . . 0.0 111.357 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.36 -80.05 0.12 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.888 -1.133 . . . . 0.0 109.852 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.58 -24.75 16.46 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 122.307 1.051 . . . . 0.0 108.411 178.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.525 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.4 m-20 -67.51 116.55 38.39 Favored Pre-proline 0 C--N 1.294 -1.844 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.727 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -62.99 -37.36 53.99 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 124.299 1.684 . . . . 0.0 111.558 -179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.446 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 0.3 OUTLIER 179.36 111.61 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 123.145 1.45 . . . . 0.0 109.908 179.423 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.644 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.298 1.2 mp -104.5 155.01 6.09 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 CA-C-N 113.665 -1.607 . . . . 0.0 111.024 -177.442 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.534 HG12 ' CE ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -110.55 147.04 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.172 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.532 ' HA ' ' CG1' ' A' ' 78' ' ' ILE . 58.1 t -128.5 106.18 14.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.15 -0.968 . . . . 0.0 110.093 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.523 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.3 mm-40 -97.16 84.06 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.779 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . 0.407 ' OD1' ' N ' ' A' ' 71' ' ' ASP . 15.7 p-10 -96.47 128.17 43.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.153 -0.967 . . . . 0.0 110.201 -179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -144.76 143.51 30.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 110.07 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -58.55 81.52 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 109.542 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 159.02 -40.11 0.49 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -139.94 173.81 11.15 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-O 121.835 0.826 . . . . 0.0 110.984 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.882 ' CE2' HG21 ' A' ' 48' ' ' ILE . 13.4 t90 -138.92 83.29 1.95 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.635 ' CE2' HG12 ' A' ' 41' ' ' VAL . 11.3 m95 -104.87 120.55 41.68 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.111 -0.993 . . . . 0.0 112.379 -177.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.564 HD13 ' CD1' ' A' ' 76' ' ' TRP . 1.1 mt -130.61 141.74 45.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.097 -1.002 . . . . 0.0 109.283 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.534 ' CE ' HG12 ' A' ' 68' ' ' VAL . 2.1 ptpt -114.12 134.17 55.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 110.028 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.496 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -120.16 148.91 43.05 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.317 -0.864 . . . . 0.0 109.838 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.485 ' HA ' ' CB ' ' A' ' 37' ' ' ALA . 1.4 m-20 -95.43 53.3 1.47 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.168 -0.958 . . . . 0.0 110.379 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.16 -116.79 0.39 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.405 ' HA ' ' HA ' ' A' ' 125' ' ' THR . . . -121.39 146.61 46.7 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.169 -1.195 . . . . 0.0 110.165 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.548 HG12 ' HB2' ' A' ' 40' ' ' LEU . 5.5 tp -133.53 159.72 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.042 -1.036 . . . . 0.0 110.698 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.479 ' N ' HG13 ' A' ' 84' ' ' ILE . 16.9 mt-10 -137.56 130.32 30.06 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.325 -0.86 . . . . 0.0 110.793 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.592 ' CB ' ' HB3' ' A' ' 122' ' ' PHE . 1.7 mm -86.37 -176.1 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.333 -0.854 . . . . 0.0 109.82 179.699 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -156.54 154.8 30.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 110.869 179.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.576 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -150.13 -25.39 0.25 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.361 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.434 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -39.52 -45.24 1.54 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.936 -1.103 . . . . 0.0 111.032 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.454 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 1.2 tp10 -54.34 -60.6 3.12 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.345 -0.847 . . . . 0.0 109.844 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.502 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -42.28 -31.71 0.42 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.5 -0.75 . . . . 0.0 109.836 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.701 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -72.09 -41.78 53.19 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.454 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 7.7 mt-10 -55.82 -24.74 38.04 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.103 -1.234 . . . . 0.0 108.29 179.105 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.528 ' CD2' HD21 ' A' ' 95' ' ' LEU . 15.4 tp -87.05 -70.95 0.58 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 121.277 0.561 . . . . 0.0 110.01 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.552 ' CD1' ' HB3' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -87.27 -29.82 21.36 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.653 179.821 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 62.5 46.36 93.95 Favored Glycine 0 N--CA 1.499 2.844 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.145 177.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.727 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 0.1 OUTLIER -143.69 -128.58 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.262 0 O-C-N 120.901 -1.352 . . . . 0.0 109.636 178.728 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.727 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.5 Cg_endo -68.9 -3.63 11.8 Favored 'Trans proline' 0 N--CA 1.499 1.852 0 CA-C-N 121.738 1.656 . . . . 0.0 110.034 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.723 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.7 p90 -30.17 -41.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.211 1.005 . . . . 0.0 111.434 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.723 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 4.4 t -53.49 -58.18 8.06 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-O 122.894 1.331 . . . . 0.0 110.082 -177.189 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.611 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 46.9 t -97.9 -37.41 6.63 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.471 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 2.9 t80 -59.6 -33.67 71.77 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 119.741 -1.849 . . . . 0.0 107.674 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.587 ' HB3' ' O ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER -76.04 -42.67 47.07 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 178.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.611 ' CD2' ' HA ' ' A' ' 101' ' ' VAL . 0.9 OUTLIER -68.01 -36.67 80.35 Favored 'General case' 0 C--O 1.209 -1.078 0 C-N-CA 117.38 -1.728 . . . . 0.0 107.563 177.933 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.61 ' CD2' ' CG1' ' A' ' 101' ' ' VAL . 0.3 OUTLIER -46.87 -49.39 20.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.801 178.852 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.45 HG21 HD11 ' A' ' 106' ' ' ILE . 4.6 mm -83.87 -26.37 7.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.598 -0.689 . . . . 0.0 110.355 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.566 ' ND2' ' HA ' ' A' ' 104' ' ' LEU . 1.2 p30 -104.34 18.37 22.28 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.176 -0.953 . . . . 0.0 110.7 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.55 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 8.4 p -121.56 -12.39 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 120.894 -1.129 . . . . 0.0 109.733 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -36.67 -27.31 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.499 -0.751 . . . . 0.0 112.222 -178.969 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.581 ' OG ' ' N ' ' A' ' 41' ' ' VAL . 54.4 p -86.06 34.05 0.61 Allowed 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.619 -1.3 . . . . 0.0 109.254 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.492 ' OG1' ' HB3' ' A' ' 115' ' ' ALA . 9.9 t -107.12 50.05 0.78 Allowed 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.645 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 66.4 t -80.75 -33.32 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.642 -0.661 . . . . 0.0 111.496 -178.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -66.92 -78.97 0.23 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.404 ' HB2' HG21 ' A' ' 125' ' ' THR . 0.4 OUTLIER -135.21 175.8 9.25 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.364 -1.08 . . . . 0.0 109.996 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 122' ' ' PHE . . . -167.39 75.16 0.14 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.905 -1.122 . . . . 0.0 111.226 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.512 ' N ' ' O ' ' A' ' 123' ' ' THR . 0.4 OUTLIER -77.76 116.72 18.5 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.189 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.1 m -79.23 129.02 34.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.063 . . . . 0.0 110.478 -179.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.548 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.4 OUTLIER -104.04 45.62 0.95 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.383 -0.823 . . . . 0.0 110.386 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.37 -58.52 0.11 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.548 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.3 OUTLIER -115.69 -12.72 11.5 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.885 -0.774 . . . . 0.0 110.995 -179.473 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 63.2 mttt -124.2 178.71 5.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.971 -1.081 . . . . 0.0 111.294 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.592 ' HB3' ' CB ' ' A' ' 86' ' ' ILE . 2.5 t80 -126.85 146.61 50.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.589 -0.695 . . . . 0.0 109.194 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.512 ' O ' ' N ' ' A' ' 116' ' ' TYR . 0.9 OUTLIER -134.8 123.03 22.91 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 120.678 -1.264 . . . . 0.0 110.688 -179.701 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.546 HD12 ' CG1' ' A' ' 86' ' ' ILE . 3.4 mp -124.39 168.51 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 83' ' ' ALA . 9.0 t -159.09 154.87 26.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.555 -1.34 . . . . 0.0 111.518 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 0.7 OUTLIER -94.61 -49.99 5.39 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.627 -0.671 . . . . 0.0 109.986 179.753 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' A' ' 128' ' ' LEU . 41.5 mt-10 -81.29 144.0 31.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 110.222 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.497 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--N 1.304 -1.394 0 O-C-N 121.574 -0.704 . . . . 0.0 110.519 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 37' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.216 0.531 . . . . 0.0 110.017 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.456 ' O ' ' C ' ' A' ' 37' ' ' ALA . 1.5 m-80 61.4 -76.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.212 -0.93 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -36.45 127.31 0.81 Allowed 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 121.372 0.606 . . . . 0.0 111.083 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.529 ' CG1' HG23 ' A' ' 124' ' ' ILE . 15.7 t -129.95 141.38 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 109.698 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.536 ' O ' ' HB2' ' A' ' 110' ' ' SER . 4.0 p -107.95 133.13 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 120.945 -1.097 . . . . 0.0 111.205 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.532 ' HB2' HG12 ' A' ' 84' ' ' ILE . 4.8 tp -105.4 143.51 33.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.643 HG12 ' CE2' ' A' ' 77' ' ' TRP . 11.4 t -139.84 129.2 28.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 O-C-N 120.462 -1.399 . . . . 0.0 111.909 -178.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.538 HD11 ' CZ3' ' A' ' 76' ' ' TRP . 11.3 mt -135.42 -172.16 3.01 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.301 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.477 ' O ' ' N ' ' A' ' 45' ' ' SER . 8.0 ptm -100.31 151.96 20.88 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.827 -1.171 . . . . 0.0 110.466 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.451 ' HB2' ' HA2' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -48.14 89.28 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.468 -0.77 . . . . 0.0 111.543 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 43' ' ' MET . 29.6 t -65.1 -88.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.175 -0.953 . . . . 0.0 109.531 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -151.78 -77.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.879 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.485 ' O ' HG12 ' A' ' 51' ' ' ILE . 4.1 mt-10 -96.07 34.28 1.59 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.356 -0.84 . . . . 0.0 110.979 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.761 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.39 -64.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.792 -1.193 . . . . 0.0 111.633 -178.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.48 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -44.58 -38.12 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 118.702 -1.199 . . . . 0.0 108.746 179.354 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.458 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.79 -49.03 19.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.53 -0.732 . . . . 0.0 110.25 178.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.761 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.04 -51.03 28.17 Favored 'Isoleucine or valine' 0 C--O 1.191 -1.995 0 O-C-N 120.703 -1.248 . . . . 0.0 109.313 179.341 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.608 ' HA ' HG21 ' A' ' 55' ' ' ILE . 41.9 mm -45.53 -39.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.097 -1.627 . . . . 0.0 108.155 177.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.561 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 48.1 tt0 -62.72 -63.48 1.2 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -81.62 -8.19 59.68 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.289 -0.882 . . . . 0.0 111.398 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.666 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.7 tp -107.09 -33.72 2.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 CA-C-O 121.776 0.798 . . . . 0.0 110.137 -179.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.582 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 3.0 t -117.88 -44.83 3.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 C-N-CA 120.041 -0.664 . . . . 0.0 112.627 -177.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.561 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -60.69 -36.82 79.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.364 -1.46 . . . . 0.0 109.033 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.8 tmtt? -100.93 -44.67 5.67 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.821 0.819 . . . . 0.0 109.037 178.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -69.2 -52.24 23.75 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.577 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.66 -43.85 73.9 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.822 -1.399 . . . . 0.0 110.155 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.548 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 12.9 ttmt -63.15 9.23 0.05 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.522 -0.987 . . . . 0.0 113.196 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.62 -63.8 1.03 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.225 -1.547 . . . . 0.0 108.854 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.12 -21.43 17.34 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 177.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.578 ' HB3' ' CD1' ' A' ' 67' ' ' ILE . 0.4 OUTLIER -68.61 124.1 89.27 Favored Pre-proline 0 C--N 1.301 -1.514 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.911 -179.648 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.451 ' O ' ' OG ' ' A' ' 66' ' ' SER . 48.7 Cg_endo -65.38 -48.23 3.55 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.093 1.862 . . . . 0.0 111.953 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.476 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 4.8 m -164.49 106.92 0.88 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 123.322 1.534 . . . . 0.0 109.539 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.691 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -100.36 163.69 2.91 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.549 0 CA-C-N 113.358 -1.747 . . . . 0.0 111.384 -176.547 . . . . . . . . 4 4 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.552 ' CG1' ' HG2' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -119.12 160.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.179 -0.951 . . . . 0.0 110.904 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.562 HG21 ' CG2' ' A' ' 52' ' ' ILE . 98.4 t -133.22 107.26 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.448 -0.782 . . . . 0.0 109.59 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.618 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.0 mm-40 -94.41 125.08 38.83 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.344 -0.848 . . . . 0.0 110.543 -179.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -134.45 117.55 16.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.029 -1.044 . . . . 0.0 109.967 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.442 ' O ' ' HG3' ' A' ' 44' ' ' LYS . 0.5 OUTLIER -136.13 161.49 35.56 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.176 -0.953 . . . . 0.0 110.235 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -48.61 106.12 0.09 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 110.11 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.579 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . 71.44 41.73 57.69 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.579 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 49.2 m-85 -160.8 102.52 1.32 Allowed 'General case' 0 C--N 1.29 -2.008 0 O-C-N 121.997 -0.708 . . . . 0.0 110.445 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.704 ' CE2' HG23 ' A' ' 48' ' ' ILE . 12.0 t90 -105.1 73.95 1.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.643 ' CE2' HG12 ' A' ' 41' ' ' VAL . 16.1 m0 -94.44 142.15 27.76 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.525 0.679 . . . . 0.0 111.047 -178.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.61 ' CD1' ' CD1' ' A' ' 76' ' ' TRP . 0.8 OUTLIER -147.25 139.49 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.137 -0.977 . . . . 0.0 109.476 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.552 ' HG2' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -115.97 129.74 56.51 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 110.291 -179.585 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.572 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -110.63 154.64 23.51 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 120.104 -0.638 . . . . 0.0 109.809 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.446 ' HB2' HD13 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -97.94 43.55 1.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.985 -1.072 . . . . 0.0 110.146 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -171.69 -114.89 0.34 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -114.63 165.17 13.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.419 -1.048 . . . . 0.0 109.206 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.532 HG12 ' HB2' ' A' ' 40' ' ' LEU . 4.4 tp -151.05 114.33 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.74 -1.225 . . . . 0.0 111.113 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -74.93 154.64 38.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.378 -0.826 . . . . 0.0 110.232 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.648 HG21 ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -161.01 130.12 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.131 -0.98 . . . . 0.0 110.695 -179.894 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.55 ' N ' HD12 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -128.87 173.61 10.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.888 . . . . 0.0 110.831 -179.964 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.559 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -151.06 -28.86 0.19 Allowed 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.041 178.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.525 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -41.51 -53.51 3.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 0.0 109.722 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.44 -57.41 7.03 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.563 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.45 -30.82 54.03 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.525 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -64.7 -56.2 18.23 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 108.359 -1.897 . . . . 0.0 108.359 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -62.47 -14.37 40.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.478 -1.013 . . . . 0.0 109.469 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.545 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 5.1 tt -75.92 -57.66 3.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.783 . . . . 0.0 109.039 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.631 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -93.72 -35.51 12.76 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.124 179.477 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -160.57 -71.49 0.02 OUTLIER Glycine 0 N--CA 1.491 2.319 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.214 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.561 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 164.95 -59.44 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.552 -0.969 . . . . 0.0 109.848 -179.769 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.0 Cg_endo -68.41 -17.28 44.08 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 124.068 1.562 . . . . 0.0 109.836 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.631 ' CG ' HD12 ' A' ' 95' ' ' LEU . 2.3 t80 -49.14 -50.3 38.2 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.078 -1.049 . . . . 0.0 108.416 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.559 ' HA ' ' CB ' ' A' ' 88' ' ' ALA . 4.5 m -30.23 -57.51 0.19 Allowed 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.703 0.763 . . . . 0.0 111.574 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.641 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 43.7 t -84.07 -54.47 8.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 121.513 -0.742 . . . . 0.0 112.685 -178.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.516 ' HA ' ' HB2' ' A' ' 105' ' ' LEU . 2.0 t80 -51.32 -40.05 58.24 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 119.7 -1.875 . . . . 0.0 107.045 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.541 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 21.6 t70 -57.14 -46.89 82.32 Favored 'General case' 0 N--CA 1.486 1.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.666 178.19 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.641 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 4.2 pp -80.2 -29.3 38.58 Favored 'General case' 0 C--O 1.201 -1.459 0 C-N-CA 117.921 -1.512 . . . . 0.0 108.245 179.109 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.536 ' CD2' HG11 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -49.67 -24.74 2.41 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 120.113 -1.617 . . . . 0.0 109.523 178.49 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.2 mp -103.51 -37.42 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.359 -0.838 . . . . 0.0 110.441 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.535 ' ND2' ' HA ' ' A' ' 104' ' ' LEU . 3.6 p30 -99.52 -13.02 19.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.909 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.576 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 5.2 p -66.7 -8.99 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 109.811 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.9 OUTLIER -39.99 -24.35 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.689 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.56 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 1.2 p -72.92 9.65 1.11 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.138 -0.976 . . . . 0.0 110.51 178.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.518 ' CG2' ' CG2' ' A' ' 108' ' ' VAL . 2.2 p -85.69 26.26 0.98 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.694 -1.254 . . . . 0.0 110.936 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.414 HG11 ' N ' ' A' ' 113' ' ' GLY . 6.9 p -57.05 -18.63 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.968 -1.082 . . . . 0.0 109.375 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.499 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -98.79 50.89 1.21 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.119 -1.592 . . . . 0.0 109.119 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.499 ' C ' ' O ' ' A' ' 113' ' ' GLY . 12.1 ttm180 28.81 95.87 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.494 0.664 . . . . 0.0 111.526 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -74.84 124.85 27.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.41 -0.806 . . . . 0.0 111.147 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' THR . 1.8 t80 -69.72 115.73 9.29 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.3 m -79.0 164.36 24.44 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.081 -1.012 . . . . 0.0 111.553 -178.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.566 ' N ' ' O ' ' A' ' 121' ' ' LYS . 0.2 OUTLIER -144.79 48.88 1.31 Allowed 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.08 -60.6 0.22 Allowed Glycine 0 N--CA 1.483 1.775 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.551 HG21 ' CG ' ' A' ' 121' ' ' LYS . 1.2 t -117.43 -17.87 9.96 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.849 -0.794 . . . . 0.0 111.529 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.566 ' O ' ' N ' ' A' ' 118' ' ' LEU . 13.5 mtmt -122.94 161.4 24.25 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 120.76 -1.212 . . . . 0.0 110.534 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.707 ' CD1' ' N ' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -134.95 162.28 32.87 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.966 -1.084 . . . . 0.0 109.218 178.653 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.492 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.7 OUTLIER -141.8 118.61 11.12 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.915 -1.116 . . . . 0.0 110.599 -178.807 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.53 HD13 ' N ' ' A' ' 124' ' ' ILE . 2.3 mp -87.02 132.84 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.552 -0.718 . . . . 0.0 109.82 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 9.5 t -156.93 159.16 37.84 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.109 -0.995 . . . . 0.0 110.629 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.432 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 1.1 t -82.4 -86.0 0.11 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.108 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' A' ' 128' ' ' LEU . 3.6 mp0 -94.92 -172.24 2.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.257 -0.902 . . . . 0.0 110.091 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.478 ' O ' ' O ' ' A' ' 127' ' ' GLU . 26.4 mt . . . . . 0 C--N 1.306 -1.323 0 O-C-N 121.466 -0.771 . . . . 0.0 110.589 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.486 ' O ' ' N ' ' A' ' 37' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.119 0.485 . . . . 0.0 110.523 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 90.5 m-20 53.09 -90.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 110.065 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -38.54 157.94 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.55 -0.719 . . . . 0.0 110.444 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 38' ' ' VAL . 4.5 p -131.56 131.41 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -0.95 . . . . 0.0 110.266 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 110' ' ' SER . 8.9 p -91.29 168.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.298 -0.876 . . . . 0.0 110.495 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.54 ' HB2' HG12 ' A' ' 84' ' ' ILE . 13.7 tp -134.23 134.23 41.78 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.667 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.618 HG23 ' CG ' ' A' ' 77' ' ' TRP . 14.9 t -136.95 127.52 40.32 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 O-C-N 120.462 -1.399 . . . . 0.0 110.707 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.614 ' CB ' ' CE3' ' A' ' 76' ' ' TRP . 1.0 OUTLIER -131.39 -174.03 3.28 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.55 -0.86 . . . . 0.0 108.94 178.923 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.425 ' O ' ' N ' ' A' ' 45' ' ' SER . 3.1 ptm -82.6 157.99 23.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.89 -1.131 . . . . 0.0 110.185 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.498 ' CE ' ' OD1' ' A' ' 46' ' ' ASP . 8.3 ptmt -47.01 94.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 111.259 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.496 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 0.3 OUTLIER -78.08 4.24 12.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.297 -0.877 . . . . 0.0 110.387 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.509 ' N ' HD12 ' A' ' 48' ' ' ILE . 35.1 m-20 64.2 -67.95 0.1 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.52 -0.738 . . . . 0.0 112.681 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.508 ' O ' HD11 ' A' ' 51' ' ' ILE . 1.5 mt-10 -80.33 16.71 1.22 Allowed 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.866 -1.146 . . . . 0.0 112.555 -177.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.784 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -65.41 -68.24 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 120.531 -1.356 . . . . 0.0 111.438 -179.303 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.548 ' C ' ' O ' ' A' ' 48' ' ' ILE . 12.8 t70 -38.5 -31.61 0.06 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 119.048 -1.061 . . . . 0.0 108.635 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.25 -56.57 4.25 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.612 -0.68 . . . . 0.0 109.765 178.051 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.784 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.02 -43.19 67.79 Favored 'Isoleucine or valine' 0 C--O 1.195 -1.786 0 O-C-N 120.903 -1.123 . . . . 0.0 109.873 179.533 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.578 ' HA ' ' CG2' ' A' ' 56' ' ' VAL . 50.3 mm -52.9 -47.69 52.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.804 0 O-C-N 119.668 -1.895 . . . . 0.0 107.226 177.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.699 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.1 tm-20 -57.61 -57.29 13.37 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.37 -0.831 . . . . 0.0 110.389 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -78.3 -20.33 51.74 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.335 -0.853 . . . . 0.0 112.667 -178.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.586 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 mm -106.17 -30.45 2.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 O-C-N 120.983 -1.073 . . . . 0.0 110.903 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.578 ' CG2' ' HA ' ' A' ' 52' ' ' ILE . 17.2 t -115.24 -42.15 3.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.699 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -68.17 -31.12 70.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.517 -1.365 . . . . 0.0 109.152 -179.89 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.516 ' N ' HD11 ' A' ' 57' ' ' LEU . 6.0 mttt -107.58 -43.89 4.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.429 -0.794 . . . . 0.0 109.483 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.69 -43.5 6.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.578 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.61 -64.7 2.84 Favored Glycine 0 N--CA 1.491 2.343 0 O-C-N 121.091 -1.241 . . . . 0.0 110.155 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.57 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.3 OUTLIER -59.73 3.51 0.05 Allowed 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.575 -0.956 . . . . 0.0 112.681 -179.506 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -55.32 -64.25 0.9 Allowed 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.657 -1.277 . . . . 0.0 109.02 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -90.72 -23.29 20.74 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.073 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.578 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 3.0 m-20 -69.0 134.8 89.65 Favored Pre-proline 0 C--N 1.3 -1.587 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.672 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -63.0 -45.32 13.04 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.111 1.874 . . . . 0.0 111.299 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.44 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.2 OUTLIER 179.12 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.307 0 CA-C-O 122.999 1.38 . . . . 0.0 109.916 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.635 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.297 1.2 mp -101.48 140.2 20.77 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.475 0 CA-C-N 113.911 -1.495 . . . . 0.0 111.415 -177.361 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.576 ' CB ' ' HB3' ' A' ' 79' ' ' LYS . 1.2 t -96.73 132.9 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.785 . . . . 0.0 109.814 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.54 ' CG1' HG22 ' A' ' 52' ' ' ILE . 58.3 t -114.23 92.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.184 -0.948 . . . . 0.0 110.341 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.629 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.0 mm-40 -87.39 73.04 9.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.456 -0.777 . . . . 0.0 110.135 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . 0.483 ' OD2' ' HB2' ' A' ' 49' ' ' ASP . 52.8 t0 -81.91 122.44 27.75 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.936 -1.103 . . . . 0.0 110.637 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.1 OUTLIER -132.76 135.86 45.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.733 179.564 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.08 -26.57 0.16 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.145 -0.972 . . . . 0.0 109.964 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . -80.76 -50.23 5.35 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -144.61 157.96 43.98 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.772 -0.84 . . . . 0.0 110.294 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.681 ' CD2' HG22 ' A' ' 48' ' ' ILE . 1.6 t90 -109.81 85.95 2.2 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.629 ' HB2' ' HB2' ' A' ' 70' ' ' GLU . 7.2 m0 -85.15 124.51 31.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.459 -0.776 . . . . 0.0 110.958 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.579 ' CG1' ' NE1' ' A' ' 76' ' ' TRP . 3.0 mm -115.93 160.19 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.014 178.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.576 ' HB3' ' CB ' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -140.69 143.72 35.23 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.899 -1.125 . . . . 0.0 110.359 -178.97 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.469 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.03 139.59 19.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.301 -0.875 . . . . 0.0 109.521 179.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -92.98 58.54 2.98 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.09 -1.006 . . . . 0.0 110.091 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -168.89 -164.69 25.03 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.03 129.84 40.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -1.142 . . . . 0.0 109.889 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.54 HG12 ' HB2' ' A' ' 40' ' ' LEU . 3.8 tp -125.02 159.99 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.383 -0.823 . . . . 0.0 110.177 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.504 ' N ' HG13 ' A' ' 84' ' ' ILE . 12.3 mt-10 -131.29 157.19 43.98 Favored 'General case' 0 C--N 1.307 -1.241 0 O-C-N 121.006 -1.058 . . . . 0.0 111.515 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.702 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -128.97 159.32 41.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.698 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.465 ' OD2' ' CG ' ' A' ' 121' ' ' LYS . 5.3 m-20 -156.05 154.91 31.75 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.645 -1.284 . . . . 0.0 111.594 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.565 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -151.83 -24.28 0.19 Allowed 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.355 -0.938 . . . . 0.0 111.49 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.516 ' HA ' ' OG ' ' A' ' 100' ' ' SER . . . -41.16 -51.83 3.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.009 -1.057 . . . . 0.0 110.303 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 94' ' ' LEU . 8.8 tt0 -48.51 -37.58 17.95 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.893 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.668 ' CB ' ' CE1' ' A' ' 99' ' ' PHE . . . -86.39 -53.18 5.15 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.549 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -50.15 -40.08 35.89 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.505 ' HG3' ' O ' ' A' ' 89' ' ' ALA . 9.6 mt-10 -75.52 -33.38 60.72 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.575 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 1.5 tt -51.27 -66.91 0.3 Allowed 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 177.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.598 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.3 OUTLIER -76.42 -59.2 2.87 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.302 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 112.3 14.7 10.44 Favored Glycine 0 N--CA 1.497 2.715 0 C-N-CA 119.021 -1.561 . . . . 0.0 109.936 178.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.584 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 0.4 OUTLIER -104.57 -166.96 0.11 Allowed Pre-proline 0 C--N 1.294 -1.835 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.343 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.584 ' HD2' ' CB ' ' A' ' 97' ' ' LYS . 38.4 Cg_endo -66.83 -0.96 5.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 N-CA-C 109.458 -1.016 . . . . 0.0 109.458 177.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.668 ' CE1' ' CB ' ' A' ' 91' ' ' ALA . 18.8 t80 -35.54 -65.54 0.24 Allowed 'General case' 0 C--N 1.314 -0.97 0 O-C-N 121.699 -0.626 . . . . 0.0 110.908 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.565 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 0.3 OUTLIER -29.81 -73.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.037 0.922 . . . . 0.0 111.353 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.649 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 29.9 t -77.22 -50.41 20.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.328 -0.857 . . . . 0.0 113.254 -178.145 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.571 ' CD1' ' HB2' ' A' ' 98' ' ' PRO . 3.7 m-85 -51.72 -43.07 62.71 Favored 'General case' 0 C--N 1.292 -1.899 0 O-C-N 119.704 -1.872 . . . . 0.0 108.15 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.569 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 13.8 t70 -60.4 -40.05 89.53 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.592 -0.692 . . . . 0.0 110.421 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.649 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 4.3 pp -82.36 -39.8 22.26 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 117.816 -1.554 . . . . 0.0 109.04 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.567 ' N ' ' CD1' ' A' ' 104' ' ' LEU . 56.3 mt -51.94 -19.71 1.94 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.824 -1.172 . . . . 0.0 110.459 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.405 ' N ' HD11 ' A' ' 106' ' ' ILE . 1.3 mp -102.44 -42.75 8.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.148 -0.97 . . . . 0.0 109.864 -179.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 4.7 p30 -88.03 -13.18 42.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.287 -0.883 . . . . 0.0 110.141 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.577 ' O ' ' N ' ' A' ' 110' ' ' SER . 2.6 t -64.48 -5.88 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.923 -1.11 . . . . 0.0 110.195 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.461 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.49 -28.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.9 -0.5 . . . . 0.0 111.978 -179.567 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.577 ' N ' ' O ' ' A' ' 108' ' ' VAL . 35.1 p -75.3 15.88 0.4 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.77 -1.206 . . . . 0.0 110.581 178.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.547 ' O ' ' N ' ' A' ' 113' ' ' GLY . 0.0 OUTLIER -58.06 -66.61 0.45 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 118.389 -1.325 . . . . 0.0 109.881 -179.032 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 111' ' ' THR . 4.9 t 63.23 -67.32 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.476 -0.765 . . . . 0.0 110.024 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -93.82 51.81 2.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.506 ' CG ' ' N ' ' A' ' 115' ' ' ALA . 0.5 OUTLIER 47.01 176.33 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 O-C-N 121.579 -0.953 . . . . 0.0 111.016 179.162 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.649 ' CB ' ' CE2' ' A' ' 122' ' ' PHE . . . -148.9 115.57 5.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.893 -1.13 . . . . 0.0 111.229 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.406 ' O ' ' HB ' ' A' ' 123' ' ' THR . 0.2 OUTLIER -76.26 112.53 12.84 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.334 -0.854 . . . . 0.0 108.887 178.678 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.3 m -79.49 125.12 29.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.072 -1.017 . . . . 0.0 110.851 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.525 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -92.3 50.34 1.62 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.412 -0.805 . . . . 0.0 110.042 179.38 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.4 -58.73 0.18 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 118' ' ' LEU . 18.4 p -115.72 -8.83 12.0 Favored 'General case' 0 C--N 1.291 -1.94 0 O-C-N 122.009 -0.701 . . . . 0.0 110.613 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.465 ' CG ' ' OD2' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -122.95 -170.53 2.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.048 -1.033 . . . . 0.0 111.836 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.702 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.269 1.8 t80 -139.33 147.16 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.078 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.491 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.9 OUTLIER -139.77 121.66 15.54 Favored 'General case' 0 C--N 1.308 -1.238 0 O-C-N 120.506 -1.371 . . . . 0.0 110.543 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.535 ' HB ' ' CG2' ' A' ' 84' ' ' ILE . 3.9 mp -118.09 142.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 109.939 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 1.8 t -144.93 136.93 25.82 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.083 -1.011 . . . . 0.0 110.421 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.482 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 0.4 OUTLIER -59.67 -84.98 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.27 -0.894 . . . . 0.0 110.492 -179.855 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.482 ' N ' ' OG ' ' A' ' 126' ' ' SER . 20.4 mt-10 -61.56 171.19 1.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.477 ' O ' ' O ' ' A' ' 127' ' ' GLU . 6.0 mt . . . . . 0 C--N 1.306 -1.307 0 O-C-N 121.461 -0.774 . . . . 0.0 111.108 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.225 0.535 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.461 ' O ' ' HB2' ' A' ' 126' ' ' SER . 35.3 m120 45.85 -100.34 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.177 -0.952 . . . . 0.0 110.054 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.46 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.29 143.81 0.12 Allowed 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.169 -0.957 . . . . 0.0 110.541 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.542 ' CG2' HG23 ' A' ' 124' ' ' ILE . 3.4 p -108.36 137.26 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.182 -0.949 . . . . 0.0 110.484 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.542 ' CG1' ' HB2' ' A' ' 110' ' ' SER . 5.8 p -112.74 136.2 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.067 -1.021 . . . . 0.0 110.491 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.511 ' CD1' ' CD1' ' A' ' 86' ' ' ILE . 11.0 tp -105.17 141.75 36.17 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.634 HG12 ' CE2' ' A' ' 77' ' ' TRP . 2.3 t -143.19 127.24 14.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 118.248 -1.381 . . . . 0.0 112.072 -177.277 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.639 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 2.7 mm? -129.48 -168.46 1.95 Allowed 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.009 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.48 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -103.33 167.43 9.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.071 179.254 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.03 103.29 0.05 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.277 -0.89 . . . . 0.0 110.812 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.524 ' HB3' ' CD1' ' A' ' 48' ' ' ILE . 18.9 t -87.74 -116.76 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.272 -0.892 . . . . 0.0 109.985 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.401 ' N ' ' OG ' ' A' ' 45' ' ' SER . 9.9 m-20 -142.11 -76.66 0.27 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.618 -1.301 . . . . 0.0 110.83 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.498 ' HB2' HG22 ' A' ' 51' ' ' ILE . 2.3 mt-10 -95.09 35.57 1.27 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.361 -0.837 . . . . 0.0 110.155 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.774 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.77 -66.45 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.251 -0.906 . . . . 0.0 111.274 -179.171 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -41.25 -40.57 1.65 Allowed 'General case' 0 C--N 1.284 -2.271 0 C-N-CA 119.106 -1.038 . . . . 0.0 108.96 179.213 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' N ' ' OD1' ' A' ' 49' ' ' ASP . . . -74.57 -50.35 18.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.592 -0.692 . . . . 0.0 110.401 178.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.774 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -72.12 -49.64 42.27 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.079 0 O-C-N 120.553 -1.342 . . . . 0.0 109.488 179.454 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.611 ' HA ' HG21 ' A' ' 55' ' ' ILE . 40.3 mm -46.59 -38.07 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.028 -1.67 . . . . 0.0 108.246 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.564 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 0.6 OUTLIER -64.3 -62.81 1.37 Allowed 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.105 -0.997 . . . . 0.0 110.082 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -79.75 -11.28 59.85 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.367 -0.833 . . . . 0.0 111.435 -179.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.687 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.2 tp -106.05 -33.38 2.79 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.034 0 CA-C-O 121.631 0.729 . . . . 0.0 110.546 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.597 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 3.8 t -117.65 -44.56 3.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.499 -0.75 . . . . 0.0 112.479 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.564 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.5 OUTLIER -61.77 -40.83 96.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.264 -1.523 . . . . 0.0 108.542 179.964 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.46 ' N ' HD21 ' A' ' 57' ' ' LEU . 2.4 mtpt -92.37 -43.21 9.36 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.521 0.677 . . . . 0.0 109.426 178.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -75.15 -50.78 8.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.28 -59.99 5.43 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.635 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.585 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -64.99 10.31 0.08 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.56 -0.965 . . . . 0.0 112.636 -179.508 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.39 -63.98 0.95 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.453 -1.404 . . . . 0.0 108.661 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -100.35 -17.83 17.06 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.585 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 1.4 m-20 -67.99 136.88 92.03 Favored Pre-proline 0 C--N 1.301 -1.533 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.684 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -62.19 -42.81 26.93 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 122.54 2.16 . . . . 0.0 112.521 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.444 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.33 112.91 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 123.1 1.429 . . . . 0.0 110.125 -179.811 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.649 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.302 1.2 mp -101.65 147.79 8.13 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 CA-C-N 113.766 -1.561 . . . . 0.0 111.577 -177.143 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.564 ' CG1' ' HB3' ' A' ' 79' ' ' LYS . 1.6 p -110.87 153.13 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.41 -0.806 . . . . 0.0 110.275 179.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.518 ' CG2' HG22 ' A' ' 52' ' ' ILE . 89.2 t -118.25 104.82 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.244 -0.91 . . . . 0.0 109.6 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.55 ' N ' ' O ' ' A' ' 77' ' ' TRP . 0.9 OUTLIER -84.05 65.2 8.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.44 -0.787 . . . . 0.0 110.729 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.24 117.24 29.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.97 -1.081 . . . . 0.0 110.249 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 5.4 tttt -146.96 143.49 28.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 110.171 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.04 96.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 109.991 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 151.64 -58.11 0.43 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.47 ' HB2' ' CD1' ' A' ' 77' ' ' TRP . 2.3 p90 -141.08 163.01 34.14 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.926 -0.749 . . . . 0.0 110.457 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.727 ' CE2' HG23 ' A' ' 48' ' ' ILE . 2.5 t90 -118.03 75.63 1.02 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.634 ' CE2' HG12 ' A' ' 41' ' ' VAL . 21.0 m0 -95.82 149.06 21.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.606 -0.684 . . . . 0.0 111.674 -178.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.53 ' CD1' ' NE1' ' A' ' 76' ' ' TRP . 1.2 mp -146.87 130.31 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.563 -0.711 . . . . 0.0 109.151 178.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.564 ' HB3' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -95.89 160.77 14.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.315 -0.866 . . . . 0.0 110.515 -179.123 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.483 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -150.14 141.46 23.25 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.535 -0.728 . . . . 0.0 109.905 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -107.33 50.41 0.77 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.81 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.28 -110.85 0.24 Allowed Glycine 0 C--N 1.301 -1.368 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -123.67 143.41 50.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.315 -1.109 . . . . 0.0 110.02 179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.557 HG13 ' N ' ' A' ' 85' ' ' GLU . 2.8 tp -142.82 160.66 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 109.876 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.557 ' N ' HG13 ' A' ' 84' ' ' ILE . 45.1 mt-10 -129.67 122.69 29.47 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.022 -1.049 . . . . 0.0 111.753 -179.119 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.615 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.6 OUTLIER -79.61 165.4 2.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 121.641 -0.662 . . . . 0.0 109.648 179.484 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 6.2 m-20 -155.89 139.43 15.92 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.763 -1.211 . . . . 0.0 111.549 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.565 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -152.47 -33.09 0.13 Allowed 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.753 177.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.535 ' HA ' ' CB ' ' A' ' 100' ' ' SER . . . -44.09 -52.62 7.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -0.844 . . . . 0.0 110.125 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.492 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 1.3 pt-20 -57.99 -44.5 87.21 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.534 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.13 -34.65 78.54 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.532 -0.73 . . . . 0.0 109.303 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.51 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -69.24 -56.87 8.17 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.492 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.3 pt-20 -54.65 -19.56 6.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.403 -1.057 . . . . 0.0 109.368 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.53 HD21 ' HG ' ' A' ' 95' ' ' LEU . 5.4 tt -78.81 -61.8 1.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.69 -0.631 . . . . 0.0 110.527 -179.441 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.617 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -77.62 -45.1 26.11 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 118.35 -1.34 . . . . 0.0 109.086 179.289 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.481 ' O ' ' HB2' ' A' ' 97' ' ' LYS . . . -145.76 -75.21 0.02 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.555 ' N ' ' HD2' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 166.46 -55.88 0.0 OUTLIER Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.883 -0.775 . . . . 0.0 109.407 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.555 ' HD2' ' N ' ' A' ' 97' ' ' LYS . 46.8 Cg_endo -73.14 -21.19 20.69 Favored 'Trans proline' 0 C--N 1.307 -1.614 0 O-C-N 124.167 1.614 . . . . 0.0 110.515 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.617 ' CG ' HD12 ' A' ' 95' ' ' LEU . 2.8 t80 -50.06 -50.04 49.22 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.009 -1.057 . . . . 0.0 109.626 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.565 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 16.7 p -31.53 -68.76 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-O 121.875 0.845 . . . . 0.0 111.216 -179.241 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.579 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 1.7 t -69.41 -56.16 12.69 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 O-C-N 121.189 -0.945 . . . . 0.0 113.238 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.503 ' N ' HG11 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -50.1 -31.92 14.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.356 -1.465 . . . . 0.0 109.345 -178.865 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.573 ' OD2' ' CE2' ' A' ' 99' ' ' PHE . 5.6 t70 -76.61 -28.83 56.26 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.673 ' HG ' ' N ' ' A' ' 105' ' ' LEU . 0.0 OUTLIER -65.81 -48.74 70.7 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.16 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.673 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 1.4 mt -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.674 -1.266 . . . . 0.0 110.042 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.45 -22.78 5.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.555 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.5 p30 -108.39 -28.76 9.2 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.178 -0.951 . . . . 0.0 110.802 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.583 ' CG2' ' CG2' ' A' ' 111' ' ' THR . 1.6 p -70.75 0.7 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.82 -1.175 . . . . 0.0 110.719 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -36.4 -26.92 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.47 -0.769 . . . . 0.0 112.0 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.575 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . 87.7 p -78.69 32.37 0.2 Allowed 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.758 -1.214 . . . . 0.0 110.595 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.583 ' CG2' ' CG2' ' A' ' 108' ' ' VAL . 25.4 p -94.77 44.42 1.1 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.682 -1.261 . . . . 0.0 109.323 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 28.3 m -60.54 -37.43 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.595 -0.691 . . . . 0.0 110.804 -179.252 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.438 ' HA3' ' O ' ' A' ' 125' ' ' THR . . . -76.17 -75.15 0.89 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.423 ' HB2' HG21 ' A' ' 125' ' ' THR . 3.3 ttt85 -145.13 -170.75 3.5 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.312 -1.111 . . . . 0.0 110.428 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.564 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -165.88 75.0 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.035 -1.041 . . . . 0.0 110.55 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.487 ' O ' ' N ' ' A' ' 123' ' ' THR . 0.1 OUTLIER -81.41 121.5 26.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.282 -0.886 . . . . 0.0 109.644 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.7 m -83.89 156.39 22.42 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.228 -0.92 . . . . 0.0 110.62 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.526 ' O ' ' N ' ' A' ' 120' ' ' THR . 7.3 mp -127.91 38.5 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.357 -0.839 . . . . 0.0 110.257 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.2 -59.5 0.41 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.824 -1.711 . . . . 0.0 108.824 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.526 ' N ' ' O ' ' A' ' 118' ' ' LEU . 58.4 p -115.14 -12.71 11.87 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 122.031 -0.687 . . . . 0.0 109.824 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.483 ' CB ' ' HB2' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -121.59 -167.12 1.47 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.43 -0.794 . . . . 0.0 110.633 -179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.655 ' CD2' ' CD1' ' A' ' 104' ' ' LEU . 16.0 t80 -153.86 164.22 38.74 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.519 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.564 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.6 OUTLIER -150.08 153.06 35.78 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.39 -1.444 . . . . 0.0 110.275 -179.154 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.593 ' N ' ' CD1' ' A' ' 124' ' ' ILE . 2.2 mp -141.38 145.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.51 -0.744 . . . . 0.0 109.181 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.438 ' O ' ' HA3' ' A' ' 113' ' ' GLY . 11.0 t -138.86 174.21 10.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.89 -1.131 . . . . 0.0 110.534 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.53 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 69.2 p -104.66 -101.27 0.32 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.319 -0.863 . . . . 0.0 110.423 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.53 ' N ' ' OG ' ' A' ' 126' ' ' SER . 3.7 mm-40 -82.1 131.98 35.24 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.903 -1.123 . . . . 0.0 110.435 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.541 ' N ' HD11 ' A' ' 128' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.946 -0.471 . . . . 0.0 112.117 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 121.216 0.531 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.47 ' ND2' ' HG2' ' A' ' 127' ' ' GLU . 1.8 m-20 -113.59 -36.2 4.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 110.304 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.437 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.7 143.52 0.15 Allowed 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.518 -0.739 . . . . 0.0 110.774 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.468 HG12 ' O ' ' A' ' 125' ' ' THR . 22.9 m -124.54 -174.71 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.226 -0.922 . . . . 0.0 110.373 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.485 ' HA ' ' HA ' ' A' ' 79' ' ' LYS . 3.0 p -148.34 127.54 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.238 -0.914 . . . . 0.0 110.844 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.499 ' CG ' HG12 ' A' ' 84' ' ' ILE . 0.2 OUTLIER -88.99 127.75 35.68 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 177.817 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.602 HG12 ' CE2' ' A' ' 77' ' ' TRP . 2.7 t -121.43 117.05 51.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.883 -1.127 . . . . 0.0 111.435 -178.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.642 ' HB2' ' CE3' ' A' ' 76' ' ' TRP . 0.6 OUTLIER -119.64 159.35 24.58 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.41 -0.916 . . . . 0.0 109.475 178.254 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.506 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 9.5 ptm -92.8 27.21 2.44 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.82 -1.175 . . . . 0.0 111.381 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.562 ' CB ' HD12 ' A' ' 48' ' ' ILE . 4.1 mmtp -86.81 -90.12 0.11 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.249 -0.907 . . . . 0.0 110.408 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.547 ' HB3' ' N ' ' A' ' 75' ' ' PHE . 1.4 p 77.37 57.96 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 CA-C-O 121.877 0.846 . . . . 0.0 110.978 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.472 ' OD1' ' O ' ' A' ' 45' ' ' SER . 0.2 OUTLIER -161.58 -91.44 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.53 ' O ' HD12 ' A' ' 51' ' ' ILE . 2.1 mt-10 -54.38 -27.41 36.24 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.281 -0.887 . . . . 0.0 111.351 179.109 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.893 ' HA ' ' CD1' ' A' ' 51' ' ' ILE . 0.4 OUTLIER -74.85 -51.38 22.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 118.397 -1.321 . . . . 0.0 112.971 -176.781 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.528 ' C ' ' O ' ' A' ' 48' ' ' ILE . 14.4 t70 -42.96 -29.97 0.38 Allowed 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.366 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.44 -54.89 5.48 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.847 177.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.893 ' CD1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -66.9 -47.82 81.44 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.158 0 C-N-CA 117.844 -1.543 . . . . 0.0 108.226 178.773 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.59 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 45.1 mm -43.05 -40.99 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 120.374 -1.454 . . . . 0.0 107.86 176.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.616 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 2.4 tt0 -62.87 -67.7 0.4 Allowed 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.307 -0.871 . . . . 0.0 110.141 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.422 ' O ' ' OD1' ' A' ' 54' ' ' ASP . 37.0 t0 -75.72 -9.86 58.95 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 121.093 -1.004 . . . . 0.0 111.723 -178.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.684 ' N ' ' O ' ' A' ' 51' ' ' ILE . 3.9 tp -107.54 -34.63 2.81 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 CA-C-O 121.588 0.709 . . . . 0.0 111.224 -178.459 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.59 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 3.5 t -117.19 -42.91 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.553 -0.717 . . . . 0.0 112.45 -177.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.616 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 10.5 tt -42.2 -55.93 3.09 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.827 -1.17 . . . . 0.0 108.943 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.535 ' O ' ' CG ' ' A' ' 61' ' ' LYS . 1.0 OUTLIER -89.73 -49.19 6.79 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.317 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -48.91 -49.91 27.98 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.519 ' HA2' ' HB2' ' A' ' 64' ' ' ASN . . . -83.87 22.38 8.11 Favored Glycine 0 N--CA 1.489 2.215 0 O-C-N 121.181 -1.188 . . . . 0.0 110.185 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.535 ' CG ' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -106.44 -9.4 16.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.697 -1.472 . . . . 0.0 110.769 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.98 -84.66 0.33 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 121.098 -1.001 . . . . 0.0 110.156 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -71.03 -32.25 68.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 122.211 1.005 . . . . 0.0 108.742 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.519 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 0.5 OUTLIER -73.38 118.91 72.79 Favored Pre-proline 0 C--N 1.296 -1.733 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 179.65 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.45 ' HG2' ' HB2' ' A' ' 81' ' ' ASP . 45.6 Cg_endo -63.96 -43.42 15.82 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 124.146 1.603 . . . . 0.0 111.053 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.43 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.1 OUTLIER 178.76 112.09 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 CA-C-O 122.944 1.354 . . . . 0.0 109.751 179.477 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.638 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.292 1.2 mp -102.7 132.12 49.48 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.488 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.208 -177.359 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.55 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -92.11 116.16 32.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.863 179.501 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.517 ' CG2' ' CG2' ' A' ' 52' ' ' ILE . 67.5 t -94.88 96.99 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.146 -0.971 . . . . 0.0 110.012 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.609 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.1 mm-40 -91.51 143.15 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.298 -0.876 . . . . 0.0 110.455 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -139.78 108.91 6.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 109.795 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.71 -166.81 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.266 -0.897 . . . . 0.0 110.795 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.522 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -53.29 107.54 0.25 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 0.0 110.396 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 42.81 44.7 5.63 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.547 ' N ' ' HB3' ' A' ' 45' ' ' SER . 7.3 m-85 -144.45 86.45 1.82 Allowed 'General case' 0 C--N 1.292 -1.895 0 O-C-N 121.871 -0.781 . . . . 0.0 111.378 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.723 ' CE2' ' CG2' ' A' ' 48' ' ' ILE . 1.2 t90 -81.55 88.19 6.21 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.058 -1.026 . . . . 0.0 108.597 178.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.609 ' HB2' ' HB2' ' A' ' 70' ' ' GLU . 8.1 m0 -90.6 124.67 35.23 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.376 -0.828 . . . . 0.0 111.04 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.612 ' CG1' ' NE1' ' A' ' 76' ' ' TRP . 13.8 mm -117.41 141.87 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.042 . . . . 0.0 110.16 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.55 ' HG2' ' HB ' ' A' ' 68' ' ' VAL . 1.1 ttpt -122.58 122.13 38.13 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.581 -0.7 . . . . 0.0 109.675 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -129.32 143.54 50.88 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.336 -0.853 . . . . 0.0 110.036 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.45 ' HB2' ' HG2' ' A' ' 65' ' ' PRO . 67.6 m-20 -88.18 49.81 1.87 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.057 -1.027 . . . . 0.0 109.956 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.35 -162.77 23.25 Favored Glycine 0 C--N 1.302 -1.357 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -72.6 154.36 40.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.183 -1.186 . . . . 0.0 109.791 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.521 HG13 ' N ' ' A' ' 85' ' ' GLU . 3.0 tp -137.11 156.03 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.941 . . . . 0.0 110.235 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.521 ' N ' HG13 ' A' ' 84' ' ' ILE . 91.0 mt-10 -121.89 155.44 35.43 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.182 -0.949 . . . . 0.0 110.99 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.64 ' CG2' ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -161.33 147.15 4.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.573 -0.704 . . . . 0.0 109.792 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.515 ' N ' HD11 ' A' ' 86' ' ' ILE . 3.5 m-20 -124.65 176.53 6.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.095 -1.003 . . . . 0.0 111.544 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.654 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -140.05 -14.28 1.04 Allowed 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.991 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.503 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -48.24 -45.86 34.82 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.664 -1.273 . . . . 0.0 110.971 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.558 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 18.2 tt0 -50.48 -36.15 32.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.551 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.563 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -68.17 -31.22 70.61 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.035 -1.041 . . . . 0.0 108.876 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.741 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -68.74 -61.4 4.7 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 108.599 -1.8 . . . . 0.0 108.599 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.558 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 6.0 pt-20 -45.4 -27.97 0.79 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.226 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.532 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 0.7 OUTLIER -68.59 -70.9 0.24 Allowed 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.341 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.563 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 0.0 OUTLIER -98.86 -46.46 5.63 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.021 -1.05 . . . . 0.0 109.224 178.99 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 93.44 51.84 2.11 Favored Glycine 0 N--CA 1.499 2.861 0 C-N-CA 120.185 -1.007 . . . . 0.0 111.538 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.694 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 30.8 pttt -145.46 -135.6 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 O-C-N 120.914 -1.345 . . . . 0.0 109.37 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.694 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.3 Cg_endo -71.7 0.17 7.42 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 CA-C-N 121.077 1.42 . . . . 0.0 108.989 178.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.796 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.8 p90 -25.62 -41.34 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 CA-C-O 121.823 0.821 . . . . 0.0 111.698 178.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.796 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -55.96 -62.39 1.73 Allowed 'General case' 0 C--N 1.292 -1.895 0 CA-C-O 123.368 1.556 . . . . 0.0 108.62 -177.073 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.567 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 24.2 t -88.26 -42.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 CA-C-N 114.558 -1.201 . . . . 0.0 113.021 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.485 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 5.0 t80 -52.02 -43.11 63.55 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 119.91 -1.744 . . . . 0.0 107.426 178.264 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.579 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 18.5 t70 -61.41 -47.95 83.46 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.687 -0.633 . . . . 0.0 110.065 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 122' ' ' PHE . 4.5 pp -74.27 -41.16 61.68 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 116.655 -2.018 . . . . 0.0 109.738 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.534 HD13 ' CG1' ' A' ' 101' ' ' VAL . 39.2 mt -51.32 -19.23 1.21 Allowed 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.481 -1.387 . . . . 0.0 110.654 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.461 HD12 ' O ' ' A' ' 102' ' ' TYR . 0.6 OUTLIER -93.71 -49.59 12.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.123 -0.985 . . . . 0.0 110.403 -178.826 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.525 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.7 OUTLIER -100.19 -11.28 20.56 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.077 -1.014 . . . . 0.0 111.471 -179.249 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.56 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 5.9 p -65.2 -6.54 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.302 -1.498 . . . . 0.0 109.947 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -33.78 -31.52 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.728 -0.607 . . . . 0.0 112.028 -179.505 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.557 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . 28.8 p -84.69 27.89 0.7 Allowed 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 118.877 -1.129 . . . . 0.0 109.348 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.56 ' N ' ' O ' ' A' ' 108' ' ' VAL . 9.6 t -64.64 -35.9 82.51 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 110.644 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.502 ' N ' HG21 ' A' ' 111' ' ' THR . 61.8 t 52.61 -88.6 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.724 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -86.15 54.97 4.76 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.246 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.535 ' CG ' ' N ' ' A' ' 115' ' ' ALA . 1.8 ttt180 45.54 176.8 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.747 -0.855 . . . . 0.0 111.444 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.535 ' N ' ' CG ' ' A' ' 114' ' ' ARG . . . -130.01 114.11 15.4 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.995 -1.066 . . . . 0.0 110.725 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.454 ' HB2' HG21 ' A' ' 123' ' ' THR . 25.7 m-85 -69.7 121.14 16.58 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.34 -0.85 . . . . 0.0 108.829 178.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 6.2 m -79.3 178.55 8.0 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.192 -0.943 . . . . 0.0 110.734 -178.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.597 ' O ' ' N ' ' A' ' 120' ' ' THR . 1.3 tt -156.9 60.56 0.52 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.448 -0.783 . . . . 0.0 110.431 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.44 -57.44 0.05 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.057 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 118' ' ' LEU . 15.7 p -115.89 -26.97 7.15 Favored 'General case' 0 C--N 1.292 -1.925 0 O-C-N 121.64 -0.917 . . . . 0.0 111.772 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.576 ' O ' ' N ' ' A' ' 118' ' ' LEU . 1.5 pttm -132.07 -169.57 2.24 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.831 -1.168 . . . . 0.0 110.991 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.64 ' CE2' ' CG2' ' A' ' 86' ' ' ILE . 0.5 OUTLIER -149.21 -179.12 6.8 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.264 -0.897 . . . . 0.0 109.12 179.124 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.527 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 1.1 t -155.62 165.67 35.86 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.755 -1.215 . . . . 0.0 110.186 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.597 ' N ' ' CD1' ' A' ' 124' ' ' ILE . 4.0 mp -134.09 144.13 36.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.336 -0.852 . . . . 0.0 110.466 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.468 ' O ' HG12 ' A' ' 38' ' ' VAL . 11.9 t -123.25 -170.09 2.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.325 -0.859 . . . . 0.0 110.201 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.443 ' HB2' HG11 ' A' ' 38' ' ' VAL . 2.8 t -118.72 -64.6 1.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.179 -0.951 . . . . 0.0 110.473 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.47 ' HG2' ' ND2' ' A' ' 36' ' ' ASN . 7.6 mt-10 -74.94 52.79 0.56 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.335 -0.853 . . . . 0.0 110.478 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.468 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--N 1.305 -1.364 0 O-C-N 121.2 -0.938 . . . . 0.0 110.44 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.307 0.575 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.502 ' OD1' ' N ' ' A' ' 36' ' ' ASN . 15.1 p-10 -78.66 -44.35 23.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.147 -0.971 . . . . 0.0 110.454 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.462 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.94 106.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.229 0.538 . . . . 0.0 111.284 -179.341 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.5 HG21 ' N ' ' A' ' 39' ' ' VAL . 4.1 p -125.84 149.79 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.317 -0.864 . . . . 0.0 109.504 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.5 ' N ' HG21 ' A' ' 38' ' ' VAL . 13.7 p -105.82 142.44 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.01 -1.056 . . . . 0.0 111.108 -179.421 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.59 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 8.1 tp -100.93 162.07 13.15 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 177.468 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.608 HG12 ' CE2' ' A' ' 77' ' ' TRP . 3.0 t -165.77 132.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 120.658 -1.276 . . . . 0.0 111.665 -178.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.634 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 0.3 OUTLIER -143.06 -171.69 3.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.19 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 7.2 ptt? -98.45 153.29 18.7 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.798 -1.189 . . . . 0.0 109.899 179.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.488 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -53.13 95.65 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 0.0 110.982 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.468 ' HB3' HG22 ' A' ' 48' ' ' ILE . 30.5 t -72.89 -92.1 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.297 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 36.1 t0 -157.95 -70.3 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.157 -0.964 . . . . 0.0 110.401 179.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.479 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.8 mt-10 -96.45 36.13 1.4 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.283 -0.885 . . . . 0.0 110.412 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.771 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -56.02 -64.34 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.997 -1.064 . . . . 0.0 111.624 -178.772 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.473 ' O ' ' HB2' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -45.44 -34.75 3.3 Favored 'General case' 0 C--N 1.285 -2.218 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.768 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.29 -49.88 12.84 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.473 -0.767 . . . . 0.0 110.341 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.771 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -71.66 -48.44 52.08 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.092 0 O-C-N 120.711 -1.243 . . . . 0.0 108.958 179.127 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.6 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 35.1 mm -46.97 -40.89 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.068 -1.645 . . . . 0.0 107.912 177.106 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.545 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 7.5 tt0 -61.69 -62.43 1.81 Allowed 'General case' 0 C--N 1.293 -1.855 0 O-C-N 121.163 -0.961 . . . . 0.0 110.575 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -80.2 -12.6 59.62 Favored 'General case' 0 N--CA 1.502 2.145 0 O-C-N 121.451 -0.781 . . . . 0.0 111.616 -178.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.666 ' N ' ' O ' ' A' ' 51' ' ' ILE . 3.8 tp -106.09 -33.27 2.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 CA-C-O 121.672 0.749 . . . . 0.0 110.659 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.6 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 14.4 t -116.57 -43.91 3.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 C-N-CA 119.91 -0.716 . . . . 0.0 112.439 -177.41 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.545 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -63.35 -35.92 81.99 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.28 -1.513 . . . . 0.0 108.937 179.978 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.528 ' N ' HD21 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -94.77 -47.53 6.43 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.439 -0.788 . . . . 0.0 109.344 179.189 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.49 -45.05 8.19 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.589 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.07 -53.42 18.7 Favored Glycine 0 N--CA 1.49 2.243 0 O-C-N 121.12 -1.224 . . . . 0.0 110.05 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.567 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.9 OUTLIER -62.41 6.58 0.08 Allowed 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.459 -1.024 . . . . 0.0 112.827 -179.421 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.26 -63.84 1.01 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.518 -1.364 . . . . 0.0 108.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -97.2 -19.96 18.26 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 178.046 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.589 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 3.9 m-20 -68.43 125.92 92.17 Favored Pre-proline 0 C--N 1.301 -1.517 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.556 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.435 ' C ' ' OG ' ' A' ' 66' ' ' SER . 46.6 Cg_endo -64.45 -42.26 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 121.96 1.773 . . . . 0.0 111.136 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.495 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 0.0 OUTLIER -177.97 110.88 0.07 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-O 123.065 1.412 . . . . 0.0 109.527 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.667 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.308 1.0 OUTLIER -103.73 145.38 12.79 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 CA-C-N 113.735 -1.575 . . . . 0.0 111.416 -176.556 . . . . . . . . 4 4 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.53 ' CG1' ' HB3' ' A' ' 79' ' ' LYS . 1.9 p -109.41 142.28 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.055 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.549 ' CG2' HG22 ' A' ' 52' ' ' ILE . 32.4 t -108.75 117.17 53.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.239 -0.913 . . . . 0.0 110.001 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.563 ' N ' ' O ' ' A' ' 77' ' ' TRP . 1.0 OUTLIER -98.64 94.67 6.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.578 -0.701 . . . . 0.0 110.482 -179.435 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -91.37 88.91 7.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.802 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -88.72 165.99 14.36 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.331 -0.856 . . . . 0.0 110.689 -179.439 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -38.22 -58.21 1.01 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.589 -0.695 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.584 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -132.03 52.51 0.82 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 74' ' ' GLY . 57.7 m-85 -159.49 103.48 1.58 Allowed 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.913 -0.757 . . . . 0.0 110.057 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.7 ' CE2' HG21 ' A' ' 48' ' ' ILE . 6.4 t90 -90.0 77.73 6.83 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.608 ' CE2' HG12 ' A' ' 41' ' ' VAL . 13.0 m0 -101.28 143.98 30.68 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.512 -0.743 . . . . 0.0 112.308 -177.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.546 ' CG1' ' HA ' ' A' ' 69' ' ' VAL . 1.6 mt -137.49 139.3 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.302 -0.874 . . . . 0.0 109.625 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.53 ' HB3' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -102.19 134.85 44.79 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.467 -0.77 . . . . 0.0 110.06 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.525 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -134.43 143.8 47.77 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 110.054 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -95.15 50.29 1.26 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.068 -1.02 . . . . 0.0 110.106 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.491 ' O ' ' CG1' ' A' ' 38' ' ' VAL . . . -171.03 -169.83 34.5 Favored Glycine 0 C--N 1.3 -1.472 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -71.41 143.79 50.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -1.136 . . . . 0.0 109.682 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.553 HG22 ' CG1' ' A' ' 124' ' ' ILE . 4.2 tp -126.36 159.69 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.243 -0.911 . . . . 0.0 109.89 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.523 ' CA ' HD12 ' A' ' 124' ' ' ILE . 37.0 mt-10 -123.13 151.77 41.77 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 121.01 -1.056 . . . . 0.0 111.813 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.61 HG21 ' CB ' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -121.11 168.18 13.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 121.48 -0.762 . . . . 0.0 109.226 179.259 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 56.8 m-20 -131.54 177.28 7.62 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.08 -1.013 . . . . 0.0 109.961 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.644 ' CA ' ' HA ' ' A' ' 100' ' ' SER . . . -151.46 -49.96 0.12 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.014 178.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.415 ' O ' ' N ' ' A' ' 92' ' ' GLY . . . -48.53 -47.54 39.11 Favored 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.155 -0.966 . . . . 0.0 111.168 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.404 ' C ' ' O ' ' A' ' 89' ' ' ALA . 9.3 mt-10 -48.53 -40.63 27.56 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.561 ' C ' ' HB2' ' A' ' 99' ' ' PHE . . . -53.0 -45.18 67.75 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.923 0.868 . . . . 0.0 108.909 177.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.668 ' N ' ' HB2' ' A' ' 99' ' ' PHE . . . -51.46 -40.4 46.61 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -178.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -64.84 -32.29 73.92 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.476 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -70.79 -64.43 0.9 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.51 -0.744 . . . . 0.0 110.048 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.564 ' CD1' ' HA ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER -107.7 -27.36 10.35 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.191 -0.943 . . . . 0.0 110.575 -179.857 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . 65.26 62.96 4.46 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.167 178.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.619 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 19.3 mttt 163.0 -68.34 0.0 OUTLIER Pre-proline 0 N--CA 1.516 2.844 0 O-C-N 121.312 -1.11 . . . . 0.0 111.009 177.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.619 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 55.9 Cg_endo -86.36 6.59 5.37 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 N-CA-C 107.391 -1.811 . . . . 0.0 107.391 176.8 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.668 ' HB2' ' N ' ' A' ' 92' ' ' GLY . 0.1 OUTLIER -52.87 -132.08 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.014 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.874 -179.448 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.644 ' HA ' ' CA ' ' A' ' 88' ' ' ALA . 40.3 p -6.65 -55.85 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.63 ' N ' ' O ' ' A' ' 99' ' ' PHE . 1.9 t -85.75 -68.78 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -177.34 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.583 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 0.3 OUTLIER -56.83 -30.86 64.17 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 116.929 -1.908 . . . . 0.0 106.21 179.631 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.55 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 38.9 t70 -66.99 -40.86 87.46 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.214 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.602 ' CD1' ' N ' ' A' ' 105' ' ' LEU . 3.0 pp -83.27 -41.48 18.28 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 117.98 -1.488 . . . . 0.0 108.913 179.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.602 ' N ' ' CD1' ' A' ' 104' ' ' LEU . 0.3 OUTLIER -54.04 -16.99 2.24 Favored 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.314 -1.492 . . . . 0.0 110.011 178.673 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.494 HD11 HG22 ' A' ' 106' ' ' ILE . 0.8 OUTLIER -108.74 -27.94 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 179.642 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 0.3 OUTLIER -114.12 -2.67 13.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.083 -1.01 . . . . 0.0 110.744 -179.451 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.575 HG22 ' CZ ' ' A' ' 122' ' ' PHE . 4.1 p -81.93 -10.09 12.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.122 -0.986 . . . . 0.0 110.627 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.4 t -43.55 -20.92 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.031 -1.043 . . . . 0.0 110.345 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.575 ' CB ' ' N ' ' A' ' 41' ' ' VAL . 92.9 p -53.05 -7.81 0.09 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.304 -0.872 . . . . 0.0 112.223 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.56 ' O ' ' CB ' ' A' ' 112' ' ' VAL . 0.2 OUTLIER -110.51 -84.79 0.56 Allowed 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.014 -1.474 . . . . 0.0 111.092 -178.752 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.56 ' CB ' ' O ' ' A' ' 111' ' ' THR . 0.4 OUTLIER 80.06 -14.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.95 -0.468 . . . . 0.0 110.317 -179.239 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -114.95 -75.45 0.63 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.493 ' O ' HG23 ' A' ' 124' ' ' ILE . 11.6 tpt180 -115.24 151.21 34.9 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.353 -1.086 . . . . 0.0 109.531 179.344 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.476 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -165.44 67.99 0.13 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.203 -0.936 . . . . 0.0 110.124 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.511 ' N ' ' O ' ' A' ' 123' ' ' THR . 0.6 OUTLIER -69.21 124.07 22.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.915 . . . . 0.0 109.908 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.41 ' O ' HG21 ' A' ' 117' ' ' THR . 4.3 t -94.68 131.69 40.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 110.356 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.516 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -100.19 45.9 0.97 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.452 -179.98 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.43 -59.2 0.29 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.516 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.6 OUTLIER -115.31 -10.48 12.05 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.947 -0.737 . . . . 0.0 110.3 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -120.38 -168.33 1.61 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.049 -1.032 . . . . 0.0 111.179 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.61 ' CB ' HG21 ' A' ' 86' ' ' ILE . 2.2 t80 -150.51 153.37 35.71 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.515 -0.741 . . . . 0.0 110.442 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.511 ' O ' ' N ' ' A' ' 116' ' ' TYR . 0.8 OUTLIER -142.35 115.38 8.79 Favored 'General case' 0 C--N 1.31 -1.121 0 O-C-N 120.971 -1.081 . . . . 0.0 109.851 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.554 HD13 ' CG1' ' A' ' 86' ' ' ILE . 0.1 OUTLIER -125.03 151.62 30.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.266 -0.896 . . . . 0.0 109.383 179.27 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.427 ' CG2' ' HB3' ' A' ' 114' ' ' ARG . 6.4 t -136.11 -168.23 2.19 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 110.265 -179.412 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 19.1 p -78.2 -106.57 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 -179.367 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 28.1 mt-10 -106.37 109.89 21.95 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.058 . . . . 0.0 110.755 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--N 1.305 -1.336 0 O-C-N 121.181 -0.95 . . . . 0.0 110.409 179.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.228 0.537 . . . . 0.0 110.163 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.477 ' OD1' ' HG2' ' A' ' 127' ' ' GLU . 69.4 m-80 -107.03 -41.17 5.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -0.909 . . . . 0.0 110.18 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -39.62 145.83 0.12 Allowed 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.464 -0.773 . . . . 0.0 110.415 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.415 HG11 ' O ' ' A' ' 36' ' ' ASN . 3.6 m -122.92 171.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.972 . . . . 0.0 110.237 -179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.536 HG11 ' CG2' ' A' ' 112' ' ' VAL . 10.8 p -131.52 120.53 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -0.88 . . . . 0.0 110.234 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.566 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 5.5 tt -73.1 157.77 36.63 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.575 HG12 ' CE2' ' A' ' 77' ' ' TRP . 24.0 t -160.04 116.48 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 121.097 -1.002 . . . . 0.0 110.592 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.607 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 2.5 mt -138.02 -169.55 2.59 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.455 ' SD ' ' OD2' ' A' ' 103' ' ' ASP . 2.8 ptt? -106.77 151.02 25.72 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.952 -1.093 . . . . 0.0 109.547 178.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.493 ' HB2' ' HA2' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -44.19 103.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.262 -0.899 . . . . 0.0 111.033 -179.034 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.489 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 1.2 m -86.84 19.4 2.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -0.922 . . . . 0.0 110.286 179.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 2.1 m-20 68.3 -57.24 0.49 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.444 -0.785 . . . . 0.0 111.412 179.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.541 ' O ' HG12 ' A' ' 51' ' ' ILE . 1.6 mm-40 -94.05 31.83 1.59 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.923 -1.11 . . . . 0.0 110.948 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.797 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -59.97 -78.26 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.201 -0.937 . . . . 0.0 111.084 -178.844 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.546 ' C ' ' O ' ' A' ' 48' ' ' ILE . 6.8 m-20 -36.79 -32.63 0.04 OUTLIER 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.77 -53.41 7.98 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.766 -0.584 . . . . 0.0 109.551 177.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.714 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.47 -50.67 33.43 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 O-C-N 120.943 -1.098 . . . . 0.0 110.089 179.466 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.603 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 32.4 mm -49.88 -40.78 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 119.829 -1.794 . . . . 0.0 108.281 178.288 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.568 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 18.6 tt0 -62.97 -57.74 9.7 Favored 'General case' 0 C--N 1.29 -1.982 0 O-C-N 120.967 -1.083 . . . . 0.0 110.576 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -81.74 -14.51 56.38 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.296 -0.878 . . . . 0.0 111.489 -178.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.647 ' N ' ' O ' ' A' ' 51' ' ' ILE . 3.7 tp -105.98 -32.35 2.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 CA-C-O 121.563 0.697 . . . . 0.0 110.736 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.603 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 12.0 t -116.34 -43.31 3.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 C-N-CA 119.839 -0.744 . . . . 0.0 112.557 -177.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.568 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.3 OUTLIER -64.32 -41.27 96.89 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.117 -1.614 . . . . 0.0 109.036 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.444 ' N ' HD21 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -85.92 -41.83 14.59 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.61 0.719 . . . . 0.0 109.49 179.323 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.99 -53.0 3.28 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.573 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -70.03 -72.11 0.91 Allowed Glycine 0 N--CA 1.49 2.294 0 O-C-N 120.96 -1.318 . . . . 0.0 110.358 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.573 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -45.33 -8.41 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.597 -0.943 . . . . 0.0 113.518 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 60' ' ' GLY . . . -49.81 -65.34 0.58 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.39 -1.443 . . . . 0.0 108.502 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -89.22 -26.95 20.95 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.573 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 5.3 m-20 -67.6 112.64 10.9 Favored Pre-proline 0 C--N 1.297 -1.676 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.294 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.468 ' O ' ' OG ' ' A' ' 66' ' ' SER . 46.3 Cg_endo -64.59 -41.69 18.64 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.839 1.693 . . . . 0.0 111.355 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.484 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 7.0 m -164.0 104.87 0.9 Allowed 'General case' 0 N--CA 1.484 1.274 0 CA-C-O 123.35 1.548 . . . . 0.0 109.777 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.655 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.312 1.1 mp -106.02 136.42 40.49 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 CA-C-N 113.314 -1.766 . . . . 0.0 110.588 -177.203 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.58 ' CG1' ' HG3' ' A' ' 79' ' ' LYS . 4.4 t -87.42 134.63 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.256 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.581 ' HA ' ' CG1' ' A' ' 78' ' ' ILE . 95.8 t -117.36 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 178.116 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.554 ' N ' ' O ' ' A' ' 77' ' ' TRP . 2.9 mm-40 -86.98 113.3 22.63 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.688 -0.633 . . . . 0.0 110.79 -178.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 71' ' ' ASP . 8.3 p-10 -123.97 112.42 17.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.312 179.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.446 ' O ' ' C ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -152.76 150.23 29.18 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.831 -1.168 . . . . 0.0 111.332 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 35.52 -102.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.818 -0.551 . . . . 0.0 111.036 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.493 ' HA2' ' HB2' ' A' ' 44' ' ' LYS . . . -128.84 37.48 2.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.651 ' CE2' ' CZ2' ' A' ' 77' ' ' TRP . 0.1 OUTLIER -129.77 103.23 6.7 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.698 0.761 . . . . 0.0 109.863 179.54 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.797 ' CE2' HG21 ' A' ' 48' ' ' ILE . 12.5 t90 -96.86 80.95 3.06 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.651 ' CZ2' ' CE2' ' A' ' 75' ' ' PHE . 11.6 m0 -103.6 131.3 50.87 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.317 -0.865 . . . . 0.0 112.68 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.601 HD12 ' CD1' ' A' ' 52' ' ' ILE . 2.1 mt -128.14 130.28 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.104 -0.998 . . . . 0.0 109.437 177.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.58 ' HG3' ' CG1' ' A' ' 68' ' ' VAL . 1.9 mtpt -97.86 136.44 38.17 Favored 'General case' 0 C--N 1.295 -1.798 0 C-N-CA 119.748 -0.781 . . . . 0.0 109.779 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.503 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -140.5 140.81 35.37 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 110.003 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -93.91 50.05 1.39 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.165 -0.959 . . . . 0.0 110.302 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.72 -167.89 31.72 Favored Glycine 0 C--N 1.3 -1.46 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.9 129.65 39.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.152 -1.205 . . . . 0.0 110.13 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.531 ' CG2' ' HB ' ' A' ' 124' ' ' ILE . 8.2 tp -120.67 123.97 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.165 -0.96 . . . . 0.0 110.585 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -87.22 161.67 17.89 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.283 -0.886 . . . . 0.0 111.257 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.654 ' CG2' ' CE2' ' A' ' 122' ' ' PHE . 0.3 OUTLIER -161.46 149.01 4.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 O-C-N 121.254 -0.904 . . . . 0.0 110.704 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.557 ' N ' HD11 ' A' ' 86' ' ' ILE . 2.1 m-20 -152.14 171.1 18.43 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.088 -1.008 . . . . 0.0 111.341 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.544 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -151.24 -37.48 0.13 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.881 -0.728 . . . . 0.0 110.158 177.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.537 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -39.51 -46.87 1.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.622 -0.674 . . . . 0.0 110.312 -179.267 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.542 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 8.9 mt-10 -65.85 -52.06 53.57 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.813 0.816 . . . . 0.0 109.436 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 95' ' ' LEU . . . -54.25 -30.88 51.89 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 110.254 179.686 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.488 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -75.38 -56.43 4.68 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.542 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 3.2 pt-20 -50.14 -20.75 1.08 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.255 -1.144 . . . . 0.0 109.706 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.597 ' CD2' ' N ' ' A' ' 95' ' ' LEU . 1.4 tt -86.44 -65.91 0.96 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.976 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.597 ' N ' ' CD2' ' A' ' 94' ' ' LEU . 3.4 pp -70.06 -44.62 68.77 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.134 -0.979 . . . . 0.0 110.74 -179.566 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.538 ' N ' ' CD1' ' A' ' 95' ' ' LEU . . . -149.14 -76.06 0.02 OUTLIER Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.186 -1.483 . . . . 0.0 109.807 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.579 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 11.7 mttt 164.68 -63.09 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.917 0 O-C-N 121.843 -0.798 . . . . 0.0 109.989 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.3 Cg_endo -71.87 -18.51 28.07 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.764 1.402 . . . . 0.0 108.945 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.591 ' CB ' ' CD1' ' A' ' 95' ' ' LEU . 3.2 t80 -44.17 -52.09 7.62 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.787 0.803 . . . . 0.0 109.434 179.129 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.544 ' HA ' ' CB ' ' A' ' 88' ' ' ALA . 50.6 m -34.16 -58.26 0.46 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.728 0.775 . . . . 0.0 111.856 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.619 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 14.5 t -81.97 -50.43 16.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.453 ' C ' ' O ' ' A' ' 101' ' ' VAL . 4.3 t80 -49.48 -41.22 39.9 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 119.867 -1.77 . . . . 0.0 107.526 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.579 ' OD1' ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -62.73 -43.64 98.27 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 121.602 -0.686 . . . . 0.0 110.146 178.903 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.619 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 4.1 pp -78.6 -38.9 38.87 Favored 'General case' 0 C--O 1.202 -1.4 0 C-N-CA 117.24 -1.784 . . . . 0.0 109.004 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.53 ' N ' HD13 ' A' ' 104' ' ' LEU . 63.2 mt -53.04 -16.29 1.06 Allowed 'General case' 0 C--N 1.29 -1.99 0 O-C-N 119.074 -2.266 . . . . 0.0 109.35 177.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.415 ' N ' ' C ' ' A' ' 104' ' ' LEU . 0.4 OUTLIER -118.06 -26.67 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.22 -0.925 . . . . 0.0 109.169 179.182 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.553 ' OD1' ' CD2' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -113.34 -3.8 13.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.375 -0.828 . . . . 0.0 110.26 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.587 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 12.1 p -60.46 -12.06 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.919 -1.113 . . . . 0.0 109.831 -179.172 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.507 ' O ' ' N ' ' A' ' 111' ' ' THR . 23.5 t -42.59 -22.29 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.429 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 108' ' ' VAL . 6.1 t -44.11 -16.89 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.373 -0.829 . . . . 0.0 110.953 177.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.576 ' CG2' ' CG1' ' A' ' 124' ' ' ILE . 3.0 p -109.22 44.84 1.11 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.648 -1.283 . . . . 0.0 110.677 -178.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.536 ' CG2' HG11 ' A' ' 39' ' ' VAL . 3.6 m -56.13 -25.63 20.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 110.055 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -96.58 -73.4 1.15 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.486 ' O ' ' HB ' ' A' ' 111' ' ' THR . 0.0 OUTLIER -126.55 155.35 42.54 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.383 -1.069 . . . . 0.0 109.804 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.522 ' CB ' ' HB ' ' A' ' 111' ' ' THR . . . -150.81 74.83 1.18 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.026 -1.047 . . . . 0.0 110.981 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -69.1 101.8 1.51 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.083 -1.011 . . . . 0.0 108.367 178.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.49 ' HA ' ' HB3' ' A' ' 122' ' ' PHE . 3.6 m -79.14 162.9 25.49 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.446 -0.784 . . . . 0.0 111.147 -178.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.671 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.9 OUTLIER -147.14 39.34 1.0 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.825 -0.547 . . . . 0.0 109.93 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 59.5 -61.07 0.01 OUTLIER Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 179.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.671 ' N ' ' O ' ' A' ' 118' ' ' LEU . 3.3 m -93.34 -16.23 24.89 Favored 'General case' 0 C--N 1.289 -2.033 0 O-C-N 121.914 -0.757 . . . . 0.0 110.473 -179.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.538 ' CG ' ' OD2' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -159.85 153.86 23.23 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.975 -1.078 . . . . 0.0 111.084 -179.535 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.658 ' CD1' ' N ' ' A' ' 122' ' ' PHE . 0.4 OUTLIER -134.48 166.38 23.0 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.256 -0.902 . . . . 0.0 109.298 178.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.505 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 9.2 t -144.11 157.95 44.01 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.958 -1.089 . . . . 0.0 110.461 -178.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.617 ' N ' ' CD1' ' A' ' 124' ' ' ILE . 3.4 mp -121.15 150.27 24.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.383 -0.823 . . . . 0.0 110.307 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.485 ' O ' ' HB2' ' A' ' 114' ' ' ARG . 5.3 t -160.47 -163.6 1.11 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.383 -0.823 . . . . 0.0 110.402 -179.568 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER -154.42 -73.28 0.12 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.49 -0.756 . . . . 0.0 109.96 179.723 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.477 ' HG2' ' OD1' ' A' ' 36' ' ' ASN . 0.7 OUTLIER -61.35 111.24 1.68 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.367 -0.833 . . . . 0.0 110.267 179.693 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 127' ' ' GLU . 1.3 mp . . . . . 0 N--CA 1.486 1.328 0 O-C-N 121.456 -0.778 . . . . 0.0 110.623 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.454 ' OG ' ' N ' ' A' ' 36' ' ' ASN . 10.4 p . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.07 0.462 . . . . 0.0 110.157 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.454 ' N ' ' OG ' ' A' ' 35' ' ' SER . 1.6 m-20 -150.9 -82.29 0.1 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.104 -0.997 . . . . 0.0 110.361 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.53 125.49 0.51 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.771 -0.581 . . . . 0.0 111.159 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 94.1 t -89.87 135.37 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 110.273 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.476 ' O ' ' HB2' ' A' ' 110' ' ' SER . 8.2 p -117.5 130.5 72.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.112 -0.993 . . . . 0.0 110.732 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.595 ' HA ' ' OG ' ' A' ' 110' ' ' SER . 25.3 tp -105.9 141.06 37.94 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.598 ' CB ' ' HB3' ' A' ' 110' ' ' SER . 56.3 t -132.11 134.12 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.316 -1.49 . . . . 0.0 110.909 -178.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.629 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 26.4 mt -140.27 -166.31 2.09 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.551 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 23.5 ptm -101.44 166.59 10.65 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.328 -0.857 . . . . 0.0 110.879 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.496 ' HG2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -65.0 90.57 0.09 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -0.921 . . . . 0.0 111.694 -179.281 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 1.2 t -83.37 8.79 12.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.231 -0.918 . . . . 0.0 109.799 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.546 ' CB ' ' O ' ' A' ' 45' ' ' SER . 3.6 t0 77.16 -71.06 0.12 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.607 -0.683 . . . . 0.0 112.582 178.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.496 ' O ' HG12 ' A' ' 51' ' ' ILE . 3.8 mt-10 -81.74 24.24 0.61 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 120.948 -1.095 . . . . 0.0 111.873 -177.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.775 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.19 -63.09 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.874 -1.142 . . . . 0.0 112.323 -179.062 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -45.85 -35.39 4.44 Favored 'General case' 0 C--N 1.291 -1.946 0 C-N-CA 118.497 -1.281 . . . . 0.0 108.142 178.958 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.463 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.25 -51.69 12.69 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.847 -0.533 . . . . 0.0 110.123 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.775 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.81 -49.51 39.55 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.009 0 O-C-N 120.6 -1.312 . . . . 0.0 109.752 179.656 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.592 ' CG2' ' CG2' ' A' ' 69' ' ' VAL . 42.0 mm -46.73 -39.75 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 119.848 -1.783 . . . . 0.0 107.916 177.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.58 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 56.3 tt0 -62.62 -64.17 1.0 Allowed 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.485 179.242 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -80.02 -9.93 59.73 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.212 -0.93 . . . . 0.0 111.51 -178.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.664 ' N ' ' O ' ' A' ' 51' ' ' ILE . 3.7 tp -106.85 -34.35 2.85 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 121.611 0.719 . . . . 0.0 110.642 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.587 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 9.7 t -116.83 -43.82 3.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 C-N-CA 119.864 -0.734 . . . . 0.0 112.701 -177.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.58 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -55.52 -32.35 62.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.182 -1.574 . . . . 0.0 108.545 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.52 ' N ' HD21 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -93.44 -43.33 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.527 -0.733 . . . . 0.0 109.634 179.329 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -73.56 -47.27 22.05 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.565 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.02 -68.22 1.71 Allowed Glycine 0 N--CA 1.49 2.272 0 O-C-N 121.082 -1.246 . . . . 0.0 110.062 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.499 ' HG3' ' HA ' ' A' ' 66' ' ' SER . 0.0 OUTLIER -60.09 5.92 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.311 -1.111 . . . . 0.0 113.291 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.63 -64.64 0.75 Allowed 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.327 -1.483 . . . . 0.0 108.525 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.6 ptpt -95.44 -24.72 16.55 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.566 1.174 . . . . 0.0 107.92 177.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.565 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 1.2 m-20 -67.31 145.66 98.62 Favored Pre-proline 0 C--N 1.295 -1.78 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.868 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.457 ' O ' ' HE3' ' A' ' 61' ' ' LYS . 41.9 Cg_endo -61.62 -47.03 12.25 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 C-N-CA 122.533 2.156 . . . . 0.0 112.164 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.499 ' HA ' ' HG3' ' A' ' 61' ' ' LYS . 0.6 OUTLIER 179.23 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 123.156 1.455 . . . . 0.0 110.272 -179.793 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.67 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.289 1.1 mp -97.38 155.33 3.62 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.489 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.312 -177.483 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.567 ' CG1' ' HG3' ' A' ' 79' ' ' LYS . 0.2 OUTLIER -128.89 132.14 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.57 -0.707 . . . . 0.0 110.241 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.592 ' CG2' ' CG2' ' A' ' 52' ' ' ILE . 16.5 t -78.62 -178.67 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.601 ' HB3' ' HB2' ' A' ' 77' ' ' TRP . 0.8 OUTLIER -160.53 66.39 0.33 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 120.646 -1.283 . . . . 0.0 110.585 -178.747 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -71.63 120.77 17.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 110.24 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -119.67 148.01 43.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.196 -0.94 . . . . 0.0 109.81 179.764 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -60.31 77.61 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.915 . . . . 0.0 110.549 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 133.54 -20.37 4.15 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.697 -1.239 . . . . 0.0 110.302 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.496 ' O ' ' HG2' ' A' ' 44' ' ' LYS . 6.1 m-85 -131.27 176.75 8.02 Favored 'General case' 0 C--N 1.288 -2.097 0 O-C-N 121.703 -0.88 . . . . 0.0 111.612 -179.204 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.728 ' CE2' HG23 ' A' ' 48' ' ' ILE . 7.4 t90 -141.39 79.11 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.601 ' HB2' ' HB3' ' A' ' 70' ' ' GLU . 11.1 m0 -93.98 162.84 13.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.823 0.82 . . . . 0.0 111.326 -178.622 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.619 HD13 ' CD1' ' A' ' 76' ' ' TRP . 1.2 mp -159.27 138.85 3.48 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.626 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.567 ' HG3' ' CG1' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -106.94 142.14 37.03 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.542 -0.724 . . . . 0.0 110.12 -178.312 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.469 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -138.2 147.26 43.6 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.541 -0.724 . . . . 0.0 110.029 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.29 49.71 0.9 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.024 -1.048 . . . . 0.0 110.218 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 177.99 43.57 Favored Glycine 0 C--N 1.302 -1.356 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.61 123.11 21.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.328 -1.101 . . . . 0.0 109.937 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.458 ' CG1' ' N ' ' A' ' 85' ' ' GLU . 15.8 tt -120.3 171.92 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.188 -0.945 . . . . 0.0 110.766 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.522 ' CG ' ' OG1' ' A' ' 123' ' ' THR . 1.3 mt-10 -133.26 158.91 41.73 Favored 'General case' 0 C--N 1.309 -1.171 0 O-C-N 121.299 -0.876 . . . . 0.0 110.966 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.613 HG21 ' CE2' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -161.51 139.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.589 -0.694 . . . . 0.0 110.502 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.491 ' N ' HD12 ' A' ' 86' ' ' ILE . 2.8 m-20 -130.5 -178.51 4.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.244 -0.91 . . . . 0.0 110.679 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -151.11 -27.66 0.2 Allowed 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.373 -0.931 . . . . 0.0 111.246 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.461 ' HA ' ' HB2' ' A' ' 100' ' ' SER . . . -43.59 -54.13 5.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.909 -1.119 . . . . 0.0 110.217 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.514 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 4.0 mt-10 -53.58 -46.4 70.31 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.624 -0.83 . . . . 0.0 109.109 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.552 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.18 -38.37 87.86 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.436 -0.79 . . . . 0.0 108.99 178.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -66.98 -56.83 10.95 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.517 ' HG3' ' N ' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -57.54 -17.58 14.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.291 -1.123 . . . . 0.0 109.542 179.644 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.527 HD22 ' N ' ' A' ' 95' ' ' LEU . 3.4 tt -80.58 -58.51 3.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.643 -0.661 . . . . 0.0 110.001 -179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.696 HD12 ' CG ' ' A' ' 99' ' ' PHE . 0.2 OUTLIER -85.09 -33.26 22.46 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.44 179.48 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.545 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -155.92 -74.59 0.02 OUTLIER Glycine 0 N--CA 1.487 2.055 0 C-N-CA 119.103 -1.522 . . . . 0.0 109.669 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.562 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 2.3 mmtp 162.97 -57.56 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.822 -0.81 . . . . 0.0 108.923 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.562 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 47.7 Cg_endo -75.52 -18.53 17.58 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 124.21 1.637 . . . . 0.0 109.785 179.035 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.696 ' CG ' HD12 ' A' ' 95' ' ' LEU . 1.1 t80 -51.3 -46.31 62.49 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 119.071 -1.052 . . . . 0.0 108.64 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.548 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 1.3 t -31.7 -68.89 0.08 Allowed 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.974 0.892 . . . . 0.0 110.519 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.6 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 1.2 t -72.68 -59.22 3.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.632 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.496 ' N ' ' CG1' ' A' ' 101' ' ' VAL . 0.1 OUTLIER -44.51 -33.05 1.6 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.467 -1.396 . . . . 0.0 108.712 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.534 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 35.2 t70 -64.81 -42.95 94.61 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.6 ' HG ' ' O ' ' A' ' 101' ' ' VAL . 1.6 pp -75.27 -41.38 57.36 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.107 -1.437 . . . . 0.0 109.542 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.457 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 52.3 mt -55.15 -16.17 2.87 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 119.86 -1.775 . . . . 0.0 109.904 178.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -95.23 -46.74 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.325 -0.859 . . . . 0.0 110.196 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.513 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.5 OUTLIER -113.27 -4.21 13.74 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.145 -0.972 . . . . 0.0 112.093 -178.711 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.599 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 5.2 p -65.91 -8.8 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.6 -1.312 . . . . 0.0 109.768 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.96 -27.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.084 0.468 . . . . 0.0 112.024 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.598 ' HB3' ' CB ' ' A' ' 41' ' ' VAL . 1.0 OUTLIER -64.52 5.88 0.25 Allowed 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.135 -0.978 . . . . 0.0 111.949 179.585 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.498 HG21 HG21 ' A' ' 108' ' ' VAL . 32.2 p -61.93 -8.52 5.21 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.402 -1.436 . . . . 0.0 111.573 -177.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.527 ' CG1' ' N ' ' A' ' 113' ' ' GLY . 25.5 t 48.66 -92.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.527 ' N ' ' CG1' ' A' ' 112' ' ' VAL . . . -138.68 -3.8 1.73 Allowed Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.512 -1.327 . . . . 0.0 110.108 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.537 ' HG2' ' CG2' ' A' ' 125' ' ' THR . 1.4 mpt_? -123.95 146.94 48.14 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.046 -1.267 . . . . 0.0 110.661 -179.53 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -169.71 80.06 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.9 m-85 -69.05 89.36 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.258 -0.901 . . . . 0.0 109.06 179.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 14.3 t -79.33 151.21 31.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.388 -0.82 . . . . 0.0 111.306 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -133.74 62.67 1.65 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.83 -60.67 0.13 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.575 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.8 OUTLIER -118.21 -34.94 3.95 Favored 'General case' 0 C--N 1.292 -1.921 0 O-C-N 121.964 -0.727 . . . . 0.0 112.004 -179.243 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.559 ' O ' ' N ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -105.0 149.51 25.7 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 120.994 -1.066 . . . . 0.0 111.003 -178.789 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.654 ' CD1' ' N ' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -136.14 164.08 28.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.027 -1.046 . . . . 0.0 110.408 179.501 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.522 ' OG1' ' CG ' ' A' ' 85' ' ' GLU . 0.8 OUTLIER -138.79 149.93 45.52 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.291 -0.881 . . . . 0.0 109.225 -179.684 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.477 HG23 ' HA ' ' A' ' 111' ' ' THR . 0.0 OUTLIER -125.24 156.82 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.065 -1.022 . . . . 0.0 110.057 -179.419 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.537 ' CG2' ' HG2' ' A' ' 114' ' ' ARG . 6.3 t -160.78 163.53 32.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.131 -0.981 . . . . 0.0 110.625 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.432 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER -83.3 -74.38 0.37 Allowed 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.281 -0.887 . . . . 0.0 110.222 179.829 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 1.6 mm-40 -81.43 174.5 11.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.343 -0.848 . . . . 0.0 110.469 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.305 -1.334 0 O-C-N 121.545 -0.722 . . . . 0.0 110.792 -179.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.256 0.55 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.476 ' O ' ' OG ' ' A' ' 126' ' ' SER . 52.1 m-20 -157.61 -91.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.317 -0.864 . . . . 0.0 110.239 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.466 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.1 117.61 0.54 Allowed 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.518 -0.739 . . . . 0.0 110.717 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.427 HG11 ' O ' ' A' ' 36' ' ' ASN . 21.2 m -102.41 173.56 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.185 -0.947 . . . . 0.0 109.921 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.472 ' O ' ' OG ' ' A' ' 110' ' ' SER . 7.7 p -137.77 145.67 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 111.008 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.545 ' HB2' ' CG1' ' A' ' 84' ' ' ILE . 10.6 tp -111.67 137.31 49.74 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.623 HG12 ' CE2' ' A' ' 77' ' ' TRP . 80.5 t -133.77 124.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 120.664 -1.272 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.627 ' CB ' ' CE3' ' A' ' 76' ' ' TRP . 16.2 mt -132.84 178.84 6.56 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.632 178.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.429 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 2.2 ppp? -88.64 172.21 9.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.139 -0.976 . . . . 0.0 110.142 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.33 83.25 0.25 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.47 ' HB2' HG21 ' A' ' 48' ' ' ILE . 13.7 m -54.17 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.194 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 0.7 OUTLIER -158.64 -83.25 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.407 -0.808 . . . . 0.0 109.964 179.272 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.525 ' HB2' HG22 ' A' ' 51' ' ' ILE . 1.5 mt-10 -96.93 38.34 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.35 -0.844 . . . . 0.0 110.064 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.779 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -45.17 -60.72 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.172 -0.955 . . . . 0.0 111.32 -179.083 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 48' ' ' ILE . 3.2 m-20 -47.31 -44.44 23.53 Favored 'General case' 0 C--N 1.282 -2.363 0 C-N-CA 118.372 -1.331 . . . . 0.0 108.622 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -71.17 -47.04 60.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.559 -0.713 . . . . 0.0 110.854 179.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.779 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -74.78 -49.76 28.35 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.062 0 O-C-N 120.649 -1.282 . . . . 0.0 110.069 -179.909 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.6 ' O ' ' HB ' ' A' ' 56' ' ' VAL . 40.7 mm -45.0 -37.53 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.056 -1.652 . . . . 0.0 108.23 177.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.555 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 1.2 tt0 -68.66 -63.18 1.11 Allowed 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.296 -0.878 . . . . 0.0 110.256 179.279 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.11 -10.34 59.33 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.283 -0.885 . . . . 0.0 110.933 -179.322 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.679 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 tp -107.58 -35.43 2.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 CA-C-O 121.575 0.702 . . . . 0.0 110.681 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.6 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 2.1 t -117.75 -44.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.974 -0.69 . . . . 0.0 112.694 -176.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.555 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.9 OUTLIER -56.55 -41.63 77.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.11 -1.619 . . . . 0.0 109.478 -179.363 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -87.78 -43.98 11.46 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.634 -0.667 . . . . 0.0 110.583 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.17 -41.52 6.58 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.056 -178.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.552 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.83 -54.36 15.09 Favored Glycine 0 N--CA 1.492 2.399 0 O-C-N 120.803 -1.41 . . . . 0.0 110.328 -179.143 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.537 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -60.64 8.86 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.45 -1.03 . . . . 0.0 113.248 -179.323 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.55 ' CB ' ' HE3' ' A' ' 63' ' ' LYS . . . -57.19 -67.77 0.29 Allowed 'General case' 0 C--N 1.308 -1.229 0 O-C-N 120.258 -1.526 . . . . 0.0 109.076 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.588 ' N ' ' CE ' ' A' ' 63' ' ' LYS . 5.4 mmpt? -90.19 -19.53 24.11 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.552 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 6.3 m-20 -69.34 121.08 80.86 Favored Pre-proline 0 C--N 1.299 -1.588 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.401 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.472 ' O ' ' OG ' ' A' ' 66' ' ' SER . 44.9 Cg_endo -64.09 -39.24 32.48 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.884 1.723 . . . . 0.0 111.16 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.482 ' C ' ' CD1' ' A' ' 67' ' ' ILE . 2.8 m -177.77 111.2 0.07 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 123.012 1.386 . . . . 0.0 109.193 179.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.615 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.299 1.3 mp -107.06 145.48 14.51 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.465 0 CA-C-N 113.823 -1.535 . . . . 0.0 111.673 -176.533 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.493 HG11 ' CB ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.04 142.66 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.931 179.454 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.533 HG11 ' CG1' ' A' ' 78' ' ' ILE . 66.1 t -115.32 100.38 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.125 -0.984 . . . . 0.0 110.154 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.566 ' N ' ' O ' ' A' ' 77' ' ' TRP . 1.1 mm-40 -83.59 124.51 30.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.489 -0.757 . . . . 0.0 109.869 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -123.25 102.47 7.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.15 -0.969 . . . . 0.0 109.587 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -103.97 144.23 31.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.164 -0.96 . . . . 0.0 109.948 -179.704 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.72 83.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.435 -0.79 . . . . 0.0 110.044 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 132.73 -24.88 3.82 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -125.08 161.63 26.36 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.778 -0.836 . . . . 0.0 110.931 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.692 ' CE2' HG23 ' A' ' 48' ' ' ILE . 11.8 t90 -135.88 79.46 1.77 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.623 ' CE2' HG12 ' A' ' 41' ' ' VAL . 11.2 m0 -98.79 137.72 36.97 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.495 -0.753 . . . . 0.0 112.433 -177.563 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.551 HD13 ' CD1' ' A' ' 76' ' ' TRP . 1.3 mt -138.29 139.15 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.304 -0.873 . . . . 0.0 109.486 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.493 ' CB ' HG11 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -109.01 162.28 14.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.188 -0.945 . . . . 0.0 110.582 -179.387 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.478 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.31 140.64 20.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.97 50.03 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -0.906 . . . . 0.0 109.961 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.53 -138.85 2.6 Favored Glycine 0 C--N 1.301 -1.374 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.29 163.28 23.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -1.179 . . . . 0.0 109.885 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.545 ' CG1' ' HB2' ' A' ' 40' ' ' LEU . 5.7 tp -150.83 161.85 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.099 -1.001 . . . . 0.0 110.307 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.504 ' N ' HG13 ' A' ' 84' ' ' ILE . 2.4 mt-10 -140.18 164.75 29.22 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.229 -0.92 . . . . 0.0 110.384 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.693 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -125.53 165.22 23.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.298 -0.876 . . . . 0.0 109.718 179.62 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.522 ' OD1' ' CG ' ' A' ' 121' ' ' LYS . 9.5 m-20 -149.46 155.29 40.15 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.304 -0.872 . . . . 0.0 110.656 -179.648 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.627 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -146.12 -22.37 0.45 Allowed 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 118.808 -1.157 . . . . 0.0 111.301 177.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -41.57 -46.48 3.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.667 -1.271 . . . . 0.0 110.624 179.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.442 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.2 tt0 -49.36 -57.76 6.31 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.401 -0.812 . . . . 0.0 109.659 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.565 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -45.55 -30.31 1.43 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.687 -0.633 . . . . 0.0 109.727 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -71.17 -37.83 63.51 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.442 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.3 mt-10 -64.69 -20.19 66.17 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.445 HD23 HD21 ' A' ' 95' ' ' LEU . 7.4 tt -84.54 -67.57 0.79 Allowed 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.527 ' CD1' ' HB3' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -100.77 -23.3 14.63 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.115 -0.99 . . . . 0.0 110.112 179.26 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 60.1 45.69 95.53 Favored Glycine 0 N--CA 1.5 2.942 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.278 178.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.689 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 13.7 mttt -138.06 -127.43 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.456 0 O-C-N 121.091 -1.241 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.689 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 42.0 Cg_endo -71.61 -4.91 15.96 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 CA-C-N 120.894 1.355 . . . . 0.0 108.605 178.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.767 ' CD1' ' N ' ' A' ' 100' ' ' SER . 2.8 p90 -24.12 -42.55 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 CA-C-O 121.599 0.714 . . . . 0.0 112.032 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.767 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.2 OUTLIER -57.94 -54.86 42.18 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 122.901 1.334 . . . . 0.0 109.18 -177.64 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.61 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 6.5 t -94.17 -43.88 13.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.672 -178.135 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.46 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 37.4 t80 -53.1 -41.12 64.64 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 120.209 -1.557 . . . . 0.0 107.652 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.587 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.4 t0 -68.5 -43.13 77.53 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.437 -0.79 . . . . 0.0 109.922 179.152 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.61 ' CD2' ' HA ' ' A' ' 101' ' ' VAL . 2.9 pp -75.25 -40.38 58.99 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 116.756 -1.978 . . . . 0.0 109.046 179.252 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.544 ' N ' HD13 ' A' ' 104' ' ' LEU . 23.6 mt -52.82 -20.02 2.93 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.094 -1.629 . . . . 0.0 109.867 178.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -92.09 -44.92 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.267 -0.896 . . . . 0.0 110.629 -179.581 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.488 ' HB2' ' O ' ' A' ' 41' ' ' VAL . 0.6 OUTLIER -114.48 -7.59 12.83 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 112.243 -178.366 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.57 ' CB ' HD11 ' A' ' 104' ' ' LEU . 6.0 p -60.89 -17.64 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.592 -1.317 . . . . 0.0 109.34 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.447 ' N ' HG11 ' A' ' 108' ' ' VAL . 1.0 OUTLIER -39.84 -22.78 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.7 -179.231 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.584 ' HB2' ' HB ' ' A' ' 41' ' ' VAL . 0.1 OUTLIER -73.28 9.52 1.26 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.698 -1.251 . . . . 0.0 110.558 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.537 ' O ' ' HB ' ' A' ' 112' ' ' VAL . 1.1 t -61.53 -10.86 8.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.762 -1.212 . . . . 0.0 110.396 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.537 ' HB ' ' O ' ' A' ' 111' ' ' THR . 2.1 t 66.89 -52.73 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.576 -0.702 . . . . 0.0 110.62 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -173.15 -26.87 0.02 OUTLIER Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.468 ' HB2' ' HB2' ' A' ' 128' ' ' LEU . 18.2 ttt180 -138.81 147.74 42.91 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.063 -1.257 . . . . 0.0 111.023 -179.494 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.484 ' HA ' HG13 ' A' ' 124' ' ' ILE . . . -155.76 93.61 1.48 Allowed 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.38 -0.825 . . . . 0.0 110.285 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.525 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 12.2 t80 -69.72 118.88 13.13 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.49 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.2 m -79.55 117.78 20.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.619 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -79.38 49.62 1.01 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.935 179.404 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.93 -60.14 0.36 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 108.674 -1.77 . . . . 0.0 108.674 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -116.01 -10.15 11.63 Favored 'General case' 0 C--N 1.293 -1.875 0 O-C-N 122.001 -0.705 . . . . 0.0 110.382 179.712 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.522 ' CG ' ' OD1' ' A' ' 87' ' ' ASP . 1.7 tttt -121.07 -161.94 0.93 Allowed 'General case' 0 N--CA 1.493 1.685 0 CA-C-O 122.052 0.929 . . . . 0.0 111.397 -179.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.693 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.26 0.2 OUTLIER -141.22 150.93 43.31 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.97 -179.105 . . . . . . . . 4 4 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.525 ' CG2' ' HB3' ' A' ' 116' ' ' TYR . 0.7 OUTLIER -137.4 110.96 8.03 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.982 -1.074 . . . . 0.0 110.001 178.705 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.487 ' HB ' ' CG2' ' A' ' 84' ' ' ILE . 4.8 mp -113.86 157.28 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 110.174 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.466 ' N ' HG21 ' A' ' 124' ' ' ILE . 15.3 t -146.96 170.24 17.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.293 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 0.2 OUTLIER -91.39 -32.62 15.58 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.307 -0.87 . . . . 0.0 110.684 -179.527 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 128' ' ' LEU . 77.8 mt-10 -84.6 28.81 0.64 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.377 -0.827 . . . . 0.0 110.668 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.47 ' O ' ' O ' ' A' ' 127' ' ' GLU . 2.9 pp . . . . . 0 C--N 1.306 -1.301 0 O-C-N 121.092 -1.005 . . . . 0.0 110.672 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 56.9 m . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.235 0.54 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.477 ' HA ' ' OG ' ' A' ' 126' ' ' SER . 26.9 p-10 -118.27 -43.43 2.73 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.332 -0.855 . . . . 0.0 110.38 -179.764 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -39.74 134.0 1.45 Allowed 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.623 -0.673 . . . . 0.0 110.995 -179.502 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 80' ' ' ALA . 7.6 p -141.18 152.45 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.308 -0.87 . . . . 0.0 109.732 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.476 HG11 ' O ' ' A' ' 39' ' ' VAL . 14.5 p -114.87 136.28 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 111.464 -179.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.483 ' N ' ' O ' ' A' ' 78' ' ' ILE . 3.8 tp -100.53 146.11 27.49 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 176.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.618 ' CG2' ' CD2' ' A' ' 77' ' ' TRP . 2.2 t -139.12 121.45 17.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 O-C-N 120.403 -1.436 . . . . 0.0 111.365 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.688 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 3.3 mm? -133.42 153.02 51.96 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.294 -0.879 . . . . 0.0 109.212 178.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 12.7 ptm -75.45 153.68 37.47 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.837 -1.164 . . . . 0.0 109.721 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.535 ' CG ' ' HA2' ' A' ' 74' ' ' GLY . 10.0 ptmt -45.16 123.59 4.06 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.032 -1.042 . . . . 0.0 110.859 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.8 m -100.05 -86.28 0.39 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.592 179.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -158.0 -79.11 0.07 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 110.92 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.486 ' C ' HD12 ' A' ' 51' ' ' ILE . 1.4 mt-10 -96.74 39.06 1.18 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.305 -0.872 . . . . 0.0 110.367 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.771 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.04 -69.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.117 -0.99 . . . . 0.0 111.586 -178.916 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.8 m-20 -41.15 -36.05 0.67 Allowed 'General case' 0 C--N 1.284 -2.267 0 C-N-CA 119.059 -1.057 . . . . 0.0 109.062 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -77.78 -50.22 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.601 -0.687 . . . . 0.0 109.9 178.601 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.771 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.31 -50.93 28.0 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.011 0 O-C-N 120.848 -1.157 . . . . 0.0 109.325 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.598 ' HA ' HG21 ' A' ' 55' ' ' ILE . 44.2 mm -47.19 -40.71 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 119.881 -1.762 . . . . 0.0 108.147 177.569 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.541 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 60.2 tt0 -60.85 -61.58 2.48 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -84.1 -9.15 58.83 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.201 -0.937 . . . . 0.0 111.669 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.675 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.5 tp -106.68 -32.81 2.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 CA-C-O 121.695 0.759 . . . . 0.0 110.098 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.586 ' HB ' ' O ' ' A' ' 52' ' ' ILE . 7.4 t -116.46 -45.05 3.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 C-N-CA 119.942 -0.703 . . . . 0.0 112.188 -177.626 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.541 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -64.81 -37.67 88.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.339 -1.475 . . . . 0.0 108.557 179.798 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.505 ' N ' HD21 ' A' ' 57' ' ' LEU . 6.6 mtpt -96.86 -42.07 8.13 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.524 -0.735 . . . . 0.0 109.221 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -77.54 -49.84 7.0 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.27 -47.86 49.48 Favored Glycine 0 N--CA 1.489 2.178 0 O-C-N 120.973 -1.31 . . . . 0.0 110.136 -179.144 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.557 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 17.6 ttpp -65.17 9.98 0.09 Allowed 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.624 -0.927 . . . . 0.0 113.124 -179.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.67 -62.88 1.35 Allowed 'General case' 0 C--N 1.304 -1.386 0 O-C-N 120.387 -1.446 . . . . 0.0 108.897 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mtmt -101.62 -17.58 16.28 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.576 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 0.5 OUTLIER -67.96 127.27 93.32 Favored Pre-proline 0 C--N 1.3 -1.544 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.229 -179.165 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -66.22 -49.52 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.321 2.014 . . . . 0.0 111.587 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.439 ' C ' HD13 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -166.97 106.23 0.6 Allowed 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 123.211 1.481 . . . . 0.0 109.489 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.678 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -97.1 148.91 5.19 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 CA-C-N 113.47 -1.696 . . . . 0.0 111.836 -176.507 . . . . . . . . 4 4 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.494 HG11 ' CB ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.44 145.44 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.298 -0.876 . . . . 0.0 110.201 179.731 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.543 ' CG2' HG23 ' A' ' 52' ' ' ILE . 99.2 t -121.31 96.7 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.152 -0.968 . . . . 0.0 110.089 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.3 mm-40 -79.36 134.6 36.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.263 -0.898 . . . . 0.0 110.092 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . 0.469 ' O ' ' OD1' ' A' ' 71' ' ' ASP . 1.1 p30 -143.31 112.24 6.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.179 -0.951 . . . . 0.0 110.017 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.47 ' HG3' ' HB2' ' A' ' 75' ' ' PHE . 0.2 OUTLIER -147.55 -171.45 3.8 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.892 -1.13 . . . . 0.0 111.241 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.465 ' O ' ' C ' ' A' ' 74' ' ' GLY . . . -40.22 110.84 0.16 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.47 -0.769 . . . . 0.0 110.911 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.535 ' HA2' ' CG ' ' A' ' 44' ' ' LYS . . . 36.47 59.62 1.01 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.47 ' HB2' ' HG3' ' A' ' 72' ' ' LYS . 2.5 m-85 -160.75 75.49 0.54 Allowed 'General case' 0 C--N 1.291 -1.961 0 O-C-N 121.849 -0.795 . . . . 0.0 110.039 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.724 ' CE2' HG21 ' A' ' 48' ' ' ILE . 4.1 t90 -82.49 78.34 9.14 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.654 0.74 . . . . 0.0 109.08 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . 0.618 ' CD2' ' CG2' ' A' ' 41' ' ' VAL . 23.2 m0 -98.94 148.27 24.14 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.594 -0.691 . . . . 0.0 111.626 -178.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.555 ' CD1' ' NE1' ' A' ' 76' ' ' TRP . 1.2 mp -146.65 141.58 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.339 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.494 ' CB ' HG11 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -116.74 141.75 47.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.129 -0.982 . . . . 0.0 110.695 -179.022 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.509 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -127.07 163.51 23.62 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.385 -0.822 . . . . 0.0 110.008 179.537 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -106.41 47.44 0.88 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.068 -1.02 . . . . 0.0 110.179 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -108.11 0.21 Allowed Glycine 0 C--N 1.299 -1.482 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -126.22 166.14 17.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.458 -1.025 . . . . 0.0 110.091 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.507 ' CG2' ' HB ' ' A' ' 124' ' ' ILE . 7.9 tp -143.91 158.61 16.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.121 -0.987 . . . . 0.0 110.524 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.46 ' O ' HG12 ' A' ' 86' ' ' ILE . 34.2 tt0 -122.76 173.8 7.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.261 -0.899 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.699 HG22 ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -157.62 149.78 9.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 O-C-N 121.148 -0.97 . . . . 0.0 111.007 -179.58 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' HG21 ' A' ' 86' ' ' ILE . 71.0 m-20 -138.54 152.21 48.0 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.06 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.57 ' CB ' ' O ' ' A' ' 100' ' ' SER . . . -151.84 -34.84 0.13 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.335 -1.346 . . . . 0.0 111.585 178.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.533 ' CB ' ' OG1' ' A' ' 120' ' ' THR . . . -40.91 -45.35 2.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.289 -0.882 . . . . 0.0 110.181 -179.235 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.557 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 3.8 tt0 -67.86 -52.02 41.52 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 178.792 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.565 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.8 -41.15 70.23 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 108.965 178.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.53 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -59.49 -55.31 31.35 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.557 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 0.9 OUTLIER -57.02 -16.94 8.16 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.174 -1.192 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.5 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 7.4 tt -86.25 -64.27 1.18 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.501 -0.749 . . . . 0.0 111.014 -179.302 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.631 HD12 ' CD1' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -71.36 -37.2 71.66 Favored 'General case' 0 N--CA 1.502 2.168 0 C-N-CA 118.485 -1.286 . . . . 0.0 109.849 -179.706 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -158.41 -74.43 0.02 OUTLIER Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.545 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 167.53 -63.24 0.0 OUTLIER Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.956 . . . . 0.0 109.52 179.855 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.9 Cg_endo -72.04 -16.22 28.93 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.476 1.25 . . . . 0.0 109.64 178.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.631 ' CD1' HD12 ' A' ' 95' ' ' LEU . 3.1 t80 -48.87 -48.51 42.09 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 121.074 -1.017 . . . . 0.0 109.171 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.57 ' O ' ' CB ' ' A' ' 88' ' ' ALA . 3.8 t -32.36 -61.87 0.24 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.752 0.787 . . . . 0.0 110.764 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.581 ' HA ' ' CD2' ' A' ' 104' ' ' LEU . 19.4 t -82.79 -54.41 9.48 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.822 0 O-C-N 121.183 -0.948 . . . . 0.0 112.793 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.419 ' HA ' HD13 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -46.56 -29.98 2.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.67 -1.269 . . . . 0.0 108.917 179.911 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.53 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 29.5 t70 -82.17 -37.18 26.53 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.451 -0.78 . . . . 0.0 109.441 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.583 ' O ' ' HB ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -68.75 -21.78 64.35 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.364 179.523 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.537 ' CD1' HG11 ' A' ' 101' ' ' VAL . 4.6 mt -86.75 -27.72 23.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.819 -1.175 . . . . 0.0 110.373 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.444 HG21 ' N ' ' A' ' 107' ' ' ASN . 0.6 OUTLIER -97.24 -28.52 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 121.134 -0.979 . . . . 0.0 109.956 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.562 ' O ' ' O ' ' A' ' 41' ' ' VAL . 2.5 p30 -87.49 -30.44 20.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.34 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.583 ' HB ' ' O ' ' A' ' 104' ' ' LEU . 9.9 p -66.3 -0.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 120.61 -1.306 . . . . 0.0 110.9 179.407 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -30.05 -34.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.813 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.57 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . 82.8 p -84.4 33.66 0.51 Allowed 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.533 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.579 ' HB ' ' CG2' ' A' ' 108' ' ' VAL . 11.5 t -96.46 44.26 1.07 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.26 179.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.573 ' CG1' ' N ' ' A' ' 113' ' ' GLY . 0.5 OUTLIER -61.68 -48.66 87.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.542 -0.724 . . . . 0.0 111.015 -178.687 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.573 ' N ' ' CG1' ' A' ' 112' ' ' VAL . . . -57.21 -77.04 0.18 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.521 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -157.72 -169.04 2.72 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.384 -1.068 . . . . 0.0 110.105 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.412 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -170.7 84.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.478 ' HB3' HG21 ' A' ' 123' ' ' THR . 4.7 t80 -69.84 105.71 2.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.003 -1.061 . . . . 0.0 108.351 178.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 7.6 m -79.03 145.95 33.58 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.299 -0.876 . . . . 0.0 110.915 -178.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.612 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.1 OUTLIER -123.69 50.3 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.587 -0.695 . . . . 0.0 110.282 179.914 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 62.15 -57.26 0.03 OUTLIER Glycine 0 N--CA 1.491 2.326 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 178.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.612 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.8 t -111.7 -15.18 13.49 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.753 -0.851 . . . . 0.0 111.406 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -143.57 150.6 39.08 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.758 -1.214 . . . . 0.0 110.77 -179.614 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.699 ' CE2' HG22 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -124.68 164.17 20.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.877 -1.139 . . . . 0.0 110.769 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.487 ' OG1' ' O ' ' A' ' 84' ' ' ILE . 2.8 t -144.27 131.85 21.09 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.514 -0.741 . . . . 0.0 109.831 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.619 HD12 ' CE1' ' A' ' 122' ' ' PHE . 2.0 mp -101.91 162.66 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 110.674 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' THR . . . . . 0.422 ' N ' ' CG2' ' A' ' 124' ' ' ILE . 3.3 t -152.34 -175.3 5.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -0.872 . . . . 0.0 109.806 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 128' ' ' LEU . 19.7 t -108.31 -50.62 3.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.086 . . . . 0.0 110.705 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 128' ' ' LEU . 1.6 mt-10 -53.54 82.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.586 -0.696 . . . . 0.0 110.686 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.543 ' N ' ' O ' ' A' ' 126' ' ' SER . 1.1 mt . . . . . 0 C--N 1.304 -1.379 0 O-C-N 121.218 -0.927 . . . . 0.0 110.288 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.49 ' O ' ' C ' ' A' ' 37' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.495 1.777 0 CA-C-O 121.099 0.476 . . . . 0.0 110.695 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.49 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -29.87 132.96 0.06 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.403 0.621 . . . . 0.0 111.846 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 1.7 p -142.48 149.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.515 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.588 ' H ' HG21 ' A' ' 112' ' ' VAL . 11.1 p -127.68 150.05 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.78 -1.2 . . . . 0.0 111.707 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 1.023 HD11 HG13 ' A' ' 86' ' ' ILE . 23.5 tp -112.36 132.05 55.21 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.865 HG13 ' NE1' ' A' ' 77' ' ' TRP . 2.6 t -127.28 124.87 64.95 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 111.603 -177.051 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.844 HD21 HD11 ' A' ' 86' ' ' ILE . 0.9 OUTLIER -119.53 -174.18 2.68 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.002 -1.061 . . . . 0.0 110.605 179.189 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.567 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.8 ptp -117.66 21.58 12.88 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.937 . . . . 0.0 110.642 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.664 ' HB3' HD11 ' A' ' 48' ' ' ILE . 3.6 mmtt -88.95 -93.14 0.11 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.456 -0.778 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.62 ' CB ' ' O ' ' A' ' 44' ' ' LYS . 1.3 p 89.36 178.01 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 45' ' ' SER . 0.1 OUTLIER 62.93 -87.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 109.663 -179.242 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.519 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.2 mt-10 -52.16 -24.95 7.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.44 -0.787 . . . . 0.0 111.895 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 1.01 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -73.48 -62.37 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.709 -178.082 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.545 ' C ' ' O ' ' A' ' 48' ' ' ILE . 85.4 m-20 -37.83 -32.57 0.06 Allowed 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.316 -0.954 . . . . 0.0 108.782 179.443 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.27 -55.98 5.06 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.814 HG12 ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -71.3 -48.69 52.66 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.165 0 O-C-N 120.679 -1.263 . . . . 0.0 109.29 178.922 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.859 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 45.8 mm -46.01 -41.23 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 119.871 -1.768 . . . . 0.0 108.604 177.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.778 ' HA ' ' HB2' ' A' ' 57' ' ' LEU . 2.1 tm-20 -64.73 -60.89 2.58 Favored 'General case' 0 C--N 1.292 -1.91 0 O-C-N 121.206 -0.933 . . . . 0.0 110.143 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -77.62 -12.59 59.98 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 120.868 -1.145 . . . . 0.0 111.488 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.776 HG23 HG23 ' A' ' 56' ' ' VAL . 4.0 tp -107.43 -34.96 2.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 O-C-N 121.59 -0.694 . . . . 0.0 111.499 -178.197 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.776 HG23 HG23 ' A' ' 55' ' ' ILE . 2.5 t -117.18 -37.89 2.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.655 -0.653 . . . . 0.0 112.632 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.778 ' HB2' ' HA ' ' A' ' 53' ' ' GLU . 1.4 tm? -37.51 -55.49 1.08 Allowed 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 122.272 1.034 . . . . 0.0 109.947 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.31 -48.97 12.2 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.487 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -50.82 -47.39 47.31 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.525 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -78.03 7.07 46.11 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.77 -8.56 16.75 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.972 -1.311 . . . . 0.0 110.891 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.5 -82.63 0.22 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.945 -1.097 . . . . 0.0 109.93 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.403 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -79.56 -30.3 41.64 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 122.432 1.111 . . . . 0.0 108.158 178.678 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.525 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 8.5 m-20 -74.65 127.03 87.96 Favored Pre-proline 0 C--N 1.295 -1.801 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.473 ' O ' ' HB2' ' A' ' 66' ' ' SER . 43.5 Cg_endo -62.86 -47.7 8.21 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 121.77 1.646 . . . . 0.0 110.822 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.656 ' C ' HD12 ' A' ' 67' ' ' ILE . 1.7 t 179.96 111.86 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.958 1.361 . . . . 0.0 109.339 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.656 HD12 ' C ' ' A' ' 66' ' ' SER 0.292 1.3 mp -104.37 134.77 44.77 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.508 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.551 -176.823 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.642 HG12 ' CB ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -92.03 162.73 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 109.374 178.925 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.802 ' CG1' HG21 ' A' ' 52' ' ' ILE . 24.3 t -136.28 106.51 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.045 -1.034 . . . . 0.0 110.31 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.612 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.7 mm-40 -102.05 145.42 29.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.841 . . . . 0.0 110.421 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ASP . . . . . 0.428 ' CG ' ' OD2' ' A' ' 49' ' ' ASP . 11.6 p-10 -136.96 119.72 16.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.451 -0.78 . . . . 0.0 108.965 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.596 ' CB ' ' HB2' ' A' ' 75' ' ' PHE . 27.0 mttm -125.49 83.28 2.15 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.019 -1.051 . . . . 0.0 111.506 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.558 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 18.64 73.66 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.237 0 CA-C-O 121.231 0.539 . . . . 0.0 111.949 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 43' ' ' MET . . . 103.54 11.18 33.86 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.596 ' HB2' ' CB ' ' A' ' 72' ' ' LYS . 20.4 m-85 -138.26 101.03 4.28 Favored 'General case' 0 C--N 1.286 -2.165 0 O-C-N 121.837 -0.802 . . . . 0.0 110.587 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 1.01 ' CE2' HG21 ' A' ' 48' ' ' ILE . 17.5 t90 -89.39 87.53 7.13 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.518 -0.738 . . . . 0.0 109.494 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.865 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.7 m0 -98.06 111.59 23.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.08 -1.012 . . . . 0.0 110.427 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.543 ' O ' HG23 ' A' ' 39' ' ' VAL . 0.3 OUTLIER -114.65 148.17 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.737 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.642 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -130.28 125.46 34.83 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.921 -1.112 . . . . 0.0 110.16 179.81 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.534 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -125.44 173.97 8.52 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.478 -0.764 . . . . 0.0 110.031 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.97 52.51 1.27 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 110.046 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -169.59 -105.94 0.19 Allowed Glycine 0 C--N 1.302 -1.337 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -133.08 115.5 15.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.505 -0.997 . . . . 0.0 110.316 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.684 HG21 ' HB2' ' A' ' 40' ' ' LEU . 8.1 tp -105.49 148.36 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 110.261 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -103.99 159.29 15.79 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.157 -0.965 . . . . 0.0 111.392 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 1.023 HG13 HD11 ' A' ' 40' ' ' LEU . 0.3 OUTLIER -162.32 149.82 4.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 O-C-N 121.442 -0.787 . . . . 0.0 110.438 179.772 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.843 ' N ' HD13 ' A' ' 86' ' ' ILE . 1.4 m-20 -135.31 -176.13 4.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.011 -1.056 . . . . 0.0 111.455 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.659 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -138.41 -9.31 1.46 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.813 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -43.71 -48.34 7.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.474 -1.392 . . . . 0.0 110.269 179.309 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.582 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 10.1 tt0 -49.36 -47.63 47.3 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.455 -0.778 . . . . 0.0 109.892 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.522 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -56.81 -26.46 58.04 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.067 -1.021 . . . . 0.0 109.649 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.699 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -73.97 -48.84 14.82 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.582 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.0 OUTLIER -58.23 -19.3 32.79 Favored 'General case' 0 C--N 1.289 -2.052 0 O-C-N 121.104 -1.233 . . . . 0.0 107.951 178.56 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.845 HD23 ' CD2' ' A' ' 95' ' ' LEU . 11.4 tp -82.11 -68.0 0.73 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.826 -0.546 . . . . 0.0 109.613 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.845 ' CD2' HD23 ' A' ' 94' ' ' LEU . 0.2 OUTLIER -100.96 -29.66 12.07 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.082 -1.011 . . . . 0.0 109.135 178.587 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 69.44 43.96 66.98 Favored Glycine 0 N--CA 1.498 2.768 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.833 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.687 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 8.2 mmmt -138.23 -124.17 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.672 0 O-C-N 121.091 -1.241 . . . . 0.0 109.724 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.687 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 45.9 Cg_endo -71.14 -4.96 15.94 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 121.172 1.454 . . . . 0.0 108.724 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.76 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.8 p90 -23.66 -44.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.076 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.76 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -49.14 -52.48 25.96 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 123.348 1.547 . . . . 0.0 107.734 -179.125 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.867 HG12 HD11 ' A' ' 105' ' ' LEU . 67.5 t -99.04 -53.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.807 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.486 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 0.5 OUTLIER -44.42 -30.02 0.79 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.773 -1.204 . . . . 0.0 108.434 179.364 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.564 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.8 t70 -83.11 -45.94 13.37 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.296 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.83 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.5 OUTLIER -60.9 -41.16 95.55 Favored 'General case' 0 C--O 1.202 -1.425 0 C-N-CA 117.928 -1.509 . . . . 0.0 109.144 179.168 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.867 HD11 HG12 ' A' ' 101' ' ' VAL . 28.0 mt -61.58 -46.47 89.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.725 -1.235 . . . . 0.0 111.341 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -73.94 -33.07 35.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 110.464 -178.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.557 ' HB2' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -90.42 -40.71 11.89 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.121 -0.987 . . . . 0.0 110.143 -179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 104' ' ' LEU . 1.6 p -65.86 1.66 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.647 -1.283 . . . . 0.0 111.32 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.509 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.42 -33.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.997 -1.064 . . . . 0.0 110.872 -179.699 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.871 ' O ' HG22 ' A' ' 112' ' ' VAL . 1.9 p -88.02 39.16 0.88 Allowed 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 108' ' ' VAL . 8.9 t -60.63 -10.93 5.9 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.377 -0.827 . . . . 0.0 111.698 -178.182 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.871 HG22 ' O ' ' A' ' 110' ' ' SER . 0.6 OUTLIER 16.56 -84.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 CA-C-O 121.094 0.473 . . . . 0.0 112.081 -179.839 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.587 ' H ' HG23 ' A' ' 112' ' ' VAL . . . -83.54 52.99 4.81 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.537 ' O ' ' O ' ' A' ' 113' ' ' GLY . 10.6 ttt85 43.49 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 O-C-N 121.539 -0.977 . . . . 0.0 111.544 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.518 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -142.41 107.83 5.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.748 -1.22 . . . . 0.0 110.346 -179.128 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.476 ' HB3' HG22 ' A' ' 123' ' ' THR . 33.3 t80 -69.43 118.39 12.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.105 -0.997 . . . . 0.0 109.247 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 7.4 t -83.84 158.09 21.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.146 -0.971 . . . . 0.0 111.301 -178.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -135.1 54.72 1.92 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.662 -0.649 . . . . 0.0 110.388 -179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.3 -57.72 0.07 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.603 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -114.4 -23.75 9.21 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.844 -0.798 . . . . 0.0 111.24 -178.93 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.539 ' O ' ' CB ' ' A' ' 118' ' ' LEU . 5.5 tttt -138.72 147.27 42.51 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.904 -1.122 . . . . 0.0 110.796 -179.329 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.728 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -116.02 -177.96 3.29 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.086 -1.009 . . . . 0.0 109.136 178.326 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.648 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.9 OUTLIER -156.42 141.23 17.06 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 110.342 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.751 HD12 ' N ' ' A' ' 124' ' ' ILE . 3.1 mp -111.28 129.65 66.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 110.34 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.429 ' OG1' ' N ' ' A' ' 126' ' ' SER . 1.7 t -145.15 -169.1 3.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.184 -0.947 . . . . 0.0 110.399 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.429 ' N ' ' OG1' ' A' ' 125' ' ' THR . 3.8 t . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.848 . . . . 0.0 110.595 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.491 ' HB2' ' HB2' ' A' ' 126' ' ' SER . 77.9 m-20 . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.467 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.41 146.38 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.656 -0.653 . . . . 0.0 110.474 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.703 HG21 ' C ' ' A' ' 125' ' ' THR . 1.9 t -136.56 120.95 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.843 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 39' ' ' VAL . 9.6 p -97.64 134.79 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.665 HD22 HD11 ' A' ' 84' ' ' ILE . 9.2 tp -106.98 147.96 29.25 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.799 HG13 ' CD1' ' A' ' 77' ' ' TRP . 50.6 t -149.07 126.58 2.65 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 120.576 -1.328 . . . . 0.0 110.322 -178.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.914 HD23 ' CZ3' ' A' ' 76' ' ' TRP . 12.4 tp -135.73 178.71 6.83 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.199 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.526 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 8.6 ptp -78.61 178.5 7.77 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.725 -1.235 . . . . 0.0 110.79 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 74' ' ' GLY . 4.4 mtmt -64.09 95.9 0.13 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.539 -0.726 . . . . 0.0 112.127 -178.795 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.515 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 0.2 OUTLIER -73.85 -0.96 17.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 0.0 109.712 178.224 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 45' ' ' SER . 8.0 t0 74.82 -58.96 0.56 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.501 -0.75 . . . . 0.0 112.297 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.549 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.4 mt-10 -95.06 23.68 5.47 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.809 -1.182 . . . . 0.0 111.781 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.847 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -63.23 -71.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 120.823 -1.173 . . . . 0.0 111.674 -179.494 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.566 ' C ' ' O ' ' A' ' 48' ' ' ILE . 15.6 t0 -36.8 -34.2 0.07 Allowed 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.051 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.516 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -77.65 -54.83 5.92 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.666 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.847 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.24 -50.8 33.75 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 O-C-N 120.757 -1.214 . . . . 0.0 109.324 178.997 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.957 HG21 HG13 ' A' ' 69' ' ' VAL . 36.4 mm -46.13 -39.33 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 119.798 -1.814 . . . . 0.0 108.506 177.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.611 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 3.8 tm-20 -64.39 -61.5 2.19 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.185 -0.947 . . . . 0.0 110.333 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -80.69 -10.83 59.7 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.254 -0.904 . . . . 0.0 111.258 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.723 HG22 ' O ' ' A' ' 51' ' ' ILE . 4.8 tp -106.18 -33.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 CA-C-O 121.644 0.735 . . . . 0.0 110.467 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.721 HG13 HG21 ' A' ' 67' ' ' ILE . 2.4 t -117.39 -45.31 3.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.3 -177.448 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.727 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.1 OUTLIER -58.61 -39.15 79.61 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.096 -1.628 . . . . 0.0 108.492 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.727 ' N ' HD23 ' A' ' 57' ' ' LEU . 1.3 tttt -100.02 -41.04 7.34 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 55' ' ' ILE . . . -67.32 -49.02 55.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -81.39 23.64 4.63 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 120.926 -1.338 . . . . 0.0 110.366 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -107.54 -9.27 15.96 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.854 -1.38 . . . . 0.0 110.76 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.47 -84.8 0.31 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 120.95 -1.094 . . . . 0.0 110.109 -179.315 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.417 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 4.7 ptpt -70.0 -35.82 74.67 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.723 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.515 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.6 OUTLIER -69.36 122.68 86.34 Favored Pre-proline 0 C--N 1.298 -1.668 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.811 179.138 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.475 ' HG2' ' HB3' ' A' ' 81' ' ' ASP . 43.7 Cg_endo -63.26 -45.6 11.78 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 121.733 1.622 . . . . 0.0 110.924 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.685 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.6 OUTLIER 179.37 111.57 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 CA-C-O 122.92 1.343 . . . . 0.0 109.653 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.721 HG21 HG13 ' A' ' 56' ' ' VAL 0.297 1.3 mp -106.68 133.97 49.67 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.403 0 CA-C-N 114.012 -1.449 . . . . 0.0 111.728 -176.799 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.577 ' HB ' ' CG ' ' A' ' 79' ' ' LYS . 1.0 OUTLIER -91.81 139.28 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.555 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.957 HG13 HG21 ' A' ' 52' ' ' ILE . 72.9 t -104.76 89.3 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.178 -0.952 . . . . 0.0 110.328 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.813 ' HB3' ' HB2' ' A' ' 77' ' ' TRP . 0.3 OUTLIER -82.04 50.55 1.59 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -0.795 . . . . 0.0 110.231 179.928 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ASP . . . . . 0.489 ' OD1' HG13 ' A' ' 48' ' ' ILE . 3.5 t70 -77.66 109.38 11.59 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.036 -1.04 . . . . 0.0 110.095 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.8 tttt -129.21 142.06 50.97 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.027 -1.046 . . . . 0.0 109.711 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.81 86.78 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.881 . . . . 0.0 109.633 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 158.72 -49.26 0.41 Allowed Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.408 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.566 ' HB3' ' CD1' ' A' ' 77' ' ' TRP . 5.1 m-85 -143.62 145.13 32.24 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.814 -0.815 . . . . 0.0 110.418 -179.574 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.914 ' CZ3' HD23 ' A' ' 42' ' ' LEU . 17.8 t90 -94.25 80.14 3.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.613 -0.679 . . . . 0.0 109.989 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.813 ' HB2' ' HB3' ' A' ' 70' ' ' GLU . 7.9 m95 -87.83 128.27 35.34 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 109.039 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.661 ' CG2' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -131.95 137.41 54.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.794 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.577 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 5.5 tttp -118.09 143.36 46.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.506 -1.371 . . . . 0.0 110.818 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.425 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -134.28 134.78 42.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.578 -0.701 . . . . 0.0 110.028 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.475 ' HB3' ' HG2' ' A' ' 65' ' ' PRO . 1.1 t0 -86.27 51.29 2.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.207 -0.933 . . . . 0.0 110.267 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.82 -120.37 0.54 Allowed Glycine 0 C--N 1.3 -1.419 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -113.8 164.29 13.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.367 -1.078 . . . . 0.0 109.372 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.665 HD11 HD22 ' A' ' 40' ' ' LEU . 4.2 tp -147.83 144.07 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.952 -1.093 . . . . 0.0 110.56 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -122.34 150.45 42.38 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.401 -0.812 . . . . 0.0 110.178 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.93 HG22 ' CG ' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -161.42 169.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.459 -0.776 . . . . 0.0 109.651 -179.158 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' A' ' 86' ' ' ILE . 77.7 m-20 -139.63 -173.13 3.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.09 -1.006 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.746 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -131.56 -19.26 2.72 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.092 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.422 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -40.67 -46.15 2.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.076 -1.015 . . . . 0.0 110.537 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -48.63 -54.31 15.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.333 -0.854 . . . . 0.0 109.674 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.683 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -52.67 -28.3 21.09 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.462 -0.774 . . . . 0.0 109.701 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.745 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -70.84 -31.15 67.44 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -69.77 -24.08 63.46 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.877 ' HB3' HD23 ' A' ' 95' ' ' LEU . 0.4 OUTLIER -78.69 -59.16 2.89 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.613 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.877 HD23 ' HB3' ' A' ' 94' ' ' LEU . 0.2 OUTLIER -110.07 -29.34 8.26 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.178 -0.951 . . . . 0.0 110.897 179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 68.56 42.65 80.24 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.663 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 33.2 mttt -133.05 -134.41 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.403 0 O-C-N 121.261 -1.141 . . . . 0.0 109.947 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.663 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.4 Cg_endo -71.78 -4.3 14.82 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 N-CA-C 108.683 -1.314 . . . . 0.0 108.683 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.75 ' CD1' ' N ' ' A' ' 100' ' ' SER . 4.1 p90 -26.56 -42.29 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.88 0.848 . . . . 0.0 111.72 178.457 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.3 OUTLIER -52.34 -53.09 49.12 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-O 122.593 1.187 . . . . 0.0 108.779 -177.493 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.789 HG12 HD11 ' A' ' 105' ' ' LEU . 59.7 t -102.63 -46.22 10.79 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.484 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 64.7 t80 -52.05 -32.17 33.36 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 117.559 -1.656 . . . . 0.0 107.588 179.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 3.1 t70 -79.63 -50.7 10.27 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.479 -0.888 . . . . 0.0 108.906 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.811 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.6 OUTLIER -55.05 -42.74 73.09 Favored 'General case' 0 C--O 1.204 -1.296 0 C-N-CA 116.913 -1.915 . . . . 0.0 108.515 179.398 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.789 HD11 HG12 ' A' ' 101' ' ' VAL . 52.6 mt -59.07 -29.4 67.3 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.871 -1.143 . . . . 0.0 111.352 179.506 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.464 HD12 ' O ' ' A' ' 102' ' ' TYR . 1.1 mt -92.05 -41.23 12.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 120.939 -1.101 . . . . 0.0 110.879 -178.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.668 ' CB ' HD12 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -90.99 -17.24 26.64 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.903 -1.123 . . . . 0.0 110.967 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.97 HG23 ' CE2' ' A' ' 122' ' ' PHE . 9.1 p -69.48 -3.58 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.089 -1.632 . . . . 0.0 110.093 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -35.1 -27.96 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.667 -0.646 . . . . 0.0 111.35 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.682 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -66.68 8.34 0.26 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 111.399 178.987 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.784 ' OG1' ' HB2' ' A' ' 115' ' ' ALA . 1.4 t -86.14 38.55 0.77 Allowed 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 117.922 -1.511 . . . . 0.0 110.633 -178.091 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 19.4 m -55.59 -21.48 9.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 O-C-N 121.42 -0.8 . . . . 0.0 110.861 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -105.72 -71.26 0.8 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -143.83 158.14 43.89 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.377 -1.072 . . . . 0.0 110.105 -179.733 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.784 ' HB2' ' OG1' ' A' ' 111' ' ' THR . . . -160.67 83.79 0.68 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.168 -0.957 . . . . 0.0 111.201 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -80.26 117.59 21.17 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.225 -0.922 . . . . 0.0 108.811 178.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.408 ' H ' HG22 ' A' ' 117' ' ' THR . 4.3 t -84.86 131.98 34.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.146 -0.971 . . . . 0.0 110.406 -179.396 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.589 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -102.01 38.37 1.66 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 110.396 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.95 -59.64 0.14 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 118' ' ' LEU . 62.3 m -107.5 -13.79 14.99 Favored 'General case' 0 C--N 1.291 -1.935 0 O-C-N 121.941 -0.741 . . . . 0.0 110.059 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.525 ' HB2' ' CB ' ' A' ' 118' ' ' LEU . 1.0 OUTLIER -125.96 165.85 18.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.078 -1.014 . . . . 0.0 111.507 -179.397 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.97 ' CE2' HG23 ' A' ' 108' ' ' VAL 0.255 0.0 OUTLIER -124.9 145.26 49.91 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.896 . . . . . . . . 4 4 . 1 . 002 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.847 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.7 OUTLIER -144.42 110.15 5.31 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.252 -1.53 . . . . 0.0 110.247 -178.18 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.905 HD13 ' CE1' ' A' ' 122' ' ' PHE . 1.5 mp -113.02 153.7 14.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.703 ' C ' HG21 ' A' ' 38' ' ' VAL . 10.2 t -159.52 -176.86 6.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.542 -1.349 . . . . 0.0 111.721 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.491 ' HB2' ' HB2' ' A' ' 36' ' ' ASN . 80.6 p . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.616 -0.677 . . . . 0.0 110.299 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.509 ' O ' HG23 ' A' ' 38' ' ' VAL . 5.7 m120 . . . . . 0 N--CA 1.502 2.155 0 CA-C-O 120.937 0.398 . . . . 0.0 110.995 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -40.35 116.03 0.63 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.138 -0.976 . . . . 0.0 110.97 -179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.552 HG21 ' N ' ' A' ' 126' ' ' SER . 3.2 t -121.86 148.96 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.384 -0.823 . . . . 0.0 109.729 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.958 HG13 ' HB2' ' A' ' 110' ' ' SER . 9.4 p -127.92 139.07 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 111.299 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.679 HD22 ' O ' ' A' ' 85' ' ' GLU . 9.3 tp -117.25 128.67 55.31 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.683 HG13 ' CD1' ' A' ' 77' ' ' TRP . 39.9 t -130.35 150.94 35.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 O-C-N 120.776 -1.203 . . . . 0.0 112.013 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.635 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 0.1 OUTLIER -143.09 176.91 8.75 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 177.544 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.52 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 6.5 ptt? -110.55 36.34 3.13 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.697 -1.252 . . . . 0.0 110.218 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.554 ' HB3' ' CD1' ' A' ' 48' ' ' ILE . 5.1 mmtt -88.51 -81.27 0.26 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.482 -0.761 . . . . 0.0 112.409 -178.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.743 ' N ' HD11 ' A' ' 48' ' ' ILE . 0.0 OUTLIER 67.99 92.97 0.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.197 -178.692 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.493 ' HB2' ' O ' ' A' ' 45' ' ' SER . 3.5 t70 170.96 -80.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.416 -0.803 . . . . 0.0 110.029 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.578 ' HB3' HD13 ' A' ' 51' ' ' ILE . 13.4 mt-10 -91.9 -10.3 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.891 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.939 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -60.65 -64.76 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.341 -0.849 . . . . 0.0 111.526 -178.933 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 2.1 t70 -41.11 -36.88 0.78 Allowed 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 118.769 -1.172 . . . . 0.0 108.961 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -76.19 -52.97 8.97 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.545 -0.722 . . . . 0.0 110.094 178.492 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.849 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.3 OUTLIER -70.6 -50.03 47.84 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.06 0 O-C-N 120.6 -1.312 . . . . 0.0 108.943 179.104 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.929 HG21 HG13 ' A' ' 69' ' ' VAL . 48.1 mm -43.41 -39.87 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.302 -1.498 . . . . 0.0 108.263 177.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.63 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 24.8 tt0 -65.86 -63.93 0.97 Allowed 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.437 179.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -77.79 -9.79 59.21 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.196 -0.94 . . . . 0.0 111.299 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.731 HG22 ' CA ' ' A' ' 52' ' ' ILE . 4.6 tp -106.61 -34.96 2.99 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-O 121.753 0.787 . . . . 0.0 110.359 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.666 HG23 HG23 ' A' ' 55' ' ' ILE . 2.2 t -117.24 -46.31 3.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.961 -0.696 . . . . 0.0 112.202 -177.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.838 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -56.53 -39.1 72.78 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.274 -1.516 . . . . 0.0 109.502 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.838 ' N ' HD23 ' A' ' 57' ' ' LEU . 1.9 tttp -93.58 -49.74 5.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.0 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.94 -42.38 9.69 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.586 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.46 -54.12 14.26 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.643 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 15.0 ttpt -67.6 12.57 0.09 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.624 -0.927 . . . . 0.0 112.552 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.89 -64.04 0.94 Allowed 'General case' 0 C--N 1.305 -1.33 0 O-C-N 120.56 -1.338 . . . . 0.0 108.351 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.2 mtmt -97.87 -22.06 16.56 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.643 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -69.25 128.98 92.25 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.179 179.779 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.74 -44.32 13.96 Favored 'Trans proline' 0 C--N 1.302 -1.905 0 C-N-CA 122.038 1.826 . . . . 0.0 111.603 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.55 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.44 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.331 0 CA-C-O 123.097 1.427 . . . . 0.0 109.567 -179.902 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.674 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.305 1.2 mp -97.8 140.87 16.98 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.538 0 CA-C-N 113.741 -1.572 . . . . 0.0 111.563 -176.898 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.547 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 3.1 t -83.23 137.0 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.454 -0.779 . . . . 0.0 110.01 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.929 HG13 HG21 ' A' ' 52' ' ' ILE . 27.6 t -119.99 81.77 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.133 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.674 ' HB2' ' CB ' ' A' ' 77' ' ' TRP . 1.9 mm-40 -78.91 141.13 37.87 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.364 -0.835 . . . . 0.0 110.289 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -145.7 127.88 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.286 -0.884 . . . . 0.0 109.614 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' HB2' ' A' ' 45' ' ' SER . 3.7 ttpt -157.91 -176.9 6.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.021 -1.049 . . . . 0.0 111.326 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.517 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -25.99 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.343 0.592 . . . . 0.0 111.819 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 41.33 44.51 3.95 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.52 ' HA ' ' HA ' ' A' ' 43' ' ' MET . 0.1 OUTLIER -137.25 90.91 2.56 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 121.554 0.692 . . . . 0.0 110.044 179.86 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.939 ' CD2' HG21 ' A' ' 48' ' ' ILE . 8.8 t90 -83.0 82.28 8.3 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.436 -0.79 . . . . 0.0 109.547 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 1.013 ' O ' HD13 ' A' ' 78' ' ' ILE . 13.6 m95 -89.59 131.27 35.69 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.141 -0.975 . . . . 0.0 110.975 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 1.013 HD13 ' O ' ' A' ' 77' ' ' TRP . 21.3 mm -134.66 153.09 34.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.366 -0.834 . . . . 0.0 109.876 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.561 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -143.55 135.46 26.59 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.947 -179.378 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.575 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -136.43 140.23 42.99 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.597 -0.689 . . . . 0.0 110.03 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -84.46 51.15 2.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.012 . . . . 0.0 110.287 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.77 -148.38 5.97 Favored Glycine 0 N--CA 1.477 1.398 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -88.18 144.77 26.27 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.277 -1.131 . . . . 0.0 109.8 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.583 HD11 HD23 ' A' ' 40' ' ' LEU . 9.8 tt -142.46 172.85 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.962 . . . . 0.0 110.67 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.679 ' O ' HD22 ' A' ' 40' ' ' LEU . 15.4 mt-10 -131.71 176.41 8.35 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.955 -1.091 . . . . 0.0 112.017 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 1.114 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -160.94 154.46 3.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 1.114 ' N ' HD13 ' A' ' 86' ' ' ILE . 4.8 m-20 -137.1 -178.7 5.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.796 -1.19 . . . . 0.0 111.903 -178.378 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.966 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -150.35 -29.9 0.21 Allowed 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.103 177.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.436 ' CA ' ' HE1' ' A' ' 99' ' ' PHE . . . -39.29 -47.03 1.64 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.062 -1.024 . . . . 0.0 110.663 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 93' ' ' GLU . 2.7 mm-40 -50.92 -63.34 1.16 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 121.871 0.843 . . . . 0.0 109.41 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.56 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -38.61 -38.08 0.37 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.464 179.474 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.68 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -64.18 -42.49 97.95 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.044 -1.623 . . . . 0.0 109.044 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' N ' ' O ' ' A' ' 90' ' ' GLU . 14.0 mt-10 -60.14 -24.65 64.88 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.522 HD23 ' N ' ' A' ' 95' ' ' LEU . 8.7 tt -79.73 -60.38 2.37 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.523 -0.735 . . . . 0.0 110.469 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -109.95 -20.46 12.73 Favored 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.97 -179.456 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.693 ' N ' HD12 ' A' ' 95' ' ' LEU . . . 63.05 90.4 0.03 OUTLIER Glycine 0 N--CA 1.497 2.71 0 C-N-CA 118.786 -1.674 . . . . 0.0 109.604 179.193 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.712 ' HB3' ' HD2' ' A' ' 98' ' ' PRO 0.261 0.2 OUTLIER -175.99 -151.69 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.192 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 -178.744 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.712 ' HD2' ' HB3' ' A' ' 97' ' ' LYS . 43.1 Cg_endo -67.8 -1.99 7.79 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 N-CA-C 108.841 -1.253 . . . . 0.0 108.841 176.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.778 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.3 p90 -21.3 -44.58 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.641 0.734 . . . . 0.0 112.427 179.017 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.966 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.5 OUTLIER -54.47 -53.78 49.65 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 122.868 1.318 . . . . 0.0 108.95 -177.104 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.978 HG12 HD11 ' A' ' 105' ' ' LEU . 48.3 t -98.44 -47.05 12.44 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.343 0 CA-C-N 115.147 -0.933 . . . . 0.0 113.267 -178.184 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.58 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 5.9 t80 -51.06 -29.22 12.24 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 117.512 -1.675 . . . . 0.0 107.843 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 8.8 t70 -80.9 -44.45 18.3 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.947 HD22 ' CZ ' ' A' ' 122' ' ' PHE . 0.4 OUTLIER -59.55 -45.23 92.4 Favored 'General case' 0 C--O 1.201 -1.476 0 C-N-CA 117.833 -1.547 . . . . 0.0 109.102 178.861 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.978 HD11 HG12 ' A' ' 101' ' ' VAL . 2.5 mt -64.21 -27.29 68.96 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 119.893 -1.755 . . . . 0.0 111.062 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -95.18 -12.73 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 109.937 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.579 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.86 -36.11 3.52 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.507 -0.745 . . . . 0.0 110.289 -179.196 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.703 HG12 ' O ' ' A' ' 104' ' ' LEU . 1.8 p -62.69 -4.86 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.207 -0.933 . . . . 0.0 111.603 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.88 -27.22 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.399 -0.813 . . . . 0.0 111.81 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.958 ' HB2' HG13 ' A' ' 39' ' ' VAL . 90.6 p -82.24 28.84 0.43 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.877 -1.14 . . . . 0.0 109.791 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.702 ' HB ' HG22 ' A' ' 108' ' ' VAL . 5.4 t -89.49 42.89 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.945 -1.097 . . . . 0.0 109.38 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 96.7 t -57.95 -47.29 86.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.762 -0.586 . . . . 0.0 111.364 -179.08 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -78.01 -75.19 0.97 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.525 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -152.95 -176.98 6.0 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.238 -1.154 . . . . 0.0 110.538 -179.14 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -170.36 73.77 0.07 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.368 -0.833 . . . . 0.0 110.317 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -72.69 140.67 48.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.521 HG22 ' H ' ' A' ' 119' ' ' GLY . 18.8 m -89.3 117.55 28.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 110.532 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.667 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -86.64 39.61 0.85 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.431 -0.793 . . . . 0.0 110.728 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.521 ' H ' HG22 ' A' ' 117' ' ' THR . . . 59.6 -62.01 0.01 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.311 -1.115 . . . . 0.0 110.311 179.196 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.667 ' N ' ' O ' ' A' ' 118' ' ' LEU . 38.3 p -88.44 -28.62 20.77 Favored 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.928 -0.748 . . . . 0.0 109.979 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.57 ' HD3' HD22 ' A' ' 118' ' ' LEU . 3.6 ptmt -146.1 -167.76 2.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.129 -0.982 . . . . 0.0 110.665 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.947 ' CZ ' HD22 ' A' ' 104' ' ' LEU . 5.8 m-85 -116.77 165.07 13.72 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.321 -0.862 . . . . 0.0 110.85 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.687 ' O ' HG22 ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.22 105.1 5.61 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.659 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.737 HD13 ' CG2' ' A' ' 86' ' ' ILE . 1.8 mp -108.2 141.57 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -0.952 . . . . 0.0 109.623 -179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 13.4 t -149.94 -170.76 3.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.06 -1.025 . . . . 0.0 111.11 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.552 ' N ' HG21 ' A' ' 38' ' ' VAL . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.44 -0.787 . . . . 0.0 110.537 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.508 ' O ' ' C ' ' A' ' 37' ' ' ALA . 31.5 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.508 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -27.25 127.28 0.06 Allowed 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.347 0.594 . . . . 0.0 111.997 -179.303 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.5 m -111.76 174.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.772 HG13 ' HB3' ' A' ' 110' ' ' SER . 13.2 p -144.78 125.1 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.139 -0.975 . . . . 0.0 110.783 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.744 HD11 HD11 ' A' ' 86' ' ' ILE . 20.6 tp -92.85 162.85 13.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.597 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.819 HG13 ' NE1' ' A' ' 77' ' ' TRP . 5.6 t -149.65 123.47 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 O-C-N 120.106 -1.621 . . . . 0.0 111.833 -178.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.997 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 0.2 OUTLIER -126.36 156.35 40.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.127 -0.983 . . . . 0.0 109.853 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.532 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.6 ptm -96.98 31.38 2.41 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.921 -1.112 . . . . 0.0 110.183 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.527 ' O ' ' HA2' ' A' ' 74' ' ' GLY . 2.3 mmtt -87.74 -86.59 0.16 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.482 -0.761 . . . . 0.0 110.956 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.647 ' CA ' HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER 73.37 113.26 0.06 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.36 -0.838 . . . . 0.0 110.746 -179.834 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 45' ' ' SER . 0.3 OUTLIER 164.73 -83.95 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.665 -0.647 . . . . 0.0 109.438 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.458 ' O ' HD13 ' A' ' 51' ' ' ILE . 5.1 mt-10 -95.52 1.1 53.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.866 . . . . 0.0 110.045 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.964 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.93 -66.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.103 -0.998 . . . . 0.0 111.046 -178.995 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.655 ' HA ' HG11 ' A' ' 69' ' ' VAL . 5.3 t0 -40.09 -33.58 0.24 Allowed 'General case' 0 C--N 1.292 -1.932 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.68 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.493 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -78.71 -55.5 5.13 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.717 -0.614 . . . . 0.0 109.835 178.235 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.839 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -68.31 -48.43 73.31 Favored 'Isoleucine or valine' 0 C--O 1.185 -2.316 0 C-N-CA 118.301 -1.36 . . . . 0.0 108.232 178.642 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.758 ' CA ' HG22 ' A' ' 55' ' ' ILE . 46.3 mm -43.32 -41.19 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.004 -1.685 . . . . 0.0 108.42 176.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.611 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 16.2 tt0 -64.84 -62.91 1.28 Allowed 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.895 -1.128 . . . . 0.0 110.025 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -77.41 -11.78 59.88 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.323 -0.86 . . . . 0.0 111.584 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.758 HG22 ' CA ' ' A' ' 52' ' ' ILE . 4.5 tp -107.23 -33.47 2.66 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.531 0.682 . . . . 0.0 111.039 -178.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.757 HG23 HG23 ' A' ' 55' ' ' ILE . 2.8 t -117.22 -45.17 3.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.598 -0.689 . . . . 0.0 112.153 -177.406 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.878 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -54.58 -30.08 53.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 119.758 -1.839 . . . . 0.0 108.959 -179.798 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.878 ' N ' HD23 ' A' ' 57' ' ' LEU . 13.4 mmtt -85.99 -47.49 9.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.473 -0.767 . . . . 0.0 110.483 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.44 -45.09 5.37 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.566 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.97 -73.04 0.76 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.622 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 22.4 ttpt -65.72 9.84 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.403 -1.057 . . . . 0.0 112.557 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.618 ' HB2' ' O ' ' A' ' 58' ' ' LYS . . . -51.63 -63.47 1.13 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.555 -1.341 . . . . 0.0 108.454 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.0 mtmt -97.97 -20.34 17.48 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 177.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.622 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.8 OUTLIER -68.68 141.1 92.43 Favored Pre-proline 0 N--CA 1.489 1.503 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.393 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.423 ' O ' ' OG ' ' A' ' 66' ' ' SER . 42.9 Cg_endo -62.38 -46.38 12.35 Favored 'Trans proline' 0 C--N 1.298 -2.107 0 C-N-CA 122.228 1.952 . . . . 0.0 112.002 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.423 ' OG ' ' O ' ' A' ' 65' ' ' PRO . 0.9 OUTLIER 178.81 112.99 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 123.158 1.456 . . . . 0.0 110.66 -179.691 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.69 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.306 1.0 OUTLIER -89.99 147.67 5.06 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.684 0 CA-C-N 113.573 -1.649 . . . . 0.0 110.86 -178.185 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.556 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -102.05 138.21 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.133 -0.98 . . . . 0.0 110.695 -179.581 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.702 HG22 HG21 ' A' ' 52' ' ' ILE . 5.5 t -116.82 90.97 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.372 -0.83 . . . . 0.0 109.073 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.599 ' CB ' ' HB2' ' A' ' 77' ' ' TRP . 13.2 mm-40 -79.61 76.51 6.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.487 -0.758 . . . . 0.0 110.655 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -89.04 113.62 24.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.973 -1.079 . . . . 0.0 109.485 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.421 ' O ' ' N ' ' A' ' 74' ' ' GLY . 13.0 mttp -145.47 -162.02 1.42 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.032 -1.042 . . . . 0.0 111.059 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.574 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -39.76 96.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.335 -0.853 . . . . 0.0 111.243 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 37.73 50.1 1.93 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.574 ' CD2' ' O ' ' A' ' 73' ' ' ALA . 8.6 m-85 -146.59 87.14 1.69 Allowed 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.875 -0.779 . . . . 0.0 109.761 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.997 ' CZ3' HD13 ' A' ' 42' ' ' LEU . 4.5 t90 -82.13 74.16 9.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.516 -0.74 . . . . 0.0 110.033 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.819 ' NE1' HG13 ' A' ' 41' ' ' VAL . 8.9 m95 -82.0 123.33 28.81 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.652 HD13 ' O ' ' A' ' 77' ' ' TRP . 5.5 mm -116.38 141.01 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.003 -1.061 . . . . 0.0 110.159 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.597 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.4 OUTLIER -123.61 130.52 52.79 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.612 -0.68 . . . . 0.0 109.598 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.47 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -130.28 165.89 21.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.222 -0.924 . . . . 0.0 110.289 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -118.35 50.32 1.18 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.341 -0.849 . . . . 0.0 110.304 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -119.77 0.52 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -112.22 152.67 28.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -1.115 . . . . 0.0 109.717 179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 124' ' ' ILE . 8.1 tt -152.41 175.19 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.483 ' HG2' ' HA ' ' A' ' 123' ' ' THR . 56.2 mt-10 -148.16 172.47 14.27 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.007 -1.058 . . . . 0.0 111.315 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.78 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -124.48 167.62 18.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 121.601 -0.687 . . . . 0.0 109.552 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.417 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 26.0 m-20 -154.98 138.97 16.37 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.015 -1.053 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.988 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.73 -37.52 0.12 Allowed 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.379 -1.328 . . . . 0.0 111.0 177.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 93' ' ' GLU . . . -39.89 -40.27 0.97 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.501 -0.75 . . . . 0.0 110.567 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.523 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 3.2 mt-10 -72.06 -43.97 64.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.317 -0.864 . . . . 0.0 109.408 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.483 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -60.35 -49.84 75.99 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 108.955 179.206 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.568 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -53.53 -57.43 15.66 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.523 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.1 pt-20 -59.98 -13.24 10.38 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.332 -1.099 . . . . 0.0 110.038 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.762 HD23 ' N ' ' A' ' 95' ' ' LEU . 0.5 OUTLIER -92.22 -43.75 9.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.317 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.762 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -97.64 -41.31 8.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.795 -1.191 . . . . 0.0 109.247 179.464 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.74 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -145.33 -74.7 0.02 OUTLIER Glycine 0 N--CA 1.483 1.805 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.27 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.565 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.3 OUTLIER 161.61 -55.77 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.858 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.737 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.546 ' HD3' ' HB3' ' A' ' 97' ' ' LYS . 52.2 Cg_endo -74.66 -23.54 14.49 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.856 1.45 . . . . 0.0 110.251 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.568 ' HB3' ' HA2' ' A' ' 92' ' ' GLY . 2.6 t80 -47.28 -49.42 23.71 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.223 -0.923 . . . . 0.0 109.996 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.988 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 29.5 p -31.97 -64.12 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.889 0.852 . . . . 0.0 110.429 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.968 ' HA ' HD23 ' A' ' 104' ' ' LEU . 13.8 t -72.69 -60.78 2.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 O-C-N 121.034 -1.041 . . . . 0.0 112.572 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 101' ' ' VAL . 1.7 t80 -44.94 -30.48 1.02 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.532 -1.355 . . . . 0.0 109.332 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 6.4 t0 -77.08 -31.52 56.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.598 -0.689 . . . . 0.0 109.287 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.971 HD13 ' CZ ' ' A' ' 122' ' ' PHE . 0.6 OUTLIER -74.81 -19.49 60.17 Favored 'General case' 0 C--O 1.2 -1.51 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.24 179.739 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 101' ' ' VAL . 1.4 mt -91.27 -26.12 19.14 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.345 -1.472 . . . . 0.0 111.226 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -97.22 -13.58 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.015 -1.053 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.555 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -105.57 -42.9 5.08 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.509 -0.745 . . . . 0.0 110.012 179.766 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.627 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 3.5 p -57.32 -2.86 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 120.879 -1.138 . . . . 0.0 112.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.504 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -25.22 -39.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.77 -0.581 . . . . 0.0 112.365 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.772 ' HB3' HG13 ' A' ' 39' ' ' VAL . 1.9 m -80.27 43.14 0.61 Allowed 'General case' 0 C--N 1.287 -2.137 0 C-N-CA 118.43 -1.308 . . . . 0.0 108.79 178.176 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.611 ' CG2' HG22 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -63.33 2.02 0.44 Allowed 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.267 -0.896 . . . . 0.0 112.45 -179.146 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.454 ' C ' ' O ' ' A' ' 111' ' ' THR . 9.6 p -38.16 -27.24 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 120.808 -1.183 . . . . 0.0 111.17 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.535 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -97.64 50.22 1.41 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.535 ' C ' ' O ' ' A' ' 113' ' ' GLY . 1.5 ttm-85 19.86 100.36 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.356 0.598 . . . . 0.0 111.982 179.165 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.578 ' HB1' ' CD2' ' A' ' 122' ' ' PHE . . . -85.09 93.69 8.68 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.266 -0.896 . . . . 0.0 111.47 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 123' ' ' THR . 0.1 OUTLIER -74.44 143.91 44.5 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.189 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 4.0 m -79.51 160.21 26.62 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.79 -1.194 . . . . 0.0 111.309 -178.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.625 HD23 ' O ' ' A' ' 118' ' ' LEU . 0.9 OUTLIER -130.62 35.33 4.03 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.665 -0.647 . . . . 0.0 109.891 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.49 -59.76 0.29 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -115.42 -9.24 12.15 Favored 'General case' 0 C--N 1.292 -1.908 0 O-C-N 122.013 -0.698 . . . . 0.0 110.186 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.454 ' HB2' ' HB3' ' A' ' 118' ' ' LEU . 20.8 mttt -137.68 -162.26 1.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.151 -0.968 . . . . 0.0 111.195 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.971 ' CZ ' HD13 ' A' ' 104' ' ' LEU 0.263 0.1 OUTLIER -132.15 160.66 35.4 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.068 -179.235 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.663 ' O ' HG22 ' A' ' 123' ' ' THR . 0.9 OUTLIER -138.3 104.14 5.1 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.034 -1.041 . . . . 0.0 110.598 178.697 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.805 ' HB ' HG23 ' A' ' 84' ' ' ILE . 3.4 mp -98.44 146.78 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.201 -0.937 . . . . 0.0 108.59 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.5 t -149.4 166.75 28.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.782 -1.199 . . . . 0.0 111.108 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.472 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 2.4 t . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 121.555 0.693 . . . . 0.0 109.533 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.717 ' O ' HG13 ' A' ' 38' ' ' VAL . 4.0 m-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.147 0.498 . . . . 0.0 110.276 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -31.87 141.32 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.569 0.699 . . . . 0.0 111.904 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.717 HG13 ' O ' ' A' ' 36' ' ' ASN . 24.2 m -141.42 176.17 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.472 -0.767 . . . . 0.0 109.709 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 39' ' ' VAL . 5.5 p -136.46 130.5 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.953 -1.092 . . . . 0.0 111.097 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.895 ' O ' HG23 ' A' ' 41' ' ' VAL . 12.4 tp -98.1 160.66 14.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 177.006 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.912 ' O ' HD22 ' A' ' 42' ' ' LEU . 2.9 t -166.31 116.4 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 O-C-N 120.871 -1.143 . . . . 0.0 110.093 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.912 HD22 ' O ' ' A' ' 41' ' ' VAL . 2.5 mm? -135.38 -171.68 2.89 Favored 'General case' 0 C--N 1.289 -2.056 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.404 ' O ' ' N ' ' A' ' 45' ' ' SER . 20.9 ptm -104.09 161.43 14.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.161 -0.962 . . . . 0.0 109.813 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -44.75 96.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.3 -0.875 . . . . 0.0 111.263 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 4.5 m -82.11 11.81 4.86 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.165 -0.959 . . . . 0.0 110.265 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' SER . 13.3 t0 78.41 -62.51 0.34 Allowed 'General case' 0 N--CA 1.503 2.18 0 O-C-N 121.569 -0.707 . . . . 0.0 112.421 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.59 ' O ' HD13 ' A' ' 51' ' ' ILE . 3.5 mt-10 -93.31 26.56 2.88 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.776 -1.203 . . . . 0.0 112.195 -177.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.81 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.61 -75.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 120.932 -1.105 . . . . 0.0 111.092 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.3 t70 -37.63 -32.22 0.05 Allowed 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.45 -56.13 4.91 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 177.404 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.81 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -71.28 -52.14 29.02 Favored 'Isoleucine or valine' 0 C--O 1.193 -1.88 0 O-C-N 120.977 -1.077 . . . . 0.0 109.869 179.075 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.701 ' HA ' HG22 ' A' ' 55' ' ' ILE . 47.2 mm -48.22 -38.73 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 119.89 -1.756 . . . . 0.0 108.121 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.729 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.7 tt0 -63.07 -61.12 2.59 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.183 -0.948 . . . . 0.0 110.352 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -81.06 -12.0 59.4 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 111.405 -178.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.745 HG23 HG23 ' A' ' 56' ' ' VAL . 4.3 tp -105.88 -32.99 2.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-O 121.645 0.736 . . . . 0.0 110.365 -178.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.745 HG23 HG23 ' A' ' 55' ' ' ILE . 2.5 t -117.89 -45.08 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.869 -0.732 . . . . 0.0 112.694 -177.372 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.729 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -49.31 -42.75 42.34 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.011 -1.681 . . . . 0.0 109.037 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.54 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 14.3 mttt -85.08 -44.22 13.2 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.574 0.702 . . . . 0.0 109.51 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -65.54 -51.36 48.67 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.54 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -69.43 -8.36 59.38 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' A' ' 57' ' ' LEU . 2.1 tptm -107.36 -9.02 16.13 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.129 -1.218 . . . . 0.0 110.954 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.17 -79.05 0.24 Allowed 'General case' 0 C--N 1.308 -1.197 0 O-C-N 120.886 -1.134 . . . . 0.0 110.69 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.9 mtmt -87.45 -29.38 21.47 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.54 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.9 m-80 -69.18 124.99 91.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.113 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.474 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 42.9 Cg_endo -62.56 -42.87 24.34 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.781 1.654 . . . . 0.0 110.671 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.598 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.4 OUTLIER 179.4 110.0 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 123.008 1.385 . . . . 0.0 109.64 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.747 HG23 ' O ' ' A' ' 79' ' ' LYS 0.297 1.1 mp -105.37 149.99 8.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 113.839 -1.528 . . . . 0.0 110.496 -177.205 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -103.44 130.36 53.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.322 -0.861 . . . . 0.0 110.013 179.725 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.685 ' CG1' HG21 ' A' ' 52' ' ' ILE . 55.5 t -113.95 100.29 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.168 -0.957 . . . . 0.0 109.889 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.565 ' N ' ' O ' ' A' ' 77' ' ' TRP . 0.7 OUTLIER -89.81 79.55 6.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.385 -0.822 . . . . 0.0 110.681 -179.487 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -80.47 91.02 5.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.073 -1.017 . . . . 0.0 109.396 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -89.78 154.45 19.9 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.159 -0.963 . . . . 0.0 110.482 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -59.63 -12.65 7.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.818 . . . . 0.0 110.548 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.452 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . -147.29 22.92 1.56 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.456 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.452 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 5.8 m-85 -160.77 108.8 1.57 Allowed 'General case' 0 C--N 1.289 -2.051 0 O-C-N 121.76 -0.847 . . . . 0.0 109.887 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.777 ' CE2' HG22 ' A' ' 48' ' ' ILE . 13.1 t90 -89.8 77.84 6.97 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.599 -0.688 . . . . 0.0 109.379 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.858 ' CE2' HG13 ' A' ' 41' ' ' VAL . 12.4 m0 -102.77 134.6 45.89 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.506 -0.746 . . . . 0.0 112.433 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.549 ' HB ' HD23 ' A' ' 40' ' ' LEU . 1.2 mp -138.65 152.39 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.747 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.4 OUTLIER -127.83 152.74 47.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.831 -1.168 . . . . 0.0 110.041 -179.728 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.461 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -139.42 178.86 6.9 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.299 -0.875 . . . . 0.0 110.603 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 37' ' ' ALA . 41.6 m-20 -122.54 50.49 1.49 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.364 -0.835 . . . . 0.0 110.138 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.55 -126.66 0.88 Allowed Glycine 0 C--N 1.301 -1.386 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -99.8 143.93 29.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -1.22 . . . . 0.0 109.925 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.59 HG23 ' HB ' ' A' ' 124' ' ' ILE . 4.8 tp -125.85 161.99 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.145 -0.972 . . . . 0.0 110.012 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.518 ' N ' HG13 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.88 164.96 23.02 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.137 -0.977 . . . . 0.0 111.717 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.791 HG13 HD13 ' A' ' 124' ' ' ILE 0.26 0.3 OUTLIER -139.91 175.02 7.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.363 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.555 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 74.9 m-20 -149.55 173.37 13.69 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.861 -1.149 . . . . 0.0 111.308 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 1.025 ' HB1' ' CA ' ' A' ' 100' ' ' SER . . . -150.96 -48.77 0.12 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.97 0.891 . . . . 0.0 109.759 177.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.414 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -41.37 -45.4 3.05 Favored 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.351 -0.843 . . . . 0.0 110.643 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.566 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 1.1 tt0 -49.81 -38.55 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 122.138 0.971 . . . . 0.0 108.483 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 1.004 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -63.45 -42.59 98.64 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.396 -0.815 . . . . 0.0 109.191 178.616 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.719 ' N ' ' CD2' ' A' ' 99' ' ' PHE . . . -63.15 -65.37 3.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.566 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 5.2 pt-20 -38.21 -31.56 0.05 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.818 -0.813 . . . . 0.0 108.94 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.722 HD13 ' HG ' ' A' ' 95' ' ' LEU . 0.1 OUTLIER -73.6 -71.16 0.33 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.68 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 1.004 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.1 OUTLIER -86.97 -55.17 3.95 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.972 -1.08 . . . . 0.0 108.847 178.599 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 88.18 50.14 3.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.696 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 15.2 mttt -150.74 -110.7 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 121.288 -1.125 . . . . 0.0 110.646 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.696 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 58.6 Cg_endo -85.5 12.98 2.89 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 CA-C-N 120.926 1.366 . . . . 0.0 109.67 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.729 ' O ' ' N ' ' A' ' 101' ' ' VAL . 29.3 p90 -49.85 -146.0 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 122.009 0.909 . . . . 0.0 110.474 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' SER . . . . . 1.025 ' CA ' ' HB1' ' A' ' 88' ' ' ALA . 2.1 p 32.73 -77.59 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 122.269 1.033 . . . . 0.0 111.323 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.729 ' N ' ' O ' ' A' ' 99' ' ' PHE . 38.0 t -66.02 -64.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.582 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.491 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 16.0 t80 -59.89 -39.9 86.9 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 119.99 -1.694 . . . . 0.0 106.69 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.581 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 0.3 OUTLIER -63.42 -38.96 93.16 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.847 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.865 HD12 ' N ' ' A' ' 105' ' ' LEU . 3.2 pp -83.75 -38.89 20.78 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 117.957 -1.497 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.865 ' N ' HD12 ' A' ' 104' ' ' LEU . 66.7 mt -49.82 -22.19 1.37 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 120.802 -1.186 . . . . 0.0 109.602 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.437 HD13 ' HA ' ' A' ' 106' ' ' ILE . 0.4 OUTLIER -107.83 -33.4 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.288 -0.882 . . . . 0.0 110.15 179.768 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.581 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.7 p30 -96.7 -3.65 42.19 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.968 -1.082 . . . . 0.0 110.027 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.664 HG12 ' O ' ' A' ' 104' ' ' LEU . 9.8 p -83.11 -7.7 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 110.804 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 108' ' ' VAL . 8.5 t -42.02 -22.91 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.193 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.595 ' CB ' ' N ' ' A' ' 41' ' ' VAL . 82.8 p -53.22 -4.31 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.313 -0.867 . . . . 0.0 112.641 179.283 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.954 HG22 HG12 ' A' ' 124' ' ' ILE . 45.1 p -71.76 -73.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.428 0 O-C-N 119.923 -1.736 . . . . 0.0 110.868 -178.105 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.567 HG12 ' O ' ' A' ' 112' ' ' VAL . 47.9 t 61.78 11.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.517 -0.74 . . . . 0.0 110.575 -179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -161.2 -68.94 0.02 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.796 ' HB3' HG22 ' A' ' 125' ' ' THR . 0.1 OUTLIER -136.58 165.86 24.88 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.305 -1.114 . . . . 0.0 110.497 -179.38 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.997 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -156.25 68.79 0.62 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.318 -0.864 . . . . 0.0 110.185 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.57 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 7.1 t80 -69.69 132.15 45.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.246 -0.908 . . . . 0.0 109.657 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.4 m -88.57 138.87 31.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.147 -0.971 . . . . 0.0 110.305 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -108.73 37.19 2.6 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.381 -0.824 . . . . 0.0 110.197 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.21 -58.47 0.25 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.553 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.8 OUTLIER -113.38 -23.35 9.92 Favored 'General case' 0 C--N 1.293 -1.871 0 O-C-N 121.95 -0.735 . . . . 0.0 110.067 -179.873 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -116.69 -168.22 1.42 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.997 ' CZ ' ' HB1' ' A' ' 115' ' ' ALA . 14.5 t80 -138.03 161.71 36.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.782 . . . . 0.0 109.159 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.603 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.8 OUTLIER -145.24 139.26 27.03 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 120.569 -1.332 . . . . 0.0 110.337 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.972 HD11 ' CD2' ' A' ' 122' ' ' PHE . 2.1 mp -134.91 154.39 36.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.467 -0.77 . . . . 0.0 110.18 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.796 HG22 ' HB3' ' A' ' 114' ' ' ARG . 1.9 t -152.34 -175.04 5.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.186 -0.946 . . . . 0.0 110.34 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 90.4 p . . . . . 0 N--CA 1.492 1.656 0 O-C-N 121.364 -0.835 . . . . 0.0 110.538 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.526 ' O ' ' C ' ' A' ' 37' ' ' ALA . 5.5 m-80 . . . . . 0 N--CA 1.496 1.851 0 CA-C-O 120.735 0.302 . . . . 0.0 110.636 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.526 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -26.38 139.43 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.353 0.596 . . . . 0.0 111.496 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.598 HG12 ' OG ' ' A' ' 126' ' ' SER . 8.7 p -102.08 136.3 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.775 HG13 ' HB2' ' A' ' 110' ' ' SER . 8.4 p -80.65 135.44 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.041 -1.037 . . . . 0.0 110.273 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.943 HD22 ' CG1' ' A' ' 84' ' ' ILE . 14.7 tp -110.42 134.48 52.29 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.756 HG13 ' NE1' ' A' ' 77' ' ' TRP . 10.1 t -130.63 121.24 50.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 O-C-N 120.86 -1.15 . . . . 0.0 110.942 -177.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.763 HD21 HG23 ' A' ' 86' ' ' ILE . 0.4 OUTLIER -120.54 -171.63 2.21 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.633 -0.667 . . . . 0.0 109.475 179.245 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.98 159.48 15.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.154 -0.967 . . . . 0.0 109.965 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.64 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.189 -0.945 . . . . 0.0 110.6 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.472 ' HB3' HG23 ' A' ' 48' ' ' ILE . 1.8 t -86.53 11.25 13.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 110.144 179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.486 ' N ' HD13 ' A' ' 48' ' ' ILE . 5.5 m-20 67.71 -62.87 0.33 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.494 -0.754 . . . . 0.0 111.108 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.486 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.0 mt-10 -87.21 30.17 0.79 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.103 -0.998 . . . . 0.0 110.616 -179.321 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.954 HG22 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.36 -75.2 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.969 -1.082 . . . . 0.0 111.393 -178.698 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.527 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -39.47 -31.61 0.1 Allowed 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.305 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -75.4 -53.79 8.12 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.763 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.41 -53.55 19.1 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.76 0 O-C-N 120.997 -1.065 . . . . 0.0 109.992 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.717 ' HA ' HG22 ' A' ' 55' ' ' ILE . 44.8 mm -47.05 -37.15 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 119.962 -1.711 . . . . 0.0 108.106 177.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.711 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 30.2 tt0 -64.39 -63.43 1.14 Allowed 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.386 -0.821 . . . . 0.0 110.282 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.44 -10.03 59.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.354 -0.841 . . . . 0.0 111.295 -178.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.717 HG22 ' HA ' ' A' ' 52' ' ' ILE . 4.4 tp -106.68 -33.79 2.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-O 121.62 0.724 . . . . 0.0 110.371 -179.122 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.715 HG23 HG23 ' A' ' 55' ' ' ILE . 2.3 t -118.67 -43.22 2.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.08 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.711 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -44.98 -38.47 4.77 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.449 -1.407 . . . . 0.0 109.775 -178.346 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.536 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 0.0 OUTLIER -86.78 -44.61 11.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.977 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -56.55 -53.35 44.2 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.53 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -72.19 0.79 37.57 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.489 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 2.0 mmtt -106.57 -9.31 16.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.845 -1.385 . . . . 0.0 111.357 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.36 -80.05 0.12 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.888 -1.133 . . . . 0.0 109.852 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.58 -24.75 16.46 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 122.307 1.051 . . . . 0.0 108.411 178.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.53 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.4 m-20 -67.51 116.55 38.39 Favored Pre-proline 0 C--N 1.294 -1.844 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.727 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 44.3 Cg_endo -62.99 -37.36 53.99 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 124.299 1.684 . . . . 0.0 111.558 -179.2 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.633 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.3 OUTLIER 179.36 111.61 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 123.145 1.45 . . . . 0.0 109.908 179.423 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.644 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.298 1.2 mp -104.5 155.01 6.09 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 CA-C-N 113.665 -1.607 . . . . 0.0 111.024 -177.442 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.632 HG11 ' CE ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -110.55 147.04 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.172 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.696 ' CG1' HG21 ' A' ' 52' ' ' ILE . 58.1 t -128.5 106.18 14.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.15 -0.968 . . . . 0.0 110.093 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.569 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.3 mm-40 -97.16 84.06 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.779 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -96.47 128.17 43.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.153 -0.967 . . . . 0.0 110.201 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -144.76 143.51 30.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 110.07 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -58.55 81.52 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 109.542 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 159.02 -40.11 0.49 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -139.94 173.81 11.15 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-O 121.835 0.826 . . . . 0.0 110.984 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.954 ' CE2' HG22 ' A' ' 48' ' ' ILE . 13.4 t90 -138.92 83.29 1.95 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.756 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.3 m95 -104.87 120.55 41.68 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.111 -0.993 . . . . 0.0 112.379 -177.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.548 ' CG1' ' HA ' ' A' ' 69' ' ' VAL . 1.1 mt -130.61 141.74 45.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.097 -1.002 . . . . 0.0 109.283 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.632 ' CE ' HG11 ' A' ' 68' ' ' VAL . 2.1 ptpt -114.12 134.17 55.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 110.028 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.505 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -120.16 148.91 43.05 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.317 -0.864 . . . . 0.0 109.838 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.46 ' HA ' ' CB ' ' A' ' 37' ' ' ALA . 1.4 m-20 -95.43 53.3 1.47 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.168 -0.958 . . . . 0.0 110.379 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.413 ' O ' ' OG ' ' A' ' 126' ' ' SER . . . -170.16 -116.79 0.39 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -121.39 146.61 46.7 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.169 -1.195 . . . . 0.0 110.165 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.943 ' CG1' HD22 ' A' ' 40' ' ' LEU . 5.5 tp -133.53 159.72 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.042 -1.036 . . . . 0.0 110.698 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.49 ' HG2' ' OG1' ' A' ' 123' ' ' THR . 16.9 mt-10 -137.56 130.32 30.06 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.325 -0.86 . . . . 0.0 110.793 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.763 HG23 HD21 ' A' ' 42' ' ' LEU . 1.7 mm -86.37 -176.1 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.333 -0.854 . . . . 0.0 109.82 179.699 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.551 ' H ' HG22 ' A' ' 86' ' ' ILE . 4.6 m-20 -156.54 154.8 30.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 110.869 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.823 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -150.13 -25.39 0.25 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.361 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.434 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -39.52 -45.24 1.54 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.936 -1.103 . . . . 0.0 111.032 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.497 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 1.2 tp10 -54.34 -60.6 3.12 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.345 -0.847 . . . . 0.0 109.844 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.569 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -42.28 -31.71 0.42 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.5 -0.75 . . . . 0.0 109.836 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.701 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -72.09 -41.78 53.19 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.497 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 7.7 mt-10 -55.82 -24.74 38.04 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.103 -1.234 . . . . 0.0 108.29 179.105 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.754 HD23 ' CD2' ' A' ' 95' ' ' LEU . 15.4 tp -87.05 -70.95 0.58 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 121.277 0.561 . . . . 0.0 110.01 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.754 ' CD2' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -87.27 -29.82 21.36 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.653 179.821 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 62.5 46.36 93.95 Favored Glycine 0 N--CA 1.499 2.844 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.145 177.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.761 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 0.1 OUTLIER -143.69 -128.58 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.262 0 O-C-N 120.901 -1.352 . . . . 0.0 109.636 178.728 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.761 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.5 Cg_endo -68.9 -3.63 11.8 Favored 'Trans proline' 0 N--CA 1.499 1.852 0 CA-C-N 121.738 1.656 . . . . 0.0 110.034 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.723 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.7 p90 -30.17 -41.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.211 1.005 . . . . 0.0 111.434 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.823 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 4.4 t -53.49 -58.18 8.06 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-O 122.894 1.331 . . . . 0.0 110.082 -177.189 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 1.027 HG12 ' CD2' ' A' ' 105' ' ' LEU . 46.9 t -97.9 -37.41 6.63 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.494 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 2.9 t80 -59.6 -33.67 71.77 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 119.741 -1.849 . . . . 0.0 107.674 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.587 ' HB3' ' O ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER -76.04 -42.67 47.07 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 178.83 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.809 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.9 OUTLIER -68.01 -36.67 80.35 Favored 'General case' 0 C--O 1.209 -1.078 0 C-N-CA 117.38 -1.728 . . . . 0.0 107.563 177.933 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 1.027 ' CD2' HG12 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -46.87 -49.39 20.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.801 178.852 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.473 HD13 ' HA ' ' A' ' 106' ' ' ILE . 4.6 mm -83.87 -26.37 7.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.598 -0.689 . . . . 0.0 110.355 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.604 ' O ' HD22 ' A' ' 42' ' ' LEU . 1.2 p30 -104.34 18.37 22.28 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.176 -0.953 . . . . 0.0 110.7 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.785 HG21 ' CE2' ' A' ' 122' ' ' PHE . 8.4 p -121.56 -12.39 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 120.894 -1.129 . . . . 0.0 109.733 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -36.67 -27.31 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.499 -0.751 . . . . 0.0 112.222 -178.969 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.775 ' HB2' HG13 ' A' ' 39' ' ' VAL . 54.4 p -86.06 34.05 0.61 Allowed 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.619 -1.3 . . . . 0.0 109.254 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.51 ' HB ' HG22 ' A' ' 108' ' ' VAL . 9.9 t -107.12 50.05 0.78 Allowed 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.645 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 66.4 t -80.75 -33.32 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.642 -0.661 . . . . 0.0 111.496 -178.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -66.92 -78.97 0.23 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.597 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.773 ' O ' HG23 ' A' ' 124' ' ' ILE . 0.4 OUTLIER -135.21 175.8 9.25 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.364 -1.08 . . . . 0.0 109.996 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.709 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -167.39 75.16 0.14 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.905 -1.122 . . . . 0.0 111.226 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.629 ' HB2' HG22 ' A' ' 123' ' ' THR . 0.4 OUTLIER -77.76 116.72 18.5 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.189 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.49 HG22 ' H ' ' A' ' 119' ' ' GLY . 17.1 m -79.23 129.02 34.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.063 . . . . 0.0 110.478 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.568 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.4 OUTLIER -104.04 45.62 0.95 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.383 -0.823 . . . . 0.0 110.386 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.49 ' H ' HG22 ' A' ' 117' ' ' THR . . . 65.37 -58.52 0.11 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.568 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.3 OUTLIER -115.69 -12.72 11.5 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.885 -0.774 . . . . 0.0 110.995 -179.473 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 63.2 mttt -124.2 178.71 5.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.971 -1.081 . . . . 0.0 111.294 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.785 ' CE2' HG21 ' A' ' 108' ' ' VAL . 2.5 t80 -126.85 146.61 50.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.589 -0.695 . . . . 0.0 109.194 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.629 HG22 ' HB2' ' A' ' 116' ' ' TYR . 0.9 OUTLIER -134.8 123.03 22.91 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 120.678 -1.264 . . . . 0.0 110.688 -179.701 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.773 HG23 ' O ' ' A' ' 114' ' ' ARG . 3.4 mp -124.39 168.51 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.691 HG22 ' HB3' ' A' ' 114' ' ' ARG . 9.0 t -159.09 154.87 26.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.555 -1.34 . . . . 0.0 111.518 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.598 ' OG ' HG12 ' A' ' 38' ' ' VAL . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.627 -0.671 . . . . 0.0 109.986 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.678 ' O ' HG23 ' A' ' 38' ' ' VAL . 1.5 m-80 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.154 0.502 . . . . 0.0 110.132 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -36.45 127.31 0.81 Allowed 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 121.372 0.606 . . . . 0.0 111.083 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.743 HG11 HG22 ' A' ' 124' ' ' ILE . 15.7 t -129.95 141.38 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 109.698 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.568 ' O ' ' HB2' ' A' ' 110' ' ' SER . 4.0 p -107.95 133.13 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 120.945 -1.097 . . . . 0.0 111.205 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.697 HD11 HG13 ' A' ' 86' ' ' ILE . 4.8 tp -105.4 143.51 33.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.793 HG13 ' CD1' ' A' ' 77' ' ' TRP . 11.4 t -139.84 129.2 28.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 O-C-N 120.462 -1.399 . . . . 0.0 111.909 -178.187 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.862 HD23 ' CG ' ' A' ' 107' ' ' ASN . 11.3 mt -135.42 -172.16 3.01 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.301 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.477 ' O ' ' N ' ' A' ' 45' ' ' SER . 8.0 ptm -100.31 151.96 20.88 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.827 -1.171 . . . . 0.0 110.466 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.471 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -48.14 89.28 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.468 -0.77 . . . . 0.0 111.543 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 43' ' ' MET . 29.6 t -65.1 -88.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.175 -0.953 . . . . 0.0 109.531 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.439 ' H ' HD13 ' A' ' 48' ' ' ILE . 5.1 m-20 -151.78 -77.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.879 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.469 ' O ' HG12 ' A' ' 51' ' ' ILE . 4.1 mt-10 -96.07 34.28 1.59 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.356 -0.84 . . . . 0.0 110.979 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.815 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.39 -64.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.792 -1.193 . . . . 0.0 111.633 -178.98 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.48 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -44.58 -38.12 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 118.702 -1.199 . . . . 0.0 108.746 179.354 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.469 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.79 -49.03 19.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.53 -0.732 . . . . 0.0 110.25 178.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.815 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.04 -51.03 28.17 Favored 'Isoleucine or valine' 0 C--O 1.191 -1.995 0 O-C-N 120.703 -1.248 . . . . 0.0 109.313 179.341 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.929 HG21 HG13 ' A' ' 69' ' ' VAL . 41.9 mm -45.53 -39.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.097 -1.627 . . . . 0.0 108.155 177.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.624 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 48.1 tt0 -62.72 -63.48 1.2 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -81.62 -8.19 59.68 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.289 -0.882 . . . . 0.0 111.398 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.788 HG23 HG23 ' A' ' 56' ' ' VAL . 4.7 tp -107.09 -33.72 2.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 CA-C-O 121.776 0.798 . . . . 0.0 110.137 -179.198 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.788 HG23 HG23 ' A' ' 55' ' ' ILE . 3.0 t -117.88 -44.83 3.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 C-N-CA 120.041 -0.664 . . . . 0.0 112.627 -177.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.845 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -60.69 -36.82 79.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.364 -1.46 . . . . 0.0 109.033 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.845 ' N ' HD23 ' A' ' 57' ' ' LEU . 2.8 tmtt? -100.93 -44.67 5.67 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.821 0.819 . . . . 0.0 109.037 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -69.2 -52.24 23.75 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.593 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.66 -43.85 73.9 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.822 -1.399 . . . . 0.0 110.155 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.599 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 12.9 ttmt -63.15 9.23 0.05 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.522 -0.987 . . . . 0.0 113.196 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.62 -63.8 1.03 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.225 -1.547 . . . . 0.0 108.854 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.12 -21.43 17.34 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 177.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.599 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -68.61 124.1 89.27 Favored Pre-proline 0 C--N 1.301 -1.514 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.911 -179.648 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.45 ' O ' ' OG ' ' A' ' 66' ' ' SER . 48.7 Cg_endo -65.38 -48.23 3.55 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.093 1.862 . . . . 0.0 111.953 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.488 ' C ' HD12 ' A' ' 67' ' ' ILE . 4.8 m -164.49 106.92 0.88 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 123.322 1.534 . . . . 0.0 109.539 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.691 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -100.36 163.69 2.91 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.549 0 CA-C-N 113.358 -1.747 . . . . 0.0 111.384 -176.547 . . . . . . . . 4 4 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.625 HG12 ' HG2' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -119.12 160.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.179 -0.951 . . . . 0.0 110.904 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.929 HG13 HG21 ' A' ' 52' ' ' ILE . 98.4 t -133.22 107.26 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.448 -0.782 . . . . 0.0 109.59 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.0 mm-40 -94.41 125.08 38.83 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.344 -0.848 . . . . 0.0 110.543 -179.426 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -134.45 117.55 16.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.029 -1.044 . . . . 0.0 109.967 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 44' ' ' LYS . 0.5 OUTLIER -136.13 161.49 35.56 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.176 -0.953 . . . . 0.0 110.235 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -48.61 106.12 0.09 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 110.11 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.579 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . 71.44 41.73 57.69 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.579 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 49.2 m-85 -160.8 102.52 1.32 Allowed 'General case' 0 C--N 1.29 -2.008 0 O-C-N 121.997 -0.708 . . . . 0.0 110.445 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.709 ' CD2' HG21 ' A' ' 48' ' ' ILE . 12.0 t90 -105.1 73.95 1.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.793 ' CD1' HG13 ' A' ' 41' ' ' VAL . 16.1 m0 -94.44 142.15 27.76 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.525 0.679 . . . . 0.0 111.047 -178.404 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.61 ' CD1' ' CD1' ' A' ' 76' ' ' TRP . 0.8 OUTLIER -147.25 139.49 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.137 -0.977 . . . . 0.0 109.476 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.625 ' HG2' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -115.97 129.74 56.51 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 110.291 -179.585 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.625 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -110.63 154.64 23.51 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 120.104 -0.638 . . . . 0.0 109.809 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.42 ' HB2' HD12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -97.94 43.55 1.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.985 -1.072 . . . . 0.0 110.146 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -171.69 -114.89 0.34 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -114.63 165.17 13.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.419 -1.048 . . . . 0.0 109.206 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.588 HG23 ' O ' ' A' ' 84' ' ' ILE . 4.4 tp -151.05 114.33 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.74 -1.225 . . . . 0.0 111.113 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -74.93 154.64 38.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.378 -0.826 . . . . 0.0 110.232 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.777 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.2 OUTLIER -161.01 130.12 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.131 -0.98 . . . . 0.0 110.695 -179.894 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.777 ' N ' HD13 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -128.87 173.61 10.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.888 . . . . 0.0 110.831 -179.964 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 1.019 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.06 -28.86 0.19 Allowed 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.041 178.02 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.532 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -41.51 -53.51 3.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 0.0 109.722 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.44 -57.41 7.03 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.563 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.45 -30.82 54.03 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.699 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.547 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -64.7 -56.2 18.23 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 108.359 -1.897 . . . . 0.0 108.359 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -62.47 -14.37 40.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.478 -1.013 . . . . 0.0 109.469 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.793 ' C ' HD23 ' A' ' 94' ' ' LEU . 5.1 tt -75.92 -57.66 3.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.783 . . . . 0.0 109.039 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.601 HD13 ' CB ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -93.72 -35.51 12.76 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.124 179.477 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -160.57 -71.49 0.02 OUTLIER Glycine 0 N--CA 1.491 2.319 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.214 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.561 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 164.95 -59.44 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.552 -0.969 . . . . 0.0 109.848 -179.769 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.0 Cg_endo -68.41 -17.28 44.08 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 124.068 1.562 . . . . 0.0 109.836 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.601 ' CB ' HD13 ' A' ' 95' ' ' LEU . 2.3 t80 -49.14 -50.3 38.2 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.078 -1.049 . . . . 0.0 108.416 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' SER . . . . . 1.019 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 4.5 m -30.23 -57.51 0.19 Allowed 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.703 0.763 . . . . 0.0 111.574 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 1.055 HG12 HD23 ' A' ' 105' ' ' LEU . 43.7 t -84.07 -54.47 8.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 121.513 -0.742 . . . . 0.0 112.685 -178.43 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.549 ' HA ' ' HB2' ' A' ' 105' ' ' LEU . 2.0 t80 -51.32 -40.05 58.24 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 119.7 -1.875 . . . . 0.0 107.045 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.541 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 21.6 t70 -57.14 -46.89 82.32 Favored 'General case' 0 N--CA 1.486 1.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.666 178.19 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.805 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.2 pp -80.2 -29.3 38.58 Favored 'General case' 0 C--O 1.201 -1.459 0 C-N-CA 117.921 -1.512 . . . . 0.0 108.245 179.109 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 1.055 HD23 HG12 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -49.67 -24.74 2.41 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 120.113 -1.617 . . . . 0.0 109.523 178.49 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.2 mp -103.51 -37.42 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.359 -0.838 . . . . 0.0 110.441 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.862 ' CG ' HD23 ' A' ' 42' ' ' LEU . 3.6 p30 -99.52 -13.02 19.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.909 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.815 HG22 ' CG2' ' A' ' 111' ' ' THR . 5.2 p -66.7 -8.99 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 109.811 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.9 OUTLIER -39.99 -24.35 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.689 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.581 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 1.2 p -72.92 9.65 1.11 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.138 -0.976 . . . . 0.0 110.51 178.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.815 ' CG2' HG22 ' A' ' 108' ' ' VAL . 2.2 p -85.69 26.26 0.98 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.694 -1.254 . . . . 0.0 110.936 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 6.9 p -57.05 -18.63 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.968 -1.082 . . . . 0.0 109.375 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.499 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -98.79 50.89 1.21 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.119 -1.592 . . . . 0.0 109.119 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.499 ' C ' ' O ' ' A' ' 113' ' ' GLY . 12.1 ttm180 28.81 95.87 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.494 0.664 . . . . 0.0 111.526 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.552 ' HB2' HG22 ' A' ' 111' ' ' THR . . . -74.84 124.85 27.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.41 -0.806 . . . . 0.0 111.147 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' THR . 1.8 t80 -69.72 115.73 9.29 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.469 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.459 ' O ' HD12 ' A' ' 118' ' ' LEU . 23.3 m -79.0 164.36 24.44 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.081 -1.012 . . . . 0.0 111.553 -178.066 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.568 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -144.79 48.88 1.31 Allowed 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.08 -60.6 0.22 Allowed Glycine 0 N--CA 1.483 1.775 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.568 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.2 t -117.43 -17.87 9.96 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.849 -0.794 . . . . 0.0 111.529 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.567 ' HG3' HG22 ' A' ' 120' ' ' THR . 13.5 mtmt -122.94 161.4 24.25 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 120.76 -1.212 . . . . 0.0 110.534 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.717 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -134.95 162.28 32.87 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.966 -1.084 . . . . 0.0 109.218 178.653 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.535 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.7 OUTLIER -141.8 118.61 11.12 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.915 -1.116 . . . . 0.0 110.599 -178.807 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.743 HG22 HG11 ' A' ' 38' ' ' VAL . 2.3 mp -87.02 132.84 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.552 -0.718 . . . . 0.0 109.82 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 9.5 t -156.93 159.16 37.84 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.109 -0.995 . . . . 0.0 110.629 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.1 t . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.108 179.911 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 90.5 m-20 . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.03 0.443 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.54 157.94 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.55 -0.719 . . . . 0.0 110.444 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.552 HG21 ' CG2' ' A' ' 124' ' ' ILE . 4.5 p -131.56 131.41 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -0.95 . . . . 0.0 110.266 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.601 HG12 HG21 ' A' ' 112' ' ' VAL . 8.9 p -91.29 168.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.298 -0.876 . . . . 0.0 110.495 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.558 ' HB2' HG12 ' A' ' 84' ' ' ILE . 13.7 tp -134.23 134.23 41.78 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.667 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.774 ' O ' HD22 ' A' ' 42' ' ' LEU . 14.9 t -136.95 127.52 40.32 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 O-C-N 120.462 -1.399 . . . . 0.0 110.707 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.774 HD22 ' O ' ' A' ' 41' ' ' VAL . 1.0 OUTLIER -131.39 -174.03 3.28 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.55 -0.86 . . . . 0.0 108.94 178.923 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.425 ' O ' ' N ' ' A' ' 45' ' ' SER . 3.1 ptm -82.6 157.99 23.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.89 -1.131 . . . . 0.0 110.185 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.498 ' CE ' ' OD1' ' A' ' 46' ' ' ASP . 8.3 ptmt -47.01 94.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 111.259 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.667 ' HB3' HG23 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -78.08 4.24 12.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.297 -0.877 . . . . 0.0 110.387 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.502 ' N ' ' CD1' ' A' ' 48' ' ' ILE . 35.1 m-20 64.2 -67.95 0.1 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.52 -0.738 . . . . 0.0 112.681 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.555 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.5 mt-10 -80.33 16.71 1.22 Allowed 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.866 -1.146 . . . . 0.0 112.555 -177.544 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.938 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -65.41 -68.24 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 120.531 -1.356 . . . . 0.0 111.438 -179.303 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.548 ' C ' ' O ' ' A' ' 48' ' ' ILE . 12.8 t70 -38.5 -31.61 0.06 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 119.048 -1.061 . . . . 0.0 108.635 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.25 -56.57 4.25 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.612 -0.68 . . . . 0.0 109.765 178.051 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.84 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.02 -43.19 67.79 Favored 'Isoleucine or valine' 0 C--O 1.195 -1.786 0 O-C-N 120.903 -1.123 . . . . 0.0 109.873 179.533 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.644 HG21 ' CG1' ' A' ' 69' ' ' VAL . 50.3 mm -52.9 -47.69 52.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.804 0 O-C-N 119.668 -1.895 . . . . 0.0 107.226 177.53 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.812 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.1 tm-20 -57.61 -57.29 13.37 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.37 -0.831 . . . . 0.0 110.389 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -78.3 -20.33 51.74 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.335 -0.853 . . . . 0.0 112.667 -178.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.586 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 mm -106.17 -30.45 2.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 O-C-N 120.983 -1.073 . . . . 0.0 110.903 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.6 ' CG2' ' HA ' ' A' ' 52' ' ' ILE . 17.2 t -115.24 -42.15 3.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.508 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 1.053 HD22 ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -68.17 -31.12 70.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.517 -1.365 . . . . 0.0 109.152 -179.89 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.554 ' N ' HD13 ' A' ' 57' ' ' LEU . 6.0 mttt -107.58 -43.89 4.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.429 -0.794 . . . . 0.0 109.483 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.69 -43.5 6.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.583 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.61 -64.7 2.84 Favored Glycine 0 N--CA 1.491 2.343 0 O-C-N 121.091 -1.241 . . . . 0.0 110.155 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.625 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.3 OUTLIER -59.73 3.51 0.05 Allowed 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.575 -0.956 . . . . 0.0 112.681 -179.506 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -55.32 -64.25 0.9 Allowed 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.657 -1.277 . . . . 0.0 109.02 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -90.72 -23.29 20.74 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.073 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.625 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 3.0 m-20 -69.0 134.8 89.65 Favored Pre-proline 0 C--N 1.3 -1.587 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.672 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -63.0 -45.32 13.04 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.111 1.874 . . . . 0.0 111.299 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.607 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.2 OUTLIER 179.12 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.307 0 CA-C-O 122.999 1.38 . . . . 0.0 109.916 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.866 HG23 ' O ' ' A' ' 79' ' ' LYS 0.297 1.2 mp -101.48 140.2 20.77 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.475 0 CA-C-N 113.911 -1.495 . . . . 0.0 111.415 -177.361 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.595 ' CB ' ' HB3' ' A' ' 79' ' ' LYS . 1.2 t -96.73 132.9 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.785 . . . . 0.0 109.814 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.644 ' CG1' HG21 ' A' ' 52' ' ' ILE . 58.3 t -114.23 92.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.184 -0.948 . . . . 0.0 110.341 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.702 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.0 mm-40 -87.39 73.04 9.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.456 -0.777 . . . . 0.0 110.135 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ASP . . . . . 0.493 ' OD2' ' HB2' ' A' ' 49' ' ' ASP . 52.8 t0 -81.91 122.44 27.75 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.936 -1.103 . . . . 0.0 110.637 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.1 OUTLIER -132.76 135.86 45.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.733 179.564 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.08 -26.57 0.16 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.145 -0.972 . . . . 0.0 109.964 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . -80.76 -50.23 5.35 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -144.61 157.96 43.98 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.772 -0.84 . . . . 0.0 110.294 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.938 ' CD2' HG21 ' A' ' 48' ' ' ILE . 1.6 t90 -109.81 85.95 2.2 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.759 ' CD1' HG13 ' A' ' 41' ' ' VAL . 7.2 m0 -85.15 124.51 31.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.459 -0.776 . . . . 0.0 110.958 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.632 HD13 ' O ' ' A' ' 77' ' ' TRP . 3.0 mm -115.93 160.19 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.014 178.294 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.866 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -140.69 143.72 35.23 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.899 -1.125 . . . . 0.0 110.359 -178.97 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.434 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.03 139.59 19.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.301 -0.875 . . . . 0.0 109.521 179.267 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -92.98 58.54 2.98 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.09 -1.006 . . . . 0.0 110.091 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -168.89 -164.69 25.03 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.03 129.84 40.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -1.142 . . . . 0.0 109.889 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.728 HG23 ' HB ' ' A' ' 124' ' ' ILE . 3.8 tp -125.02 159.99 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.383 -0.823 . . . . 0.0 110.177 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.496 ' N ' HG13 ' A' ' 84' ' ' ILE . 12.3 mt-10 -131.29 157.19 43.98 Favored 'General case' 0 C--N 1.307 -1.241 0 O-C-N 121.006 -1.058 . . . . 0.0 111.515 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.749 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -128.97 159.32 41.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.698 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.477 ' OD2' ' HE2' ' A' ' 121' ' ' LYS . 5.3 m-20 -156.05 154.91 31.75 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.645 -1.284 . . . . 0.0 111.594 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.934 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.83 -24.28 0.19 Allowed 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.355 -0.938 . . . . 0.0 111.49 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.522 ' HA ' ' OG ' ' A' ' 100' ' ' SER . . . -41.16 -51.83 3.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.009 -1.057 . . . . 0.0 110.303 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.472 ' O ' ' HB2' ' A' ' 94' ' ' LEU . 8.8 tt0 -48.51 -37.58 17.95 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.893 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.839 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -86.39 -53.18 5.15 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.572 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -50.15 -40.08 35.89 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.507 ' HG3' ' O ' ' A' ' 89' ' ' ALA . 9.6 mt-10 -75.52 -33.38 60.72 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.667 ' C ' HD23 ' A' ' 94' ' ' LEU . 1.5 tt -51.27 -66.91 0.3 Allowed 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 177.737 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.839 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.3 OUTLIER -76.42 -59.2 2.87 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.302 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 112.3 14.7 10.44 Favored Glycine 0 N--CA 1.497 2.715 0 C-N-CA 119.021 -1.561 . . . . 0.0 109.936 178.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.611 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 0.4 OUTLIER -104.57 -166.96 0.11 Allowed Pre-proline 0 C--N 1.294 -1.835 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.343 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.611 ' HD2' ' CB ' ' A' ' 97' ' ' LYS . 38.4 Cg_endo -66.83 -0.96 5.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 N-CA-C 109.458 -1.016 . . . . 0.0 109.458 177.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.799 ' CE1' ' HB1' ' A' ' 91' ' ' ALA . 18.8 t80 -35.54 -65.54 0.24 Allowed 'General case' 0 C--N 1.314 -0.97 0 O-C-N 121.699 -0.626 . . . . 0.0 110.908 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.934 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.3 OUTLIER -29.81 -73.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.037 0.922 . . . . 0.0 111.353 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.673 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 29.9 t -77.22 -50.41 20.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.328 -0.857 . . . . 0.0 113.254 -178.145 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.598 ' CD1' ' HB2' ' A' ' 98' ' ' PRO . 3.7 m-85 -51.72 -43.07 62.71 Favored 'General case' 0 C--N 1.292 -1.899 0 O-C-N 119.704 -1.872 . . . . 0.0 108.15 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.569 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 13.8 t70 -60.4 -40.05 89.53 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.592 -0.692 . . . . 0.0 110.421 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.941 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.3 pp -82.36 -39.8 22.26 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 117.816 -1.554 . . . . 0.0 109.04 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.941 ' N ' HD12 ' A' ' 104' ' ' LEU . 56.3 mt -51.94 -19.71 1.94 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.824 -1.172 . . . . 0.0 110.459 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.3 mp -102.44 -42.75 8.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.148 -0.97 . . . . 0.0 109.864 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.683 ' CG ' HD13 ' A' ' 42' ' ' LEU . 4.7 p30 -88.03 -13.18 42.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.287 -0.883 . . . . 0.0 110.141 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.807 HG13 HG23 ' A' ' 111' ' ' THR . 2.6 t -64.48 -5.88 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.923 -1.11 . . . . 0.0 110.195 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.461 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.49 -28.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.9 -0.5 . . . . 0.0 111.978 -179.567 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.585 ' HB3' HG23 ' A' ' 41' ' ' VAL . 35.1 p -75.3 15.88 0.4 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.77 -1.206 . . . . 0.0 110.581 178.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.807 HG23 HG13 ' A' ' 108' ' ' VAL . 0.0 OUTLIER -58.06 -66.61 0.45 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 118.389 -1.325 . . . . 0.0 109.881 -179.032 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.601 HG21 HG12 ' A' ' 39' ' ' VAL . 4.9 t 63.23 -67.32 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.476 -0.765 . . . . 0.0 110.024 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -93.82 51.81 2.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.435 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.516 ' HG2' ' N ' ' A' ' 115' ' ' ALA . 0.5 OUTLIER 47.01 176.33 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 O-C-N 121.579 -0.953 . . . . 0.0 111.016 179.162 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.66 ' HB2' HG22 ' A' ' 111' ' ' THR . . . -148.9 115.57 5.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.893 -1.13 . . . . 0.0 111.229 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.421 ' O ' ' HB ' ' A' ' 123' ' ' THR . 0.2 OUTLIER -76.26 112.53 12.84 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.334 -0.854 . . . . 0.0 108.887 178.678 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.3 m -79.49 125.12 29.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.072 -1.017 . . . . 0.0 110.851 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.576 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -92.3 50.34 1.62 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.412 -0.805 . . . . 0.0 110.042 179.38 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.4 -58.73 0.18 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.576 ' N ' ' O ' ' A' ' 118' ' ' LEU . 18.4 p -115.72 -8.83 12.0 Favored 'General case' 0 C--N 1.291 -1.94 0 O-C-N 122.009 -0.701 . . . . 0.0 110.613 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.477 ' HE2' ' OD2' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -122.95 -170.53 2.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.048 -1.033 . . . . 0.0 111.836 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.822 ' HD2' HD11 ' A' ' 124' ' ' ILE 0.269 1.8 t80 -139.33 147.16 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.078 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.624 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.9 OUTLIER -139.77 121.66 15.54 Favored 'General case' 0 C--N 1.308 -1.238 0 O-C-N 120.506 -1.371 . . . . 0.0 110.543 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.822 HD11 ' HD2' ' A' ' 122' ' ' PHE . 3.9 mp -118.09 142.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 109.939 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 1.8 t -144.93 136.93 25.82 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.083 -1.011 . . . . 0.0 110.421 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.27 -0.894 . . . . 0.0 110.492 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 126' ' ' SER . 35.3 m120 . . . . . 0 N--CA 1.492 1.657 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.46 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.29 143.81 0.12 Allowed 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.169 -0.957 . . . . 0.0 110.541 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.521 HG12 ' O ' ' A' ' 80' ' ' ALA . 3.4 p -108.36 137.26 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.182 -0.949 . . . . 0.0 110.484 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.977 HG13 ' HB2' ' A' ' 110' ' ' SER . 5.8 p -112.74 136.2 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.067 -1.021 . . . . 0.0 110.491 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.625 HD13 HG12 ' A' ' 86' ' ' ILE . 11.0 tp -105.17 141.75 36.17 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.868 HG13 ' NE1' ' A' ' 77' ' ' TRP . 2.3 t -143.19 127.24 14.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 118.248 -1.381 . . . . 0.0 112.072 -177.277 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.71 HD22 ' O ' ' A' ' 41' ' ' VAL . 2.7 mm? -129.48 -168.46 1.95 Allowed 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.009 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.502 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -103.33 167.43 9.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.071 179.254 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.409 ' HG3' ' H ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -51.03 103.29 0.05 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.277 -0.89 . . . . 0.0 110.812 -179.378 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.579 ' HB3' HD12 ' A' ' 48' ' ' ILE . 18.9 t -87.74 -116.76 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.272 -0.892 . . . . 0.0 109.985 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.53 ' N ' HD13 ' A' ' 48' ' ' ILE . 9.9 m-20 -142.11 -76.66 0.27 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.618 -1.301 . . . . 0.0 110.83 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.448 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.3 mt-10 -95.09 35.57 1.27 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.361 -0.837 . . . . 0.0 110.155 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.832 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.77 -66.45 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.251 -0.906 . . . . 0.0 111.274 -179.171 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -41.25 -40.57 1.65 Allowed 'General case' 0 C--N 1.284 -2.271 0 C-N-CA 119.106 -1.038 . . . . 0.0 108.96 179.213 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' N ' ' OD1' ' A' ' 49' ' ' ASP . . . -74.57 -50.35 18.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.592 -0.692 . . . . 0.0 110.401 178.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.832 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -72.12 -49.64 42.27 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.079 0 O-C-N 120.553 -1.342 . . . . 0.0 109.488 179.454 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.731 ' HA ' HG22 ' A' ' 55' ' ' ILE . 40.3 mm -46.59 -38.07 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.028 -1.67 . . . . 0.0 108.246 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 0.6 OUTLIER -64.3 -62.81 1.37 Allowed 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.105 -0.997 . . . . 0.0 110.082 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -79.75 -11.28 59.85 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.367 -0.833 . . . . 0.0 111.435 -179.018 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.841 HG23 HG23 ' A' ' 56' ' ' VAL . 4.2 tp -106.05 -33.38 2.79 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.034 0 CA-C-O 121.631 0.729 . . . . 0.0 110.546 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.841 HG23 HG23 ' A' ' 55' ' ' ILE . 3.8 t -117.65 -44.56 3.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.499 -0.75 . . . . 0.0 112.479 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.5 OUTLIER -61.77 -40.83 96.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.264 -1.523 . . . . 0.0 108.542 179.964 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.781 ' N ' HD23 ' A' ' 57' ' ' LEU . 2.4 mtpt -92.37 -43.21 9.36 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.521 0.677 . . . . 0.0 109.426 178.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -75.15 -50.78 8.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.562 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.28 -59.99 5.43 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.635 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.636 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -64.99 10.31 0.08 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.56 -0.965 . . . . 0.0 112.636 -179.508 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.39 -63.98 0.95 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.453 -1.404 . . . . 0.0 108.661 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -100.35 -17.83 17.06 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.636 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 1.4 m-20 -67.99 136.88 92.03 Favored Pre-proline 0 C--N 1.301 -1.533 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.684 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -62.19 -42.81 26.93 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 122.54 2.16 . . . . 0.0 112.521 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.577 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.33 112.91 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 123.1 1.429 . . . . 0.0 110.125 -179.811 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.649 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.302 1.2 mp -101.65 147.79 8.13 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 CA-C-N 113.766 -1.561 . . . . 0.0 111.577 -177.143 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.616 ' O ' HG23 ' A' ' 78' ' ' ILE . 1.6 p -110.87 153.13 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.41 -0.806 . . . . 0.0 110.275 179.478 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.662 HG22 HG21 ' A' ' 52' ' ' ILE . 89.2 t -118.25 104.82 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.244 -0.91 . . . . 0.0 109.6 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.575 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 0.9 OUTLIER -84.05 65.2 8.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.44 -0.787 . . . . 0.0 110.729 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.24 117.24 29.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.97 -1.081 . . . . 0.0 110.249 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 5.4 tttt -146.96 143.49 28.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 110.171 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.04 96.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 109.991 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 151.64 -58.11 0.43 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.477 ' HB2' ' CD1' ' A' ' 77' ' ' TRP . 2.3 p90 -141.08 163.01 34.14 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.926 -0.749 . . . . 0.0 110.457 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.703 ' CE2' HG22 ' A' ' 48' ' ' ILE . 2.5 t90 -118.03 75.63 1.02 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.868 ' NE1' HG13 ' A' ' 41' ' ' VAL . 21.0 m0 -95.82 149.06 21.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.606 -0.684 . . . . 0.0 111.674 -178.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.616 HG23 ' O ' ' A' ' 68' ' ' VAL . 1.2 mp -146.87 130.31 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.563 -0.711 . . . . 0.0 109.151 178.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.603 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -95.89 160.77 14.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.315 -0.866 . . . . 0.0 110.515 -179.123 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.521 ' O ' HG12 ' A' ' 38' ' ' VAL . . . -150.14 141.46 23.25 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.535 -0.728 . . . . 0.0 109.905 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -107.33 50.41 0.77 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.81 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.28 -110.85 0.24 Allowed Glycine 0 C--N 1.301 -1.368 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -123.67 143.41 50.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.315 -1.109 . . . . 0.0 110.02 179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.557 HG13 ' N ' ' A' ' 85' ' ' GLU . 2.8 tp -142.82 160.66 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 109.876 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.557 ' N ' HG13 ' A' ' 84' ' ' ILE . 45.1 mt-10 -129.67 122.69 29.47 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.022 -1.049 . . . . 0.0 111.753 -179.119 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.75 ' CG1' HD11 ' A' ' 124' ' ' ILE . 0.6 OUTLIER -79.61 165.4 2.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 121.641 -0.662 . . . . 0.0 109.648 179.484 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 6.2 m-20 -155.89 139.43 15.92 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.763 -1.211 . . . . 0.0 111.549 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.874 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -152.47 -33.09 0.13 Allowed 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.753 177.358 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.559 ' N ' ' HB2' ' A' ' 100' ' ' SER . . . -44.09 -52.62 7.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -0.844 . . . . 0.0 110.125 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.519 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 1.3 pt-20 -57.99 -44.5 87.21 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.534 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.13 -34.65 78.54 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.532 -0.73 . . . . 0.0 109.303 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -69.24 -56.87 8.17 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.519 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.3 pt-20 -54.65 -19.56 6.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.403 -1.057 . . . . 0.0 109.368 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.846 HD23 ' N ' ' A' ' 95' ' ' LEU . 5.4 tt -78.81 -61.8 1.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.69 -0.631 . . . . 0.0 110.527 -179.441 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.846 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -77.62 -45.1 26.11 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 118.35 -1.34 . . . . 0.0 109.086 179.289 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.739 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -145.76 -75.21 0.02 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.57 ' N ' ' HD2' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 166.46 -55.88 0.0 OUTLIER Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.883 -0.775 . . . . 0.0 109.407 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.57 ' HD2' ' N ' ' A' ' 97' ' ' LYS . 46.8 Cg_endo -73.14 -21.19 20.69 Favored 'Trans proline' 0 C--N 1.307 -1.614 0 O-C-N 124.167 1.614 . . . . 0.0 110.515 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.573 ' CE2' ' OD2' ' A' ' 103' ' ' ASP . 2.8 t80 -50.06 -50.04 49.22 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.009 -1.057 . . . . 0.0 109.626 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.874 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 16.7 p -31.53 -68.76 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-O 121.875 0.845 . . . . 0.0 111.216 -179.241 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.649 ' CA ' HD23 ' A' ' 104' ' ' LEU . 1.7 t -69.41 -56.16 12.69 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 O-C-N 121.189 -0.945 . . . . 0.0 113.238 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.551 ' HA ' HD12 ' A' ' 105' ' ' LEU . 0.1 OUTLIER -50.1 -31.92 14.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.356 -1.465 . . . . 0.0 109.345 -178.865 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.573 ' OD2' ' CE2' ' A' ' 99' ' ' PHE . 5.6 t70 -76.61 -28.83 56.26 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.7 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.697 ' HG ' ' N ' ' A' ' 105' ' ' LEU . 0.0 OUTLIER -65.81 -48.74 70.7 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.16 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.697 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 1.4 mt -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.674 -1.266 . . . . 0.0 110.042 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.45 -22.78 5.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.555 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.5 p30 -108.39 -28.76 9.2 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.178 -0.951 . . . . 0.0 110.802 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.099 HG22 ' CG2' ' A' ' 111' ' ' THR . 1.6 p -70.75 0.7 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.82 -1.175 . . . . 0.0 110.719 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -36.4 -26.92 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.47 -0.769 . . . . 0.0 112.0 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.977 ' HB2' HG13 ' A' ' 39' ' ' VAL . 87.7 p -78.69 32.37 0.2 Allowed 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.758 -1.214 . . . . 0.0 110.595 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' THR . . . . . 1.099 ' CG2' HG22 ' A' ' 108' ' ' VAL . 25.4 p -94.77 44.42 1.1 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.682 -1.261 . . . . 0.0 109.323 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.48 HG23 ' N ' ' A' ' 113' ' ' GLY . 28.3 m -60.54 -37.43 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.595 -0.691 . . . . 0.0 110.804 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.48 ' N ' HG23 ' A' ' 112' ' ' VAL . . . -76.17 -75.15 0.89 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.858 ' O ' HG23 ' A' ' 124' ' ' ILE . 3.3 ttt85 -145.13 -170.75 3.5 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.312 -1.111 . . . . 0.0 110.428 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.889 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -165.88 75.0 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.035 -1.041 . . . . 0.0 110.55 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.68 ' HB2' HG22 ' A' ' 123' ' ' THR . 0.1 OUTLIER -81.41 121.5 26.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.282 -0.886 . . . . 0.0 109.644 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.717 ' C ' HD12 ' A' ' 118' ' ' LEU . 9.7 m -83.89 156.39 22.42 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.228 -0.92 . . . . 0.0 110.62 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.717 HD12 ' C ' ' A' ' 117' ' ' THR . 7.3 mp -127.91 38.5 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.357 -0.839 . . . . 0.0 110.257 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.2 -59.5 0.41 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.824 -1.711 . . . . 0.0 108.824 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.556 ' N ' ' O ' ' A' ' 118' ' ' LEU . 58.4 p -115.14 -12.71 11.87 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 122.031 -0.687 . . . . 0.0 109.824 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.505 ' CB ' ' HB2' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -121.59 -167.12 1.47 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.43 -0.794 . . . . 0.0 110.633 -179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.889 ' CZ ' ' HB1' ' A' ' 115' ' ' ALA . 16.0 t80 -153.86 164.22 38.74 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.519 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.68 HG22 ' HB2' ' A' ' 116' ' ' TYR . 0.6 OUTLIER -150.08 153.06 35.78 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.39 -1.444 . . . . 0.0 110.275 -179.154 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.858 HG23 ' O ' ' A' ' 114' ' ' ARG . 2.2 mp -141.38 145.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.51 -0.744 . . . . 0.0 109.181 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.786 HG22 ' HB3' ' A' ' 114' ' ' ARG . 11.0 t -138.86 174.21 10.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.89 -1.131 . . . . 0.0 110.534 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.483 ' HB2' ' O ' ' A' ' 36' ' ' ASN . 69.2 p . . . . . 0 C--N 1.304 -1.397 0 O-C-N 121.319 -0.863 . . . . 0.0 110.423 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.437 ' O ' ' C ' ' A' ' 37' ' ' ALA . 1.8 m-20 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.222 0.534 . . . . 0.0 110.304 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.437 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.7 143.52 0.15 Allowed 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.518 -0.739 . . . . 0.0 110.774 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.583 HG13 ' HB2' ' A' ' 126' ' ' SER . 22.9 m -124.54 -174.71 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.226 -0.922 . . . . 0.0 110.373 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.734 HG13 ' HB2' ' A' ' 110' ' ' SER . 3.0 p -148.34 127.54 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.238 -0.914 . . . . 0.0 110.844 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.985 HD11 ' HB ' ' A' ' 86' ' ' ILE . 0.2 OUTLIER -88.99 127.75 35.68 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 177.817 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.865 HG22 ' CD2' ' A' ' 77' ' ' TRP . 2.7 t -121.43 117.05 51.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.883 -1.127 . . . . 0.0 111.435 -178.007 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.67 ' HB2' ' CE3' ' A' ' 76' ' ' TRP . 0.6 OUTLIER -119.64 159.35 24.58 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.41 -0.916 . . . . 0.0 109.475 178.254 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.539 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 9.5 ptm -92.8 27.21 2.44 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.82 -1.175 . . . . 0.0 111.381 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.872 ' HB3' HD11 ' A' ' 48' ' ' ILE . 4.1 mmtp -86.81 -90.12 0.11 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.249 -0.907 . . . . 0.0 110.408 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.569 ' HB3' ' N ' ' A' ' 75' ' ' PHE . 1.4 p 77.37 57.96 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 CA-C-O 121.877 0.846 . . . . 0.0 110.978 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.695 ' H ' HD12 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -161.58 -91.44 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.513 ' O ' HD13 ' A' ' 51' ' ' ILE . 2.1 mt-10 -54.38 -27.41 36.24 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.281 -0.887 . . . . 0.0 111.351 179.109 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 1.188 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.4 OUTLIER -74.85 -51.38 22.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 118.397 -1.321 . . . . 0.0 112.971 -176.781 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.528 ' C ' ' O ' ' A' ' 48' ' ' ILE . 14.4 t70 -42.96 -29.97 0.38 Allowed 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.366 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.44 -54.89 5.48 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.847 177.702 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.921 ' CD1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -66.9 -47.82 81.44 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.158 0 C-N-CA 117.844 -1.543 . . . . 0.0 108.226 178.773 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.955 HG12 HG22 ' A' ' 48' ' ' ILE . 45.1 mm -43.05 -40.99 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 120.374 -1.454 . . . . 0.0 107.86 176.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.655 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 2.4 tt0 -62.87 -67.7 0.4 Allowed 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.307 -0.871 . . . . 0.0 110.141 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.422 ' O ' ' OD1' ' A' ' 54' ' ' ASP . 37.0 t0 -75.72 -9.86 58.95 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 121.093 -1.004 . . . . 0.0 111.723 -178.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.838 HG23 HG23 ' A' ' 56' ' ' VAL . 3.9 tp -107.54 -34.63 2.81 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 CA-C-O 121.588 0.709 . . . . 0.0 111.224 -178.459 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.838 HG23 HG23 ' A' ' 55' ' ' ILE . 3.5 t -117.19 -42.91 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.553 -0.717 . . . . 0.0 112.45 -177.009 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.655 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 10.5 tt -42.2 -55.93 3.09 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.827 -1.17 . . . . 0.0 108.943 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.535 ' O ' ' CG ' ' A' ' 61' ' ' LYS . 1.0 OUTLIER -89.73 -49.19 6.79 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.317 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -48.91 -49.91 27.98 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.544 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -83.87 22.38 8.11 Favored Glycine 0 N--CA 1.489 2.215 0 O-C-N 121.181 -1.188 . . . . 0.0 110.185 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.535 ' CG ' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -106.44 -9.4 16.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.697 -1.472 . . . . 0.0 110.769 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.98 -84.66 0.33 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 121.098 -1.001 . . . . 0.0 110.156 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -71.03 -32.25 68.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 122.211 1.005 . . . . 0.0 108.742 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.544 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.5 OUTLIER -73.38 118.91 72.79 Favored Pre-proline 0 C--N 1.296 -1.733 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 179.65 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.488 ' HG2' ' HB2' ' A' ' 81' ' ' ASP . 45.6 Cg_endo -63.96 -43.42 15.82 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 124.146 1.603 . . . . 0.0 111.053 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.62 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.1 OUTLIER 178.76 112.09 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 CA-C-O 122.944 1.354 . . . . 0.0 109.751 179.477 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.638 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.292 1.2 mp -102.7 132.12 49.48 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.488 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.208 -177.359 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.572 ' HB ' ' HB3' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -92.11 116.16 32.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.863 179.501 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.82 ' CG1' HG21 ' A' ' 52' ' ' ILE . 67.5 t -94.88 96.99 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.146 -0.971 . . . . 0.0 110.012 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.674 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.1 mm-40 -91.51 143.15 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.298 -0.876 . . . . 0.0 110.455 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -139.78 108.91 6.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 109.795 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.71 -166.81 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.266 -0.897 . . . . 0.0 110.795 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.522 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -53.29 107.54 0.25 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 0.0 110.396 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 42.81 44.7 5.63 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.569 ' N ' ' HB3' ' A' ' 45' ' ' SER . 7.3 m-85 -144.45 86.45 1.82 Allowed 'General case' 0 C--N 1.292 -1.895 0 O-C-N 121.871 -0.781 . . . . 0.0 111.378 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 1.188 ' CE2' HG21 ' A' ' 48' ' ' ILE . 1.2 t90 -81.55 88.19 6.21 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.058 -1.026 . . . . 0.0 108.597 178.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.865 ' CD2' HG22 ' A' ' 41' ' ' VAL . 8.1 m0 -90.6 124.67 35.23 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.376 -0.828 . . . . 0.0 111.04 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.658 ' O ' HG23 ' A' ' 39' ' ' VAL . 13.8 mm -117.41 141.87 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.042 . . . . 0.0 110.16 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.572 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 1.1 ttpt -122.58 122.13 38.13 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.581 -0.7 . . . . 0.0 109.675 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -129.32 143.54 50.88 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.336 -0.853 . . . . 0.0 110.036 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.488 ' HB2' ' HG2' ' A' ' 65' ' ' PRO . 67.6 m-20 -88.18 49.81 1.87 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.057 -1.027 . . . . 0.0 109.956 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.35 -162.77 23.25 Favored Glycine 0 C--N 1.302 -1.357 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -72.6 154.36 40.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.183 -1.186 . . . . 0.0 109.791 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.612 ' CG1' HD12 ' A' ' 40' ' ' LEU . 3.0 tp -137.11 156.03 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.941 . . . . 0.0 110.235 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.516 ' N ' HG13 ' A' ' 84' ' ' ILE . 91.0 mt-10 -121.89 155.44 35.43 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.182 -0.949 . . . . 0.0 110.99 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.985 ' HB ' HD11 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -161.33 147.15 4.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.573 -0.704 . . . . 0.0 109.792 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.92 ' N ' HD13 ' A' ' 86' ' ' ILE . 3.5 m-20 -124.65 176.53 6.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.095 -1.003 . . . . 0.0 111.544 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.876 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -140.05 -14.28 1.04 Allowed 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.991 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.54 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -48.24 -45.86 34.82 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.664 -1.273 . . . . 0.0 110.971 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.558 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 18.2 tt0 -50.48 -36.15 32.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.551 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.943 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -68.17 -31.22 70.61 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.035 -1.041 . . . . 0.0 108.876 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.741 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -68.74 -61.4 4.7 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 108.599 -1.8 . . . . 0.0 108.599 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.558 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 6.0 pt-20 -45.4 -27.97 0.79 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.226 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.544 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 0.7 OUTLIER -68.59 -70.9 0.24 Allowed 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.341 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.943 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.0 OUTLIER -98.86 -46.46 5.63 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.021 -1.05 . . . . 0.0 109.224 178.99 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 93.44 51.84 2.11 Favored Glycine 0 N--CA 1.499 2.861 0 C-N-CA 120.185 -1.007 . . . . 0.0 111.538 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.721 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 30.8 pttt -145.46 -135.6 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 O-C-N 120.914 -1.345 . . . . 0.0 109.37 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.721 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.3 Cg_endo -71.7 0.17 7.42 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 CA-C-N 121.077 1.42 . . . . 0.0 108.989 178.421 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.796 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.8 p90 -25.62 -41.34 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 CA-C-O 121.823 0.821 . . . . 0.0 111.698 178.642 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.876 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.5 OUTLIER -55.96 -62.39 1.73 Allowed 'General case' 0 C--N 1.292 -1.895 0 CA-C-O 123.368 1.556 . . . . 0.0 108.62 -177.073 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 1.035 HG12 HD11 ' A' ' 105' ' ' LEU . 24.2 t -88.26 -42.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 CA-C-N 114.558 -1.201 . . . . 0.0 113.021 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.502 ' O ' HD13 ' A' ' 106' ' ' ILE . 5.0 t80 -52.02 -43.11 63.55 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 119.91 -1.744 . . . . 0.0 107.426 178.264 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.641 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 18.5 t70 -61.41 -47.95 83.46 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.687 -0.633 . . . . 0.0 110.065 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.736 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.5 pp -74.27 -41.16 61.68 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 116.655 -2.018 . . . . 0.0 109.738 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 1.035 HD11 HG12 ' A' ' 101' ' ' VAL . 39.2 mt -51.32 -19.23 1.21 Allowed 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.481 -1.387 . . . . 0.0 110.654 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.502 HD13 ' O ' ' A' ' 102' ' ' TYR . 0.6 OUTLIER -93.71 -49.59 12.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.123 -0.985 . . . . 0.0 110.403 -178.826 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.641 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 16.1 p30 -100.19 -11.28 20.56 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.077 -1.014 . . . . 0.0 111.471 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.661 HG22 ' HB ' ' A' ' 111' ' ' THR . 5.9 p -65.2 -6.54 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.302 -1.498 . . . . 0.0 109.947 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -33.78 -31.52 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.728 -0.607 . . . . 0.0 112.028 -179.505 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.734 ' HB2' HG13 ' A' ' 39' ' ' VAL . 28.8 p -84.69 27.89 0.7 Allowed 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 118.877 -1.129 . . . . 0.0 109.348 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.661 ' HB ' HG22 ' A' ' 108' ' ' VAL . 9.6 t -64.64 -35.9 82.51 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 110.644 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.445 ' N ' HG23 ' A' ' 111' ' ' THR . 61.8 t 52.61 -88.6 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.724 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -86.15 54.97 4.76 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.246 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.54 ' HG2' ' N ' ' A' ' 115' ' ' ALA . 1.8 ttt180 45.54 176.8 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.747 -0.855 . . . . 0.0 111.444 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -130.01 114.11 15.4 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.995 -1.066 . . . . 0.0 110.725 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.556 ' HB2' HG22 ' A' ' 123' ' ' THR . 25.7 m-85 -69.7 121.14 16.58 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.34 -0.85 . . . . 0.0 108.829 178.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.594 HG22 ' H ' ' A' ' 118' ' ' LEU . 6.2 m -79.3 178.55 8.0 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.192 -0.943 . . . . 0.0 110.734 -178.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.597 ' O ' ' N ' ' A' ' 120' ' ' THR . 1.3 tt -156.9 60.56 0.52 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.448 -0.783 . . . . 0.0 110.431 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.44 -57.44 0.05 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.057 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 118' ' ' LEU . 15.7 p -115.89 -26.97 7.15 Favored 'General case' 0 C--N 1.292 -1.925 0 O-C-N 121.64 -0.917 . . . . 0.0 111.772 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.576 ' O ' ' N ' ' A' ' 118' ' ' LEU . 1.5 pttm -132.07 -169.57 2.24 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.831 -1.168 . . . . 0.0 110.991 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.69 ' CZ ' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -149.21 -179.12 6.8 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.264 -0.897 . . . . 0.0 109.12 179.124 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.88 ' C ' HD12 ' A' ' 124' ' ' ILE . 1.1 t -155.62 165.67 35.86 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.755 -1.215 . . . . 0.0 110.186 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.88 HD12 ' C ' ' A' ' 123' ' ' THR . 4.0 mp -134.09 144.13 36.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.336 -0.852 . . . . 0.0 110.466 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.578 ' O ' HG11 ' A' ' 38' ' ' VAL . 11.9 t -123.25 -170.09 2.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.325 -0.859 . . . . 0.0 110.201 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.583 ' HB2' HG13 ' A' ' 38' ' ' VAL . 2.8 t . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.179 -0.951 . . . . 0.0 110.473 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.502 ' OD1' ' N ' ' A' ' 36' ' ' ASN . 15.1 p-10 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.444 0.64 . . . . 0.0 110.454 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.462 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.94 106.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.229 0.538 . . . . 0.0 111.284 -179.341 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.491 ' CG1' ' O ' ' A' ' 82' ' ' GLY . 4.1 p -125.84 149.79 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.317 -0.864 . . . . 0.0 109.504 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.7 p -105.82 142.44 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.01 -1.056 . . . . 0.0 111.108 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.875 ' O ' HG23 ' A' ' 41' ' ' VAL . 8.1 tp -100.93 162.07 13.15 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 177.468 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.884 HG22 ' CD2' ' A' ' 77' ' ' TRP . 3.0 t -165.77 132.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 120.658 -1.276 . . . . 0.0 111.665 -178.302 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.672 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 0.3 OUTLIER -143.06 -171.69 3.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.19 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 7.2 ptt? -98.45 153.29 18.7 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.798 -1.189 . . . . 0.0 109.899 179.526 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.531 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -53.13 95.65 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 0.0 110.982 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.494 ' HB3' HG23 ' A' ' 48' ' ' ILE . 30.5 t -72.89 -92.1 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.297 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.433 ' N ' HD13 ' A' ' 48' ' ' ILE . 36.1 t0 -157.95 -70.3 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.157 -0.964 . . . . 0.0 110.401 179.458 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.46 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.8 mt-10 -96.45 36.13 1.4 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.283 -0.885 . . . . 0.0 110.412 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.83 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -56.02 -64.34 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.997 -1.064 . . . . 0.0 111.624 -178.772 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.494 ' O ' ' HB2' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -45.44 -34.75 3.3 Favored 'General case' 0 C--N 1.285 -2.218 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.768 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.29 -49.88 12.84 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.473 -0.767 . . . . 0.0 110.341 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.83 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -71.66 -48.44 52.08 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.092 0 O-C-N 120.711 -1.243 . . . . 0.0 108.958 179.127 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.751 HG21 ' CG2' ' A' ' 69' ' ' VAL . 35.1 mm -46.97 -40.89 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.068 -1.645 . . . . 0.0 107.912 177.106 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.628 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 7.5 tt0 -61.69 -62.43 1.81 Allowed 'General case' 0 C--N 1.293 -1.855 0 O-C-N 121.163 -0.961 . . . . 0.0 110.575 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -80.2 -12.6 59.62 Favored 'General case' 0 N--CA 1.502 2.145 0 O-C-N 121.451 -0.781 . . . . 0.0 111.616 -178.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.948 HG23 HG23 ' A' ' 56' ' ' VAL . 3.8 tp -106.09 -33.27 2.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 CA-C-O 121.672 0.749 . . . . 0.0 110.659 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.948 HG23 HG23 ' A' ' 55' ' ' ILE . 14.4 t -116.57 -43.91 3.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 C-N-CA 119.91 -0.716 . . . . 0.0 112.439 -177.41 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.836 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -63.35 -35.92 81.99 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.28 -1.513 . . . . 0.0 108.937 179.978 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.836 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -94.77 -47.53 6.43 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.439 -0.788 . . . . 0.0 109.344 179.189 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.49 -45.05 8.19 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.598 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.07 -53.42 18.7 Favored Glycine 0 N--CA 1.49 2.243 0 O-C-N 121.12 -1.224 . . . . 0.0 110.05 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.625 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.9 OUTLIER -62.41 6.58 0.08 Allowed 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.459 -1.024 . . . . 0.0 112.827 -179.421 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.26 -63.84 1.01 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.518 -1.364 . . . . 0.0 108.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -97.2 -19.96 18.26 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 178.046 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.625 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 3.9 m-20 -68.43 125.92 92.17 Favored Pre-proline 0 C--N 1.301 -1.517 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.556 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.435 ' C ' ' OG ' ' A' ' 66' ' ' SER . 46.6 Cg_endo -64.45 -42.26 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 121.96 1.773 . . . . 0.0 111.136 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.577 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -177.97 110.88 0.07 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-O 123.065 1.412 . . . . 0.0 109.527 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.667 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.308 1.0 OUTLIER -103.73 145.38 12.79 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 CA-C-N 113.735 -1.575 . . . . 0.0 111.416 -176.556 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.818 HG12 ' CG ' ' A' ' 79' ' ' LYS . 1.9 p -109.41 142.28 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.055 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.751 ' CG2' HG21 ' A' ' 52' ' ' ILE . 32.4 t -108.75 117.17 53.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.239 -0.913 . . . . 0.0 110.001 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.563 ' N ' ' O ' ' A' ' 77' ' ' TRP . 1.0 OUTLIER -98.64 94.67 6.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.578 -0.701 . . . . 0.0 110.482 -179.435 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -91.37 88.91 7.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.802 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.445 ' HB2' ' HB2' ' A' ' 75' ' ' PHE . 0.3 OUTLIER -88.72 165.99 14.36 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.331 -0.856 . . . . 0.0 110.689 -179.439 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -38.22 -58.21 1.01 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.589 -0.695 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.584 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -132.03 52.51 0.82 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 74' ' ' GLY . 57.7 m-85 -159.49 103.48 1.58 Allowed 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.913 -0.757 . . . . 0.0 110.057 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.714 ' CD2' HG21 ' A' ' 48' ' ' ILE . 6.4 t90 -90.0 77.73 6.83 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.884 ' CD2' HG22 ' A' ' 41' ' ' VAL . 13.0 m0 -101.28 143.98 30.68 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.512 -0.743 . . . . 0.0 112.308 -177.767 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.69 ' HB ' HD23 ' A' ' 40' ' ' LEU . 1.6 mt -137.49 139.3 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.302 -0.874 . . . . 0.0 109.625 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.818 ' CG ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -102.19 134.85 44.79 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.467 -0.77 . . . . 0.0 110.06 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.543 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -134.43 143.8 47.77 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 110.054 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -95.15 50.29 1.26 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.068 -1.02 . . . . 0.0 110.106 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.491 ' O ' ' CG1' ' A' ' 38' ' ' VAL . . . -171.03 -169.83 34.5 Favored Glycine 0 C--N 1.3 -1.472 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -71.41 143.79 50.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -1.136 . . . . 0.0 109.682 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.817 HG23 ' CG1' ' A' ' 124' ' ' ILE . 4.2 tp -126.36 159.69 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.243 -0.911 . . . . 0.0 109.89 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.471 ' N ' HG13 ' A' ' 84' ' ' ILE . 37.0 mt-10 -123.13 151.77 41.77 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 121.01 -1.056 . . . . 0.0 111.813 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.642 HG22 ' CB ' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -121.11 168.18 13.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 121.48 -0.762 . . . . 0.0 109.226 179.259 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 56.8 m-20 -131.54 177.28 7.62 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.08 -1.013 . . . . 0.0 109.961 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 1.103 ' HB1' ' CB ' ' A' ' 100' ' ' SER . . . -151.46 -49.96 0.12 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.014 178.627 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.415 ' O ' ' N ' ' A' ' 92' ' ' GLY . . . -48.53 -47.54 39.11 Favored 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.155 -0.966 . . . . 0.0 111.168 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.412 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.3 mt-10 -48.53 -40.63 27.56 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.813 ' HB3' ' O ' ' A' ' 88' ' ' ALA . . . -53.0 -45.18 67.75 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.923 0.868 . . . . 0.0 108.909 177.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.718 ' N ' ' HB2' ' A' ' 99' ' ' PHE . . . -51.46 -40.4 46.61 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -178.419 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.412 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.8 mt-10 -64.84 -32.29 73.92 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.476 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -70.79 -64.43 0.9 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.51 -0.744 . . . . 0.0 110.048 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.618 ' H ' HD12 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -107.7 -27.36 10.35 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.191 -0.943 . . . . 0.0 110.575 -179.857 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . 65.26 62.96 4.46 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.167 178.6 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.642 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 19.3 mttt 163.0 -68.34 0.0 OUTLIER Pre-proline 0 N--CA 1.516 2.844 0 O-C-N 121.312 -1.11 . . . . 0.0 111.009 177.632 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.642 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 55.9 Cg_endo -86.36 6.59 5.37 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 N-CA-C 107.391 -1.811 . . . . 0.0 107.391 176.8 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.718 ' HB2' ' N ' ' A' ' 92' ' ' GLY . 0.1 OUTLIER -52.87 -132.08 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.014 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.874 -179.448 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 100' ' ' SER . . . . . 1.103 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 40.3 p -6.65 -55.85 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.911 HG12 ' CD1' ' A' ' 105' ' ' LEU . 1.9 t -85.75 -68.78 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -177.34 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.583 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 0.3 OUTLIER -56.83 -30.86 64.17 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 116.929 -1.908 . . . . 0.0 106.21 179.631 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.591 ' HB2' ' HA ' ' A' ' 99' ' ' PHE . 38.9 t70 -66.99 -40.86 87.46 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.214 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.941 HD12 ' N ' ' A' ' 105' ' ' LEU . 3.0 pp -83.27 -41.48 18.28 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 117.98 -1.488 . . . . 0.0 108.913 179.074 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.941 ' N ' HD12 ' A' ' 104' ' ' LEU . 0.3 OUTLIER -54.04 -16.99 2.24 Favored 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.314 -1.492 . . . . 0.0 110.011 178.673 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.403 ' HB ' ' O ' ' A' ' 102' ' ' TYR . 0.8 OUTLIER -108.74 -27.94 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 179.642 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 0.3 OUTLIER -114.12 -2.67 13.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.083 -1.01 . . . . 0.0 110.744 -179.451 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.662 ' O ' HG22 ' A' ' 111' ' ' THR . 4.1 p -81.93 -10.09 12.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.122 -0.986 . . . . 0.0 110.627 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.4 t -43.55 -20.92 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.031 -1.043 . . . . 0.0 110.345 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.591 ' CA ' ' HB ' ' A' ' 41' ' ' VAL . 92.9 p -53.05 -7.81 0.09 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.304 -0.872 . . . . 0.0 112.223 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.734 ' O ' HG12 ' A' ' 112' ' ' VAL . 0.2 OUTLIER -110.51 -84.79 0.56 Allowed 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.014 -1.474 . . . . 0.0 111.092 -178.752 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.734 HG12 ' O ' ' A' ' 111' ' ' THR . 0.4 OUTLIER 80.06 -14.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.95 -0.468 . . . . 0.0 110.317 -179.239 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -114.95 -75.45 0.63 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.944 ' HB3' HG22 ' A' ' 125' ' ' THR . 11.6 tpt180 -115.24 151.21 34.9 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.353 -1.086 . . . . 0.0 109.531 179.344 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.732 ' HB1' ' CE1' ' A' ' 122' ' ' PHE . . . -165.44 67.99 0.13 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.203 -0.936 . . . . 0.0 110.124 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.511 ' N ' ' O ' ' A' ' 123' ' ' THR . 0.6 OUTLIER -69.21 124.07 22.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.915 . . . . 0.0 109.908 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.465 ' H ' HG22 ' A' ' 117' ' ' THR . 4.3 t -94.68 131.69 40.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 110.356 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.555 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -100.19 45.9 0.97 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.452 -179.98 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.43 -59.2 0.29 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.555 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.6 OUTLIER -115.31 -10.48 12.05 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.947 -0.737 . . . . 0.0 110.3 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -120.38 -168.33 1.61 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.049 -1.032 . . . . 0.0 111.179 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.732 ' CE1' ' HB1' ' A' ' 115' ' ' ALA . 2.2 t80 -150.51 153.37 35.71 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.515 -0.741 . . . . 0.0 110.442 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.552 ' O ' HG22 ' A' ' 123' ' ' THR . 0.8 OUTLIER -142.35 115.38 8.79 Favored 'General case' 0 C--N 1.31 -1.121 0 O-C-N 120.971 -1.081 . . . . 0.0 109.851 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.817 ' CG1' HG23 ' A' ' 84' ' ' ILE . 0.1 OUTLIER -125.03 151.62 30.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.266 -0.896 . . . . 0.0 109.383 179.27 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.944 HG22 ' HB3' ' A' ' 114' ' ' ARG . 6.4 t -136.11 -168.23 2.19 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 110.265 -179.412 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.493 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 19.1 p . . . . . 0 N--CA 1.488 1.43 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 -179.367 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.457 ' O ' ' C ' ' A' ' 37' ' ' ALA . 69.4 m-80 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.261 0.553 . . . . 0.0 110.18 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -39.62 145.83 0.12 Allowed 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.464 -0.773 . . . . 0.0 110.415 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 3.6 m -122.92 171.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.972 . . . . 0.0 110.237 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.69 HG12 HG21 ' A' ' 112' ' ' VAL . 10.8 p -131.52 120.53 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -0.88 . . . . 0.0 110.234 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 1.078 HD12 ' CG1' ' A' ' 84' ' ' ILE . 5.5 tt -73.1 157.77 36.63 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.451 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.859 HG13 ' NE1' ' A' ' 77' ' ' TRP . 24.0 t -160.04 116.48 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 121.097 -1.002 . . . . 0.0 110.592 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.874 HD23 ' CG ' ' A' ' 107' ' ' ASN . 2.5 mt -138.02 -169.55 2.59 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.455 ' SD ' ' OD2' ' A' ' 103' ' ' ASP . 2.8 ptt? -106.77 151.02 25.72 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.952 -1.093 . . . . 0.0 109.547 178.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.506 ' HB2' ' HA2' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -44.19 103.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.262 -0.899 . . . . 0.0 111.033 -179.034 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.479 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 1.2 m -86.84 19.4 2.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -0.922 . . . . 0.0 110.286 179.526 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 2.1 m-20 68.3 -57.24 0.49 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.444 -0.785 . . . . 0.0 111.412 179.4 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.537 ' O ' HG12 ' A' ' 51' ' ' ILE . 1.6 mm-40 -94.05 31.83 1.59 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.923 -1.11 . . . . 0.0 110.948 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.861 HG22 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -59.97 -78.26 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.201 -0.937 . . . . 0.0 111.084 -178.844 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.546 ' C ' ' O ' ' A' ' 48' ' ' ILE . 6.8 m-20 -36.79 -32.63 0.04 OUTLIER 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.77 -53.41 7.98 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.766 -0.584 . . . . 0.0 109.551 177.749 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.757 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.47 -50.67 33.43 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 O-C-N 120.943 -1.098 . . . . 0.0 110.089 179.466 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.7 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 32.4 mm -49.88 -40.78 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 119.829 -1.794 . . . . 0.0 108.281 178.288 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.643 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 18.6 tt0 -62.97 -57.74 9.7 Favored 'General case' 0 C--N 1.29 -1.982 0 O-C-N 120.967 -1.083 . . . . 0.0 110.576 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -81.74 -14.51 56.38 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.296 -0.878 . . . . 0.0 111.489 -178.834 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.913 HG23 HG23 ' A' ' 56' ' ' VAL . 3.7 tp -105.98 -32.35 2.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 CA-C-O 121.563 0.697 . . . . 0.0 110.736 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.913 HG23 HG23 ' A' ' 55' ' ' ILE . 12.0 t -116.34 -43.31 3.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 C-N-CA 119.839 -0.744 . . . . 0.0 112.557 -177.414 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.783 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -64.32 -41.27 96.89 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.117 -1.614 . . . . 0.0 109.036 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.783 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -85.92 -41.83 14.59 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.61 0.719 . . . . 0.0 109.49 179.323 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.99 -53.0 3.28 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -70.03 -72.11 0.91 Allowed Glycine 0 N--CA 1.49 2.294 0 O-C-N 120.96 -1.318 . . . . 0.0 110.358 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.634 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -45.33 -8.41 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.597 -0.943 . . . . 0.0 113.518 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 60' ' ' GLY . . . -49.81 -65.34 0.58 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.39 -1.443 . . . . 0.0 108.502 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -89.22 -26.95 20.95 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.634 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 5.3 m-20 -67.6 112.64 10.9 Favored Pre-proline 0 C--N 1.297 -1.676 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.294 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.468 ' O ' ' OG ' ' A' ' 66' ' ' SER . 46.3 Cg_endo -64.59 -41.69 18.64 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.839 1.693 . . . . 0.0 111.355 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.638 ' C ' HD12 ' A' ' 67' ' ' ILE . 7.0 m -164.0 104.87 0.9 Allowed 'General case' 0 N--CA 1.484 1.274 0 CA-C-O 123.35 1.548 . . . . 0.0 109.777 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.655 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.312 1.1 mp -106.02 136.42 40.49 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 CA-C-N 113.314 -1.766 . . . . 0.0 110.588 -177.203 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.581 ' CG1' ' HG3' ' A' ' 79' ' ' LYS . 4.4 t -87.42 134.63 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.256 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.648 HG22 HG12 ' A' ' 78' ' ' ILE . 95.8 t -117.36 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 178.116 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.554 ' N ' ' O ' ' A' ' 77' ' ' TRP . 2.9 mm-40 -86.98 113.3 22.63 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.688 -0.633 . . . . 0.0 110.79 -178.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 71' ' ' ASP . 8.3 p-10 -123.97 112.42 17.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.312 179.012 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.446 ' O ' ' C ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -152.76 150.23 29.18 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.831 -1.168 . . . . 0.0 111.332 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 35.52 -102.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.818 -0.551 . . . . 0.0 111.036 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.506 ' HA2' ' HB2' ' A' ' 44' ' ' LYS . . . -128.84 37.48 2.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.651 ' CE2' ' CZ2' ' A' ' 77' ' ' TRP . 0.1 OUTLIER -129.77 103.23 6.7 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.698 0.761 . . . . 0.0 109.863 179.54 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.861 ' CE2' HG22 ' A' ' 48' ' ' ILE . 12.5 t90 -96.86 80.95 3.06 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.859 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.6 m0 -103.6 131.3 50.87 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.317 -0.865 . . . . 0.0 112.68 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.682 HD11 ' HE1' ' A' ' 76' ' ' TRP . 2.1 mt -128.14 130.28 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.104 -0.998 . . . . 0.0 109.437 177.329 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.581 ' HG3' ' CG1' ' A' ' 68' ' ' VAL . 1.9 mtpt -97.86 136.44 38.17 Favored 'General case' 0 C--N 1.295 -1.798 0 C-N-CA 119.748 -0.781 . . . . 0.0 109.779 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.474 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -140.5 140.81 35.37 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 110.003 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -93.91 50.05 1.39 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.165 -0.959 . . . . 0.0 110.302 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.72 -167.89 31.72 Favored Glycine 0 C--N 1.3 -1.46 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.9 129.65 39.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.152 -1.205 . . . . 0.0 110.13 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 1.078 ' CG1' HD12 ' A' ' 40' ' ' LEU . 8.2 tp -120.67 123.97 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.165 -0.96 . . . . 0.0 110.585 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -87.22 161.67 17.89 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.283 -0.886 . . . . 0.0 111.257 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.857 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -161.46 149.01 4.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 O-C-N 121.254 -0.904 . . . . 0.0 110.704 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.857 ' N ' HD13 ' A' ' 86' ' ' ILE . 2.1 m-20 -152.14 171.1 18.43 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.088 -1.008 . . . . 0.0 111.341 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.968 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.24 -37.48 0.13 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.881 -0.728 . . . . 0.0 110.158 177.637 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.544 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -39.51 -46.87 1.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.622 -0.674 . . . . 0.0 110.312 -179.267 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.609 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 8.9 mt-10 -65.85 -52.06 53.57 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.813 0.816 . . . . 0.0 109.436 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 95' ' ' LEU . . . -54.25 -30.88 51.89 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 110.254 179.686 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.523 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -75.38 -56.43 4.68 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.609 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 3.2 pt-20 -50.14 -20.75 1.08 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.255 -1.144 . . . . 0.0 109.706 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 1.015 HD23 ' N ' ' A' ' 95' ' ' LEU . 1.4 tt -86.44 -65.91 0.96 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.976 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 1.095 HD11 ' CB ' ' A' ' 99' ' ' PHE . 3.4 pp -70.06 -44.62 68.77 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.134 -0.979 . . . . 0.0 110.74 -179.566 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.853 ' N ' HD12 ' A' ' 95' ' ' LEU . . . -149.14 -76.06 0.02 OUTLIER Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.186 -1.483 . . . . 0.0 109.807 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.579 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 11.7 mttt 164.68 -63.09 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.917 0 O-C-N 121.843 -0.798 . . . . 0.0 109.989 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.3 Cg_endo -71.87 -18.51 28.07 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.764 1.402 . . . . 0.0 108.945 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 1.095 ' CB ' HD11 ' A' ' 95' ' ' LEU . 3.2 t80 -44.17 -52.09 7.62 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.787 0.803 . . . . 0.0 109.434 179.129 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.968 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 50.6 m -34.16 -58.26 0.46 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.728 0.775 . . . . 0.0 111.856 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.723 HG12 HD11 ' A' ' 105' ' ' LEU . 14.5 t -81.97 -50.43 16.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.453 ' C ' ' O ' ' A' ' 101' ' ' VAL . 4.3 t80 -49.48 -41.22 39.9 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 119.867 -1.77 . . . . 0.0 107.526 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.579 ' OD1' ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -62.73 -43.64 98.27 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 121.602 -0.686 . . . . 0.0 110.146 178.903 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.756 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.1 pp -78.6 -38.9 38.87 Favored 'General case' 0 C--O 1.202 -1.4 0 C-N-CA 117.24 -1.784 . . . . 0.0 109.004 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.756 ' N ' HD12 ' A' ' 104' ' ' LEU . 63.2 mt -53.04 -16.29 1.06 Allowed 'General case' 0 C--N 1.29 -1.99 0 O-C-N 119.074 -2.266 . . . . 0.0 109.35 177.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.415 ' N ' ' C ' ' A' ' 104' ' ' LEU . 0.4 OUTLIER -118.06 -26.67 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.22 -0.925 . . . . 0.0 109.169 179.182 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.874 ' CG ' HD23 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -113.34 -3.8 13.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.375 -0.828 . . . . 0.0 110.26 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.687 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.1 p -60.46 -12.06 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.919 -1.113 . . . . 0.0 109.831 -179.172 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.55 ' O ' HG13 ' A' ' 112' ' ' VAL . 23.5 t -42.59 -22.29 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.429 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 108' ' ' VAL . 6.1 t -44.11 -16.89 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.373 -0.829 . . . . 0.0 110.953 177.608 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' THR . . . . . 1.0 HG22 ' CG1' ' A' ' 124' ' ' ILE . 3.0 p -109.22 44.84 1.11 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.648 -1.283 . . . . 0.0 110.677 -178.614 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.69 HG21 HG12 ' A' ' 39' ' ' VAL . 3.6 m -56.13 -25.63 20.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 110.055 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -96.58 -73.4 1.15 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.517 ' HB3' HG22 ' A' ' 125' ' ' THR . 0.0 OUTLIER -126.55 155.35 42.54 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.383 -1.069 . . . . 0.0 109.804 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.859 ' HB2' ' HB ' ' A' ' 111' ' ' THR . . . -150.81 74.83 1.18 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.026 -1.047 . . . . 0.0 110.981 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.583 ' HB3' HG22 ' A' ' 123' ' ' THR . 4.7 t80 -69.1 101.8 1.51 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.083 -1.011 . . . . 0.0 108.367 178.749 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.476 ' HA ' ' HB3' ' A' ' 122' ' ' PHE . 3.6 m -79.14 162.9 25.49 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.446 -0.784 . . . . 0.0 111.147 -178.36 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.836 HD13 ' HE3' ' A' ' 121' ' ' LYS . 0.9 OUTLIER -147.14 39.34 1.0 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.825 -0.547 . . . . 0.0 109.93 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.421 ' H ' HG22 ' A' ' 117' ' ' THR . . . 59.5 -61.07 0.01 OUTLIER Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 179.162 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.671 ' N ' ' O ' ' A' ' 118' ' ' LEU . 3.3 m -93.34 -16.23 24.89 Favored 'General case' 0 C--N 1.289 -2.033 0 O-C-N 121.914 -0.757 . . . . 0.0 110.473 -179.451 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.836 ' HE3' HD13 ' A' ' 118' ' ' LEU . 0.0 OUTLIER -159.85 153.86 23.23 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.975 -1.078 . . . . 0.0 111.084 -179.535 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.699 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.4 OUTLIER -134.48 166.38 23.0 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.256 -0.902 . . . . 0.0 109.298 178.792 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.865 ' C ' HD12 ' A' ' 124' ' ' ILE . 9.2 t -144.11 157.95 44.01 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.958 -1.089 . . . . 0.0 110.461 -178.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 1.0 ' CG1' HG22 ' A' ' 111' ' ' THR . 3.4 mp -121.15 150.27 24.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.383 -0.823 . . . . 0.0 110.307 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.517 HG22 ' HB3' ' A' ' 114' ' ' ARG . 5.3 t -160.47 -163.6 1.11 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.383 -0.823 . . . . 0.0 110.402 -179.568 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.63 0 O-C-N 121.49 -0.756 . . . . 0.0 109.96 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 1.6 m-20 . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.53 125.49 0.51 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.771 -0.581 . . . . 0.0 111.159 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.426 HG23 ' HB3' ' A' ' 126' ' ' SER . 94.1 t -89.87 135.37 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 110.273 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.658 HG12 HG23 ' A' ' 112' ' ' VAL . 8.2 p -117.5 130.5 72.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.112 -0.993 . . . . 0.0 110.732 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.606 ' HA ' ' OG ' ' A' ' 110' ' ' SER . 25.3 tp -105.9 141.06 37.94 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.641 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.936 HG23 ' CB ' ' A' ' 110' ' ' SER . 56.3 t -132.11 134.12 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.316 -1.49 . . . . 0.0 110.909 -178.555 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.675 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 26.4 mt -140.27 -166.31 2.09 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.551 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 23.5 ptm -101.44 166.59 10.65 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.328 -0.857 . . . . 0.0 110.879 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.505 ' HG2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -65.0 90.57 0.09 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -0.921 . . . . 0.0 111.694 -179.281 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 1.2 t -83.37 8.79 12.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.231 -0.918 . . . . 0.0 109.799 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.546 ' CB ' ' O ' ' A' ' 45' ' ' SER . 3.6 t0 77.16 -71.06 0.12 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.607 -0.683 . . . . 0.0 112.582 178.791 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.536 ' C ' HD13 ' A' ' 51' ' ' ILE . 3.8 mt-10 -81.74 24.24 0.61 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 120.948 -1.095 . . . . 0.0 111.873 -177.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.846 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.19 -63.09 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.874 -1.142 . . . . 0.0 112.323 -179.062 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -45.85 -35.39 4.44 Favored 'General case' 0 C--N 1.291 -1.946 0 C-N-CA 118.497 -1.281 . . . . 0.0 108.142 178.958 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.466 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.25 -51.69 12.69 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.847 -0.533 . . . . 0.0 110.123 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.846 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.81 -49.51 39.55 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.009 0 O-C-N 120.6 -1.312 . . . . 0.0 109.752 179.656 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.981 ' CG2' HG22 ' A' ' 69' ' ' VAL . 42.0 mm -46.73 -39.75 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 119.848 -1.783 . . . . 0.0 107.916 177.755 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.601 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 56.3 tt0 -62.62 -64.17 1.0 Allowed 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.485 179.242 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -80.02 -9.93 59.73 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.212 -0.93 . . . . 0.0 111.51 -178.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.906 HG23 HG23 ' A' ' 56' ' ' VAL . 3.7 tp -106.85 -34.35 2.85 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 121.611 0.719 . . . . 0.0 110.642 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.906 HG23 HG23 ' A' ' 55' ' ' ILE . 9.7 t -116.83 -43.82 3.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 C-N-CA 119.864 -0.734 . . . . 0.0 112.701 -177.074 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.908 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.1 OUTLIER -55.52 -32.35 62.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.182 -1.574 . . . . 0.0 108.545 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.908 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -93.44 -43.33 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.527 -0.733 . . . . 0.0 109.634 179.329 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -73.56 -47.27 22.05 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.582 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.02 -68.22 1.71 Allowed Glycine 0 N--CA 1.49 2.272 0 O-C-N 121.082 -1.246 . . . . 0.0 110.062 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HG3' ' HA ' ' A' ' 66' ' ' SER . 0.0 OUTLIER -60.09 5.92 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.311 -1.111 . . . . 0.0 113.291 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.63 -64.64 0.75 Allowed 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.327 -1.483 . . . . 0.0 108.525 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.6 ptpt -95.44 -24.72 16.55 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.566 1.174 . . . . 0.0 107.92 177.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.582 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 1.2 m-20 -67.31 145.66 98.62 Favored Pre-proline 0 C--N 1.295 -1.78 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.868 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.462 ' HD2' ' OD1' ' A' ' 64' ' ' ASN . 41.9 Cg_endo -61.62 -47.03 12.25 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 C-N-CA 122.533 2.156 . . . . 0.0 112.164 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.534 ' HA ' ' HG3' ' A' ' 61' ' ' LYS . 0.6 OUTLIER 179.23 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 123.156 1.455 . . . . 0.0 110.272 -179.793 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.67 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.289 1.1 mp -97.38 155.33 3.62 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.489 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.312 -177.483 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.862 HG13 ' HG3' ' A' ' 79' ' ' LYS . 0.2 OUTLIER -128.89 132.14 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.57 -0.707 . . . . 0.0 110.241 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.981 HG22 ' CG2' ' A' ' 52' ' ' ILE . 16.5 t -78.62 -178.67 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.651 ' H ' HG12 ' A' ' 69' ' ' VAL . 0.8 OUTLIER -160.53 66.39 0.33 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 120.646 -1.283 . . . . 0.0 110.585 -178.747 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -71.63 120.77 17.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 110.24 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -119.67 148.01 43.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.196 -0.94 . . . . 0.0 109.81 179.764 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -60.31 77.61 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.915 . . . . 0.0 110.549 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 133.54 -20.37 4.15 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.697 -1.239 . . . . 0.0 110.302 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.505 ' O ' ' HG2' ' A' ' 44' ' ' LYS . 6.1 m-85 -131.27 176.75 8.02 Favored 'General case' 0 C--N 1.288 -2.097 0 O-C-N 121.703 -0.88 . . . . 0.0 111.612 -179.204 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.766 ' CZ2' HD11 ' A' ' 52' ' ' ILE . 7.4 t90 -141.39 79.11 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.718 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.1 m0 -93.98 162.84 13.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.823 0.82 . . . . 0.0 111.326 -178.622 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.724 HD11 ' NE1' ' A' ' 76' ' ' TRP . 1.2 mp -159.27 138.85 3.48 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.626 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.862 ' HG3' HG13 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -106.94 142.14 37.03 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.542 -0.724 . . . . 0.0 110.12 -178.312 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.466 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -138.2 147.26 43.6 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.541 -0.724 . . . . 0.0 110.029 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.29 49.71 0.9 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.024 -1.048 . . . . 0.0 110.218 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 177.99 43.57 Favored Glycine 0 C--N 1.302 -1.356 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.61 123.11 21.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.328 -1.101 . . . . 0.0 109.937 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.458 ' CG1' ' N ' ' A' ' 85' ' ' GLU . 15.8 tt -120.3 171.92 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.188 -0.945 . . . . 0.0 110.766 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.522 ' CG ' ' OG1' ' A' ' 123' ' ' THR . 1.3 mt-10 -133.26 158.91 41.73 Favored 'General case' 0 C--N 1.309 -1.171 0 O-C-N 121.299 -0.876 . . . . 0.0 110.966 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 1.005 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -161.51 139.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.589 -0.694 . . . . 0.0 110.502 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 1.005 ' N ' HD13 ' A' ' 86' ' ' ILE . 2.8 m-20 -130.5 -178.51 4.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.244 -0.91 . . . . 0.0 110.679 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.874 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.11 -27.66 0.2 Allowed 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.373 -0.931 . . . . 0.0 111.246 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.644 ' HB2' ' HB ' ' A' ' 120' ' ' THR . . . -43.59 -54.13 5.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.909 -1.119 . . . . 0.0 110.217 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.566 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 4.0 mt-10 -53.58 -46.4 70.31 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.624 -0.83 . . . . 0.0 109.109 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.552 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.18 -38.37 87.86 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.436 -0.79 . . . . 0.0 108.99 178.727 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.651 ' HA2' HD11 ' A' ' 95' ' ' LEU . . . -66.98 -56.83 10.95 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.566 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.1 OUTLIER -57.54 -17.58 14.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.291 -1.123 . . . . 0.0 109.542 179.644 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.832 HD23 ' N ' ' A' ' 95' ' ' LEU . 3.4 tt -80.58 -58.51 3.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.643 -0.661 . . . . 0.0 110.001 -179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.832 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.2 OUTLIER -85.09 -33.26 22.46 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.44 179.48 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.808 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -155.92 -74.59 0.02 OUTLIER Glycine 0 N--CA 1.487 2.055 0 C-N-CA 119.103 -1.522 . . . . 0.0 109.669 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.58 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 2.3 mmtp 162.97 -57.56 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.822 -0.81 . . . . 0.0 108.923 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.58 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 47.7 Cg_endo -75.52 -18.53 17.58 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 124.21 1.637 . . . . 0.0 109.785 179.035 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.534 ' CZ ' ' CG ' ' A' ' 103' ' ' ASP . 1.1 t80 -51.3 -46.31 62.49 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 119.071 -1.052 . . . . 0.0 108.64 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.874 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 1.3 t -31.7 -68.89 0.08 Allowed 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.974 0.892 . . . . 0.0 110.519 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.792 ' HA ' HD23 ' A' ' 104' ' ' LEU . 1.2 t -72.68 -59.22 3.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.632 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.666 ' N ' HG12 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -44.51 -33.05 1.6 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.467 -1.396 . . . . 0.0 108.712 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.628 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 35.2 t70 -64.81 -42.95 94.61 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.792 HD23 ' HA ' ' A' ' 101' ' ' VAL . 1.6 pp -75.27 -41.38 57.36 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.107 -1.437 . . . . 0.0 109.542 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.47 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 52.3 mt -55.15 -16.17 2.87 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 119.86 -1.775 . . . . 0.0 109.904 178.717 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -95.23 -46.74 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.325 -0.859 . . . . 0.0 110.196 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.628 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 10.6 p30 -113.27 -4.21 13.74 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.145 -0.972 . . . . 0.0 112.093 -178.711 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.948 ' O ' HG23 ' A' ' 111' ' ' THR . 5.2 p -65.91 -8.8 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.6 -1.312 . . . . 0.0 109.768 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.96 -27.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.084 0.468 . . . . 0.0 112.024 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.936 ' CB ' HG23 ' A' ' 41' ' ' VAL . 1.0 OUTLIER -64.52 5.88 0.25 Allowed 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.135 -0.978 . . . . 0.0 111.949 179.585 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.948 HG23 ' O ' ' A' ' 108' ' ' VAL . 32.2 p -61.93 -8.52 5.21 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.402 -1.436 . . . . 0.0 111.573 -177.615 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.779 HG12 ' N ' ' A' ' 113' ' ' GLY . 25.5 t 48.66 -92.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.779 ' N ' HG12 ' A' ' 112' ' ' VAL . . . -138.68 -3.8 1.73 Allowed Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.512 -1.327 . . . . 0.0 110.108 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.532 ' HG2' ' CG2' ' A' ' 125' ' ' THR . 1.4 mpt_? -123.95 146.94 48.14 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.046 -1.267 . . . . 0.0 110.661 -179.53 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -169.71 80.06 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.9 m-85 -69.05 89.36 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.258 -0.901 . . . . 0.0 109.06 179.46 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 14.3 t -79.33 151.21 31.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.388 -0.82 . . . . 0.0 111.306 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -133.74 62.67 1.65 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.83 -60.67 0.13 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.644 ' HB ' ' HB2' ' A' ' 89' ' ' ALA . 0.8 OUTLIER -118.21 -34.94 3.95 Favored 'General case' 0 C--N 1.292 -1.921 0 O-C-N 121.964 -0.727 . . . . 0.0 112.004 -179.243 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.567 ' O ' ' N ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -105.0 149.51 25.7 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 120.994 -1.066 . . . . 0.0 111.003 -178.789 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.701 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -136.14 164.08 28.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.027 -1.046 . . . . 0.0 110.408 179.501 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.841 ' C ' HD13 ' A' ' 124' ' ' ILE . 0.8 OUTLIER -138.79 149.93 45.52 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.291 -0.881 . . . . 0.0 109.225 -179.684 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.841 HD13 ' C ' ' A' ' 123' ' ' THR . 0.0 OUTLIER -125.24 156.82 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.065 -1.022 . . . . 0.0 110.057 -179.419 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.532 ' CG2' ' HG2' ' A' ' 114' ' ' ARG . 6.3 t -160.78 163.53 32.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.131 -0.981 . . . . 0.0 110.625 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.444 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER . . . . . 0 N--CA 1.485 1.302 0 O-C-N 121.281 -0.887 . . . . 0.0 110.222 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.476 ' O ' ' OG ' ' A' ' 126' ' ' SER . 52.1 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.053 0.454 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.466 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.1 117.61 0.54 Allowed 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.518 -0.739 . . . . 0.0 110.717 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.467 HG13 ' O ' ' A' ' 36' ' ' ASN . 21.2 m -102.41 173.56 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.185 -0.947 . . . . 0.0 109.921 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.602 HG22 ' OG ' ' A' ' 110' ' ' SER . 7.7 p -137.77 145.67 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 111.008 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.587 ' HB2' HD11 ' A' ' 84' ' ' ILE . 10.6 tp -111.67 137.31 49.74 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.511 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.064 HG23 ' OG ' ' A' ' 110' ' ' SER . 80.5 t -133.77 124.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 120.664 -1.272 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.8 HD23 ' OD1' ' A' ' 107' ' ' ASN . 16.2 mt -132.84 178.84 6.56 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.632 178.531 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.446 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 2.2 ppp? -88.64 172.21 9.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.139 -0.976 . . . . 0.0 110.142 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.33 83.25 0.25 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.502 ' HB2' HG23 ' A' ' 48' ' ' ILE . 13.7 m -54.17 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.194 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 0.7 OUTLIER -158.64 -83.25 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.407 -0.808 . . . . 0.0 109.964 179.272 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.551 ' HB3' ' HB3' ' A' ' 50' ' ' ALA . 1.5 mt-10 -96.93 38.34 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.35 -0.844 . . . . 0.0 110.064 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.833 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -45.17 -60.72 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.172 -0.955 . . . . 0.0 111.32 -179.083 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 48' ' ' ILE . 3.2 m-20 -47.31 -44.44 23.53 Favored 'General case' 0 C--N 1.282 -2.363 0 C-N-CA 118.372 -1.331 . . . . 0.0 108.622 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB3' ' HB3' ' A' ' 47' ' ' GLU . . . -71.17 -47.04 60.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.559 -0.713 . . . . 0.0 110.854 179.319 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.833 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -74.78 -49.76 28.35 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.062 0 O-C-N 120.649 -1.282 . . . . 0.0 110.069 -179.909 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.762 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 40.7 mm -45.0 -37.53 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.056 -1.652 . . . . 0.0 108.23 177.754 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.58 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 1.2 tt0 -68.66 -63.18 1.11 Allowed 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.296 -0.878 . . . . 0.0 110.256 179.279 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.11 -10.34 59.33 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.283 -0.885 . . . . 0.0 110.933 -179.322 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.707 HG22 ' HA ' ' A' ' 52' ' ' ILE . 4.0 tp -107.58 -35.43 2.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 CA-C-O 121.575 0.702 . . . . 0.0 110.681 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.644 HG23 HG23 ' A' ' 55' ' ' ILE . 2.1 t -117.75 -44.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.974 -0.69 . . . . 0.0 112.694 -176.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.776 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -56.55 -41.63 77.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.11 -1.619 . . . . 0.0 109.478 -179.363 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.776 ' N ' HD23 ' A' ' 57' ' ' LEU . 3.7 tttt -87.78 -43.98 11.46 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.634 -0.667 . . . . 0.0 110.583 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.17 -41.52 6.58 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.056 -178.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.558 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.83 -54.36 15.09 Favored Glycine 0 N--CA 1.492 2.399 0 O-C-N 120.803 -1.41 . . . . 0.0 110.328 -179.143 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.602 ' HA ' ' HB2' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -60.64 8.86 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.45 -1.03 . . . . 0.0 113.248 -179.323 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.603 ' HB1' ' HE3' ' A' ' 63' ' ' LYS . . . -57.19 -67.77 0.29 Allowed 'General case' 0 C--N 1.308 -1.229 0 O-C-N 120.258 -1.526 . . . . 0.0 109.076 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.603 ' HE3' ' HB1' ' A' ' 62' ' ' ALA . 5.4 mmpt? -90.19 -19.53 24.11 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.551 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.602 ' HB2' ' HA ' ' A' ' 61' ' ' LYS . 6.3 m-20 -69.34 121.08 80.86 Favored Pre-proline 0 C--N 1.299 -1.588 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.401 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.498 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 44.9 Cg_endo -64.09 -39.24 32.48 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.884 1.723 . . . . 0.0 111.16 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.688 ' C ' HD12 ' A' ' 67' ' ' ILE . 2.8 m -177.77 111.2 0.07 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 123.012 1.386 . . . . 0.0 109.193 179.418 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.688 HD12 ' C ' ' A' ' 66' ' ' SER 0.299 1.3 mp -107.06 145.48 14.51 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.465 0 CA-C-N 113.823 -1.535 . . . . 0.0 111.673 -176.533 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.579 HG12 ' CG ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.04 142.66 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.931 179.454 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.657 ' CG2' HG21 ' A' ' 52' ' ' ILE . 66.1 t -115.32 100.38 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.125 -0.984 . . . . 0.0 110.154 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 1.1 mm-40 -83.59 124.51 30.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.489 -0.757 . . . . 0.0 109.869 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -123.25 102.47 7.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.15 -0.969 . . . . 0.0 109.587 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -103.97 144.23 31.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.164 -0.96 . . . . 0.0 109.948 -179.704 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.72 83.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.435 -0.79 . . . . 0.0 110.044 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 132.73 -24.88 3.82 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -125.08 161.63 26.36 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.778 -0.836 . . . . 0.0 110.931 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.762 ' CZ2' HD11 ' A' ' 52' ' ' ILE . 11.8 t90 -135.88 79.46 1.77 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.724 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.2 m0 -98.79 137.72 36.97 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.495 -0.753 . . . . 0.0 112.433 -177.563 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.556 HD11 ' HE1' ' A' ' 76' ' ' TRP . 1.3 mt -138.29 139.15 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.304 -0.873 . . . . 0.0 109.486 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.579 ' CG ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -109.01 162.28 14.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.188 -0.945 . . . . 0.0 110.582 -179.387 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.439 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.31 140.64 20.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.97 50.03 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -0.906 . . . . 0.0 109.961 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.53 -138.85 2.6 Favored Glycine 0 C--N 1.301 -1.374 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.29 163.28 23.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -1.179 . . . . 0.0 109.885 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 124' ' ' ILE . 5.7 tp -150.83 161.85 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.099 -1.001 . . . . 0.0 110.307 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.577 ' O ' HD13 ' A' ' 40' ' ' LEU . 2.4 mt-10 -140.18 164.75 29.22 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.229 -0.92 . . . . 0.0 110.384 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.773 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -125.53 165.22 23.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.298 -0.876 . . . . 0.0 109.718 179.62 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.522 ' OD1' ' CG ' ' A' ' 121' ' ' LYS . 9.5 m-20 -149.46 155.29 40.15 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.304 -0.872 . . . . 0.0 110.656 -179.648 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.923 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -146.12 -22.37 0.45 Allowed 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 118.808 -1.157 . . . . 0.0 111.301 177.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.442 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -41.57 -46.48 3.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.667 -1.271 . . . . 0.0 110.624 179.268 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.492 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.2 tt0 -49.36 -57.76 6.31 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.401 -0.812 . . . . 0.0 109.659 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.708 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -45.55 -30.31 1.43 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.687 -0.633 . . . . 0.0 109.727 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -71.17 -37.83 63.51 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.492 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.3 mt-10 -64.69 -20.19 66.17 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.341 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.628 ' HB3' HD23 ' A' ' 95' ' ' LEU . 7.4 tt -84.54 -67.57 0.79 Allowed 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.631 HD11 ' HB3' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -100.77 -23.3 14.63 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.115 -0.99 . . . . 0.0 110.112 179.26 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 60.1 45.69 95.53 Favored Glycine 0 N--CA 1.5 2.942 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.278 178.812 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.689 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 13.7 mttt -138.06 -127.43 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.456 0 O-C-N 121.091 -1.241 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.689 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 42.0 Cg_endo -71.61 -4.91 15.96 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 CA-C-N 120.894 1.355 . . . . 0.0 108.605 178.385 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.767 ' CD1' ' N ' ' A' ' 100' ' ' SER . 2.8 p90 -24.12 -42.55 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 CA-C-O 121.599 0.714 . . . . 0.0 112.032 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.923 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.2 OUTLIER -57.94 -54.86 42.18 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 122.901 1.334 . . . . 0.0 109.18 -177.64 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.945 HG12 HD11 ' A' ' 105' ' ' LEU . 6.5 t -94.17 -43.88 13.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.672 -178.135 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.607 ' O ' HD12 ' A' ' 106' ' ' ILE . 37.4 t80 -53.1 -41.12 64.64 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 120.209 -1.557 . . . . 0.0 107.652 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.636 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 11.4 t0 -68.5 -43.13 77.53 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.437 -0.79 . . . . 0.0 109.922 179.152 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.759 HD12 ' N ' ' A' ' 105' ' ' LEU . 2.9 pp -75.25 -40.38 58.99 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 116.756 -1.978 . . . . 0.0 109.046 179.252 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.945 HD11 HG12 ' A' ' 101' ' ' VAL . 23.6 mt -52.82 -20.02 2.93 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.094 -1.629 . . . . 0.0 109.867 178.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.607 HD12 ' O ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -92.09 -44.92 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.267 -0.896 . . . . 0.0 110.629 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.8 ' OD1' HD23 ' A' ' 42' ' ' LEU . 9.2 p30 -114.48 -7.59 12.83 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 112.243 -178.366 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 104' ' ' LEU . 6.0 p -60.89 -17.64 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.592 -1.317 . . . . 0.0 109.34 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -39.84 -22.78 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.7 -179.231 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 110' ' ' SER . . . . . 1.064 ' OG ' HG23 ' A' ' 41' ' ' VAL . 0.1 OUTLIER -73.28 9.52 1.26 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.698 -1.251 . . . . 0.0 110.558 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 111' ' ' THR . . . . . 0.562 ' O ' ' HB ' ' A' ' 112' ' ' VAL . 1.1 t -61.53 -10.86 8.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.762 -1.212 . . . . 0.0 110.396 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.562 ' HB ' ' O ' ' A' ' 111' ' ' THR . 2.1 t 66.89 -52.73 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.576 -0.702 . . . . 0.0 110.62 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -173.15 -26.87 0.02 OUTLIER Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' HG23 ' A' ' 124' ' ' ILE . 18.2 ttt180 -138.81 147.74 42.91 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.063 -1.257 . . . . 0.0 111.023 -179.494 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.631 ' HB1' ' CD2' ' A' ' 122' ' ' PHE . . . -155.76 93.61 1.48 Allowed 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.38 -0.825 . . . . 0.0 110.285 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.551 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 12.2 t80 -69.72 118.88 13.13 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.49 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.2 m -79.55 117.78 20.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.619 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -79.38 49.62 1.01 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.935 179.404 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.93 -60.14 0.36 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 108.674 -1.77 . . . . 0.0 108.674 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -116.01 -10.15 11.63 Favored 'General case' 0 C--N 1.293 -1.875 0 O-C-N 122.001 -0.705 . . . . 0.0 110.382 179.712 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.522 ' CG ' ' OD1' ' A' ' 87' ' ' ASP . 1.7 tttt -121.07 -161.94 0.93 Allowed 'General case' 0 N--CA 1.493 1.685 0 CA-C-O 122.052 0.929 . . . . 0.0 111.397 -179.094 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.773 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.26 0.2 OUTLIER -141.22 150.93 43.31 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.97 -179.105 . . . . . . . . 4 4 . 1 . 014 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.594 ' O ' HG22 ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.4 110.96 8.03 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.982 -1.074 . . . . 0.0 110.001 178.705 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.886 ' HB ' HG23 ' A' ' 84' ' ' ILE . 4.8 mp -113.86 157.28 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 110.174 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 15.3 t -146.96 170.24 17.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.293 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.307 -0.87 . . . . 0.0 110.684 -179.527 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.517 ' HA ' ' OG ' ' A' ' 126' ' ' SER . 26.9 p-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.506 0.67 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.443 ' N ' ' OD1' ' A' ' 36' ' ' ASN . . . -39.74 134.0 1.45 Allowed 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.623 -0.673 . . . . 0.0 110.995 -179.502 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.18 152.45 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.308 -0.87 . . . . 0.0 109.732 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.937 HG13 ' HB2' ' A' ' 110' ' ' SER . 14.5 p -114.87 136.28 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 111.464 -179.641 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.646 HD22 HG12 ' A' ' 84' ' ' ILE . 3.8 tp -100.53 146.11 27.49 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 176.821 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.007 HG22 ' CD2' ' A' ' 77' ' ' TRP . 2.2 t -139.12 121.45 17.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 O-C-N 120.403 -1.436 . . . . 0.0 111.365 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.953 HD22 ' O ' ' A' ' 41' ' ' VAL . 3.3 mm? -133.42 153.02 51.96 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.294 -0.879 . . . . 0.0 109.212 178.763 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 12.7 ptm -75.45 153.68 37.47 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.837 -1.164 . . . . 0.0 109.721 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.553 ' CG ' ' HA2' ' A' ' 74' ' ' GLY . 10.0 ptmt -45.16 123.59 4.06 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.032 -1.042 . . . . 0.0 110.859 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.439 ' H ' HD12 ' A' ' 48' ' ' ILE . 12.8 m -100.05 -86.28 0.39 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.592 179.466 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -158.0 -79.11 0.07 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 110.92 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.487 ' C ' HD13 ' A' ' 51' ' ' ILE . 1.4 mt-10 -96.74 39.06 1.18 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.305 -0.872 . . . . 0.0 110.367 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.83 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.04 -69.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.117 -0.99 . . . . 0.0 111.586 -178.916 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.8 m-20 -41.15 -36.05 0.67 Allowed 'General case' 0 C--N 1.284 -2.267 0 C-N-CA 119.059 -1.057 . . . . 0.0 109.062 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.406 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -77.78 -50.22 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.601 -0.687 . . . . 0.0 109.9 178.601 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.83 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.31 -50.93 28.0 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.011 0 O-C-N 120.848 -1.157 . . . . 0.0 109.325 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.712 ' HA ' HG22 ' A' ' 55' ' ' ILE . 44.2 mm -47.19 -40.71 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 119.881 -1.762 . . . . 0.0 108.147 177.569 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.617 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 60.2 tt0 -60.85 -61.58 2.48 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -84.1 -9.15 58.83 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.201 -0.937 . . . . 0.0 111.669 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.875 HG23 HG23 ' A' ' 56' ' ' VAL . 4.5 tp -106.68 -32.81 2.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 CA-C-O 121.695 0.759 . . . . 0.0 110.098 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.875 HG23 HG23 ' A' ' 55' ' ' ILE . 7.4 t -116.46 -45.05 3.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 C-N-CA 119.942 -0.703 . . . . 0.0 112.188 -177.626 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.842 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -64.81 -37.67 88.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.339 -1.475 . . . . 0.0 108.557 179.798 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.842 ' N ' HD23 ' A' ' 57' ' ' LEU . 6.6 mtpt -96.86 -42.07 8.13 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.524 -0.735 . . . . 0.0 109.221 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -77.54 -49.84 7.0 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.585 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.27 -47.86 49.48 Favored Glycine 0 N--CA 1.489 2.178 0 O-C-N 120.973 -1.31 . . . . 0.0 110.136 -179.144 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.641 ' HA ' ' HB2' ' A' ' 64' ' ' ASN . 17.6 ttpp -65.17 9.98 0.09 Allowed 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.624 -0.927 . . . . 0.0 113.124 -179.092 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.67 -62.88 1.35 Allowed 'General case' 0 C--N 1.304 -1.386 0 O-C-N 120.387 -1.446 . . . . 0.0 108.897 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mtmt -101.62 -17.58 16.28 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.048 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.641 ' HB2' ' HA ' ' A' ' 61' ' ' LYS . 0.5 OUTLIER -67.96 127.27 93.32 Favored Pre-proline 0 C--N 1.3 -1.544 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.229 -179.165 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -66.22 -49.52 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.321 2.014 . . . . 0.0 111.587 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.44 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -166.97 106.23 0.6 Allowed 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 123.211 1.481 . . . . 0.0 109.489 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.678 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -97.1 148.91 5.19 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 CA-C-N 113.47 -1.696 . . . . 0.0 111.836 -176.507 . . . . . . . . 4 4 . 1 . 015 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.556 HG12 ' CB ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.44 145.44 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.298 -0.876 . . . . 0.0 110.201 179.731 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.698 ' CG1' HG21 ' A' ' 52' ' ' ILE . 99.2 t -121.31 96.7 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.152 -0.968 . . . . 0.0 110.089 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.6 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.3 mm-40 -79.36 134.6 36.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.263 -0.898 . . . . 0.0 110.092 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ASP . . . . . 0.469 ' O ' ' OD1' ' A' ' 71' ' ' ASP . 1.1 p30 -143.31 112.24 6.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.179 -0.951 . . . . 0.0 110.017 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.521 ' HG3' ' HB2' ' A' ' 75' ' ' PHE . 0.2 OUTLIER -147.55 -171.45 3.8 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.892 -1.13 . . . . 0.0 111.241 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.465 ' O ' ' C ' ' A' ' 74' ' ' GLY . . . -40.22 110.84 0.16 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.47 -0.769 . . . . 0.0 110.911 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.553 ' HA2' ' CG ' ' A' ' 44' ' ' LYS . . . 36.47 59.62 1.01 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.521 ' HB2' ' HG3' ' A' ' 72' ' ' LYS . 2.5 m-85 -160.75 75.49 0.54 Allowed 'General case' 0 C--N 1.291 -1.961 0 O-C-N 121.849 -0.795 . . . . 0.0 110.039 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.753 ' CE2' HG22 ' A' ' 48' ' ' ILE . 4.1 t90 -82.49 78.34 9.14 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.654 0.74 . . . . 0.0 109.08 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 1.007 ' CD2' HG22 ' A' ' 41' ' ' VAL . 23.2 m0 -98.94 148.27 24.14 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.594 -0.691 . . . . 0.0 111.626 -178.552 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.595 HG13 ' HA ' ' A' ' 69' ' ' VAL . 1.2 mp -146.65 141.58 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.339 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.556 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -116.74 141.75 47.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.129 -0.982 . . . . 0.0 110.695 -179.022 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.507 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -127.07 163.51 23.62 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.385 -0.822 . . . . 0.0 110.008 179.537 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -106.41 47.44 0.88 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.068 -1.02 . . . . 0.0 110.179 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -108.11 0.21 Allowed Glycine 0 C--N 1.299 -1.482 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -126.22 166.14 17.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.458 -1.025 . . . . 0.0 110.091 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.646 HG12 HD22 ' A' ' 40' ' ' LEU . 7.9 tp -143.91 158.61 16.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.121 -0.987 . . . . 0.0 110.524 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.468 ' O ' HG12 ' A' ' 86' ' ' ILE . 34.2 tt0 -122.76 173.8 7.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.261 -0.899 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 1.001 HG21 ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -157.62 149.78 9.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 O-C-N 121.148 -0.97 . . . . 0.0 111.007 -179.58 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -138.54 152.21 48.0 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.06 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.974 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.84 -34.84 0.13 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.335 -1.346 . . . . 0.0 111.585 178.751 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.533 ' CB ' ' OG1' ' A' ' 120' ' ' THR . . . -40.91 -45.35 2.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.289 -0.882 . . . . 0.0 110.181 -179.235 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.582 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 3.8 tt0 -67.86 -52.02 41.52 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 178.792 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.565 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.8 -41.15 70.23 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 108.965 178.677 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.522 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -59.49 -55.31 31.35 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.582 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.9 OUTLIER -57.02 -16.94 8.16 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.174 -1.192 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.818 HD23 ' N ' ' A' ' 95' ' ' LEU . 7.4 tt -86.25 -64.27 1.18 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.501 -0.749 . . . . 0.0 111.014 -179.302 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.818 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -71.36 -37.2 71.66 Favored 'General case' 0 N--CA 1.502 2.168 0 C-N-CA 118.485 -1.286 . . . . 0.0 109.849 -179.706 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.56 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -158.41 -74.43 0.02 OUTLIER Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.545 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 167.53 -63.24 0.0 OUTLIER Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.956 . . . . 0.0 109.52 179.855 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.9 Cg_endo -72.04 -16.22 28.93 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.476 1.25 . . . . 0.0 109.64 178.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.661 ' CB ' HD13 ' A' ' 95' ' ' LEU . 3.1 t80 -48.87 -48.51 42.09 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 121.074 -1.017 . . . . 0.0 109.171 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.974 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 3.8 t -32.36 -61.87 0.24 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.752 0.787 . . . . 0.0 110.764 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.86 ' HA ' HD23 ' A' ' 104' ' ' LEU . 19.4 t -82.79 -54.41 9.48 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.822 0 O-C-N 121.183 -0.948 . . . . 0.0 112.793 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.574 ' HA ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -46.56 -29.98 2.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.67 -1.269 . . . . 0.0 108.917 179.911 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.53 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 29.5 t70 -82.17 -37.18 26.53 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.451 -0.78 . . . . 0.0 109.441 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.86 HD23 ' HA ' ' A' ' 101' ' ' VAL . 0.4 OUTLIER -68.75 -21.78 64.35 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.364 179.523 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.748 HD11 ' CG1' ' A' ' 101' ' ' VAL . 4.6 mt -86.75 -27.72 23.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.819 -1.175 . . . . 0.0 110.373 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.441 HG22 ' HA ' ' A' ' 103' ' ' ASP . 0.6 OUTLIER -97.24 -28.52 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 121.134 -0.979 . . . . 0.0 109.956 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.642 ' CG ' HD13 ' A' ' 42' ' ' LEU . 2.5 p30 -87.49 -30.44 20.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.34 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.109 HG22 ' HB ' ' A' ' 111' ' ' THR . 9.9 p -66.3 -0.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 120.61 -1.306 . . . . 0.0 110.9 179.407 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -30.05 -34.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.813 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 110' ' ' SER . . . . . 0.937 ' HB2' HG13 ' A' ' 39' ' ' VAL . 82.8 p -84.4 33.66 0.51 Allowed 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.533 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' THR . . . . . 1.109 ' HB ' HG22 ' A' ' 108' ' ' VAL . 11.5 t -96.46 44.26 1.07 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.26 179.738 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.573 ' CG1' ' N ' ' A' ' 113' ' ' GLY . 0.5 OUTLIER -61.68 -48.66 87.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.542 -0.724 . . . . 0.0 111.015 -178.687 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.573 ' N ' ' CG1' ' A' ' 112' ' ' VAL . . . -57.21 -77.04 0.18 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.531 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -157.72 -169.04 2.72 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.384 -1.068 . . . . 0.0 110.105 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.647 ' HB2' ' OG1' ' A' ' 111' ' ' THR . . . -170.7 84.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.583 ' HB3' HG22 ' A' ' 123' ' ' THR . 4.7 t80 -69.84 105.71 2.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.003 -1.061 . . . . 0.0 108.351 178.595 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 119' ' ' GLY . 7.6 m -79.03 145.95 33.58 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.299 -0.876 . . . . 0.0 110.915 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' LEU . . . . . 0.612 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.1 OUTLIER -123.69 50.3 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.587 -0.695 . . . . 0.0 110.282 179.914 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.422 ' H ' HG22 ' A' ' 117' ' ' THR . . . 62.15 -57.26 0.03 OUTLIER Glycine 0 N--CA 1.491 2.326 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 178.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.612 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.8 t -111.7 -15.18 13.49 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.753 -0.851 . . . . 0.0 111.406 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.538 ' CG ' ' HB3' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -143.57 150.6 39.08 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.758 -1.214 . . . . 0.0 110.77 -179.614 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 1.001 ' CE2' HG21 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -124.68 164.17 20.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.877 -1.139 . . . . 0.0 110.769 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.583 HG22 ' HB3' ' A' ' 116' ' ' TYR . 2.8 t -144.27 131.85 21.09 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.514 -0.741 . . . . 0.0 109.831 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.697 HD12 ' N ' ' A' ' 124' ' ' ILE . 2.0 mp -101.91 162.66 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 110.674 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 114' ' ' ARG . 3.3 t -152.34 -175.3 5.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -0.872 . . . . 0.0 109.806 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.517 ' OG ' ' HA ' ' A' ' 36' ' ' ASN . 19.7 t . . . . . 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.086 . . . . 0.0 110.705 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' A' ' 36' ' ' ASN . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.276 0.56 . . . . 0.0 110.367 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 35' ' ' SER . 0.4 OUTLIER 68.96 -57.08 0.52 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.142 -0.974 . . . . 0.0 110.695 179.782 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.49 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -29.87 132.96 0.06 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.403 0.621 . . . . 0.0 111.846 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 1.7 p -142.48 149.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.515 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.588 ' H ' HG21 ' A' ' 112' ' ' VAL . 11.1 p -127.68 150.05 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.78 -1.2 . . . . 0.0 111.707 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 1.023 HD11 HG13 ' A' ' 86' ' ' ILE . 23.5 tp -112.36 132.05 55.21 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.865 HG13 ' NE1' ' A' ' 77' ' ' TRP . 2.6 t -127.28 124.87 64.95 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 111.603 -177.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.844 HD21 HD11 ' A' ' 86' ' ' ILE . 0.9 OUTLIER -119.53 -174.18 2.68 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.002 -1.061 . . . . 0.0 110.605 179.189 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.567 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.8 ptp -117.66 21.58 12.88 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.937 . . . . 0.0 110.642 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.664 ' HB3' HD11 ' A' ' 48' ' ' ILE . 3.6 mmtt -88.95 -93.14 0.11 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.456 -0.778 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.62 ' CB ' ' O ' ' A' ' 44' ' ' LYS . 1.3 p 89.36 178.01 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 45' ' ' SER . 0.1 OUTLIER 62.93 -87.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 109.663 -179.242 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.519 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.2 mt-10 -52.16 -24.95 7.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.44 -0.787 . . . . 0.0 111.895 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 1.01 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -73.48 -62.37 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.709 -178.082 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.545 ' C ' ' O ' ' A' ' 48' ' ' ILE . 85.4 m-20 -37.83 -32.57 0.06 Allowed 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.316 -0.954 . . . . 0.0 108.782 179.443 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.27 -55.98 5.06 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.814 HG12 ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -71.3 -48.69 52.66 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.165 0 O-C-N 120.679 -1.263 . . . . 0.0 109.29 178.922 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.859 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 45.8 mm -46.01 -41.23 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 119.871 -1.768 . . . . 0.0 108.604 177.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.778 ' HA ' ' HB2' ' A' ' 57' ' ' LEU . 2.1 tm-20 -64.73 -60.89 2.58 Favored 'General case' 0 C--N 1.292 -1.91 0 O-C-N 121.206 -0.933 . . . . 0.0 110.143 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -77.62 -12.59 59.98 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 120.868 -1.145 . . . . 0.0 111.488 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.776 HG23 HG23 ' A' ' 56' ' ' VAL . 4.0 tp -107.43 -34.96 2.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 O-C-N 121.59 -0.694 . . . . 0.0 111.499 -178.197 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.776 HG23 HG23 ' A' ' 55' ' ' ILE . 2.5 t -117.18 -37.89 2.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.655 -0.653 . . . . 0.0 112.632 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.778 ' HB2' ' HA ' ' A' ' 53' ' ' GLU . 1.4 tm? -37.51 -55.49 1.08 Allowed 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 122.272 1.034 . . . . 0.0 109.947 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.31 -48.97 12.2 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.487 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -50.82 -47.39 47.31 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.525 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -78.03 7.07 46.11 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.77 -8.56 16.75 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.972 -1.311 . . . . 0.0 110.891 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.5 -82.63 0.22 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.945 -1.097 . . . . 0.0 109.93 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.403 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -79.56 -30.3 41.64 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 122.432 1.111 . . . . 0.0 108.158 178.678 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.525 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 8.5 m-20 -74.65 127.03 87.96 Favored Pre-proline 0 C--N 1.295 -1.801 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.473 ' O ' ' HB2' ' A' ' 66' ' ' SER . 43.5 Cg_endo -62.86 -47.7 8.21 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 121.77 1.646 . . . . 0.0 110.822 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.656 ' C ' HD12 ' A' ' 67' ' ' ILE . 1.7 t 179.96 111.86 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.958 1.361 . . . . 0.0 109.339 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.656 HD12 ' C ' ' A' ' 66' ' ' SER 0.292 1.3 mp -104.37 134.77 44.77 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.508 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.551 -176.823 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.642 HG12 ' CB ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -92.03 162.73 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 109.374 178.925 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.802 ' CG1' HG21 ' A' ' 52' ' ' ILE . 24.3 t -136.28 106.51 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.045 -1.034 . . . . 0.0 110.31 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.612 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.7 mm-40 -102.05 145.42 29.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.841 . . . . 0.0 110.421 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASP . . . . . 0.428 ' CG ' ' OD2' ' A' ' 49' ' ' ASP . 11.6 p-10 -136.96 119.72 16.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.451 -0.78 . . . . 0.0 108.965 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.596 ' CB ' ' HB2' ' A' ' 75' ' ' PHE . 27.0 mttm -125.49 83.28 2.15 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.019 -1.051 . . . . 0.0 111.506 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.558 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 18.64 73.66 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.237 0 CA-C-O 121.231 0.539 . . . . 0.0 111.949 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 43' ' ' MET . . . 103.54 11.18 33.86 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.596 ' HB2' ' CB ' ' A' ' 72' ' ' LYS . 20.4 m-85 -138.26 101.03 4.28 Favored 'General case' 0 C--N 1.286 -2.165 0 O-C-N 121.837 -0.802 . . . . 0.0 110.587 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 1.01 ' CE2' HG21 ' A' ' 48' ' ' ILE . 17.5 t90 -89.39 87.53 7.13 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.518 -0.738 . . . . 0.0 109.494 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.865 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.7 m0 -98.06 111.59 23.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.08 -1.012 . . . . 0.0 110.427 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.543 ' O ' HG23 ' A' ' 39' ' ' VAL . 0.3 OUTLIER -114.65 148.17 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.737 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.642 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -130.28 125.46 34.83 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.921 -1.112 . . . . 0.0 110.16 179.81 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.534 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -125.44 173.97 8.52 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.478 -0.764 . . . . 0.0 110.031 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.97 52.51 1.27 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 110.046 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -169.59 -105.94 0.19 Allowed Glycine 0 C--N 1.302 -1.337 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -133.08 115.5 15.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.505 -0.997 . . . . 0.0 110.316 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.684 HG21 ' HB2' ' A' ' 40' ' ' LEU . 8.1 tp -105.49 148.36 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 110.261 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -103.99 159.29 15.79 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.157 -0.965 . . . . 0.0 111.392 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 1.023 HG13 HD11 ' A' ' 40' ' ' LEU . 0.3 OUTLIER -162.32 149.82 4.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 O-C-N 121.442 -0.787 . . . . 0.0 110.438 179.772 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.843 ' N ' HD13 ' A' ' 86' ' ' ILE . 1.4 m-20 -135.31 -176.13 4.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.011 -1.056 . . . . 0.0 111.455 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.659 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -138.41 -9.31 1.46 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.813 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -43.71 -48.34 7.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.474 -1.392 . . . . 0.0 110.269 179.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.582 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 10.1 tt0 -49.36 -47.63 47.3 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.455 -0.778 . . . . 0.0 109.892 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.522 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -56.81 -26.46 58.04 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.067 -1.021 . . . . 0.0 109.649 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.699 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -73.97 -48.84 14.82 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.582 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.0 OUTLIER -58.23 -19.3 32.79 Favored 'General case' 0 C--N 1.289 -2.052 0 O-C-N 121.104 -1.233 . . . . 0.0 107.951 178.56 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.845 HD23 ' CD2' ' A' ' 95' ' ' LEU . 11.4 tp -82.11 -68.0 0.73 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.826 -0.546 . . . . 0.0 109.613 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.845 ' CD2' HD23 ' A' ' 94' ' ' LEU . 0.2 OUTLIER -100.96 -29.66 12.07 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.082 -1.011 . . . . 0.0 109.135 178.587 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 69.44 43.96 66.98 Favored Glycine 0 N--CA 1.498 2.768 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.833 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.687 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 8.2 mmmt -138.23 -124.17 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.672 0 O-C-N 121.091 -1.241 . . . . 0.0 109.724 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.687 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 45.9 Cg_endo -71.14 -4.96 15.94 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 121.172 1.454 . . . . 0.0 108.724 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.76 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.8 p90 -23.66 -44.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.076 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.76 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -49.14 -52.48 25.96 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 123.348 1.547 . . . . 0.0 107.734 -179.125 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.867 HG12 HD11 ' A' ' 105' ' ' LEU . 67.5 t -99.04 -53.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.807 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.486 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 0.5 OUTLIER -44.42 -30.02 0.79 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.773 -1.204 . . . . 0.0 108.434 179.364 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.564 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.8 t70 -83.11 -45.94 13.37 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.83 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.5 OUTLIER -60.9 -41.16 95.55 Favored 'General case' 0 C--O 1.202 -1.425 0 C-N-CA 117.928 -1.509 . . . . 0.0 109.144 179.168 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.867 HD11 HG12 ' A' ' 101' ' ' VAL . 28.0 mt -61.58 -46.47 89.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.725 -1.235 . . . . 0.0 111.341 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -73.94 -33.07 35.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 110.464 -178.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.557 ' HB2' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -90.42 -40.71 11.89 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.121 -0.987 . . . . 0.0 110.143 -179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 104' ' ' LEU . 1.6 p -65.86 1.66 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.647 -1.283 . . . . 0.0 111.32 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.509 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.42 -33.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.997 -1.064 . . . . 0.0 110.872 -179.699 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.871 ' O ' HG22 ' A' ' 112' ' ' VAL . 1.9 p -88.02 39.16 0.88 Allowed 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 108' ' ' VAL . 8.9 t -60.63 -10.93 5.9 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.377 -0.827 . . . . 0.0 111.698 -178.182 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.871 HG22 ' O ' ' A' ' 110' ' ' SER . 0.6 OUTLIER 16.56 -84.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 CA-C-O 121.094 0.473 . . . . 0.0 112.081 -179.839 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.587 ' H ' HG23 ' A' ' 112' ' ' VAL . . . -83.54 52.99 4.81 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.537 ' O ' ' O ' ' A' ' 113' ' ' GLY . 10.6 ttt85 43.49 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 O-C-N 121.539 -0.977 . . . . 0.0 111.544 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.518 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -142.41 107.83 5.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.748 -1.22 . . . . 0.0 110.346 -179.128 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.476 ' HB3' HG22 ' A' ' 123' ' ' THR . 33.3 t80 -69.43 118.39 12.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.105 -0.997 . . . . 0.0 109.247 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 7.4 t -83.84 158.09 21.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.146 -0.971 . . . . 0.0 111.301 -178.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -135.1 54.72 1.92 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.662 -0.649 . . . . 0.0 110.388 -179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.3 -57.72 0.07 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.603 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -114.4 -23.75 9.21 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.844 -0.798 . . . . 0.0 111.24 -178.93 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.539 ' O ' ' CB ' ' A' ' 118' ' ' LEU . 5.5 tttt -138.72 147.27 42.51 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.904 -1.122 . . . . 0.0 110.796 -179.329 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.728 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -116.02 -177.96 3.29 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.086 -1.009 . . . . 0.0 109.136 178.326 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.648 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.9 OUTLIER -156.42 141.23 17.06 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 110.342 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.751 HD12 ' N ' ' A' ' 124' ' ' ILE . 3.1 mp -111.28 129.65 66.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 110.34 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.429 ' OG1' ' N ' ' A' ' 126' ' ' SER . 1.7 t -145.15 -169.1 3.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.184 -0.947 . . . . 0.0 110.399 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.429 ' N ' ' OG1' ' A' ' 125' ' ' THR . 3.8 t -120.45 -89.25 0.61 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.848 . . . . 0.0 110.595 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' A' ' 128' ' ' LEU . 13.3 mt-10 -52.78 161.6 0.72 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.419 -0.8 . . . . 0.0 110.511 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.475 ' O ' ' O ' ' A' ' 127' ' ' GLU . 29.6 mt . . . . . 0 C--N 1.307 -1.256 0 O-C-N 121.551 -0.718 . . . . 0.0 110.888 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.118 0.485 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.491 ' HB2' ' HB2' ' A' ' 126' ' ' SER . 19.9 m120 -86.25 109.89 19.25 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.186 -0.946 . . . . 0.0 110.457 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.467 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.41 146.38 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.656 -0.653 . . . . 0.0 110.474 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.703 HG21 ' C ' ' A' ' 125' ' ' THR . 1.9 t -136.56 120.95 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.843 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 39' ' ' VAL . 9.6 p -97.64 134.79 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.665 HD22 HD11 ' A' ' 84' ' ' ILE . 9.2 tp -106.98 147.96 29.25 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.799 HG13 ' CD1' ' A' ' 77' ' ' TRP . 50.6 t -149.07 126.58 2.65 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 120.576 -1.328 . . . . 0.0 110.322 -178.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.914 HD23 ' CZ3' ' A' ' 76' ' ' TRP . 12.4 tp -135.73 178.71 6.83 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.199 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.526 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 8.6 ptp -78.61 178.5 7.77 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.725 -1.235 . . . . 0.0 110.79 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 74' ' ' GLY . 4.4 mtmt -64.09 95.9 0.13 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.539 -0.726 . . . . 0.0 112.127 -178.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.515 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 0.2 OUTLIER -73.85 -0.96 17.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 0.0 109.712 178.224 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 45' ' ' SER . 8.0 t0 74.82 -58.96 0.56 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.501 -0.75 . . . . 0.0 112.297 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.549 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.4 mt-10 -95.06 23.68 5.47 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.809 -1.182 . . . . 0.0 111.781 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.847 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -63.23 -71.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 120.823 -1.173 . . . . 0.0 111.674 -179.494 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.566 ' C ' ' O ' ' A' ' 48' ' ' ILE . 15.6 t0 -36.8 -34.2 0.07 Allowed 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.051 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.516 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -77.65 -54.83 5.92 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.847 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.24 -50.8 33.75 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 O-C-N 120.757 -1.214 . . . . 0.0 109.324 178.997 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.957 HG21 HG13 ' A' ' 69' ' ' VAL . 36.4 mm -46.13 -39.33 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 119.798 -1.814 . . . . 0.0 108.506 177.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.611 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 3.8 tm-20 -64.39 -61.5 2.19 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.185 -0.947 . . . . 0.0 110.333 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -80.69 -10.83 59.7 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.254 -0.904 . . . . 0.0 111.258 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.723 HG22 ' O ' ' A' ' 51' ' ' ILE . 4.8 tp -106.18 -33.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 CA-C-O 121.644 0.735 . . . . 0.0 110.467 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.721 HG13 HG21 ' A' ' 67' ' ' ILE . 2.4 t -117.39 -45.31 3.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.3 -177.448 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.727 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.1 OUTLIER -58.61 -39.15 79.61 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.096 -1.628 . . . . 0.0 108.492 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.727 ' N ' HD23 ' A' ' 57' ' ' LEU . 1.3 tttt -100.02 -41.04 7.34 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 55' ' ' ILE . . . -67.32 -49.02 55.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -81.39 23.64 4.63 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 120.926 -1.338 . . . . 0.0 110.366 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -107.54 -9.27 15.96 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.854 -1.38 . . . . 0.0 110.76 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.47 -84.8 0.31 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 120.95 -1.094 . . . . 0.0 110.109 -179.315 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.417 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 4.7 ptpt -70.0 -35.82 74.67 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.723 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.515 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.6 OUTLIER -69.36 122.68 86.34 Favored Pre-proline 0 C--N 1.298 -1.668 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.811 179.138 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.475 ' HG2' ' HB3' ' A' ' 81' ' ' ASP . 43.7 Cg_endo -63.26 -45.6 11.78 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 121.733 1.622 . . . . 0.0 110.924 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.685 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.6 OUTLIER 179.37 111.57 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 CA-C-O 122.92 1.343 . . . . 0.0 109.653 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.721 HG21 HG13 ' A' ' 56' ' ' VAL 0.297 1.3 mp -106.68 133.97 49.67 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.403 0 CA-C-N 114.012 -1.449 . . . . 0.0 111.728 -176.799 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.577 ' HB ' ' CG ' ' A' ' 79' ' ' LYS . 1.0 OUTLIER -91.81 139.28 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.555 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.957 HG13 HG21 ' A' ' 52' ' ' ILE . 72.9 t -104.76 89.3 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.178 -0.952 . . . . 0.0 110.328 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.813 ' HB3' ' HB2' ' A' ' 77' ' ' TRP . 0.3 OUTLIER -82.04 50.55 1.59 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -0.795 . . . . 0.0 110.231 179.928 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASP . . . . . 0.489 ' OD1' HG13 ' A' ' 48' ' ' ILE . 3.5 t70 -77.66 109.38 11.59 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.036 -1.04 . . . . 0.0 110.095 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.8 tttt -129.21 142.06 50.97 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.027 -1.046 . . . . 0.0 109.711 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.81 86.78 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.881 . . . . 0.0 109.633 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 158.72 -49.26 0.41 Allowed Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.408 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.566 ' HB3' ' CD1' ' A' ' 77' ' ' TRP . 5.1 m-85 -143.62 145.13 32.24 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.814 -0.815 . . . . 0.0 110.418 -179.574 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.914 ' CZ3' HD23 ' A' ' 42' ' ' LEU . 17.8 t90 -94.25 80.14 3.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.613 -0.679 . . . . 0.0 109.989 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.813 ' HB2' ' HB3' ' A' ' 70' ' ' GLU . 7.9 m95 -87.83 128.27 35.34 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 109.039 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.661 ' CG2' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -131.95 137.41 54.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.794 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.577 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 5.5 tttp -118.09 143.36 46.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.506 -1.371 . . . . 0.0 110.818 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.425 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -134.28 134.78 42.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.578 -0.701 . . . . 0.0 110.028 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.475 ' HB3' ' HG2' ' A' ' 65' ' ' PRO . 1.1 t0 -86.27 51.29 2.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.207 -0.933 . . . . 0.0 110.267 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.82 -120.37 0.54 Allowed Glycine 0 C--N 1.3 -1.419 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -113.8 164.29 13.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.367 -1.078 . . . . 0.0 109.372 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.665 HD11 HD22 ' A' ' 40' ' ' LEU . 4.2 tp -147.83 144.07 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.952 -1.093 . . . . 0.0 110.56 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -122.34 150.45 42.38 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.401 -0.812 . . . . 0.0 110.178 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.93 HG22 ' CG ' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -161.42 169.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.459 -0.776 . . . . 0.0 109.651 -179.158 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' A' ' 86' ' ' ILE . 77.7 m-20 -139.63 -173.13 3.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.09 -1.006 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.746 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -131.56 -19.26 2.72 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.092 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.422 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -40.67 -46.15 2.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.076 -1.015 . . . . 0.0 110.537 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -48.63 -54.31 15.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.333 -0.854 . . . . 0.0 109.674 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.683 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -52.67 -28.3 21.09 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.462 -0.774 . . . . 0.0 109.701 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.745 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -70.84 -31.15 67.44 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -69.77 -24.08 63.46 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.877 ' HB3' HD23 ' A' ' 95' ' ' LEU . 0.4 OUTLIER -78.69 -59.16 2.89 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.613 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.877 HD23 ' HB3' ' A' ' 94' ' ' LEU . 0.2 OUTLIER -110.07 -29.34 8.26 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.178 -0.951 . . . . 0.0 110.897 179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 68.56 42.65 80.24 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.663 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 33.2 mttt -133.05 -134.41 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.403 0 O-C-N 121.261 -1.141 . . . . 0.0 109.947 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.663 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.4 Cg_endo -71.78 -4.3 14.82 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 N-CA-C 108.683 -1.314 . . . . 0.0 108.683 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.75 ' CD1' ' N ' ' A' ' 100' ' ' SER . 4.1 p90 -26.56 -42.29 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.88 0.848 . . . . 0.0 111.72 178.457 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.3 OUTLIER -52.34 -53.09 49.12 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-O 122.593 1.187 . . . . 0.0 108.779 -177.493 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.789 HG12 HD11 ' A' ' 105' ' ' LEU . 59.7 t -102.63 -46.22 10.79 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.484 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 64.7 t80 -52.05 -32.17 33.36 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 117.559 -1.656 . . . . 0.0 107.588 179.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 3.1 t70 -79.63 -50.7 10.27 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.479 -0.888 . . . . 0.0 108.906 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.811 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.6 OUTLIER -55.05 -42.74 73.09 Favored 'General case' 0 C--O 1.204 -1.296 0 C-N-CA 116.913 -1.915 . . . . 0.0 108.515 179.398 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.789 HD11 HG12 ' A' ' 101' ' ' VAL . 52.6 mt -59.07 -29.4 67.3 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.871 -1.143 . . . . 0.0 111.352 179.506 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.464 HD12 ' O ' ' A' ' 102' ' ' TYR . 1.1 mt -92.05 -41.23 12.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 120.939 -1.101 . . . . 0.0 110.879 -178.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.668 ' CB ' HD12 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -90.99 -17.24 26.64 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.903 -1.123 . . . . 0.0 110.967 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.97 HG23 ' CE2' ' A' ' 122' ' ' PHE . 9.1 p -69.48 -3.58 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.089 -1.632 . . . . 0.0 110.093 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -35.1 -27.96 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.667 -0.646 . . . . 0.0 111.35 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.682 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -66.68 8.34 0.26 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 111.399 178.987 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.784 ' OG1' ' HB2' ' A' ' 115' ' ' ALA . 1.4 t -86.14 38.55 0.77 Allowed 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 117.922 -1.511 . . . . 0.0 110.633 -178.091 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 19.4 m -55.59 -21.48 9.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 O-C-N 121.42 -0.8 . . . . 0.0 110.861 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -105.72 -71.26 0.8 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -143.83 158.14 43.89 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.377 -1.072 . . . . 0.0 110.105 -179.733 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.784 ' HB2' ' OG1' ' A' ' 111' ' ' THR . . . -160.67 83.79 0.68 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.168 -0.957 . . . . 0.0 111.201 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -80.26 117.59 21.17 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.225 -0.922 . . . . 0.0 108.811 178.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.408 ' H ' HG22 ' A' ' 117' ' ' THR . 4.3 t -84.86 131.98 34.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.146 -0.971 . . . . 0.0 110.406 -179.396 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.589 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -102.01 38.37 1.66 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 110.396 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.95 -59.64 0.14 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 118' ' ' LEU . 62.3 m -107.5 -13.79 14.99 Favored 'General case' 0 C--N 1.291 -1.935 0 O-C-N 121.941 -0.741 . . . . 0.0 110.059 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.525 ' HB2' ' CB ' ' A' ' 118' ' ' LEU . 1.0 OUTLIER -125.96 165.85 18.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.078 -1.014 . . . . 0.0 111.507 -179.397 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.97 ' CE2' HG23 ' A' ' 108' ' ' VAL 0.255 0.0 OUTLIER -124.9 145.26 49.91 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.896 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.847 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.7 OUTLIER -144.42 110.15 5.31 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.252 -1.53 . . . . 0.0 110.247 -178.18 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.905 HD13 ' CE1' ' A' ' 122' ' ' PHE . 1.5 mp -113.02 153.7 14.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.703 ' C ' HG21 ' A' ' 38' ' ' VAL . 10.2 t -159.52 -176.86 6.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.542 -1.349 . . . . 0.0 111.721 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.491 ' HB2' ' HB2' ' A' ' 36' ' ' ASN . 80.6 p -86.68 -76.07 0.37 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.616 -0.677 . . . . 0.0 110.299 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 6.0 mt-10 -94.26 -166.82 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.384 -0.823 . . . . 0.0 110.711 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--N 1.307 -1.275 0 O-C-N 121.554 -0.716 . . . . 0.0 111.237 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 36' ' ' ASN . 8.1 p . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 120.987 0.423 . . . . 0.0 110.051 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.546 ' CB ' ' O ' ' A' ' 35' ' ' SER . 5.7 m120 77.31 -13.13 0.98 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.791 -0.568 . . . . 0.0 110.995 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -40.35 116.03 0.63 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.138 -0.976 . . . . 0.0 110.97 -179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.552 HG21 ' N ' ' A' ' 126' ' ' SER . 3.2 t -121.86 148.96 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.384 -0.823 . . . . 0.0 109.729 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.958 HG13 ' HB2' ' A' ' 110' ' ' SER . 9.4 p -127.92 139.07 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 111.299 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.679 HD22 ' O ' ' A' ' 85' ' ' GLU . 9.3 tp -117.25 128.67 55.31 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.683 HG13 ' CD1' ' A' ' 77' ' ' TRP . 39.9 t -130.35 150.94 35.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 O-C-N 120.776 -1.203 . . . . 0.0 112.013 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.635 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 0.1 OUTLIER -143.09 176.91 8.75 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 177.544 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.52 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 6.5 ptt? -110.55 36.34 3.13 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.697 -1.252 . . . . 0.0 110.218 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.554 ' HB3' ' CD1' ' A' ' 48' ' ' ILE . 5.1 mmtt -88.51 -81.27 0.26 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.482 -0.761 . . . . 0.0 112.409 -178.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.743 ' N ' HD11 ' A' ' 48' ' ' ILE . 0.0 OUTLIER 67.99 92.97 0.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.197 -178.692 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.493 ' HB2' ' O ' ' A' ' 45' ' ' SER . 3.5 t70 170.96 -80.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.416 -0.803 . . . . 0.0 110.029 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.578 ' HB3' HD13 ' A' ' 51' ' ' ILE . 13.4 mt-10 -91.9 -10.3 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.891 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.939 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -60.65 -64.76 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.341 -0.849 . . . . 0.0 111.526 -178.933 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 2.1 t70 -41.11 -36.88 0.78 Allowed 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 118.769 -1.172 . . . . 0.0 108.961 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -76.19 -52.97 8.97 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.545 -0.722 . . . . 0.0 110.094 178.492 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.849 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.3 OUTLIER -70.6 -50.03 47.84 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.06 0 O-C-N 120.6 -1.312 . . . . 0.0 108.943 179.104 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.929 HG21 HG13 ' A' ' 69' ' ' VAL . 48.1 mm -43.41 -39.87 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.302 -1.498 . . . . 0.0 108.263 177.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.63 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 24.8 tt0 -65.86 -63.93 0.97 Allowed 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.437 179.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -77.79 -9.79 59.21 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.196 -0.94 . . . . 0.0 111.299 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.731 HG22 ' CA ' ' A' ' 52' ' ' ILE . 4.6 tp -106.61 -34.96 2.99 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-O 121.753 0.787 . . . . 0.0 110.359 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.666 HG23 HG23 ' A' ' 55' ' ' ILE . 2.2 t -117.24 -46.31 3.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.961 -0.696 . . . . 0.0 112.202 -177.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.838 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -56.53 -39.1 72.78 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.274 -1.516 . . . . 0.0 109.502 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.838 ' N ' HD23 ' A' ' 57' ' ' LEU . 1.9 tttp -93.58 -49.74 5.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.0 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.94 -42.38 9.69 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.586 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.46 -54.12 14.26 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.643 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 15.0 ttpt -67.6 12.57 0.09 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.624 -0.927 . . . . 0.0 112.552 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.89 -64.04 0.94 Allowed 'General case' 0 C--N 1.305 -1.33 0 O-C-N 120.56 -1.338 . . . . 0.0 108.351 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.2 mtmt -97.87 -22.06 16.56 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.643 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -69.25 128.98 92.25 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.179 179.779 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.74 -44.32 13.96 Favored 'Trans proline' 0 C--N 1.302 -1.905 0 C-N-CA 122.038 1.826 . . . . 0.0 111.603 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.55 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.44 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.331 0 CA-C-O 123.097 1.427 . . . . 0.0 109.567 -179.902 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.674 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.305 1.2 mp -97.8 140.87 16.98 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.538 0 CA-C-N 113.741 -1.572 . . . . 0.0 111.563 -176.898 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.547 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 3.1 t -83.23 137.0 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.454 -0.779 . . . . 0.0 110.01 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.929 HG13 HG21 ' A' ' 52' ' ' ILE . 27.6 t -119.99 81.77 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.133 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.674 ' HB2' ' CB ' ' A' ' 77' ' ' TRP . 1.9 mm-40 -78.91 141.13 37.87 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.364 -0.835 . . . . 0.0 110.289 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -145.7 127.88 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.286 -0.884 . . . . 0.0 109.614 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' HB2' ' A' ' 45' ' ' SER . 3.7 ttpt -157.91 -176.9 6.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.021 -1.049 . . . . 0.0 111.326 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.517 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -25.99 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.343 0.592 . . . . 0.0 111.819 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 41.33 44.51 3.95 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.52 ' HA ' ' HA ' ' A' ' 43' ' ' MET . 0.1 OUTLIER -137.25 90.91 2.56 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 121.554 0.692 . . . . 0.0 110.044 179.86 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.939 ' CD2' HG21 ' A' ' 48' ' ' ILE . 8.8 t90 -83.0 82.28 8.3 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.436 -0.79 . . . . 0.0 109.547 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 1.013 ' O ' HD13 ' A' ' 78' ' ' ILE . 13.6 m95 -89.59 131.27 35.69 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.141 -0.975 . . . . 0.0 110.975 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 1.013 HD13 ' O ' ' A' ' 77' ' ' TRP . 21.3 mm -134.66 153.09 34.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.366 -0.834 . . . . 0.0 109.876 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.561 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -143.55 135.46 26.59 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.947 -179.378 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.575 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -136.43 140.23 42.99 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.597 -0.689 . . . . 0.0 110.03 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -84.46 51.15 2.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.012 . . . . 0.0 110.287 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.77 -148.38 5.97 Favored Glycine 0 N--CA 1.477 1.398 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -88.18 144.77 26.27 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.277 -1.131 . . . . 0.0 109.8 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.583 HD11 HD23 ' A' ' 40' ' ' LEU . 9.8 tt -142.46 172.85 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.962 . . . . 0.0 110.67 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.679 ' O ' HD22 ' A' ' 40' ' ' LEU . 15.4 mt-10 -131.71 176.41 8.35 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.955 -1.091 . . . . 0.0 112.017 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 1.114 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -160.94 154.46 3.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 1.114 ' N ' HD13 ' A' ' 86' ' ' ILE . 4.8 m-20 -137.1 -178.7 5.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.796 -1.19 . . . . 0.0 111.903 -178.378 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.966 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -150.35 -29.9 0.21 Allowed 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.103 177.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.436 ' CA ' ' HE1' ' A' ' 99' ' ' PHE . . . -39.29 -47.03 1.64 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.062 -1.024 . . . . 0.0 110.663 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 93' ' ' GLU . 2.7 mm-40 -50.92 -63.34 1.16 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 121.871 0.843 . . . . 0.0 109.41 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.56 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -38.61 -38.08 0.37 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.464 179.474 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.68 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -64.18 -42.49 97.95 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.044 -1.623 . . . . 0.0 109.044 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' N ' ' O ' ' A' ' 90' ' ' GLU . 14.0 mt-10 -60.14 -24.65 64.88 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.522 HD23 ' N ' ' A' ' 95' ' ' LEU . 8.7 tt -79.73 -60.38 2.37 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.523 -0.735 . . . . 0.0 110.469 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -109.95 -20.46 12.73 Favored 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.97 -179.456 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.693 ' N ' HD12 ' A' ' 95' ' ' LEU . . . 63.05 90.4 0.03 OUTLIER Glycine 0 N--CA 1.497 2.71 0 C-N-CA 118.786 -1.674 . . . . 0.0 109.604 179.193 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.712 ' HB3' ' HD2' ' A' ' 98' ' ' PRO 0.261 0.2 OUTLIER -175.99 -151.69 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.192 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 -178.744 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.712 ' HD2' ' HB3' ' A' ' 97' ' ' LYS . 43.1 Cg_endo -67.8 -1.99 7.79 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 N-CA-C 108.841 -1.253 . . . . 0.0 108.841 176.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.778 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.3 p90 -21.3 -44.58 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.641 0.734 . . . . 0.0 112.427 179.017 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.966 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.5 OUTLIER -54.47 -53.78 49.65 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 122.868 1.318 . . . . 0.0 108.95 -177.104 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.978 HG12 HD11 ' A' ' 105' ' ' LEU . 48.3 t -98.44 -47.05 12.44 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.343 0 CA-C-N 115.147 -0.933 . . . . 0.0 113.267 -178.184 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.58 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 5.9 t80 -51.06 -29.22 12.24 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 117.512 -1.675 . . . . 0.0 107.843 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 8.8 t70 -80.9 -44.45 18.3 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.947 HD22 ' CZ ' ' A' ' 122' ' ' PHE . 0.4 OUTLIER -59.55 -45.23 92.4 Favored 'General case' 0 C--O 1.201 -1.476 0 C-N-CA 117.833 -1.547 . . . . 0.0 109.102 178.861 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.978 HD11 HG12 ' A' ' 101' ' ' VAL . 2.5 mt -64.21 -27.29 68.96 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 119.893 -1.755 . . . . 0.0 111.062 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -95.18 -12.73 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 109.937 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.579 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.86 -36.11 3.52 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.507 -0.745 . . . . 0.0 110.289 -179.196 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.703 HG12 ' O ' ' A' ' 104' ' ' LEU . 1.8 p -62.69 -4.86 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.207 -0.933 . . . . 0.0 111.603 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.88 -27.22 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.399 -0.813 . . . . 0.0 111.81 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.958 ' HB2' HG13 ' A' ' 39' ' ' VAL . 90.6 p -82.24 28.84 0.43 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.877 -1.14 . . . . 0.0 109.791 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.702 ' HB ' HG22 ' A' ' 108' ' ' VAL . 5.4 t -89.49 42.89 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.945 -1.097 . . . . 0.0 109.38 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 96.7 t -57.95 -47.29 86.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.762 -0.586 . . . . 0.0 111.364 -179.08 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -78.01 -75.19 0.97 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.525 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -152.95 -176.98 6.0 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.238 -1.154 . . . . 0.0 110.538 -179.14 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -170.36 73.77 0.07 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.368 -0.833 . . . . 0.0 110.317 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -72.69 140.67 48.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.521 HG22 ' H ' ' A' ' 119' ' ' GLY . 18.8 m -89.3 117.55 28.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 110.532 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.667 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -86.64 39.61 0.85 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.431 -0.793 . . . . 0.0 110.728 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.521 ' H ' HG22 ' A' ' 117' ' ' THR . . . 59.6 -62.01 0.01 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.311 -1.115 . . . . 0.0 110.311 179.196 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.667 ' N ' ' O ' ' A' ' 118' ' ' LEU . 38.3 p -88.44 -28.62 20.77 Favored 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.928 -0.748 . . . . 0.0 109.979 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.57 ' HD3' HD22 ' A' ' 118' ' ' LEU . 3.6 ptmt -146.1 -167.76 2.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.129 -0.982 . . . . 0.0 110.665 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.947 ' CZ ' HD22 ' A' ' 104' ' ' LEU . 5.8 m-85 -116.77 165.07 13.72 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.321 -0.862 . . . . 0.0 110.85 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.687 ' O ' HG22 ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.22 105.1 5.61 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.659 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.737 HD13 ' CG2' ' A' ' 86' ' ' ILE . 1.8 mp -108.2 141.57 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -0.952 . . . . 0.0 109.623 -179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 13.4 t -149.94 -170.76 3.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.06 -1.025 . . . . 0.0 111.11 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.552 ' N ' HG21 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -96.54 -33.51 11.8 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.44 -0.787 . . . . 0.0 110.537 -179.929 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' A' ' 128' ' ' LEU . 1.7 mm-40 -37.65 105.49 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.65 -0.656 . . . . 0.0 110.68 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.496 ' O ' ' O ' ' A' ' 127' ' ' GLU . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.275 0 O-C-N 121.63 -0.669 . . . . 0.0 110.582 -179.703 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.147 0.499 . . . . 0.0 109.839 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.508 ' O ' ' C ' ' A' ' 37' ' ' ALA . 31.5 m-20 -129.86 -92.86 0.43 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 110.59 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.508 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -27.25 127.28 0.06 Allowed 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.347 0.594 . . . . 0.0 111.997 -179.303 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.5 m -111.76 174.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.772 HG13 ' HB3' ' A' ' 110' ' ' SER . 13.2 p -144.78 125.1 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.139 -0.975 . . . . 0.0 110.783 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.744 HD11 HD11 ' A' ' 86' ' ' ILE . 20.6 tp -92.85 162.85 13.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.597 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.819 HG13 ' NE1' ' A' ' 77' ' ' TRP . 5.6 t -149.65 123.47 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 O-C-N 120.106 -1.621 . . . . 0.0 111.833 -178.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.997 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 0.2 OUTLIER -126.36 156.35 40.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.127 -0.983 . . . . 0.0 109.853 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.532 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.6 ptm -96.98 31.38 2.41 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.921 -1.112 . . . . 0.0 110.183 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.527 ' O ' ' HA2' ' A' ' 74' ' ' GLY . 2.3 mmtt -87.74 -86.59 0.16 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.482 -0.761 . . . . 0.0 110.956 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.647 ' CA ' HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER 73.37 113.26 0.06 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.36 -0.838 . . . . 0.0 110.746 -179.834 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 45' ' ' SER . 0.3 OUTLIER 164.73 -83.95 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.665 -0.647 . . . . 0.0 109.438 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.458 ' O ' HD13 ' A' ' 51' ' ' ILE . 5.1 mt-10 -95.52 1.1 53.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.866 . . . . 0.0 110.045 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.964 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.93 -66.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.103 -0.998 . . . . 0.0 111.046 -178.995 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.655 ' HA ' HG11 ' A' ' 69' ' ' VAL . 5.3 t0 -40.09 -33.58 0.24 Allowed 'General case' 0 C--N 1.292 -1.932 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.68 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.493 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -78.71 -55.5 5.13 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.717 -0.614 . . . . 0.0 109.835 178.235 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.839 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -68.31 -48.43 73.31 Favored 'Isoleucine or valine' 0 C--O 1.185 -2.316 0 C-N-CA 118.301 -1.36 . . . . 0.0 108.232 178.642 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.758 ' CA ' HG22 ' A' ' 55' ' ' ILE . 46.3 mm -43.32 -41.19 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.004 -1.685 . . . . 0.0 108.42 176.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.611 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 16.2 tt0 -64.84 -62.91 1.28 Allowed 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.895 -1.128 . . . . 0.0 110.025 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -77.41 -11.78 59.88 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.323 -0.86 . . . . 0.0 111.584 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.758 HG22 ' CA ' ' A' ' 52' ' ' ILE . 4.5 tp -107.23 -33.47 2.66 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.531 0.682 . . . . 0.0 111.039 -178.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.757 HG23 HG23 ' A' ' 55' ' ' ILE . 2.8 t -117.22 -45.17 3.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.598 -0.689 . . . . 0.0 112.153 -177.406 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.878 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -54.58 -30.08 53.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 119.758 -1.839 . . . . 0.0 108.959 -179.798 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.878 ' N ' HD23 ' A' ' 57' ' ' LEU . 13.4 mmtt -85.99 -47.49 9.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.473 -0.767 . . . . 0.0 110.483 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.44 -45.09 5.37 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.566 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.97 -73.04 0.76 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.622 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 22.4 ttpt -65.72 9.84 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.403 -1.057 . . . . 0.0 112.557 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.618 ' HB2' ' O ' ' A' ' 58' ' ' LYS . . . -51.63 -63.47 1.13 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.555 -1.341 . . . . 0.0 108.454 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.0 mtmt -97.97 -20.34 17.48 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 177.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.622 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.8 OUTLIER -68.68 141.1 92.43 Favored Pre-proline 0 N--CA 1.489 1.503 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.393 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.423 ' O ' ' OG ' ' A' ' 66' ' ' SER . 42.9 Cg_endo -62.38 -46.38 12.35 Favored 'Trans proline' 0 C--N 1.298 -2.107 0 C-N-CA 122.228 1.952 . . . . 0.0 112.002 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.423 ' OG ' ' O ' ' A' ' 65' ' ' PRO . 0.9 OUTLIER 178.81 112.99 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 123.158 1.456 . . . . 0.0 110.66 -179.691 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.69 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.306 1.0 OUTLIER -89.99 147.67 5.06 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.684 0 CA-C-N 113.573 -1.649 . . . . 0.0 110.86 -178.185 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.556 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -102.05 138.21 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.133 -0.98 . . . . 0.0 110.695 -179.581 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.702 HG22 HG21 ' A' ' 52' ' ' ILE . 5.5 t -116.82 90.97 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.372 -0.83 . . . . 0.0 109.073 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.599 ' CB ' ' HB2' ' A' ' 77' ' ' TRP . 13.2 mm-40 -79.61 76.51 6.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.487 -0.758 . . . . 0.0 110.655 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -89.04 113.62 24.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.973 -1.079 . . . . 0.0 109.485 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.421 ' O ' ' N ' ' A' ' 74' ' ' GLY . 13.0 mttp -145.47 -162.02 1.42 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.032 -1.042 . . . . 0.0 111.059 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.574 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -39.76 96.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.335 -0.853 . . . . 0.0 111.243 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 37.73 50.1 1.93 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.574 ' CD2' ' O ' ' A' ' 73' ' ' ALA . 8.6 m-85 -146.59 87.14 1.69 Allowed 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.875 -0.779 . . . . 0.0 109.761 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.997 ' CZ3' HD13 ' A' ' 42' ' ' LEU . 4.5 t90 -82.13 74.16 9.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.516 -0.74 . . . . 0.0 110.033 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.819 ' NE1' HG13 ' A' ' 41' ' ' VAL . 8.9 m95 -82.0 123.33 28.81 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.652 HD13 ' O ' ' A' ' 77' ' ' TRP . 5.5 mm -116.38 141.01 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.003 -1.061 . . . . 0.0 110.159 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.597 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.4 OUTLIER -123.61 130.52 52.79 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.612 -0.68 . . . . 0.0 109.598 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.47 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -130.28 165.89 21.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.222 -0.924 . . . . 0.0 110.289 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -118.35 50.32 1.18 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.341 -0.849 . . . . 0.0 110.304 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -119.77 0.52 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -112.22 152.67 28.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -1.115 . . . . 0.0 109.717 179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 124' ' ' ILE . 8.1 tt -152.41 175.19 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.483 ' HG2' ' HA ' ' A' ' 123' ' ' THR . 56.2 mt-10 -148.16 172.47 14.27 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.007 -1.058 . . . . 0.0 111.315 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.78 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -124.48 167.62 18.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 121.601 -0.687 . . . . 0.0 109.552 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.417 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 26.0 m-20 -154.98 138.97 16.37 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.015 -1.053 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.988 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.73 -37.52 0.12 Allowed 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.379 -1.328 . . . . 0.0 111.0 177.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 93' ' ' GLU . . . -39.89 -40.27 0.97 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.501 -0.75 . . . . 0.0 110.567 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.523 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 3.2 mt-10 -72.06 -43.97 64.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.317 -0.864 . . . . 0.0 109.408 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.483 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -60.35 -49.84 75.99 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 108.955 179.206 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.568 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -53.53 -57.43 15.66 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.523 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.1 pt-20 -59.98 -13.24 10.38 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.332 -1.099 . . . . 0.0 110.038 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.762 HD23 ' N ' ' A' ' 95' ' ' LEU . 0.5 OUTLIER -92.22 -43.75 9.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.317 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.762 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -97.64 -41.31 8.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.795 -1.191 . . . . 0.0 109.247 179.464 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.74 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -145.33 -74.7 0.02 OUTLIER Glycine 0 N--CA 1.483 1.805 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.27 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.565 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.3 OUTLIER 161.61 -55.77 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.858 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.737 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.546 ' HD3' ' HB3' ' A' ' 97' ' ' LYS . 52.2 Cg_endo -74.66 -23.54 14.49 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.856 1.45 . . . . 0.0 110.251 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.568 ' HB3' ' HA2' ' A' ' 92' ' ' GLY . 2.6 t80 -47.28 -49.42 23.71 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.223 -0.923 . . . . 0.0 109.996 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.988 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 29.5 p -31.97 -64.12 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.889 0.852 . . . . 0.0 110.429 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.968 ' HA ' HD23 ' A' ' 104' ' ' LEU . 13.8 t -72.69 -60.78 2.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 O-C-N 121.034 -1.041 . . . . 0.0 112.572 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 101' ' ' VAL . 1.7 t80 -44.94 -30.48 1.02 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.532 -1.355 . . . . 0.0 109.332 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 6.4 t0 -77.08 -31.52 56.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.598 -0.689 . . . . 0.0 109.287 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.971 HD13 ' CZ ' ' A' ' 122' ' ' PHE . 0.6 OUTLIER -74.81 -19.49 60.17 Favored 'General case' 0 C--O 1.2 -1.51 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.24 179.739 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 101' ' ' VAL . 1.4 mt -91.27 -26.12 19.14 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.345 -1.472 . . . . 0.0 111.226 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -97.22 -13.58 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.015 -1.053 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.555 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -105.57 -42.9 5.08 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.509 -0.745 . . . . 0.0 110.012 179.766 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.627 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 3.5 p -57.32 -2.86 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 120.879 -1.138 . . . . 0.0 112.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.504 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -25.22 -39.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.77 -0.581 . . . . 0.0 112.365 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.772 ' HB3' HG13 ' A' ' 39' ' ' VAL . 1.9 m -80.27 43.14 0.61 Allowed 'General case' 0 C--N 1.287 -2.137 0 C-N-CA 118.43 -1.308 . . . . 0.0 108.79 178.176 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.611 ' CG2' HG22 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -63.33 2.02 0.44 Allowed 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.267 -0.896 . . . . 0.0 112.45 -179.146 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.454 ' C ' ' O ' ' A' ' 111' ' ' THR . 9.6 p -38.16 -27.24 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 120.808 -1.183 . . . . 0.0 111.17 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.535 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -97.64 50.22 1.41 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.535 ' C ' ' O ' ' A' ' 113' ' ' GLY . 1.5 ttm-85 19.86 100.36 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.356 0.598 . . . . 0.0 111.982 179.165 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.578 ' HB1' ' CD2' ' A' ' 122' ' ' PHE . . . -85.09 93.69 8.68 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.266 -0.896 . . . . 0.0 111.47 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 123' ' ' THR . 0.1 OUTLIER -74.44 143.91 44.5 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.189 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 4.0 m -79.51 160.21 26.62 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.79 -1.194 . . . . 0.0 111.309 -178.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.625 HD23 ' O ' ' A' ' 118' ' ' LEU . 0.9 OUTLIER -130.62 35.33 4.03 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.665 -0.647 . . . . 0.0 109.891 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.49 -59.76 0.29 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -115.42 -9.24 12.15 Favored 'General case' 0 C--N 1.292 -1.908 0 O-C-N 122.013 -0.698 . . . . 0.0 110.186 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.454 ' HB2' ' HB3' ' A' ' 118' ' ' LEU . 20.8 mttt -137.68 -162.26 1.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.151 -0.968 . . . . 0.0 111.195 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.971 ' CZ ' HD13 ' A' ' 104' ' ' LEU 0.263 0.1 OUTLIER -132.15 160.66 35.4 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.068 -179.235 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.663 ' O ' HG22 ' A' ' 123' ' ' THR . 0.9 OUTLIER -138.3 104.14 5.1 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.034 -1.041 . . . . 0.0 110.598 178.697 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.805 ' HB ' HG23 ' A' ' 84' ' ' ILE . 3.4 mp -98.44 146.78 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.201 -0.937 . . . . 0.0 108.59 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.5 t -149.4 166.75 28.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.782 -1.199 . . . . 0.0 111.108 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.476 ' O ' ' O ' ' A' ' 127' ' ' GLU . 2.4 t -94.27 -32.69 13.54 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.555 0.693 . . . . 0.0 109.533 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' A' ' 128' ' ' LEU . 14.4 mm-40 -42.51 167.59 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.746 -0.596 . . . . 0.0 110.452 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.8 OUTLIER . . . . . 0 C--N 1.307 -1.277 0 O-C-N 121.297 -0.877 . . . . 0.0 110.804 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.1 m . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 121.212 0.53 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.717 ' O ' HG13 ' A' ' 38' ' ' VAL . 4.0 m-20 -110.07 -1.69 17.4 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.374 -0.829 . . . . 0.0 110.276 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -31.87 141.32 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.569 0.699 . . . . 0.0 111.904 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.717 HG13 ' O ' ' A' ' 36' ' ' ASN . 24.2 m -141.42 176.17 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.472 -0.767 . . . . 0.0 109.709 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 39' ' ' VAL . 5.5 p -136.46 130.5 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.953 -1.092 . . . . 0.0 111.097 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.895 ' O ' HG23 ' A' ' 41' ' ' VAL . 12.4 tp -98.1 160.66 14.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 177.006 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.912 ' O ' HD22 ' A' ' 42' ' ' LEU . 2.9 t -166.31 116.4 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 O-C-N 120.871 -1.143 . . . . 0.0 110.093 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.912 HD22 ' O ' ' A' ' 41' ' ' VAL . 2.5 mm? -135.38 -171.68 2.89 Favored 'General case' 0 C--N 1.289 -2.056 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.404 ' O ' ' N ' ' A' ' 45' ' ' SER . 20.9 ptm -104.09 161.43 14.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.161 -0.962 . . . . 0.0 109.813 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -44.75 96.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.3 -0.875 . . . . 0.0 111.263 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 4.5 m -82.11 11.81 4.86 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.165 -0.959 . . . . 0.0 110.265 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' SER . 13.3 t0 78.41 -62.51 0.34 Allowed 'General case' 0 N--CA 1.503 2.18 0 O-C-N 121.569 -0.707 . . . . 0.0 112.421 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.59 ' O ' HD13 ' A' ' 51' ' ' ILE . 3.5 mt-10 -93.31 26.56 2.88 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.776 -1.203 . . . . 0.0 112.195 -177.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.81 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.61 -75.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 120.932 -1.105 . . . . 0.0 111.092 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.3 t70 -37.63 -32.22 0.05 Allowed 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.45 -56.13 4.91 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 177.404 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.81 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -71.28 -52.14 29.02 Favored 'Isoleucine or valine' 0 C--O 1.193 -1.88 0 O-C-N 120.977 -1.077 . . . . 0.0 109.869 179.075 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.701 ' HA ' HG22 ' A' ' 55' ' ' ILE . 47.2 mm -48.22 -38.73 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 119.89 -1.756 . . . . 0.0 108.121 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.729 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.7 tt0 -63.07 -61.12 2.59 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.183 -0.948 . . . . 0.0 110.352 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -81.06 -12.0 59.4 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 111.405 -178.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.745 HG23 HG23 ' A' ' 56' ' ' VAL . 4.3 tp -105.88 -32.99 2.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-O 121.645 0.736 . . . . 0.0 110.365 -178.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.745 HG23 HG23 ' A' ' 55' ' ' ILE . 2.5 t -117.89 -45.08 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.869 -0.732 . . . . 0.0 112.694 -177.372 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.729 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -49.31 -42.75 42.34 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.011 -1.681 . . . . 0.0 109.037 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.54 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 14.3 mttt -85.08 -44.22 13.2 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.574 0.702 . . . . 0.0 109.51 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -65.54 -51.36 48.67 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.54 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -69.43 -8.36 59.38 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' A' ' 57' ' ' LEU . 2.1 tptm -107.36 -9.02 16.13 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.129 -1.218 . . . . 0.0 110.954 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.17 -79.05 0.24 Allowed 'General case' 0 C--N 1.308 -1.197 0 O-C-N 120.886 -1.134 . . . . 0.0 110.69 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.9 mtmt -87.45 -29.38 21.47 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.54 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.9 m-80 -69.18 124.99 91.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.113 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.474 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 42.9 Cg_endo -62.56 -42.87 24.34 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.781 1.654 . . . . 0.0 110.671 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.598 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.4 OUTLIER 179.4 110.0 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 123.008 1.385 . . . . 0.0 109.64 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.747 HG23 ' O ' ' A' ' 79' ' ' LYS 0.297 1.1 mp -105.37 149.99 8.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 113.839 -1.528 . . . . 0.0 110.496 -177.205 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -103.44 130.36 53.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.322 -0.861 . . . . 0.0 110.013 179.725 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.685 ' CG1' HG21 ' A' ' 52' ' ' ILE . 55.5 t -113.95 100.29 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.168 -0.957 . . . . 0.0 109.889 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.565 ' N ' ' O ' ' A' ' 77' ' ' TRP . 0.7 OUTLIER -89.81 79.55 6.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.385 -0.822 . . . . 0.0 110.681 -179.487 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -80.47 91.02 5.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.073 -1.017 . . . . 0.0 109.396 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -89.78 154.45 19.9 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.159 -0.963 . . . . 0.0 110.482 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -59.63 -12.65 7.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.818 . . . . 0.0 110.548 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.452 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . -147.29 22.92 1.56 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.456 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.452 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 5.8 m-85 -160.77 108.8 1.57 Allowed 'General case' 0 C--N 1.289 -2.051 0 O-C-N 121.76 -0.847 . . . . 0.0 109.887 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.777 ' CE2' HG22 ' A' ' 48' ' ' ILE . 13.1 t90 -89.8 77.84 6.97 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.599 -0.688 . . . . 0.0 109.379 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.858 ' CE2' HG13 ' A' ' 41' ' ' VAL . 12.4 m0 -102.77 134.6 45.89 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.506 -0.746 . . . . 0.0 112.433 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.549 ' HB ' HD23 ' A' ' 40' ' ' LEU . 1.2 mp -138.65 152.39 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.747 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.4 OUTLIER -127.83 152.74 47.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.831 -1.168 . . . . 0.0 110.041 -179.728 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.461 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -139.42 178.86 6.9 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.299 -0.875 . . . . 0.0 110.603 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 37' ' ' ALA . 41.6 m-20 -122.54 50.49 1.49 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.364 -0.835 . . . . 0.0 110.138 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.55 -126.66 0.88 Allowed Glycine 0 C--N 1.301 -1.386 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -99.8 143.93 29.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -1.22 . . . . 0.0 109.925 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.59 HG23 ' HB ' ' A' ' 124' ' ' ILE . 4.8 tp -125.85 161.99 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.145 -0.972 . . . . 0.0 110.012 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.518 ' N ' HG13 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.88 164.96 23.02 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.137 -0.977 . . . . 0.0 111.717 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.791 HG13 HD13 ' A' ' 124' ' ' ILE 0.26 0.3 OUTLIER -139.91 175.02 7.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.363 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.555 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 74.9 m-20 -149.55 173.37 13.69 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.861 -1.149 . . . . 0.0 111.308 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 1.025 ' HB1' ' CA ' ' A' ' 100' ' ' SER . . . -150.96 -48.77 0.12 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.97 0.891 . . . . 0.0 109.759 177.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.414 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -41.37 -45.4 3.05 Favored 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.351 -0.843 . . . . 0.0 110.643 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.566 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 1.1 tt0 -49.81 -38.55 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 122.138 0.971 . . . . 0.0 108.483 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 1.004 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -63.45 -42.59 98.64 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.396 -0.815 . . . . 0.0 109.191 178.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.719 ' N ' ' CD2' ' A' ' 99' ' ' PHE . . . -63.15 -65.37 3.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.566 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 5.2 pt-20 -38.21 -31.56 0.05 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.818 -0.813 . . . . 0.0 108.94 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.722 HD13 ' HG ' ' A' ' 95' ' ' LEU . 0.1 OUTLIER -73.6 -71.16 0.33 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.68 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 1.004 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.1 OUTLIER -86.97 -55.17 3.95 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.972 -1.08 . . . . 0.0 108.847 178.599 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 88.18 50.14 3.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.696 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 15.2 mttt -150.74 -110.7 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 121.288 -1.125 . . . . 0.0 110.646 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.696 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 58.6 Cg_endo -85.5 12.98 2.89 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 CA-C-N 120.926 1.366 . . . . 0.0 109.67 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.729 ' O ' ' N ' ' A' ' 101' ' ' VAL . 29.3 p90 -49.85 -146.0 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 122.009 0.909 . . . . 0.0 110.474 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' SER . . . . . 1.025 ' CA ' ' HB1' ' A' ' 88' ' ' ALA . 2.1 p 32.73 -77.59 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 122.269 1.033 . . . . 0.0 111.323 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.729 ' N ' ' O ' ' A' ' 99' ' ' PHE . 38.0 t -66.02 -64.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.582 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.491 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 16.0 t80 -59.89 -39.9 86.9 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 119.99 -1.694 . . . . 0.0 106.69 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.581 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 0.3 OUTLIER -63.42 -38.96 93.16 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.847 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.865 HD12 ' N ' ' A' ' 105' ' ' LEU . 3.2 pp -83.75 -38.89 20.78 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 117.957 -1.497 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.865 ' N ' HD12 ' A' ' 104' ' ' LEU . 66.7 mt -49.82 -22.19 1.37 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 120.802 -1.186 . . . . 0.0 109.602 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.437 HD13 ' HA ' ' A' ' 106' ' ' ILE . 0.4 OUTLIER -107.83 -33.4 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.288 -0.882 . . . . 0.0 110.15 179.768 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.581 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.7 p30 -96.7 -3.65 42.19 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.968 -1.082 . . . . 0.0 110.027 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.664 HG12 ' O ' ' A' ' 104' ' ' LEU . 9.8 p -83.11 -7.7 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 110.804 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 108' ' ' VAL . 8.5 t -42.02 -22.91 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.193 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.595 ' CB ' ' N ' ' A' ' 41' ' ' VAL . 82.8 p -53.22 -4.31 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.313 -0.867 . . . . 0.0 112.641 179.283 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.954 HG22 HG12 ' A' ' 124' ' ' ILE . 45.1 p -71.76 -73.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.428 0 O-C-N 119.923 -1.736 . . . . 0.0 110.868 -178.105 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.567 HG12 ' O ' ' A' ' 112' ' ' VAL . 47.9 t 61.78 11.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.517 -0.74 . . . . 0.0 110.575 -179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -161.2 -68.94 0.02 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.796 ' HB3' HG22 ' A' ' 125' ' ' THR . 0.1 OUTLIER -136.58 165.86 24.88 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.305 -1.114 . . . . 0.0 110.497 -179.38 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.997 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -156.25 68.79 0.62 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.318 -0.864 . . . . 0.0 110.185 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.57 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 7.1 t80 -69.69 132.15 45.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.246 -0.908 . . . . 0.0 109.657 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.4 m -88.57 138.87 31.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.147 -0.971 . . . . 0.0 110.305 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -108.73 37.19 2.6 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.381 -0.824 . . . . 0.0 110.197 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.21 -58.47 0.25 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.553 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.8 OUTLIER -113.38 -23.35 9.92 Favored 'General case' 0 C--N 1.293 -1.871 0 O-C-N 121.95 -0.735 . . . . 0.0 110.067 -179.873 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -116.69 -168.22 1.42 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.997 ' CZ ' ' HB1' ' A' ' 115' ' ' ALA . 14.5 t80 -138.03 161.71 36.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.782 . . . . 0.0 109.159 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.603 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.8 OUTLIER -145.24 139.26 27.03 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 120.569 -1.332 . . . . 0.0 110.337 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.972 HD11 ' CD2' ' A' ' 122' ' ' PHE . 2.1 mp -134.91 154.39 36.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.467 -0.77 . . . . 0.0 110.18 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.796 HG22 ' HB3' ' A' ' 114' ' ' ARG . 1.9 t -152.34 -175.04 5.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.186 -0.946 . . . . 0.0 110.34 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 90.4 p -89.51 -90.08 0.14 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.364 -0.835 . . . . 0.0 110.538 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.464 ' N ' ' OG ' ' A' ' 126' ' ' SER . 2.6 mt-10 -93.33 122.73 36.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.114 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.517 ' H ' HD12 ' A' ' 128' ' ' LEU . 1.9 mp . . . . . 0 C--N 1.306 -1.286 0 O-C-N 121.451 -0.781 . . . . 0.0 110.335 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 37' ' ' ALA . 62.0 m . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 120.874 0.368 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.526 ' O ' ' C ' ' A' ' 37' ' ' ALA . 5.5 m-80 62.94 -64.91 0.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.719 . . . . 0.0 110.636 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -26.38 139.43 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.353 0.596 . . . . 0.0 111.496 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.598 HG12 ' OG ' ' A' ' 126' ' ' SER . 8.7 p -102.08 136.3 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.775 HG13 ' HB2' ' A' ' 110' ' ' SER . 8.4 p -80.65 135.44 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.041 -1.037 . . . . 0.0 110.273 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.943 HD22 ' CG1' ' A' ' 84' ' ' ILE . 14.7 tp -110.42 134.48 52.29 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.756 HG13 ' NE1' ' A' ' 77' ' ' TRP . 10.1 t -130.63 121.24 50.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 O-C-N 120.86 -1.15 . . . . 0.0 110.942 -177.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.763 HD21 HG23 ' A' ' 86' ' ' ILE . 0.4 OUTLIER -120.54 -171.63 2.21 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.633 -0.667 . . . . 0.0 109.475 179.245 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.98 159.48 15.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.154 -0.967 . . . . 0.0 109.965 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.64 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.189 -0.945 . . . . 0.0 110.6 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.472 ' HB3' HG23 ' A' ' 48' ' ' ILE . 1.8 t -86.53 11.25 13.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 110.144 179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.486 ' N ' HD13 ' A' ' 48' ' ' ILE . 5.5 m-20 67.71 -62.87 0.33 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.494 -0.754 . . . . 0.0 111.108 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.486 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.0 mt-10 -87.21 30.17 0.79 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.103 -0.998 . . . . 0.0 110.616 -179.321 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.954 HG22 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.36 -75.2 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.969 -1.082 . . . . 0.0 111.393 -178.698 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.527 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -39.47 -31.61 0.1 Allowed 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.305 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -75.4 -53.79 8.12 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.763 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.41 -53.55 19.1 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.76 0 O-C-N 120.997 -1.065 . . . . 0.0 109.992 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.717 ' HA ' HG22 ' A' ' 55' ' ' ILE . 44.8 mm -47.05 -37.15 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 119.962 -1.711 . . . . 0.0 108.106 177.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.711 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 30.2 tt0 -64.39 -63.43 1.14 Allowed 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.386 -0.821 . . . . 0.0 110.282 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.44 -10.03 59.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.354 -0.841 . . . . 0.0 111.295 -178.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.717 HG22 ' HA ' ' A' ' 52' ' ' ILE . 4.4 tp -106.68 -33.79 2.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-O 121.62 0.724 . . . . 0.0 110.371 -179.122 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.715 HG23 HG23 ' A' ' 55' ' ' ILE . 2.3 t -118.67 -43.22 2.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.08 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.711 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -44.98 -38.47 4.77 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.449 -1.407 . . . . 0.0 109.775 -178.346 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.536 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 0.0 OUTLIER -86.78 -44.61 11.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.977 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -56.55 -53.35 44.2 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.53 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -72.19 0.79 37.57 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.489 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 2.0 mmtt -106.57 -9.31 16.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.845 -1.385 . . . . 0.0 111.357 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.36 -80.05 0.12 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.888 -1.133 . . . . 0.0 109.852 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.58 -24.75 16.46 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 122.307 1.051 . . . . 0.0 108.411 178.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.53 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.4 m-20 -67.51 116.55 38.39 Favored Pre-proline 0 C--N 1.294 -1.844 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.727 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 44.3 Cg_endo -62.99 -37.36 53.99 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 124.299 1.684 . . . . 0.0 111.558 -179.2 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.633 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.3 OUTLIER 179.36 111.61 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 123.145 1.45 . . . . 0.0 109.908 179.423 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.644 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.298 1.2 mp -104.5 155.01 6.09 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 CA-C-N 113.665 -1.607 . . . . 0.0 111.024 -177.442 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.632 HG11 ' CE ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -110.55 147.04 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.172 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.696 ' CG1' HG21 ' A' ' 52' ' ' ILE . 58.1 t -128.5 106.18 14.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.15 -0.968 . . . . 0.0 110.093 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.569 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.3 mm-40 -97.16 84.06 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.779 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -96.47 128.17 43.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.153 -0.967 . . . . 0.0 110.201 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -144.76 143.51 30.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 110.07 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -58.55 81.52 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 109.542 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 159.02 -40.11 0.49 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -139.94 173.81 11.15 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-O 121.835 0.826 . . . . 0.0 110.984 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.954 ' CE2' HG22 ' A' ' 48' ' ' ILE . 13.4 t90 -138.92 83.29 1.95 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.756 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.3 m95 -104.87 120.55 41.68 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.111 -0.993 . . . . 0.0 112.379 -177.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.548 ' CG1' ' HA ' ' A' ' 69' ' ' VAL . 1.1 mt -130.61 141.74 45.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.097 -1.002 . . . . 0.0 109.283 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.632 ' CE ' HG11 ' A' ' 68' ' ' VAL . 2.1 ptpt -114.12 134.17 55.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 110.028 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.505 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -120.16 148.91 43.05 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.317 -0.864 . . . . 0.0 109.838 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.46 ' HA ' ' CB ' ' A' ' 37' ' ' ALA . 1.4 m-20 -95.43 53.3 1.47 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.168 -0.958 . . . . 0.0 110.379 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.413 ' O ' ' OG ' ' A' ' 126' ' ' SER . . . -170.16 -116.79 0.39 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -121.39 146.61 46.7 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.169 -1.195 . . . . 0.0 110.165 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.943 ' CG1' HD22 ' A' ' 40' ' ' LEU . 5.5 tp -133.53 159.72 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.042 -1.036 . . . . 0.0 110.698 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.49 ' HG2' ' OG1' ' A' ' 123' ' ' THR . 16.9 mt-10 -137.56 130.32 30.06 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.325 -0.86 . . . . 0.0 110.793 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.763 HG23 HD21 ' A' ' 42' ' ' LEU . 1.7 mm -86.37 -176.1 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.333 -0.854 . . . . 0.0 109.82 179.699 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.551 ' H ' HG22 ' A' ' 86' ' ' ILE . 4.6 m-20 -156.54 154.8 30.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 110.869 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.823 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -150.13 -25.39 0.25 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.361 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.434 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -39.52 -45.24 1.54 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.936 -1.103 . . . . 0.0 111.032 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.497 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 1.2 tp10 -54.34 -60.6 3.12 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.345 -0.847 . . . . 0.0 109.844 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.569 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -42.28 -31.71 0.42 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.5 -0.75 . . . . 0.0 109.836 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.701 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -72.09 -41.78 53.19 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.497 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 7.7 mt-10 -55.82 -24.74 38.04 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.103 -1.234 . . . . 0.0 108.29 179.105 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.754 HD23 ' CD2' ' A' ' 95' ' ' LEU . 15.4 tp -87.05 -70.95 0.58 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 121.277 0.561 . . . . 0.0 110.01 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.754 ' CD2' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -87.27 -29.82 21.36 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.653 179.821 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 62.5 46.36 93.95 Favored Glycine 0 N--CA 1.499 2.844 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.145 177.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.761 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 0.1 OUTLIER -143.69 -128.58 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.262 0 O-C-N 120.901 -1.352 . . . . 0.0 109.636 178.728 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.761 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.5 Cg_endo -68.9 -3.63 11.8 Favored 'Trans proline' 0 N--CA 1.499 1.852 0 CA-C-N 121.738 1.656 . . . . 0.0 110.034 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.723 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.7 p90 -30.17 -41.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.211 1.005 . . . . 0.0 111.434 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.823 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 4.4 t -53.49 -58.18 8.06 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-O 122.894 1.331 . . . . 0.0 110.082 -177.189 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 1.027 HG12 ' CD2' ' A' ' 105' ' ' LEU . 46.9 t -97.9 -37.41 6.63 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.494 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 2.9 t80 -59.6 -33.67 71.77 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 119.741 -1.849 . . . . 0.0 107.674 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.587 ' HB3' ' O ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER -76.04 -42.67 47.07 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 178.83 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.809 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.9 OUTLIER -68.01 -36.67 80.35 Favored 'General case' 0 C--O 1.209 -1.078 0 C-N-CA 117.38 -1.728 . . . . 0.0 107.563 177.933 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 1.027 ' CD2' HG12 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -46.87 -49.39 20.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.801 178.852 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.473 HD13 ' HA ' ' A' ' 106' ' ' ILE . 4.6 mm -83.87 -26.37 7.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.598 -0.689 . . . . 0.0 110.355 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.604 ' O ' HD22 ' A' ' 42' ' ' LEU . 1.2 p30 -104.34 18.37 22.28 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.176 -0.953 . . . . 0.0 110.7 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.785 HG21 ' CE2' ' A' ' 122' ' ' PHE . 8.4 p -121.56 -12.39 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 120.894 -1.129 . . . . 0.0 109.733 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -36.67 -27.31 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.499 -0.751 . . . . 0.0 112.222 -178.969 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.775 ' HB2' HG13 ' A' ' 39' ' ' VAL . 54.4 p -86.06 34.05 0.61 Allowed 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.619 -1.3 . . . . 0.0 109.254 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.51 ' HB ' HG22 ' A' ' 108' ' ' VAL . 9.9 t -107.12 50.05 0.78 Allowed 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.645 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 66.4 t -80.75 -33.32 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.642 -0.661 . . . . 0.0 111.496 -178.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -66.92 -78.97 0.23 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.773 ' O ' HG23 ' A' ' 124' ' ' ILE . 0.4 OUTLIER -135.21 175.8 9.25 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.364 -1.08 . . . . 0.0 109.996 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.709 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -167.39 75.16 0.14 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.905 -1.122 . . . . 0.0 111.226 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.629 ' HB2' HG22 ' A' ' 123' ' ' THR . 0.4 OUTLIER -77.76 116.72 18.5 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.189 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.49 HG22 ' H ' ' A' ' 119' ' ' GLY . 17.1 m -79.23 129.02 34.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.063 . . . . 0.0 110.478 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.568 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.4 OUTLIER -104.04 45.62 0.95 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.383 -0.823 . . . . 0.0 110.386 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.49 ' H ' HG22 ' A' ' 117' ' ' THR . . . 65.37 -58.52 0.11 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.568 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.3 OUTLIER -115.69 -12.72 11.5 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.885 -0.774 . . . . 0.0 110.995 -179.473 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 63.2 mttt -124.2 178.71 5.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.971 -1.081 . . . . 0.0 111.294 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.785 ' CE2' HG21 ' A' ' 108' ' ' VAL . 2.5 t80 -126.85 146.61 50.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.589 -0.695 . . . . 0.0 109.194 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.629 HG22 ' HB2' ' A' ' 116' ' ' TYR . 0.9 OUTLIER -134.8 123.03 22.91 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 120.678 -1.264 . . . . 0.0 110.688 -179.701 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.773 HG23 ' O ' ' A' ' 114' ' ' ARG . 3.4 mp -124.39 168.51 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.691 HG22 ' HB3' ' A' ' 114' ' ' ARG . 9.0 t -159.09 154.87 26.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.555 -1.34 . . . . 0.0 111.518 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.598 ' OG ' HG12 ' A' ' 38' ' ' VAL . 0.7 OUTLIER -94.61 -49.99 5.39 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.627 -0.671 . . . . 0.0 109.986 179.753 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' A' ' 128' ' ' LEU . 41.5 mt-10 -81.29 144.0 31.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 110.222 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.731 HD23 ' H ' ' A' ' 128' ' ' LEU . 0.7 OUTLIER . . . . . 0 C--N 1.304 -1.394 0 O-C-N 121.574 -0.704 . . . . 0.0 110.519 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 37' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.216 0.531 . . . . 0.0 110.017 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.678 ' O ' HG23 ' A' ' 38' ' ' VAL . 1.5 m-80 61.4 -76.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.212 -0.93 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -36.45 127.31 0.81 Allowed 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 121.372 0.606 . . . . 0.0 111.083 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.743 HG11 HG22 ' A' ' 124' ' ' ILE . 15.7 t -129.95 141.38 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 109.698 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.568 ' O ' ' HB2' ' A' ' 110' ' ' SER . 4.0 p -107.95 133.13 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 120.945 -1.097 . . . . 0.0 111.205 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.697 HD11 HG13 ' A' ' 86' ' ' ILE . 4.8 tp -105.4 143.51 33.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.793 HG13 ' CD1' ' A' ' 77' ' ' TRP . 11.4 t -139.84 129.2 28.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 O-C-N 120.462 -1.399 . . . . 0.0 111.909 -178.187 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.862 HD23 ' CG ' ' A' ' 107' ' ' ASN . 11.3 mt -135.42 -172.16 3.01 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.301 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.477 ' O ' ' N ' ' A' ' 45' ' ' SER . 8.0 ptm -100.31 151.96 20.88 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.827 -1.171 . . . . 0.0 110.466 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.471 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -48.14 89.28 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.468 -0.77 . . . . 0.0 111.543 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 43' ' ' MET . 29.6 t -65.1 -88.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.175 -0.953 . . . . 0.0 109.531 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.439 ' H ' HD13 ' A' ' 48' ' ' ILE . 5.1 m-20 -151.78 -77.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.879 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.469 ' O ' HG12 ' A' ' 51' ' ' ILE . 4.1 mt-10 -96.07 34.28 1.59 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.356 -0.84 . . . . 0.0 110.979 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.815 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.39 -64.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.792 -1.193 . . . . 0.0 111.633 -178.98 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.48 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -44.58 -38.12 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 118.702 -1.199 . . . . 0.0 108.746 179.354 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.469 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.79 -49.03 19.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.53 -0.732 . . . . 0.0 110.25 178.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.815 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.04 -51.03 28.17 Favored 'Isoleucine or valine' 0 C--O 1.191 -1.995 0 O-C-N 120.703 -1.248 . . . . 0.0 109.313 179.341 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.929 HG21 HG13 ' A' ' 69' ' ' VAL . 41.9 mm -45.53 -39.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.097 -1.627 . . . . 0.0 108.155 177.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.624 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 48.1 tt0 -62.72 -63.48 1.2 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -81.62 -8.19 59.68 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.289 -0.882 . . . . 0.0 111.398 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.788 HG23 HG23 ' A' ' 56' ' ' VAL . 4.7 tp -107.09 -33.72 2.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 CA-C-O 121.776 0.798 . . . . 0.0 110.137 -179.198 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.788 HG23 HG23 ' A' ' 55' ' ' ILE . 3.0 t -117.88 -44.83 3.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 C-N-CA 120.041 -0.664 . . . . 0.0 112.627 -177.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.845 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -60.69 -36.82 79.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.364 -1.46 . . . . 0.0 109.033 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.845 ' N ' HD23 ' A' ' 57' ' ' LEU . 2.8 tmtt? -100.93 -44.67 5.67 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.821 0.819 . . . . 0.0 109.037 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -69.2 -52.24 23.75 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.593 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.66 -43.85 73.9 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.822 -1.399 . . . . 0.0 110.155 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.599 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 12.9 ttmt -63.15 9.23 0.05 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.522 -0.987 . . . . 0.0 113.196 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.62 -63.8 1.03 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.225 -1.547 . . . . 0.0 108.854 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.12 -21.43 17.34 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 177.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.599 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -68.61 124.1 89.27 Favored Pre-proline 0 C--N 1.301 -1.514 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.911 -179.648 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.45 ' O ' ' OG ' ' A' ' 66' ' ' SER . 48.7 Cg_endo -65.38 -48.23 3.55 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.093 1.862 . . . . 0.0 111.953 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.488 ' C ' HD12 ' A' ' 67' ' ' ILE . 4.8 m -164.49 106.92 0.88 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 123.322 1.534 . . . . 0.0 109.539 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.691 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -100.36 163.69 2.91 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.549 0 CA-C-N 113.358 -1.747 . . . . 0.0 111.384 -176.547 . . . . . . . . 4 4 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.625 HG12 ' HG2' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -119.12 160.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.179 -0.951 . . . . 0.0 110.904 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.929 HG13 HG21 ' A' ' 52' ' ' ILE . 98.4 t -133.22 107.26 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.448 -0.782 . . . . 0.0 109.59 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.0 mm-40 -94.41 125.08 38.83 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.344 -0.848 . . . . 0.0 110.543 -179.426 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -134.45 117.55 16.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.029 -1.044 . . . . 0.0 109.967 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 44' ' ' LYS . 0.5 OUTLIER -136.13 161.49 35.56 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.176 -0.953 . . . . 0.0 110.235 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -48.61 106.12 0.09 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 110.11 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.579 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . 71.44 41.73 57.69 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.579 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 49.2 m-85 -160.8 102.52 1.32 Allowed 'General case' 0 C--N 1.29 -2.008 0 O-C-N 121.997 -0.708 . . . . 0.0 110.445 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.709 ' CD2' HG21 ' A' ' 48' ' ' ILE . 12.0 t90 -105.1 73.95 1.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.793 ' CD1' HG13 ' A' ' 41' ' ' VAL . 16.1 m0 -94.44 142.15 27.76 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.525 0.679 . . . . 0.0 111.047 -178.404 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.61 ' CD1' ' CD1' ' A' ' 76' ' ' TRP . 0.8 OUTLIER -147.25 139.49 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.137 -0.977 . . . . 0.0 109.476 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.625 ' HG2' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -115.97 129.74 56.51 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 110.291 -179.585 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.625 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -110.63 154.64 23.51 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 120.104 -0.638 . . . . 0.0 109.809 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.42 ' HB2' HD12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -97.94 43.55 1.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.985 -1.072 . . . . 0.0 110.146 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -171.69 -114.89 0.34 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -114.63 165.17 13.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.419 -1.048 . . . . 0.0 109.206 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.588 HG23 ' O ' ' A' ' 84' ' ' ILE . 4.4 tp -151.05 114.33 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.74 -1.225 . . . . 0.0 111.113 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -74.93 154.64 38.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.378 -0.826 . . . . 0.0 110.232 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.777 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.2 OUTLIER -161.01 130.12 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.131 -0.98 . . . . 0.0 110.695 -179.894 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.777 ' N ' HD13 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -128.87 173.61 10.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.888 . . . . 0.0 110.831 -179.964 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 1.019 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.06 -28.86 0.19 Allowed 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.041 178.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.532 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -41.51 -53.51 3.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 0.0 109.722 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.44 -57.41 7.03 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.563 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.45 -30.82 54.03 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.699 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.547 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -64.7 -56.2 18.23 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 108.359 -1.897 . . . . 0.0 108.359 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -62.47 -14.37 40.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.478 -1.013 . . . . 0.0 109.469 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.793 ' C ' HD23 ' A' ' 94' ' ' LEU . 5.1 tt -75.92 -57.66 3.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.783 . . . . 0.0 109.039 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.601 HD13 ' CB ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -93.72 -35.51 12.76 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.124 179.477 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -160.57 -71.49 0.02 OUTLIER Glycine 0 N--CA 1.491 2.319 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.214 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.561 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 164.95 -59.44 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.552 -0.969 . . . . 0.0 109.848 -179.769 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.0 Cg_endo -68.41 -17.28 44.08 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 124.068 1.562 . . . . 0.0 109.836 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.601 ' CB ' HD13 ' A' ' 95' ' ' LEU . 2.3 t80 -49.14 -50.3 38.2 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.078 -1.049 . . . . 0.0 108.416 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' SER . . . . . 1.019 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 4.5 m -30.23 -57.51 0.19 Allowed 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.703 0.763 . . . . 0.0 111.574 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 1.055 HG12 HD23 ' A' ' 105' ' ' LEU . 43.7 t -84.07 -54.47 8.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 121.513 -0.742 . . . . 0.0 112.685 -178.43 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.549 ' HA ' ' HB2' ' A' ' 105' ' ' LEU . 2.0 t80 -51.32 -40.05 58.24 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 119.7 -1.875 . . . . 0.0 107.045 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.541 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 21.6 t70 -57.14 -46.89 82.32 Favored 'General case' 0 N--CA 1.486 1.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.666 178.19 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.805 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.2 pp -80.2 -29.3 38.58 Favored 'General case' 0 C--O 1.201 -1.459 0 C-N-CA 117.921 -1.512 . . . . 0.0 108.245 179.109 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 1.055 HD23 HG12 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -49.67 -24.74 2.41 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 120.113 -1.617 . . . . 0.0 109.523 178.49 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.2 mp -103.51 -37.42 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.359 -0.838 . . . . 0.0 110.441 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.862 ' CG ' HD23 ' A' ' 42' ' ' LEU . 3.6 p30 -99.52 -13.02 19.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.909 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.815 HG22 ' CG2' ' A' ' 111' ' ' THR . 5.2 p -66.7 -8.99 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 109.811 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.9 OUTLIER -39.99 -24.35 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.689 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.581 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 1.2 p -72.92 9.65 1.11 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.138 -0.976 . . . . 0.0 110.51 178.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.815 ' CG2' HG22 ' A' ' 108' ' ' VAL . 2.2 p -85.69 26.26 0.98 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.694 -1.254 . . . . 0.0 110.936 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 6.9 p -57.05 -18.63 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.968 -1.082 . . . . 0.0 109.375 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.499 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -98.79 50.89 1.21 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.119 -1.592 . . . . 0.0 109.119 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.499 ' C ' ' O ' ' A' ' 113' ' ' GLY . 12.1 ttm180 28.81 95.87 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.494 0.664 . . . . 0.0 111.526 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.552 ' HB2' HG22 ' A' ' 111' ' ' THR . . . -74.84 124.85 27.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.41 -0.806 . . . . 0.0 111.147 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' THR . 1.8 t80 -69.72 115.73 9.29 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.469 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.459 ' O ' HD12 ' A' ' 118' ' ' LEU . 23.3 m -79.0 164.36 24.44 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.081 -1.012 . . . . 0.0 111.553 -178.066 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.568 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -144.79 48.88 1.31 Allowed 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.08 -60.6 0.22 Allowed Glycine 0 N--CA 1.483 1.775 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.568 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.2 t -117.43 -17.87 9.96 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.849 -0.794 . . . . 0.0 111.529 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.567 ' HG3' HG22 ' A' ' 120' ' ' THR . 13.5 mtmt -122.94 161.4 24.25 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 120.76 -1.212 . . . . 0.0 110.534 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.717 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -134.95 162.28 32.87 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.966 -1.084 . . . . 0.0 109.218 178.653 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.535 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.7 OUTLIER -141.8 118.61 11.12 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.915 -1.116 . . . . 0.0 110.599 -178.807 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.743 HG22 HG11 ' A' ' 38' ' ' VAL . 2.3 mp -87.02 132.84 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.552 -0.718 . . . . 0.0 109.82 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 9.5 t -156.93 159.16 37.84 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.109 -0.995 . . . . 0.0 110.629 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.432 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 1.1 t -82.4 -86.0 0.11 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.108 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' A' ' 128' ' ' LEU . 3.6 mp0 -94.92 -172.24 2.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.257 -0.902 . . . . 0.0 110.091 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.478 ' O ' ' O ' ' A' ' 127' ' ' GLU . 26.4 mt . . . . . 0 C--N 1.306 -1.323 0 O-C-N 121.466 -0.771 . . . . 0.0 110.589 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.486 ' O ' ' N ' ' A' ' 37' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.119 0.485 . . . . 0.0 110.523 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 90.5 m-20 53.09 -90.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 110.065 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -38.54 157.94 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.55 -0.719 . . . . 0.0 110.444 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.552 HG21 ' CG2' ' A' ' 124' ' ' ILE . 4.5 p -131.56 131.41 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -0.95 . . . . 0.0 110.266 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.601 HG12 HG21 ' A' ' 112' ' ' VAL . 8.9 p -91.29 168.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.298 -0.876 . . . . 0.0 110.495 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.558 ' HB2' HG12 ' A' ' 84' ' ' ILE . 13.7 tp -134.23 134.23 41.78 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.667 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.774 ' O ' HD22 ' A' ' 42' ' ' LEU . 14.9 t -136.95 127.52 40.32 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 O-C-N 120.462 -1.399 . . . . 0.0 110.707 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.774 HD22 ' O ' ' A' ' 41' ' ' VAL . 1.0 OUTLIER -131.39 -174.03 3.28 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.55 -0.86 . . . . 0.0 108.94 178.923 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.425 ' O ' ' N ' ' A' ' 45' ' ' SER . 3.1 ptm -82.6 157.99 23.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.89 -1.131 . . . . 0.0 110.185 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.498 ' CE ' ' OD1' ' A' ' 46' ' ' ASP . 8.3 ptmt -47.01 94.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 111.259 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.667 ' HB3' HG23 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -78.08 4.24 12.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.297 -0.877 . . . . 0.0 110.387 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.502 ' N ' ' CD1' ' A' ' 48' ' ' ILE . 35.1 m-20 64.2 -67.95 0.1 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.52 -0.738 . . . . 0.0 112.681 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.555 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.5 mt-10 -80.33 16.71 1.22 Allowed 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.866 -1.146 . . . . 0.0 112.555 -177.544 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.938 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -65.41 -68.24 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 120.531 -1.356 . . . . 0.0 111.438 -179.303 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.548 ' C ' ' O ' ' A' ' 48' ' ' ILE . 12.8 t70 -38.5 -31.61 0.06 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 119.048 -1.061 . . . . 0.0 108.635 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.25 -56.57 4.25 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.612 -0.68 . . . . 0.0 109.765 178.051 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.84 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.02 -43.19 67.79 Favored 'Isoleucine or valine' 0 C--O 1.195 -1.786 0 O-C-N 120.903 -1.123 . . . . 0.0 109.873 179.533 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.644 HG21 ' CG1' ' A' ' 69' ' ' VAL . 50.3 mm -52.9 -47.69 52.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.804 0 O-C-N 119.668 -1.895 . . . . 0.0 107.226 177.53 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.812 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.1 tm-20 -57.61 -57.29 13.37 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.37 -0.831 . . . . 0.0 110.389 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -78.3 -20.33 51.74 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.335 -0.853 . . . . 0.0 112.667 -178.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.586 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 mm -106.17 -30.45 2.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 O-C-N 120.983 -1.073 . . . . 0.0 110.903 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.6 ' CG2' ' HA ' ' A' ' 52' ' ' ILE . 17.2 t -115.24 -42.15 3.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 1.053 HD22 ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -68.17 -31.12 70.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.517 -1.365 . . . . 0.0 109.152 -179.89 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.554 ' N ' HD13 ' A' ' 57' ' ' LEU . 6.0 mttt -107.58 -43.89 4.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.429 -0.794 . . . . 0.0 109.483 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.69 -43.5 6.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.583 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.61 -64.7 2.84 Favored Glycine 0 N--CA 1.491 2.343 0 O-C-N 121.091 -1.241 . . . . 0.0 110.155 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.625 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.3 OUTLIER -59.73 3.51 0.05 Allowed 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.575 -0.956 . . . . 0.0 112.681 -179.506 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -55.32 -64.25 0.9 Allowed 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.657 -1.277 . . . . 0.0 109.02 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -90.72 -23.29 20.74 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.073 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.625 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 3.0 m-20 -69.0 134.8 89.65 Favored Pre-proline 0 C--N 1.3 -1.587 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.672 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -63.0 -45.32 13.04 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.111 1.874 . . . . 0.0 111.299 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.607 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.2 OUTLIER 179.12 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.307 0 CA-C-O 122.999 1.38 . . . . 0.0 109.916 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.866 HG23 ' O ' ' A' ' 79' ' ' LYS 0.297 1.2 mp -101.48 140.2 20.77 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.475 0 CA-C-N 113.911 -1.495 . . . . 0.0 111.415 -177.361 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.595 ' CB ' ' HB3' ' A' ' 79' ' ' LYS . 1.2 t -96.73 132.9 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.785 . . . . 0.0 109.814 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.644 ' CG1' HG21 ' A' ' 52' ' ' ILE . 58.3 t -114.23 92.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.184 -0.948 . . . . 0.0 110.341 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.702 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.0 mm-40 -87.39 73.04 9.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.456 -0.777 . . . . 0.0 110.135 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASP . . . . . 0.493 ' OD2' ' HB2' ' A' ' 49' ' ' ASP . 52.8 t0 -81.91 122.44 27.75 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.936 -1.103 . . . . 0.0 110.637 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.1 OUTLIER -132.76 135.86 45.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.733 179.564 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.08 -26.57 0.16 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.145 -0.972 . . . . 0.0 109.964 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . -80.76 -50.23 5.35 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -144.61 157.96 43.98 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.772 -0.84 . . . . 0.0 110.294 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.938 ' CD2' HG21 ' A' ' 48' ' ' ILE . 1.6 t90 -109.81 85.95 2.2 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.759 ' CD1' HG13 ' A' ' 41' ' ' VAL . 7.2 m0 -85.15 124.51 31.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.459 -0.776 . . . . 0.0 110.958 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.632 HD13 ' O ' ' A' ' 77' ' ' TRP . 3.0 mm -115.93 160.19 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.014 178.294 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.866 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -140.69 143.72 35.23 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.899 -1.125 . . . . 0.0 110.359 -178.97 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.434 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.03 139.59 19.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.301 -0.875 . . . . 0.0 109.521 179.267 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -92.98 58.54 2.98 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.09 -1.006 . . . . 0.0 110.091 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -168.89 -164.69 25.03 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.03 129.84 40.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -1.142 . . . . 0.0 109.889 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.728 HG23 ' HB ' ' A' ' 124' ' ' ILE . 3.8 tp -125.02 159.99 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.383 -0.823 . . . . 0.0 110.177 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.496 ' N ' HG13 ' A' ' 84' ' ' ILE . 12.3 mt-10 -131.29 157.19 43.98 Favored 'General case' 0 C--N 1.307 -1.241 0 O-C-N 121.006 -1.058 . . . . 0.0 111.515 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.749 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -128.97 159.32 41.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.698 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.477 ' OD2' ' HE2' ' A' ' 121' ' ' LYS . 5.3 m-20 -156.05 154.91 31.75 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.645 -1.284 . . . . 0.0 111.594 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.934 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.83 -24.28 0.19 Allowed 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.355 -0.938 . . . . 0.0 111.49 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.522 ' HA ' ' OG ' ' A' ' 100' ' ' SER . . . -41.16 -51.83 3.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.009 -1.057 . . . . 0.0 110.303 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.472 ' O ' ' HB2' ' A' ' 94' ' ' LEU . 8.8 tt0 -48.51 -37.58 17.95 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.893 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.839 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -86.39 -53.18 5.15 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.572 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -50.15 -40.08 35.89 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.507 ' HG3' ' O ' ' A' ' 89' ' ' ALA . 9.6 mt-10 -75.52 -33.38 60.72 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.667 ' C ' HD23 ' A' ' 94' ' ' LEU . 1.5 tt -51.27 -66.91 0.3 Allowed 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 177.737 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.839 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.3 OUTLIER -76.42 -59.2 2.87 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.302 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 112.3 14.7 10.44 Favored Glycine 0 N--CA 1.497 2.715 0 C-N-CA 119.021 -1.561 . . . . 0.0 109.936 178.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.611 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 0.4 OUTLIER -104.57 -166.96 0.11 Allowed Pre-proline 0 C--N 1.294 -1.835 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.343 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.611 ' HD2' ' CB ' ' A' ' 97' ' ' LYS . 38.4 Cg_endo -66.83 -0.96 5.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 N-CA-C 109.458 -1.016 . . . . 0.0 109.458 177.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.799 ' CE1' ' HB1' ' A' ' 91' ' ' ALA . 18.8 t80 -35.54 -65.54 0.24 Allowed 'General case' 0 C--N 1.314 -0.97 0 O-C-N 121.699 -0.626 . . . . 0.0 110.908 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.934 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.3 OUTLIER -29.81 -73.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.037 0.922 . . . . 0.0 111.353 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.673 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 29.9 t -77.22 -50.41 20.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.328 -0.857 . . . . 0.0 113.254 -178.145 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.598 ' CD1' ' HB2' ' A' ' 98' ' ' PRO . 3.7 m-85 -51.72 -43.07 62.71 Favored 'General case' 0 C--N 1.292 -1.899 0 O-C-N 119.704 -1.872 . . . . 0.0 108.15 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.569 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 13.8 t70 -60.4 -40.05 89.53 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.592 -0.692 . . . . 0.0 110.421 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.941 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.3 pp -82.36 -39.8 22.26 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 117.816 -1.554 . . . . 0.0 109.04 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.941 ' N ' HD12 ' A' ' 104' ' ' LEU . 56.3 mt -51.94 -19.71 1.94 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.824 -1.172 . . . . 0.0 110.459 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.3 mp -102.44 -42.75 8.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.148 -0.97 . . . . 0.0 109.864 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.683 ' CG ' HD13 ' A' ' 42' ' ' LEU . 4.7 p30 -88.03 -13.18 42.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.287 -0.883 . . . . 0.0 110.141 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.807 HG13 HG23 ' A' ' 111' ' ' THR . 2.6 t -64.48 -5.88 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.923 -1.11 . . . . 0.0 110.195 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.461 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.49 -28.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.9 -0.5 . . . . 0.0 111.978 -179.567 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.585 ' HB3' HG23 ' A' ' 41' ' ' VAL . 35.1 p -75.3 15.88 0.4 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.77 -1.206 . . . . 0.0 110.581 178.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.807 HG23 HG13 ' A' ' 108' ' ' VAL . 0.0 OUTLIER -58.06 -66.61 0.45 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 118.389 -1.325 . . . . 0.0 109.881 -179.032 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.601 HG21 HG12 ' A' ' 39' ' ' VAL . 4.9 t 63.23 -67.32 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.476 -0.765 . . . . 0.0 110.024 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -93.82 51.81 2.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.435 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.516 ' HG2' ' N ' ' A' ' 115' ' ' ALA . 0.5 OUTLIER 47.01 176.33 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 O-C-N 121.579 -0.953 . . . . 0.0 111.016 179.162 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.66 ' HB2' HG22 ' A' ' 111' ' ' THR . . . -148.9 115.57 5.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.893 -1.13 . . . . 0.0 111.229 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.421 ' O ' ' HB ' ' A' ' 123' ' ' THR . 0.2 OUTLIER -76.26 112.53 12.84 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.334 -0.854 . . . . 0.0 108.887 178.678 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.3 m -79.49 125.12 29.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.072 -1.017 . . . . 0.0 110.851 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.576 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -92.3 50.34 1.62 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.412 -0.805 . . . . 0.0 110.042 179.38 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.4 -58.73 0.18 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.576 ' N ' ' O ' ' A' ' 118' ' ' LEU . 18.4 p -115.72 -8.83 12.0 Favored 'General case' 0 C--N 1.291 -1.94 0 O-C-N 122.009 -0.701 . . . . 0.0 110.613 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.477 ' HE2' ' OD2' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -122.95 -170.53 2.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.048 -1.033 . . . . 0.0 111.836 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.822 ' HD2' HD11 ' A' ' 124' ' ' ILE 0.269 1.8 t80 -139.33 147.16 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.078 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.624 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.9 OUTLIER -139.77 121.66 15.54 Favored 'General case' 0 C--N 1.308 -1.238 0 O-C-N 120.506 -1.371 . . . . 0.0 110.543 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.822 HD11 ' HD2' ' A' ' 122' ' ' PHE . 3.9 mp -118.09 142.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 109.939 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 1.8 t -144.93 136.93 25.82 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.083 -1.011 . . . . 0.0 110.421 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.482 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 0.4 OUTLIER -59.67 -84.98 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.27 -0.894 . . . . 0.0 110.492 -179.855 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.482 ' N ' ' OG ' ' A' ' 126' ' ' SER . 20.4 mt-10 -61.56 171.19 1.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.513 HD23 ' HA ' ' A' ' 128' ' ' LEU . 6.0 mt . . . . . 0 C--N 1.306 -1.307 0 O-C-N 121.461 -0.774 . . . . 0.0 111.108 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.225 0.535 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 126' ' ' SER . 35.3 m120 45.85 -100.34 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.177 -0.952 . . . . 0.0 110.054 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.46 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.29 143.81 0.12 Allowed 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.169 -0.957 . . . . 0.0 110.541 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.521 HG12 ' O ' ' A' ' 80' ' ' ALA . 3.4 p -108.36 137.26 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.182 -0.949 . . . . 0.0 110.484 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.977 HG13 ' HB2' ' A' ' 110' ' ' SER . 5.8 p -112.74 136.2 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.067 -1.021 . . . . 0.0 110.491 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.625 HD13 HG12 ' A' ' 86' ' ' ILE . 11.0 tp -105.17 141.75 36.17 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.868 HG13 ' NE1' ' A' ' 77' ' ' TRP . 2.3 t -143.19 127.24 14.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 118.248 -1.381 . . . . 0.0 112.072 -177.277 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.71 HD22 ' O ' ' A' ' 41' ' ' VAL . 2.7 mm? -129.48 -168.46 1.95 Allowed 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.009 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.502 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -103.33 167.43 9.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.071 179.254 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.409 ' HG3' ' H ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -51.03 103.29 0.05 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.277 -0.89 . . . . 0.0 110.812 -179.378 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.579 ' HB3' HD12 ' A' ' 48' ' ' ILE . 18.9 t -87.74 -116.76 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.272 -0.892 . . . . 0.0 109.985 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.53 ' N ' HD13 ' A' ' 48' ' ' ILE . 9.9 m-20 -142.11 -76.66 0.27 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.618 -1.301 . . . . 0.0 110.83 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.448 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.3 mt-10 -95.09 35.57 1.27 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.361 -0.837 . . . . 0.0 110.155 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.832 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.77 -66.45 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.251 -0.906 . . . . 0.0 111.274 -179.171 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -41.25 -40.57 1.65 Allowed 'General case' 0 C--N 1.284 -2.271 0 C-N-CA 119.106 -1.038 . . . . 0.0 108.96 179.213 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' N ' ' OD1' ' A' ' 49' ' ' ASP . . . -74.57 -50.35 18.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.592 -0.692 . . . . 0.0 110.401 178.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.832 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -72.12 -49.64 42.27 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.079 0 O-C-N 120.553 -1.342 . . . . 0.0 109.488 179.454 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.731 ' HA ' HG22 ' A' ' 55' ' ' ILE . 40.3 mm -46.59 -38.07 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.028 -1.67 . . . . 0.0 108.246 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 0.6 OUTLIER -64.3 -62.81 1.37 Allowed 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.105 -0.997 . . . . 0.0 110.082 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -79.75 -11.28 59.85 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.367 -0.833 . . . . 0.0 111.435 -179.018 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.841 HG23 HG23 ' A' ' 56' ' ' VAL . 4.2 tp -106.05 -33.38 2.79 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.034 0 CA-C-O 121.631 0.729 . . . . 0.0 110.546 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.841 HG23 HG23 ' A' ' 55' ' ' ILE . 3.8 t -117.65 -44.56 3.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.499 -0.75 . . . . 0.0 112.479 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.5 OUTLIER -61.77 -40.83 96.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.264 -1.523 . . . . 0.0 108.542 179.964 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.781 ' N ' HD23 ' A' ' 57' ' ' LEU . 2.4 mtpt -92.37 -43.21 9.36 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.521 0.677 . . . . 0.0 109.426 178.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -75.15 -50.78 8.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.562 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.28 -59.99 5.43 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.635 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.636 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -64.99 10.31 0.08 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.56 -0.965 . . . . 0.0 112.636 -179.508 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.39 -63.98 0.95 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.453 -1.404 . . . . 0.0 108.661 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -100.35 -17.83 17.06 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.636 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 1.4 m-20 -67.99 136.88 92.03 Favored Pre-proline 0 C--N 1.301 -1.533 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.684 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -62.19 -42.81 26.93 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 122.54 2.16 . . . . 0.0 112.521 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.577 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.33 112.91 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 123.1 1.429 . . . . 0.0 110.125 -179.811 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.649 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.302 1.2 mp -101.65 147.79 8.13 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 CA-C-N 113.766 -1.561 . . . . 0.0 111.577 -177.143 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.616 ' O ' HG23 ' A' ' 78' ' ' ILE . 1.6 p -110.87 153.13 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.41 -0.806 . . . . 0.0 110.275 179.478 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.662 HG22 HG21 ' A' ' 52' ' ' ILE . 89.2 t -118.25 104.82 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.244 -0.91 . . . . 0.0 109.6 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.575 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 0.9 OUTLIER -84.05 65.2 8.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.44 -0.787 . . . . 0.0 110.729 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.24 117.24 29.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.97 -1.081 . . . . 0.0 110.249 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 5.4 tttt -146.96 143.49 28.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 110.171 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.04 96.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 109.991 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 151.64 -58.11 0.43 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.477 ' HB2' ' CD1' ' A' ' 77' ' ' TRP . 2.3 p90 -141.08 163.01 34.14 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.926 -0.749 . . . . 0.0 110.457 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.703 ' CE2' HG22 ' A' ' 48' ' ' ILE . 2.5 t90 -118.03 75.63 1.02 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.868 ' NE1' HG13 ' A' ' 41' ' ' VAL . 21.0 m0 -95.82 149.06 21.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.606 -0.684 . . . . 0.0 111.674 -178.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.616 HG23 ' O ' ' A' ' 68' ' ' VAL . 1.2 mp -146.87 130.31 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.563 -0.711 . . . . 0.0 109.151 178.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.603 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -95.89 160.77 14.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.315 -0.866 . . . . 0.0 110.515 -179.123 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.521 ' O ' HG12 ' A' ' 38' ' ' VAL . . . -150.14 141.46 23.25 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.535 -0.728 . . . . 0.0 109.905 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -107.33 50.41 0.77 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.81 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.28 -110.85 0.24 Allowed Glycine 0 C--N 1.301 -1.368 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -123.67 143.41 50.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.315 -1.109 . . . . 0.0 110.02 179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.557 HG13 ' N ' ' A' ' 85' ' ' GLU . 2.8 tp -142.82 160.66 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 109.876 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.557 ' N ' HG13 ' A' ' 84' ' ' ILE . 45.1 mt-10 -129.67 122.69 29.47 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.022 -1.049 . . . . 0.0 111.753 -179.119 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.75 ' CG1' HD11 ' A' ' 124' ' ' ILE . 0.6 OUTLIER -79.61 165.4 2.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 121.641 -0.662 . . . . 0.0 109.648 179.484 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 6.2 m-20 -155.89 139.43 15.92 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.763 -1.211 . . . . 0.0 111.549 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.874 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -152.47 -33.09 0.13 Allowed 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.753 177.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.559 ' N ' ' HB2' ' A' ' 100' ' ' SER . . . -44.09 -52.62 7.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -0.844 . . . . 0.0 110.125 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.519 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 1.3 pt-20 -57.99 -44.5 87.21 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.534 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.13 -34.65 78.54 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.532 -0.73 . . . . 0.0 109.303 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -69.24 -56.87 8.17 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.519 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.3 pt-20 -54.65 -19.56 6.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.403 -1.057 . . . . 0.0 109.368 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.846 HD23 ' N ' ' A' ' 95' ' ' LEU . 5.4 tt -78.81 -61.8 1.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.69 -0.631 . . . . 0.0 110.527 -179.441 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.846 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -77.62 -45.1 26.11 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 118.35 -1.34 . . . . 0.0 109.086 179.289 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.739 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -145.76 -75.21 0.02 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.57 ' N ' ' HD2' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 166.46 -55.88 0.0 OUTLIER Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.883 -0.775 . . . . 0.0 109.407 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.57 ' HD2' ' N ' ' A' ' 97' ' ' LYS . 46.8 Cg_endo -73.14 -21.19 20.69 Favored 'Trans proline' 0 C--N 1.307 -1.614 0 O-C-N 124.167 1.614 . . . . 0.0 110.515 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.573 ' CE2' ' OD2' ' A' ' 103' ' ' ASP . 2.8 t80 -50.06 -50.04 49.22 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.009 -1.057 . . . . 0.0 109.626 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.874 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 16.7 p -31.53 -68.76 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-O 121.875 0.845 . . . . 0.0 111.216 -179.241 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.649 ' CA ' HD23 ' A' ' 104' ' ' LEU . 1.7 t -69.41 -56.16 12.69 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 O-C-N 121.189 -0.945 . . . . 0.0 113.238 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.551 ' HA ' HD12 ' A' ' 105' ' ' LEU . 0.1 OUTLIER -50.1 -31.92 14.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.356 -1.465 . . . . 0.0 109.345 -178.865 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.573 ' OD2' ' CE2' ' A' ' 99' ' ' PHE . 5.6 t70 -76.61 -28.83 56.26 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.7 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.697 ' HG ' ' N ' ' A' ' 105' ' ' LEU . 0.0 OUTLIER -65.81 -48.74 70.7 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.16 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.697 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 1.4 mt -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.674 -1.266 . . . . 0.0 110.042 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.45 -22.78 5.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.555 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.5 p30 -108.39 -28.76 9.2 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.178 -0.951 . . . . 0.0 110.802 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.099 HG22 ' CG2' ' A' ' 111' ' ' THR . 1.6 p -70.75 0.7 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.82 -1.175 . . . . 0.0 110.719 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -36.4 -26.92 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.47 -0.769 . . . . 0.0 112.0 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.977 ' HB2' HG13 ' A' ' 39' ' ' VAL . 87.7 p -78.69 32.37 0.2 Allowed 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.758 -1.214 . . . . 0.0 110.595 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' THR . . . . . 1.099 ' CG2' HG22 ' A' ' 108' ' ' VAL . 25.4 p -94.77 44.42 1.1 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.682 -1.261 . . . . 0.0 109.323 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.48 HG23 ' N ' ' A' ' 113' ' ' GLY . 28.3 m -60.54 -37.43 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.595 -0.691 . . . . 0.0 110.804 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.48 ' N ' HG23 ' A' ' 112' ' ' VAL . . . -76.17 -75.15 0.89 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.858 ' O ' HG23 ' A' ' 124' ' ' ILE . 3.3 ttt85 -145.13 -170.75 3.5 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.312 -1.111 . . . . 0.0 110.428 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.889 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -165.88 75.0 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.035 -1.041 . . . . 0.0 110.55 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.68 ' HB2' HG22 ' A' ' 123' ' ' THR . 0.1 OUTLIER -81.41 121.5 26.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.282 -0.886 . . . . 0.0 109.644 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.717 ' C ' HD12 ' A' ' 118' ' ' LEU . 9.7 m -83.89 156.39 22.42 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.228 -0.92 . . . . 0.0 110.62 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.717 HD12 ' C ' ' A' ' 117' ' ' THR . 7.3 mp -127.91 38.5 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.357 -0.839 . . . . 0.0 110.257 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.2 -59.5 0.41 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.824 -1.711 . . . . 0.0 108.824 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.556 ' N ' ' O ' ' A' ' 118' ' ' LEU . 58.4 p -115.14 -12.71 11.87 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 122.031 -0.687 . . . . 0.0 109.824 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.505 ' CB ' ' HB2' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -121.59 -167.12 1.47 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.43 -0.794 . . . . 0.0 110.633 -179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.889 ' CZ ' ' HB1' ' A' ' 115' ' ' ALA . 16.0 t80 -153.86 164.22 38.74 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.519 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.68 HG22 ' HB2' ' A' ' 116' ' ' TYR . 0.6 OUTLIER -150.08 153.06 35.78 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.39 -1.444 . . . . 0.0 110.275 -179.154 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.858 HG23 ' O ' ' A' ' 114' ' ' ARG . 2.2 mp -141.38 145.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.51 -0.744 . . . . 0.0 109.181 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.786 HG22 ' HB3' ' A' ' 114' ' ' ARG . 11.0 t -138.86 174.21 10.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.89 -1.131 . . . . 0.0 110.534 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.53 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 69.2 p -104.66 -101.27 0.32 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.319 -0.863 . . . . 0.0 110.423 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.53 ' N ' ' OG ' ' A' ' 126' ' ' SER . 3.7 mm-40 -82.1 131.98 35.24 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.903 -1.123 . . . . 0.0 110.435 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.677 ' N ' HD12 ' A' ' 128' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.946 -0.471 . . . . 0.0 112.117 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 121.216 0.531 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.467 ' ND2' ' HG2' ' A' ' 127' ' ' GLU . 1.8 m-20 -113.59 -36.2 4.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 110.304 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.437 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.7 143.52 0.15 Allowed 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.518 -0.739 . . . . 0.0 110.774 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.583 HG13 ' HB2' ' A' ' 126' ' ' SER . 22.9 m -124.54 -174.71 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.226 -0.922 . . . . 0.0 110.373 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.734 HG13 ' HB2' ' A' ' 110' ' ' SER . 3.0 p -148.34 127.54 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.238 -0.914 . . . . 0.0 110.844 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.985 HD11 ' HB ' ' A' ' 86' ' ' ILE . 0.2 OUTLIER -88.99 127.75 35.68 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 177.817 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.865 HG22 ' CD2' ' A' ' 77' ' ' TRP . 2.7 t -121.43 117.05 51.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.883 -1.127 . . . . 0.0 111.435 -178.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.67 ' HB2' ' CE3' ' A' ' 76' ' ' TRP . 0.6 OUTLIER -119.64 159.35 24.58 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.41 -0.916 . . . . 0.0 109.475 178.254 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.539 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 9.5 ptm -92.8 27.21 2.44 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.82 -1.175 . . . . 0.0 111.381 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.872 ' HB3' HD11 ' A' ' 48' ' ' ILE . 4.1 mmtp -86.81 -90.12 0.11 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.249 -0.907 . . . . 0.0 110.408 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.569 ' HB3' ' N ' ' A' ' 75' ' ' PHE . 1.4 p 77.37 57.96 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 CA-C-O 121.877 0.846 . . . . 0.0 110.978 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.695 ' H ' HD12 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -161.58 -91.44 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.513 ' O ' HD13 ' A' ' 51' ' ' ILE . 2.1 mt-10 -54.38 -27.41 36.24 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.281 -0.887 . . . . 0.0 111.351 179.109 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 1.188 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.4 OUTLIER -74.85 -51.38 22.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 118.397 -1.321 . . . . 0.0 112.971 -176.781 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.528 ' C ' ' O ' ' A' ' 48' ' ' ILE . 14.4 t70 -42.96 -29.97 0.38 Allowed 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.366 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.44 -54.89 5.48 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.847 177.702 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.921 ' CD1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -66.9 -47.82 81.44 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.158 0 C-N-CA 117.844 -1.543 . . . . 0.0 108.226 178.773 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.955 HG12 HG22 ' A' ' 48' ' ' ILE . 45.1 mm -43.05 -40.99 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 120.374 -1.454 . . . . 0.0 107.86 176.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.655 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 2.4 tt0 -62.87 -67.7 0.4 Allowed 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.307 -0.871 . . . . 0.0 110.141 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.422 ' O ' ' OD1' ' A' ' 54' ' ' ASP . 37.0 t0 -75.72 -9.86 58.95 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 121.093 -1.004 . . . . 0.0 111.723 -178.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.838 HG23 HG23 ' A' ' 56' ' ' VAL . 3.9 tp -107.54 -34.63 2.81 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 CA-C-O 121.588 0.709 . . . . 0.0 111.224 -178.459 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.838 HG23 HG23 ' A' ' 55' ' ' ILE . 3.5 t -117.19 -42.91 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.553 -0.717 . . . . 0.0 112.45 -177.009 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.655 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 10.5 tt -42.2 -55.93 3.09 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.827 -1.17 . . . . 0.0 108.943 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.535 ' O ' ' CG ' ' A' ' 61' ' ' LYS . 1.0 OUTLIER -89.73 -49.19 6.79 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.317 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -48.91 -49.91 27.98 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.544 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -83.87 22.38 8.11 Favored Glycine 0 N--CA 1.489 2.215 0 O-C-N 121.181 -1.188 . . . . 0.0 110.185 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.535 ' CG ' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -106.44 -9.4 16.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.697 -1.472 . . . . 0.0 110.769 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.98 -84.66 0.33 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 121.098 -1.001 . . . . 0.0 110.156 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -71.03 -32.25 68.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 122.211 1.005 . . . . 0.0 108.742 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.544 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.5 OUTLIER -73.38 118.91 72.79 Favored Pre-proline 0 C--N 1.296 -1.733 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 179.65 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.488 ' HG2' ' HB2' ' A' ' 81' ' ' ASP . 45.6 Cg_endo -63.96 -43.42 15.82 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 124.146 1.603 . . . . 0.0 111.053 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.62 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.1 OUTLIER 178.76 112.09 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 CA-C-O 122.944 1.354 . . . . 0.0 109.751 179.477 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.638 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.292 1.2 mp -102.7 132.12 49.48 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.488 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.208 -177.359 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.572 ' HB ' ' HB3' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -92.11 116.16 32.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.863 179.501 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.82 ' CG1' HG21 ' A' ' 52' ' ' ILE . 67.5 t -94.88 96.99 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.146 -0.971 . . . . 0.0 110.012 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.674 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.1 mm-40 -91.51 143.15 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.298 -0.876 . . . . 0.0 110.455 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -139.78 108.91 6.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 109.795 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.71 -166.81 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.266 -0.897 . . . . 0.0 110.795 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.522 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -53.29 107.54 0.25 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 0.0 110.396 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 42.81 44.7 5.63 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.569 ' N ' ' HB3' ' A' ' 45' ' ' SER . 7.3 m-85 -144.45 86.45 1.82 Allowed 'General case' 0 C--N 1.292 -1.895 0 O-C-N 121.871 -0.781 . . . . 0.0 111.378 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 1.188 ' CE2' HG21 ' A' ' 48' ' ' ILE . 1.2 t90 -81.55 88.19 6.21 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.058 -1.026 . . . . 0.0 108.597 178.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.865 ' CD2' HG22 ' A' ' 41' ' ' VAL . 8.1 m0 -90.6 124.67 35.23 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.376 -0.828 . . . . 0.0 111.04 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.658 ' O ' HG23 ' A' ' 39' ' ' VAL . 13.8 mm -117.41 141.87 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.042 . . . . 0.0 110.16 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.572 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 1.1 ttpt -122.58 122.13 38.13 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.581 -0.7 . . . . 0.0 109.675 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -129.32 143.54 50.88 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.336 -0.853 . . . . 0.0 110.036 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.488 ' HB2' ' HG2' ' A' ' 65' ' ' PRO . 67.6 m-20 -88.18 49.81 1.87 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.057 -1.027 . . . . 0.0 109.956 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.35 -162.77 23.25 Favored Glycine 0 C--N 1.302 -1.357 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -72.6 154.36 40.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.183 -1.186 . . . . 0.0 109.791 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.612 ' CG1' HD12 ' A' ' 40' ' ' LEU . 3.0 tp -137.11 156.03 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.941 . . . . 0.0 110.235 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.516 ' N ' HG13 ' A' ' 84' ' ' ILE . 91.0 mt-10 -121.89 155.44 35.43 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.182 -0.949 . . . . 0.0 110.99 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.985 ' HB ' HD11 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -161.33 147.15 4.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.573 -0.704 . . . . 0.0 109.792 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.92 ' N ' HD13 ' A' ' 86' ' ' ILE . 3.5 m-20 -124.65 176.53 6.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.095 -1.003 . . . . 0.0 111.544 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.876 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -140.05 -14.28 1.04 Allowed 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.991 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.54 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -48.24 -45.86 34.82 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.664 -1.273 . . . . 0.0 110.971 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.558 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 18.2 tt0 -50.48 -36.15 32.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.551 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.943 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -68.17 -31.22 70.61 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.035 -1.041 . . . . 0.0 108.876 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.741 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -68.74 -61.4 4.7 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 108.599 -1.8 . . . . 0.0 108.599 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.558 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 6.0 pt-20 -45.4 -27.97 0.79 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.226 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.544 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 0.7 OUTLIER -68.59 -70.9 0.24 Allowed 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.341 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.943 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.0 OUTLIER -98.86 -46.46 5.63 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.021 -1.05 . . . . 0.0 109.224 178.99 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 93.44 51.84 2.11 Favored Glycine 0 N--CA 1.499 2.861 0 C-N-CA 120.185 -1.007 . . . . 0.0 111.538 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.721 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 30.8 pttt -145.46 -135.6 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 O-C-N 120.914 -1.345 . . . . 0.0 109.37 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.721 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.3 Cg_endo -71.7 0.17 7.42 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 CA-C-N 121.077 1.42 . . . . 0.0 108.989 178.421 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.796 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.8 p90 -25.62 -41.34 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 CA-C-O 121.823 0.821 . . . . 0.0 111.698 178.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.876 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.5 OUTLIER -55.96 -62.39 1.73 Allowed 'General case' 0 C--N 1.292 -1.895 0 CA-C-O 123.368 1.556 . . . . 0.0 108.62 -177.073 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 1.035 HG12 HD11 ' A' ' 105' ' ' LEU . 24.2 t -88.26 -42.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 CA-C-N 114.558 -1.201 . . . . 0.0 113.021 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.502 ' O ' HD13 ' A' ' 106' ' ' ILE . 5.0 t80 -52.02 -43.11 63.55 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 119.91 -1.744 . . . . 0.0 107.426 178.264 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.641 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 18.5 t70 -61.41 -47.95 83.46 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.687 -0.633 . . . . 0.0 110.065 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.736 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.5 pp -74.27 -41.16 61.68 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 116.655 -2.018 . . . . 0.0 109.738 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 1.035 HD11 HG12 ' A' ' 101' ' ' VAL . 39.2 mt -51.32 -19.23 1.21 Allowed 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.481 -1.387 . . . . 0.0 110.654 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.502 HD13 ' O ' ' A' ' 102' ' ' TYR . 0.6 OUTLIER -93.71 -49.59 12.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.123 -0.985 . . . . 0.0 110.403 -178.826 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.641 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 16.1 p30 -100.19 -11.28 20.56 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.077 -1.014 . . . . 0.0 111.471 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.661 HG22 ' HB ' ' A' ' 111' ' ' THR . 5.9 p -65.2 -6.54 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.302 -1.498 . . . . 0.0 109.947 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -33.78 -31.52 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.728 -0.607 . . . . 0.0 112.028 -179.505 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.734 ' HB2' HG13 ' A' ' 39' ' ' VAL . 28.8 p -84.69 27.89 0.7 Allowed 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 118.877 -1.129 . . . . 0.0 109.348 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.661 ' HB ' HG22 ' A' ' 108' ' ' VAL . 9.6 t -64.64 -35.9 82.51 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 110.644 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.445 ' N ' HG23 ' A' ' 111' ' ' THR . 61.8 t 52.61 -88.6 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.724 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -86.15 54.97 4.76 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.246 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.54 ' HG2' ' N ' ' A' ' 115' ' ' ALA . 1.8 ttt180 45.54 176.8 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.747 -0.855 . . . . 0.0 111.444 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -130.01 114.11 15.4 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.995 -1.066 . . . . 0.0 110.725 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.556 ' HB2' HG22 ' A' ' 123' ' ' THR . 25.7 m-85 -69.7 121.14 16.58 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.34 -0.85 . . . . 0.0 108.829 178.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.594 HG22 ' H ' ' A' ' 118' ' ' LEU . 6.2 m -79.3 178.55 8.0 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.192 -0.943 . . . . 0.0 110.734 -178.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.597 ' O ' ' N ' ' A' ' 120' ' ' THR . 1.3 tt -156.9 60.56 0.52 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.448 -0.783 . . . . 0.0 110.431 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.44 -57.44 0.05 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.057 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 118' ' ' LEU . 15.7 p -115.89 -26.97 7.15 Favored 'General case' 0 C--N 1.292 -1.925 0 O-C-N 121.64 -0.917 . . . . 0.0 111.772 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.576 ' O ' ' N ' ' A' ' 118' ' ' LEU . 1.5 pttm -132.07 -169.57 2.24 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.831 -1.168 . . . . 0.0 110.991 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.69 ' CZ ' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -149.21 -179.12 6.8 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.264 -0.897 . . . . 0.0 109.12 179.124 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.88 ' C ' HD12 ' A' ' 124' ' ' ILE . 1.1 t -155.62 165.67 35.86 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.755 -1.215 . . . . 0.0 110.186 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.88 HD12 ' C ' ' A' ' 123' ' ' THR . 4.0 mp -134.09 144.13 36.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.336 -0.852 . . . . 0.0 110.466 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.578 ' O ' HG11 ' A' ' 38' ' ' VAL . 11.9 t -123.25 -170.09 2.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.325 -0.859 . . . . 0.0 110.201 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.633 ' O ' HD23 ' A' ' 128' ' ' LEU . 2.8 t -118.72 -64.6 1.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.179 -0.951 . . . . 0.0 110.473 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' A' ' 128' ' ' LEU . 7.6 mt-10 -74.94 52.79 0.56 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.335 -0.853 . . . . 0.0 110.478 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.633 HD23 ' O ' ' A' ' 126' ' ' SER . 0.4 OUTLIER . . . . . 0 C--N 1.305 -1.364 0 O-C-N 121.2 -0.938 . . . . 0.0 110.44 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.307 0.575 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.502 ' OD1' ' N ' ' A' ' 36' ' ' ASN . 15.1 p-10 -78.66 -44.35 23.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.147 -0.971 . . . . 0.0 110.454 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.462 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.94 106.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.229 0.538 . . . . 0.0 111.284 -179.341 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.491 ' CG1' ' O ' ' A' ' 82' ' ' GLY . 4.1 p -125.84 149.79 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.317 -0.864 . . . . 0.0 109.504 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.7 p -105.82 142.44 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.01 -1.056 . . . . 0.0 111.108 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.875 ' O ' HG23 ' A' ' 41' ' ' VAL . 8.1 tp -100.93 162.07 13.15 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 177.468 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.884 HG22 ' CD2' ' A' ' 77' ' ' TRP . 3.0 t -165.77 132.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 120.658 -1.276 . . . . 0.0 111.665 -178.302 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.672 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 0.3 OUTLIER -143.06 -171.69 3.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.19 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 7.2 ptt? -98.45 153.29 18.7 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.798 -1.189 . . . . 0.0 109.899 179.526 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.531 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -53.13 95.65 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 0.0 110.982 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.494 ' HB3' HG23 ' A' ' 48' ' ' ILE . 30.5 t -72.89 -92.1 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.297 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.433 ' N ' HD13 ' A' ' 48' ' ' ILE . 36.1 t0 -157.95 -70.3 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.157 -0.964 . . . . 0.0 110.401 179.458 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.46 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.8 mt-10 -96.45 36.13 1.4 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.283 -0.885 . . . . 0.0 110.412 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.83 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -56.02 -64.34 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.997 -1.064 . . . . 0.0 111.624 -178.772 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.494 ' O ' ' HB2' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -45.44 -34.75 3.3 Favored 'General case' 0 C--N 1.285 -2.218 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.768 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.29 -49.88 12.84 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.473 -0.767 . . . . 0.0 110.341 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.83 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -71.66 -48.44 52.08 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.092 0 O-C-N 120.711 -1.243 . . . . 0.0 108.958 179.127 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.751 HG21 ' CG2' ' A' ' 69' ' ' VAL . 35.1 mm -46.97 -40.89 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.068 -1.645 . . . . 0.0 107.912 177.106 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.628 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 7.5 tt0 -61.69 -62.43 1.81 Allowed 'General case' 0 C--N 1.293 -1.855 0 O-C-N 121.163 -0.961 . . . . 0.0 110.575 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -80.2 -12.6 59.62 Favored 'General case' 0 N--CA 1.502 2.145 0 O-C-N 121.451 -0.781 . . . . 0.0 111.616 -178.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.948 HG23 HG23 ' A' ' 56' ' ' VAL . 3.8 tp -106.09 -33.27 2.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 CA-C-O 121.672 0.749 . . . . 0.0 110.659 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.948 HG23 HG23 ' A' ' 55' ' ' ILE . 14.4 t -116.57 -43.91 3.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 C-N-CA 119.91 -0.716 . . . . 0.0 112.439 -177.41 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.836 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -63.35 -35.92 81.99 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.28 -1.513 . . . . 0.0 108.937 179.978 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.836 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -94.77 -47.53 6.43 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.439 -0.788 . . . . 0.0 109.344 179.189 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.49 -45.05 8.19 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.598 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.07 -53.42 18.7 Favored Glycine 0 N--CA 1.49 2.243 0 O-C-N 121.12 -1.224 . . . . 0.0 110.05 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.625 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.9 OUTLIER -62.41 6.58 0.08 Allowed 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.459 -1.024 . . . . 0.0 112.827 -179.421 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.26 -63.84 1.01 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.518 -1.364 . . . . 0.0 108.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -97.2 -19.96 18.26 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 178.046 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.625 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 3.9 m-20 -68.43 125.92 92.17 Favored Pre-proline 0 C--N 1.301 -1.517 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.556 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.435 ' C ' ' OG ' ' A' ' 66' ' ' SER . 46.6 Cg_endo -64.45 -42.26 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 121.96 1.773 . . . . 0.0 111.136 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.577 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -177.97 110.88 0.07 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-O 123.065 1.412 . . . . 0.0 109.527 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.667 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.308 1.0 OUTLIER -103.73 145.38 12.79 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 CA-C-N 113.735 -1.575 . . . . 0.0 111.416 -176.556 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.818 HG12 ' CG ' ' A' ' 79' ' ' LYS . 1.9 p -109.41 142.28 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.055 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.751 ' CG2' HG21 ' A' ' 52' ' ' ILE . 32.4 t -108.75 117.17 53.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.239 -0.913 . . . . 0.0 110.001 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.563 ' N ' ' O ' ' A' ' 77' ' ' TRP . 1.0 OUTLIER -98.64 94.67 6.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.578 -0.701 . . . . 0.0 110.482 -179.435 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -91.37 88.91 7.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.802 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.445 ' HB2' ' HB2' ' A' ' 75' ' ' PHE . 0.3 OUTLIER -88.72 165.99 14.36 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.331 -0.856 . . . . 0.0 110.689 -179.439 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -38.22 -58.21 1.01 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.589 -0.695 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.584 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -132.03 52.51 0.82 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 74' ' ' GLY . 57.7 m-85 -159.49 103.48 1.58 Allowed 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.913 -0.757 . . . . 0.0 110.057 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.714 ' CD2' HG21 ' A' ' 48' ' ' ILE . 6.4 t90 -90.0 77.73 6.83 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.884 ' CD2' HG22 ' A' ' 41' ' ' VAL . 13.0 m0 -101.28 143.98 30.68 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.512 -0.743 . . . . 0.0 112.308 -177.767 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.69 ' HB ' HD23 ' A' ' 40' ' ' LEU . 1.6 mt -137.49 139.3 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.302 -0.874 . . . . 0.0 109.625 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.818 ' CG ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -102.19 134.85 44.79 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.467 -0.77 . . . . 0.0 110.06 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.543 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -134.43 143.8 47.77 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 110.054 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -95.15 50.29 1.26 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.068 -1.02 . . . . 0.0 110.106 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.491 ' O ' ' CG1' ' A' ' 38' ' ' VAL . . . -171.03 -169.83 34.5 Favored Glycine 0 C--N 1.3 -1.472 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -71.41 143.79 50.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -1.136 . . . . 0.0 109.682 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.817 HG23 ' CG1' ' A' ' 124' ' ' ILE . 4.2 tp -126.36 159.69 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.243 -0.911 . . . . 0.0 109.89 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.471 ' N ' HG13 ' A' ' 84' ' ' ILE . 37.0 mt-10 -123.13 151.77 41.77 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 121.01 -1.056 . . . . 0.0 111.813 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.642 HG22 ' CB ' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -121.11 168.18 13.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 121.48 -0.762 . . . . 0.0 109.226 179.259 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 56.8 m-20 -131.54 177.28 7.62 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.08 -1.013 . . . . 0.0 109.961 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 1.103 ' HB1' ' CB ' ' A' ' 100' ' ' SER . . . -151.46 -49.96 0.12 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.014 178.627 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.415 ' O ' ' N ' ' A' ' 92' ' ' GLY . . . -48.53 -47.54 39.11 Favored 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.155 -0.966 . . . . 0.0 111.168 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.412 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.3 mt-10 -48.53 -40.63 27.56 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.813 ' HB3' ' O ' ' A' ' 88' ' ' ALA . . . -53.0 -45.18 67.75 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.923 0.868 . . . . 0.0 108.909 177.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.718 ' N ' ' HB2' ' A' ' 99' ' ' PHE . . . -51.46 -40.4 46.61 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -178.419 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.412 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.8 mt-10 -64.84 -32.29 73.92 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.476 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -70.79 -64.43 0.9 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.51 -0.744 . . . . 0.0 110.048 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.618 ' H ' HD12 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -107.7 -27.36 10.35 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.191 -0.943 . . . . 0.0 110.575 -179.857 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . 65.26 62.96 4.46 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.167 178.6 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.642 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 19.3 mttt 163.0 -68.34 0.0 OUTLIER Pre-proline 0 N--CA 1.516 2.844 0 O-C-N 121.312 -1.11 . . . . 0.0 111.009 177.632 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.642 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 55.9 Cg_endo -86.36 6.59 5.37 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 N-CA-C 107.391 -1.811 . . . . 0.0 107.391 176.8 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.718 ' HB2' ' N ' ' A' ' 92' ' ' GLY . 0.1 OUTLIER -52.87 -132.08 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.014 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.874 -179.448 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 100' ' ' SER . . . . . 1.103 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 40.3 p -6.65 -55.85 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.911 HG12 ' CD1' ' A' ' 105' ' ' LEU . 1.9 t -85.75 -68.78 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -177.34 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.583 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 0.3 OUTLIER -56.83 -30.86 64.17 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 116.929 -1.908 . . . . 0.0 106.21 179.631 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.591 ' HB2' ' HA ' ' A' ' 99' ' ' PHE . 38.9 t70 -66.99 -40.86 87.46 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.214 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.941 HD12 ' N ' ' A' ' 105' ' ' LEU . 3.0 pp -83.27 -41.48 18.28 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 117.98 -1.488 . . . . 0.0 108.913 179.074 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.941 ' N ' HD12 ' A' ' 104' ' ' LEU . 0.3 OUTLIER -54.04 -16.99 2.24 Favored 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.314 -1.492 . . . . 0.0 110.011 178.673 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.403 ' HB ' ' O ' ' A' ' 102' ' ' TYR . 0.8 OUTLIER -108.74 -27.94 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 179.642 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 0.3 OUTLIER -114.12 -2.67 13.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.083 -1.01 . . . . 0.0 110.744 -179.451 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.662 ' O ' HG22 ' A' ' 111' ' ' THR . 4.1 p -81.93 -10.09 12.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.122 -0.986 . . . . 0.0 110.627 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.4 t -43.55 -20.92 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.031 -1.043 . . . . 0.0 110.345 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.591 ' CA ' ' HB ' ' A' ' 41' ' ' VAL . 92.9 p -53.05 -7.81 0.09 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.304 -0.872 . . . . 0.0 112.223 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.734 ' O ' HG12 ' A' ' 112' ' ' VAL . 0.2 OUTLIER -110.51 -84.79 0.56 Allowed 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.014 -1.474 . . . . 0.0 111.092 -178.752 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.734 HG12 ' O ' ' A' ' 111' ' ' THR . 0.4 OUTLIER 80.06 -14.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.95 -0.468 . . . . 0.0 110.317 -179.239 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -114.95 -75.45 0.63 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.944 ' HB3' HG22 ' A' ' 125' ' ' THR . 11.6 tpt180 -115.24 151.21 34.9 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.353 -1.086 . . . . 0.0 109.531 179.344 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.732 ' HB1' ' CE1' ' A' ' 122' ' ' PHE . . . -165.44 67.99 0.13 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.203 -0.936 . . . . 0.0 110.124 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.511 ' N ' ' O ' ' A' ' 123' ' ' THR . 0.6 OUTLIER -69.21 124.07 22.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.915 . . . . 0.0 109.908 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.465 ' H ' HG22 ' A' ' 117' ' ' THR . 4.3 t -94.68 131.69 40.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 110.356 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.555 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -100.19 45.9 0.97 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.452 -179.98 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.43 -59.2 0.29 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.555 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.6 OUTLIER -115.31 -10.48 12.05 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.947 -0.737 . . . . 0.0 110.3 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -120.38 -168.33 1.61 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.049 -1.032 . . . . 0.0 111.179 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.732 ' CE1' ' HB1' ' A' ' 115' ' ' ALA . 2.2 t80 -150.51 153.37 35.71 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.515 -0.741 . . . . 0.0 110.442 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.552 ' O ' HG22 ' A' ' 123' ' ' THR . 0.8 OUTLIER -142.35 115.38 8.79 Favored 'General case' 0 C--N 1.31 -1.121 0 O-C-N 120.971 -1.081 . . . . 0.0 109.851 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.817 ' CG1' HG23 ' A' ' 84' ' ' ILE . 0.1 OUTLIER -125.03 151.62 30.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.266 -0.896 . . . . 0.0 109.383 179.27 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.944 HG22 ' HB3' ' A' ' 114' ' ' ARG . 6.4 t -136.11 -168.23 2.19 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 110.265 -179.412 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.493 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 19.1 p -78.2 -106.57 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 -179.367 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 28.1 mt-10 -106.37 109.89 21.95 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.058 . . . . 0.0 110.755 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--N 1.305 -1.336 0 O-C-N 121.181 -0.95 . . . . 0.0 110.409 179.812 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.228 0.537 . . . . 0.0 110.163 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.498 ' OD1' ' HG2' ' A' ' 127' ' ' GLU . 69.4 m-80 -107.03 -41.17 5.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -0.909 . . . . 0.0 110.18 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -39.62 145.83 0.12 Allowed 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.464 -0.773 . . . . 0.0 110.415 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 3.6 m -122.92 171.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.972 . . . . 0.0 110.237 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.69 HG12 HG21 ' A' ' 112' ' ' VAL . 10.8 p -131.52 120.53 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -0.88 . . . . 0.0 110.234 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 1.078 HD12 ' CG1' ' A' ' 84' ' ' ILE . 5.5 tt -73.1 157.77 36.63 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.451 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.859 HG13 ' NE1' ' A' ' 77' ' ' TRP . 24.0 t -160.04 116.48 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 121.097 -1.002 . . . . 0.0 110.592 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.874 HD23 ' CG ' ' A' ' 107' ' ' ASN . 2.5 mt -138.02 -169.55 2.59 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.455 ' SD ' ' OD2' ' A' ' 103' ' ' ASP . 2.8 ptt? -106.77 151.02 25.72 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.952 -1.093 . . . . 0.0 109.547 178.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.506 ' HB2' ' HA2' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -44.19 103.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.262 -0.899 . . . . 0.0 111.033 -179.034 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.479 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 1.2 m -86.84 19.4 2.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -0.922 . . . . 0.0 110.286 179.526 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 2.1 m-20 68.3 -57.24 0.49 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.444 -0.785 . . . . 0.0 111.412 179.4 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.537 ' O ' HG12 ' A' ' 51' ' ' ILE . 1.6 mm-40 -94.05 31.83 1.59 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.923 -1.11 . . . . 0.0 110.948 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.861 HG22 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -59.97 -78.26 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.201 -0.937 . . . . 0.0 111.084 -178.844 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.546 ' C ' ' O ' ' A' ' 48' ' ' ILE . 6.8 m-20 -36.79 -32.63 0.04 OUTLIER 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.77 -53.41 7.98 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.766 -0.584 . . . . 0.0 109.551 177.749 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.757 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.47 -50.67 33.43 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 O-C-N 120.943 -1.098 . . . . 0.0 110.089 179.466 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.7 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 32.4 mm -49.88 -40.78 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 119.829 -1.794 . . . . 0.0 108.281 178.288 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.643 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 18.6 tt0 -62.97 -57.74 9.7 Favored 'General case' 0 C--N 1.29 -1.982 0 O-C-N 120.967 -1.083 . . . . 0.0 110.576 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -81.74 -14.51 56.38 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.296 -0.878 . . . . 0.0 111.489 -178.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.913 HG23 HG23 ' A' ' 56' ' ' VAL . 3.7 tp -105.98 -32.35 2.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 CA-C-O 121.563 0.697 . . . . 0.0 110.736 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.913 HG23 HG23 ' A' ' 55' ' ' ILE . 12.0 t -116.34 -43.31 3.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 C-N-CA 119.839 -0.744 . . . . 0.0 112.557 -177.414 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.783 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -64.32 -41.27 96.89 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.117 -1.614 . . . . 0.0 109.036 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.783 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -85.92 -41.83 14.59 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.61 0.719 . . . . 0.0 109.49 179.323 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.99 -53.0 3.28 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -70.03 -72.11 0.91 Allowed Glycine 0 N--CA 1.49 2.294 0 O-C-N 120.96 -1.318 . . . . 0.0 110.358 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.634 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -45.33 -8.41 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.597 -0.943 . . . . 0.0 113.518 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 60' ' ' GLY . . . -49.81 -65.34 0.58 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.39 -1.443 . . . . 0.0 108.502 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -89.22 -26.95 20.95 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.634 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 5.3 m-20 -67.6 112.64 10.9 Favored Pre-proline 0 C--N 1.297 -1.676 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.294 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.468 ' O ' ' OG ' ' A' ' 66' ' ' SER . 46.3 Cg_endo -64.59 -41.69 18.64 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.839 1.693 . . . . 0.0 111.355 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.638 ' C ' HD12 ' A' ' 67' ' ' ILE . 7.0 m -164.0 104.87 0.9 Allowed 'General case' 0 N--CA 1.484 1.274 0 CA-C-O 123.35 1.548 . . . . 0.0 109.777 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.655 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.312 1.1 mp -106.02 136.42 40.49 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 CA-C-N 113.314 -1.766 . . . . 0.0 110.588 -177.203 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.581 ' CG1' ' HG3' ' A' ' 79' ' ' LYS . 4.4 t -87.42 134.63 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.256 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.648 HG22 HG12 ' A' ' 78' ' ' ILE . 95.8 t -117.36 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 178.116 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.554 ' N ' ' O ' ' A' ' 77' ' ' TRP . 2.9 mm-40 -86.98 113.3 22.63 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.688 -0.633 . . . . 0.0 110.79 -178.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 71' ' ' ASP . 8.3 p-10 -123.97 112.42 17.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.312 179.012 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.446 ' O ' ' C ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -152.76 150.23 29.18 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.831 -1.168 . . . . 0.0 111.332 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 35.52 -102.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.818 -0.551 . . . . 0.0 111.036 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.506 ' HA2' ' HB2' ' A' ' 44' ' ' LYS . . . -128.84 37.48 2.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.651 ' CE2' ' CZ2' ' A' ' 77' ' ' TRP . 0.1 OUTLIER -129.77 103.23 6.7 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.698 0.761 . . . . 0.0 109.863 179.54 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.861 ' CE2' HG22 ' A' ' 48' ' ' ILE . 12.5 t90 -96.86 80.95 3.06 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.859 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.6 m0 -103.6 131.3 50.87 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.317 -0.865 . . . . 0.0 112.68 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.682 HD11 ' HE1' ' A' ' 76' ' ' TRP . 2.1 mt -128.14 130.28 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.104 -0.998 . . . . 0.0 109.437 177.329 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.581 ' HG3' ' CG1' ' A' ' 68' ' ' VAL . 1.9 mtpt -97.86 136.44 38.17 Favored 'General case' 0 C--N 1.295 -1.798 0 C-N-CA 119.748 -0.781 . . . . 0.0 109.779 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.474 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -140.5 140.81 35.37 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 110.003 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -93.91 50.05 1.39 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.165 -0.959 . . . . 0.0 110.302 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.72 -167.89 31.72 Favored Glycine 0 C--N 1.3 -1.46 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.9 129.65 39.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.152 -1.205 . . . . 0.0 110.13 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 1.078 ' CG1' HD12 ' A' ' 40' ' ' LEU . 8.2 tp -120.67 123.97 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.165 -0.96 . . . . 0.0 110.585 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -87.22 161.67 17.89 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.283 -0.886 . . . . 0.0 111.257 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.857 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -161.46 149.01 4.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 O-C-N 121.254 -0.904 . . . . 0.0 110.704 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.857 ' N ' HD13 ' A' ' 86' ' ' ILE . 2.1 m-20 -152.14 171.1 18.43 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.088 -1.008 . . . . 0.0 111.341 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.968 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.24 -37.48 0.13 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.881 -0.728 . . . . 0.0 110.158 177.637 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.544 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -39.51 -46.87 1.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.622 -0.674 . . . . 0.0 110.312 -179.267 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.609 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 8.9 mt-10 -65.85 -52.06 53.57 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.813 0.816 . . . . 0.0 109.436 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 95' ' ' LEU . . . -54.25 -30.88 51.89 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 110.254 179.686 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.523 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -75.38 -56.43 4.68 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.609 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 3.2 pt-20 -50.14 -20.75 1.08 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.255 -1.144 . . . . 0.0 109.706 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 1.015 HD23 ' N ' ' A' ' 95' ' ' LEU . 1.4 tt -86.44 -65.91 0.96 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.976 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 1.095 HD11 ' CB ' ' A' ' 99' ' ' PHE . 3.4 pp -70.06 -44.62 68.77 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.134 -0.979 . . . . 0.0 110.74 -179.566 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.853 ' N ' HD12 ' A' ' 95' ' ' LEU . . . -149.14 -76.06 0.02 OUTLIER Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.186 -1.483 . . . . 0.0 109.807 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.579 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 11.7 mttt 164.68 -63.09 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.917 0 O-C-N 121.843 -0.798 . . . . 0.0 109.989 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.3 Cg_endo -71.87 -18.51 28.07 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.764 1.402 . . . . 0.0 108.945 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 1.095 ' CB ' HD11 ' A' ' 95' ' ' LEU . 3.2 t80 -44.17 -52.09 7.62 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.787 0.803 . . . . 0.0 109.434 179.129 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.968 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 50.6 m -34.16 -58.26 0.46 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.728 0.775 . . . . 0.0 111.856 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.723 HG12 HD11 ' A' ' 105' ' ' LEU . 14.5 t -81.97 -50.43 16.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.453 ' C ' ' O ' ' A' ' 101' ' ' VAL . 4.3 t80 -49.48 -41.22 39.9 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 119.867 -1.77 . . . . 0.0 107.526 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.579 ' OD1' ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -62.73 -43.64 98.27 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 121.602 -0.686 . . . . 0.0 110.146 178.903 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.756 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.1 pp -78.6 -38.9 38.87 Favored 'General case' 0 C--O 1.202 -1.4 0 C-N-CA 117.24 -1.784 . . . . 0.0 109.004 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.756 ' N ' HD12 ' A' ' 104' ' ' LEU . 63.2 mt -53.04 -16.29 1.06 Allowed 'General case' 0 C--N 1.29 -1.99 0 O-C-N 119.074 -2.266 . . . . 0.0 109.35 177.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.415 ' N ' ' C ' ' A' ' 104' ' ' LEU . 0.4 OUTLIER -118.06 -26.67 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.22 -0.925 . . . . 0.0 109.169 179.182 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.874 ' CG ' HD23 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -113.34 -3.8 13.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.375 -0.828 . . . . 0.0 110.26 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.687 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.1 p -60.46 -12.06 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.919 -1.113 . . . . 0.0 109.831 -179.172 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.55 ' O ' HG13 ' A' ' 112' ' ' VAL . 23.5 t -42.59 -22.29 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.429 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 108' ' ' VAL . 6.1 t -44.11 -16.89 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.373 -0.829 . . . . 0.0 110.953 177.608 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' THR . . . . . 1.0 HG22 ' CG1' ' A' ' 124' ' ' ILE . 3.0 p -109.22 44.84 1.11 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.648 -1.283 . . . . 0.0 110.677 -178.614 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.69 HG21 HG12 ' A' ' 39' ' ' VAL . 3.6 m -56.13 -25.63 20.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 110.055 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -96.58 -73.4 1.15 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.517 ' HB3' HG22 ' A' ' 125' ' ' THR . 0.0 OUTLIER -126.55 155.35 42.54 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.383 -1.069 . . . . 0.0 109.804 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.859 ' HB2' ' HB ' ' A' ' 111' ' ' THR . . . -150.81 74.83 1.18 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.026 -1.047 . . . . 0.0 110.981 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.583 ' HB3' HG22 ' A' ' 123' ' ' THR . 4.7 t80 -69.1 101.8 1.51 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.083 -1.011 . . . . 0.0 108.367 178.749 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.476 ' HA ' ' HB3' ' A' ' 122' ' ' PHE . 3.6 m -79.14 162.9 25.49 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.446 -0.784 . . . . 0.0 111.147 -178.36 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.836 HD13 ' HE3' ' A' ' 121' ' ' LYS . 0.9 OUTLIER -147.14 39.34 1.0 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.825 -0.547 . . . . 0.0 109.93 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.421 ' H ' HG22 ' A' ' 117' ' ' THR . . . 59.5 -61.07 0.01 OUTLIER Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 179.162 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.671 ' N ' ' O ' ' A' ' 118' ' ' LEU . 3.3 m -93.34 -16.23 24.89 Favored 'General case' 0 C--N 1.289 -2.033 0 O-C-N 121.914 -0.757 . . . . 0.0 110.473 -179.451 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.836 ' HE3' HD13 ' A' ' 118' ' ' LEU . 0.0 OUTLIER -159.85 153.86 23.23 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.975 -1.078 . . . . 0.0 111.084 -179.535 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.699 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.4 OUTLIER -134.48 166.38 23.0 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.256 -0.902 . . . . 0.0 109.298 178.792 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.865 ' C ' HD12 ' A' ' 124' ' ' ILE . 9.2 t -144.11 157.95 44.01 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.958 -1.089 . . . . 0.0 110.461 -178.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 1.0 ' CG1' HG22 ' A' ' 111' ' ' THR . 3.4 mp -121.15 150.27 24.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.383 -0.823 . . . . 0.0 110.307 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.517 HG22 ' HB3' ' A' ' 114' ' ' ARG . 5.3 t -160.47 -163.6 1.11 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.383 -0.823 . . . . 0.0 110.402 -179.568 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER -154.42 -73.28 0.12 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.49 -0.756 . . . . 0.0 109.96 179.723 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.498 ' HG2' ' OD1' ' A' ' 36' ' ' ASN . 0.7 OUTLIER -61.35 111.24 1.68 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.367 -0.833 . . . . 0.0 110.267 179.693 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 127' ' ' GLU . 1.3 mp . . . . . 0 N--CA 1.486 1.328 0 O-C-N 121.456 -0.778 . . . . 0.0 110.623 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.454 ' OG ' ' N ' ' A' ' 36' ' ' ASN . 10.4 p . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.07 0.462 . . . . 0.0 110.157 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.454 ' N ' ' OG ' ' A' ' 35' ' ' SER . 1.6 m-20 -150.9 -82.29 0.1 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.104 -0.997 . . . . 0.0 110.361 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.53 125.49 0.51 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.771 -0.581 . . . . 0.0 111.159 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.426 HG23 ' HB3' ' A' ' 126' ' ' SER . 94.1 t -89.87 135.37 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 110.273 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.658 HG12 HG23 ' A' ' 112' ' ' VAL . 8.2 p -117.5 130.5 72.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.112 -0.993 . . . . 0.0 110.732 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.606 ' HA ' ' OG ' ' A' ' 110' ' ' SER . 25.3 tp -105.9 141.06 37.94 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.641 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.936 HG23 ' CB ' ' A' ' 110' ' ' SER . 56.3 t -132.11 134.12 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.316 -1.49 . . . . 0.0 110.909 -178.555 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.675 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 26.4 mt -140.27 -166.31 2.09 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.551 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 23.5 ptm -101.44 166.59 10.65 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.328 -0.857 . . . . 0.0 110.879 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.505 ' HG2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -65.0 90.57 0.09 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -0.921 . . . . 0.0 111.694 -179.281 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 1.2 t -83.37 8.79 12.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.231 -0.918 . . . . 0.0 109.799 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.546 ' CB ' ' O ' ' A' ' 45' ' ' SER . 3.6 t0 77.16 -71.06 0.12 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.607 -0.683 . . . . 0.0 112.582 178.791 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.536 ' C ' HD13 ' A' ' 51' ' ' ILE . 3.8 mt-10 -81.74 24.24 0.61 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 120.948 -1.095 . . . . 0.0 111.873 -177.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.846 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.19 -63.09 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.874 -1.142 . . . . 0.0 112.323 -179.062 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -45.85 -35.39 4.44 Favored 'General case' 0 C--N 1.291 -1.946 0 C-N-CA 118.497 -1.281 . . . . 0.0 108.142 178.958 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.466 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.25 -51.69 12.69 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.847 -0.533 . . . . 0.0 110.123 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.846 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.81 -49.51 39.55 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.009 0 O-C-N 120.6 -1.312 . . . . 0.0 109.752 179.656 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.981 ' CG2' HG22 ' A' ' 69' ' ' VAL . 42.0 mm -46.73 -39.75 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 119.848 -1.783 . . . . 0.0 107.916 177.755 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.601 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 56.3 tt0 -62.62 -64.17 1.0 Allowed 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.485 179.242 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -80.02 -9.93 59.73 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.212 -0.93 . . . . 0.0 111.51 -178.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.906 HG23 HG23 ' A' ' 56' ' ' VAL . 3.7 tp -106.85 -34.35 2.85 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 121.611 0.719 . . . . 0.0 110.642 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.906 HG23 HG23 ' A' ' 55' ' ' ILE . 9.7 t -116.83 -43.82 3.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 C-N-CA 119.864 -0.734 . . . . 0.0 112.701 -177.074 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.908 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.1 OUTLIER -55.52 -32.35 62.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.182 -1.574 . . . . 0.0 108.545 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.908 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -93.44 -43.33 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.527 -0.733 . . . . 0.0 109.634 179.329 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -73.56 -47.27 22.05 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.582 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.02 -68.22 1.71 Allowed Glycine 0 N--CA 1.49 2.272 0 O-C-N 121.082 -1.246 . . . . 0.0 110.062 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HG3' ' HA ' ' A' ' 66' ' ' SER . 0.0 OUTLIER -60.09 5.92 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.311 -1.111 . . . . 0.0 113.291 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.63 -64.64 0.75 Allowed 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.327 -1.483 . . . . 0.0 108.525 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.6 ptpt -95.44 -24.72 16.55 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.566 1.174 . . . . 0.0 107.92 177.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.582 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 1.2 m-20 -67.31 145.66 98.62 Favored Pre-proline 0 C--N 1.295 -1.78 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.868 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.462 ' HD2' ' OD1' ' A' ' 64' ' ' ASN . 41.9 Cg_endo -61.62 -47.03 12.25 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 C-N-CA 122.533 2.156 . . . . 0.0 112.164 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.534 ' HA ' ' HG3' ' A' ' 61' ' ' LYS . 0.6 OUTLIER 179.23 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 123.156 1.455 . . . . 0.0 110.272 -179.793 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.67 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.289 1.1 mp -97.38 155.33 3.62 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.489 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.312 -177.483 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.862 HG13 ' HG3' ' A' ' 79' ' ' LYS . 0.2 OUTLIER -128.89 132.14 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.57 -0.707 . . . . 0.0 110.241 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.981 HG22 ' CG2' ' A' ' 52' ' ' ILE . 16.5 t -78.62 -178.67 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.651 ' H ' HG12 ' A' ' 69' ' ' VAL . 0.8 OUTLIER -160.53 66.39 0.33 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 120.646 -1.283 . . . . 0.0 110.585 -178.747 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -71.63 120.77 17.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 110.24 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -119.67 148.01 43.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.196 -0.94 . . . . 0.0 109.81 179.764 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -60.31 77.61 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.915 . . . . 0.0 110.549 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 133.54 -20.37 4.15 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.697 -1.239 . . . . 0.0 110.302 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.505 ' O ' ' HG2' ' A' ' 44' ' ' LYS . 6.1 m-85 -131.27 176.75 8.02 Favored 'General case' 0 C--N 1.288 -2.097 0 O-C-N 121.703 -0.88 . . . . 0.0 111.612 -179.204 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.766 ' CZ2' HD11 ' A' ' 52' ' ' ILE . 7.4 t90 -141.39 79.11 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.718 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.1 m0 -93.98 162.84 13.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.823 0.82 . . . . 0.0 111.326 -178.622 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.724 HD11 ' NE1' ' A' ' 76' ' ' TRP . 1.2 mp -159.27 138.85 3.48 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.626 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.862 ' HG3' HG13 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -106.94 142.14 37.03 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.542 -0.724 . . . . 0.0 110.12 -178.312 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.466 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -138.2 147.26 43.6 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.541 -0.724 . . . . 0.0 110.029 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.29 49.71 0.9 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.024 -1.048 . . . . 0.0 110.218 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 177.99 43.57 Favored Glycine 0 C--N 1.302 -1.356 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.61 123.11 21.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.328 -1.101 . . . . 0.0 109.937 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.458 ' CG1' ' N ' ' A' ' 85' ' ' GLU . 15.8 tt -120.3 171.92 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.188 -0.945 . . . . 0.0 110.766 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.522 ' CG ' ' OG1' ' A' ' 123' ' ' THR . 1.3 mt-10 -133.26 158.91 41.73 Favored 'General case' 0 C--N 1.309 -1.171 0 O-C-N 121.299 -0.876 . . . . 0.0 110.966 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 1.005 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -161.51 139.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.589 -0.694 . . . . 0.0 110.502 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 1.005 ' N ' HD13 ' A' ' 86' ' ' ILE . 2.8 m-20 -130.5 -178.51 4.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.244 -0.91 . . . . 0.0 110.679 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.874 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.11 -27.66 0.2 Allowed 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.373 -0.931 . . . . 0.0 111.246 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.644 ' HB2' ' HB ' ' A' ' 120' ' ' THR . . . -43.59 -54.13 5.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.909 -1.119 . . . . 0.0 110.217 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.566 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 4.0 mt-10 -53.58 -46.4 70.31 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.624 -0.83 . . . . 0.0 109.109 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.552 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.18 -38.37 87.86 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.436 -0.79 . . . . 0.0 108.99 178.727 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.651 ' HA2' HD11 ' A' ' 95' ' ' LEU . . . -66.98 -56.83 10.95 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.566 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.1 OUTLIER -57.54 -17.58 14.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.291 -1.123 . . . . 0.0 109.542 179.644 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.832 HD23 ' N ' ' A' ' 95' ' ' LEU . 3.4 tt -80.58 -58.51 3.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.643 -0.661 . . . . 0.0 110.001 -179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.832 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.2 OUTLIER -85.09 -33.26 22.46 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.44 179.48 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.808 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -155.92 -74.59 0.02 OUTLIER Glycine 0 N--CA 1.487 2.055 0 C-N-CA 119.103 -1.522 . . . . 0.0 109.669 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.58 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 2.3 mmtp 162.97 -57.56 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.822 -0.81 . . . . 0.0 108.923 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.58 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 47.7 Cg_endo -75.52 -18.53 17.58 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 124.21 1.637 . . . . 0.0 109.785 179.035 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.534 ' CZ ' ' CG ' ' A' ' 103' ' ' ASP . 1.1 t80 -51.3 -46.31 62.49 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 119.071 -1.052 . . . . 0.0 108.64 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.874 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 1.3 t -31.7 -68.89 0.08 Allowed 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.974 0.892 . . . . 0.0 110.519 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.792 ' HA ' HD23 ' A' ' 104' ' ' LEU . 1.2 t -72.68 -59.22 3.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.632 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.666 ' N ' HG12 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -44.51 -33.05 1.6 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.467 -1.396 . . . . 0.0 108.712 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.628 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 35.2 t70 -64.81 -42.95 94.61 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.792 HD23 ' HA ' ' A' ' 101' ' ' VAL . 1.6 pp -75.27 -41.38 57.36 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.107 -1.437 . . . . 0.0 109.542 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.47 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 52.3 mt -55.15 -16.17 2.87 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 119.86 -1.775 . . . . 0.0 109.904 178.717 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -95.23 -46.74 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.325 -0.859 . . . . 0.0 110.196 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.628 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 10.6 p30 -113.27 -4.21 13.74 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.145 -0.972 . . . . 0.0 112.093 -178.711 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.948 ' O ' HG23 ' A' ' 111' ' ' THR . 5.2 p -65.91 -8.8 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.6 -1.312 . . . . 0.0 109.768 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.96 -27.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.084 0.468 . . . . 0.0 112.024 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.936 ' CB ' HG23 ' A' ' 41' ' ' VAL . 1.0 OUTLIER -64.52 5.88 0.25 Allowed 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.135 -0.978 . . . . 0.0 111.949 179.585 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.948 HG23 ' O ' ' A' ' 108' ' ' VAL . 32.2 p -61.93 -8.52 5.21 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.402 -1.436 . . . . 0.0 111.573 -177.615 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.779 HG12 ' N ' ' A' ' 113' ' ' GLY . 25.5 t 48.66 -92.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.779 ' N ' HG12 ' A' ' 112' ' ' VAL . . . -138.68 -3.8 1.73 Allowed Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.512 -1.327 . . . . 0.0 110.108 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.532 ' HG2' ' CG2' ' A' ' 125' ' ' THR . 1.4 mpt_? -123.95 146.94 48.14 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.046 -1.267 . . . . 0.0 110.661 -179.53 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -169.71 80.06 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.9 m-85 -69.05 89.36 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.258 -0.901 . . . . 0.0 109.06 179.46 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 14.3 t -79.33 151.21 31.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.388 -0.82 . . . . 0.0 111.306 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -133.74 62.67 1.65 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.83 -60.67 0.13 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.644 ' HB ' ' HB2' ' A' ' 89' ' ' ALA . 0.8 OUTLIER -118.21 -34.94 3.95 Favored 'General case' 0 C--N 1.292 -1.921 0 O-C-N 121.964 -0.727 . . . . 0.0 112.004 -179.243 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.567 ' O ' ' N ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -105.0 149.51 25.7 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 120.994 -1.066 . . . . 0.0 111.003 -178.789 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.701 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -136.14 164.08 28.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.027 -1.046 . . . . 0.0 110.408 179.501 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.841 ' C ' HD13 ' A' ' 124' ' ' ILE . 0.8 OUTLIER -138.79 149.93 45.52 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.291 -0.881 . . . . 0.0 109.225 -179.684 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.841 HD13 ' C ' ' A' ' 123' ' ' THR . 0.0 OUTLIER -125.24 156.82 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.065 -1.022 . . . . 0.0 110.057 -179.419 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.532 ' CG2' ' HG2' ' A' ' 114' ' ' ARG . 6.3 t -160.78 163.53 32.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.131 -0.981 . . . . 0.0 110.625 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.444 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER -83.3 -74.38 0.37 Allowed 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.281 -0.887 . . . . 0.0 110.222 179.829 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 1.6 mm-40 -81.43 174.5 11.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.343 -0.848 . . . . 0.0 110.469 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.305 -1.334 0 O-C-N 121.545 -0.722 . . . . 0.0 110.792 -179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.256 0.55 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.476 ' O ' ' OG ' ' A' ' 126' ' ' SER . 52.1 m-20 -157.61 -91.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.317 -0.864 . . . . 0.0 110.239 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.466 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.1 117.61 0.54 Allowed 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.518 -0.739 . . . . 0.0 110.717 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.467 HG13 ' O ' ' A' ' 36' ' ' ASN . 21.2 m -102.41 173.56 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.185 -0.947 . . . . 0.0 109.921 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.602 HG22 ' OG ' ' A' ' 110' ' ' SER . 7.7 p -137.77 145.67 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 111.008 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.587 ' HB2' HD11 ' A' ' 84' ' ' ILE . 10.6 tp -111.67 137.31 49.74 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.511 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.064 HG23 ' OG ' ' A' ' 110' ' ' SER . 80.5 t -133.77 124.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 120.664 -1.272 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.8 HD23 ' OD1' ' A' ' 107' ' ' ASN . 16.2 mt -132.84 178.84 6.56 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.632 178.531 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.446 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 2.2 ppp? -88.64 172.21 9.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.139 -0.976 . . . . 0.0 110.142 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.33 83.25 0.25 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.502 ' HB2' HG23 ' A' ' 48' ' ' ILE . 13.7 m -54.17 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.194 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 0.7 OUTLIER -158.64 -83.25 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.407 -0.808 . . . . 0.0 109.964 179.272 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.551 ' HB3' ' HB3' ' A' ' 50' ' ' ALA . 1.5 mt-10 -96.93 38.34 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.35 -0.844 . . . . 0.0 110.064 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.833 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -45.17 -60.72 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.172 -0.955 . . . . 0.0 111.32 -179.083 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 48' ' ' ILE . 3.2 m-20 -47.31 -44.44 23.53 Favored 'General case' 0 C--N 1.282 -2.363 0 C-N-CA 118.372 -1.331 . . . . 0.0 108.622 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB3' ' HB3' ' A' ' 47' ' ' GLU . . . -71.17 -47.04 60.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.559 -0.713 . . . . 0.0 110.854 179.319 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.833 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -74.78 -49.76 28.35 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.062 0 O-C-N 120.649 -1.282 . . . . 0.0 110.069 -179.909 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.762 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 40.7 mm -45.0 -37.53 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.056 -1.652 . . . . 0.0 108.23 177.754 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.58 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 1.2 tt0 -68.66 -63.18 1.11 Allowed 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.296 -0.878 . . . . 0.0 110.256 179.279 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.11 -10.34 59.33 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.283 -0.885 . . . . 0.0 110.933 -179.322 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.707 HG22 ' HA ' ' A' ' 52' ' ' ILE . 4.0 tp -107.58 -35.43 2.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 CA-C-O 121.575 0.702 . . . . 0.0 110.681 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.644 HG23 HG23 ' A' ' 55' ' ' ILE . 2.1 t -117.75 -44.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.974 -0.69 . . . . 0.0 112.694 -176.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.776 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -56.55 -41.63 77.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.11 -1.619 . . . . 0.0 109.478 -179.363 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.776 ' N ' HD23 ' A' ' 57' ' ' LEU . 3.7 tttt -87.78 -43.98 11.46 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.634 -0.667 . . . . 0.0 110.583 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.17 -41.52 6.58 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.056 -178.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.558 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.83 -54.36 15.09 Favored Glycine 0 N--CA 1.492 2.399 0 O-C-N 120.803 -1.41 . . . . 0.0 110.328 -179.143 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.602 ' HA ' ' HB2' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -60.64 8.86 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.45 -1.03 . . . . 0.0 113.248 -179.323 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.603 ' HB1' ' HE3' ' A' ' 63' ' ' LYS . . . -57.19 -67.77 0.29 Allowed 'General case' 0 C--N 1.308 -1.229 0 O-C-N 120.258 -1.526 . . . . 0.0 109.076 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.603 ' HE3' ' HB1' ' A' ' 62' ' ' ALA . 5.4 mmpt? -90.19 -19.53 24.11 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.551 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.602 ' HB2' ' HA ' ' A' ' 61' ' ' LYS . 6.3 m-20 -69.34 121.08 80.86 Favored Pre-proline 0 C--N 1.299 -1.588 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.401 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.498 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 44.9 Cg_endo -64.09 -39.24 32.48 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.884 1.723 . . . . 0.0 111.16 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.688 ' C ' HD12 ' A' ' 67' ' ' ILE . 2.8 m -177.77 111.2 0.07 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 123.012 1.386 . . . . 0.0 109.193 179.418 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.688 HD12 ' C ' ' A' ' 66' ' ' SER 0.299 1.3 mp -107.06 145.48 14.51 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.465 0 CA-C-N 113.823 -1.535 . . . . 0.0 111.673 -176.533 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.579 HG12 ' CG ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.04 142.66 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.931 179.454 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.657 ' CG2' HG21 ' A' ' 52' ' ' ILE . 66.1 t -115.32 100.38 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.125 -0.984 . . . . 0.0 110.154 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 1.1 mm-40 -83.59 124.51 30.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.489 -0.757 . . . . 0.0 109.869 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -123.25 102.47 7.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.15 -0.969 . . . . 0.0 109.587 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -103.97 144.23 31.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.164 -0.96 . . . . 0.0 109.948 -179.704 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.72 83.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.435 -0.79 . . . . 0.0 110.044 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 132.73 -24.88 3.82 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -125.08 161.63 26.36 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.778 -0.836 . . . . 0.0 110.931 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.762 ' CZ2' HD11 ' A' ' 52' ' ' ILE . 11.8 t90 -135.88 79.46 1.77 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.724 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.2 m0 -98.79 137.72 36.97 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.495 -0.753 . . . . 0.0 112.433 -177.563 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.556 HD11 ' HE1' ' A' ' 76' ' ' TRP . 1.3 mt -138.29 139.15 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.304 -0.873 . . . . 0.0 109.486 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.579 ' CG ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -109.01 162.28 14.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.188 -0.945 . . . . 0.0 110.582 -179.387 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.439 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.31 140.64 20.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.97 50.03 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -0.906 . . . . 0.0 109.961 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.53 -138.85 2.6 Favored Glycine 0 C--N 1.301 -1.374 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.29 163.28 23.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -1.179 . . . . 0.0 109.885 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 124' ' ' ILE . 5.7 tp -150.83 161.85 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.099 -1.001 . . . . 0.0 110.307 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.577 ' O ' HD13 ' A' ' 40' ' ' LEU . 2.4 mt-10 -140.18 164.75 29.22 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.229 -0.92 . . . . 0.0 110.384 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.773 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -125.53 165.22 23.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.298 -0.876 . . . . 0.0 109.718 179.62 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.522 ' OD1' ' CG ' ' A' ' 121' ' ' LYS . 9.5 m-20 -149.46 155.29 40.15 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.304 -0.872 . . . . 0.0 110.656 -179.648 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.923 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -146.12 -22.37 0.45 Allowed 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 118.808 -1.157 . . . . 0.0 111.301 177.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.442 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -41.57 -46.48 3.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.667 -1.271 . . . . 0.0 110.624 179.268 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.492 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.2 tt0 -49.36 -57.76 6.31 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.401 -0.812 . . . . 0.0 109.659 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.708 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -45.55 -30.31 1.43 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.687 -0.633 . . . . 0.0 109.727 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -71.17 -37.83 63.51 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.492 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.3 mt-10 -64.69 -20.19 66.17 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.341 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.628 ' HB3' HD23 ' A' ' 95' ' ' LEU . 7.4 tt -84.54 -67.57 0.79 Allowed 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.631 HD11 ' HB3' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -100.77 -23.3 14.63 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.115 -0.99 . . . . 0.0 110.112 179.26 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 60.1 45.69 95.53 Favored Glycine 0 N--CA 1.5 2.942 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.278 178.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.689 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 13.7 mttt -138.06 -127.43 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.456 0 O-C-N 121.091 -1.241 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.689 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 42.0 Cg_endo -71.61 -4.91 15.96 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 CA-C-N 120.894 1.355 . . . . 0.0 108.605 178.385 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.767 ' CD1' ' N ' ' A' ' 100' ' ' SER . 2.8 p90 -24.12 -42.55 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 CA-C-O 121.599 0.714 . . . . 0.0 112.032 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.923 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.2 OUTLIER -57.94 -54.86 42.18 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 122.901 1.334 . . . . 0.0 109.18 -177.64 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.945 HG12 HD11 ' A' ' 105' ' ' LEU . 6.5 t -94.17 -43.88 13.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.672 -178.135 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.607 ' O ' HD12 ' A' ' 106' ' ' ILE . 37.4 t80 -53.1 -41.12 64.64 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 120.209 -1.557 . . . . 0.0 107.652 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.636 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 11.4 t0 -68.5 -43.13 77.53 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.437 -0.79 . . . . 0.0 109.922 179.152 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.759 HD12 ' N ' ' A' ' 105' ' ' LEU . 2.9 pp -75.25 -40.38 58.99 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 116.756 -1.978 . . . . 0.0 109.046 179.252 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.945 HD11 HG12 ' A' ' 101' ' ' VAL . 23.6 mt -52.82 -20.02 2.93 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.094 -1.629 . . . . 0.0 109.867 178.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.607 HD12 ' O ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -92.09 -44.92 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.267 -0.896 . . . . 0.0 110.629 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.8 ' OD1' HD23 ' A' ' 42' ' ' LEU . 9.2 p30 -114.48 -7.59 12.83 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 112.243 -178.366 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 104' ' ' LEU . 6.0 p -60.89 -17.64 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.592 -1.317 . . . . 0.0 109.34 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -39.84 -22.78 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.7 -179.231 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 110' ' ' SER . . . . . 1.064 ' OG ' HG23 ' A' ' 41' ' ' VAL . 0.1 OUTLIER -73.28 9.52 1.26 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.698 -1.251 . . . . 0.0 110.558 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.562 ' O ' ' HB ' ' A' ' 112' ' ' VAL . 1.1 t -61.53 -10.86 8.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.762 -1.212 . . . . 0.0 110.396 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.562 ' HB ' ' O ' ' A' ' 111' ' ' THR . 2.1 t 66.89 -52.73 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.576 -0.702 . . . . 0.0 110.62 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -173.15 -26.87 0.02 OUTLIER Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.516 ' HB2' ' HB2' ' A' ' 128' ' ' LEU . 18.2 ttt180 -138.81 147.74 42.91 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.063 -1.257 . . . . 0.0 111.023 -179.494 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.631 ' HB1' ' CD2' ' A' ' 122' ' ' PHE . . . -155.76 93.61 1.48 Allowed 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.38 -0.825 . . . . 0.0 110.285 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.551 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 12.2 t80 -69.72 118.88 13.13 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.49 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.2 m -79.55 117.78 20.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.619 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -79.38 49.62 1.01 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.935 179.404 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.93 -60.14 0.36 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 108.674 -1.77 . . . . 0.0 108.674 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -116.01 -10.15 11.63 Favored 'General case' 0 C--N 1.293 -1.875 0 O-C-N 122.001 -0.705 . . . . 0.0 110.382 179.712 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.522 ' CG ' ' OD1' ' A' ' 87' ' ' ASP . 1.7 tttt -121.07 -161.94 0.93 Allowed 'General case' 0 N--CA 1.493 1.685 0 CA-C-O 122.052 0.929 . . . . 0.0 111.397 -179.094 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.773 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.26 0.2 OUTLIER -141.22 150.93 43.31 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.97 -179.105 . . . . . . . . 4 4 . 1 . 014 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.594 ' O ' HG22 ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.4 110.96 8.03 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.982 -1.074 . . . . 0.0 110.001 178.705 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.886 ' HB ' HG23 ' A' ' 84' ' ' ILE . 4.8 mp -113.86 157.28 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 110.174 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 15.3 t -146.96 170.24 17.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.293 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 0.2 OUTLIER -91.39 -32.62 15.58 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.307 -0.87 . . . . 0.0 110.684 -179.527 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 128' ' ' LEU . 77.8 mt-10 -84.6 28.81 0.64 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.377 -0.827 . . . . 0.0 110.668 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.516 ' HB2' ' HB2' ' A' ' 114' ' ' ARG . 2.9 pp . . . . . 0 C--N 1.306 -1.301 0 O-C-N 121.092 -1.005 . . . . 0.0 110.672 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 56.9 m . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.235 0.54 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.517 ' HA ' ' OG ' ' A' ' 126' ' ' SER . 26.9 p-10 -118.27 -43.43 2.73 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.332 -0.855 . . . . 0.0 110.38 -179.764 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.443 ' N ' ' OD1' ' A' ' 36' ' ' ASN . . . -39.74 134.0 1.45 Allowed 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.623 -0.673 . . . . 0.0 110.995 -179.502 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.18 152.45 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.308 -0.87 . . . . 0.0 109.732 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.937 HG13 ' HB2' ' A' ' 110' ' ' SER . 14.5 p -114.87 136.28 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 111.464 -179.641 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.646 HD22 HG12 ' A' ' 84' ' ' ILE . 3.8 tp -100.53 146.11 27.49 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 176.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.007 HG22 ' CD2' ' A' ' 77' ' ' TRP . 2.2 t -139.12 121.45 17.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 O-C-N 120.403 -1.436 . . . . 0.0 111.365 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.953 HD22 ' O ' ' A' ' 41' ' ' VAL . 3.3 mm? -133.42 153.02 51.96 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.294 -0.879 . . . . 0.0 109.212 178.763 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 12.7 ptm -75.45 153.68 37.47 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.837 -1.164 . . . . 0.0 109.721 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.553 ' CG ' ' HA2' ' A' ' 74' ' ' GLY . 10.0 ptmt -45.16 123.59 4.06 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.032 -1.042 . . . . 0.0 110.859 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.439 ' H ' HD12 ' A' ' 48' ' ' ILE . 12.8 m -100.05 -86.28 0.39 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.592 179.466 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -158.0 -79.11 0.07 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 110.92 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.487 ' C ' HD13 ' A' ' 51' ' ' ILE . 1.4 mt-10 -96.74 39.06 1.18 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.305 -0.872 . . . . 0.0 110.367 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.83 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.04 -69.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.117 -0.99 . . . . 0.0 111.586 -178.916 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.8 m-20 -41.15 -36.05 0.67 Allowed 'General case' 0 C--N 1.284 -2.267 0 C-N-CA 119.059 -1.057 . . . . 0.0 109.062 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.406 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -77.78 -50.22 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.601 -0.687 . . . . 0.0 109.9 178.601 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.83 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.31 -50.93 28.0 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.011 0 O-C-N 120.848 -1.157 . . . . 0.0 109.325 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.712 ' HA ' HG22 ' A' ' 55' ' ' ILE . 44.2 mm -47.19 -40.71 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 119.881 -1.762 . . . . 0.0 108.147 177.569 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.617 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 60.2 tt0 -60.85 -61.58 2.48 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -84.1 -9.15 58.83 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.201 -0.937 . . . . 0.0 111.669 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.875 HG23 HG23 ' A' ' 56' ' ' VAL . 4.5 tp -106.68 -32.81 2.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 CA-C-O 121.695 0.759 . . . . 0.0 110.098 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.875 HG23 HG23 ' A' ' 55' ' ' ILE . 7.4 t -116.46 -45.05 3.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 C-N-CA 119.942 -0.703 . . . . 0.0 112.188 -177.626 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.842 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -64.81 -37.67 88.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.339 -1.475 . . . . 0.0 108.557 179.798 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.842 ' N ' HD23 ' A' ' 57' ' ' LEU . 6.6 mtpt -96.86 -42.07 8.13 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.524 -0.735 . . . . 0.0 109.221 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -77.54 -49.84 7.0 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.585 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.27 -47.86 49.48 Favored Glycine 0 N--CA 1.489 2.178 0 O-C-N 120.973 -1.31 . . . . 0.0 110.136 -179.144 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.641 ' HA ' ' HB2' ' A' ' 64' ' ' ASN . 17.6 ttpp -65.17 9.98 0.09 Allowed 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.624 -0.927 . . . . 0.0 113.124 -179.092 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.67 -62.88 1.35 Allowed 'General case' 0 C--N 1.304 -1.386 0 O-C-N 120.387 -1.446 . . . . 0.0 108.897 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mtmt -101.62 -17.58 16.28 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.048 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.641 ' HB2' ' HA ' ' A' ' 61' ' ' LYS . 0.5 OUTLIER -67.96 127.27 93.32 Favored Pre-proline 0 C--N 1.3 -1.544 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.229 -179.165 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -66.22 -49.52 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.321 2.014 . . . . 0.0 111.587 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.44 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -166.97 106.23 0.6 Allowed 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 123.211 1.481 . . . . 0.0 109.489 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.678 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -97.1 148.91 5.19 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 CA-C-N 113.47 -1.696 . . . . 0.0 111.836 -176.507 . . . . . . . . 4 4 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.556 HG12 ' CB ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.44 145.44 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.298 -0.876 . . . . 0.0 110.201 179.731 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.698 ' CG1' HG21 ' A' ' 52' ' ' ILE . 99.2 t -121.31 96.7 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.152 -0.968 . . . . 0.0 110.089 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.6 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.3 mm-40 -79.36 134.6 36.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.263 -0.898 . . . . 0.0 110.092 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASP . . . . . 0.469 ' O ' ' OD1' ' A' ' 71' ' ' ASP . 1.1 p30 -143.31 112.24 6.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.179 -0.951 . . . . 0.0 110.017 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.521 ' HG3' ' HB2' ' A' ' 75' ' ' PHE . 0.2 OUTLIER -147.55 -171.45 3.8 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.892 -1.13 . . . . 0.0 111.241 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.465 ' O ' ' C ' ' A' ' 74' ' ' GLY . . . -40.22 110.84 0.16 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.47 -0.769 . . . . 0.0 110.911 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.553 ' HA2' ' CG ' ' A' ' 44' ' ' LYS . . . 36.47 59.62 1.01 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.521 ' HB2' ' HG3' ' A' ' 72' ' ' LYS . 2.5 m-85 -160.75 75.49 0.54 Allowed 'General case' 0 C--N 1.291 -1.961 0 O-C-N 121.849 -0.795 . . . . 0.0 110.039 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.753 ' CE2' HG22 ' A' ' 48' ' ' ILE . 4.1 t90 -82.49 78.34 9.14 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.654 0.74 . . . . 0.0 109.08 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 1.007 ' CD2' HG22 ' A' ' 41' ' ' VAL . 23.2 m0 -98.94 148.27 24.14 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.594 -0.691 . . . . 0.0 111.626 -178.552 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.595 HG13 ' HA ' ' A' ' 69' ' ' VAL . 1.2 mp -146.65 141.58 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.339 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.556 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -116.74 141.75 47.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.129 -0.982 . . . . 0.0 110.695 -179.022 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.507 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -127.07 163.51 23.62 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.385 -0.822 . . . . 0.0 110.008 179.537 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -106.41 47.44 0.88 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.068 -1.02 . . . . 0.0 110.179 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -108.11 0.21 Allowed Glycine 0 C--N 1.299 -1.482 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -126.22 166.14 17.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.458 -1.025 . . . . 0.0 110.091 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.646 HG12 HD22 ' A' ' 40' ' ' LEU . 7.9 tp -143.91 158.61 16.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.121 -0.987 . . . . 0.0 110.524 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.468 ' O ' HG12 ' A' ' 86' ' ' ILE . 34.2 tt0 -122.76 173.8 7.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.261 -0.899 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 1.001 HG21 ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -157.62 149.78 9.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 O-C-N 121.148 -0.97 . . . . 0.0 111.007 -179.58 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -138.54 152.21 48.0 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.06 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.974 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.84 -34.84 0.13 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.335 -1.346 . . . . 0.0 111.585 178.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.533 ' CB ' ' OG1' ' A' ' 120' ' ' THR . . . -40.91 -45.35 2.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.289 -0.882 . . . . 0.0 110.181 -179.235 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.582 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 3.8 tt0 -67.86 -52.02 41.52 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 178.792 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.565 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.8 -41.15 70.23 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 108.965 178.677 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.522 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -59.49 -55.31 31.35 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.582 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.9 OUTLIER -57.02 -16.94 8.16 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.174 -1.192 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.818 HD23 ' N ' ' A' ' 95' ' ' LEU . 7.4 tt -86.25 -64.27 1.18 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.501 -0.749 . . . . 0.0 111.014 -179.302 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.818 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -71.36 -37.2 71.66 Favored 'General case' 0 N--CA 1.502 2.168 0 C-N-CA 118.485 -1.286 . . . . 0.0 109.849 -179.706 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.56 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -158.41 -74.43 0.02 OUTLIER Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.545 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 167.53 -63.24 0.0 OUTLIER Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.956 . . . . 0.0 109.52 179.855 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.9 Cg_endo -72.04 -16.22 28.93 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.476 1.25 . . . . 0.0 109.64 178.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.661 ' CB ' HD13 ' A' ' 95' ' ' LEU . 3.1 t80 -48.87 -48.51 42.09 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 121.074 -1.017 . . . . 0.0 109.171 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.974 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 3.8 t -32.36 -61.87 0.24 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.752 0.787 . . . . 0.0 110.764 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.86 ' HA ' HD23 ' A' ' 104' ' ' LEU . 19.4 t -82.79 -54.41 9.48 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.822 0 O-C-N 121.183 -0.948 . . . . 0.0 112.793 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.574 ' HA ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -46.56 -29.98 2.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.67 -1.269 . . . . 0.0 108.917 179.911 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.53 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 29.5 t70 -82.17 -37.18 26.53 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.451 -0.78 . . . . 0.0 109.441 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.86 HD23 ' HA ' ' A' ' 101' ' ' VAL . 0.4 OUTLIER -68.75 -21.78 64.35 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.364 179.523 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.748 HD11 ' CG1' ' A' ' 101' ' ' VAL . 4.6 mt -86.75 -27.72 23.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.819 -1.175 . . . . 0.0 110.373 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.441 HG22 ' HA ' ' A' ' 103' ' ' ASP . 0.6 OUTLIER -97.24 -28.52 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 121.134 -0.979 . . . . 0.0 109.956 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.642 ' CG ' HD13 ' A' ' 42' ' ' LEU . 2.5 p30 -87.49 -30.44 20.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.34 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.109 HG22 ' HB ' ' A' ' 111' ' ' THR . 9.9 p -66.3 -0.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 120.61 -1.306 . . . . 0.0 110.9 179.407 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -30.05 -34.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.813 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.937 ' HB2' HG13 ' A' ' 39' ' ' VAL . 82.8 p -84.4 33.66 0.51 Allowed 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.533 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' THR . . . . . 1.109 ' HB ' HG22 ' A' ' 108' ' ' VAL . 11.5 t -96.46 44.26 1.07 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.26 179.738 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.573 ' CG1' ' N ' ' A' ' 113' ' ' GLY . 0.5 OUTLIER -61.68 -48.66 87.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.542 -0.724 . . . . 0.0 111.015 -178.687 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.573 ' N ' ' CG1' ' A' ' 112' ' ' VAL . . . -57.21 -77.04 0.18 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.531 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -157.72 -169.04 2.72 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.384 -1.068 . . . . 0.0 110.105 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.647 ' HB2' ' OG1' ' A' ' 111' ' ' THR . . . -170.7 84.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.583 ' HB3' HG22 ' A' ' 123' ' ' THR . 4.7 t80 -69.84 105.71 2.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.003 -1.061 . . . . 0.0 108.351 178.595 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 119' ' ' GLY . 7.6 m -79.03 145.95 33.58 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.299 -0.876 . . . . 0.0 110.915 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.612 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.1 OUTLIER -123.69 50.3 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.587 -0.695 . . . . 0.0 110.282 179.914 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.422 ' H ' HG22 ' A' ' 117' ' ' THR . . . 62.15 -57.26 0.03 OUTLIER Glycine 0 N--CA 1.491 2.326 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 178.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.612 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.8 t -111.7 -15.18 13.49 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.753 -0.851 . . . . 0.0 111.406 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.538 ' CG ' ' HB3' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -143.57 150.6 39.08 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.758 -1.214 . . . . 0.0 110.77 -179.614 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 1.001 ' CE2' HG21 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -124.68 164.17 20.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.877 -1.139 . . . . 0.0 110.769 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.583 HG22 ' HB3' ' A' ' 116' ' ' TYR . 2.8 t -144.27 131.85 21.09 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.514 -0.741 . . . . 0.0 109.831 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.697 HD12 ' N ' ' A' ' 124' ' ' ILE . 2.0 mp -101.91 162.66 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 110.674 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 114' ' ' ARG . 3.3 t -152.34 -175.3 5.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -0.872 . . . . 0.0 109.806 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 128' ' ' LEU . 19.7 t -108.31 -50.62 3.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.086 . . . . 0.0 110.705 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 128' ' ' LEU . 1.6 mt-10 -53.54 82.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.586 -0.696 . . . . 0.0 110.686 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.543 ' N ' ' O ' ' A' ' 126' ' ' SER . 1.1 mt . . . . . 0 C--N 1.304 -1.379 0 O-C-N 121.218 -0.927 . . . . 0.0 110.288 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.49 ' O ' ' C ' ' A' ' 37' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.495 1.777 0 CA-C-O 121.099 0.476 . . . . 0.0 110.695 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.49 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -29.87 132.96 0.06 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.403 0.621 . . . . 0.0 111.846 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 1.7 p -142.48 149.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.515 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.588 ' H ' HG21 ' A' ' 112' ' ' VAL . 11.1 p -127.68 150.05 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.78 -1.2 . . . . 0.0 111.707 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 1.023 HD11 HG13 ' A' ' 86' ' ' ILE . 23.5 tp -112.36 132.05 55.21 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.865 HG13 ' NE1' ' A' ' 77' ' ' TRP . 2.6 t -127.28 124.87 64.95 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 111.603 -177.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.844 HD21 HD11 ' A' ' 86' ' ' ILE . 0.9 OUTLIER -119.53 -174.18 2.68 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.002 -1.061 . . . . 0.0 110.605 179.189 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.567 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.8 ptp -117.66 21.58 12.88 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.937 . . . . 0.0 110.642 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.664 ' HB3' HD11 ' A' ' 48' ' ' ILE . 3.6 mmtt -88.95 -93.14 0.11 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.456 -0.778 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.62 ' CB ' ' O ' ' A' ' 44' ' ' LYS . 1.3 p 89.36 178.01 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 45' ' ' SER . 0.1 OUTLIER 62.93 -87.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 109.663 -179.242 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.519 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.2 mt-10 -52.16 -24.95 7.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.44 -0.787 . . . . 0.0 111.895 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 1.01 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -73.48 -62.37 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.709 -178.082 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.545 ' C ' ' O ' ' A' ' 48' ' ' ILE . 85.4 m-20 -37.83 -32.57 0.06 Allowed 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.316 -0.954 . . . . 0.0 108.782 179.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.27 -55.98 5.06 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.814 HG12 ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -71.3 -48.69 52.66 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.165 0 O-C-N 120.679 -1.263 . . . . 0.0 109.29 178.922 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.859 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 45.8 mm -46.01 -41.23 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 119.871 -1.768 . . . . 0.0 108.604 177.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.778 ' HA ' ' HB2' ' A' ' 57' ' ' LEU . 2.1 tm-20 -64.73 -60.89 2.58 Favored 'General case' 0 C--N 1.292 -1.91 0 O-C-N 121.206 -0.933 . . . . 0.0 110.143 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -77.62 -12.59 59.98 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 120.868 -1.145 . . . . 0.0 111.488 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.776 HG23 HG23 ' A' ' 56' ' ' VAL . 4.0 tp -107.43 -34.96 2.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 O-C-N 121.59 -0.694 . . . . 0.0 111.499 -178.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.776 HG23 HG23 ' A' ' 55' ' ' ILE . 2.5 t -117.18 -37.89 2.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.655 -0.653 . . . . 0.0 112.632 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.778 ' HB2' ' HA ' ' A' ' 53' ' ' GLU . 1.4 tm? -37.51 -55.49 1.08 Allowed 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 122.272 1.034 . . . . 0.0 109.947 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.31 -48.97 12.2 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.487 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -50.82 -47.39 47.31 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.525 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -78.03 7.07 46.11 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.77 -8.56 16.75 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.972 -1.311 . . . . 0.0 110.891 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.5 -82.63 0.22 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.945 -1.097 . . . . 0.0 109.93 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.403 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -79.56 -30.3 41.64 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 122.432 1.111 . . . . 0.0 108.158 178.678 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.525 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 8.5 m-20 -74.65 127.03 87.96 Favored Pre-proline 0 C--N 1.295 -1.801 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.473 ' O ' ' HB2' ' A' ' 66' ' ' SER . 43.5 Cg_endo -62.86 -47.7 8.21 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 121.77 1.646 . . . . 0.0 110.822 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.656 ' C ' HD12 ' A' ' 67' ' ' ILE . 1.7 t 179.96 111.86 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.958 1.361 . . . . 0.0 109.339 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.656 HD12 ' C ' ' A' ' 66' ' ' SER 0.292 1.3 mp -104.37 134.77 44.77 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.508 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.551 -176.823 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.642 HG12 ' CB ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -92.03 162.73 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 109.374 178.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.802 ' CG1' HG21 ' A' ' 52' ' ' ILE . 24.3 t -136.28 106.51 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.045 -1.034 . . . . 0.0 110.31 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.612 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.7 mm-40 -102.05 145.42 29.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.841 . . . . 0.0 110.421 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . 0.428 ' CG ' ' OD2' ' A' ' 49' ' ' ASP . 11.6 p-10 -136.96 119.72 16.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.451 -0.78 . . . . 0.0 108.965 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.596 ' CB ' ' HB2' ' A' ' 75' ' ' PHE . 27.0 mttm -125.49 83.28 2.15 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.019 -1.051 . . . . 0.0 111.506 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.558 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 18.64 73.66 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.237 0 CA-C-O 121.231 0.539 . . . . 0.0 111.949 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 43' ' ' MET . . . 103.54 11.18 33.86 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.596 ' HB2' ' CB ' ' A' ' 72' ' ' LYS . 20.4 m-85 -138.26 101.03 4.28 Favored 'General case' 0 C--N 1.286 -2.165 0 O-C-N 121.837 -0.802 . . . . 0.0 110.587 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 1.01 ' CE2' HG21 ' A' ' 48' ' ' ILE . 17.5 t90 -89.39 87.53 7.13 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.518 -0.738 . . . . 0.0 109.494 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.865 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.7 m0 -98.06 111.59 23.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.08 -1.012 . . . . 0.0 110.427 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.543 ' O ' HG23 ' A' ' 39' ' ' VAL . 0.3 OUTLIER -114.65 148.17 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.737 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.642 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -130.28 125.46 34.83 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.921 -1.112 . . . . 0.0 110.16 179.81 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.534 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -125.44 173.97 8.52 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.478 -0.764 . . . . 0.0 110.031 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.97 52.51 1.27 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 110.046 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -169.59 -105.94 0.19 Allowed Glycine 0 C--N 1.302 -1.337 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -133.08 115.5 15.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.505 -0.997 . . . . 0.0 110.316 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.684 HG21 ' HB2' ' A' ' 40' ' ' LEU . 8.1 tp -105.49 148.36 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 110.261 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -103.99 159.29 15.79 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.157 -0.965 . . . . 0.0 111.392 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 1.023 HG13 HD11 ' A' ' 40' ' ' LEU . 0.3 OUTLIER -162.32 149.82 4.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 O-C-N 121.442 -0.787 . . . . 0.0 110.438 179.772 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.843 ' N ' HD13 ' A' ' 86' ' ' ILE . 1.4 m-20 -135.31 -176.13 4.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.011 -1.056 . . . . 0.0 111.455 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.659 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -138.41 -9.31 1.46 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.813 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -43.71 -48.34 7.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.474 -1.392 . . . . 0.0 110.269 179.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.582 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 10.1 tt0 -49.36 -47.63 47.3 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.455 -0.778 . . . . 0.0 109.892 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.522 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -56.81 -26.46 58.04 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.067 -1.021 . . . . 0.0 109.649 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.699 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -73.97 -48.84 14.82 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.582 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.0 OUTLIER -58.23 -19.3 32.79 Favored 'General case' 0 C--N 1.289 -2.052 0 O-C-N 121.104 -1.233 . . . . 0.0 107.951 178.56 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.845 HD23 ' CD2' ' A' ' 95' ' ' LEU . 11.4 tp -82.11 -68.0 0.73 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.826 -0.546 . . . . 0.0 109.613 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.845 ' CD2' HD23 ' A' ' 94' ' ' LEU . 0.2 OUTLIER -100.96 -29.66 12.07 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.082 -1.011 . . . . 0.0 109.135 178.587 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 69.44 43.96 66.98 Favored Glycine 0 N--CA 1.498 2.768 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.833 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.687 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 8.2 mmmt -138.23 -124.17 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.672 0 O-C-N 121.091 -1.241 . . . . 0.0 109.724 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.687 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 45.9 Cg_endo -71.14 -4.96 15.94 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 121.172 1.454 . . . . 0.0 108.724 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.76 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.8 p90 -23.66 -44.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.076 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.76 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -49.14 -52.48 25.96 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 123.348 1.547 . . . . 0.0 107.734 -179.125 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.867 HG12 HD11 ' A' ' 105' ' ' LEU . 67.5 t -99.04 -53.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.807 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.486 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 0.5 OUTLIER -44.42 -30.02 0.79 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.773 -1.204 . . . . 0.0 108.434 179.364 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.564 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.8 t70 -83.11 -45.94 13.37 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.83 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.5 OUTLIER -60.9 -41.16 95.55 Favored 'General case' 0 C--O 1.202 -1.425 0 C-N-CA 117.928 -1.509 . . . . 0.0 109.144 179.168 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.867 HD11 HG12 ' A' ' 101' ' ' VAL . 28.0 mt -61.58 -46.47 89.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.725 -1.235 . . . . 0.0 111.341 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -73.94 -33.07 35.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 110.464 -178.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.557 ' HB2' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -90.42 -40.71 11.89 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.121 -0.987 . . . . 0.0 110.143 -179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 104' ' ' LEU . 1.6 p -65.86 1.66 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.647 -1.283 . . . . 0.0 111.32 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.509 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.42 -33.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.997 -1.064 . . . . 0.0 110.872 -179.699 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.871 ' O ' HG22 ' A' ' 112' ' ' VAL . 1.9 p -88.02 39.16 0.88 Allowed 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 108' ' ' VAL . 8.9 t -60.63 -10.93 5.9 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.377 -0.827 . . . . 0.0 111.698 -178.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.871 HG22 ' O ' ' A' ' 110' ' ' SER . 0.6 OUTLIER 16.56 -84.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 CA-C-O 121.094 0.473 . . . . 0.0 112.081 -179.839 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.587 ' H ' HG23 ' A' ' 112' ' ' VAL . . . -83.54 52.99 4.81 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.537 ' O ' ' O ' ' A' ' 113' ' ' GLY . 10.6 ttt85 43.49 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 O-C-N 121.539 -0.977 . . . . 0.0 111.544 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.518 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -142.41 107.83 5.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.748 -1.22 . . . . 0.0 110.346 -179.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.476 ' HB3' HG22 ' A' ' 123' ' ' THR . 33.3 t80 -69.43 118.39 12.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.105 -0.997 . . . . 0.0 109.247 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 7.4 t -83.84 158.09 21.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.146 -0.971 . . . . 0.0 111.301 -178.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -135.1 54.72 1.92 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.662 -0.649 . . . . 0.0 110.388 -179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.3 -57.72 0.07 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.603 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -114.4 -23.75 9.21 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.844 -0.798 . . . . 0.0 111.24 -178.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.539 ' O ' ' CB ' ' A' ' 118' ' ' LEU . 5.5 tttt -138.72 147.27 42.51 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.904 -1.122 . . . . 0.0 110.796 -179.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.728 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -116.02 -177.96 3.29 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.086 -1.009 . . . . 0.0 109.136 178.326 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.648 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.9 OUTLIER -156.42 141.23 17.06 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 110.342 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.751 HD12 ' N ' ' A' ' 124' ' ' ILE . 3.1 mp -111.28 129.65 66.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 110.34 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.429 ' OG1' ' N ' ' A' ' 126' ' ' SER . 1.7 t -145.15 -169.1 3.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.184 -0.947 . . . . 0.0 110.399 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.429 ' N ' ' OG1' ' A' ' 125' ' ' THR . 3.8 t . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.848 . . . . 0.0 110.595 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.491 ' HB2' ' HB2' ' A' ' 126' ' ' SER . 77.9 m-20 . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.467 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.41 146.38 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.656 -0.653 . . . . 0.0 110.474 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.703 HG21 ' C ' ' A' ' 125' ' ' THR . 1.9 t -136.56 120.95 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.843 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 39' ' ' VAL . 9.6 p -97.64 134.79 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.665 HD22 HD11 ' A' ' 84' ' ' ILE . 9.2 tp -106.98 147.96 29.25 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.799 HG13 ' CD1' ' A' ' 77' ' ' TRP . 50.6 t -149.07 126.58 2.65 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 120.576 -1.328 . . . . 0.0 110.322 -178.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.914 HD23 ' CZ3' ' A' ' 76' ' ' TRP . 12.4 tp -135.73 178.71 6.83 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.526 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 8.6 ptp -78.61 178.5 7.77 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.725 -1.235 . . . . 0.0 110.79 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 74' ' ' GLY . 4.4 mtmt -64.09 95.9 0.13 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.539 -0.726 . . . . 0.0 112.127 -178.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.515 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 0.2 OUTLIER -73.85 -0.96 17.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 0.0 109.712 178.224 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 45' ' ' SER . 8.0 t0 74.82 -58.96 0.56 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.501 -0.75 . . . . 0.0 112.297 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.549 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.4 mt-10 -95.06 23.68 5.47 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.809 -1.182 . . . . 0.0 111.781 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.847 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -63.23 -71.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 120.823 -1.173 . . . . 0.0 111.674 -179.494 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.566 ' C ' ' O ' ' A' ' 48' ' ' ILE . 15.6 t0 -36.8 -34.2 0.07 Allowed 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.051 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.516 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -77.65 -54.83 5.92 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.847 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.24 -50.8 33.75 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 O-C-N 120.757 -1.214 . . . . 0.0 109.324 178.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.957 HG21 HG13 ' A' ' 69' ' ' VAL . 36.4 mm -46.13 -39.33 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 119.798 -1.814 . . . . 0.0 108.506 177.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.611 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 3.8 tm-20 -64.39 -61.5 2.19 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.185 -0.947 . . . . 0.0 110.333 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -80.69 -10.83 59.7 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.254 -0.904 . . . . 0.0 111.258 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.723 HG22 ' O ' ' A' ' 51' ' ' ILE . 4.8 tp -106.18 -33.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 CA-C-O 121.644 0.735 . . . . 0.0 110.467 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.721 HG13 HG21 ' A' ' 67' ' ' ILE . 2.4 t -117.39 -45.31 3.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.3 -177.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.727 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.1 OUTLIER -58.61 -39.15 79.61 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.096 -1.628 . . . . 0.0 108.492 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.727 ' N ' HD23 ' A' ' 57' ' ' LEU . 1.3 tttt -100.02 -41.04 7.34 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 55' ' ' ILE . . . -67.32 -49.02 55.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -81.39 23.64 4.63 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 120.926 -1.338 . . . . 0.0 110.366 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -107.54 -9.27 15.96 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.854 -1.38 . . . . 0.0 110.76 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.47 -84.8 0.31 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 120.95 -1.094 . . . . 0.0 110.109 -179.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.417 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 4.7 ptpt -70.0 -35.82 74.67 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.515 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.6 OUTLIER -69.36 122.68 86.34 Favored Pre-proline 0 C--N 1.298 -1.668 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.811 179.138 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.475 ' HG2' ' HB3' ' A' ' 81' ' ' ASP . 43.7 Cg_endo -63.26 -45.6 11.78 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 121.733 1.622 . . . . 0.0 110.924 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.685 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.6 OUTLIER 179.37 111.57 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 CA-C-O 122.92 1.343 . . . . 0.0 109.653 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.721 HG21 HG13 ' A' ' 56' ' ' VAL 0.297 1.3 mp -106.68 133.97 49.67 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.403 0 CA-C-N 114.012 -1.449 . . . . 0.0 111.728 -176.799 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.577 ' HB ' ' CG ' ' A' ' 79' ' ' LYS . 1.0 OUTLIER -91.81 139.28 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.555 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.957 HG13 HG21 ' A' ' 52' ' ' ILE . 72.9 t -104.76 89.3 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.178 -0.952 . . . . 0.0 110.328 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.813 ' HB3' ' HB2' ' A' ' 77' ' ' TRP . 0.3 OUTLIER -82.04 50.55 1.59 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -0.795 . . . . 0.0 110.231 179.928 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . 0.489 ' OD1' HG13 ' A' ' 48' ' ' ILE . 3.5 t70 -77.66 109.38 11.59 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.036 -1.04 . . . . 0.0 110.095 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.8 tttt -129.21 142.06 50.97 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.027 -1.046 . . . . 0.0 109.711 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.81 86.78 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.881 . . . . 0.0 109.633 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 158.72 -49.26 0.41 Allowed Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.566 ' HB3' ' CD1' ' A' ' 77' ' ' TRP . 5.1 m-85 -143.62 145.13 32.24 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.814 -0.815 . . . . 0.0 110.418 -179.574 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.914 ' CZ3' HD23 ' A' ' 42' ' ' LEU . 17.8 t90 -94.25 80.14 3.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.613 -0.679 . . . . 0.0 109.989 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.813 ' HB2' ' HB3' ' A' ' 70' ' ' GLU . 7.9 m95 -87.83 128.27 35.34 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 109.039 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.661 ' CG2' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -131.95 137.41 54.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.794 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.577 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 5.5 tttp -118.09 143.36 46.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.506 -1.371 . . . . 0.0 110.818 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.425 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -134.28 134.78 42.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.578 -0.701 . . . . 0.0 110.028 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.475 ' HB3' ' HG2' ' A' ' 65' ' ' PRO . 1.1 t0 -86.27 51.29 2.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.207 -0.933 . . . . 0.0 110.267 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.82 -120.37 0.54 Allowed Glycine 0 C--N 1.3 -1.419 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -113.8 164.29 13.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.367 -1.078 . . . . 0.0 109.372 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.665 HD11 HD22 ' A' ' 40' ' ' LEU . 4.2 tp -147.83 144.07 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.952 -1.093 . . . . 0.0 110.56 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -122.34 150.45 42.38 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.401 -0.812 . . . . 0.0 110.178 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.93 HG22 ' CG ' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -161.42 169.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.459 -0.776 . . . . 0.0 109.651 -179.158 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' A' ' 86' ' ' ILE . 77.7 m-20 -139.63 -173.13 3.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.09 -1.006 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.746 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -131.56 -19.26 2.72 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.092 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.422 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -40.67 -46.15 2.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.076 -1.015 . . . . 0.0 110.537 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -48.63 -54.31 15.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.333 -0.854 . . . . 0.0 109.674 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.683 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -52.67 -28.3 21.09 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.462 -0.774 . . . . 0.0 109.701 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.745 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -70.84 -31.15 67.44 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -69.77 -24.08 63.46 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.877 ' HB3' HD23 ' A' ' 95' ' ' LEU . 0.4 OUTLIER -78.69 -59.16 2.89 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.613 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.877 HD23 ' HB3' ' A' ' 94' ' ' LEU . 0.2 OUTLIER -110.07 -29.34 8.26 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.178 -0.951 . . . . 0.0 110.897 179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 68.56 42.65 80.24 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.663 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 33.2 mttt -133.05 -134.41 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.403 0 O-C-N 121.261 -1.141 . . . . 0.0 109.947 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.663 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.4 Cg_endo -71.78 -4.3 14.82 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 N-CA-C 108.683 -1.314 . . . . 0.0 108.683 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.75 ' CD1' ' N ' ' A' ' 100' ' ' SER . 4.1 p90 -26.56 -42.29 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.88 0.848 . . . . 0.0 111.72 178.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.3 OUTLIER -52.34 -53.09 49.12 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-O 122.593 1.187 . . . . 0.0 108.779 -177.493 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.789 HG12 HD11 ' A' ' 105' ' ' LEU . 59.7 t -102.63 -46.22 10.79 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.484 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 64.7 t80 -52.05 -32.17 33.36 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 117.559 -1.656 . . . . 0.0 107.588 179.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 3.1 t70 -79.63 -50.7 10.27 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.479 -0.888 . . . . 0.0 108.906 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.811 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.6 OUTLIER -55.05 -42.74 73.09 Favored 'General case' 0 C--O 1.204 -1.296 0 C-N-CA 116.913 -1.915 . . . . 0.0 108.515 179.398 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.789 HD11 HG12 ' A' ' 101' ' ' VAL . 52.6 mt -59.07 -29.4 67.3 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.871 -1.143 . . . . 0.0 111.352 179.506 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.464 HD12 ' O ' ' A' ' 102' ' ' TYR . 1.1 mt -92.05 -41.23 12.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 120.939 -1.101 . . . . 0.0 110.879 -178.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.668 ' CB ' HD12 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -90.99 -17.24 26.64 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.903 -1.123 . . . . 0.0 110.967 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.97 HG23 ' CE2' ' A' ' 122' ' ' PHE . 9.1 p -69.48 -3.58 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.089 -1.632 . . . . 0.0 110.093 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -35.1 -27.96 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.667 -0.646 . . . . 0.0 111.35 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.682 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -66.68 8.34 0.26 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 111.399 178.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.784 ' OG1' ' HB2' ' A' ' 115' ' ' ALA . 1.4 t -86.14 38.55 0.77 Allowed 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 117.922 -1.511 . . . . 0.0 110.633 -178.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 19.4 m -55.59 -21.48 9.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 O-C-N 121.42 -0.8 . . . . 0.0 110.861 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -105.72 -71.26 0.8 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -143.83 158.14 43.89 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.377 -1.072 . . . . 0.0 110.105 -179.733 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.784 ' HB2' ' OG1' ' A' ' 111' ' ' THR . . . -160.67 83.79 0.68 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.168 -0.957 . . . . 0.0 111.201 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -80.26 117.59 21.17 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.225 -0.922 . . . . 0.0 108.811 178.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.408 ' H ' HG22 ' A' ' 117' ' ' THR . 4.3 t -84.86 131.98 34.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.146 -0.971 . . . . 0.0 110.406 -179.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.589 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -102.01 38.37 1.66 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 110.396 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.95 -59.64 0.14 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 118' ' ' LEU . 62.3 m -107.5 -13.79 14.99 Favored 'General case' 0 C--N 1.291 -1.935 0 O-C-N 121.941 -0.741 . . . . 0.0 110.059 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.525 ' HB2' ' CB ' ' A' ' 118' ' ' LEU . 1.0 OUTLIER -125.96 165.85 18.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.078 -1.014 . . . . 0.0 111.507 -179.397 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.97 ' CE2' HG23 ' A' ' 108' ' ' VAL 0.255 0.0 OUTLIER -124.9 145.26 49.91 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.896 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.847 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.7 OUTLIER -144.42 110.15 5.31 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.252 -1.53 . . . . 0.0 110.247 -178.18 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.905 HD13 ' CE1' ' A' ' 122' ' ' PHE . 1.5 mp -113.02 153.7 14.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.703 ' C ' HG21 ' A' ' 38' ' ' VAL . 10.2 t -159.52 -176.86 6.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.542 -1.349 . . . . 0.0 111.721 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.491 ' HB2' ' HB2' ' A' ' 36' ' ' ASN . 80.6 p . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.616 -0.677 . . . . 0.0 110.299 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.509 ' O ' HG23 ' A' ' 38' ' ' VAL . 5.7 m120 . . . . . 0 N--CA 1.502 2.155 0 CA-C-O 120.937 0.398 . . . . 0.0 110.995 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -40.35 116.03 0.63 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.138 -0.976 . . . . 0.0 110.97 -179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.552 HG21 ' N ' ' A' ' 126' ' ' SER . 3.2 t -121.86 148.96 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.384 -0.823 . . . . 0.0 109.729 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.958 HG13 ' HB2' ' A' ' 110' ' ' SER . 9.4 p -127.92 139.07 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 111.299 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.679 HD22 ' O ' ' A' ' 85' ' ' GLU . 9.3 tp -117.25 128.67 55.31 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.683 HG13 ' CD1' ' A' ' 77' ' ' TRP . 39.9 t -130.35 150.94 35.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 O-C-N 120.776 -1.203 . . . . 0.0 112.013 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.635 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 0.1 OUTLIER -143.09 176.91 8.75 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 177.544 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.52 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 6.5 ptt? -110.55 36.34 3.13 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.697 -1.252 . . . . 0.0 110.218 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.554 ' HB3' ' CD1' ' A' ' 48' ' ' ILE . 5.1 mmtt -88.51 -81.27 0.26 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.482 -0.761 . . . . 0.0 112.409 -178.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.743 ' N ' HD11 ' A' ' 48' ' ' ILE . 0.0 OUTLIER 67.99 92.97 0.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.197 -178.692 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.493 ' HB2' ' O ' ' A' ' 45' ' ' SER . 3.5 t70 170.96 -80.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.416 -0.803 . . . . 0.0 110.029 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.578 ' HB3' HD13 ' A' ' 51' ' ' ILE . 13.4 mt-10 -91.9 -10.3 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.891 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.939 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -60.65 -64.76 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.341 -0.849 . . . . 0.0 111.526 -178.933 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 2.1 t70 -41.11 -36.88 0.78 Allowed 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 118.769 -1.172 . . . . 0.0 108.961 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -76.19 -52.97 8.97 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.545 -0.722 . . . . 0.0 110.094 178.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.849 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.3 OUTLIER -70.6 -50.03 47.84 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.06 0 O-C-N 120.6 -1.312 . . . . 0.0 108.943 179.104 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.929 HG21 HG13 ' A' ' 69' ' ' VAL . 48.1 mm -43.41 -39.87 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.302 -1.498 . . . . 0.0 108.263 177.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.63 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 24.8 tt0 -65.86 -63.93 0.97 Allowed 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.437 179.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -77.79 -9.79 59.21 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.196 -0.94 . . . . 0.0 111.299 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.731 HG22 ' CA ' ' A' ' 52' ' ' ILE . 4.6 tp -106.61 -34.96 2.99 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-O 121.753 0.787 . . . . 0.0 110.359 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.666 HG23 HG23 ' A' ' 55' ' ' ILE . 2.2 t -117.24 -46.31 3.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.961 -0.696 . . . . 0.0 112.202 -177.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.838 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -56.53 -39.1 72.78 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.274 -1.516 . . . . 0.0 109.502 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.838 ' N ' HD23 ' A' ' 57' ' ' LEU . 1.9 tttp -93.58 -49.74 5.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.0 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.94 -42.38 9.69 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.586 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.46 -54.12 14.26 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.643 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 15.0 ttpt -67.6 12.57 0.09 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.624 -0.927 . . . . 0.0 112.552 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.89 -64.04 0.94 Allowed 'General case' 0 C--N 1.305 -1.33 0 O-C-N 120.56 -1.338 . . . . 0.0 108.351 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.2 mtmt -97.87 -22.06 16.56 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.643 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -69.25 128.98 92.25 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.179 179.779 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.74 -44.32 13.96 Favored 'Trans proline' 0 C--N 1.302 -1.905 0 C-N-CA 122.038 1.826 . . . . 0.0 111.603 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.55 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.44 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.331 0 CA-C-O 123.097 1.427 . . . . 0.0 109.567 -179.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.674 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.305 1.2 mp -97.8 140.87 16.98 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.538 0 CA-C-N 113.741 -1.572 . . . . 0.0 111.563 -176.898 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.547 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 3.1 t -83.23 137.0 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.454 -0.779 . . . . 0.0 110.01 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.929 HG13 HG21 ' A' ' 52' ' ' ILE . 27.6 t -119.99 81.77 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.133 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.674 ' HB2' ' CB ' ' A' ' 77' ' ' TRP . 1.9 mm-40 -78.91 141.13 37.87 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.364 -0.835 . . . . 0.0 110.289 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -145.7 127.88 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.286 -0.884 . . . . 0.0 109.614 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' HB2' ' A' ' 45' ' ' SER . 3.7 ttpt -157.91 -176.9 6.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.021 -1.049 . . . . 0.0 111.326 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.517 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -25.99 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.343 0.592 . . . . 0.0 111.819 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 41.33 44.51 3.95 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.52 ' HA ' ' HA ' ' A' ' 43' ' ' MET . 0.1 OUTLIER -137.25 90.91 2.56 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 121.554 0.692 . . . . 0.0 110.044 179.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.939 ' CD2' HG21 ' A' ' 48' ' ' ILE . 8.8 t90 -83.0 82.28 8.3 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.436 -0.79 . . . . 0.0 109.547 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 1.013 ' O ' HD13 ' A' ' 78' ' ' ILE . 13.6 m95 -89.59 131.27 35.69 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.141 -0.975 . . . . 0.0 110.975 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 1.013 HD13 ' O ' ' A' ' 77' ' ' TRP . 21.3 mm -134.66 153.09 34.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.366 -0.834 . . . . 0.0 109.876 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.561 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -143.55 135.46 26.59 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.947 -179.378 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.575 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -136.43 140.23 42.99 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.597 -0.689 . . . . 0.0 110.03 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -84.46 51.15 2.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.012 . . . . 0.0 110.287 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.77 -148.38 5.97 Favored Glycine 0 N--CA 1.477 1.398 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -88.18 144.77 26.27 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.277 -1.131 . . . . 0.0 109.8 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.583 HD11 HD23 ' A' ' 40' ' ' LEU . 9.8 tt -142.46 172.85 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.962 . . . . 0.0 110.67 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.679 ' O ' HD22 ' A' ' 40' ' ' LEU . 15.4 mt-10 -131.71 176.41 8.35 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.955 -1.091 . . . . 0.0 112.017 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 1.114 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -160.94 154.46 3.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 1.114 ' N ' HD13 ' A' ' 86' ' ' ILE . 4.8 m-20 -137.1 -178.7 5.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.796 -1.19 . . . . 0.0 111.903 -178.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.966 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -150.35 -29.9 0.21 Allowed 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.103 177.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.436 ' CA ' ' HE1' ' A' ' 99' ' ' PHE . . . -39.29 -47.03 1.64 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.062 -1.024 . . . . 0.0 110.663 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 93' ' ' GLU . 2.7 mm-40 -50.92 -63.34 1.16 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 121.871 0.843 . . . . 0.0 109.41 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.56 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -38.61 -38.08 0.37 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.464 179.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.68 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -64.18 -42.49 97.95 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.044 -1.623 . . . . 0.0 109.044 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' N ' ' O ' ' A' ' 90' ' ' GLU . 14.0 mt-10 -60.14 -24.65 64.88 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.522 HD23 ' N ' ' A' ' 95' ' ' LEU . 8.7 tt -79.73 -60.38 2.37 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.523 -0.735 . . . . 0.0 110.469 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -109.95 -20.46 12.73 Favored 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.97 -179.456 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.693 ' N ' HD12 ' A' ' 95' ' ' LEU . . . 63.05 90.4 0.03 OUTLIER Glycine 0 N--CA 1.497 2.71 0 C-N-CA 118.786 -1.674 . . . . 0.0 109.604 179.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.712 ' HB3' ' HD2' ' A' ' 98' ' ' PRO 0.261 0.2 OUTLIER -175.99 -151.69 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.192 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 -178.744 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.712 ' HD2' ' HB3' ' A' ' 97' ' ' LYS . 43.1 Cg_endo -67.8 -1.99 7.79 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 N-CA-C 108.841 -1.253 . . . . 0.0 108.841 176.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.778 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.3 p90 -21.3 -44.58 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.641 0.734 . . . . 0.0 112.427 179.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.966 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.5 OUTLIER -54.47 -53.78 49.65 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 122.868 1.318 . . . . 0.0 108.95 -177.104 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.978 HG12 HD11 ' A' ' 105' ' ' LEU . 48.3 t -98.44 -47.05 12.44 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.343 0 CA-C-N 115.147 -0.933 . . . . 0.0 113.267 -178.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.58 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 5.9 t80 -51.06 -29.22 12.24 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 117.512 -1.675 . . . . 0.0 107.843 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 8.8 t70 -80.9 -44.45 18.3 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.947 HD22 ' CZ ' ' A' ' 122' ' ' PHE . 0.4 OUTLIER -59.55 -45.23 92.4 Favored 'General case' 0 C--O 1.201 -1.476 0 C-N-CA 117.833 -1.547 . . . . 0.0 109.102 178.861 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.978 HD11 HG12 ' A' ' 101' ' ' VAL . 2.5 mt -64.21 -27.29 68.96 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 119.893 -1.755 . . . . 0.0 111.062 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -95.18 -12.73 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 109.937 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.579 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.86 -36.11 3.52 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.507 -0.745 . . . . 0.0 110.289 -179.196 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.703 HG12 ' O ' ' A' ' 104' ' ' LEU . 1.8 p -62.69 -4.86 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.207 -0.933 . . . . 0.0 111.603 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.88 -27.22 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.399 -0.813 . . . . 0.0 111.81 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.958 ' HB2' HG13 ' A' ' 39' ' ' VAL . 90.6 p -82.24 28.84 0.43 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.877 -1.14 . . . . 0.0 109.791 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.702 ' HB ' HG22 ' A' ' 108' ' ' VAL . 5.4 t -89.49 42.89 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.945 -1.097 . . . . 0.0 109.38 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 96.7 t -57.95 -47.29 86.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.762 -0.586 . . . . 0.0 111.364 -179.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -78.01 -75.19 0.97 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.525 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -152.95 -176.98 6.0 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.238 -1.154 . . . . 0.0 110.538 -179.14 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -170.36 73.77 0.07 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.368 -0.833 . . . . 0.0 110.317 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -72.69 140.67 48.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.521 HG22 ' H ' ' A' ' 119' ' ' GLY . 18.8 m -89.3 117.55 28.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 110.532 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.667 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -86.64 39.61 0.85 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.431 -0.793 . . . . 0.0 110.728 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.521 ' H ' HG22 ' A' ' 117' ' ' THR . . . 59.6 -62.01 0.01 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.311 -1.115 . . . . 0.0 110.311 179.196 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.667 ' N ' ' O ' ' A' ' 118' ' ' LEU . 38.3 p -88.44 -28.62 20.77 Favored 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.928 -0.748 . . . . 0.0 109.979 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.57 ' HD3' HD22 ' A' ' 118' ' ' LEU . 3.6 ptmt -146.1 -167.76 2.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.129 -0.982 . . . . 0.0 110.665 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.947 ' CZ ' HD22 ' A' ' 104' ' ' LEU . 5.8 m-85 -116.77 165.07 13.72 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.321 -0.862 . . . . 0.0 110.85 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.687 ' O ' HG22 ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.22 105.1 5.61 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.659 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.737 HD13 ' CG2' ' A' ' 86' ' ' ILE . 1.8 mp -108.2 141.57 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -0.952 . . . . 0.0 109.623 -179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 13.4 t -149.94 -170.76 3.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.06 -1.025 . . . . 0.0 111.11 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.552 ' N ' HG21 ' A' ' 38' ' ' VAL . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.44 -0.787 . . . . 0.0 110.537 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.508 ' O ' ' C ' ' A' ' 37' ' ' ALA . 31.5 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 120.764 0.316 . . . . 0.0 110.59 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.508 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -27.25 127.28 0.06 Allowed 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.347 0.594 . . . . 0.0 111.997 -179.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.5 m -111.76 174.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.772 HG13 ' HB3' ' A' ' 110' ' ' SER . 13.2 p -144.78 125.1 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.139 -0.975 . . . . 0.0 110.783 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.744 HD11 HD11 ' A' ' 86' ' ' ILE . 20.6 tp -92.85 162.85 13.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.819 HG13 ' NE1' ' A' ' 77' ' ' TRP . 5.6 t -149.65 123.47 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 O-C-N 120.106 -1.621 . . . . 0.0 111.833 -178.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.997 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 0.2 OUTLIER -126.36 156.35 40.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.127 -0.983 . . . . 0.0 109.853 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.532 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.6 ptm -96.98 31.38 2.41 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.921 -1.112 . . . . 0.0 110.183 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.527 ' O ' ' HA2' ' A' ' 74' ' ' GLY . 2.3 mmtt -87.74 -86.59 0.16 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.482 -0.761 . . . . 0.0 110.956 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.647 ' CA ' HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER 73.37 113.26 0.06 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.36 -0.838 . . . . 0.0 110.746 -179.834 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 45' ' ' SER . 0.3 OUTLIER 164.73 -83.95 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.665 -0.647 . . . . 0.0 109.438 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.458 ' O ' HD13 ' A' ' 51' ' ' ILE . 5.1 mt-10 -95.52 1.1 53.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.866 . . . . 0.0 110.045 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.964 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.93 -66.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.103 -0.998 . . . . 0.0 111.046 -178.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.655 ' HA ' HG11 ' A' ' 69' ' ' VAL . 5.3 t0 -40.09 -33.58 0.24 Allowed 'General case' 0 C--N 1.292 -1.932 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.68 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.493 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -78.71 -55.5 5.13 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.717 -0.614 . . . . 0.0 109.835 178.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.839 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -68.31 -48.43 73.31 Favored 'Isoleucine or valine' 0 C--O 1.185 -2.316 0 C-N-CA 118.301 -1.36 . . . . 0.0 108.232 178.642 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.758 ' CA ' HG22 ' A' ' 55' ' ' ILE . 46.3 mm -43.32 -41.19 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.004 -1.685 . . . . 0.0 108.42 176.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.611 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 16.2 tt0 -64.84 -62.91 1.28 Allowed 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.895 -1.128 . . . . 0.0 110.025 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -77.41 -11.78 59.88 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.323 -0.86 . . . . 0.0 111.584 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.758 HG22 ' CA ' ' A' ' 52' ' ' ILE . 4.5 tp -107.23 -33.47 2.66 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.531 0.682 . . . . 0.0 111.039 -178.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.757 HG23 HG23 ' A' ' 55' ' ' ILE . 2.8 t -117.22 -45.17 3.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.598 -0.689 . . . . 0.0 112.153 -177.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.878 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -54.58 -30.08 53.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 119.758 -1.839 . . . . 0.0 108.959 -179.798 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.878 ' N ' HD23 ' A' ' 57' ' ' LEU . 13.4 mmtt -85.99 -47.49 9.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.473 -0.767 . . . . 0.0 110.483 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.44 -45.09 5.37 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.566 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.97 -73.04 0.76 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.622 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 22.4 ttpt -65.72 9.84 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.403 -1.057 . . . . 0.0 112.557 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.618 ' HB2' ' O ' ' A' ' 58' ' ' LYS . . . -51.63 -63.47 1.13 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.555 -1.341 . . . . 0.0 108.454 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.0 mtmt -97.97 -20.34 17.48 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 177.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.622 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.8 OUTLIER -68.68 141.1 92.43 Favored Pre-proline 0 N--CA 1.489 1.503 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.393 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.423 ' O ' ' OG ' ' A' ' 66' ' ' SER . 42.9 Cg_endo -62.38 -46.38 12.35 Favored 'Trans proline' 0 C--N 1.298 -2.107 0 C-N-CA 122.228 1.952 . . . . 0.0 112.002 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.423 ' OG ' ' O ' ' A' ' 65' ' ' PRO . 0.9 OUTLIER 178.81 112.99 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 123.158 1.456 . . . . 0.0 110.66 -179.691 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.69 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.306 1.0 OUTLIER -89.99 147.67 5.06 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.684 0 CA-C-N 113.573 -1.649 . . . . 0.0 110.86 -178.185 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.556 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -102.05 138.21 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.133 -0.98 . . . . 0.0 110.695 -179.581 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.702 HG22 HG21 ' A' ' 52' ' ' ILE . 5.5 t -116.82 90.97 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.372 -0.83 . . . . 0.0 109.073 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.599 ' CB ' ' HB2' ' A' ' 77' ' ' TRP . 13.2 mm-40 -79.61 76.51 6.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.487 -0.758 . . . . 0.0 110.655 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -89.04 113.62 24.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.973 -1.079 . . . . 0.0 109.485 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.421 ' O ' ' N ' ' A' ' 74' ' ' GLY . 13.0 mttp -145.47 -162.02 1.42 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.032 -1.042 . . . . 0.0 111.059 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.574 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -39.76 96.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.335 -0.853 . . . . 0.0 111.243 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 37.73 50.1 1.93 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.574 ' CD2' ' O ' ' A' ' 73' ' ' ALA . 8.6 m-85 -146.59 87.14 1.69 Allowed 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.875 -0.779 . . . . 0.0 109.761 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.997 ' CZ3' HD13 ' A' ' 42' ' ' LEU . 4.5 t90 -82.13 74.16 9.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.516 -0.74 . . . . 0.0 110.033 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.819 ' NE1' HG13 ' A' ' 41' ' ' VAL . 8.9 m95 -82.0 123.33 28.81 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.652 HD13 ' O ' ' A' ' 77' ' ' TRP . 5.5 mm -116.38 141.01 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.003 -1.061 . . . . 0.0 110.159 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.597 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.4 OUTLIER -123.61 130.52 52.79 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.612 -0.68 . . . . 0.0 109.598 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.47 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -130.28 165.89 21.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.222 -0.924 . . . . 0.0 110.289 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -118.35 50.32 1.18 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.341 -0.849 . . . . 0.0 110.304 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -119.77 0.52 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -112.22 152.67 28.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -1.115 . . . . 0.0 109.717 179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 124' ' ' ILE . 8.1 tt -152.41 175.19 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.483 ' HG2' ' HA ' ' A' ' 123' ' ' THR . 56.2 mt-10 -148.16 172.47 14.27 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.007 -1.058 . . . . 0.0 111.315 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.78 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -124.48 167.62 18.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 121.601 -0.687 . . . . 0.0 109.552 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.417 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 26.0 m-20 -154.98 138.97 16.37 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.015 -1.053 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.988 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.73 -37.52 0.12 Allowed 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.379 -1.328 . . . . 0.0 111.0 177.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 93' ' ' GLU . . . -39.89 -40.27 0.97 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.501 -0.75 . . . . 0.0 110.567 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.523 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 3.2 mt-10 -72.06 -43.97 64.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.317 -0.864 . . . . 0.0 109.408 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.483 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -60.35 -49.84 75.99 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 108.955 179.206 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.568 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -53.53 -57.43 15.66 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.523 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.1 pt-20 -59.98 -13.24 10.38 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.332 -1.099 . . . . 0.0 110.038 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.762 HD23 ' N ' ' A' ' 95' ' ' LEU . 0.5 OUTLIER -92.22 -43.75 9.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.317 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.762 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -97.64 -41.31 8.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.795 -1.191 . . . . 0.0 109.247 179.464 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.74 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -145.33 -74.7 0.02 OUTLIER Glycine 0 N--CA 1.483 1.805 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.565 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.3 OUTLIER 161.61 -55.77 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.858 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.737 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.546 ' HD3' ' HB3' ' A' ' 97' ' ' LYS . 52.2 Cg_endo -74.66 -23.54 14.49 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.856 1.45 . . . . 0.0 110.251 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.568 ' HB3' ' HA2' ' A' ' 92' ' ' GLY . 2.6 t80 -47.28 -49.42 23.71 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.223 -0.923 . . . . 0.0 109.996 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.988 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 29.5 p -31.97 -64.12 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.889 0.852 . . . . 0.0 110.429 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.968 ' HA ' HD23 ' A' ' 104' ' ' LEU . 13.8 t -72.69 -60.78 2.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 O-C-N 121.034 -1.041 . . . . 0.0 112.572 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 101' ' ' VAL . 1.7 t80 -44.94 -30.48 1.02 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.532 -1.355 . . . . 0.0 109.332 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 6.4 t0 -77.08 -31.52 56.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.598 -0.689 . . . . 0.0 109.287 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.971 HD13 ' CZ ' ' A' ' 122' ' ' PHE . 0.6 OUTLIER -74.81 -19.49 60.17 Favored 'General case' 0 C--O 1.2 -1.51 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.24 179.739 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 101' ' ' VAL . 1.4 mt -91.27 -26.12 19.14 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.345 -1.472 . . . . 0.0 111.226 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -97.22 -13.58 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.015 -1.053 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.555 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -105.57 -42.9 5.08 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.509 -0.745 . . . . 0.0 110.012 179.766 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.627 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 3.5 p -57.32 -2.86 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 120.879 -1.138 . . . . 0.0 112.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.504 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -25.22 -39.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.77 -0.581 . . . . 0.0 112.365 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.772 ' HB3' HG13 ' A' ' 39' ' ' VAL . 1.9 m -80.27 43.14 0.61 Allowed 'General case' 0 C--N 1.287 -2.137 0 C-N-CA 118.43 -1.308 . . . . 0.0 108.79 178.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.611 ' CG2' HG22 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -63.33 2.02 0.44 Allowed 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.267 -0.896 . . . . 0.0 112.45 -179.146 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.454 ' C ' ' O ' ' A' ' 111' ' ' THR . 9.6 p -38.16 -27.24 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 120.808 -1.183 . . . . 0.0 111.17 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.535 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -97.64 50.22 1.41 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.535 ' C ' ' O ' ' A' ' 113' ' ' GLY . 1.5 ttm-85 19.86 100.36 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.356 0.598 . . . . 0.0 111.982 179.165 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.578 ' HB1' ' CD2' ' A' ' 122' ' ' PHE . . . -85.09 93.69 8.68 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.266 -0.896 . . . . 0.0 111.47 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 123' ' ' THR . 0.1 OUTLIER -74.44 143.91 44.5 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.189 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 4.0 m -79.51 160.21 26.62 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.79 -1.194 . . . . 0.0 111.309 -178.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.625 HD23 ' O ' ' A' ' 118' ' ' LEU . 0.9 OUTLIER -130.62 35.33 4.03 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.665 -0.647 . . . . 0.0 109.891 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.49 -59.76 0.29 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -115.42 -9.24 12.15 Favored 'General case' 0 C--N 1.292 -1.908 0 O-C-N 122.013 -0.698 . . . . 0.0 110.186 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.454 ' HB2' ' HB3' ' A' ' 118' ' ' LEU . 20.8 mttt -137.68 -162.26 1.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.151 -0.968 . . . . 0.0 111.195 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.971 ' CZ ' HD13 ' A' ' 104' ' ' LEU 0.263 0.1 OUTLIER -132.15 160.66 35.4 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.068 -179.235 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.663 ' O ' HG22 ' A' ' 123' ' ' THR . 0.9 OUTLIER -138.3 104.14 5.1 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.034 -1.041 . . . . 0.0 110.598 178.697 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.805 ' HB ' HG23 ' A' ' 84' ' ' ILE . 3.4 mp -98.44 146.78 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.201 -0.937 . . . . 0.0 108.59 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.5 t -149.4 166.75 28.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.782 -1.199 . . . . 0.0 111.108 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.472 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 2.4 t . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 121.555 0.693 . . . . 0.0 109.533 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.717 ' O ' HG13 ' A' ' 38' ' ' VAL . 4.0 m-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.147 0.498 . . . . 0.0 110.276 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -31.87 141.32 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.569 0.699 . . . . 0.0 111.904 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.717 HG13 ' O ' ' A' ' 36' ' ' ASN . 24.2 m -141.42 176.17 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.472 -0.767 . . . . 0.0 109.709 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 39' ' ' VAL . 5.5 p -136.46 130.5 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.953 -1.092 . . . . 0.0 111.097 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.895 ' O ' HG23 ' A' ' 41' ' ' VAL . 12.4 tp -98.1 160.66 14.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 177.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.912 ' O ' HD22 ' A' ' 42' ' ' LEU . 2.9 t -166.31 116.4 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 O-C-N 120.871 -1.143 . . . . 0.0 110.093 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.912 HD22 ' O ' ' A' ' 41' ' ' VAL . 2.5 mm? -135.38 -171.68 2.89 Favored 'General case' 0 C--N 1.289 -2.056 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.404 ' O ' ' N ' ' A' ' 45' ' ' SER . 20.9 ptm -104.09 161.43 14.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.161 -0.962 . . . . 0.0 109.813 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -44.75 96.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.3 -0.875 . . . . 0.0 111.263 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 4.5 m -82.11 11.81 4.86 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.165 -0.959 . . . . 0.0 110.265 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' SER . 13.3 t0 78.41 -62.51 0.34 Allowed 'General case' 0 N--CA 1.503 2.18 0 O-C-N 121.569 -0.707 . . . . 0.0 112.421 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.59 ' O ' HD13 ' A' ' 51' ' ' ILE . 3.5 mt-10 -93.31 26.56 2.88 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.776 -1.203 . . . . 0.0 112.195 -177.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.81 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.61 -75.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 120.932 -1.105 . . . . 0.0 111.092 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.3 t70 -37.63 -32.22 0.05 Allowed 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.45 -56.13 4.91 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 177.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.81 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -71.28 -52.14 29.02 Favored 'Isoleucine or valine' 0 C--O 1.193 -1.88 0 O-C-N 120.977 -1.077 . . . . 0.0 109.869 179.075 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.701 ' HA ' HG22 ' A' ' 55' ' ' ILE . 47.2 mm -48.22 -38.73 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 119.89 -1.756 . . . . 0.0 108.121 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.729 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.7 tt0 -63.07 -61.12 2.59 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.183 -0.948 . . . . 0.0 110.352 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -81.06 -12.0 59.4 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 111.405 -178.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.745 HG23 HG23 ' A' ' 56' ' ' VAL . 4.3 tp -105.88 -32.99 2.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-O 121.645 0.736 . . . . 0.0 110.365 -178.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.745 HG23 HG23 ' A' ' 55' ' ' ILE . 2.5 t -117.89 -45.08 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.869 -0.732 . . . . 0.0 112.694 -177.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.729 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -49.31 -42.75 42.34 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.011 -1.681 . . . . 0.0 109.037 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.54 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 14.3 mttt -85.08 -44.22 13.2 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.574 0.702 . . . . 0.0 109.51 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -65.54 -51.36 48.67 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.54 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -69.43 -8.36 59.38 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' A' ' 57' ' ' LEU . 2.1 tptm -107.36 -9.02 16.13 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.129 -1.218 . . . . 0.0 110.954 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.17 -79.05 0.24 Allowed 'General case' 0 C--N 1.308 -1.197 0 O-C-N 120.886 -1.134 . . . . 0.0 110.69 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.9 mtmt -87.45 -29.38 21.47 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.54 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.9 m-80 -69.18 124.99 91.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.113 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.474 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 42.9 Cg_endo -62.56 -42.87 24.34 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.781 1.654 . . . . 0.0 110.671 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.598 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.4 OUTLIER 179.4 110.0 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 123.008 1.385 . . . . 0.0 109.64 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.747 HG23 ' O ' ' A' ' 79' ' ' LYS 0.297 1.1 mp -105.37 149.99 8.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 113.839 -1.528 . . . . 0.0 110.496 -177.205 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -103.44 130.36 53.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.322 -0.861 . . . . 0.0 110.013 179.725 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.685 ' CG1' HG21 ' A' ' 52' ' ' ILE . 55.5 t -113.95 100.29 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.168 -0.957 . . . . 0.0 109.889 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.565 ' N ' ' O ' ' A' ' 77' ' ' TRP . 0.7 OUTLIER -89.81 79.55 6.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.385 -0.822 . . . . 0.0 110.681 -179.487 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -80.47 91.02 5.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.073 -1.017 . . . . 0.0 109.396 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -89.78 154.45 19.9 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.159 -0.963 . . . . 0.0 110.482 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -59.63 -12.65 7.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.818 . . . . 0.0 110.548 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.452 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . -147.29 22.92 1.56 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.456 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.452 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 5.8 m-85 -160.77 108.8 1.57 Allowed 'General case' 0 C--N 1.289 -2.051 0 O-C-N 121.76 -0.847 . . . . 0.0 109.887 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.777 ' CE2' HG22 ' A' ' 48' ' ' ILE . 13.1 t90 -89.8 77.84 6.97 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.599 -0.688 . . . . 0.0 109.379 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.858 ' CE2' HG13 ' A' ' 41' ' ' VAL . 12.4 m0 -102.77 134.6 45.89 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.506 -0.746 . . . . 0.0 112.433 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.549 ' HB ' HD23 ' A' ' 40' ' ' LEU . 1.2 mp -138.65 152.39 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.747 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.4 OUTLIER -127.83 152.74 47.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.831 -1.168 . . . . 0.0 110.041 -179.728 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.461 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -139.42 178.86 6.9 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.299 -0.875 . . . . 0.0 110.603 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 37' ' ' ALA . 41.6 m-20 -122.54 50.49 1.49 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.364 -0.835 . . . . 0.0 110.138 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.55 -126.66 0.88 Allowed Glycine 0 C--N 1.301 -1.386 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -99.8 143.93 29.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -1.22 . . . . 0.0 109.925 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.59 HG23 ' HB ' ' A' ' 124' ' ' ILE . 4.8 tp -125.85 161.99 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.145 -0.972 . . . . 0.0 110.012 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.518 ' N ' HG13 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.88 164.96 23.02 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.137 -0.977 . . . . 0.0 111.717 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.791 HG13 HD13 ' A' ' 124' ' ' ILE 0.26 0.3 OUTLIER -139.91 175.02 7.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.363 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.555 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 74.9 m-20 -149.55 173.37 13.69 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.861 -1.149 . . . . 0.0 111.308 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 1.025 ' HB1' ' CA ' ' A' ' 100' ' ' SER . . . -150.96 -48.77 0.12 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.97 0.891 . . . . 0.0 109.759 177.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.414 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -41.37 -45.4 3.05 Favored 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.351 -0.843 . . . . 0.0 110.643 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.566 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 1.1 tt0 -49.81 -38.55 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 122.138 0.971 . . . . 0.0 108.483 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 1.004 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -63.45 -42.59 98.64 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.396 -0.815 . . . . 0.0 109.191 178.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.719 ' N ' ' CD2' ' A' ' 99' ' ' PHE . . . -63.15 -65.37 3.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.566 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 5.2 pt-20 -38.21 -31.56 0.05 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.818 -0.813 . . . . 0.0 108.94 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.722 HD13 ' HG ' ' A' ' 95' ' ' LEU . 0.1 OUTLIER -73.6 -71.16 0.33 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.68 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 1.004 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.1 OUTLIER -86.97 -55.17 3.95 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.972 -1.08 . . . . 0.0 108.847 178.599 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 88.18 50.14 3.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.696 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 15.2 mttt -150.74 -110.7 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 121.288 -1.125 . . . . 0.0 110.646 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.696 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 58.6 Cg_endo -85.5 12.98 2.89 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 CA-C-N 120.926 1.366 . . . . 0.0 109.67 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.729 ' O ' ' N ' ' A' ' 101' ' ' VAL . 29.3 p90 -49.85 -146.0 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 122.009 0.909 . . . . 0.0 110.474 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 1.025 ' CA ' ' HB1' ' A' ' 88' ' ' ALA . 2.1 p 32.73 -77.59 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 122.269 1.033 . . . . 0.0 111.323 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.729 ' N ' ' O ' ' A' ' 99' ' ' PHE . 38.0 t -66.02 -64.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.582 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.491 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 16.0 t80 -59.89 -39.9 86.9 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 119.99 -1.694 . . . . 0.0 106.69 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.581 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 0.3 OUTLIER -63.42 -38.96 93.16 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.847 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.865 HD12 ' N ' ' A' ' 105' ' ' LEU . 3.2 pp -83.75 -38.89 20.78 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 117.957 -1.497 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.865 ' N ' HD12 ' A' ' 104' ' ' LEU . 66.7 mt -49.82 -22.19 1.37 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 120.802 -1.186 . . . . 0.0 109.602 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.437 HD13 ' HA ' ' A' ' 106' ' ' ILE . 0.4 OUTLIER -107.83 -33.4 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.288 -0.882 . . . . 0.0 110.15 179.768 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.581 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.7 p30 -96.7 -3.65 42.19 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.968 -1.082 . . . . 0.0 110.027 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.664 HG12 ' O ' ' A' ' 104' ' ' LEU . 9.8 p -83.11 -7.7 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 110.804 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 108' ' ' VAL . 8.5 t -42.02 -22.91 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.193 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.595 ' CB ' ' N ' ' A' ' 41' ' ' VAL . 82.8 p -53.22 -4.31 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.313 -0.867 . . . . 0.0 112.641 179.283 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.954 HG22 HG12 ' A' ' 124' ' ' ILE . 45.1 p -71.76 -73.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.428 0 O-C-N 119.923 -1.736 . . . . 0.0 110.868 -178.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.567 HG12 ' O ' ' A' ' 112' ' ' VAL . 47.9 t 61.78 11.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.517 -0.74 . . . . 0.0 110.575 -179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -161.2 -68.94 0.02 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.796 ' HB3' HG22 ' A' ' 125' ' ' THR . 0.1 OUTLIER -136.58 165.86 24.88 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.305 -1.114 . . . . 0.0 110.497 -179.38 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.997 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -156.25 68.79 0.62 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.318 -0.864 . . . . 0.0 110.185 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.57 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 7.1 t80 -69.69 132.15 45.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.246 -0.908 . . . . 0.0 109.657 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.4 m -88.57 138.87 31.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.147 -0.971 . . . . 0.0 110.305 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -108.73 37.19 2.6 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.381 -0.824 . . . . 0.0 110.197 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.21 -58.47 0.25 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.553 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.8 OUTLIER -113.38 -23.35 9.92 Favored 'General case' 0 C--N 1.293 -1.871 0 O-C-N 121.95 -0.735 . . . . 0.0 110.067 -179.873 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -116.69 -168.22 1.42 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.997 ' CZ ' ' HB1' ' A' ' 115' ' ' ALA . 14.5 t80 -138.03 161.71 36.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.782 . . . . 0.0 109.159 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.603 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.8 OUTLIER -145.24 139.26 27.03 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 120.569 -1.332 . . . . 0.0 110.337 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.972 HD11 ' CD2' ' A' ' 122' ' ' PHE . 2.1 mp -134.91 154.39 36.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.467 -0.77 . . . . 0.0 110.18 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.796 HG22 ' HB3' ' A' ' 114' ' ' ARG . 1.9 t -152.34 -175.04 5.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.186 -0.946 . . . . 0.0 110.34 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 90.4 p . . . . . 0 N--CA 1.492 1.656 0 O-C-N 121.364 -0.835 . . . . 0.0 110.538 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.526 ' O ' ' C ' ' A' ' 37' ' ' ALA . 5.5 m-80 . . . . . 0 N--CA 1.496 1.851 0 CA-C-O 120.735 0.302 . . . . 0.0 110.636 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.526 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -26.38 139.43 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.353 0.596 . . . . 0.0 111.496 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.598 HG12 ' OG ' ' A' ' 126' ' ' SER . 8.7 p -102.08 136.3 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.775 HG13 ' HB2' ' A' ' 110' ' ' SER . 8.4 p -80.65 135.44 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.041 -1.037 . . . . 0.0 110.273 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.943 HD22 ' CG1' ' A' ' 84' ' ' ILE . 14.7 tp -110.42 134.48 52.29 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.756 HG13 ' NE1' ' A' ' 77' ' ' TRP . 10.1 t -130.63 121.24 50.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 O-C-N 120.86 -1.15 . . . . 0.0 110.942 -177.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.763 HD21 HG23 ' A' ' 86' ' ' ILE . 0.4 OUTLIER -120.54 -171.63 2.21 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.633 -0.667 . . . . 0.0 109.475 179.245 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.98 159.48 15.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.154 -0.967 . . . . 0.0 109.965 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.64 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.189 -0.945 . . . . 0.0 110.6 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.472 ' HB3' HG23 ' A' ' 48' ' ' ILE . 1.8 t -86.53 11.25 13.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 110.144 179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.486 ' N ' HD13 ' A' ' 48' ' ' ILE . 5.5 m-20 67.71 -62.87 0.33 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.494 -0.754 . . . . 0.0 111.108 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.486 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.0 mt-10 -87.21 30.17 0.79 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.103 -0.998 . . . . 0.0 110.616 -179.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.954 HG22 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.36 -75.2 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.969 -1.082 . . . . 0.0 111.393 -178.698 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.527 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -39.47 -31.61 0.1 Allowed 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.305 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -75.4 -53.79 8.12 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.763 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.41 -53.55 19.1 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.76 0 O-C-N 120.997 -1.065 . . . . 0.0 109.992 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.717 ' HA ' HG22 ' A' ' 55' ' ' ILE . 44.8 mm -47.05 -37.15 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 119.962 -1.711 . . . . 0.0 108.106 177.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.711 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 30.2 tt0 -64.39 -63.43 1.14 Allowed 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.386 -0.821 . . . . 0.0 110.282 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.44 -10.03 59.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.354 -0.841 . . . . 0.0 111.295 -178.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.717 HG22 ' HA ' ' A' ' 52' ' ' ILE . 4.4 tp -106.68 -33.79 2.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-O 121.62 0.724 . . . . 0.0 110.371 -179.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.715 HG23 HG23 ' A' ' 55' ' ' ILE . 2.3 t -118.67 -43.22 2.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.711 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -44.98 -38.47 4.77 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.449 -1.407 . . . . 0.0 109.775 -178.346 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.536 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 0.0 OUTLIER -86.78 -44.61 11.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -56.55 -53.35 44.2 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.53 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -72.19 0.79 37.57 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.489 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 2.0 mmtt -106.57 -9.31 16.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.845 -1.385 . . . . 0.0 111.357 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.36 -80.05 0.12 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.888 -1.133 . . . . 0.0 109.852 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.58 -24.75 16.46 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 122.307 1.051 . . . . 0.0 108.411 178.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.53 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.4 m-20 -67.51 116.55 38.39 Favored Pre-proline 0 C--N 1.294 -1.844 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.727 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 44.3 Cg_endo -62.99 -37.36 53.99 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 124.299 1.684 . . . . 0.0 111.558 -179.2 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.633 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.3 OUTLIER 179.36 111.61 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 123.145 1.45 . . . . 0.0 109.908 179.423 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.644 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.298 1.2 mp -104.5 155.01 6.09 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 CA-C-N 113.665 -1.607 . . . . 0.0 111.024 -177.442 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.632 HG11 ' CE ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -110.55 147.04 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.172 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.696 ' CG1' HG21 ' A' ' 52' ' ' ILE . 58.1 t -128.5 106.18 14.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.15 -0.968 . . . . 0.0 110.093 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.569 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.3 mm-40 -97.16 84.06 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.779 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -96.47 128.17 43.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.153 -0.967 . . . . 0.0 110.201 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -144.76 143.51 30.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 110.07 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -58.55 81.52 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 109.542 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 159.02 -40.11 0.49 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -139.94 173.81 11.15 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-O 121.835 0.826 . . . . 0.0 110.984 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.954 ' CE2' HG22 ' A' ' 48' ' ' ILE . 13.4 t90 -138.92 83.29 1.95 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.756 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.3 m95 -104.87 120.55 41.68 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.111 -0.993 . . . . 0.0 112.379 -177.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.548 ' CG1' ' HA ' ' A' ' 69' ' ' VAL . 1.1 mt -130.61 141.74 45.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.097 -1.002 . . . . 0.0 109.283 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.632 ' CE ' HG11 ' A' ' 68' ' ' VAL . 2.1 ptpt -114.12 134.17 55.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 110.028 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.505 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -120.16 148.91 43.05 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.317 -0.864 . . . . 0.0 109.838 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.46 ' HA ' ' CB ' ' A' ' 37' ' ' ALA . 1.4 m-20 -95.43 53.3 1.47 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.168 -0.958 . . . . 0.0 110.379 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.413 ' O ' ' OG ' ' A' ' 126' ' ' SER . . . -170.16 -116.79 0.39 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -121.39 146.61 46.7 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.169 -1.195 . . . . 0.0 110.165 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.943 ' CG1' HD22 ' A' ' 40' ' ' LEU . 5.5 tp -133.53 159.72 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.042 -1.036 . . . . 0.0 110.698 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.49 ' HG2' ' OG1' ' A' ' 123' ' ' THR . 16.9 mt-10 -137.56 130.32 30.06 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.325 -0.86 . . . . 0.0 110.793 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.763 HG23 HD21 ' A' ' 42' ' ' LEU . 1.7 mm -86.37 -176.1 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.333 -0.854 . . . . 0.0 109.82 179.699 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.551 ' H ' HG22 ' A' ' 86' ' ' ILE . 4.6 m-20 -156.54 154.8 30.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 110.869 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.823 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -150.13 -25.39 0.25 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.361 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.434 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -39.52 -45.24 1.54 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.936 -1.103 . . . . 0.0 111.032 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.497 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 1.2 tp10 -54.34 -60.6 3.12 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.345 -0.847 . . . . 0.0 109.844 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.569 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -42.28 -31.71 0.42 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.5 -0.75 . . . . 0.0 109.836 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.701 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -72.09 -41.78 53.19 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.497 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 7.7 mt-10 -55.82 -24.74 38.04 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.103 -1.234 . . . . 0.0 108.29 179.105 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.754 HD23 ' CD2' ' A' ' 95' ' ' LEU . 15.4 tp -87.05 -70.95 0.58 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 121.277 0.561 . . . . 0.0 110.01 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.754 ' CD2' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -87.27 -29.82 21.36 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.653 179.821 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 62.5 46.36 93.95 Favored Glycine 0 N--CA 1.499 2.844 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.145 177.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.761 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 0.1 OUTLIER -143.69 -128.58 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.262 0 O-C-N 120.901 -1.352 . . . . 0.0 109.636 178.728 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.761 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.5 Cg_endo -68.9 -3.63 11.8 Favored 'Trans proline' 0 N--CA 1.499 1.852 0 CA-C-N 121.738 1.656 . . . . 0.0 110.034 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.723 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.7 p90 -30.17 -41.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.211 1.005 . . . . 0.0 111.434 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.823 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 4.4 t -53.49 -58.18 8.06 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-O 122.894 1.331 . . . . 0.0 110.082 -177.189 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 1.027 HG12 ' CD2' ' A' ' 105' ' ' LEU . 46.9 t -97.9 -37.41 6.63 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.494 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 2.9 t80 -59.6 -33.67 71.77 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 119.741 -1.849 . . . . 0.0 107.674 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.587 ' HB3' ' O ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER -76.04 -42.67 47.07 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 178.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.809 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.9 OUTLIER -68.01 -36.67 80.35 Favored 'General case' 0 C--O 1.209 -1.078 0 C-N-CA 117.38 -1.728 . . . . 0.0 107.563 177.933 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 1.027 ' CD2' HG12 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -46.87 -49.39 20.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.801 178.852 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.473 HD13 ' HA ' ' A' ' 106' ' ' ILE . 4.6 mm -83.87 -26.37 7.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.598 -0.689 . . . . 0.0 110.355 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.604 ' O ' HD22 ' A' ' 42' ' ' LEU . 1.2 p30 -104.34 18.37 22.28 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.176 -0.953 . . . . 0.0 110.7 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.785 HG21 ' CE2' ' A' ' 122' ' ' PHE . 8.4 p -121.56 -12.39 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 120.894 -1.129 . . . . 0.0 109.733 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -36.67 -27.31 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.499 -0.751 . . . . 0.0 112.222 -178.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.775 ' HB2' HG13 ' A' ' 39' ' ' VAL . 54.4 p -86.06 34.05 0.61 Allowed 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.619 -1.3 . . . . 0.0 109.254 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.51 ' HB ' HG22 ' A' ' 108' ' ' VAL . 9.9 t -107.12 50.05 0.78 Allowed 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.645 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 66.4 t -80.75 -33.32 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.642 -0.661 . . . . 0.0 111.496 -178.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -66.92 -78.97 0.23 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.773 ' O ' HG23 ' A' ' 124' ' ' ILE . 0.4 OUTLIER -135.21 175.8 9.25 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.364 -1.08 . . . . 0.0 109.996 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.709 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -167.39 75.16 0.14 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.905 -1.122 . . . . 0.0 111.226 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.629 ' HB2' HG22 ' A' ' 123' ' ' THR . 0.4 OUTLIER -77.76 116.72 18.5 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.189 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.49 HG22 ' H ' ' A' ' 119' ' ' GLY . 17.1 m -79.23 129.02 34.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.063 . . . . 0.0 110.478 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.568 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.4 OUTLIER -104.04 45.62 0.95 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.383 -0.823 . . . . 0.0 110.386 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.49 ' H ' HG22 ' A' ' 117' ' ' THR . . . 65.37 -58.52 0.11 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.568 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.3 OUTLIER -115.69 -12.72 11.5 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.885 -0.774 . . . . 0.0 110.995 -179.473 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 63.2 mttt -124.2 178.71 5.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.971 -1.081 . . . . 0.0 111.294 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.785 ' CE2' HG21 ' A' ' 108' ' ' VAL . 2.5 t80 -126.85 146.61 50.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.589 -0.695 . . . . 0.0 109.194 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.629 HG22 ' HB2' ' A' ' 116' ' ' TYR . 0.9 OUTLIER -134.8 123.03 22.91 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 120.678 -1.264 . . . . 0.0 110.688 -179.701 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.773 HG23 ' O ' ' A' ' 114' ' ' ARG . 3.4 mp -124.39 168.51 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.691 HG22 ' HB3' ' A' ' 114' ' ' ARG . 9.0 t -159.09 154.87 26.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.555 -1.34 . . . . 0.0 111.518 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.598 ' OG ' HG12 ' A' ' 38' ' ' VAL . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.627 -0.671 . . . . 0.0 109.986 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.678 ' O ' HG23 ' A' ' 38' ' ' VAL . 1.5 m-80 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.154 0.502 . . . . 0.0 110.132 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -36.45 127.31 0.81 Allowed 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 121.372 0.606 . . . . 0.0 111.083 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.743 HG11 HG22 ' A' ' 124' ' ' ILE . 15.7 t -129.95 141.38 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 109.698 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.568 ' O ' ' HB2' ' A' ' 110' ' ' SER . 4.0 p -107.95 133.13 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 120.945 -1.097 . . . . 0.0 111.205 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.697 HD11 HG13 ' A' ' 86' ' ' ILE . 4.8 tp -105.4 143.51 33.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.793 HG13 ' CD1' ' A' ' 77' ' ' TRP . 11.4 t -139.84 129.2 28.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 O-C-N 120.462 -1.399 . . . . 0.0 111.909 -178.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.862 HD23 ' CG ' ' A' ' 107' ' ' ASN . 11.3 mt -135.42 -172.16 3.01 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.477 ' O ' ' N ' ' A' ' 45' ' ' SER . 8.0 ptm -100.31 151.96 20.88 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.827 -1.171 . . . . 0.0 110.466 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.471 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -48.14 89.28 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.468 -0.77 . . . . 0.0 111.543 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 43' ' ' MET . 29.6 t -65.1 -88.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.175 -0.953 . . . . 0.0 109.531 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.439 ' H ' HD13 ' A' ' 48' ' ' ILE . 5.1 m-20 -151.78 -77.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.879 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.469 ' O ' HG12 ' A' ' 51' ' ' ILE . 4.1 mt-10 -96.07 34.28 1.59 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.356 -0.84 . . . . 0.0 110.979 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.815 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.39 -64.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.792 -1.193 . . . . 0.0 111.633 -178.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.48 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -44.58 -38.12 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 118.702 -1.199 . . . . 0.0 108.746 179.354 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.469 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.79 -49.03 19.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.53 -0.732 . . . . 0.0 110.25 178.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.815 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.04 -51.03 28.17 Favored 'Isoleucine or valine' 0 C--O 1.191 -1.995 0 O-C-N 120.703 -1.248 . . . . 0.0 109.313 179.341 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.929 HG21 HG13 ' A' ' 69' ' ' VAL . 41.9 mm -45.53 -39.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.097 -1.627 . . . . 0.0 108.155 177.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.624 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 48.1 tt0 -62.72 -63.48 1.2 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -81.62 -8.19 59.68 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.289 -0.882 . . . . 0.0 111.398 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.788 HG23 HG23 ' A' ' 56' ' ' VAL . 4.7 tp -107.09 -33.72 2.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 CA-C-O 121.776 0.798 . . . . 0.0 110.137 -179.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.788 HG23 HG23 ' A' ' 55' ' ' ILE . 3.0 t -117.88 -44.83 3.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 C-N-CA 120.041 -0.664 . . . . 0.0 112.627 -177.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.845 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -60.69 -36.82 79.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.364 -1.46 . . . . 0.0 109.033 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.845 ' N ' HD23 ' A' ' 57' ' ' LEU . 2.8 tmtt? -100.93 -44.67 5.67 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.821 0.819 . . . . 0.0 109.037 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -69.2 -52.24 23.75 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.593 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.66 -43.85 73.9 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.822 -1.399 . . . . 0.0 110.155 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.599 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 12.9 ttmt -63.15 9.23 0.05 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.522 -0.987 . . . . 0.0 113.196 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.62 -63.8 1.03 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.225 -1.547 . . . . 0.0 108.854 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.12 -21.43 17.34 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 177.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.599 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -68.61 124.1 89.27 Favored Pre-proline 0 C--N 1.301 -1.514 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.911 -179.648 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.45 ' O ' ' OG ' ' A' ' 66' ' ' SER . 48.7 Cg_endo -65.38 -48.23 3.55 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.093 1.862 . . . . 0.0 111.953 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.488 ' C ' HD12 ' A' ' 67' ' ' ILE . 4.8 m -164.49 106.92 0.88 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 123.322 1.534 . . . . 0.0 109.539 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.691 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -100.36 163.69 2.91 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.549 0 CA-C-N 113.358 -1.747 . . . . 0.0 111.384 -176.547 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.625 HG12 ' HG2' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -119.12 160.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.179 -0.951 . . . . 0.0 110.904 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.929 HG13 HG21 ' A' ' 52' ' ' ILE . 98.4 t -133.22 107.26 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.448 -0.782 . . . . 0.0 109.59 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.0 mm-40 -94.41 125.08 38.83 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.344 -0.848 . . . . 0.0 110.543 -179.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -134.45 117.55 16.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.029 -1.044 . . . . 0.0 109.967 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 44' ' ' LYS . 0.5 OUTLIER -136.13 161.49 35.56 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.176 -0.953 . . . . 0.0 110.235 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -48.61 106.12 0.09 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 110.11 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.579 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . 71.44 41.73 57.69 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.579 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 49.2 m-85 -160.8 102.52 1.32 Allowed 'General case' 0 C--N 1.29 -2.008 0 O-C-N 121.997 -0.708 . . . . 0.0 110.445 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.709 ' CD2' HG21 ' A' ' 48' ' ' ILE . 12.0 t90 -105.1 73.95 1.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.793 ' CD1' HG13 ' A' ' 41' ' ' VAL . 16.1 m0 -94.44 142.15 27.76 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.525 0.679 . . . . 0.0 111.047 -178.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.61 ' CD1' ' CD1' ' A' ' 76' ' ' TRP . 0.8 OUTLIER -147.25 139.49 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.137 -0.977 . . . . 0.0 109.476 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.625 ' HG2' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -115.97 129.74 56.51 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 110.291 -179.585 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.625 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -110.63 154.64 23.51 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 120.104 -0.638 . . . . 0.0 109.809 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.42 ' HB2' HD12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -97.94 43.55 1.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.985 -1.072 . . . . 0.0 110.146 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -171.69 -114.89 0.34 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -114.63 165.17 13.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.419 -1.048 . . . . 0.0 109.206 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.588 HG23 ' O ' ' A' ' 84' ' ' ILE . 4.4 tp -151.05 114.33 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.74 -1.225 . . . . 0.0 111.113 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -74.93 154.64 38.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.378 -0.826 . . . . 0.0 110.232 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.777 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.2 OUTLIER -161.01 130.12 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.131 -0.98 . . . . 0.0 110.695 -179.894 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.777 ' N ' HD13 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -128.87 173.61 10.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.888 . . . . 0.0 110.831 -179.964 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 1.019 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.06 -28.86 0.19 Allowed 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.041 178.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.532 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -41.51 -53.51 3.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 0.0 109.722 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.44 -57.41 7.03 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.563 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.45 -30.82 54.03 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.547 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -64.7 -56.2 18.23 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 108.359 -1.897 . . . . 0.0 108.359 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -62.47 -14.37 40.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.478 -1.013 . . . . 0.0 109.469 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.793 ' C ' HD23 ' A' ' 94' ' ' LEU . 5.1 tt -75.92 -57.66 3.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.783 . . . . 0.0 109.039 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.601 HD13 ' CB ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -93.72 -35.51 12.76 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.124 179.477 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -160.57 -71.49 0.02 OUTLIER Glycine 0 N--CA 1.491 2.319 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.214 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.561 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 164.95 -59.44 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.552 -0.969 . . . . 0.0 109.848 -179.769 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.0 Cg_endo -68.41 -17.28 44.08 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 124.068 1.562 . . . . 0.0 109.836 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.601 ' CB ' HD13 ' A' ' 95' ' ' LEU . 2.3 t80 -49.14 -50.3 38.2 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.078 -1.049 . . . . 0.0 108.416 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 1.019 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 4.5 m -30.23 -57.51 0.19 Allowed 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.703 0.763 . . . . 0.0 111.574 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 1.055 HG12 HD23 ' A' ' 105' ' ' LEU . 43.7 t -84.07 -54.47 8.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 121.513 -0.742 . . . . 0.0 112.685 -178.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.549 ' HA ' ' HB2' ' A' ' 105' ' ' LEU . 2.0 t80 -51.32 -40.05 58.24 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 119.7 -1.875 . . . . 0.0 107.045 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.541 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 21.6 t70 -57.14 -46.89 82.32 Favored 'General case' 0 N--CA 1.486 1.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.666 178.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.805 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.2 pp -80.2 -29.3 38.58 Favored 'General case' 0 C--O 1.201 -1.459 0 C-N-CA 117.921 -1.512 . . . . 0.0 108.245 179.109 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 1.055 HD23 HG12 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -49.67 -24.74 2.41 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 120.113 -1.617 . . . . 0.0 109.523 178.49 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.2 mp -103.51 -37.42 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.359 -0.838 . . . . 0.0 110.441 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.862 ' CG ' HD23 ' A' ' 42' ' ' LEU . 3.6 p30 -99.52 -13.02 19.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.909 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.815 HG22 ' CG2' ' A' ' 111' ' ' THR . 5.2 p -66.7 -8.99 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 109.811 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.9 OUTLIER -39.99 -24.35 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.689 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.581 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 1.2 p -72.92 9.65 1.11 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.138 -0.976 . . . . 0.0 110.51 178.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.815 ' CG2' HG22 ' A' ' 108' ' ' VAL . 2.2 p -85.69 26.26 0.98 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.694 -1.254 . . . . 0.0 110.936 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 6.9 p -57.05 -18.63 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.968 -1.082 . . . . 0.0 109.375 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.499 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -98.79 50.89 1.21 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.119 -1.592 . . . . 0.0 109.119 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.499 ' C ' ' O ' ' A' ' 113' ' ' GLY . 12.1 ttm180 28.81 95.87 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.494 0.664 . . . . 0.0 111.526 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.552 ' HB2' HG22 ' A' ' 111' ' ' THR . . . -74.84 124.85 27.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.41 -0.806 . . . . 0.0 111.147 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' THR . 1.8 t80 -69.72 115.73 9.29 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.459 ' O ' HD12 ' A' ' 118' ' ' LEU . 23.3 m -79.0 164.36 24.44 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.081 -1.012 . . . . 0.0 111.553 -178.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.568 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -144.79 48.88 1.31 Allowed 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.08 -60.6 0.22 Allowed Glycine 0 N--CA 1.483 1.775 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.568 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.2 t -117.43 -17.87 9.96 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.849 -0.794 . . . . 0.0 111.529 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.567 ' HG3' HG22 ' A' ' 120' ' ' THR . 13.5 mtmt -122.94 161.4 24.25 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 120.76 -1.212 . . . . 0.0 110.534 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.717 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -134.95 162.28 32.87 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.966 -1.084 . . . . 0.0 109.218 178.653 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.535 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.7 OUTLIER -141.8 118.61 11.12 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.915 -1.116 . . . . 0.0 110.599 -178.807 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.743 HG22 HG11 ' A' ' 38' ' ' VAL . 2.3 mp -87.02 132.84 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.552 -0.718 . . . . 0.0 109.82 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 9.5 t -156.93 159.16 37.84 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.109 -0.995 . . . . 0.0 110.629 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.1 t . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.108 179.911 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 90.5 m-20 . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.03 0.443 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.54 157.94 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.55 -0.719 . . . . 0.0 110.444 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.552 HG21 ' CG2' ' A' ' 124' ' ' ILE . 4.5 p -131.56 131.41 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -0.95 . . . . 0.0 110.266 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.601 HG12 HG21 ' A' ' 112' ' ' VAL . 8.9 p -91.29 168.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.298 -0.876 . . . . 0.0 110.495 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.558 ' HB2' HG12 ' A' ' 84' ' ' ILE . 13.7 tp -134.23 134.23 41.78 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.667 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.774 ' O ' HD22 ' A' ' 42' ' ' LEU . 14.9 t -136.95 127.52 40.32 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 O-C-N 120.462 -1.399 . . . . 0.0 110.707 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.774 HD22 ' O ' ' A' ' 41' ' ' VAL . 1.0 OUTLIER -131.39 -174.03 3.28 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.55 -0.86 . . . . 0.0 108.94 178.923 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.425 ' O ' ' N ' ' A' ' 45' ' ' SER . 3.1 ptm -82.6 157.99 23.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.89 -1.131 . . . . 0.0 110.185 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.498 ' CE ' ' OD1' ' A' ' 46' ' ' ASP . 8.3 ptmt -47.01 94.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 111.259 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.667 ' HB3' HG23 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -78.08 4.24 12.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.297 -0.877 . . . . 0.0 110.387 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.502 ' N ' ' CD1' ' A' ' 48' ' ' ILE . 35.1 m-20 64.2 -67.95 0.1 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.52 -0.738 . . . . 0.0 112.681 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.555 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.5 mt-10 -80.33 16.71 1.22 Allowed 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.866 -1.146 . . . . 0.0 112.555 -177.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.938 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -65.41 -68.24 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 120.531 -1.356 . . . . 0.0 111.438 -179.303 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.548 ' C ' ' O ' ' A' ' 48' ' ' ILE . 12.8 t70 -38.5 -31.61 0.06 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 119.048 -1.061 . . . . 0.0 108.635 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.25 -56.57 4.25 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.612 -0.68 . . . . 0.0 109.765 178.051 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.84 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.02 -43.19 67.79 Favored 'Isoleucine or valine' 0 C--O 1.195 -1.786 0 O-C-N 120.903 -1.123 . . . . 0.0 109.873 179.533 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.644 HG21 ' CG1' ' A' ' 69' ' ' VAL . 50.3 mm -52.9 -47.69 52.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.804 0 O-C-N 119.668 -1.895 . . . . 0.0 107.226 177.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.812 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.1 tm-20 -57.61 -57.29 13.37 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.37 -0.831 . . . . 0.0 110.389 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -78.3 -20.33 51.74 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.335 -0.853 . . . . 0.0 112.667 -178.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.586 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 mm -106.17 -30.45 2.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 O-C-N 120.983 -1.073 . . . . 0.0 110.903 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.6 ' CG2' ' HA ' ' A' ' 52' ' ' ILE . 17.2 t -115.24 -42.15 3.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 1.053 HD22 ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -68.17 -31.12 70.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.517 -1.365 . . . . 0.0 109.152 -179.89 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.554 ' N ' HD13 ' A' ' 57' ' ' LEU . 6.0 mttt -107.58 -43.89 4.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.429 -0.794 . . . . 0.0 109.483 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.69 -43.5 6.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.583 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.61 -64.7 2.84 Favored Glycine 0 N--CA 1.491 2.343 0 O-C-N 121.091 -1.241 . . . . 0.0 110.155 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.625 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.3 OUTLIER -59.73 3.51 0.05 Allowed 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.575 -0.956 . . . . 0.0 112.681 -179.506 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -55.32 -64.25 0.9 Allowed 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.657 -1.277 . . . . 0.0 109.02 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -90.72 -23.29 20.74 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.073 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.625 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 3.0 m-20 -69.0 134.8 89.65 Favored Pre-proline 0 C--N 1.3 -1.587 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.672 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -63.0 -45.32 13.04 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.111 1.874 . . . . 0.0 111.299 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.607 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.2 OUTLIER 179.12 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.307 0 CA-C-O 122.999 1.38 . . . . 0.0 109.916 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.866 HG23 ' O ' ' A' ' 79' ' ' LYS 0.297 1.2 mp -101.48 140.2 20.77 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.475 0 CA-C-N 113.911 -1.495 . . . . 0.0 111.415 -177.361 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.595 ' CB ' ' HB3' ' A' ' 79' ' ' LYS . 1.2 t -96.73 132.9 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.785 . . . . 0.0 109.814 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.644 ' CG1' HG21 ' A' ' 52' ' ' ILE . 58.3 t -114.23 92.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.184 -0.948 . . . . 0.0 110.341 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.702 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.0 mm-40 -87.39 73.04 9.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.456 -0.777 . . . . 0.0 110.135 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . 0.493 ' OD2' ' HB2' ' A' ' 49' ' ' ASP . 52.8 t0 -81.91 122.44 27.75 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.936 -1.103 . . . . 0.0 110.637 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.1 OUTLIER -132.76 135.86 45.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.733 179.564 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.08 -26.57 0.16 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.145 -0.972 . . . . 0.0 109.964 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . -80.76 -50.23 5.35 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -144.61 157.96 43.98 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.772 -0.84 . . . . 0.0 110.294 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.938 ' CD2' HG21 ' A' ' 48' ' ' ILE . 1.6 t90 -109.81 85.95 2.2 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.759 ' CD1' HG13 ' A' ' 41' ' ' VAL . 7.2 m0 -85.15 124.51 31.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.459 -0.776 . . . . 0.0 110.958 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.632 HD13 ' O ' ' A' ' 77' ' ' TRP . 3.0 mm -115.93 160.19 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.014 178.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.866 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -140.69 143.72 35.23 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.899 -1.125 . . . . 0.0 110.359 -178.97 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.434 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.03 139.59 19.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.301 -0.875 . . . . 0.0 109.521 179.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -92.98 58.54 2.98 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.09 -1.006 . . . . 0.0 110.091 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -168.89 -164.69 25.03 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.03 129.84 40.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -1.142 . . . . 0.0 109.889 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.728 HG23 ' HB ' ' A' ' 124' ' ' ILE . 3.8 tp -125.02 159.99 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.383 -0.823 . . . . 0.0 110.177 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.496 ' N ' HG13 ' A' ' 84' ' ' ILE . 12.3 mt-10 -131.29 157.19 43.98 Favored 'General case' 0 C--N 1.307 -1.241 0 O-C-N 121.006 -1.058 . . . . 0.0 111.515 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.749 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -128.97 159.32 41.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.698 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.477 ' OD2' ' HE2' ' A' ' 121' ' ' LYS . 5.3 m-20 -156.05 154.91 31.75 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.645 -1.284 . . . . 0.0 111.594 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.934 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.83 -24.28 0.19 Allowed 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.355 -0.938 . . . . 0.0 111.49 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.522 ' HA ' ' OG ' ' A' ' 100' ' ' SER . . . -41.16 -51.83 3.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.009 -1.057 . . . . 0.0 110.303 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.472 ' O ' ' HB2' ' A' ' 94' ' ' LEU . 8.8 tt0 -48.51 -37.58 17.95 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.893 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.839 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -86.39 -53.18 5.15 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.572 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -50.15 -40.08 35.89 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.507 ' HG3' ' O ' ' A' ' 89' ' ' ALA . 9.6 mt-10 -75.52 -33.38 60.72 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.667 ' C ' HD23 ' A' ' 94' ' ' LEU . 1.5 tt -51.27 -66.91 0.3 Allowed 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 177.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.839 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.3 OUTLIER -76.42 -59.2 2.87 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.302 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 112.3 14.7 10.44 Favored Glycine 0 N--CA 1.497 2.715 0 C-N-CA 119.021 -1.561 . . . . 0.0 109.936 178.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.611 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 0.4 OUTLIER -104.57 -166.96 0.11 Allowed Pre-proline 0 C--N 1.294 -1.835 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.343 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.611 ' HD2' ' CB ' ' A' ' 97' ' ' LYS . 38.4 Cg_endo -66.83 -0.96 5.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 N-CA-C 109.458 -1.016 . . . . 0.0 109.458 177.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.799 ' CE1' ' HB1' ' A' ' 91' ' ' ALA . 18.8 t80 -35.54 -65.54 0.24 Allowed 'General case' 0 C--N 1.314 -0.97 0 O-C-N 121.699 -0.626 . . . . 0.0 110.908 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.934 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.3 OUTLIER -29.81 -73.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.037 0.922 . . . . 0.0 111.353 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.673 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 29.9 t -77.22 -50.41 20.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.328 -0.857 . . . . 0.0 113.254 -178.145 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.598 ' CD1' ' HB2' ' A' ' 98' ' ' PRO . 3.7 m-85 -51.72 -43.07 62.71 Favored 'General case' 0 C--N 1.292 -1.899 0 O-C-N 119.704 -1.872 . . . . 0.0 108.15 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.569 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 13.8 t70 -60.4 -40.05 89.53 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.592 -0.692 . . . . 0.0 110.421 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.941 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.3 pp -82.36 -39.8 22.26 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 117.816 -1.554 . . . . 0.0 109.04 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.941 ' N ' HD12 ' A' ' 104' ' ' LEU . 56.3 mt -51.94 -19.71 1.94 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.824 -1.172 . . . . 0.0 110.459 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.3 mp -102.44 -42.75 8.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.148 -0.97 . . . . 0.0 109.864 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.683 ' CG ' HD13 ' A' ' 42' ' ' LEU . 4.7 p30 -88.03 -13.18 42.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.287 -0.883 . . . . 0.0 110.141 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.807 HG13 HG23 ' A' ' 111' ' ' THR . 2.6 t -64.48 -5.88 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.923 -1.11 . . . . 0.0 110.195 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.461 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.49 -28.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.9 -0.5 . . . . 0.0 111.978 -179.567 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.585 ' HB3' HG23 ' A' ' 41' ' ' VAL . 35.1 p -75.3 15.88 0.4 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.77 -1.206 . . . . 0.0 110.581 178.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.807 HG23 HG13 ' A' ' 108' ' ' VAL . 0.0 OUTLIER -58.06 -66.61 0.45 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 118.389 -1.325 . . . . 0.0 109.881 -179.032 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.601 HG21 HG12 ' A' ' 39' ' ' VAL . 4.9 t 63.23 -67.32 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.476 -0.765 . . . . 0.0 110.024 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -93.82 51.81 2.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.516 ' HG2' ' N ' ' A' ' 115' ' ' ALA . 0.5 OUTLIER 47.01 176.33 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 O-C-N 121.579 -0.953 . . . . 0.0 111.016 179.162 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.66 ' HB2' HG22 ' A' ' 111' ' ' THR . . . -148.9 115.57 5.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.893 -1.13 . . . . 0.0 111.229 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.421 ' O ' ' HB ' ' A' ' 123' ' ' THR . 0.2 OUTLIER -76.26 112.53 12.84 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.334 -0.854 . . . . 0.0 108.887 178.678 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.3 m -79.49 125.12 29.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.072 -1.017 . . . . 0.0 110.851 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.576 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -92.3 50.34 1.62 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.412 -0.805 . . . . 0.0 110.042 179.38 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.4 -58.73 0.18 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.576 ' N ' ' O ' ' A' ' 118' ' ' LEU . 18.4 p -115.72 -8.83 12.0 Favored 'General case' 0 C--N 1.291 -1.94 0 O-C-N 122.009 -0.701 . . . . 0.0 110.613 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.477 ' HE2' ' OD2' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -122.95 -170.53 2.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.048 -1.033 . . . . 0.0 111.836 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.822 ' HD2' HD11 ' A' ' 124' ' ' ILE 0.269 1.8 t80 -139.33 147.16 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.078 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.624 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.9 OUTLIER -139.77 121.66 15.54 Favored 'General case' 0 C--N 1.308 -1.238 0 O-C-N 120.506 -1.371 . . . . 0.0 110.543 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.822 HD11 ' HD2' ' A' ' 122' ' ' PHE . 3.9 mp -118.09 142.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 109.939 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 1.8 t -144.93 136.93 25.82 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.083 -1.011 . . . . 0.0 110.421 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.27 -0.894 . . . . 0.0 110.492 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 126' ' ' SER . 35.3 m120 . . . . . 0 N--CA 1.492 1.657 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.46 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.29 143.81 0.12 Allowed 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.169 -0.957 . . . . 0.0 110.541 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.521 HG12 ' O ' ' A' ' 80' ' ' ALA . 3.4 p -108.36 137.26 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.182 -0.949 . . . . 0.0 110.484 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.977 HG13 ' HB2' ' A' ' 110' ' ' SER . 5.8 p -112.74 136.2 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.067 -1.021 . . . . 0.0 110.491 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.625 HD13 HG12 ' A' ' 86' ' ' ILE . 11.0 tp -105.17 141.75 36.17 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.868 HG13 ' NE1' ' A' ' 77' ' ' TRP . 2.3 t -143.19 127.24 14.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 118.248 -1.381 . . . . 0.0 112.072 -177.277 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.71 HD22 ' O ' ' A' ' 41' ' ' VAL . 2.7 mm? -129.48 -168.46 1.95 Allowed 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.009 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.502 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -103.33 167.43 9.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.071 179.254 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.409 ' HG3' ' H ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -51.03 103.29 0.05 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.277 -0.89 . . . . 0.0 110.812 -179.378 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.579 ' HB3' HD12 ' A' ' 48' ' ' ILE . 18.9 t -87.74 -116.76 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.272 -0.892 . . . . 0.0 109.985 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.53 ' N ' HD13 ' A' ' 48' ' ' ILE . 9.9 m-20 -142.11 -76.66 0.27 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.618 -1.301 . . . . 0.0 110.83 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.448 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.3 mt-10 -95.09 35.57 1.27 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.361 -0.837 . . . . 0.0 110.155 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.832 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.77 -66.45 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.251 -0.906 . . . . 0.0 111.274 -179.171 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -41.25 -40.57 1.65 Allowed 'General case' 0 C--N 1.284 -2.271 0 C-N-CA 119.106 -1.038 . . . . 0.0 108.96 179.213 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' N ' ' OD1' ' A' ' 49' ' ' ASP . . . -74.57 -50.35 18.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.592 -0.692 . . . . 0.0 110.401 178.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.832 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -72.12 -49.64 42.27 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.079 0 O-C-N 120.553 -1.342 . . . . 0.0 109.488 179.454 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.731 ' HA ' HG22 ' A' ' 55' ' ' ILE . 40.3 mm -46.59 -38.07 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.028 -1.67 . . . . 0.0 108.246 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 0.6 OUTLIER -64.3 -62.81 1.37 Allowed 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.105 -0.997 . . . . 0.0 110.082 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -79.75 -11.28 59.85 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.367 -0.833 . . . . 0.0 111.435 -179.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.841 HG23 HG23 ' A' ' 56' ' ' VAL . 4.2 tp -106.05 -33.38 2.79 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.034 0 CA-C-O 121.631 0.729 . . . . 0.0 110.546 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.841 HG23 HG23 ' A' ' 55' ' ' ILE . 3.8 t -117.65 -44.56 3.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.499 -0.75 . . . . 0.0 112.479 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.5 OUTLIER -61.77 -40.83 96.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.264 -1.523 . . . . 0.0 108.542 179.964 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.781 ' N ' HD23 ' A' ' 57' ' ' LEU . 2.4 mtpt -92.37 -43.21 9.36 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.521 0.677 . . . . 0.0 109.426 178.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -75.15 -50.78 8.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.562 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.28 -59.99 5.43 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.635 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.636 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -64.99 10.31 0.08 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.56 -0.965 . . . . 0.0 112.636 -179.508 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.39 -63.98 0.95 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.453 -1.404 . . . . 0.0 108.661 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -100.35 -17.83 17.06 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.636 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 1.4 m-20 -67.99 136.88 92.03 Favored Pre-proline 0 C--N 1.301 -1.533 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.684 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -62.19 -42.81 26.93 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 122.54 2.16 . . . . 0.0 112.521 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.577 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.33 112.91 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 123.1 1.429 . . . . 0.0 110.125 -179.811 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.649 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.302 1.2 mp -101.65 147.79 8.13 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 CA-C-N 113.766 -1.561 . . . . 0.0 111.577 -177.143 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.616 ' O ' HG23 ' A' ' 78' ' ' ILE . 1.6 p -110.87 153.13 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.41 -0.806 . . . . 0.0 110.275 179.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.662 HG22 HG21 ' A' ' 52' ' ' ILE . 89.2 t -118.25 104.82 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.244 -0.91 . . . . 0.0 109.6 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.575 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 0.9 OUTLIER -84.05 65.2 8.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.44 -0.787 . . . . 0.0 110.729 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.24 117.24 29.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.97 -1.081 . . . . 0.0 110.249 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 5.4 tttt -146.96 143.49 28.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 110.171 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.04 96.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 109.991 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 151.64 -58.11 0.43 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.477 ' HB2' ' CD1' ' A' ' 77' ' ' TRP . 2.3 p90 -141.08 163.01 34.14 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.926 -0.749 . . . . 0.0 110.457 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.703 ' CE2' HG22 ' A' ' 48' ' ' ILE . 2.5 t90 -118.03 75.63 1.02 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.868 ' NE1' HG13 ' A' ' 41' ' ' VAL . 21.0 m0 -95.82 149.06 21.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.606 -0.684 . . . . 0.0 111.674 -178.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.616 HG23 ' O ' ' A' ' 68' ' ' VAL . 1.2 mp -146.87 130.31 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.563 -0.711 . . . . 0.0 109.151 178.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.603 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -95.89 160.77 14.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.315 -0.866 . . . . 0.0 110.515 -179.123 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.521 ' O ' HG12 ' A' ' 38' ' ' VAL . . . -150.14 141.46 23.25 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.535 -0.728 . . . . 0.0 109.905 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -107.33 50.41 0.77 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.81 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.28 -110.85 0.24 Allowed Glycine 0 C--N 1.301 -1.368 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -123.67 143.41 50.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.315 -1.109 . . . . 0.0 110.02 179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.557 HG13 ' N ' ' A' ' 85' ' ' GLU . 2.8 tp -142.82 160.66 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 109.876 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.557 ' N ' HG13 ' A' ' 84' ' ' ILE . 45.1 mt-10 -129.67 122.69 29.47 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.022 -1.049 . . . . 0.0 111.753 -179.119 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.75 ' CG1' HD11 ' A' ' 124' ' ' ILE . 0.6 OUTLIER -79.61 165.4 2.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 121.641 -0.662 . . . . 0.0 109.648 179.484 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 6.2 m-20 -155.89 139.43 15.92 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.763 -1.211 . . . . 0.0 111.549 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.874 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -152.47 -33.09 0.13 Allowed 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.753 177.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.559 ' N ' ' HB2' ' A' ' 100' ' ' SER . . . -44.09 -52.62 7.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -0.844 . . . . 0.0 110.125 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.519 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 1.3 pt-20 -57.99 -44.5 87.21 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.534 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.13 -34.65 78.54 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.532 -0.73 . . . . 0.0 109.303 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -69.24 -56.87 8.17 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.519 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.3 pt-20 -54.65 -19.56 6.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.403 -1.057 . . . . 0.0 109.368 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.846 HD23 ' N ' ' A' ' 95' ' ' LEU . 5.4 tt -78.81 -61.8 1.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.69 -0.631 . . . . 0.0 110.527 -179.441 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.846 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -77.62 -45.1 26.11 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 118.35 -1.34 . . . . 0.0 109.086 179.289 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.739 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -145.76 -75.21 0.02 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.57 ' N ' ' HD2' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 166.46 -55.88 0.0 OUTLIER Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.883 -0.775 . . . . 0.0 109.407 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.57 ' HD2' ' N ' ' A' ' 97' ' ' LYS . 46.8 Cg_endo -73.14 -21.19 20.69 Favored 'Trans proline' 0 C--N 1.307 -1.614 0 O-C-N 124.167 1.614 . . . . 0.0 110.515 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.573 ' CE2' ' OD2' ' A' ' 103' ' ' ASP . 2.8 t80 -50.06 -50.04 49.22 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.009 -1.057 . . . . 0.0 109.626 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.874 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 16.7 p -31.53 -68.76 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-O 121.875 0.845 . . . . 0.0 111.216 -179.241 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.649 ' CA ' HD23 ' A' ' 104' ' ' LEU . 1.7 t -69.41 -56.16 12.69 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 O-C-N 121.189 -0.945 . . . . 0.0 113.238 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.551 ' HA ' HD12 ' A' ' 105' ' ' LEU . 0.1 OUTLIER -50.1 -31.92 14.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.356 -1.465 . . . . 0.0 109.345 -178.865 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.573 ' OD2' ' CE2' ' A' ' 99' ' ' PHE . 5.6 t70 -76.61 -28.83 56.26 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.697 ' HG ' ' N ' ' A' ' 105' ' ' LEU . 0.0 OUTLIER -65.81 -48.74 70.7 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.16 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.697 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 1.4 mt -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.674 -1.266 . . . . 0.0 110.042 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.45 -22.78 5.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.555 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.5 p30 -108.39 -28.76 9.2 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.178 -0.951 . . . . 0.0 110.802 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.099 HG22 ' CG2' ' A' ' 111' ' ' THR . 1.6 p -70.75 0.7 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.82 -1.175 . . . . 0.0 110.719 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -36.4 -26.92 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.47 -0.769 . . . . 0.0 112.0 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.977 ' HB2' HG13 ' A' ' 39' ' ' VAL . 87.7 p -78.69 32.37 0.2 Allowed 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.758 -1.214 . . . . 0.0 110.595 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 1.099 ' CG2' HG22 ' A' ' 108' ' ' VAL . 25.4 p -94.77 44.42 1.1 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.682 -1.261 . . . . 0.0 109.323 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.48 HG23 ' N ' ' A' ' 113' ' ' GLY . 28.3 m -60.54 -37.43 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.595 -0.691 . . . . 0.0 110.804 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.48 ' N ' HG23 ' A' ' 112' ' ' VAL . . . -76.17 -75.15 0.89 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.858 ' O ' HG23 ' A' ' 124' ' ' ILE . 3.3 ttt85 -145.13 -170.75 3.5 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.312 -1.111 . . . . 0.0 110.428 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.889 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -165.88 75.0 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.035 -1.041 . . . . 0.0 110.55 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.68 ' HB2' HG22 ' A' ' 123' ' ' THR . 0.1 OUTLIER -81.41 121.5 26.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.282 -0.886 . . . . 0.0 109.644 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.717 ' C ' HD12 ' A' ' 118' ' ' LEU . 9.7 m -83.89 156.39 22.42 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.228 -0.92 . . . . 0.0 110.62 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.717 HD12 ' C ' ' A' ' 117' ' ' THR . 7.3 mp -127.91 38.5 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.357 -0.839 . . . . 0.0 110.257 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.2 -59.5 0.41 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.824 -1.711 . . . . 0.0 108.824 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.556 ' N ' ' O ' ' A' ' 118' ' ' LEU . 58.4 p -115.14 -12.71 11.87 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 122.031 -0.687 . . . . 0.0 109.824 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.505 ' CB ' ' HB2' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -121.59 -167.12 1.47 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.43 -0.794 . . . . 0.0 110.633 -179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.889 ' CZ ' ' HB1' ' A' ' 115' ' ' ALA . 16.0 t80 -153.86 164.22 38.74 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.519 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.68 HG22 ' HB2' ' A' ' 116' ' ' TYR . 0.6 OUTLIER -150.08 153.06 35.78 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.39 -1.444 . . . . 0.0 110.275 -179.154 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.858 HG23 ' O ' ' A' ' 114' ' ' ARG . 2.2 mp -141.38 145.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.51 -0.744 . . . . 0.0 109.181 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.786 HG22 ' HB3' ' A' ' 114' ' ' ARG . 11.0 t -138.86 174.21 10.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.89 -1.131 . . . . 0.0 110.534 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.483 ' HB2' ' O ' ' A' ' 36' ' ' ASN . 69.2 p . . . . . 0 C--N 1.304 -1.397 0 O-C-N 121.319 -0.863 . . . . 0.0 110.423 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.437 ' O ' ' C ' ' A' ' 37' ' ' ALA . 1.8 m-20 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.222 0.534 . . . . 0.0 110.304 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.437 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.7 143.52 0.15 Allowed 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.518 -0.739 . . . . 0.0 110.774 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.583 HG13 ' HB2' ' A' ' 126' ' ' SER . 22.9 m -124.54 -174.71 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.226 -0.922 . . . . 0.0 110.373 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.734 HG13 ' HB2' ' A' ' 110' ' ' SER . 3.0 p -148.34 127.54 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.238 -0.914 . . . . 0.0 110.844 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.985 HD11 ' HB ' ' A' ' 86' ' ' ILE . 0.2 OUTLIER -88.99 127.75 35.68 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 177.817 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.865 HG22 ' CD2' ' A' ' 77' ' ' TRP . 2.7 t -121.43 117.05 51.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.883 -1.127 . . . . 0.0 111.435 -178.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.67 ' HB2' ' CE3' ' A' ' 76' ' ' TRP . 0.6 OUTLIER -119.64 159.35 24.58 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.41 -0.916 . . . . 0.0 109.475 178.254 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.539 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 9.5 ptm -92.8 27.21 2.44 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.82 -1.175 . . . . 0.0 111.381 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.872 ' HB3' HD11 ' A' ' 48' ' ' ILE . 4.1 mmtp -86.81 -90.12 0.11 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.249 -0.907 . . . . 0.0 110.408 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.569 ' HB3' ' N ' ' A' ' 75' ' ' PHE . 1.4 p 77.37 57.96 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 CA-C-O 121.877 0.846 . . . . 0.0 110.978 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.695 ' H ' HD12 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -161.58 -91.44 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.513 ' O ' HD13 ' A' ' 51' ' ' ILE . 2.1 mt-10 -54.38 -27.41 36.24 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.281 -0.887 . . . . 0.0 111.351 179.109 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 1.188 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.4 OUTLIER -74.85 -51.38 22.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 118.397 -1.321 . . . . 0.0 112.971 -176.781 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.528 ' C ' ' O ' ' A' ' 48' ' ' ILE . 14.4 t70 -42.96 -29.97 0.38 Allowed 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.366 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.44 -54.89 5.48 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.847 177.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.921 ' CD1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -66.9 -47.82 81.44 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.158 0 C-N-CA 117.844 -1.543 . . . . 0.0 108.226 178.773 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.955 HG12 HG22 ' A' ' 48' ' ' ILE . 45.1 mm -43.05 -40.99 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 120.374 -1.454 . . . . 0.0 107.86 176.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.655 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 2.4 tt0 -62.87 -67.7 0.4 Allowed 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.307 -0.871 . . . . 0.0 110.141 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.422 ' O ' ' OD1' ' A' ' 54' ' ' ASP . 37.0 t0 -75.72 -9.86 58.95 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 121.093 -1.004 . . . . 0.0 111.723 -178.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.838 HG23 HG23 ' A' ' 56' ' ' VAL . 3.9 tp -107.54 -34.63 2.81 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 CA-C-O 121.588 0.709 . . . . 0.0 111.224 -178.459 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.838 HG23 HG23 ' A' ' 55' ' ' ILE . 3.5 t -117.19 -42.91 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.553 -0.717 . . . . 0.0 112.45 -177.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.655 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 10.5 tt -42.2 -55.93 3.09 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.827 -1.17 . . . . 0.0 108.943 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.535 ' O ' ' CG ' ' A' ' 61' ' ' LYS . 1.0 OUTLIER -89.73 -49.19 6.79 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.317 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -48.91 -49.91 27.98 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.544 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -83.87 22.38 8.11 Favored Glycine 0 N--CA 1.489 2.215 0 O-C-N 121.181 -1.188 . . . . 0.0 110.185 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.535 ' CG ' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -106.44 -9.4 16.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.697 -1.472 . . . . 0.0 110.769 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.98 -84.66 0.33 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 121.098 -1.001 . . . . 0.0 110.156 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -71.03 -32.25 68.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 122.211 1.005 . . . . 0.0 108.742 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.544 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.5 OUTLIER -73.38 118.91 72.79 Favored Pre-proline 0 C--N 1.296 -1.733 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 179.65 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.488 ' HG2' ' HB2' ' A' ' 81' ' ' ASP . 45.6 Cg_endo -63.96 -43.42 15.82 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 124.146 1.603 . . . . 0.0 111.053 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.62 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.1 OUTLIER 178.76 112.09 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 CA-C-O 122.944 1.354 . . . . 0.0 109.751 179.477 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.638 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.292 1.2 mp -102.7 132.12 49.48 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.488 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.208 -177.359 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.572 ' HB ' ' HB3' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -92.11 116.16 32.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.863 179.501 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.82 ' CG1' HG21 ' A' ' 52' ' ' ILE . 67.5 t -94.88 96.99 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.146 -0.971 . . . . 0.0 110.012 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.674 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.1 mm-40 -91.51 143.15 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.298 -0.876 . . . . 0.0 110.455 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -139.78 108.91 6.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 109.795 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.71 -166.81 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.266 -0.897 . . . . 0.0 110.795 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.522 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -53.29 107.54 0.25 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 0.0 110.396 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 42.81 44.7 5.63 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.569 ' N ' ' HB3' ' A' ' 45' ' ' SER . 7.3 m-85 -144.45 86.45 1.82 Allowed 'General case' 0 C--N 1.292 -1.895 0 O-C-N 121.871 -0.781 . . . . 0.0 111.378 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 1.188 ' CE2' HG21 ' A' ' 48' ' ' ILE . 1.2 t90 -81.55 88.19 6.21 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.058 -1.026 . . . . 0.0 108.597 178.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.865 ' CD2' HG22 ' A' ' 41' ' ' VAL . 8.1 m0 -90.6 124.67 35.23 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.376 -0.828 . . . . 0.0 111.04 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.658 ' O ' HG23 ' A' ' 39' ' ' VAL . 13.8 mm -117.41 141.87 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.042 . . . . 0.0 110.16 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.572 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 1.1 ttpt -122.58 122.13 38.13 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.581 -0.7 . . . . 0.0 109.675 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -129.32 143.54 50.88 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.336 -0.853 . . . . 0.0 110.036 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.488 ' HB2' ' HG2' ' A' ' 65' ' ' PRO . 67.6 m-20 -88.18 49.81 1.87 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.057 -1.027 . . . . 0.0 109.956 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.35 -162.77 23.25 Favored Glycine 0 C--N 1.302 -1.357 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -72.6 154.36 40.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.183 -1.186 . . . . 0.0 109.791 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.612 ' CG1' HD12 ' A' ' 40' ' ' LEU . 3.0 tp -137.11 156.03 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.941 . . . . 0.0 110.235 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.516 ' N ' HG13 ' A' ' 84' ' ' ILE . 91.0 mt-10 -121.89 155.44 35.43 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.182 -0.949 . . . . 0.0 110.99 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.985 ' HB ' HD11 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -161.33 147.15 4.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.573 -0.704 . . . . 0.0 109.792 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.92 ' N ' HD13 ' A' ' 86' ' ' ILE . 3.5 m-20 -124.65 176.53 6.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.095 -1.003 . . . . 0.0 111.544 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.876 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -140.05 -14.28 1.04 Allowed 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.991 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.54 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -48.24 -45.86 34.82 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.664 -1.273 . . . . 0.0 110.971 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.558 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 18.2 tt0 -50.48 -36.15 32.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.551 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.943 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -68.17 -31.22 70.61 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.035 -1.041 . . . . 0.0 108.876 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.741 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -68.74 -61.4 4.7 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 108.599 -1.8 . . . . 0.0 108.599 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.558 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 6.0 pt-20 -45.4 -27.97 0.79 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.226 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.544 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 0.7 OUTLIER -68.59 -70.9 0.24 Allowed 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.341 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.943 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.0 OUTLIER -98.86 -46.46 5.63 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.021 -1.05 . . . . 0.0 109.224 178.99 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 93.44 51.84 2.11 Favored Glycine 0 N--CA 1.499 2.861 0 C-N-CA 120.185 -1.007 . . . . 0.0 111.538 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.721 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 30.8 pttt -145.46 -135.6 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 O-C-N 120.914 -1.345 . . . . 0.0 109.37 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.721 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.3 Cg_endo -71.7 0.17 7.42 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 CA-C-N 121.077 1.42 . . . . 0.0 108.989 178.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.796 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.8 p90 -25.62 -41.34 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 CA-C-O 121.823 0.821 . . . . 0.0 111.698 178.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.876 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.5 OUTLIER -55.96 -62.39 1.73 Allowed 'General case' 0 C--N 1.292 -1.895 0 CA-C-O 123.368 1.556 . . . . 0.0 108.62 -177.073 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 1.035 HG12 HD11 ' A' ' 105' ' ' LEU . 24.2 t -88.26 -42.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 CA-C-N 114.558 -1.201 . . . . 0.0 113.021 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.502 ' O ' HD13 ' A' ' 106' ' ' ILE . 5.0 t80 -52.02 -43.11 63.55 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 119.91 -1.744 . . . . 0.0 107.426 178.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.579 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 18.5 t70 -61.41 -47.95 83.46 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.687 -0.633 . . . . 0.0 110.065 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.736 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.5 pp -74.27 -41.16 61.68 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 116.655 -2.018 . . . . 0.0 109.738 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 1.035 HD11 HG12 ' A' ' 101' ' ' VAL . 39.2 mt -51.32 -19.23 1.21 Allowed 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.481 -1.387 . . . . 0.0 110.654 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.502 HD13 ' O ' ' A' ' 102' ' ' TYR . 0.6 OUTLIER -93.71 -49.59 12.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.123 -0.985 . . . . 0.0 110.403 -178.826 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.559 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.7 OUTLIER -100.19 -11.28 20.56 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.077 -1.014 . . . . 0.0 111.471 -179.249 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.661 HG22 ' HB ' ' A' ' 111' ' ' THR . 5.9 p -65.2 -6.54 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.302 -1.498 . . . . 0.0 109.947 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -33.78 -31.52 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.728 -0.607 . . . . 0.0 112.028 -179.505 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.734 ' HB2' HG13 ' A' ' 39' ' ' VAL . 28.8 p -84.69 27.89 0.7 Allowed 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 118.877 -1.129 . . . . 0.0 109.348 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.661 ' HB ' HG22 ' A' ' 108' ' ' VAL . 9.6 t -64.64 -35.9 82.51 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 110.644 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.445 ' N ' HG23 ' A' ' 111' ' ' THR . 61.8 t 52.61 -88.6 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.724 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -86.15 54.97 4.76 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.54 ' HG2' ' N ' ' A' ' 115' ' ' ALA . 1.8 ttt180 45.54 176.8 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.747 -0.855 . . . . 0.0 111.444 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -130.01 114.11 15.4 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.995 -1.066 . . . . 0.0 110.725 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.556 ' HB2' HG22 ' A' ' 123' ' ' THR . 25.7 m-85 -69.7 121.14 16.58 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.34 -0.85 . . . . 0.0 108.829 178.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.594 HG22 ' H ' ' A' ' 118' ' ' LEU . 6.2 m -79.3 178.55 8.0 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.192 -0.943 . . . . 0.0 110.734 -178.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.597 ' O ' ' N ' ' A' ' 120' ' ' THR . 1.3 tt -156.9 60.56 0.52 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.448 -0.783 . . . . 0.0 110.431 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.44 -57.44 0.05 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.057 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 118' ' ' LEU . 15.7 p -115.89 -26.97 7.15 Favored 'General case' 0 C--N 1.292 -1.925 0 O-C-N 121.64 -0.917 . . . . 0.0 111.772 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.576 ' O ' ' N ' ' A' ' 118' ' ' LEU . 1.5 pttm -132.07 -169.57 2.24 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.831 -1.168 . . . . 0.0 110.991 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.69 ' CZ ' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -149.21 -179.12 6.8 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.264 -0.897 . . . . 0.0 109.12 179.124 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.88 ' C ' HD12 ' A' ' 124' ' ' ILE . 1.1 t -155.62 165.67 35.86 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.755 -1.215 . . . . 0.0 110.186 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.88 HD12 ' C ' ' A' ' 123' ' ' THR . 4.0 mp -134.09 144.13 36.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.336 -0.852 . . . . 0.0 110.466 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.578 ' O ' HG11 ' A' ' 38' ' ' VAL . 11.9 t -123.25 -170.09 2.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.325 -0.859 . . . . 0.0 110.201 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.583 ' HB2' HG13 ' A' ' 38' ' ' VAL . 2.8 t . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.179 -0.951 . . . . 0.0 110.473 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.502 ' OD1' ' N ' ' A' ' 36' ' ' ASN . 15.1 p-10 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.444 0.64 . . . . 0.0 110.454 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.462 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.94 106.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.229 0.538 . . . . 0.0 111.284 -179.341 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.491 ' CG1' ' O ' ' A' ' 82' ' ' GLY . 4.1 p -125.84 149.79 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.317 -0.864 . . . . 0.0 109.504 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.7 p -105.82 142.44 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.01 -1.056 . . . . 0.0 111.108 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.875 ' O ' HG23 ' A' ' 41' ' ' VAL . 8.1 tp -100.93 162.07 13.15 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 177.468 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.884 HG22 ' CD2' ' A' ' 77' ' ' TRP . 3.0 t -165.77 132.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 120.658 -1.276 . . . . 0.0 111.665 -178.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.672 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 0.3 OUTLIER -143.06 -171.69 3.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.19 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 7.2 ptt? -98.45 153.29 18.7 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.798 -1.189 . . . . 0.0 109.899 179.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.531 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -53.13 95.65 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 0.0 110.982 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.494 ' HB3' HG23 ' A' ' 48' ' ' ILE . 30.5 t -72.89 -92.1 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.297 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.433 ' N ' HD13 ' A' ' 48' ' ' ILE . 36.1 t0 -157.95 -70.3 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.157 -0.964 . . . . 0.0 110.401 179.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.46 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.8 mt-10 -96.45 36.13 1.4 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.283 -0.885 . . . . 0.0 110.412 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.83 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -56.02 -64.34 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.997 -1.064 . . . . 0.0 111.624 -178.772 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.494 ' O ' ' HB2' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -45.44 -34.75 3.3 Favored 'General case' 0 C--N 1.285 -2.218 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.768 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.29 -49.88 12.84 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.473 -0.767 . . . . 0.0 110.341 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.83 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -71.66 -48.44 52.08 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.092 0 O-C-N 120.711 -1.243 . . . . 0.0 108.958 179.127 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.751 HG21 ' CG2' ' A' ' 69' ' ' VAL . 35.1 mm -46.97 -40.89 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.068 -1.645 . . . . 0.0 107.912 177.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.628 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 7.5 tt0 -61.69 -62.43 1.81 Allowed 'General case' 0 C--N 1.293 -1.855 0 O-C-N 121.163 -0.961 . . . . 0.0 110.575 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -80.2 -12.6 59.62 Favored 'General case' 0 N--CA 1.502 2.145 0 O-C-N 121.451 -0.781 . . . . 0.0 111.616 -178.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.948 HG23 HG23 ' A' ' 56' ' ' VAL . 3.8 tp -106.09 -33.27 2.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 CA-C-O 121.672 0.749 . . . . 0.0 110.659 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.948 HG23 HG23 ' A' ' 55' ' ' ILE . 14.4 t -116.57 -43.91 3.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 C-N-CA 119.91 -0.716 . . . . 0.0 112.439 -177.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.836 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -63.35 -35.92 81.99 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.28 -1.513 . . . . 0.0 108.937 179.978 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.836 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -94.77 -47.53 6.43 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.439 -0.788 . . . . 0.0 109.344 179.189 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.49 -45.05 8.19 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.598 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.07 -53.42 18.7 Favored Glycine 0 N--CA 1.49 2.243 0 O-C-N 121.12 -1.224 . . . . 0.0 110.05 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.625 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.9 OUTLIER -62.41 6.58 0.08 Allowed 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.459 -1.024 . . . . 0.0 112.827 -179.421 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.26 -63.84 1.01 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.518 -1.364 . . . . 0.0 108.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -97.2 -19.96 18.26 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 178.046 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.625 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 3.9 m-20 -68.43 125.92 92.17 Favored Pre-proline 0 C--N 1.301 -1.517 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.556 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.435 ' C ' ' OG ' ' A' ' 66' ' ' SER . 46.6 Cg_endo -64.45 -42.26 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 121.96 1.773 . . . . 0.0 111.136 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.577 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -177.97 110.88 0.07 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-O 123.065 1.412 . . . . 0.0 109.527 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.667 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.308 1.0 OUTLIER -103.73 145.38 12.79 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 CA-C-N 113.735 -1.575 . . . . 0.0 111.416 -176.556 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.818 HG12 ' CG ' ' A' ' 79' ' ' LYS . 1.9 p -109.41 142.28 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.055 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.751 ' CG2' HG21 ' A' ' 52' ' ' ILE . 32.4 t -108.75 117.17 53.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.239 -0.913 . . . . 0.0 110.001 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.563 ' N ' ' O ' ' A' ' 77' ' ' TRP . 1.0 OUTLIER -98.64 94.67 6.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.578 -0.701 . . . . 0.0 110.482 -179.435 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -91.37 88.91 7.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.802 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.445 ' HB2' ' HB2' ' A' ' 75' ' ' PHE . 0.3 OUTLIER -88.72 165.99 14.36 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.331 -0.856 . . . . 0.0 110.689 -179.439 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -38.22 -58.21 1.01 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.589 -0.695 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.584 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -132.03 52.51 0.82 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 74' ' ' GLY . 57.7 m-85 -159.49 103.48 1.58 Allowed 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.913 -0.757 . . . . 0.0 110.057 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.714 ' CD2' HG21 ' A' ' 48' ' ' ILE . 6.4 t90 -90.0 77.73 6.83 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.884 ' CD2' HG22 ' A' ' 41' ' ' VAL . 13.0 m0 -101.28 143.98 30.68 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.512 -0.743 . . . . 0.0 112.308 -177.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.69 ' HB ' HD23 ' A' ' 40' ' ' LEU . 1.6 mt -137.49 139.3 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.302 -0.874 . . . . 0.0 109.625 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.818 ' CG ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -102.19 134.85 44.79 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.467 -0.77 . . . . 0.0 110.06 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.543 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -134.43 143.8 47.77 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 110.054 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -95.15 50.29 1.26 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.068 -1.02 . . . . 0.0 110.106 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.491 ' O ' ' CG1' ' A' ' 38' ' ' VAL . . . -171.03 -169.83 34.5 Favored Glycine 0 C--N 1.3 -1.472 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -71.41 143.79 50.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -1.136 . . . . 0.0 109.682 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.817 HG23 ' CG1' ' A' ' 124' ' ' ILE . 4.2 tp -126.36 159.69 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.243 -0.911 . . . . 0.0 109.89 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.471 ' N ' HG13 ' A' ' 84' ' ' ILE . 37.0 mt-10 -123.13 151.77 41.77 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 121.01 -1.056 . . . . 0.0 111.813 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.642 HG22 ' CB ' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -121.11 168.18 13.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 121.48 -0.762 . . . . 0.0 109.226 179.259 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 56.8 m-20 -131.54 177.28 7.62 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.08 -1.013 . . . . 0.0 109.961 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 1.103 ' HB1' ' CB ' ' A' ' 100' ' ' SER . . . -151.46 -49.96 0.12 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.014 178.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.415 ' O ' ' N ' ' A' ' 92' ' ' GLY . . . -48.53 -47.54 39.11 Favored 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.155 -0.966 . . . . 0.0 111.168 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.412 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.3 mt-10 -48.53 -40.63 27.56 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.813 ' HB3' ' O ' ' A' ' 88' ' ' ALA . . . -53.0 -45.18 67.75 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.923 0.868 . . . . 0.0 108.909 177.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.718 ' N ' ' HB2' ' A' ' 99' ' ' PHE . . . -51.46 -40.4 46.61 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -178.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.412 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.8 mt-10 -64.84 -32.29 73.92 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.476 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -70.79 -64.43 0.9 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.51 -0.744 . . . . 0.0 110.048 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.618 ' H ' HD12 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -107.7 -27.36 10.35 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.191 -0.943 . . . . 0.0 110.575 -179.857 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . 65.26 62.96 4.46 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.167 178.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.642 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 19.3 mttt 163.0 -68.34 0.0 OUTLIER Pre-proline 0 N--CA 1.516 2.844 0 O-C-N 121.312 -1.11 . . . . 0.0 111.009 177.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.642 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 55.9 Cg_endo -86.36 6.59 5.37 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 N-CA-C 107.391 -1.811 . . . . 0.0 107.391 176.8 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.718 ' HB2' ' N ' ' A' ' 92' ' ' GLY . 0.1 OUTLIER -52.87 -132.08 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.014 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.874 -179.448 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 1.103 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 40.3 p -6.65 -55.85 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.911 HG12 ' CD1' ' A' ' 105' ' ' LEU . 1.9 t -85.75 -68.78 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -177.34 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.583 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 0.3 OUTLIER -56.83 -30.86 64.17 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 116.929 -1.908 . . . . 0.0 106.21 179.631 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.591 ' HB2' ' HA ' ' A' ' 99' ' ' PHE . 38.9 t70 -66.99 -40.86 87.46 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.214 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.941 HD12 ' N ' ' A' ' 105' ' ' LEU . 3.0 pp -83.27 -41.48 18.28 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 117.98 -1.488 . . . . 0.0 108.913 179.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.941 ' N ' HD12 ' A' ' 104' ' ' LEU . 0.3 OUTLIER -54.04 -16.99 2.24 Favored 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.314 -1.492 . . . . 0.0 110.011 178.673 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.403 ' HB ' ' O ' ' A' ' 102' ' ' TYR . 0.8 OUTLIER -108.74 -27.94 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 179.642 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 0.3 OUTLIER -114.12 -2.67 13.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.083 -1.01 . . . . 0.0 110.744 -179.451 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.662 ' O ' HG22 ' A' ' 111' ' ' THR . 4.1 p -81.93 -10.09 12.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.122 -0.986 . . . . 0.0 110.627 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.4 t -43.55 -20.92 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.031 -1.043 . . . . 0.0 110.345 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.591 ' CA ' ' HB ' ' A' ' 41' ' ' VAL . 92.9 p -53.05 -7.81 0.09 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.304 -0.872 . . . . 0.0 112.223 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.734 ' O ' HG12 ' A' ' 112' ' ' VAL . 0.2 OUTLIER -110.51 -84.79 0.56 Allowed 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.014 -1.474 . . . . 0.0 111.092 -178.752 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.734 HG12 ' O ' ' A' ' 111' ' ' THR . 0.4 OUTLIER 80.06 -14.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.95 -0.468 . . . . 0.0 110.317 -179.239 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -114.95 -75.45 0.63 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.944 ' HB3' HG22 ' A' ' 125' ' ' THR . 11.6 tpt180 -115.24 151.21 34.9 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.353 -1.086 . . . . 0.0 109.531 179.344 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.732 ' HB1' ' CE1' ' A' ' 122' ' ' PHE . . . -165.44 67.99 0.13 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.203 -0.936 . . . . 0.0 110.124 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.511 ' N ' ' O ' ' A' ' 123' ' ' THR . 0.6 OUTLIER -69.21 124.07 22.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.915 . . . . 0.0 109.908 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.465 ' H ' HG22 ' A' ' 117' ' ' THR . 4.3 t -94.68 131.69 40.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 110.356 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.555 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -100.19 45.9 0.97 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.452 -179.98 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.43 -59.2 0.29 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.555 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.6 OUTLIER -115.31 -10.48 12.05 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.947 -0.737 . . . . 0.0 110.3 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -120.38 -168.33 1.61 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.049 -1.032 . . . . 0.0 111.179 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.732 ' CE1' ' HB1' ' A' ' 115' ' ' ALA . 2.2 t80 -150.51 153.37 35.71 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.515 -0.741 . . . . 0.0 110.442 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.552 ' O ' HG22 ' A' ' 123' ' ' THR . 0.8 OUTLIER -142.35 115.38 8.79 Favored 'General case' 0 C--N 1.31 -1.121 0 O-C-N 120.971 -1.081 . . . . 0.0 109.851 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.817 ' CG1' HG23 ' A' ' 84' ' ' ILE . 0.1 OUTLIER -125.03 151.62 30.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.266 -0.896 . . . . 0.0 109.383 179.27 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.944 HG22 ' HB3' ' A' ' 114' ' ' ARG . 6.4 t -136.11 -168.23 2.19 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 110.265 -179.412 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.493 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 19.1 p . . . . . 0 N--CA 1.488 1.43 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 -179.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.457 ' O ' ' C ' ' A' ' 37' ' ' ALA . 69.4 m-80 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.261 0.553 . . . . 0.0 110.18 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -39.62 145.83 0.12 Allowed 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.464 -0.773 . . . . 0.0 110.415 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 3.6 m -122.92 171.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.972 . . . . 0.0 110.237 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.69 HG12 HG21 ' A' ' 112' ' ' VAL . 10.8 p -131.52 120.53 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -0.88 . . . . 0.0 110.234 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 1.078 HD12 ' CG1' ' A' ' 84' ' ' ILE . 5.5 tt -73.1 157.77 36.63 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.859 HG13 ' NE1' ' A' ' 77' ' ' TRP . 24.0 t -160.04 116.48 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 121.097 -1.002 . . . . 0.0 110.592 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.874 HD23 ' CG ' ' A' ' 107' ' ' ASN . 2.5 mt -138.02 -169.55 2.59 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.455 ' SD ' ' OD2' ' A' ' 103' ' ' ASP . 2.8 ptt? -106.77 151.02 25.72 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.952 -1.093 . . . . 0.0 109.547 178.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.506 ' HB2' ' HA2' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -44.19 103.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.262 -0.899 . . . . 0.0 111.033 -179.034 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.479 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 1.2 m -86.84 19.4 2.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -0.922 . . . . 0.0 110.286 179.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 2.1 m-20 68.3 -57.24 0.49 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.444 -0.785 . . . . 0.0 111.412 179.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.537 ' O ' HG12 ' A' ' 51' ' ' ILE . 1.6 mm-40 -94.05 31.83 1.59 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.923 -1.11 . . . . 0.0 110.948 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.861 HG22 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -59.97 -78.26 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.201 -0.937 . . . . 0.0 111.084 -178.844 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.546 ' C ' ' O ' ' A' ' 48' ' ' ILE . 6.8 m-20 -36.79 -32.63 0.04 OUTLIER 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.77 -53.41 7.98 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.766 -0.584 . . . . 0.0 109.551 177.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.757 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.47 -50.67 33.43 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 O-C-N 120.943 -1.098 . . . . 0.0 110.089 179.466 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.7 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 32.4 mm -49.88 -40.78 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 119.829 -1.794 . . . . 0.0 108.281 178.288 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.643 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 18.6 tt0 -62.97 -57.74 9.7 Favored 'General case' 0 C--N 1.29 -1.982 0 O-C-N 120.967 -1.083 . . . . 0.0 110.576 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -81.74 -14.51 56.38 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.296 -0.878 . . . . 0.0 111.489 -178.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.913 HG23 HG23 ' A' ' 56' ' ' VAL . 3.7 tp -105.98 -32.35 2.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 CA-C-O 121.563 0.697 . . . . 0.0 110.736 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.913 HG23 HG23 ' A' ' 55' ' ' ILE . 12.0 t -116.34 -43.31 3.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 C-N-CA 119.839 -0.744 . . . . 0.0 112.557 -177.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.783 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -64.32 -41.27 96.89 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.117 -1.614 . . . . 0.0 109.036 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.783 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -85.92 -41.83 14.59 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.61 0.719 . . . . 0.0 109.49 179.323 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.99 -53.0 3.28 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -70.03 -72.11 0.91 Allowed Glycine 0 N--CA 1.49 2.294 0 O-C-N 120.96 -1.318 . . . . 0.0 110.358 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.634 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -45.33 -8.41 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.597 -0.943 . . . . 0.0 113.518 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 60' ' ' GLY . . . -49.81 -65.34 0.58 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.39 -1.443 . . . . 0.0 108.502 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -89.22 -26.95 20.95 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.634 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 5.3 m-20 -67.6 112.64 10.9 Favored Pre-proline 0 C--N 1.297 -1.676 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.294 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.468 ' O ' ' OG ' ' A' ' 66' ' ' SER . 46.3 Cg_endo -64.59 -41.69 18.64 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.839 1.693 . . . . 0.0 111.355 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.638 ' C ' HD12 ' A' ' 67' ' ' ILE . 7.0 m -164.0 104.87 0.9 Allowed 'General case' 0 N--CA 1.484 1.274 0 CA-C-O 123.35 1.548 . . . . 0.0 109.777 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.655 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.312 1.1 mp -106.02 136.42 40.49 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 CA-C-N 113.314 -1.766 . . . . 0.0 110.588 -177.203 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.581 ' CG1' ' HG3' ' A' ' 79' ' ' LYS . 4.4 t -87.42 134.63 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.256 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.648 HG22 HG12 ' A' ' 78' ' ' ILE . 95.8 t -117.36 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 178.116 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.554 ' N ' ' O ' ' A' ' 77' ' ' TRP . 2.9 mm-40 -86.98 113.3 22.63 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.688 -0.633 . . . . 0.0 110.79 -178.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 71' ' ' ASP . 8.3 p-10 -123.97 112.42 17.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.312 179.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.446 ' O ' ' C ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -152.76 150.23 29.18 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.831 -1.168 . . . . 0.0 111.332 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 35.52 -102.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.818 -0.551 . . . . 0.0 111.036 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.506 ' HA2' ' HB2' ' A' ' 44' ' ' LYS . . . -128.84 37.48 2.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.651 ' CE2' ' CZ2' ' A' ' 77' ' ' TRP . 0.1 OUTLIER -129.77 103.23 6.7 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.698 0.761 . . . . 0.0 109.863 179.54 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.861 ' CE2' HG22 ' A' ' 48' ' ' ILE . 12.5 t90 -96.86 80.95 3.06 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.859 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.6 m0 -103.6 131.3 50.87 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.317 -0.865 . . . . 0.0 112.68 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.682 HD11 ' HE1' ' A' ' 76' ' ' TRP . 2.1 mt -128.14 130.28 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.104 -0.998 . . . . 0.0 109.437 177.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.581 ' HG3' ' CG1' ' A' ' 68' ' ' VAL . 1.9 mtpt -97.86 136.44 38.17 Favored 'General case' 0 C--N 1.295 -1.798 0 C-N-CA 119.748 -0.781 . . . . 0.0 109.779 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.474 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -140.5 140.81 35.37 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 110.003 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -93.91 50.05 1.39 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.165 -0.959 . . . . 0.0 110.302 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.72 -167.89 31.72 Favored Glycine 0 C--N 1.3 -1.46 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.9 129.65 39.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.152 -1.205 . . . . 0.0 110.13 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 1.078 ' CG1' HD12 ' A' ' 40' ' ' LEU . 8.2 tp -120.67 123.97 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.165 -0.96 . . . . 0.0 110.585 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -87.22 161.67 17.89 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.283 -0.886 . . . . 0.0 111.257 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.857 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -161.46 149.01 4.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 O-C-N 121.254 -0.904 . . . . 0.0 110.704 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.857 ' N ' HD13 ' A' ' 86' ' ' ILE . 2.1 m-20 -152.14 171.1 18.43 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.088 -1.008 . . . . 0.0 111.341 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.968 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.24 -37.48 0.13 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.881 -0.728 . . . . 0.0 110.158 177.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.544 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -39.51 -46.87 1.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.622 -0.674 . . . . 0.0 110.312 -179.267 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.609 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 8.9 mt-10 -65.85 -52.06 53.57 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.813 0.816 . . . . 0.0 109.436 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 95' ' ' LEU . . . -54.25 -30.88 51.89 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 110.254 179.686 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.523 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -75.38 -56.43 4.68 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.609 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 3.2 pt-20 -50.14 -20.75 1.08 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.255 -1.144 . . . . 0.0 109.706 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 1.015 HD23 ' N ' ' A' ' 95' ' ' LEU . 1.4 tt -86.44 -65.91 0.96 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.976 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 1.095 HD11 ' CB ' ' A' ' 99' ' ' PHE . 3.4 pp -70.06 -44.62 68.77 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.134 -0.979 . . . . 0.0 110.74 -179.566 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.853 ' N ' HD12 ' A' ' 95' ' ' LEU . . . -149.14 -76.06 0.02 OUTLIER Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.186 -1.483 . . . . 0.0 109.807 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.579 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 11.7 mttt 164.68 -63.09 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.917 0 O-C-N 121.843 -0.798 . . . . 0.0 109.989 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.3 Cg_endo -71.87 -18.51 28.07 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.764 1.402 . . . . 0.0 108.945 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 1.095 ' CB ' HD11 ' A' ' 95' ' ' LEU . 3.2 t80 -44.17 -52.09 7.62 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.787 0.803 . . . . 0.0 109.434 179.129 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.968 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 50.6 m -34.16 -58.26 0.46 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.728 0.775 . . . . 0.0 111.856 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.723 HG12 HD11 ' A' ' 105' ' ' LEU . 14.5 t -81.97 -50.43 16.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.453 ' C ' ' O ' ' A' ' 101' ' ' VAL . 4.3 t80 -49.48 -41.22 39.9 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 119.867 -1.77 . . . . 0.0 107.526 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.579 ' OD1' ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -62.73 -43.64 98.27 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 121.602 -0.686 . . . . 0.0 110.146 178.903 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.756 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.1 pp -78.6 -38.9 38.87 Favored 'General case' 0 C--O 1.202 -1.4 0 C-N-CA 117.24 -1.784 . . . . 0.0 109.004 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.756 ' N ' HD12 ' A' ' 104' ' ' LEU . 63.2 mt -53.04 -16.29 1.06 Allowed 'General case' 0 C--N 1.29 -1.99 0 O-C-N 119.074 -2.266 . . . . 0.0 109.35 177.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.415 ' N ' ' C ' ' A' ' 104' ' ' LEU . 0.4 OUTLIER -118.06 -26.67 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.22 -0.925 . . . . 0.0 109.169 179.182 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.874 ' CG ' HD23 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -113.34 -3.8 13.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.375 -0.828 . . . . 0.0 110.26 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.687 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.1 p -60.46 -12.06 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.919 -1.113 . . . . 0.0 109.831 -179.172 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.55 ' O ' HG13 ' A' ' 112' ' ' VAL . 23.5 t -42.59 -22.29 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.429 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 108' ' ' VAL . 6.1 t -44.11 -16.89 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.373 -0.829 . . . . 0.0 110.953 177.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 1.0 HG22 ' CG1' ' A' ' 124' ' ' ILE . 3.0 p -109.22 44.84 1.11 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.648 -1.283 . . . . 0.0 110.677 -178.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.69 HG21 HG12 ' A' ' 39' ' ' VAL . 3.6 m -56.13 -25.63 20.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 110.055 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -96.58 -73.4 1.15 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.517 ' HB3' HG22 ' A' ' 125' ' ' THR . 0.0 OUTLIER -126.55 155.35 42.54 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.383 -1.069 . . . . 0.0 109.804 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.859 ' HB2' ' HB ' ' A' ' 111' ' ' THR . . . -150.81 74.83 1.18 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.026 -1.047 . . . . 0.0 110.981 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.583 ' HB3' HG22 ' A' ' 123' ' ' THR . 4.7 t80 -69.1 101.8 1.51 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.083 -1.011 . . . . 0.0 108.367 178.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.476 ' HA ' ' HB3' ' A' ' 122' ' ' PHE . 3.6 m -79.14 162.9 25.49 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.446 -0.784 . . . . 0.0 111.147 -178.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.836 HD13 ' HE3' ' A' ' 121' ' ' LYS . 0.9 OUTLIER -147.14 39.34 1.0 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.825 -0.547 . . . . 0.0 109.93 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.421 ' H ' HG22 ' A' ' 117' ' ' THR . . . 59.5 -61.07 0.01 OUTLIER Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 179.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.671 ' N ' ' O ' ' A' ' 118' ' ' LEU . 3.3 m -93.34 -16.23 24.89 Favored 'General case' 0 C--N 1.289 -2.033 0 O-C-N 121.914 -0.757 . . . . 0.0 110.473 -179.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.836 ' HE3' HD13 ' A' ' 118' ' ' LEU . 0.0 OUTLIER -159.85 153.86 23.23 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.975 -1.078 . . . . 0.0 111.084 -179.535 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.699 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.4 OUTLIER -134.48 166.38 23.0 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.256 -0.902 . . . . 0.0 109.298 178.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.865 ' C ' HD12 ' A' ' 124' ' ' ILE . 9.2 t -144.11 157.95 44.01 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.958 -1.089 . . . . 0.0 110.461 -178.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 1.0 ' CG1' HG22 ' A' ' 111' ' ' THR . 3.4 mp -121.15 150.27 24.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.383 -0.823 . . . . 0.0 110.307 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.517 HG22 ' HB3' ' A' ' 114' ' ' ARG . 5.3 t -160.47 -163.6 1.11 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.383 -0.823 . . . . 0.0 110.402 -179.568 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER . . . . . 0 C--N 1.299 -1.63 0 O-C-N 121.49 -0.756 . . . . 0.0 109.96 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 1.6 m-20 . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.53 125.49 0.51 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.771 -0.581 . . . . 0.0 111.159 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.426 HG23 ' HB3' ' A' ' 126' ' ' SER . 94.1 t -89.87 135.37 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 110.273 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.658 HG12 HG23 ' A' ' 112' ' ' VAL . 8.2 p -117.5 130.5 72.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.112 -0.993 . . . . 0.0 110.732 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.606 ' HA ' ' OG ' ' A' ' 110' ' ' SER . 25.3 tp -105.9 141.06 37.94 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.936 HG23 ' CB ' ' A' ' 110' ' ' SER . 56.3 t -132.11 134.12 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.316 -1.49 . . . . 0.0 110.909 -178.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.675 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 26.4 mt -140.27 -166.31 2.09 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.551 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 23.5 ptm -101.44 166.59 10.65 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.328 -0.857 . . . . 0.0 110.879 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.505 ' HG2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -65.0 90.57 0.09 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -0.921 . . . . 0.0 111.694 -179.281 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 1.2 t -83.37 8.79 12.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.231 -0.918 . . . . 0.0 109.799 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.546 ' CB ' ' O ' ' A' ' 45' ' ' SER . 3.6 t0 77.16 -71.06 0.12 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.607 -0.683 . . . . 0.0 112.582 178.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.536 ' C ' HD13 ' A' ' 51' ' ' ILE . 3.8 mt-10 -81.74 24.24 0.61 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 120.948 -1.095 . . . . 0.0 111.873 -177.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.846 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.19 -63.09 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.874 -1.142 . . . . 0.0 112.323 -179.062 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -45.85 -35.39 4.44 Favored 'General case' 0 C--N 1.291 -1.946 0 C-N-CA 118.497 -1.281 . . . . 0.0 108.142 178.958 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.466 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.25 -51.69 12.69 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.847 -0.533 . . . . 0.0 110.123 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.846 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.81 -49.51 39.55 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.009 0 O-C-N 120.6 -1.312 . . . . 0.0 109.752 179.656 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.981 ' CG2' HG22 ' A' ' 69' ' ' VAL . 42.0 mm -46.73 -39.75 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 119.848 -1.783 . . . . 0.0 107.916 177.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.601 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 56.3 tt0 -62.62 -64.17 1.0 Allowed 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.485 179.242 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -80.02 -9.93 59.73 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.212 -0.93 . . . . 0.0 111.51 -178.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.906 HG23 HG23 ' A' ' 56' ' ' VAL . 3.7 tp -106.85 -34.35 2.85 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 121.611 0.719 . . . . 0.0 110.642 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.906 HG23 HG23 ' A' ' 55' ' ' ILE . 9.7 t -116.83 -43.82 3.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 C-N-CA 119.864 -0.734 . . . . 0.0 112.701 -177.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.908 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.1 OUTLIER -55.52 -32.35 62.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.182 -1.574 . . . . 0.0 108.545 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.908 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -93.44 -43.33 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.527 -0.733 . . . . 0.0 109.634 179.329 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -73.56 -47.27 22.05 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.582 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.02 -68.22 1.71 Allowed Glycine 0 N--CA 1.49 2.272 0 O-C-N 121.082 -1.246 . . . . 0.0 110.062 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HG3' ' HA ' ' A' ' 66' ' ' SER . 0.0 OUTLIER -60.09 5.92 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.311 -1.111 . . . . 0.0 113.291 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.63 -64.64 0.75 Allowed 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.327 -1.483 . . . . 0.0 108.525 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.6 ptpt -95.44 -24.72 16.55 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.566 1.174 . . . . 0.0 107.92 177.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.582 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 1.2 m-20 -67.31 145.66 98.62 Favored Pre-proline 0 C--N 1.295 -1.78 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.868 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.462 ' HD2' ' OD1' ' A' ' 64' ' ' ASN . 41.9 Cg_endo -61.62 -47.03 12.25 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 C-N-CA 122.533 2.156 . . . . 0.0 112.164 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.534 ' HA ' ' HG3' ' A' ' 61' ' ' LYS . 0.6 OUTLIER 179.23 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 123.156 1.455 . . . . 0.0 110.272 -179.793 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.67 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.289 1.1 mp -97.38 155.33 3.62 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.489 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.312 -177.483 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.862 HG13 ' HG3' ' A' ' 79' ' ' LYS . 0.2 OUTLIER -128.89 132.14 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.57 -0.707 . . . . 0.0 110.241 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.981 HG22 ' CG2' ' A' ' 52' ' ' ILE . 16.5 t -78.62 -178.67 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.651 ' H ' HG12 ' A' ' 69' ' ' VAL . 0.8 OUTLIER -160.53 66.39 0.33 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 120.646 -1.283 . . . . 0.0 110.585 -178.747 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -71.63 120.77 17.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 110.24 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -119.67 148.01 43.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.196 -0.94 . . . . 0.0 109.81 179.764 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -60.31 77.61 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.915 . . . . 0.0 110.549 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 133.54 -20.37 4.15 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.697 -1.239 . . . . 0.0 110.302 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.505 ' O ' ' HG2' ' A' ' 44' ' ' LYS . 6.1 m-85 -131.27 176.75 8.02 Favored 'General case' 0 C--N 1.288 -2.097 0 O-C-N 121.703 -0.88 . . . . 0.0 111.612 -179.204 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.766 ' CZ2' HD11 ' A' ' 52' ' ' ILE . 7.4 t90 -141.39 79.11 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.718 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.1 m0 -93.98 162.84 13.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.823 0.82 . . . . 0.0 111.326 -178.622 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.724 HD11 ' NE1' ' A' ' 76' ' ' TRP . 1.2 mp -159.27 138.85 3.48 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.862 ' HG3' HG13 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -106.94 142.14 37.03 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.542 -0.724 . . . . 0.0 110.12 -178.312 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.466 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -138.2 147.26 43.6 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.541 -0.724 . . . . 0.0 110.029 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.29 49.71 0.9 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.024 -1.048 . . . . 0.0 110.218 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 177.99 43.57 Favored Glycine 0 C--N 1.302 -1.356 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.61 123.11 21.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.328 -1.101 . . . . 0.0 109.937 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.458 ' CG1' ' N ' ' A' ' 85' ' ' GLU . 15.8 tt -120.3 171.92 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.188 -0.945 . . . . 0.0 110.766 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.522 ' CG ' ' OG1' ' A' ' 123' ' ' THR . 1.3 mt-10 -133.26 158.91 41.73 Favored 'General case' 0 C--N 1.309 -1.171 0 O-C-N 121.299 -0.876 . . . . 0.0 110.966 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 1.005 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -161.51 139.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.589 -0.694 . . . . 0.0 110.502 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 1.005 ' N ' HD13 ' A' ' 86' ' ' ILE . 2.8 m-20 -130.5 -178.51 4.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.244 -0.91 . . . . 0.0 110.679 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.874 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.11 -27.66 0.2 Allowed 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.373 -0.931 . . . . 0.0 111.246 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.644 ' HB2' ' HB ' ' A' ' 120' ' ' THR . . . -43.59 -54.13 5.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.909 -1.119 . . . . 0.0 110.217 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.566 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 4.0 mt-10 -53.58 -46.4 70.31 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.624 -0.83 . . . . 0.0 109.109 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.552 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.18 -38.37 87.86 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.436 -0.79 . . . . 0.0 108.99 178.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.651 ' HA2' HD11 ' A' ' 95' ' ' LEU . . . -66.98 -56.83 10.95 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.566 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.1 OUTLIER -57.54 -17.58 14.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.291 -1.123 . . . . 0.0 109.542 179.644 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.832 HD23 ' N ' ' A' ' 95' ' ' LEU . 3.4 tt -80.58 -58.51 3.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.643 -0.661 . . . . 0.0 110.001 -179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.832 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.2 OUTLIER -85.09 -33.26 22.46 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.44 179.48 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.808 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -155.92 -74.59 0.02 OUTLIER Glycine 0 N--CA 1.487 2.055 0 C-N-CA 119.103 -1.522 . . . . 0.0 109.669 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.58 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 2.3 mmtp 162.97 -57.56 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.822 -0.81 . . . . 0.0 108.923 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.58 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 47.7 Cg_endo -75.52 -18.53 17.58 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 124.21 1.637 . . . . 0.0 109.785 179.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.534 ' CZ ' ' CG ' ' A' ' 103' ' ' ASP . 1.1 t80 -51.3 -46.31 62.49 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 119.071 -1.052 . . . . 0.0 108.64 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.874 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 1.3 t -31.7 -68.89 0.08 Allowed 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.974 0.892 . . . . 0.0 110.519 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.792 ' HA ' HD23 ' A' ' 104' ' ' LEU . 1.2 t -72.68 -59.22 3.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.632 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.666 ' N ' HG12 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -44.51 -33.05 1.6 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.467 -1.396 . . . . 0.0 108.712 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.534 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 35.2 t70 -64.81 -42.95 94.61 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.792 HD23 ' HA ' ' A' ' 101' ' ' VAL . 1.6 pp -75.27 -41.38 57.36 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.107 -1.437 . . . . 0.0 109.542 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.47 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 52.3 mt -55.15 -16.17 2.87 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 119.86 -1.775 . . . . 0.0 109.904 178.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -95.23 -46.74 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.325 -0.859 . . . . 0.0 110.196 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.551 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.5 OUTLIER -113.27 -4.21 13.74 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.145 -0.972 . . . . 0.0 112.093 -178.711 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.948 ' O ' HG23 ' A' ' 111' ' ' THR . 5.2 p -65.91 -8.8 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.6 -1.312 . . . . 0.0 109.768 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.96 -27.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.084 0.468 . . . . 0.0 112.024 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.936 ' CB ' HG23 ' A' ' 41' ' ' VAL . 1.0 OUTLIER -64.52 5.88 0.25 Allowed 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.135 -0.978 . . . . 0.0 111.949 179.585 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.948 HG23 ' O ' ' A' ' 108' ' ' VAL . 32.2 p -61.93 -8.52 5.21 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.402 -1.436 . . . . 0.0 111.573 -177.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.779 HG12 ' N ' ' A' ' 113' ' ' GLY . 25.5 t 48.66 -92.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.779 ' N ' HG12 ' A' ' 112' ' ' VAL . . . -138.68 -3.8 1.73 Allowed Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.512 -1.327 . . . . 0.0 110.108 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.532 ' HG2' ' CG2' ' A' ' 125' ' ' THR . 1.4 mpt_? -123.95 146.94 48.14 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.046 -1.267 . . . . 0.0 110.661 -179.53 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -169.71 80.06 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.9 m-85 -69.05 89.36 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.258 -0.901 . . . . 0.0 109.06 179.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 14.3 t -79.33 151.21 31.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.388 -0.82 . . . . 0.0 111.306 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -133.74 62.67 1.65 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.83 -60.67 0.13 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.644 ' HB ' ' HB2' ' A' ' 89' ' ' ALA . 0.8 OUTLIER -118.21 -34.94 3.95 Favored 'General case' 0 C--N 1.292 -1.921 0 O-C-N 121.964 -0.727 . . . . 0.0 112.004 -179.243 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.567 ' O ' ' N ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -105.0 149.51 25.7 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 120.994 -1.066 . . . . 0.0 111.003 -178.789 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.701 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -136.14 164.08 28.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.027 -1.046 . . . . 0.0 110.408 179.501 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.841 ' C ' HD13 ' A' ' 124' ' ' ILE . 0.8 OUTLIER -138.79 149.93 45.52 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.291 -0.881 . . . . 0.0 109.225 -179.684 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.841 HD13 ' C ' ' A' ' 123' ' ' THR . 0.0 OUTLIER -125.24 156.82 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.065 -1.022 . . . . 0.0 110.057 -179.419 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.532 ' CG2' ' HG2' ' A' ' 114' ' ' ARG . 6.3 t -160.78 163.53 32.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.131 -0.981 . . . . 0.0 110.625 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.444 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER . . . . . 0 N--CA 1.485 1.302 0 O-C-N 121.281 -0.887 . . . . 0.0 110.222 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.476 ' O ' ' OG ' ' A' ' 126' ' ' SER . 52.1 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.053 0.454 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.466 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.1 117.61 0.54 Allowed 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.518 -0.739 . . . . 0.0 110.717 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.467 HG13 ' O ' ' A' ' 36' ' ' ASN . 21.2 m -102.41 173.56 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.185 -0.947 . . . . 0.0 109.921 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.602 HG22 ' OG ' ' A' ' 110' ' ' SER . 7.7 p -137.77 145.67 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 111.008 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.587 ' HB2' HD11 ' A' ' 84' ' ' ILE . 10.6 tp -111.67 137.31 49.74 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.064 HG23 ' OG ' ' A' ' 110' ' ' SER . 80.5 t -133.77 124.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 120.664 -1.272 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.95 HD23 ' ND2' ' A' ' 107' ' ' ASN . 16.2 mt -132.84 178.84 6.56 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.632 178.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.446 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 2.2 ppp? -88.64 172.21 9.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.139 -0.976 . . . . 0.0 110.142 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.33 83.25 0.25 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.502 ' HB2' HG23 ' A' ' 48' ' ' ILE . 13.7 m -54.17 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.194 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 0.7 OUTLIER -158.64 -83.25 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.407 -0.808 . . . . 0.0 109.964 179.272 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.551 ' HB3' ' HB3' ' A' ' 50' ' ' ALA . 1.5 mt-10 -96.93 38.34 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.35 -0.844 . . . . 0.0 110.064 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.833 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -45.17 -60.72 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.172 -0.955 . . . . 0.0 111.32 -179.083 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 48' ' ' ILE . 3.2 m-20 -47.31 -44.44 23.53 Favored 'General case' 0 C--N 1.282 -2.363 0 C-N-CA 118.372 -1.331 . . . . 0.0 108.622 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB3' ' HB3' ' A' ' 47' ' ' GLU . . . -71.17 -47.04 60.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.559 -0.713 . . . . 0.0 110.854 179.319 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.833 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -74.78 -49.76 28.35 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.062 0 O-C-N 120.649 -1.282 . . . . 0.0 110.069 -179.909 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.762 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 40.7 mm -45.0 -37.53 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.056 -1.652 . . . . 0.0 108.23 177.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.58 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 1.2 tt0 -68.66 -63.18 1.11 Allowed 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.296 -0.878 . . . . 0.0 110.256 179.279 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.11 -10.34 59.33 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.283 -0.885 . . . . 0.0 110.933 -179.322 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.707 HG22 ' HA ' ' A' ' 52' ' ' ILE . 4.0 tp -107.58 -35.43 2.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 CA-C-O 121.575 0.702 . . . . 0.0 110.681 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.644 HG23 HG23 ' A' ' 55' ' ' ILE . 2.1 t -117.75 -44.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.974 -0.69 . . . . 0.0 112.694 -176.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.776 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -56.55 -41.63 77.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.11 -1.619 . . . . 0.0 109.478 -179.363 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.776 ' N ' HD23 ' A' ' 57' ' ' LEU . 3.7 tttt -87.78 -43.98 11.46 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.634 -0.667 . . . . 0.0 110.583 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.17 -41.52 6.58 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.056 -178.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.558 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.83 -54.36 15.09 Favored Glycine 0 N--CA 1.492 2.399 0 O-C-N 120.803 -1.41 . . . . 0.0 110.328 -179.143 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.602 ' HA ' ' HB2' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -60.64 8.86 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.45 -1.03 . . . . 0.0 113.248 -179.323 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.603 ' HB1' ' HE3' ' A' ' 63' ' ' LYS . . . -57.19 -67.77 0.29 Allowed 'General case' 0 C--N 1.308 -1.229 0 O-C-N 120.258 -1.526 . . . . 0.0 109.076 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.603 ' HE3' ' HB1' ' A' ' 62' ' ' ALA . 5.4 mmpt? -90.19 -19.53 24.11 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.602 ' HB2' ' HA ' ' A' ' 61' ' ' LYS . 6.3 m-20 -69.34 121.08 80.86 Favored Pre-proline 0 C--N 1.299 -1.588 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.401 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.498 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 44.9 Cg_endo -64.09 -39.24 32.48 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.884 1.723 . . . . 0.0 111.16 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.688 ' C ' HD12 ' A' ' 67' ' ' ILE . 2.8 m -177.77 111.2 0.07 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 123.012 1.386 . . . . 0.0 109.193 179.418 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.688 HD12 ' C ' ' A' ' 66' ' ' SER 0.299 1.3 mp -107.06 145.48 14.51 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.465 0 CA-C-N 113.823 -1.535 . . . . 0.0 111.673 -176.533 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.579 HG12 ' CG ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.04 142.66 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.931 179.454 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.657 ' CG2' HG21 ' A' ' 52' ' ' ILE . 66.1 t -115.32 100.38 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.125 -0.984 . . . . 0.0 110.154 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 1.1 mm-40 -83.59 124.51 30.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.489 -0.757 . . . . 0.0 109.869 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -123.25 102.47 7.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.15 -0.969 . . . . 0.0 109.587 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -103.97 144.23 31.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.164 -0.96 . . . . 0.0 109.948 -179.704 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.72 83.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.435 -0.79 . . . . 0.0 110.044 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 132.73 -24.88 3.82 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -125.08 161.63 26.36 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.778 -0.836 . . . . 0.0 110.931 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.762 ' CZ2' HD11 ' A' ' 52' ' ' ILE . 11.8 t90 -135.88 79.46 1.77 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.724 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.2 m0 -98.79 137.72 36.97 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.495 -0.753 . . . . 0.0 112.433 -177.563 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.556 HD11 ' HE1' ' A' ' 76' ' ' TRP . 1.3 mt -138.29 139.15 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.304 -0.873 . . . . 0.0 109.486 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.579 ' CG ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -109.01 162.28 14.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.188 -0.945 . . . . 0.0 110.582 -179.387 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.439 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.31 140.64 20.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.97 50.03 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -0.906 . . . . 0.0 109.961 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.53 -138.85 2.6 Favored Glycine 0 C--N 1.301 -1.374 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.29 163.28 23.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -1.179 . . . . 0.0 109.885 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 124' ' ' ILE . 5.7 tp -150.83 161.85 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.099 -1.001 . . . . 0.0 110.307 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.577 ' O ' HD13 ' A' ' 40' ' ' LEU . 2.4 mt-10 -140.18 164.75 29.22 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.229 -0.92 . . . . 0.0 110.384 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.773 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -125.53 165.22 23.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.298 -0.876 . . . . 0.0 109.718 179.62 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.522 ' OD1' ' CG ' ' A' ' 121' ' ' LYS . 9.5 m-20 -149.46 155.29 40.15 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.304 -0.872 . . . . 0.0 110.656 -179.648 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.923 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -146.12 -22.37 0.45 Allowed 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 118.808 -1.157 . . . . 0.0 111.301 177.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.442 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -41.57 -46.48 3.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.667 -1.271 . . . . 0.0 110.624 179.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.492 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.2 tt0 -49.36 -57.76 6.31 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.401 -0.812 . . . . 0.0 109.659 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.708 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -45.55 -30.31 1.43 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.687 -0.633 . . . . 0.0 109.727 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -71.17 -37.83 63.51 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.492 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.3 mt-10 -64.69 -20.19 66.17 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.628 ' HB3' HD23 ' A' ' 95' ' ' LEU . 7.4 tt -84.54 -67.57 0.79 Allowed 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.631 HD11 ' HB3' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -100.77 -23.3 14.63 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.115 -0.99 . . . . 0.0 110.112 179.26 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 60.1 45.69 95.53 Favored Glycine 0 N--CA 1.5 2.942 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.278 178.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.689 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 13.7 mttt -138.06 -127.43 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.456 0 O-C-N 121.091 -1.241 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.689 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 42.0 Cg_endo -71.61 -4.91 15.96 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 CA-C-N 120.894 1.355 . . . . 0.0 108.605 178.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.767 ' CD1' ' N ' ' A' ' 100' ' ' SER . 2.8 p90 -24.12 -42.55 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 CA-C-O 121.599 0.714 . . . . 0.0 112.032 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.923 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.2 OUTLIER -57.94 -54.86 42.18 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 122.901 1.334 . . . . 0.0 109.18 -177.64 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.945 HG12 HD11 ' A' ' 105' ' ' LEU . 6.5 t -94.17 -43.88 13.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.672 -178.135 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.607 ' O ' HD12 ' A' ' 106' ' ' ILE . 37.4 t80 -53.1 -41.12 64.64 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 120.209 -1.557 . . . . 0.0 107.652 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.587 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.4 t0 -68.5 -43.13 77.53 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.437 -0.79 . . . . 0.0 109.922 179.152 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.759 HD12 ' N ' ' A' ' 105' ' ' LEU . 2.9 pp -75.25 -40.38 58.99 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 116.756 -1.978 . . . . 0.0 109.046 179.252 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.945 HD11 HG12 ' A' ' 101' ' ' VAL . 23.6 mt -52.82 -20.02 2.93 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.094 -1.629 . . . . 0.0 109.867 178.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.607 HD12 ' O ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -92.09 -44.92 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.267 -0.896 . . . . 0.0 110.629 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.95 ' ND2' HD23 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -114.48 -7.59 12.83 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 112.243 -178.366 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 104' ' ' LEU . 6.0 p -60.89 -17.64 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.592 -1.317 . . . . 0.0 109.34 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -39.84 -22.78 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.7 -179.231 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 1.064 ' OG ' HG23 ' A' ' 41' ' ' VAL . 0.1 OUTLIER -73.28 9.52 1.26 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.698 -1.251 . . . . 0.0 110.558 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 0.562 ' O ' ' HB ' ' A' ' 112' ' ' VAL . 1.1 t -61.53 -10.86 8.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.762 -1.212 . . . . 0.0 110.396 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.562 ' HB ' ' O ' ' A' ' 111' ' ' THR . 2.1 t 66.89 -52.73 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.576 -0.702 . . . . 0.0 110.62 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -173.15 -26.87 0.02 OUTLIER Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' HG23 ' A' ' 124' ' ' ILE . 18.2 ttt180 -138.81 147.74 42.91 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.063 -1.257 . . . . 0.0 111.023 -179.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.631 ' HB1' ' CD2' ' A' ' 122' ' ' PHE . . . -155.76 93.61 1.48 Allowed 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.38 -0.825 . . . . 0.0 110.285 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.551 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 12.2 t80 -69.72 118.88 13.13 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.49 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.2 m -79.55 117.78 20.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.619 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -79.38 49.62 1.01 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.935 179.404 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.93 -60.14 0.36 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 108.674 -1.77 . . . . 0.0 108.674 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -116.01 -10.15 11.63 Favored 'General case' 0 C--N 1.293 -1.875 0 O-C-N 122.001 -0.705 . . . . 0.0 110.382 179.712 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.522 ' CG ' ' OD1' ' A' ' 87' ' ' ASP . 1.7 tttt -121.07 -161.94 0.93 Allowed 'General case' 0 N--CA 1.493 1.685 0 CA-C-O 122.052 0.929 . . . . 0.0 111.397 -179.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.773 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.26 0.2 OUTLIER -141.22 150.93 43.31 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.97 -179.105 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.594 ' O ' HG22 ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.4 110.96 8.03 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.982 -1.074 . . . . 0.0 110.001 178.705 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.886 ' HB ' HG23 ' A' ' 84' ' ' ILE . 4.8 mp -113.86 157.28 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 110.174 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 15.3 t -146.96 170.24 17.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.293 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.307 -0.87 . . . . 0.0 110.684 -179.527 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.517 ' HA ' ' OG ' ' A' ' 126' ' ' SER . 26.9 p-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.506 0.67 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.443 ' N ' ' OD1' ' A' ' 36' ' ' ASN . . . -39.74 134.0 1.45 Allowed 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.623 -0.673 . . . . 0.0 110.995 -179.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.18 152.45 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.308 -0.87 . . . . 0.0 109.732 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.937 HG13 ' HB2' ' A' ' 110' ' ' SER . 14.5 p -114.87 136.28 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 111.464 -179.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.646 HD22 HG12 ' A' ' 84' ' ' ILE . 3.8 tp -100.53 146.11 27.49 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 176.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.007 HG22 ' CD2' ' A' ' 77' ' ' TRP . 2.2 t -139.12 121.45 17.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 O-C-N 120.403 -1.436 . . . . 0.0 111.365 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.953 HD22 ' O ' ' A' ' 41' ' ' VAL . 3.3 mm? -133.42 153.02 51.96 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.294 -0.879 . . . . 0.0 109.212 178.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 12.7 ptm -75.45 153.68 37.47 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.837 -1.164 . . . . 0.0 109.721 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.553 ' CG ' ' HA2' ' A' ' 74' ' ' GLY . 10.0 ptmt -45.16 123.59 4.06 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.032 -1.042 . . . . 0.0 110.859 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.439 ' H ' HD12 ' A' ' 48' ' ' ILE . 12.8 m -100.05 -86.28 0.39 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.592 179.466 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -158.0 -79.11 0.07 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 110.92 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.487 ' C ' HD13 ' A' ' 51' ' ' ILE . 1.4 mt-10 -96.74 39.06 1.18 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.305 -0.872 . . . . 0.0 110.367 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.83 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.04 -69.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.117 -0.99 . . . . 0.0 111.586 -178.916 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.8 m-20 -41.15 -36.05 0.67 Allowed 'General case' 0 C--N 1.284 -2.267 0 C-N-CA 119.059 -1.057 . . . . 0.0 109.062 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.406 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -77.78 -50.22 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.601 -0.687 . . . . 0.0 109.9 178.601 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.83 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.31 -50.93 28.0 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.011 0 O-C-N 120.848 -1.157 . . . . 0.0 109.325 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.712 ' HA ' HG22 ' A' ' 55' ' ' ILE . 44.2 mm -47.19 -40.71 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 119.881 -1.762 . . . . 0.0 108.147 177.569 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.617 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 60.2 tt0 -60.85 -61.58 2.48 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -84.1 -9.15 58.83 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.201 -0.937 . . . . 0.0 111.669 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.875 HG23 HG23 ' A' ' 56' ' ' VAL . 4.5 tp -106.68 -32.81 2.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 CA-C-O 121.695 0.759 . . . . 0.0 110.098 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.875 HG23 HG23 ' A' ' 55' ' ' ILE . 7.4 t -116.46 -45.05 3.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 C-N-CA 119.942 -0.703 . . . . 0.0 112.188 -177.626 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.842 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -64.81 -37.67 88.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.339 -1.475 . . . . 0.0 108.557 179.798 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.842 ' N ' HD23 ' A' ' 57' ' ' LEU . 6.6 mtpt -96.86 -42.07 8.13 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.524 -0.735 . . . . 0.0 109.221 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -77.54 -49.84 7.0 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.585 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.27 -47.86 49.48 Favored Glycine 0 N--CA 1.489 2.178 0 O-C-N 120.973 -1.31 . . . . 0.0 110.136 -179.144 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.641 ' HA ' ' HB2' ' A' ' 64' ' ' ASN . 17.6 ttpp -65.17 9.98 0.09 Allowed 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.624 -0.927 . . . . 0.0 113.124 -179.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.67 -62.88 1.35 Allowed 'General case' 0 C--N 1.304 -1.386 0 O-C-N 120.387 -1.446 . . . . 0.0 108.897 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mtmt -101.62 -17.58 16.28 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.641 ' HB2' ' HA ' ' A' ' 61' ' ' LYS . 0.5 OUTLIER -67.96 127.27 93.32 Favored Pre-proline 0 C--N 1.3 -1.544 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.229 -179.165 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -66.22 -49.52 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.321 2.014 . . . . 0.0 111.587 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.44 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -166.97 106.23 0.6 Allowed 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 123.211 1.481 . . . . 0.0 109.489 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.678 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -97.1 148.91 5.19 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 CA-C-N 113.47 -1.696 . . . . 0.0 111.836 -176.507 . . . . . . . . 4 4 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.556 HG12 ' CB ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.44 145.44 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.298 -0.876 . . . . 0.0 110.201 179.731 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.698 ' CG1' HG21 ' A' ' 52' ' ' ILE . 99.2 t -121.31 96.7 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.152 -0.968 . . . . 0.0 110.089 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.6 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.3 mm-40 -79.36 134.6 36.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.263 -0.898 . . . . 0.0 110.092 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ASP . . . . . 0.469 ' O ' ' OD1' ' A' ' 71' ' ' ASP . 1.1 p30 -143.31 112.24 6.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.179 -0.951 . . . . 0.0 110.017 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.521 ' HG3' ' HB2' ' A' ' 75' ' ' PHE . 0.2 OUTLIER -147.55 -171.45 3.8 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.892 -1.13 . . . . 0.0 111.241 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.465 ' O ' ' C ' ' A' ' 74' ' ' GLY . . . -40.22 110.84 0.16 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.47 -0.769 . . . . 0.0 110.911 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.553 ' HA2' ' CG ' ' A' ' 44' ' ' LYS . . . 36.47 59.62 1.01 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.521 ' HB2' ' HG3' ' A' ' 72' ' ' LYS . 2.5 m-85 -160.75 75.49 0.54 Allowed 'General case' 0 C--N 1.291 -1.961 0 O-C-N 121.849 -0.795 . . . . 0.0 110.039 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.753 ' CE2' HG22 ' A' ' 48' ' ' ILE . 4.1 t90 -82.49 78.34 9.14 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.654 0.74 . . . . 0.0 109.08 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 1.007 ' CD2' HG22 ' A' ' 41' ' ' VAL . 23.2 m0 -98.94 148.27 24.14 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.594 -0.691 . . . . 0.0 111.626 -178.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.595 HG13 ' HA ' ' A' ' 69' ' ' VAL . 1.2 mp -146.65 141.58 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.339 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.556 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -116.74 141.75 47.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.129 -0.982 . . . . 0.0 110.695 -179.022 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.507 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -127.07 163.51 23.62 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.385 -0.822 . . . . 0.0 110.008 179.537 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -106.41 47.44 0.88 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.068 -1.02 . . . . 0.0 110.179 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -108.11 0.21 Allowed Glycine 0 C--N 1.299 -1.482 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -126.22 166.14 17.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.458 -1.025 . . . . 0.0 110.091 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.646 HG12 HD22 ' A' ' 40' ' ' LEU . 7.9 tp -143.91 158.61 16.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.121 -0.987 . . . . 0.0 110.524 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.468 ' O ' HG12 ' A' ' 86' ' ' ILE . 34.2 tt0 -122.76 173.8 7.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.261 -0.899 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 1.001 HG21 ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -157.62 149.78 9.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 O-C-N 121.148 -0.97 . . . . 0.0 111.007 -179.58 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -138.54 152.21 48.0 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.974 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.84 -34.84 0.13 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.335 -1.346 . . . . 0.0 111.585 178.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.533 ' CB ' ' OG1' ' A' ' 120' ' ' THR . . . -40.91 -45.35 2.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.289 -0.882 . . . . 0.0 110.181 -179.235 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.582 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 3.8 tt0 -67.86 -52.02 41.52 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 178.792 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.565 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.8 -41.15 70.23 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 108.965 178.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.522 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -59.49 -55.31 31.35 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.582 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.9 OUTLIER -57.02 -16.94 8.16 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.174 -1.192 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.818 HD23 ' N ' ' A' ' 95' ' ' LEU . 7.4 tt -86.25 -64.27 1.18 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.501 -0.749 . . . . 0.0 111.014 -179.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.818 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -71.36 -37.2 71.66 Favored 'General case' 0 N--CA 1.502 2.168 0 C-N-CA 118.485 -1.286 . . . . 0.0 109.849 -179.706 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.56 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -158.41 -74.43 0.02 OUTLIER Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.545 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 167.53 -63.24 0.0 OUTLIER Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.956 . . . . 0.0 109.52 179.855 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.9 Cg_endo -72.04 -16.22 28.93 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.476 1.25 . . . . 0.0 109.64 178.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.661 ' CB ' HD13 ' A' ' 95' ' ' LEU . 3.1 t80 -48.87 -48.51 42.09 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 121.074 -1.017 . . . . 0.0 109.171 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.974 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 3.8 t -32.36 -61.87 0.24 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.752 0.787 . . . . 0.0 110.764 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.86 ' HA ' HD23 ' A' ' 104' ' ' LEU . 19.4 t -82.79 -54.41 9.48 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.822 0 O-C-N 121.183 -0.948 . . . . 0.0 112.793 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.574 ' HA ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -46.56 -29.98 2.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.67 -1.269 . . . . 0.0 108.917 179.911 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.53 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 29.5 t70 -82.17 -37.18 26.53 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.451 -0.78 . . . . 0.0 109.441 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.86 HD23 ' HA ' ' A' ' 101' ' ' VAL . 0.4 OUTLIER -68.75 -21.78 64.35 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.364 179.523 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.748 HD11 ' CG1' ' A' ' 101' ' ' VAL . 4.6 mt -86.75 -27.72 23.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.819 -1.175 . . . . 0.0 110.373 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.441 HG22 ' HA ' ' A' ' 103' ' ' ASP . 0.6 OUTLIER -97.24 -28.52 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 121.134 -0.979 . . . . 0.0 109.956 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.642 ' CG ' HD13 ' A' ' 42' ' ' LEU . 2.5 p30 -87.49 -30.44 20.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.34 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.109 HG22 ' HB ' ' A' ' 111' ' ' THR . 9.9 p -66.3 -0.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 120.61 -1.306 . . . . 0.0 110.9 179.407 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -30.05 -34.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.813 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . 0.937 ' HB2' HG13 ' A' ' 39' ' ' VAL . 82.8 p -84.4 33.66 0.51 Allowed 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.533 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . 1.109 ' HB ' HG22 ' A' ' 108' ' ' VAL . 11.5 t -96.46 44.26 1.07 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.26 179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.573 ' CG1' ' N ' ' A' ' 113' ' ' GLY . 0.5 OUTLIER -61.68 -48.66 87.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.542 -0.724 . . . . 0.0 111.015 -178.687 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.573 ' N ' ' CG1' ' A' ' 112' ' ' VAL . . . -57.21 -77.04 0.18 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.531 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -157.72 -169.04 2.72 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.384 -1.068 . . . . 0.0 110.105 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.647 ' HB2' ' OG1' ' A' ' 111' ' ' THR . . . -170.7 84.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.583 ' HB3' HG22 ' A' ' 123' ' ' THR . 4.7 t80 -69.84 105.71 2.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.003 -1.061 . . . . 0.0 108.351 178.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 119' ' ' GLY . 7.6 m -79.03 145.95 33.58 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.299 -0.876 . . . . 0.0 110.915 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . 0.612 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.1 OUTLIER -123.69 50.3 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.587 -0.695 . . . . 0.0 110.282 179.914 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.422 ' H ' HG22 ' A' ' 117' ' ' THR . . . 62.15 -57.26 0.03 OUTLIER Glycine 0 N--CA 1.491 2.326 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 178.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.612 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.8 t -111.7 -15.18 13.49 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.753 -0.851 . . . . 0.0 111.406 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.538 ' CG ' ' HB3' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -143.57 150.6 39.08 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.758 -1.214 . . . . 0.0 110.77 -179.614 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 1.001 ' CE2' HG21 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -124.68 164.17 20.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.877 -1.139 . . . . 0.0 110.769 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.583 HG22 ' HB3' ' A' ' 116' ' ' TYR . 2.8 t -144.27 131.85 21.09 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.514 -0.741 . . . . 0.0 109.831 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.697 HD12 ' N ' ' A' ' 124' ' ' ILE . 2.0 mp -101.91 162.66 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 110.674 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 114' ' ' ARG . 3.3 t -152.34 -175.3 5.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -0.872 . . . . 0.0 109.806 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.517 ' OG ' ' HA ' ' A' ' 36' ' ' ASN . 19.7 t . . . . . 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.086 . . . . 0.0 110.705 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' A' ' 36' ' ' ASN . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.276 0.56 . . . . 0.0 110.367 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 35' ' ' SER . 0.4 OUTLIER 68.96 -57.08 0.52 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.142 -0.974 . . . . 0.0 110.695 179.782 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.49 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -29.87 132.96 0.06 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.403 0.621 . . . . 0.0 111.846 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 1.7 p -142.48 149.85 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.515 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.588 ' H ' HG21 ' A' ' 112' ' ' VAL . 11.1 p -127.68 150.05 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.78 -1.2 . . . . 0.0 111.707 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 1.023 HD11 HG13 ' A' ' 86' ' ' ILE . 23.5 tp -112.36 132.05 55.21 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.865 HG13 ' NE1' ' A' ' 77' ' ' TRP . 2.6 t -127.28 124.87 64.95 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 111.603 -177.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.844 HD21 HD11 ' A' ' 86' ' ' ILE . 0.9 OUTLIER -119.53 -174.18 2.68 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.002 -1.061 . . . . 0.0 110.605 179.189 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.567 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.8 ptp -117.66 21.58 12.88 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.937 . . . . 0.0 110.642 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.664 ' HB3' HD11 ' A' ' 48' ' ' ILE . 3.6 mmtt -88.95 -93.14 0.11 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.456 -0.778 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.62 ' CB ' ' O ' ' A' ' 44' ' ' LYS . 1.3 p 89.36 178.01 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 45' ' ' SER . 0.1 OUTLIER 62.93 -87.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 109.663 -179.242 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.519 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.2 mt-10 -52.16 -24.95 7.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.44 -0.787 . . . . 0.0 111.895 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 1.01 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -73.48 -62.37 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.709 -178.082 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.545 ' C ' ' O ' ' A' ' 48' ' ' ILE . 85.4 m-20 -37.83 -32.57 0.06 Allowed 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.316 -0.954 . . . . 0.0 108.782 179.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.27 -55.98 5.06 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.814 HG12 ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -71.3 -48.69 52.66 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.165 0 O-C-N 120.679 -1.263 . . . . 0.0 109.29 178.922 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.859 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 45.8 mm -46.01 -41.23 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 119.871 -1.768 . . . . 0.0 108.604 177.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.778 ' HA ' ' HB2' ' A' ' 57' ' ' LEU . 2.1 tm-20 -64.73 -60.89 2.58 Favored 'General case' 0 C--N 1.292 -1.91 0 O-C-N 121.206 -0.933 . . . . 0.0 110.143 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -77.62 -12.59 59.98 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 120.868 -1.145 . . . . 0.0 111.488 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.776 HG23 HG23 ' A' ' 56' ' ' VAL . 4.0 tp -107.43 -34.96 2.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 O-C-N 121.59 -0.694 . . . . 0.0 111.499 -178.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.776 HG23 HG23 ' A' ' 55' ' ' ILE . 2.5 t -117.18 -37.89 2.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.655 -0.653 . . . . 0.0 112.632 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.778 ' HB2' ' HA ' ' A' ' 53' ' ' GLU . 1.4 tm? -37.51 -55.49 1.08 Allowed 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 122.272 1.034 . . . . 0.0 109.947 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.31 -48.97 12.2 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.487 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -50.82 -47.39 47.31 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.525 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -78.03 7.07 46.11 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.77 -8.56 16.75 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.972 -1.311 . . . . 0.0 110.891 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.5 -82.63 0.22 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.945 -1.097 . . . . 0.0 109.93 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.403 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -79.56 -30.3 41.64 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 122.432 1.111 . . . . 0.0 108.158 178.678 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.525 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 8.5 m-20 -74.65 127.03 87.96 Favored Pre-proline 0 C--N 1.295 -1.801 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.487 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.473 ' O ' ' HB2' ' A' ' 66' ' ' SER . 43.5 Cg_endo -62.86 -47.7 8.21 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 121.77 1.646 . . . . 0.0 110.822 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.656 ' C ' HD12 ' A' ' 67' ' ' ILE . 1.7 t 179.96 111.86 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.958 1.361 . . . . 0.0 109.339 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.656 HD12 ' C ' ' A' ' 66' ' ' SER 0.292 1.3 mp -104.37 134.77 44.77 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.508 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.551 -176.823 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.642 HG12 ' CB ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -92.03 162.73 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 109.374 178.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.802 ' CG1' HG21 ' A' ' 52' ' ' ILE . 24.3 t -136.28 106.51 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.045 -1.034 . . . . 0.0 110.31 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.612 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.7 mm-40 -102.05 145.42 29.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.355 -0.841 . . . . 0.0 110.421 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . 0.428 ' CG ' ' OD2' ' A' ' 49' ' ' ASP . 11.6 p-10 -136.96 119.72 16.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.451 -0.78 . . . . 0.0 108.965 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.596 ' CB ' ' HB2' ' A' ' 75' ' ' PHE . 27.0 mttm -125.49 83.28 2.15 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.019 -1.051 . . . . 0.0 111.506 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.558 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 18.64 73.66 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.237 0 CA-C-O 121.231 0.539 . . . . 0.0 111.949 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 43' ' ' MET . . . 103.54 11.18 33.86 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.596 ' HB2' ' CB ' ' A' ' 72' ' ' LYS . 20.4 m-85 -138.26 101.03 4.28 Favored 'General case' 0 C--N 1.286 -2.165 0 O-C-N 121.837 -0.802 . . . . 0.0 110.587 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 1.01 ' CE2' HG21 ' A' ' 48' ' ' ILE . 17.5 t90 -89.39 87.53 7.13 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.518 -0.738 . . . . 0.0 109.494 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.865 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.7 m0 -98.06 111.59 23.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.08 -1.012 . . . . 0.0 110.427 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.543 ' O ' HG23 ' A' ' 39' ' ' VAL . 0.3 OUTLIER -114.65 148.17 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.737 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.642 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -130.28 125.46 34.83 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.921 -1.112 . . . . 0.0 110.16 179.81 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.534 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -125.44 173.97 8.52 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.478 -0.764 . . . . 0.0 110.031 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.97 52.51 1.27 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 110.046 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -169.59 -105.94 0.19 Allowed Glycine 0 C--N 1.302 -1.337 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -133.08 115.5 15.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.505 -0.997 . . . . 0.0 110.316 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.684 HG21 ' HB2' ' A' ' 40' ' ' LEU . 8.1 tp -105.49 148.36 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 110.261 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -103.99 159.29 15.79 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.157 -0.965 . . . . 0.0 111.392 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 1.023 HG13 HD11 ' A' ' 40' ' ' LEU . 0.3 OUTLIER -162.32 149.82 4.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 O-C-N 121.442 -0.787 . . . . 0.0 110.438 179.772 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.843 ' N ' HD13 ' A' ' 86' ' ' ILE . 1.4 m-20 -135.31 -176.13 4.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.011 -1.056 . . . . 0.0 111.455 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.659 ' CB ' ' HA ' ' A' ' 100' ' ' SER . . . -138.41 -9.31 1.46 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.813 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -43.71 -48.34 7.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.474 -1.392 . . . . 0.0 110.269 179.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.582 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 10.1 tt0 -49.36 -47.63 47.3 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.455 -0.778 . . . . 0.0 109.892 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.522 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -56.81 -26.46 58.04 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.067 -1.021 . . . . 0.0 109.649 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.699 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -73.97 -48.84 14.82 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.582 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.0 OUTLIER -58.23 -19.3 32.79 Favored 'General case' 0 C--N 1.289 -2.052 0 O-C-N 121.104 -1.233 . . . . 0.0 107.951 178.56 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.845 HD23 ' CD2' ' A' ' 95' ' ' LEU . 11.4 tp -82.11 -68.0 0.73 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.826 -0.546 . . . . 0.0 109.613 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.845 ' CD2' HD23 ' A' ' 94' ' ' LEU . 0.2 OUTLIER -100.96 -29.66 12.07 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.082 -1.011 . . . . 0.0 109.135 178.587 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 69.44 43.96 66.98 Favored Glycine 0 N--CA 1.498 2.768 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.833 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.687 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 8.2 mmmt -138.23 -124.17 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.672 0 O-C-N 121.091 -1.241 . . . . 0.0 109.724 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.687 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 45.9 Cg_endo -71.14 -4.96 15.94 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 121.172 1.454 . . . . 0.0 108.724 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.76 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.8 p90 -23.66 -44.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.076 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.76 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -49.14 -52.48 25.96 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 123.348 1.547 . . . . 0.0 107.734 -179.125 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.867 HG12 HD11 ' A' ' 105' ' ' LEU . 67.5 t -99.04 -53.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.807 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.486 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 0.5 OUTLIER -44.42 -30.02 0.79 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.773 -1.204 . . . . 0.0 108.434 179.364 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.564 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.8 t70 -83.11 -45.94 13.37 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.83 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.5 OUTLIER -60.9 -41.16 95.55 Favored 'General case' 0 C--O 1.202 -1.425 0 C-N-CA 117.928 -1.509 . . . . 0.0 109.144 179.168 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.867 HD11 HG12 ' A' ' 101' ' ' VAL . 28.0 mt -61.58 -46.47 89.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.725 -1.235 . . . . 0.0 111.341 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -73.94 -33.07 35.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 110.464 -178.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.557 ' HB2' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -90.42 -40.71 11.89 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.121 -0.987 . . . . 0.0 110.143 -179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 104' ' ' LEU . 1.6 p -65.86 1.66 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.647 -1.283 . . . . 0.0 111.32 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.509 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.42 -33.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.997 -1.064 . . . . 0.0 110.872 -179.699 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.871 ' O ' HG22 ' A' ' 112' ' ' VAL . 1.9 p -88.02 39.16 0.88 Allowed 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 108' ' ' VAL . 8.9 t -60.63 -10.93 5.9 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.377 -0.827 . . . . 0.0 111.698 -178.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.871 HG22 ' O ' ' A' ' 110' ' ' SER . 0.6 OUTLIER 16.56 -84.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 CA-C-O 121.094 0.473 . . . . 0.0 112.081 -179.839 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.587 ' H ' HG23 ' A' ' 112' ' ' VAL . . . -83.54 52.99 4.81 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.537 ' O ' ' O ' ' A' ' 113' ' ' GLY . 10.6 ttt85 43.49 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 O-C-N 121.539 -0.977 . . . . 0.0 111.544 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.518 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -142.41 107.83 5.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.748 -1.22 . . . . 0.0 110.346 -179.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.476 ' HB3' HG22 ' A' ' 123' ' ' THR . 33.3 t80 -69.43 118.39 12.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.105 -0.997 . . . . 0.0 109.247 179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 7.4 t -83.84 158.09 21.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.146 -0.971 . . . . 0.0 111.301 -178.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -135.1 54.72 1.92 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.662 -0.649 . . . . 0.0 110.388 -179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 64.3 -57.72 0.07 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.603 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -114.4 -23.75 9.21 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.844 -0.798 . . . . 0.0 111.24 -178.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.539 ' O ' ' CB ' ' A' ' 118' ' ' LEU . 5.5 tttt -138.72 147.27 42.51 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.904 -1.122 . . . . 0.0 110.796 -179.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.728 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -116.02 -177.96 3.29 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.086 -1.009 . . . . 0.0 109.136 178.326 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.648 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.9 OUTLIER -156.42 141.23 17.06 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 110.342 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.751 HD12 ' N ' ' A' ' 124' ' ' ILE . 3.1 mp -111.28 129.65 66.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 110.34 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.429 ' OG1' ' N ' ' A' ' 126' ' ' SER . 1.7 t -145.15 -169.1 3.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.184 -0.947 . . . . 0.0 110.399 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.429 ' N ' ' OG1' ' A' ' 125' ' ' THR . 3.8 t -120.45 -89.25 0.61 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.848 . . . . 0.0 110.595 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' A' ' 128' ' ' LEU . 13.3 mt-10 -52.78 161.6 0.72 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.419 -0.8 . . . . 0.0 110.511 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.475 ' O ' ' O ' ' A' ' 127' ' ' GLU . 29.6 mt . . . . . 0 C--N 1.307 -1.256 0 O-C-N 121.551 -0.718 . . . . 0.0 110.888 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.118 0.485 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.491 ' HB2' ' HB2' ' A' ' 126' ' ' SER . 77.9 m-20 -86.25 109.89 19.25 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.186 -0.946 . . . . 0.0 110.457 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.467 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.41 146.38 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.656 -0.653 . . . . 0.0 110.474 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.703 HG21 ' C ' ' A' ' 125' ' ' THR . 1.9 t -136.56 120.95 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.843 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 39' ' ' VAL . 9.6 p -97.64 134.79 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.665 HD22 HD11 ' A' ' 84' ' ' ILE . 9.2 tp -106.98 147.96 29.25 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.799 HG13 ' CD1' ' A' ' 77' ' ' TRP . 50.6 t -149.07 126.58 2.65 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 120.576 -1.328 . . . . 0.0 110.322 -178.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.914 HD23 ' CZ3' ' A' ' 76' ' ' TRP . 12.4 tp -135.73 178.71 6.83 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.526 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 8.6 ptp -78.61 178.5 7.77 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.725 -1.235 . . . . 0.0 110.79 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 74' ' ' GLY . 4.4 mtmt -64.09 95.9 0.13 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.539 -0.726 . . . . 0.0 112.127 -178.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.515 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 0.2 OUTLIER -73.85 -0.96 17.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 0.0 109.712 178.224 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 45' ' ' SER . 8.0 t0 74.82 -58.96 0.56 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.501 -0.75 . . . . 0.0 112.297 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.549 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.4 mt-10 -95.06 23.68 5.47 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.809 -1.182 . . . . 0.0 111.781 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.847 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -63.23 -71.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 120.823 -1.173 . . . . 0.0 111.674 -179.494 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.566 ' C ' ' O ' ' A' ' 48' ' ' ILE . 15.6 t0 -36.8 -34.2 0.07 Allowed 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.051 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.516 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -77.65 -54.83 5.92 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.847 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.24 -50.8 33.75 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 O-C-N 120.757 -1.214 . . . . 0.0 109.324 178.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.957 HG21 HG13 ' A' ' 69' ' ' VAL . 36.4 mm -46.13 -39.33 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 119.798 -1.814 . . . . 0.0 108.506 177.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.611 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 3.8 tm-20 -64.39 -61.5 2.19 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.185 -0.947 . . . . 0.0 110.333 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -80.69 -10.83 59.7 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.254 -0.904 . . . . 0.0 111.258 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.723 HG22 ' O ' ' A' ' 51' ' ' ILE . 4.8 tp -106.18 -33.19 2.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 CA-C-O 121.644 0.735 . . . . 0.0 110.467 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.721 HG13 HG21 ' A' ' 67' ' ' ILE . 2.4 t -117.39 -45.31 3.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.3 -177.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.727 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.1 OUTLIER -58.61 -39.15 79.61 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.096 -1.628 . . . . 0.0 108.492 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.727 ' N ' HD23 ' A' ' 57' ' ' LEU . 1.3 tttt -100.02 -41.04 7.34 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 55' ' ' ILE . . . -67.32 -49.02 55.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -81.39 23.64 4.63 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 120.926 -1.338 . . . . 0.0 110.366 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -107.54 -9.27 15.96 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.854 -1.38 . . . . 0.0 110.76 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.47 -84.8 0.31 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 120.95 -1.094 . . . . 0.0 110.109 -179.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.417 ' CG ' ' N ' ' A' ' 64' ' ' ASN . 4.7 ptpt -70.0 -35.82 74.67 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.515 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.6 OUTLIER -69.36 122.68 86.34 Favored Pre-proline 0 C--N 1.298 -1.668 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.811 179.138 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.475 ' HG2' ' HB3' ' A' ' 81' ' ' ASP . 43.7 Cg_endo -63.26 -45.6 11.78 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 121.733 1.622 . . . . 0.0 110.924 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.685 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.6 OUTLIER 179.37 111.57 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.355 0 CA-C-O 122.92 1.343 . . . . 0.0 109.653 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.721 HG21 HG13 ' A' ' 56' ' ' VAL 0.297 1.3 mp -106.68 133.97 49.67 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.403 0 CA-C-N 114.012 -1.449 . . . . 0.0 111.728 -176.799 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.577 ' HB ' ' CG ' ' A' ' 79' ' ' LYS . 1.0 OUTLIER -91.81 139.28 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.555 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.957 HG13 HG21 ' A' ' 52' ' ' ILE . 72.9 t -104.76 89.3 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.178 -0.952 . . . . 0.0 110.328 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.813 ' HB3' ' HB2' ' A' ' 77' ' ' TRP . 0.3 OUTLIER -82.04 50.55 1.59 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -0.795 . . . . 0.0 110.231 179.928 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . 0.489 ' OD1' HG13 ' A' ' 48' ' ' ILE . 3.5 t70 -77.66 109.38 11.59 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.036 -1.04 . . . . 0.0 110.095 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.8 tttt -129.21 142.06 50.97 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.027 -1.046 . . . . 0.0 109.711 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.81 86.78 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.291 -0.881 . . . . 0.0 109.633 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 158.72 -49.26 0.41 Allowed Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.566 ' HB3' ' CD1' ' A' ' 77' ' ' TRP . 5.1 m-85 -143.62 145.13 32.24 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.814 -0.815 . . . . 0.0 110.418 -179.574 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.914 ' CZ3' HD23 ' A' ' 42' ' ' LEU . 17.8 t90 -94.25 80.14 3.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.613 -0.679 . . . . 0.0 109.989 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.813 ' HB2' ' HB3' ' A' ' 70' ' ' GLU . 7.9 m95 -87.83 128.27 35.34 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 109.039 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.661 ' CG2' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -131.95 137.41 54.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.794 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.577 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 5.5 tttp -118.09 143.36 46.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.506 -1.371 . . . . 0.0 110.818 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.425 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -134.28 134.78 42.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.578 -0.701 . . . . 0.0 110.028 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.475 ' HB3' ' HG2' ' A' ' 65' ' ' PRO . 1.1 t0 -86.27 51.29 2.18 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.207 -0.933 . . . . 0.0 110.267 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.82 -120.37 0.54 Allowed Glycine 0 C--N 1.3 -1.419 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -113.8 164.29 13.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.367 -1.078 . . . . 0.0 109.372 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.665 HD11 HD22 ' A' ' 40' ' ' LEU . 4.2 tp -147.83 144.07 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.952 -1.093 . . . . 0.0 110.56 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -122.34 150.45 42.38 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.401 -0.812 . . . . 0.0 110.178 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.93 HG22 ' CG ' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -161.42 169.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.459 -0.776 . . . . 0.0 109.651 -179.158 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.463 ' OD1' ' O ' ' A' ' 86' ' ' ILE . 77.7 m-20 -139.63 -173.13 3.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.09 -1.006 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.746 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -131.56 -19.26 2.72 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.092 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.422 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -40.67 -46.15 2.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.076 -1.015 . . . . 0.0 110.537 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -48.63 -54.31 15.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.333 -0.854 . . . . 0.0 109.674 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.683 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -52.67 -28.3 21.09 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.462 -0.774 . . . . 0.0 109.701 179.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.745 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -70.84 -31.15 67.44 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -69.77 -24.08 63.46 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.877 ' HB3' HD23 ' A' ' 95' ' ' LEU . 0.4 OUTLIER -78.69 -59.16 2.89 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.613 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.877 HD23 ' HB3' ' A' ' 94' ' ' LEU . 0.2 OUTLIER -110.07 -29.34 8.26 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.178 -0.951 . . . . 0.0 110.897 179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 68.56 42.65 80.24 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.663 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 33.2 mttt -133.05 -134.41 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.403 0 O-C-N 121.261 -1.141 . . . . 0.0 109.947 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.663 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.4 Cg_endo -71.78 -4.3 14.82 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 N-CA-C 108.683 -1.314 . . . . 0.0 108.683 178.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.75 ' CD1' ' N ' ' A' ' 100' ' ' SER . 4.1 p90 -26.56 -42.29 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.88 0.848 . . . . 0.0 111.72 178.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.3 OUTLIER -52.34 -53.09 49.12 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-O 122.593 1.187 . . . . 0.0 108.779 -177.493 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.789 HG12 HD11 ' A' ' 105' ' ' LEU . 59.7 t -102.63 -46.22 10.79 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.484 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 64.7 t80 -52.05 -32.17 33.36 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 117.559 -1.656 . . . . 0.0 107.588 179.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 3.1 t70 -79.63 -50.7 10.27 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.479 -0.888 . . . . 0.0 108.906 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.811 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.6 OUTLIER -55.05 -42.74 73.09 Favored 'General case' 0 C--O 1.204 -1.296 0 C-N-CA 116.913 -1.915 . . . . 0.0 108.515 179.398 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.789 HD11 HG12 ' A' ' 101' ' ' VAL . 52.6 mt -59.07 -29.4 67.3 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.871 -1.143 . . . . 0.0 111.352 179.506 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.464 HD12 ' O ' ' A' ' 102' ' ' TYR . 1.1 mt -92.05 -41.23 12.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 120.939 -1.101 . . . . 0.0 110.879 -178.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.668 ' CB ' HD12 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -90.99 -17.24 26.64 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.903 -1.123 . . . . 0.0 110.967 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.97 HG23 ' CE2' ' A' ' 122' ' ' PHE . 9.1 p -69.48 -3.58 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.089 -1.632 . . . . 0.0 110.093 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -35.1 -27.96 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.667 -0.646 . . . . 0.0 111.35 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.682 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -66.68 8.34 0.26 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 111.399 178.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.784 ' OG1' ' HB2' ' A' ' 115' ' ' ALA . 1.4 t -86.14 38.55 0.77 Allowed 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 117.922 -1.511 . . . . 0.0 110.633 -178.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 19.4 m -55.59 -21.48 9.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 O-C-N 121.42 -0.8 . . . . 0.0 110.861 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -105.72 -71.26 0.8 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -143.83 158.14 43.89 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.377 -1.072 . . . . 0.0 110.105 -179.733 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.784 ' HB2' ' OG1' ' A' ' 111' ' ' THR . . . -160.67 83.79 0.68 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.168 -0.957 . . . . 0.0 111.201 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -80.26 117.59 21.17 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.225 -0.922 . . . . 0.0 108.811 178.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.408 ' H ' HG22 ' A' ' 117' ' ' THR . 4.3 t -84.86 131.98 34.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.146 -0.971 . . . . 0.0 110.406 -179.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.589 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -102.01 38.37 1.66 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 110.396 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.95 -59.64 0.14 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 118' ' ' LEU . 62.3 m -107.5 -13.79 14.99 Favored 'General case' 0 C--N 1.291 -1.935 0 O-C-N 121.941 -0.741 . . . . 0.0 110.059 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.525 ' HB2' ' CB ' ' A' ' 118' ' ' LEU . 1.0 OUTLIER -125.96 165.85 18.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.078 -1.014 . . . . 0.0 111.507 -179.397 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.97 ' CE2' HG23 ' A' ' 108' ' ' VAL 0.255 0.0 OUTLIER -124.9 145.26 49.91 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.896 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.847 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.7 OUTLIER -144.42 110.15 5.31 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.252 -1.53 . . . . 0.0 110.247 -178.18 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.905 HD13 ' CE1' ' A' ' 122' ' ' PHE . 1.5 mp -113.02 153.7 14.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.703 ' C ' HG21 ' A' ' 38' ' ' VAL . 10.2 t -159.52 -176.86 6.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.542 -1.349 . . . . 0.0 111.721 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.491 ' HB2' ' HB2' ' A' ' 36' ' ' ASN . 80.6 p -86.68 -76.07 0.37 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.616 -0.677 . . . . 0.0 110.299 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 6.0 mt-10 -94.26 -166.82 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.384 -0.823 . . . . 0.0 110.711 -179.639 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--N 1.307 -1.275 0 O-C-N 121.554 -0.716 . . . . 0.0 111.237 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 36' ' ' ASN . 8.1 p . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 120.987 0.423 . . . . 0.0 110.051 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.546 ' CB ' ' O ' ' A' ' 35' ' ' SER . 5.7 m120 77.31 -13.13 0.98 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.791 -0.568 . . . . 0.0 110.995 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -40.35 116.03 0.63 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.138 -0.976 . . . . 0.0 110.97 -179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.552 HG21 ' N ' ' A' ' 126' ' ' SER . 3.2 t -121.86 148.96 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.384 -0.823 . . . . 0.0 109.729 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.958 HG13 ' HB2' ' A' ' 110' ' ' SER . 9.4 p -127.92 139.07 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 111.299 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.679 HD22 ' O ' ' A' ' 85' ' ' GLU . 9.3 tp -117.25 128.67 55.31 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.683 HG13 ' CD1' ' A' ' 77' ' ' TRP . 39.9 t -130.35 150.94 35.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 O-C-N 120.776 -1.203 . . . . 0.0 112.013 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.635 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 0.1 OUTLIER -143.09 176.91 8.75 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 177.544 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.52 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 6.5 ptt? -110.55 36.34 3.13 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.697 -1.252 . . . . 0.0 110.218 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.554 ' HB3' ' CD1' ' A' ' 48' ' ' ILE . 5.1 mmtt -88.51 -81.27 0.26 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.482 -0.761 . . . . 0.0 112.409 -178.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.743 ' N ' HD11 ' A' ' 48' ' ' ILE . 0.0 OUTLIER 67.99 92.97 0.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.197 -178.692 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.493 ' HB2' ' O ' ' A' ' 45' ' ' SER . 3.5 t70 170.96 -80.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.416 -0.803 . . . . 0.0 110.029 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.578 ' HB3' HD13 ' A' ' 51' ' ' ILE . 13.4 mt-10 -91.9 -10.3 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.891 -179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.939 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -60.65 -64.76 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.341 -0.849 . . . . 0.0 111.526 -178.933 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 2.1 t70 -41.11 -36.88 0.78 Allowed 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 118.769 -1.172 . . . . 0.0 108.961 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -76.19 -52.97 8.97 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.545 -0.722 . . . . 0.0 110.094 178.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.849 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.3 OUTLIER -70.6 -50.03 47.84 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.06 0 O-C-N 120.6 -1.312 . . . . 0.0 108.943 179.104 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.929 HG21 HG13 ' A' ' 69' ' ' VAL . 48.1 mm -43.41 -39.87 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.302 -1.498 . . . . 0.0 108.263 177.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.63 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 24.8 tt0 -65.86 -63.93 0.97 Allowed 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.437 179.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -77.79 -9.79 59.21 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.196 -0.94 . . . . 0.0 111.299 -179.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.731 HG22 ' CA ' ' A' ' 52' ' ' ILE . 4.6 tp -106.61 -34.96 2.99 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-O 121.753 0.787 . . . . 0.0 110.359 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.666 HG23 HG23 ' A' ' 55' ' ' ILE . 2.2 t -117.24 -46.31 3.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.961 -0.696 . . . . 0.0 112.202 -177.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.838 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -56.53 -39.1 72.78 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.274 -1.516 . . . . 0.0 109.502 -179.708 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.838 ' N ' HD23 ' A' ' 57' ' ' LEU . 1.9 tttp -93.58 -49.74 5.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.0 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.94 -42.38 9.69 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.586 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.46 -54.12 14.26 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.643 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 15.0 ttpt -67.6 12.57 0.09 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.624 -0.927 . . . . 0.0 112.552 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.89 -64.04 0.94 Allowed 'General case' 0 C--N 1.305 -1.33 0 O-C-N 120.56 -1.338 . . . . 0.0 108.351 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.2 mtmt -97.87 -22.06 16.56 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.643 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -69.25 128.98 92.25 Favored Pre-proline 0 C--N 1.303 -1.448 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.179 179.779 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.74 -44.32 13.96 Favored 'Trans proline' 0 C--N 1.302 -1.905 0 C-N-CA 122.038 1.826 . . . . 0.0 111.603 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.55 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.44 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.331 0 CA-C-O 123.097 1.427 . . . . 0.0 109.567 -179.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.674 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.305 1.2 mp -97.8 140.87 16.98 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.538 0 CA-C-N 113.741 -1.572 . . . . 0.0 111.563 -176.898 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.547 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 3.1 t -83.23 137.0 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.454 -0.779 . . . . 0.0 110.01 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.929 HG13 HG21 ' A' ' 52' ' ' ILE . 27.6 t -119.99 81.77 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.133 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.674 ' HB2' ' CB ' ' A' ' 77' ' ' TRP . 1.9 mm-40 -78.91 141.13 37.87 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.364 -0.835 . . . . 0.0 110.289 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -145.7 127.88 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.286 -0.884 . . . . 0.0 109.614 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' HB2' ' A' ' 45' ' ' SER . 3.7 ttpt -157.91 -176.9 6.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.021 -1.049 . . . . 0.0 111.326 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.517 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -25.99 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.343 0.592 . . . . 0.0 111.819 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 41.33 44.51 3.95 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.52 ' HA ' ' HA ' ' A' ' 43' ' ' MET . 0.1 OUTLIER -137.25 90.91 2.56 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 121.554 0.692 . . . . 0.0 110.044 179.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.939 ' CD2' HG21 ' A' ' 48' ' ' ILE . 8.8 t90 -83.0 82.28 8.3 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.436 -0.79 . . . . 0.0 109.547 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 1.013 ' O ' HD13 ' A' ' 78' ' ' ILE . 13.6 m95 -89.59 131.27 35.69 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.141 -0.975 . . . . 0.0 110.975 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 1.013 HD13 ' O ' ' A' ' 77' ' ' TRP . 21.3 mm -134.66 153.09 34.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.366 -0.834 . . . . 0.0 109.876 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.561 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -143.55 135.46 26.59 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.947 -179.378 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.575 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -136.43 140.23 42.99 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.597 -0.689 . . . . 0.0 110.03 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -84.46 51.15 2.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.012 . . . . 0.0 110.287 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.77 -148.38 5.97 Favored Glycine 0 N--CA 1.477 1.398 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -88.18 144.77 26.27 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.277 -1.131 . . . . 0.0 109.8 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.583 HD11 HD23 ' A' ' 40' ' ' LEU . 9.8 tt -142.46 172.85 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.962 . . . . 0.0 110.67 -179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.679 ' O ' HD22 ' A' ' 40' ' ' LEU . 15.4 mt-10 -131.71 176.41 8.35 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.955 -1.091 . . . . 0.0 112.017 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 1.114 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -160.94 154.46 3.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 1.114 ' N ' HD13 ' A' ' 86' ' ' ILE . 4.8 m-20 -137.1 -178.7 5.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.796 -1.19 . . . . 0.0 111.903 -178.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.966 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -150.35 -29.9 0.21 Allowed 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.103 177.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.436 ' CA ' ' HE1' ' A' ' 99' ' ' PHE . . . -39.29 -47.03 1.64 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.062 -1.024 . . . . 0.0 110.663 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 93' ' ' GLU . 2.7 mm-40 -50.92 -63.34 1.16 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 121.871 0.843 . . . . 0.0 109.41 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.56 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -38.61 -38.08 0.37 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.464 179.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.68 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -64.18 -42.49 97.95 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.044 -1.623 . . . . 0.0 109.044 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' N ' ' O ' ' A' ' 90' ' ' GLU . 14.0 mt-10 -60.14 -24.65 64.88 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.522 HD23 ' N ' ' A' ' 95' ' ' LEU . 8.7 tt -79.73 -60.38 2.37 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.523 -0.735 . . . . 0.0 110.469 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -109.95 -20.46 12.73 Favored 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 118.762 -1.175 . . . . 0.0 111.97 -179.456 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.693 ' N ' HD12 ' A' ' 95' ' ' LEU . . . 63.05 90.4 0.03 OUTLIER Glycine 0 N--CA 1.497 2.71 0 C-N-CA 118.786 -1.674 . . . . 0.0 109.604 179.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.712 ' HB3' ' HD2' ' A' ' 98' ' ' PRO 0.261 0.2 OUTLIER -175.99 -151.69 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.192 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 -178.744 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.712 ' HD2' ' HB3' ' A' ' 97' ' ' LYS . 43.1 Cg_endo -67.8 -1.99 7.79 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 N-CA-C 108.841 -1.253 . . . . 0.0 108.841 176.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.778 ' CD1' ' N ' ' A' ' 100' ' ' SER . 3.3 p90 -21.3 -44.58 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.641 0.734 . . . . 0.0 112.427 179.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.966 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.5 OUTLIER -54.47 -53.78 49.65 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 122.868 1.318 . . . . 0.0 108.95 -177.104 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.978 HG12 HD11 ' A' ' 105' ' ' LEU . 48.3 t -98.44 -47.05 12.44 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.343 0 CA-C-N 115.147 -0.933 . . . . 0.0 113.267 -178.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.58 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 5.9 t80 -51.06 -29.22 12.24 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 117.512 -1.675 . . . . 0.0 107.843 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 8.8 t70 -80.9 -44.45 18.3 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.947 HD22 ' CZ ' ' A' ' 122' ' ' PHE . 0.4 OUTLIER -59.55 -45.23 92.4 Favored 'General case' 0 C--O 1.201 -1.476 0 C-N-CA 117.833 -1.547 . . . . 0.0 109.102 178.861 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.978 HD11 HG12 ' A' ' 101' ' ' VAL . 2.5 mt -64.21 -27.29 68.96 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 119.893 -1.755 . . . . 0.0 111.062 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -95.18 -12.73 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 109.937 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.579 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.86 -36.11 3.52 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.507 -0.745 . . . . 0.0 110.289 -179.196 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.703 HG12 ' O ' ' A' ' 104' ' ' LEU . 1.8 p -62.69 -4.86 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.207 -0.933 . . . . 0.0 111.603 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -35.88 -27.22 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.399 -0.813 . . . . 0.0 111.81 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.958 ' HB2' HG13 ' A' ' 39' ' ' VAL . 90.6 p -82.24 28.84 0.43 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.877 -1.14 . . . . 0.0 109.791 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.702 ' HB ' HG22 ' A' ' 108' ' ' VAL . 5.4 t -89.49 42.89 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.945 -1.097 . . . . 0.0 109.38 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 96.7 t -57.95 -47.29 86.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.762 -0.586 . . . . 0.0 111.364 -179.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -78.01 -75.19 0.97 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.525 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -152.95 -176.98 6.0 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.238 -1.154 . . . . 0.0 110.538 -179.14 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -170.36 73.77 0.07 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.368 -0.833 . . . . 0.0 110.317 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -72.69 140.67 48.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.521 HG22 ' H ' ' A' ' 119' ' ' GLY . 18.8 m -89.3 117.55 28.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 110.532 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.667 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -86.64 39.61 0.85 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.431 -0.793 . . . . 0.0 110.728 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.521 ' H ' HG22 ' A' ' 117' ' ' THR . . . 59.6 -62.01 0.01 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.311 -1.115 . . . . 0.0 110.311 179.196 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.667 ' N ' ' O ' ' A' ' 118' ' ' LEU . 38.3 p -88.44 -28.62 20.77 Favored 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.928 -0.748 . . . . 0.0 109.979 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.57 ' HD3' HD22 ' A' ' 118' ' ' LEU . 3.6 ptmt -146.1 -167.76 2.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.129 -0.982 . . . . 0.0 110.665 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.947 ' CZ ' HD22 ' A' ' 104' ' ' LEU . 5.8 m-85 -116.77 165.07 13.72 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.321 -0.862 . . . . 0.0 110.85 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.687 ' O ' HG22 ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.22 105.1 5.61 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.659 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.737 HD13 ' CG2' ' A' ' 86' ' ' ILE . 1.8 mp -108.2 141.57 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -0.952 . . . . 0.0 109.623 -179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 13.4 t -149.94 -170.76 3.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.06 -1.025 . . . . 0.0 111.11 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.552 ' N ' HG21 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -96.54 -33.51 11.8 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.44 -0.787 . . . . 0.0 110.537 -179.929 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' A' ' 128' ' ' LEU . 1.7 mm-40 -37.65 105.49 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.65 -0.656 . . . . 0.0 110.68 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.496 ' O ' ' O ' ' A' ' 127' ' ' GLU . 1.0 OUTLIER . . . . . 0 C--N 1.307 -1.275 0 O-C-N 121.63 -0.669 . . . . 0.0 110.582 -179.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.147 0.499 . . . . 0.0 109.839 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.508 ' O ' ' C ' ' A' ' 37' ' ' ALA . 31.5 m-20 -129.86 -92.86 0.43 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 110.59 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.508 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -27.25 127.28 0.06 Allowed 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.347 0.594 . . . . 0.0 111.997 -179.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.5 m -111.76 174.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.772 HG13 ' HB3' ' A' ' 110' ' ' SER . 13.2 p -144.78 125.1 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.139 -0.975 . . . . 0.0 110.783 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.744 HD11 HD11 ' A' ' 86' ' ' ILE . 20.6 tp -92.85 162.85 13.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.819 HG13 ' NE1' ' A' ' 77' ' ' TRP . 5.6 t -149.65 123.47 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 O-C-N 120.106 -1.621 . . . . 0.0 111.833 -178.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.997 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 0.2 OUTLIER -126.36 156.35 40.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.127 -0.983 . . . . 0.0 109.853 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.532 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 1.6 ptm -96.98 31.38 2.41 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.921 -1.112 . . . . 0.0 110.183 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.527 ' O ' ' HA2' ' A' ' 74' ' ' GLY . 2.3 mmtt -87.74 -86.59 0.16 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.482 -0.761 . . . . 0.0 110.956 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.647 ' CA ' HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER 73.37 113.26 0.06 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.36 -0.838 . . . . 0.0 110.746 -179.834 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 45' ' ' SER . 0.3 OUTLIER 164.73 -83.95 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.665 -0.647 . . . . 0.0 109.438 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.458 ' O ' HD13 ' A' ' 51' ' ' ILE . 5.1 mt-10 -95.52 1.1 53.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.866 . . . . 0.0 110.045 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.964 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.93 -66.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.103 -0.998 . . . . 0.0 111.046 -178.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.655 ' HA ' HG11 ' A' ' 69' ' ' VAL . 5.3 t0 -40.09 -33.58 0.24 Allowed 'General case' 0 C--N 1.292 -1.932 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.68 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.493 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -78.71 -55.5 5.13 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.717 -0.614 . . . . 0.0 109.835 178.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.839 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -68.31 -48.43 73.31 Favored 'Isoleucine or valine' 0 C--O 1.185 -2.316 0 C-N-CA 118.301 -1.36 . . . . 0.0 108.232 178.642 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.758 ' CA ' HG22 ' A' ' 55' ' ' ILE . 46.3 mm -43.32 -41.19 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.004 -1.685 . . . . 0.0 108.42 176.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.611 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 16.2 tt0 -64.84 -62.91 1.28 Allowed 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.895 -1.128 . . . . 0.0 110.025 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -77.41 -11.78 59.88 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.323 -0.86 . . . . 0.0 111.584 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.758 HG22 ' CA ' ' A' ' 52' ' ' ILE . 4.5 tp -107.23 -33.47 2.66 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.531 0.682 . . . . 0.0 111.039 -178.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.757 HG23 HG23 ' A' ' 55' ' ' ILE . 2.8 t -117.22 -45.17 3.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.598 -0.689 . . . . 0.0 112.153 -177.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.878 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -54.58 -30.08 53.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 119.758 -1.839 . . . . 0.0 108.959 -179.798 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.878 ' N ' HD23 ' A' ' 57' ' ' LEU . 13.4 mmtt -85.99 -47.49 9.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.473 -0.767 . . . . 0.0 110.483 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.44 -45.09 5.37 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.566 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.97 -73.04 0.76 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.622 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 22.4 ttpt -65.72 9.84 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.403 -1.057 . . . . 0.0 112.557 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.618 ' HB2' ' O ' ' A' ' 58' ' ' LYS . . . -51.63 -63.47 1.13 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.555 -1.341 . . . . 0.0 108.454 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.0 mtmt -97.97 -20.34 17.48 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 177.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.622 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.8 OUTLIER -68.68 141.1 92.43 Favored Pre-proline 0 N--CA 1.489 1.503 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.393 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.423 ' O ' ' OG ' ' A' ' 66' ' ' SER . 42.9 Cg_endo -62.38 -46.38 12.35 Favored 'Trans proline' 0 C--N 1.298 -2.107 0 C-N-CA 122.228 1.952 . . . . 0.0 112.002 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.423 ' OG ' ' O ' ' A' ' 65' ' ' PRO . 0.9 OUTLIER 178.81 112.99 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 123.158 1.456 . . . . 0.0 110.66 -179.691 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.69 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.306 1.0 OUTLIER -89.99 147.67 5.06 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.684 0 CA-C-N 113.573 -1.649 . . . . 0.0 110.86 -178.185 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.556 ' HB ' ' HG2' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -102.05 138.21 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.133 -0.98 . . . . 0.0 110.695 -179.581 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.702 HG22 HG21 ' A' ' 52' ' ' ILE . 5.5 t -116.82 90.97 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.372 -0.83 . . . . 0.0 109.073 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.599 ' CB ' ' HB2' ' A' ' 77' ' ' TRP . 13.2 mm-40 -79.61 76.51 6.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.487 -0.758 . . . . 0.0 110.655 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -89.04 113.62 24.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.973 -1.079 . . . . 0.0 109.485 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.421 ' O ' ' N ' ' A' ' 74' ' ' GLY . 13.0 mttp -145.47 -162.02 1.42 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.032 -1.042 . . . . 0.0 111.059 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.574 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -39.76 96.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.335 -0.853 . . . . 0.0 111.243 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 37.73 50.1 1.93 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.574 ' CD2' ' O ' ' A' ' 73' ' ' ALA . 8.6 m-85 -146.59 87.14 1.69 Allowed 'General case' 0 C--N 1.29 -1.994 0 O-C-N 121.875 -0.779 . . . . 0.0 109.761 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.997 ' CZ3' HD13 ' A' ' 42' ' ' LEU . 4.5 t90 -82.13 74.16 9.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.516 -0.74 . . . . 0.0 110.033 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.819 ' NE1' HG13 ' A' ' 41' ' ' VAL . 8.9 m95 -82.0 123.33 28.81 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.652 HD13 ' O ' ' A' ' 77' ' ' TRP . 5.5 mm -116.38 141.01 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.003 -1.061 . . . . 0.0 110.159 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.597 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.4 OUTLIER -123.61 130.52 52.79 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.612 -0.68 . . . . 0.0 109.598 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.47 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -130.28 165.89 21.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.222 -0.924 . . . . 0.0 110.289 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -118.35 50.32 1.18 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.341 -0.849 . . . . 0.0 110.304 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -119.77 0.52 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -112.22 152.67 28.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -1.115 . . . . 0.0 109.717 179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 124' ' ' ILE . 8.1 tt -152.41 175.19 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.483 ' HG2' ' HA ' ' A' ' 123' ' ' THR . 56.2 mt-10 -148.16 172.47 14.27 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.007 -1.058 . . . . 0.0 111.315 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.78 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.1 OUTLIER -124.48 167.62 18.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 121.601 -0.687 . . . . 0.0 109.552 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.417 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 26.0 m-20 -154.98 138.97 16.37 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.015 -1.053 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.988 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.73 -37.52 0.12 Allowed 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.379 -1.328 . . . . 0.0 111.0 177.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 93' ' ' GLU . . . -39.89 -40.27 0.97 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.501 -0.75 . . . . 0.0 110.567 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.523 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 3.2 mt-10 -72.06 -43.97 64.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.317 -0.864 . . . . 0.0 109.408 179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.483 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -60.35 -49.84 75.99 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 108.955 179.206 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.568 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -53.53 -57.43 15.66 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.523 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.1 pt-20 -59.98 -13.24 10.38 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.332 -1.099 . . . . 0.0 110.038 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.762 HD23 ' N ' ' A' ' 95' ' ' LEU . 0.5 OUTLIER -92.22 -43.75 9.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.317 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.762 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -97.64 -41.31 8.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.795 -1.191 . . . . 0.0 109.247 179.464 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.74 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -145.33 -74.7 0.02 OUTLIER Glycine 0 N--CA 1.483 1.805 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.565 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.3 OUTLIER 161.61 -55.77 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.858 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.737 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.546 ' HD3' ' HB3' ' A' ' 97' ' ' LYS . 52.2 Cg_endo -74.66 -23.54 14.49 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.856 1.45 . . . . 0.0 110.251 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.568 ' HB3' ' HA2' ' A' ' 92' ' ' GLY . 2.6 t80 -47.28 -49.42 23.71 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.223 -0.923 . . . . 0.0 109.996 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.988 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 29.5 p -31.97 -64.12 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.889 0.852 . . . . 0.0 110.429 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.968 ' HA ' HD23 ' A' ' 104' ' ' LEU . 13.8 t -72.69 -60.78 2.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 O-C-N 121.034 -1.041 . . . . 0.0 112.572 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.43 ' C ' ' O ' ' A' ' 101' ' ' VAL . 1.7 t80 -44.94 -30.48 1.02 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.532 -1.355 . . . . 0.0 109.332 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 6.4 t0 -77.08 -31.52 56.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.598 -0.689 . . . . 0.0 109.287 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.971 HD13 ' CZ ' ' A' ' 122' ' ' PHE . 0.6 OUTLIER -74.81 -19.49 60.17 Favored 'General case' 0 C--O 1.2 -1.51 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.24 179.739 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 101' ' ' VAL . 1.4 mt -91.27 -26.12 19.14 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.345 -1.472 . . . . 0.0 111.226 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -97.22 -13.58 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.015 -1.053 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.555 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -105.57 -42.9 5.08 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.509 -0.745 . . . . 0.0 110.012 179.766 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.627 ' CG1' ' O ' ' A' ' 104' ' ' LEU . 3.5 p -57.32 -2.86 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 120.879 -1.138 . . . . 0.0 112.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.504 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -25.22 -39.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.77 -0.581 . . . . 0.0 112.365 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.772 ' HB3' HG13 ' A' ' 39' ' ' VAL . 1.9 m -80.27 43.14 0.61 Allowed 'General case' 0 C--N 1.287 -2.137 0 C-N-CA 118.43 -1.308 . . . . 0.0 108.79 178.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.611 ' CG2' HG22 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -63.33 2.02 0.44 Allowed 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.267 -0.896 . . . . 0.0 112.45 -179.146 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.454 ' C ' ' O ' ' A' ' 111' ' ' THR . 9.6 p -38.16 -27.24 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 120.808 -1.183 . . . . 0.0 111.17 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.535 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -97.64 50.22 1.41 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.535 ' C ' ' O ' ' A' ' 113' ' ' GLY . 1.5 ttm-85 19.86 100.36 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.356 0.598 . . . . 0.0 111.982 179.165 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.578 ' HB1' ' CD2' ' A' ' 122' ' ' PHE . . . -85.09 93.69 8.68 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.266 -0.896 . . . . 0.0 111.47 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 123' ' ' THR . 0.1 OUTLIER -74.44 143.91 44.5 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.189 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 4.0 m -79.51 160.21 26.62 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.79 -1.194 . . . . 0.0 111.309 -178.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.625 HD23 ' O ' ' A' ' 118' ' ' LEU . 0.9 OUTLIER -130.62 35.33 4.03 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.665 -0.647 . . . . 0.0 109.891 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.49 -59.76 0.29 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.2 OUTLIER -115.42 -9.24 12.15 Favored 'General case' 0 C--N 1.292 -1.908 0 O-C-N 122.013 -0.698 . . . . 0.0 110.186 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.454 ' HB2' ' HB3' ' A' ' 118' ' ' LEU . 20.8 mttt -137.68 -162.26 1.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.151 -0.968 . . . . 0.0 111.195 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.971 ' CZ ' HD13 ' A' ' 104' ' ' LEU 0.263 0.1 OUTLIER -132.15 160.66 35.4 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.068 -179.235 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.663 ' O ' HG22 ' A' ' 123' ' ' THR . 0.9 OUTLIER -138.3 104.14 5.1 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.034 -1.041 . . . . 0.0 110.598 178.697 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.805 ' HB ' HG23 ' A' ' 84' ' ' ILE . 3.4 mp -98.44 146.78 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.201 -0.937 . . . . 0.0 108.59 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.5 t -149.4 166.75 28.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.782 -1.199 . . . . 0.0 111.108 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.476 ' O ' ' O ' ' A' ' 127' ' ' GLU . 2.4 t -94.27 -32.69 13.54 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.555 0.693 . . . . 0.0 109.533 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' A' ' 128' ' ' LEU . 14.4 mm-40 -42.51 167.59 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.746 -0.596 . . . . 0.0 110.452 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.8 OUTLIER . . . . . 0 C--N 1.307 -1.277 0 O-C-N 121.297 -0.877 . . . . 0.0 110.804 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.1 m . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 121.212 0.53 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.717 ' O ' HG13 ' A' ' 38' ' ' VAL . 4.0 m-20 -110.07 -1.69 17.4 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.374 -0.829 . . . . 0.0 110.276 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.456 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -31.87 141.32 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.569 0.699 . . . . 0.0 111.904 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.717 HG13 ' O ' ' A' ' 36' ' ' ASN . 24.2 m -141.42 176.17 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.472 -0.767 . . . . 0.0 109.709 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 39' ' ' VAL . 5.5 p -136.46 130.5 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.953 -1.092 . . . . 0.0 111.097 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.895 ' O ' HG23 ' A' ' 41' ' ' VAL . 12.4 tp -98.1 160.66 14.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 177.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.912 ' O ' HD22 ' A' ' 42' ' ' LEU . 2.9 t -166.31 116.4 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 O-C-N 120.871 -1.143 . . . . 0.0 110.093 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.912 HD22 ' O ' ' A' ' 41' ' ' VAL . 2.5 mm? -135.38 -171.68 2.89 Favored 'General case' 0 C--N 1.289 -2.056 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.404 ' O ' ' N ' ' A' ' 45' ' ' SER . 20.9 ptm -104.09 161.43 14.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.161 -0.962 . . . . 0.0 109.813 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -44.75 96.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.3 -0.875 . . . . 0.0 111.263 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 4.5 m -82.11 11.81 4.86 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.165 -0.959 . . . . 0.0 110.265 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' SER . 13.3 t0 78.41 -62.51 0.34 Allowed 'General case' 0 N--CA 1.503 2.18 0 O-C-N 121.569 -0.707 . . . . 0.0 112.421 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.59 ' O ' HD13 ' A' ' 51' ' ' ILE . 3.5 mt-10 -93.31 26.56 2.88 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.776 -1.203 . . . . 0.0 112.195 -177.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.81 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.61 -75.24 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 120.932 -1.105 . . . . 0.0 111.092 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.3 t70 -37.63 -32.22 0.05 Allowed 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.45 -56.13 4.91 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 177.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.81 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -71.28 -52.14 29.02 Favored 'Isoleucine or valine' 0 C--O 1.193 -1.88 0 O-C-N 120.977 -1.077 . . . . 0.0 109.869 179.075 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.701 ' HA ' HG22 ' A' ' 55' ' ' ILE . 47.2 mm -48.22 -38.73 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 119.89 -1.756 . . . . 0.0 108.121 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.729 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.7 tt0 -63.07 -61.12 2.59 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.183 -0.948 . . . . 0.0 110.352 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -81.06 -12.0 59.4 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 111.405 -178.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.745 HG23 HG23 ' A' ' 56' ' ' VAL . 4.3 tp -105.88 -32.99 2.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-O 121.645 0.736 . . . . 0.0 110.365 -178.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.745 HG23 HG23 ' A' ' 55' ' ' ILE . 2.5 t -117.89 -45.08 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.869 -0.732 . . . . 0.0 112.694 -177.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.729 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -49.31 -42.75 42.34 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.011 -1.681 . . . . 0.0 109.037 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.54 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 14.3 mttt -85.08 -44.22 13.2 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.574 0.702 . . . . 0.0 109.51 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -65.54 -51.36 48.67 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.54 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -69.43 -8.36 59.38 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' A' ' 57' ' ' LEU . 2.1 tptm -107.36 -9.02 16.13 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.129 -1.218 . . . . 0.0 110.954 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.17 -79.05 0.24 Allowed 'General case' 0 C--N 1.308 -1.197 0 O-C-N 120.886 -1.134 . . . . 0.0 110.69 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.9 mtmt -87.45 -29.38 21.47 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.54 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.9 m-80 -69.18 124.99 91.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.113 179.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.474 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 42.9 Cg_endo -62.56 -42.87 24.34 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.781 1.654 . . . . 0.0 110.671 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.598 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.4 OUTLIER 179.4 110.0 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 123.008 1.385 . . . . 0.0 109.64 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.747 HG23 ' O ' ' A' ' 79' ' ' LYS 0.297 1.1 mp -105.37 149.99 8.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.331 0 CA-C-N 113.839 -1.528 . . . . 0.0 110.496 -177.205 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -103.44 130.36 53.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.322 -0.861 . . . . 0.0 110.013 179.725 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.685 ' CG1' HG21 ' A' ' 52' ' ' ILE . 55.5 t -113.95 100.29 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.168 -0.957 . . . . 0.0 109.889 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.565 ' N ' ' O ' ' A' ' 77' ' ' TRP . 0.7 OUTLIER -89.81 79.55 6.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.385 -0.822 . . . . 0.0 110.681 -179.487 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -80.47 91.02 5.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.073 -1.017 . . . . 0.0 109.396 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -89.78 154.45 19.9 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.159 -0.963 . . . . 0.0 110.482 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -59.63 -12.65 7.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.818 . . . . 0.0 110.548 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.452 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . -147.29 22.92 1.56 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.456 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.452 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 5.8 m-85 -160.77 108.8 1.57 Allowed 'General case' 0 C--N 1.289 -2.051 0 O-C-N 121.76 -0.847 . . . . 0.0 109.887 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.777 ' CE2' HG22 ' A' ' 48' ' ' ILE . 13.1 t90 -89.8 77.84 6.97 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.599 -0.688 . . . . 0.0 109.379 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.858 ' CE2' HG13 ' A' ' 41' ' ' VAL . 12.4 m0 -102.77 134.6 45.89 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.506 -0.746 . . . . 0.0 112.433 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.549 ' HB ' HD23 ' A' ' 40' ' ' LEU . 1.2 mp -138.65 152.39 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 177.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.747 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.4 OUTLIER -127.83 152.74 47.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.831 -1.168 . . . . 0.0 110.041 -179.728 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.461 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -139.42 178.86 6.9 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.299 -0.875 . . . . 0.0 110.603 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 37' ' ' ALA . 41.6 m-20 -122.54 50.49 1.49 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.364 -0.835 . . . . 0.0 110.138 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.55 -126.66 0.88 Allowed Glycine 0 C--N 1.301 -1.386 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -99.8 143.93 29.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -1.22 . . . . 0.0 109.925 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.59 HG23 ' HB ' ' A' ' 124' ' ' ILE . 4.8 tp -125.85 161.99 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.145 -0.972 . . . . 0.0 110.012 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.518 ' N ' HG13 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.88 164.96 23.02 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.137 -0.977 . . . . 0.0 111.717 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.791 HG13 HD13 ' A' ' 124' ' ' ILE 0.26 0.3 OUTLIER -139.91 175.02 7.53 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.363 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.555 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 74.9 m-20 -149.55 173.37 13.69 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.861 -1.149 . . . . 0.0 111.308 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 1.025 ' HB1' ' CA ' ' A' ' 100' ' ' SER . . . -150.96 -48.77 0.12 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.97 0.891 . . . . 0.0 109.759 177.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.414 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -41.37 -45.4 3.05 Favored 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.351 -0.843 . . . . 0.0 110.643 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.566 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 1.1 tt0 -49.81 -38.55 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 122.138 0.971 . . . . 0.0 108.483 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 1.004 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -63.45 -42.59 98.64 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.396 -0.815 . . . . 0.0 109.191 178.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.719 ' N ' ' CD2' ' A' ' 99' ' ' PHE . . . -63.15 -65.37 3.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.566 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 5.2 pt-20 -38.21 -31.56 0.05 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.818 -0.813 . . . . 0.0 108.94 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.722 HD13 ' HG ' ' A' ' 95' ' ' LEU . 0.1 OUTLIER -73.6 -71.16 0.33 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.68 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 1.004 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.1 OUTLIER -86.97 -55.17 3.95 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.972 -1.08 . . . . 0.0 108.847 178.599 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 88.18 50.14 3.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.696 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 15.2 mttt -150.74 -110.7 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 121.288 -1.125 . . . . 0.0 110.646 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.696 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 58.6 Cg_endo -85.5 12.98 2.89 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 CA-C-N 120.926 1.366 . . . . 0.0 109.67 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.729 ' O ' ' N ' ' A' ' 101' ' ' VAL . 29.3 p90 -49.85 -146.0 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 122.009 0.909 . . . . 0.0 110.474 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 1.025 ' CA ' ' HB1' ' A' ' 88' ' ' ALA . 2.1 p 32.73 -77.59 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 122.269 1.033 . . . . 0.0 111.323 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.729 ' N ' ' O ' ' A' ' 99' ' ' PHE . 38.0 t -66.02 -64.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.582 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.491 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 16.0 t80 -59.89 -39.9 86.9 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 119.99 -1.694 . . . . 0.0 106.69 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.581 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 0.3 OUTLIER -63.42 -38.96 93.16 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.847 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.865 HD12 ' N ' ' A' ' 105' ' ' LEU . 3.2 pp -83.75 -38.89 20.78 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 117.957 -1.497 . . . . 0.0 109.195 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.865 ' N ' HD12 ' A' ' 104' ' ' LEU . 66.7 mt -49.82 -22.19 1.37 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 120.802 -1.186 . . . . 0.0 109.602 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.437 HD13 ' HA ' ' A' ' 106' ' ' ILE . 0.4 OUTLIER -107.83 -33.4 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.288 -0.882 . . . . 0.0 110.15 179.768 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.581 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.7 p30 -96.7 -3.65 42.19 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.968 -1.082 . . . . 0.0 110.027 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.664 HG12 ' O ' ' A' ' 104' ' ' LEU . 9.8 p -83.11 -7.7 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 110.804 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 108' ' ' VAL . 8.5 t -42.02 -22.91 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.193 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.595 ' CB ' ' N ' ' A' ' 41' ' ' VAL . 82.8 p -53.22 -4.31 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.313 -0.867 . . . . 0.0 112.641 179.283 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.954 HG22 HG12 ' A' ' 124' ' ' ILE . 45.1 p -71.76 -73.79 0.17 Allowed 'General case' 0 N--CA 1.488 1.428 0 O-C-N 119.923 -1.736 . . . . 0.0 110.868 -178.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.567 HG12 ' O ' ' A' ' 112' ' ' VAL . 47.9 t 61.78 11.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.517 -0.74 . . . . 0.0 110.575 -179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -161.2 -68.94 0.02 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.796 ' HB3' HG22 ' A' ' 125' ' ' THR . 0.1 OUTLIER -136.58 165.86 24.88 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.305 -1.114 . . . . 0.0 110.497 -179.38 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.997 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -156.25 68.79 0.62 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.318 -0.864 . . . . 0.0 110.185 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.57 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 7.1 t80 -69.69 132.15 45.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.246 -0.908 . . . . 0.0 109.657 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.4 m -88.57 138.87 31.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.147 -0.971 . . . . 0.0 110.305 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -108.73 37.19 2.6 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.381 -0.824 . . . . 0.0 110.197 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.21 -58.47 0.25 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.553 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.8 OUTLIER -113.38 -23.35 9.92 Favored 'General case' 0 C--N 1.293 -1.871 0 O-C-N 121.95 -0.735 . . . . 0.0 110.067 -179.873 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 mtpp -116.69 -168.22 1.42 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.997 ' CZ ' ' HB1' ' A' ' 115' ' ' ALA . 14.5 t80 -138.03 161.71 36.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.448 -0.782 . . . . 0.0 109.159 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.603 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.8 OUTLIER -145.24 139.26 27.03 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 120.569 -1.332 . . . . 0.0 110.337 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.972 HD11 ' CD2' ' A' ' 122' ' ' PHE . 2.1 mp -134.91 154.39 36.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.467 -0.77 . . . . 0.0 110.18 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.796 HG22 ' HB3' ' A' ' 114' ' ' ARG . 1.9 t -152.34 -175.04 5.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.186 -0.946 . . . . 0.0 110.34 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 90.4 p -89.51 -90.08 0.14 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.364 -0.835 . . . . 0.0 110.538 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.464 ' N ' ' OG ' ' A' ' 126' ' ' SER . 2.6 mt-10 -93.33 122.73 36.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.114 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.517 ' H ' HD12 ' A' ' 128' ' ' LEU . 1.9 mp . . . . . 0 C--N 1.306 -1.286 0 O-C-N 121.451 -0.781 . . . . 0.0 110.335 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 37' ' ' ALA . 62.0 m . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 120.874 0.368 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.526 ' O ' ' C ' ' A' ' 37' ' ' ALA . 5.5 m-80 62.94 -64.91 0.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.719 . . . . 0.0 110.636 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -26.38 139.43 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.353 0.596 . . . . 0.0 111.496 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.598 HG12 ' OG ' ' A' ' 126' ' ' SER . 8.7 p -102.08 136.3 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.775 HG13 ' HB2' ' A' ' 110' ' ' SER . 8.4 p -80.65 135.44 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.041 -1.037 . . . . 0.0 110.273 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.943 HD22 ' CG1' ' A' ' 84' ' ' ILE . 14.7 tp -110.42 134.48 52.29 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.756 HG13 ' NE1' ' A' ' 77' ' ' TRP . 10.1 t -130.63 121.24 50.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 O-C-N 120.86 -1.15 . . . . 0.0 110.942 -177.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.763 HD21 HG23 ' A' ' 86' ' ' ILE . 0.4 OUTLIER -120.54 -171.63 2.21 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.633 -0.667 . . . . 0.0 109.475 179.245 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.98 159.48 15.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.154 -0.967 . . . . 0.0 109.965 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.64 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.189 -0.945 . . . . 0.0 110.6 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.472 ' HB3' HG23 ' A' ' 48' ' ' ILE . 1.8 t -86.53 11.25 13.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 110.144 179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.486 ' N ' HD13 ' A' ' 48' ' ' ILE . 5.5 m-20 67.71 -62.87 0.33 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.494 -0.754 . . . . 0.0 111.108 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.486 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.0 mt-10 -87.21 30.17 0.79 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.103 -0.998 . . . . 0.0 110.616 -179.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.954 HG22 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -61.36 -75.2 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.969 -1.082 . . . . 0.0 111.393 -178.698 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.527 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -39.47 -31.61 0.1 Allowed 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.305 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -75.4 -53.79 8.12 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.763 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.41 -53.55 19.1 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.76 0 O-C-N 120.997 -1.065 . . . . 0.0 109.992 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.717 ' HA ' HG22 ' A' ' 55' ' ' ILE . 44.8 mm -47.05 -37.15 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 119.962 -1.711 . . . . 0.0 108.106 177.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.711 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 30.2 tt0 -64.39 -63.43 1.14 Allowed 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.386 -0.821 . . . . 0.0 110.282 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.44 -10.03 59.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.354 -0.841 . . . . 0.0 111.295 -178.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.717 HG22 ' HA ' ' A' ' 52' ' ' ILE . 4.4 tp -106.68 -33.79 2.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-O 121.62 0.724 . . . . 0.0 110.371 -179.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.715 HG23 HG23 ' A' ' 55' ' ' ILE . 2.3 t -118.67 -43.22 2.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.711 ' HB3' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -44.98 -38.47 4.77 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.449 -1.407 . . . . 0.0 109.775 -178.346 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.536 ' N ' ' HG ' ' A' ' 57' ' ' LEU . 0.0 OUTLIER -86.78 -44.61 11.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -56.55 -53.35 44.2 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.53 ' HA2' ' CB ' ' A' ' 64' ' ' ASN . . . -72.19 0.79 37.57 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.489 ' HB2' ' O ' ' A' ' 57' ' ' LEU . 2.0 mmtt -106.57 -9.31 16.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.845 -1.385 . . . . 0.0 111.357 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.36 -80.05 0.12 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.888 -1.133 . . . . 0.0 109.852 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.58 -24.75 16.46 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 122.307 1.051 . . . . 0.0 108.411 178.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.53 ' CB ' ' HA2' ' A' ' 60' ' ' GLY . 6.4 m-20 -67.51 116.55 38.39 Favored Pre-proline 0 C--N 1.294 -1.844 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.727 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 44.3 Cg_endo -62.99 -37.36 53.99 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 124.299 1.684 . . . . 0.0 111.558 -179.2 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.633 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.3 OUTLIER 179.36 111.61 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 123.145 1.45 . . . . 0.0 109.908 179.423 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.644 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.298 1.2 mp -104.5 155.01 6.09 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 CA-C-N 113.665 -1.607 . . . . 0.0 111.024 -177.442 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.632 HG11 ' CE ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -110.55 147.04 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.172 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.696 ' CG1' HG21 ' A' ' 52' ' ' ILE . 58.1 t -128.5 106.18 14.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.15 -0.968 . . . . 0.0 110.093 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.569 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.3 mm-40 -97.16 84.06 3.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.779 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -96.47 128.17 43.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.153 -0.967 . . . . 0.0 110.201 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.534 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -144.76 143.51 30.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 0.0 110.07 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -58.55 81.52 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 109.542 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 159.02 -40.11 0.49 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -139.94 173.81 11.15 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-O 121.835 0.826 . . . . 0.0 110.984 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.954 ' CE2' HG22 ' A' ' 48' ' ' ILE . 13.4 t90 -138.92 83.29 1.95 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.756 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.3 m95 -104.87 120.55 41.68 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.111 -0.993 . . . . 0.0 112.379 -177.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.548 ' CG1' ' HA ' ' A' ' 69' ' ' VAL . 1.1 mt -130.61 141.74 45.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.097 -1.002 . . . . 0.0 109.283 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.632 ' CE ' HG11 ' A' ' 68' ' ' VAL . 2.1 ptpt -114.12 134.17 55.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 110.028 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.505 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -120.16 148.91 43.05 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.317 -0.864 . . . . 0.0 109.838 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.46 ' HA ' ' CB ' ' A' ' 37' ' ' ALA . 1.4 m-20 -95.43 53.3 1.47 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.168 -0.958 . . . . 0.0 110.379 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.413 ' O ' ' OG ' ' A' ' 126' ' ' SER . . . -170.16 -116.79 0.39 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -121.39 146.61 46.7 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.169 -1.195 . . . . 0.0 110.165 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.943 ' CG1' HD22 ' A' ' 40' ' ' LEU . 5.5 tp -133.53 159.72 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.042 -1.036 . . . . 0.0 110.698 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.49 ' HG2' ' OG1' ' A' ' 123' ' ' THR . 16.9 mt-10 -137.56 130.32 30.06 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.325 -0.86 . . . . 0.0 110.793 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.763 HG23 HD21 ' A' ' 42' ' ' LEU . 1.7 mm -86.37 -176.1 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.333 -0.854 . . . . 0.0 109.82 179.699 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.551 ' H ' HG22 ' A' ' 86' ' ' ILE . 4.6 m-20 -156.54 154.8 30.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 110.869 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.823 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -150.13 -25.39 0.25 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.361 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.434 ' C ' ' O ' ' A' ' 88' ' ' ALA . . . -39.52 -45.24 1.54 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.936 -1.103 . . . . 0.0 111.032 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.497 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 1.2 tp10 -54.34 -60.6 3.12 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.345 -0.847 . . . . 0.0 109.844 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.569 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -42.28 -31.71 0.42 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.5 -0.75 . . . . 0.0 109.836 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.701 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -72.09 -41.78 53.19 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.497 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 7.7 mt-10 -55.82 -24.74 38.04 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.103 -1.234 . . . . 0.0 108.29 179.105 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.754 HD23 ' CD2' ' A' ' 95' ' ' LEU . 15.4 tp -87.05 -70.95 0.58 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 121.277 0.561 . . . . 0.0 110.01 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.754 ' CD2' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -87.27 -29.82 21.36 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.653 179.821 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 62.5 46.36 93.95 Favored Glycine 0 N--CA 1.499 2.844 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.145 177.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.761 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 0.1 OUTLIER -143.69 -128.58 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.262 0 O-C-N 120.901 -1.352 . . . . 0.0 109.636 178.728 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.761 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.5 Cg_endo -68.9 -3.63 11.8 Favored 'Trans proline' 0 N--CA 1.499 1.852 0 CA-C-N 121.738 1.656 . . . . 0.0 110.034 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.723 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.7 p90 -30.17 -41.78 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.211 1.005 . . . . 0.0 111.434 178.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.823 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 4.4 t -53.49 -58.18 8.06 Favored 'General case' 0 C--N 1.291 -1.942 0 CA-C-O 122.894 1.331 . . . . 0.0 110.082 -177.189 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 1.027 HG12 ' CD2' ' A' ' 105' ' ' LEU . 46.9 t -97.9 -37.41 6.63 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.494 ' HB2' ' HB2' ' A' ' 98' ' ' PRO . 2.9 t80 -59.6 -33.67 71.77 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 119.741 -1.849 . . . . 0.0 107.674 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.587 ' HB3' ' O ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER -76.04 -42.67 47.07 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 178.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.809 HD12 ' C ' ' A' ' 104' ' ' LEU . 0.9 OUTLIER -68.01 -36.67 80.35 Favored 'General case' 0 C--O 1.209 -1.078 0 C-N-CA 117.38 -1.728 . . . . 0.0 107.563 177.933 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 1.027 ' CD2' HG12 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -46.87 -49.39 20.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.801 178.852 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.473 HD13 ' HA ' ' A' ' 106' ' ' ILE . 4.6 mm -83.87 -26.37 7.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.598 -0.689 . . . . 0.0 110.355 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.604 ' O ' HD22 ' A' ' 42' ' ' LEU . 1.2 p30 -104.34 18.37 22.28 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.176 -0.953 . . . . 0.0 110.7 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.785 HG21 ' CE2' ' A' ' 122' ' ' PHE . 8.4 p -121.56 -12.39 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 120.894 -1.129 . . . . 0.0 109.733 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -36.67 -27.31 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.499 -0.751 . . . . 0.0 112.222 -178.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.775 ' HB2' HG13 ' A' ' 39' ' ' VAL . 54.4 p -86.06 34.05 0.61 Allowed 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.619 -1.3 . . . . 0.0 109.254 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.51 ' HB ' HG22 ' A' ' 108' ' ' VAL . 9.9 t -107.12 50.05 0.78 Allowed 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.645 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 66.4 t -80.75 -33.32 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.642 -0.661 . . . . 0.0 111.496 -178.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -66.92 -78.97 0.23 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.773 ' O ' HG23 ' A' ' 124' ' ' ILE . 0.4 OUTLIER -135.21 175.8 9.25 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.364 -1.08 . . . . 0.0 109.996 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.709 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -167.39 75.16 0.14 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.905 -1.122 . . . . 0.0 111.226 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.629 ' HB2' HG22 ' A' ' 123' ' ' THR . 0.4 OUTLIER -77.76 116.72 18.5 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.189 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.49 HG22 ' H ' ' A' ' 119' ' ' GLY . 17.1 m -79.23 129.02 34.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.063 . . . . 0.0 110.478 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.568 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.4 OUTLIER -104.04 45.62 0.95 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.383 -0.823 . . . . 0.0 110.386 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.49 ' H ' HG22 ' A' ' 117' ' ' THR . . . 65.37 -58.52 0.11 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.568 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.3 OUTLIER -115.69 -12.72 11.5 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.885 -0.774 . . . . 0.0 110.995 -179.473 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 63.2 mttt -124.2 178.71 5.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.971 -1.081 . . . . 0.0 111.294 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.785 ' CE2' HG21 ' A' ' 108' ' ' VAL . 2.5 t80 -126.85 146.61 50.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.589 -0.695 . . . . 0.0 109.194 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.629 HG22 ' HB2' ' A' ' 116' ' ' TYR . 0.9 OUTLIER -134.8 123.03 22.91 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 120.678 -1.264 . . . . 0.0 110.688 -179.701 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.773 HG23 ' O ' ' A' ' 114' ' ' ARG . 3.4 mp -124.39 168.51 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.691 HG22 ' HB3' ' A' ' 114' ' ' ARG . 9.0 t -159.09 154.87 26.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.555 -1.34 . . . . 0.0 111.518 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.598 ' OG ' HG12 ' A' ' 38' ' ' VAL . 0.7 OUTLIER -94.61 -49.99 5.39 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.627 -0.671 . . . . 0.0 109.986 179.753 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' A' ' 128' ' ' LEU . 41.5 mt-10 -81.29 144.0 31.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 110.222 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.731 HD23 ' H ' ' A' ' 128' ' ' LEU . 0.7 OUTLIER . . . . . 0 C--N 1.304 -1.394 0 O-C-N 121.574 -0.704 . . . . 0.0 110.519 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 37' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.216 0.531 . . . . 0.0 110.017 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.678 ' O ' HG23 ' A' ' 38' ' ' VAL . 1.5 m-80 61.4 -76.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.212 -0.93 . . . . 0.0 110.132 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -36.45 127.31 0.81 Allowed 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 121.372 0.606 . . . . 0.0 111.083 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.743 HG11 HG22 ' A' ' 124' ' ' ILE . 15.7 t -129.95 141.38 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 109.698 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.568 ' O ' ' HB2' ' A' ' 110' ' ' SER . 4.0 p -107.95 133.13 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 120.945 -1.097 . . . . 0.0 111.205 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.697 HD11 HG13 ' A' ' 86' ' ' ILE . 4.8 tp -105.4 143.51 33.47 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.793 HG13 ' CD1' ' A' ' 77' ' ' TRP . 11.4 t -139.84 129.2 28.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 O-C-N 120.462 -1.399 . . . . 0.0 111.909 -178.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.862 HD23 ' CG ' ' A' ' 107' ' ' ASN . 11.3 mt -135.42 -172.16 3.01 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 178.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.477 ' O ' ' N ' ' A' ' 45' ' ' SER . 8.0 ptm -100.31 151.96 20.88 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.827 -1.171 . . . . 0.0 110.466 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.471 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -48.14 89.28 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.468 -0.77 . . . . 0.0 111.543 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 43' ' ' MET . 29.6 t -65.1 -88.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.175 -0.953 . . . . 0.0 109.531 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.439 ' H ' HD13 ' A' ' 48' ' ' ILE . 5.1 m-20 -151.78 -77.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.879 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.469 ' O ' HG12 ' A' ' 51' ' ' ILE . 4.1 mt-10 -96.07 34.28 1.59 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.356 -0.84 . . . . 0.0 110.979 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.815 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.39 -64.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.792 -1.193 . . . . 0.0 111.633 -178.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.48 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -44.58 -38.12 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 118.702 -1.199 . . . . 0.0 108.746 179.354 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.469 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.79 -49.03 19.28 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.53 -0.732 . . . . 0.0 110.25 178.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.815 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.04 -51.03 28.17 Favored 'Isoleucine or valine' 0 C--O 1.191 -1.995 0 O-C-N 120.703 -1.248 . . . . 0.0 109.313 179.341 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.929 HG21 HG13 ' A' ' 69' ' ' VAL . 41.9 mm -45.53 -39.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.097 -1.627 . . . . 0.0 108.155 177.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.624 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 48.1 tt0 -62.72 -63.48 1.2 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -81.62 -8.19 59.68 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.289 -0.882 . . . . 0.0 111.398 -179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.788 HG23 HG23 ' A' ' 56' ' ' VAL . 4.7 tp -107.09 -33.72 2.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 CA-C-O 121.776 0.798 . . . . 0.0 110.137 -179.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.788 HG23 HG23 ' A' ' 55' ' ' ILE . 3.0 t -117.88 -44.83 3.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 C-N-CA 120.041 -0.664 . . . . 0.0 112.627 -177.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.845 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -60.69 -36.82 79.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.364 -1.46 . . . . 0.0 109.033 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.845 ' N ' HD23 ' A' ' 57' ' ' LEU . 2.8 tmtt? -100.93 -44.67 5.67 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.821 0.819 . . . . 0.0 109.037 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -69.2 -52.24 23.75 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.593 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.66 -43.85 73.9 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.822 -1.399 . . . . 0.0 110.155 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.599 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 12.9 ttmt -63.15 9.23 0.05 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.522 -0.987 . . . . 0.0 113.196 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.62 -63.8 1.03 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.225 -1.547 . . . . 0.0 108.854 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.12 -21.43 17.34 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 177.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.599 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 0.4 OUTLIER -68.61 124.1 89.27 Favored Pre-proline 0 C--N 1.301 -1.514 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.911 -179.648 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.45 ' O ' ' OG ' ' A' ' 66' ' ' SER . 48.7 Cg_endo -65.38 -48.23 3.55 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.093 1.862 . . . . 0.0 111.953 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.488 ' C ' HD12 ' A' ' 67' ' ' ILE . 4.8 m -164.49 106.92 0.88 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 123.322 1.534 . . . . 0.0 109.539 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.691 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -100.36 163.69 2.91 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.549 0 CA-C-N 113.358 -1.747 . . . . 0.0 111.384 -176.547 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.625 HG12 ' HG2' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -119.12 160.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.179 -0.951 . . . . 0.0 110.904 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.929 HG13 HG21 ' A' ' 52' ' ' ILE . 98.4 t -133.22 107.26 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.448 -0.782 . . . . 0.0 109.59 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 2.0 mm-40 -94.41 125.08 38.83 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.344 -0.848 . . . . 0.0 110.543 -179.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -134.45 117.55 16.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.029 -1.044 . . . . 0.0 109.967 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 44' ' ' LYS . 0.5 OUTLIER -136.13 161.49 35.56 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.176 -0.953 . . . . 0.0 110.235 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -48.61 106.12 0.09 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 110.11 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.579 ' O ' ' CG ' ' A' ' 75' ' ' PHE . . . 71.44 41.73 57.69 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.579 ' CG ' ' O ' ' A' ' 74' ' ' GLY . 49.2 m-85 -160.8 102.52 1.32 Allowed 'General case' 0 C--N 1.29 -2.008 0 O-C-N 121.997 -0.708 . . . . 0.0 110.445 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.709 ' CD2' HG21 ' A' ' 48' ' ' ILE . 12.0 t90 -105.1 73.95 1.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.793 ' CD1' HG13 ' A' ' 41' ' ' VAL . 16.1 m0 -94.44 142.15 27.76 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.525 0.679 . . . . 0.0 111.047 -178.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.61 ' CD1' ' CD1' ' A' ' 76' ' ' TRP . 0.8 OUTLIER -147.25 139.49 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.137 -0.977 . . . . 0.0 109.476 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.625 ' HG2' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -115.97 129.74 56.51 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 110.291 -179.585 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.625 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -110.63 154.64 23.51 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 120.104 -0.638 . . . . 0.0 109.809 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.42 ' HB2' HD12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -97.94 43.55 1.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.985 -1.072 . . . . 0.0 110.146 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -171.69 -114.89 0.34 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -114.63 165.17 13.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.419 -1.048 . . . . 0.0 109.206 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.588 HG23 ' O ' ' A' ' 84' ' ' ILE . 4.4 tp -151.05 114.33 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 120.74 -1.225 . . . . 0.0 111.113 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -74.93 154.64 38.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.378 -0.826 . . . . 0.0 110.232 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.777 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.2 OUTLIER -161.01 130.12 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.131 -0.98 . . . . 0.0 110.695 -179.894 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.777 ' N ' HD13 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -128.87 173.61 10.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.888 . . . . 0.0 110.831 -179.964 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 1.019 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.06 -28.86 0.19 Allowed 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.041 178.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.532 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -41.51 -53.51 3.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 0.0 109.722 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.44 -57.41 7.03 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.563 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.45 -30.82 54.03 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.547 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -64.7 -56.2 18.23 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 108.359 -1.897 . . . . 0.0 108.359 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -62.47 -14.37 40.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.478 -1.013 . . . . 0.0 109.469 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.793 ' C ' HD23 ' A' ' 94' ' ' LEU . 5.1 tt -75.92 -57.66 3.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.783 . . . . 0.0 109.039 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.601 HD13 ' CB ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER -93.72 -35.51 12.76 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.124 179.477 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . -160.57 -71.49 0.02 OUTLIER Glycine 0 N--CA 1.491 2.319 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.214 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.561 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 164.95 -59.44 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.552 -0.969 . . . . 0.0 109.848 -179.769 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 41.0 Cg_endo -68.41 -17.28 44.08 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 124.068 1.562 . . . . 0.0 109.836 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.601 ' CB ' HD13 ' A' ' 95' ' ' LEU . 2.3 t80 -49.14 -50.3 38.2 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.078 -1.049 . . . . 0.0 108.416 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 1.019 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 4.5 m -30.23 -57.51 0.19 Allowed 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.703 0.763 . . . . 0.0 111.574 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 1.055 HG12 HD23 ' A' ' 105' ' ' LEU . 43.7 t -84.07 -54.47 8.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 121.513 -0.742 . . . . 0.0 112.685 -178.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.549 ' HA ' ' HB2' ' A' ' 105' ' ' LEU . 2.0 t80 -51.32 -40.05 58.24 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 119.7 -1.875 . . . . 0.0 107.045 179.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.541 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 21.6 t70 -57.14 -46.89 82.32 Favored 'General case' 0 N--CA 1.486 1.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.666 178.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.805 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.2 pp -80.2 -29.3 38.58 Favored 'General case' 0 C--O 1.201 -1.459 0 C-N-CA 117.921 -1.512 . . . . 0.0 108.245 179.109 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 1.055 HD23 HG12 ' A' ' 101' ' ' VAL . 0.3 OUTLIER -49.67 -24.74 2.41 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 120.113 -1.617 . . . . 0.0 109.523 178.49 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.2 mp -103.51 -37.42 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.359 -0.838 . . . . 0.0 110.441 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.862 ' CG ' HD23 ' A' ' 42' ' ' LEU . 3.6 p30 -99.52 -13.02 19.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.909 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.815 HG22 ' CG2' ' A' ' 111' ' ' THR . 5.2 p -66.7 -8.99 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 109.811 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.9 OUTLIER -39.99 -24.35 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.689 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.581 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 1.2 p -72.92 9.65 1.11 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.138 -0.976 . . . . 0.0 110.51 178.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.815 ' CG2' HG22 ' A' ' 108' ' ' VAL . 2.2 p -85.69 26.26 0.98 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.694 -1.254 . . . . 0.0 110.936 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 6.9 p -57.05 -18.63 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.968 -1.082 . . . . 0.0 109.375 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.499 ' O ' ' C ' ' A' ' 114' ' ' ARG . . . -98.79 50.89 1.21 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.119 -1.592 . . . . 0.0 109.119 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.499 ' C ' ' O ' ' A' ' 113' ' ' GLY . 12.1 ttm180 28.81 95.87 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.494 0.664 . . . . 0.0 111.526 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.552 ' HB2' HG22 ' A' ' 111' ' ' THR . . . -74.84 124.85 27.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.41 -0.806 . . . . 0.0 111.147 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' THR . 1.8 t80 -69.72 115.73 9.29 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.459 ' O ' HD12 ' A' ' 118' ' ' LEU . 23.3 m -79.0 164.36 24.44 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.081 -1.012 . . . . 0.0 111.553 -178.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.568 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -144.79 48.88 1.31 Allowed 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.08 -60.6 0.22 Allowed Glycine 0 N--CA 1.483 1.775 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.568 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.2 t -117.43 -17.87 9.96 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.849 -0.794 . . . . 0.0 111.529 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.567 ' HG3' HG22 ' A' ' 120' ' ' THR . 13.5 mtmt -122.94 161.4 24.25 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 120.76 -1.212 . . . . 0.0 110.534 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.717 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -134.95 162.28 32.87 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.966 -1.084 . . . . 0.0 109.218 178.653 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.535 ' O ' ' HA ' ' A' ' 115' ' ' ALA . 0.7 OUTLIER -141.8 118.61 11.12 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.915 -1.116 . . . . 0.0 110.599 -178.807 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.743 HG22 HG11 ' A' ' 38' ' ' VAL . 2.3 mp -87.02 132.84 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.552 -0.718 . . . . 0.0 109.82 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 9.5 t -156.93 159.16 37.84 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.109 -0.995 . . . . 0.0 110.629 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.432 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 1.1 t -82.4 -86.0 0.11 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.108 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' A' ' 128' ' ' LEU . 3.6 mp0 -94.92 -172.24 2.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.257 -0.902 . . . . 0.0 110.091 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.478 ' O ' ' O ' ' A' ' 127' ' ' GLU . 26.4 mt . . . . . 0 C--N 1.306 -1.323 0 O-C-N 121.466 -0.771 . . . . 0.0 110.589 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.486 ' O ' ' N ' ' A' ' 37' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.119 0.485 . . . . 0.0 110.523 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.446 ' O ' ' C ' ' A' ' 37' ' ' ALA . 90.5 m-20 53.09 -90.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 110.065 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 35' ' ' SER . . . -38.54 157.94 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.55 -0.719 . . . . 0.0 110.444 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.552 HG21 ' CG2' ' A' ' 124' ' ' ILE . 4.5 p -131.56 131.41 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -0.95 . . . . 0.0 110.266 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.601 HG12 HG21 ' A' ' 112' ' ' VAL . 8.9 p -91.29 168.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.298 -0.876 . . . . 0.0 110.495 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.558 ' HB2' HG12 ' A' ' 84' ' ' ILE . 13.7 tp -134.23 134.23 41.78 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.667 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.774 ' O ' HD22 ' A' ' 42' ' ' LEU . 14.9 t -136.95 127.52 40.32 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 O-C-N 120.462 -1.399 . . . . 0.0 110.707 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.774 HD22 ' O ' ' A' ' 41' ' ' VAL . 1.0 OUTLIER -131.39 -174.03 3.28 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.55 -0.86 . . . . 0.0 108.94 178.923 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.425 ' O ' ' N ' ' A' ' 45' ' ' SER . 3.1 ptm -82.6 157.99 23.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.89 -1.131 . . . . 0.0 110.185 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.498 ' CE ' ' OD1' ' A' ' 46' ' ' ASP . 8.3 ptmt -47.01 94.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 111.259 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.667 ' HB3' HG23 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -78.08 4.24 12.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.297 -0.877 . . . . 0.0 110.387 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.502 ' N ' ' CD1' ' A' ' 48' ' ' ILE . 35.1 m-20 64.2 -67.95 0.1 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.52 -0.738 . . . . 0.0 112.681 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.555 ' O ' HD13 ' A' ' 51' ' ' ILE . 1.5 mt-10 -80.33 16.71 1.22 Allowed 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.866 -1.146 . . . . 0.0 112.555 -177.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.938 HG21 ' CD2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -65.41 -68.24 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 120.531 -1.356 . . . . 0.0 111.438 -179.303 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.548 ' C ' ' O ' ' A' ' 48' ' ' ILE . 12.8 t70 -38.5 -31.61 0.06 Allowed 'General case' 0 N--CA 1.496 1.835 0 C-N-CA 119.048 -1.061 . . . . 0.0 108.635 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.25 -56.57 4.25 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.612 -0.68 . . . . 0.0 109.765 178.051 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.84 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.6 OUTLIER -72.02 -43.19 67.79 Favored 'Isoleucine or valine' 0 C--O 1.195 -1.786 0 O-C-N 120.903 -1.123 . . . . 0.0 109.873 179.533 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.644 HG21 ' CG1' ' A' ' 69' ' ' VAL . 50.3 mm -52.9 -47.69 52.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.804 0 O-C-N 119.668 -1.895 . . . . 0.0 107.226 177.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.812 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 12.1 tm-20 -57.61 -57.29 13.37 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.37 -0.831 . . . . 0.0 110.389 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -78.3 -20.33 51.74 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.335 -0.853 . . . . 0.0 112.667 -178.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.586 ' N ' ' O ' ' A' ' 51' ' ' ILE . 4.0 mm -106.17 -30.45 2.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 O-C-N 120.983 -1.073 . . . . 0.0 110.903 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.6 ' CG2' ' HA ' ' A' ' 52' ' ' ILE . 17.2 t -115.24 -42.15 3.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 1.053 HD22 ' O ' ' A' ' 57' ' ' LEU . 0.1 OUTLIER -68.17 -31.12 70.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.517 -1.365 . . . . 0.0 109.152 -179.89 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.554 ' N ' HD13 ' A' ' 57' ' ' LEU . 6.0 mttt -107.58 -43.89 4.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.429 -0.794 . . . . 0.0 109.483 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.69 -43.5 6.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.583 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.61 -64.7 2.84 Favored Glycine 0 N--CA 1.491 2.343 0 O-C-N 121.091 -1.241 . . . . 0.0 110.155 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.625 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.3 OUTLIER -59.73 3.51 0.05 Allowed 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.575 -0.956 . . . . 0.0 112.681 -179.506 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -55.32 -64.25 0.9 Allowed 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.657 -1.277 . . . . 0.0 109.02 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -90.72 -23.29 20.74 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.073 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.625 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 3.0 m-20 -69.0 134.8 89.65 Favored Pre-proline 0 C--N 1.3 -1.587 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.672 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -63.0 -45.32 13.04 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.111 1.874 . . . . 0.0 111.299 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.607 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.2 OUTLIER 179.12 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.307 0 CA-C-O 122.999 1.38 . . . . 0.0 109.916 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.866 HG23 ' O ' ' A' ' 79' ' ' LYS 0.297 1.2 mp -101.48 140.2 20.77 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.475 0 CA-C-N 113.911 -1.495 . . . . 0.0 111.415 -177.361 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.595 ' CB ' ' HB3' ' A' ' 79' ' ' LYS . 1.2 t -96.73 132.9 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.785 . . . . 0.0 109.814 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.644 ' CG1' HG21 ' A' ' 52' ' ' ILE . 58.3 t -114.23 92.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.184 -0.948 . . . . 0.0 110.341 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.702 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.0 mm-40 -87.39 73.04 9.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.456 -0.777 . . . . 0.0 110.135 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . 0.493 ' OD2' ' HB2' ' A' ' 49' ' ' ASP . 52.8 t0 -81.91 122.44 27.75 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.936 -1.103 . . . . 0.0 110.637 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.1 OUTLIER -132.76 135.86 45.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.733 179.564 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.08 -26.57 0.16 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.145 -0.972 . . . . 0.0 109.964 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . -80.76 -50.23 5.35 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -144.61 157.96 43.98 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.772 -0.84 . . . . 0.0 110.294 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.938 ' CD2' HG21 ' A' ' 48' ' ' ILE . 1.6 t90 -109.81 85.95 2.2 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.759 ' CD1' HG13 ' A' ' 41' ' ' VAL . 7.2 m0 -85.15 124.51 31.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.459 -0.776 . . . . 0.0 110.958 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.632 HD13 ' O ' ' A' ' 77' ' ' TRP . 3.0 mm -115.93 160.19 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.014 178.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.866 ' O ' HG23 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -140.69 143.72 35.23 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.899 -1.125 . . . . 0.0 110.359 -178.97 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.434 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.03 139.59 19.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.301 -0.875 . . . . 0.0 109.521 179.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -92.98 58.54 2.98 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.09 -1.006 . . . . 0.0 110.091 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -168.89 -164.69 25.03 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.03 129.84 40.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -1.142 . . . . 0.0 109.889 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.728 HG23 ' HB ' ' A' ' 124' ' ' ILE . 3.8 tp -125.02 159.99 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.383 -0.823 . . . . 0.0 110.177 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.496 ' N ' HG13 ' A' ' 84' ' ' ILE . 12.3 mt-10 -131.29 157.19 43.98 Favored 'General case' 0 C--N 1.307 -1.241 0 O-C-N 121.006 -1.058 . . . . 0.0 111.515 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.749 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -128.97 159.32 41.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.698 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.477 ' OD2' ' HE2' ' A' ' 121' ' ' LYS . 5.3 m-20 -156.05 154.91 31.75 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.645 -1.284 . . . . 0.0 111.594 -179.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.934 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.83 -24.28 0.19 Allowed 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.355 -0.938 . . . . 0.0 111.49 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.522 ' HA ' ' OG ' ' A' ' 100' ' ' SER . . . -41.16 -51.83 3.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.009 -1.057 . . . . 0.0 110.303 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.472 ' O ' ' HB2' ' A' ' 94' ' ' LEU . 8.8 tt0 -48.51 -37.58 17.95 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.893 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.839 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -86.39 -53.18 5.15 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.572 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -50.15 -40.08 35.89 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.507 ' HG3' ' O ' ' A' ' 89' ' ' ALA . 9.6 mt-10 -75.52 -33.38 60.72 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.667 ' C ' HD23 ' A' ' 94' ' ' LEU . 1.5 tt -51.27 -66.91 0.3 Allowed 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 177.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.839 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.3 OUTLIER -76.42 -59.2 2.87 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.302 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 112.3 14.7 10.44 Favored Glycine 0 N--CA 1.497 2.715 0 C-N-CA 119.021 -1.561 . . . . 0.0 109.936 178.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.611 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 0.4 OUTLIER -104.57 -166.96 0.11 Allowed Pre-proline 0 C--N 1.294 -1.835 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.343 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.611 ' HD2' ' CB ' ' A' ' 97' ' ' LYS . 38.4 Cg_endo -66.83 -0.96 5.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 N-CA-C 109.458 -1.016 . . . . 0.0 109.458 177.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.799 ' CE1' ' HB1' ' A' ' 91' ' ' ALA . 18.8 t80 -35.54 -65.54 0.24 Allowed 'General case' 0 C--N 1.314 -0.97 0 O-C-N 121.699 -0.626 . . . . 0.0 110.908 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.934 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.3 OUTLIER -29.81 -73.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.037 0.922 . . . . 0.0 111.353 -179.5 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.673 ' O ' ' HG ' ' A' ' 104' ' ' LEU . 29.9 t -77.22 -50.41 20.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.328 -0.857 . . . . 0.0 113.254 -178.145 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.598 ' CD1' ' HB2' ' A' ' 98' ' ' PRO . 3.7 m-85 -51.72 -43.07 62.71 Favored 'General case' 0 C--N 1.292 -1.899 0 O-C-N 119.704 -1.872 . . . . 0.0 108.15 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.569 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 13.8 t70 -60.4 -40.05 89.53 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.592 -0.692 . . . . 0.0 110.421 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.941 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.3 pp -82.36 -39.8 22.26 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 117.816 -1.554 . . . . 0.0 109.04 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.941 ' N ' HD12 ' A' ' 104' ' ' LEU . 56.3 mt -51.94 -19.71 1.94 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.824 -1.172 . . . . 0.0 110.459 178.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.3 mp -102.44 -42.75 8.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.148 -0.97 . . . . 0.0 109.864 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.683 ' CG ' HD13 ' A' ' 42' ' ' LEU . 4.7 p30 -88.03 -13.18 42.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.287 -0.883 . . . . 0.0 110.141 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.807 HG13 HG23 ' A' ' 111' ' ' THR . 2.6 t -64.48 -5.88 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.923 -1.11 . . . . 0.0 110.195 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.461 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.49 -28.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.9 -0.5 . . . . 0.0 111.978 -179.567 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.585 ' HB3' HG23 ' A' ' 41' ' ' VAL . 35.1 p -75.3 15.88 0.4 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.77 -1.206 . . . . 0.0 110.581 178.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.807 HG23 HG13 ' A' ' 108' ' ' VAL . 0.0 OUTLIER -58.06 -66.61 0.45 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 118.389 -1.325 . . . . 0.0 109.881 -179.032 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.601 HG21 HG12 ' A' ' 39' ' ' VAL . 4.9 t 63.23 -67.32 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.476 -0.765 . . . . 0.0 110.024 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -93.82 51.81 2.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.516 ' HG2' ' N ' ' A' ' 115' ' ' ALA . 0.5 OUTLIER 47.01 176.33 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 O-C-N 121.579 -0.953 . . . . 0.0 111.016 179.162 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.66 ' HB2' HG22 ' A' ' 111' ' ' THR . . . -148.9 115.57 5.94 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.893 -1.13 . . . . 0.0 111.229 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.421 ' O ' ' HB ' ' A' ' 123' ' ' THR . 0.2 OUTLIER -76.26 112.53 12.84 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.334 -0.854 . . . . 0.0 108.887 178.678 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.3 m -79.49 125.12 29.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.072 -1.017 . . . . 0.0 110.851 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.576 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.6 OUTLIER -92.3 50.34 1.62 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.412 -0.805 . . . . 0.0 110.042 179.38 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.4 -58.73 0.18 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.576 ' N ' ' O ' ' A' ' 118' ' ' LEU . 18.4 p -115.72 -8.83 12.0 Favored 'General case' 0 C--N 1.291 -1.94 0 O-C-N 122.009 -0.701 . . . . 0.0 110.613 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.477 ' HE2' ' OD2' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -122.95 -170.53 2.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.048 -1.033 . . . . 0.0 111.836 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.822 ' HD2' HD11 ' A' ' 124' ' ' ILE 0.269 1.8 t80 -139.33 147.16 41.19 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.078 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.624 ' C ' HD12 ' A' ' 124' ' ' ILE . 0.9 OUTLIER -139.77 121.66 15.54 Favored 'General case' 0 C--N 1.308 -1.238 0 O-C-N 120.506 -1.371 . . . . 0.0 110.543 -179.525 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.822 HD11 ' HD2' ' A' ' 122' ' ' PHE . 3.9 mp -118.09 142.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 109.939 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 1.8 t -144.93 136.93 25.82 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.083 -1.011 . . . . 0.0 110.421 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.482 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 0.4 OUTLIER -59.67 -84.98 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.27 -0.894 . . . . 0.0 110.492 -179.855 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.482 ' N ' ' OG ' ' A' ' 126' ' ' SER . 20.4 mt-10 -61.56 171.19 1.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.513 HD23 ' HA ' ' A' ' 128' ' ' LEU . 6.0 mt . . . . . 0 C--N 1.306 -1.307 0 O-C-N 121.461 -0.774 . . . . 0.0 111.108 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.225 0.535 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 126' ' ' SER . 35.3 m120 45.85 -100.34 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.177 -0.952 . . . . 0.0 110.054 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.46 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.29 143.81 0.12 Allowed 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.169 -0.957 . . . . 0.0 110.541 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.521 HG12 ' O ' ' A' ' 80' ' ' ALA . 3.4 p -108.36 137.26 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.182 -0.949 . . . . 0.0 110.484 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.977 HG13 ' HB2' ' A' ' 110' ' ' SER . 5.8 p -112.74 136.2 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.067 -1.021 . . . . 0.0 110.491 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.625 HD13 HG12 ' A' ' 86' ' ' ILE . 11.0 tp -105.17 141.75 36.17 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.868 HG13 ' NE1' ' A' ' 77' ' ' TRP . 2.3 t -143.19 127.24 14.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 118.248 -1.381 . . . . 0.0 112.072 -177.277 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.71 HD22 ' O ' ' A' ' 41' ' ' VAL . 2.7 mm? -129.48 -168.46 1.95 Allowed 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.009 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.502 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -103.33 167.43 9.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.071 179.254 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.409 ' HG3' ' H ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -51.03 103.29 0.05 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.277 -0.89 . . . . 0.0 110.812 -179.378 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.579 ' HB3' HD12 ' A' ' 48' ' ' ILE . 18.9 t -87.74 -116.76 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.272 -0.892 . . . . 0.0 109.985 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.53 ' N ' HD13 ' A' ' 48' ' ' ILE . 9.9 m-20 -142.11 -76.66 0.27 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.618 -1.301 . . . . 0.0 110.83 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.448 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.3 mt-10 -95.09 35.57 1.27 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.361 -0.837 . . . . 0.0 110.155 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.832 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.77 -66.45 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.251 -0.906 . . . . 0.0 111.274 -179.171 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -41.25 -40.57 1.65 Allowed 'General case' 0 C--N 1.284 -2.271 0 C-N-CA 119.106 -1.038 . . . . 0.0 108.96 179.213 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' N ' ' OD1' ' A' ' 49' ' ' ASP . . . -74.57 -50.35 18.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.592 -0.692 . . . . 0.0 110.401 178.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.832 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -72.12 -49.64 42.27 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.079 0 O-C-N 120.553 -1.342 . . . . 0.0 109.488 179.454 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.731 ' HA ' HG22 ' A' ' 55' ' ' ILE . 40.3 mm -46.59 -38.07 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.028 -1.67 . . . . 0.0 108.246 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 0.6 OUTLIER -64.3 -62.81 1.37 Allowed 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.105 -0.997 . . . . 0.0 110.082 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -79.75 -11.28 59.85 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.367 -0.833 . . . . 0.0 111.435 -179.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.841 HG23 HG23 ' A' ' 56' ' ' VAL . 4.2 tp -106.05 -33.38 2.79 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.034 0 CA-C-O 121.631 0.729 . . . . 0.0 110.546 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.841 HG23 HG23 ' A' ' 55' ' ' ILE . 3.8 t -117.65 -44.56 3.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.499 -0.75 . . . . 0.0 112.479 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.5 OUTLIER -61.77 -40.83 96.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.264 -1.523 . . . . 0.0 108.542 179.964 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.781 ' N ' HD23 ' A' ' 57' ' ' LEU . 2.4 mtpt -92.37 -43.21 9.36 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.521 0.677 . . . . 0.0 109.426 178.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -75.15 -50.78 8.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.959 -1.256 . . . . 0.0 109.959 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.562 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.28 -59.99 5.43 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.635 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.636 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -64.99 10.31 0.08 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.56 -0.965 . . . . 0.0 112.636 -179.508 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.39 -63.98 0.95 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.453 -1.404 . . . . 0.0 108.661 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -100.35 -17.83 17.06 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.636 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 1.4 m-20 -67.99 136.88 92.03 Favored Pre-proline 0 C--N 1.301 -1.533 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.684 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -62.19 -42.81 26.93 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 122.54 2.16 . . . . 0.0 112.521 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.577 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.5 OUTLIER 179.33 112.91 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 123.1 1.429 . . . . 0.0 110.125 -179.811 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.649 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.302 1.2 mp -101.65 147.79 8.13 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 CA-C-N 113.766 -1.561 . . . . 0.0 111.577 -177.143 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.616 ' O ' HG23 ' A' ' 78' ' ' ILE . 1.6 p -110.87 153.13 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.41 -0.806 . . . . 0.0 110.275 179.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.662 HG22 HG21 ' A' ' 52' ' ' ILE . 89.2 t -118.25 104.82 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.244 -0.91 . . . . 0.0 109.6 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.575 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 0.9 OUTLIER -84.05 65.2 8.59 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.44 -0.787 . . . . 0.0 110.729 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -92.24 117.24 29.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.97 -1.081 . . . . 0.0 110.249 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 5.4 tttt -146.96 143.49 28.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 110.171 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -43.04 96.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 109.991 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 151.64 -58.11 0.43 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.477 ' HB2' ' CD1' ' A' ' 77' ' ' TRP . 2.3 p90 -141.08 163.01 34.14 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.926 -0.749 . . . . 0.0 110.457 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.703 ' CE2' HG22 ' A' ' 48' ' ' ILE . 2.5 t90 -118.03 75.63 1.02 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.868 ' NE1' HG13 ' A' ' 41' ' ' VAL . 21.0 m0 -95.82 149.06 21.94 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.606 -0.684 . . . . 0.0 111.674 -178.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.616 HG23 ' O ' ' A' ' 68' ' ' VAL . 1.2 mp -146.87 130.31 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.563 -0.711 . . . . 0.0 109.151 178.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.603 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -95.89 160.77 14.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.315 -0.866 . . . . 0.0 110.515 -179.123 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.521 ' O ' HG12 ' A' ' 38' ' ' VAL . . . -150.14 141.46 23.25 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.535 -0.728 . . . . 0.0 109.905 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -107.33 50.41 0.77 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.81 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.28 -110.85 0.24 Allowed Glycine 0 C--N 1.301 -1.368 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -123.67 143.41 50.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.315 -1.109 . . . . 0.0 110.02 179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.557 HG13 ' N ' ' A' ' 85' ' ' GLU . 2.8 tp -142.82 160.66 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 109.876 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.557 ' N ' HG13 ' A' ' 84' ' ' ILE . 45.1 mt-10 -129.67 122.69 29.47 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.022 -1.049 . . . . 0.0 111.753 -179.119 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.75 ' CG1' HD11 ' A' ' 124' ' ' ILE . 0.6 OUTLIER -79.61 165.4 2.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 121.641 -0.662 . . . . 0.0 109.648 179.484 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 6.2 m-20 -155.89 139.43 15.92 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.763 -1.211 . . . . 0.0 111.549 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.874 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -152.47 -33.09 0.13 Allowed 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.753 177.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.559 ' N ' ' HB2' ' A' ' 100' ' ' SER . . . -44.09 -52.62 7.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -0.844 . . . . 0.0 110.125 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.519 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 1.3 pt-20 -57.99 -44.5 87.21 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.534 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.13 -34.65 78.54 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.532 -0.73 . . . . 0.0 109.303 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -69.24 -56.87 8.17 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.519 ' HG2' ' O ' ' A' ' 90' ' ' GLU . 7.3 pt-20 -54.65 -19.56 6.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.403 -1.057 . . . . 0.0 109.368 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.846 HD23 ' N ' ' A' ' 95' ' ' LEU . 5.4 tt -78.81 -61.8 1.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.69 -0.631 . . . . 0.0 110.527 -179.441 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.846 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -77.62 -45.1 26.11 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 118.35 -1.34 . . . . 0.0 109.086 179.289 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.739 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -145.76 -75.21 0.02 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.57 ' N ' ' HD2' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 166.46 -55.88 0.0 OUTLIER Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.883 -0.775 . . . . 0.0 109.407 179.953 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.57 ' HD2' ' N ' ' A' ' 97' ' ' LYS . 46.8 Cg_endo -73.14 -21.19 20.69 Favored 'Trans proline' 0 C--N 1.307 -1.614 0 O-C-N 124.167 1.614 . . . . 0.0 110.515 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.573 ' CE2' ' OD2' ' A' ' 103' ' ' ASP . 2.8 t80 -50.06 -50.04 49.22 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.009 -1.057 . . . . 0.0 109.626 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.874 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 16.7 p -31.53 -68.76 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-O 121.875 0.845 . . . . 0.0 111.216 -179.241 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.649 ' CA ' HD23 ' A' ' 104' ' ' LEU . 1.7 t -69.41 -56.16 12.69 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 O-C-N 121.189 -0.945 . . . . 0.0 113.238 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.551 ' HA ' HD12 ' A' ' 105' ' ' LEU . 0.1 OUTLIER -50.1 -31.92 14.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.356 -1.465 . . . . 0.0 109.345 -178.865 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.573 ' OD2' ' CE2' ' A' ' 99' ' ' PHE . 5.6 t70 -76.61 -28.83 56.26 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.697 ' HG ' ' N ' ' A' ' 105' ' ' LEU . 0.0 OUTLIER -65.81 -48.74 70.7 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.16 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.697 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 1.4 mt -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.674 -1.266 . . . . 0.0 110.042 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 1.1 mp -96.45 -22.78 5.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.555 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 2.5 p30 -108.39 -28.76 9.2 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.178 -0.951 . . . . 0.0 110.802 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.099 HG22 ' CG2' ' A' ' 111' ' ' THR . 1.6 p -70.75 0.7 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.82 -1.175 . . . . 0.0 110.719 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -36.4 -26.92 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.47 -0.769 . . . . 0.0 112.0 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.977 ' HB2' HG13 ' A' ' 39' ' ' VAL . 87.7 p -78.69 32.37 0.2 Allowed 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.758 -1.214 . . . . 0.0 110.595 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 1.099 ' CG2' HG22 ' A' ' 108' ' ' VAL . 25.4 p -94.77 44.42 1.1 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.682 -1.261 . . . . 0.0 109.323 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.48 HG23 ' N ' ' A' ' 113' ' ' GLY . 28.3 m -60.54 -37.43 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.595 -0.691 . . . . 0.0 110.804 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.48 ' N ' HG23 ' A' ' 112' ' ' VAL . . . -76.17 -75.15 0.89 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.858 ' O ' HG23 ' A' ' 124' ' ' ILE . 3.3 ttt85 -145.13 -170.75 3.5 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.312 -1.111 . . . . 0.0 110.428 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.889 ' HB1' ' CZ ' ' A' ' 122' ' ' PHE . . . -165.88 75.0 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.035 -1.041 . . . . 0.0 110.55 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.68 ' HB2' HG22 ' A' ' 123' ' ' THR . 0.1 OUTLIER -81.41 121.5 26.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.282 -0.886 . . . . 0.0 109.644 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.717 ' C ' HD12 ' A' ' 118' ' ' LEU . 9.7 m -83.89 156.39 22.42 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.228 -0.92 . . . . 0.0 110.62 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.717 HD12 ' C ' ' A' ' 117' ' ' THR . 7.3 mp -127.91 38.5 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.357 -0.839 . . . . 0.0 110.257 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 68.2 -59.5 0.41 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.824 -1.711 . . . . 0.0 108.824 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.556 ' N ' ' O ' ' A' ' 118' ' ' LEU . 58.4 p -115.14 -12.71 11.87 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 122.031 -0.687 . . . . 0.0 109.824 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.505 ' CB ' ' HB2' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -121.59 -167.12 1.47 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.43 -0.794 . . . . 0.0 110.633 -179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.889 ' CZ ' ' HB1' ' A' ' 115' ' ' ALA . 16.0 t80 -153.86 164.22 38.74 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.519 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.68 HG22 ' HB2' ' A' ' 116' ' ' TYR . 0.6 OUTLIER -150.08 153.06 35.78 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.39 -1.444 . . . . 0.0 110.275 -179.154 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.858 HG23 ' O ' ' A' ' 114' ' ' ARG . 2.2 mp -141.38 145.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.51 -0.744 . . . . 0.0 109.181 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.786 HG22 ' HB3' ' A' ' 114' ' ' ARG . 11.0 t -138.86 174.21 10.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.89 -1.131 . . . . 0.0 110.534 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.53 ' OG ' ' N ' ' A' ' 127' ' ' GLU . 69.2 p -104.66 -101.27 0.32 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.319 -0.863 . . . . 0.0 110.423 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.53 ' N ' ' OG ' ' A' ' 126' ' ' SER . 3.7 mm-40 -82.1 131.98 35.24 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.903 -1.123 . . . . 0.0 110.435 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.677 ' N ' HD12 ' A' ' 128' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.946 -0.471 . . . . 0.0 112.117 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 121.216 0.531 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.467 ' ND2' ' HG2' ' A' ' 127' ' ' GLU . 1.8 m-20 -113.59 -36.2 4.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 110.304 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.437 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -38.7 143.52 0.15 Allowed 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.518 -0.739 . . . . 0.0 110.774 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.583 HG13 ' HB2' ' A' ' 126' ' ' SER . 22.9 m -124.54 -174.71 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.226 -0.922 . . . . 0.0 110.373 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.734 HG13 ' HB2' ' A' ' 110' ' ' SER . 3.0 p -148.34 127.54 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.238 -0.914 . . . . 0.0 110.844 179.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.985 HD11 ' HB ' ' A' ' 86' ' ' ILE . 0.2 OUTLIER -88.99 127.75 35.68 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 177.817 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.865 HG22 ' CD2' ' A' ' 77' ' ' TRP . 2.7 t -121.43 117.05 51.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 C-N-CA 118.883 -1.127 . . . . 0.0 111.435 -178.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.67 ' HB2' ' CE3' ' A' ' 76' ' ' TRP . 0.6 OUTLIER -119.64 159.35 24.58 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.41 -0.916 . . . . 0.0 109.475 178.254 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.539 ' HA ' ' HA ' ' A' ' 75' ' ' PHE . 9.5 ptm -92.8 27.21 2.44 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.82 -1.175 . . . . 0.0 111.381 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.872 ' HB3' HD11 ' A' ' 48' ' ' ILE . 4.1 mmtp -86.81 -90.12 0.11 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.249 -0.907 . . . . 0.0 110.408 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.569 ' HB3' ' N ' ' A' ' 75' ' ' PHE . 1.4 p 77.37 57.96 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 CA-C-O 121.877 0.846 . . . . 0.0 110.978 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.695 ' H ' HD12 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -161.58 -91.44 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.513 ' O ' HD13 ' A' ' 51' ' ' ILE . 2.1 mt-10 -54.38 -27.41 36.24 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.281 -0.887 . . . . 0.0 111.351 179.109 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 1.188 HG21 ' CE2' ' A' ' 76' ' ' TRP . 0.4 OUTLIER -74.85 -51.38 22.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 118.397 -1.321 . . . . 0.0 112.971 -176.781 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.528 ' C ' ' O ' ' A' ' 48' ' ' ILE . 14.4 t70 -42.96 -29.97 0.38 Allowed 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.366 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -79.44 -54.89 5.48 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.847 177.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.921 ' CD1' ' HA ' ' A' ' 48' ' ' ILE . 0.4 OUTLIER -66.9 -47.82 81.44 Favored 'Isoleucine or valine' 0 C--O 1.188 -2.158 0 C-N-CA 117.844 -1.543 . . . . 0.0 108.226 178.773 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.955 HG12 HG22 ' A' ' 48' ' ' ILE . 45.1 mm -43.05 -40.99 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 120.374 -1.454 . . . . 0.0 107.86 176.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.655 ' O ' ' HB3' ' A' ' 57' ' ' LEU . 2.4 tt0 -62.87 -67.7 0.4 Allowed 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.307 -0.871 . . . . 0.0 110.141 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.422 ' O ' ' OD1' ' A' ' 54' ' ' ASP . 37.0 t0 -75.72 -9.86 58.95 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 121.093 -1.004 . . . . 0.0 111.723 -178.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.838 HG23 HG23 ' A' ' 56' ' ' VAL . 3.9 tp -107.54 -34.63 2.81 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 CA-C-O 121.588 0.709 . . . . 0.0 111.224 -178.459 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.838 HG23 HG23 ' A' ' 55' ' ' ILE . 3.5 t -117.19 -42.91 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.553 -0.717 . . . . 0.0 112.45 -177.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.655 ' HB3' ' O ' ' A' ' 53' ' ' GLU . 10.5 tt -42.2 -55.93 3.09 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.827 -1.17 . . . . 0.0 108.943 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.535 ' O ' ' CG ' ' A' ' 61' ' ' LYS . 1.0 OUTLIER -89.73 -49.19 6.79 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.317 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -48.91 -49.91 27.98 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.544 ' O ' ' HB3' ' A' ' 64' ' ' ASN . . . -83.87 22.38 8.11 Favored Glycine 0 N--CA 1.489 2.215 0 O-C-N 121.181 -1.188 . . . . 0.0 110.185 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.535 ' CG ' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -106.44 -9.4 16.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.697 -1.472 . . . . 0.0 110.769 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.98 -84.66 0.33 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 121.098 -1.001 . . . . 0.0 110.156 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -71.03 -32.25 68.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 122.211 1.005 . . . . 0.0 108.742 179.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.544 ' HB3' ' O ' ' A' ' 60' ' ' GLY . 0.5 OUTLIER -73.38 118.91 72.79 Favored Pre-proline 0 C--N 1.296 -1.733 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 179.65 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.488 ' HG2' ' HB2' ' A' ' 81' ' ' ASP . 45.6 Cg_endo -63.96 -43.42 15.82 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 124.146 1.603 . . . . 0.0 111.053 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.62 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.1 OUTLIER 178.76 112.09 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 CA-C-O 122.944 1.354 . . . . 0.0 109.751 179.477 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.638 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.292 1.2 mp -102.7 132.12 49.48 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.488 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.208 -177.359 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.572 ' HB ' ' HB3' ' A' ' 79' ' ' LYS . 0.9 OUTLIER -92.11 116.16 32.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.863 179.501 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.82 ' CG1' HG21 ' A' ' 52' ' ' ILE . 67.5 t -94.88 96.99 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.146 -0.971 . . . . 0.0 110.012 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.674 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.1 mm-40 -91.51 143.15 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.298 -0.876 . . . . 0.0 110.455 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -139.78 108.91 6.06 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 109.795 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.71 -166.81 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.266 -0.897 . . . . 0.0 110.795 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.522 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -53.29 107.54 0.25 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 0.0 110.396 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 44' ' ' LYS . . . 42.81 44.7 5.63 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.569 ' N ' ' HB3' ' A' ' 45' ' ' SER . 7.3 m-85 -144.45 86.45 1.82 Allowed 'General case' 0 C--N 1.292 -1.895 0 O-C-N 121.871 -0.781 . . . . 0.0 111.378 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 1.188 ' CE2' HG21 ' A' ' 48' ' ' ILE . 1.2 t90 -81.55 88.19 6.21 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.058 -1.026 . . . . 0.0 108.597 178.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.865 ' CD2' HG22 ' A' ' 41' ' ' VAL . 8.1 m0 -90.6 124.67 35.23 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.376 -0.828 . . . . 0.0 111.04 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.658 ' O ' HG23 ' A' ' 39' ' ' VAL . 13.8 mm -117.41 141.87 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.042 . . . . 0.0 110.16 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.572 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 1.1 ttpt -122.58 122.13 38.13 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.581 -0.7 . . . . 0.0 109.675 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -129.32 143.54 50.88 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.336 -0.853 . . . . 0.0 110.036 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.488 ' HB2' ' HG2' ' A' ' 65' ' ' PRO . 67.6 m-20 -88.18 49.81 1.87 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.057 -1.027 . . . . 0.0 109.956 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.35 -162.77 23.25 Favored Glycine 0 C--N 1.302 -1.357 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -72.6 154.36 40.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.183 -1.186 . . . . 0.0 109.791 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.612 ' CG1' HD12 ' A' ' 40' ' ' LEU . 3.0 tp -137.11 156.03 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.941 . . . . 0.0 110.235 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.516 ' N ' HG13 ' A' ' 84' ' ' ILE . 91.0 mt-10 -121.89 155.44 35.43 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.182 -0.949 . . . . 0.0 110.99 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.985 ' HB ' HD11 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -161.33 147.15 4.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.573 -0.704 . . . . 0.0 109.792 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.92 ' N ' HD13 ' A' ' 86' ' ' ILE . 3.5 m-20 -124.65 176.53 6.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.095 -1.003 . . . . 0.0 111.544 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.876 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -140.05 -14.28 1.04 Allowed 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.991 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.54 ' HA ' ' CE1' ' A' ' 99' ' ' PHE . . . -48.24 -45.86 34.82 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.664 -1.273 . . . . 0.0 110.971 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.558 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 18.2 tt0 -50.48 -36.15 32.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.551 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.943 ' O ' HD12 ' A' ' 95' ' ' LEU . . . -68.17 -31.22 70.61 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.035 -1.041 . . . . 0.0 108.876 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.741 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -68.74 -61.4 4.7 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 108.599 -1.8 . . . . 0.0 108.599 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.558 ' CG ' ' O ' ' A' ' 90' ' ' GLU . 6.0 pt-20 -45.4 -27.97 0.79 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.226 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.544 ' N ' ' HG3' ' A' ' 93' ' ' GLU . 0.7 OUTLIER -68.59 -70.9 0.24 Allowed 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.341 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.943 HD12 ' O ' ' A' ' 91' ' ' ALA . 0.0 OUTLIER -98.86 -46.46 5.63 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.021 -1.05 . . . . 0.0 109.224 178.99 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 93.44 51.84 2.11 Favored Glycine 0 N--CA 1.499 2.861 0 C-N-CA 120.185 -1.007 . . . . 0.0 111.538 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.721 ' HB2' ' CD ' ' A' ' 98' ' ' PRO . 30.8 pttt -145.46 -135.6 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.461 0 O-C-N 120.914 -1.345 . . . . 0.0 109.37 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.721 ' CD ' ' HB2' ' A' ' 97' ' ' LYS . 42.3 Cg_endo -71.7 0.17 7.42 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 CA-C-N 121.077 1.42 . . . . 0.0 108.989 178.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.796 ' CD1' ' N ' ' A' ' 100' ' ' SER . 5.8 p90 -25.62 -41.34 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 CA-C-O 121.823 0.821 . . . . 0.0 111.698 178.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.876 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.5 OUTLIER -55.96 -62.39 1.73 Allowed 'General case' 0 C--N 1.292 -1.895 0 CA-C-O 123.368 1.556 . . . . 0.0 108.62 -177.073 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 1.035 HG12 HD11 ' A' ' 105' ' ' LEU . 24.2 t -88.26 -42.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 CA-C-N 114.558 -1.201 . . . . 0.0 113.021 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.502 ' O ' HD13 ' A' ' 106' ' ' ILE . 5.0 t80 -52.02 -43.11 63.55 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 119.91 -1.744 . . . . 0.0 107.426 178.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.579 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 18.5 t70 -61.41 -47.95 83.46 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.687 -0.633 . . . . 0.0 110.065 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.736 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.5 pp -74.27 -41.16 61.68 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 116.655 -2.018 . . . . 0.0 109.738 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 1.035 HD11 HG12 ' A' ' 101' ' ' VAL . 39.2 mt -51.32 -19.23 1.21 Allowed 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.481 -1.387 . . . . 0.0 110.654 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.502 HD13 ' O ' ' A' ' 102' ' ' TYR . 0.6 OUTLIER -93.71 -49.59 12.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.123 -0.985 . . . . 0.0 110.403 -178.826 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.559 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.7 OUTLIER -100.19 -11.28 20.56 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.077 -1.014 . . . . 0.0 111.471 -179.249 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.661 HG22 ' HB ' ' A' ' 111' ' ' THR . 5.9 p -65.2 -6.54 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.302 -1.498 . . . . 0.0 109.947 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -33.78 -31.52 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.728 -0.607 . . . . 0.0 112.028 -179.505 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.734 ' HB2' HG13 ' A' ' 39' ' ' VAL . 28.8 p -84.69 27.89 0.7 Allowed 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 118.877 -1.129 . . . . 0.0 109.348 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.661 ' HB ' HG22 ' A' ' 108' ' ' VAL . 9.6 t -64.64 -35.9 82.51 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 110.644 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.445 ' N ' HG23 ' A' ' 111' ' ' THR . 61.8 t 52.61 -88.6 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.724 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -86.15 54.97 4.76 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.54 ' HG2' ' N ' ' A' ' 115' ' ' ALA . 1.8 ttt180 45.54 176.8 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.747 -0.855 . . . . 0.0 111.444 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -130.01 114.11 15.4 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.995 -1.066 . . . . 0.0 110.725 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.556 ' HB2' HG22 ' A' ' 123' ' ' THR . 25.7 m-85 -69.7 121.14 16.58 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.34 -0.85 . . . . 0.0 108.829 178.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.594 HG22 ' H ' ' A' ' 118' ' ' LEU . 6.2 m -79.3 178.55 8.0 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.192 -0.943 . . . . 0.0 110.734 -178.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.597 ' O ' ' N ' ' A' ' 120' ' ' THR . 1.3 tt -156.9 60.56 0.52 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.448 -0.783 . . . . 0.0 110.431 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 63.44 -57.44 0.05 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.057 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 118' ' ' LEU . 15.7 p -115.89 -26.97 7.15 Favored 'General case' 0 C--N 1.292 -1.925 0 O-C-N 121.64 -0.917 . . . . 0.0 111.772 -178.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.576 ' O ' ' N ' ' A' ' 118' ' ' LEU . 1.5 pttm -132.07 -169.57 2.24 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.831 -1.168 . . . . 0.0 110.991 -179.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.69 ' CZ ' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -149.21 -179.12 6.8 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.264 -0.897 . . . . 0.0 109.12 179.124 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.88 ' C ' HD12 ' A' ' 124' ' ' ILE . 1.1 t -155.62 165.67 35.86 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.755 -1.215 . . . . 0.0 110.186 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.88 HD12 ' C ' ' A' ' 123' ' ' THR . 4.0 mp -134.09 144.13 36.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.336 -0.852 . . . . 0.0 110.466 -179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.578 ' O ' HG11 ' A' ' 38' ' ' VAL . 11.9 t -123.25 -170.09 2.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.325 -0.859 . . . . 0.0 110.201 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.633 ' O ' HD23 ' A' ' 128' ' ' LEU . 2.8 t -118.72 -64.6 1.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.179 -0.951 . . . . 0.0 110.473 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' A' ' 128' ' ' LEU . 7.6 mt-10 -74.94 52.79 0.56 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.335 -0.853 . . . . 0.0 110.478 -179.581 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.633 HD23 ' O ' ' A' ' 126' ' ' SER . 0.4 OUTLIER . . . . . 0 C--N 1.305 -1.364 0 O-C-N 121.2 -0.938 . . . . 0.0 110.44 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.307 0.575 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.502 ' OD1' ' N ' ' A' ' 36' ' ' ASN . 15.1 p-10 -78.66 -44.35 23.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.147 -0.971 . . . . 0.0 110.454 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.462 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.94 106.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.229 0.538 . . . . 0.0 111.284 -179.341 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.491 ' CG1' ' O ' ' A' ' 82' ' ' GLY . 4.1 p -125.84 149.79 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.317 -0.864 . . . . 0.0 109.504 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.7 p -105.82 142.44 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.01 -1.056 . . . . 0.0 111.108 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.875 ' O ' HG23 ' A' ' 41' ' ' VAL . 8.1 tp -100.93 162.07 13.15 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 177.468 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.884 HG22 ' CD2' ' A' ' 77' ' ' TRP . 3.0 t -165.77 132.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 120.658 -1.276 . . . . 0.0 111.665 -178.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.672 ' HB3' ' CE3' ' A' ' 76' ' ' TRP . 0.3 OUTLIER -143.06 -171.69 3.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.19 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 7.2 ptt? -98.45 153.29 18.7 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.798 -1.189 . . . . 0.0 109.899 179.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.531 ' HA ' ' HB2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -53.13 95.65 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 0.0 110.982 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.494 ' HB3' HG23 ' A' ' 48' ' ' ILE . 30.5 t -72.89 -92.1 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.297 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.433 ' N ' HD13 ' A' ' 48' ' ' ILE . 36.1 t0 -157.95 -70.3 0.09 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.157 -0.964 . . . . 0.0 110.401 179.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.46 ' O ' HG12 ' A' ' 51' ' ' ILE . 2.8 mt-10 -96.45 36.13 1.4 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.283 -0.885 . . . . 0.0 110.412 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.83 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -56.02 -64.34 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.997 -1.064 . . . . 0.0 111.624 -178.772 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.494 ' O ' ' HB2' ' A' ' 53' ' ' GLU . 0.2 OUTLIER -45.44 -34.75 3.3 Favored 'General case' 0 C--N 1.285 -2.218 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.768 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.29 -49.88 12.84 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.473 -0.767 . . . . 0.0 110.341 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.83 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -71.66 -48.44 52.08 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.092 0 O-C-N 120.711 -1.243 . . . . 0.0 108.958 179.127 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.751 HG21 ' CG2' ' A' ' 69' ' ' VAL . 35.1 mm -46.97 -40.89 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.068 -1.645 . . . . 0.0 107.912 177.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.628 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 7.5 tt0 -61.69 -62.43 1.81 Allowed 'General case' 0 C--N 1.293 -1.855 0 O-C-N 121.163 -0.961 . . . . 0.0 110.575 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -80.2 -12.6 59.62 Favored 'General case' 0 N--CA 1.502 2.145 0 O-C-N 121.451 -0.781 . . . . 0.0 111.616 -178.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.948 HG23 HG23 ' A' ' 56' ' ' VAL . 3.8 tp -106.09 -33.27 2.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 CA-C-O 121.672 0.749 . . . . 0.0 110.659 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.948 HG23 HG23 ' A' ' 55' ' ' ILE . 14.4 t -116.57 -43.91 3.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 C-N-CA 119.91 -0.716 . . . . 0.0 112.439 -177.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.836 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -63.35 -35.92 81.99 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.28 -1.513 . . . . 0.0 108.937 179.978 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.836 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -94.77 -47.53 6.43 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.439 -0.788 . . . . 0.0 109.344 179.189 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.49 -45.05 8.19 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.598 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.07 -53.42 18.7 Favored Glycine 0 N--CA 1.49 2.243 0 O-C-N 121.12 -1.224 . . . . 0.0 110.05 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.625 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.9 OUTLIER -62.41 6.58 0.08 Allowed 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.459 -1.024 . . . . 0.0 112.827 -179.421 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.26 -63.84 1.01 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.518 -1.364 . . . . 0.0 108.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -97.2 -19.96 18.26 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 178.046 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.625 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 3.9 m-20 -68.43 125.92 92.17 Favored Pre-proline 0 C--N 1.301 -1.517 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.556 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.435 ' C ' ' OG ' ' A' ' 66' ' ' SER . 46.6 Cg_endo -64.45 -42.26 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 121.96 1.773 . . . . 0.0 111.136 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.577 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -177.97 110.88 0.07 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-O 123.065 1.412 . . . . 0.0 109.527 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.667 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.308 1.0 OUTLIER -103.73 145.38 12.79 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 CA-C-N 113.735 -1.575 . . . . 0.0 111.416 -176.556 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.818 HG12 ' CG ' ' A' ' 79' ' ' LYS . 1.9 p -109.41 142.28 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.055 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.751 ' CG2' HG21 ' A' ' 52' ' ' ILE . 32.4 t -108.75 117.17 53.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.239 -0.913 . . . . 0.0 110.001 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.563 ' N ' ' O ' ' A' ' 77' ' ' TRP . 1.0 OUTLIER -98.64 94.67 6.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.578 -0.701 . . . . 0.0 110.482 -179.435 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -91.37 88.91 7.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.802 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.445 ' HB2' ' HB2' ' A' ' 75' ' ' PHE . 0.3 OUTLIER -88.72 165.99 14.36 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.331 -0.856 . . . . 0.0 110.689 -179.439 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.43 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . -38.22 -58.21 1.01 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.589 -0.695 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.584 ' O ' ' CD2' ' A' ' 75' ' ' PHE . . . -132.03 52.51 0.82 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 74' ' ' GLY . 57.7 m-85 -159.49 103.48 1.58 Allowed 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.913 -0.757 . . . . 0.0 110.057 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.714 ' CD2' HG21 ' A' ' 48' ' ' ILE . 6.4 t90 -90.0 77.73 6.83 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.884 ' CD2' HG22 ' A' ' 41' ' ' VAL . 13.0 m0 -101.28 143.98 30.68 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.512 -0.743 . . . . 0.0 112.308 -177.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.69 ' HB ' HD23 ' A' ' 40' ' ' LEU . 1.6 mt -137.49 139.3 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.302 -0.874 . . . . 0.0 109.625 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.818 ' CG ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -102.19 134.85 44.79 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.467 -0.77 . . . . 0.0 110.06 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.543 ' CB ' HG13 ' A' ' 67' ' ' ILE . . . -134.43 143.8 47.77 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 110.054 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -95.15 50.29 1.26 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.068 -1.02 . . . . 0.0 110.106 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.491 ' O ' ' CG1' ' A' ' 38' ' ' VAL . . . -171.03 -169.83 34.5 Favored Glycine 0 C--N 1.3 -1.472 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -71.41 143.79 50.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -1.136 . . . . 0.0 109.682 179.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.817 HG23 ' CG1' ' A' ' 124' ' ' ILE . 4.2 tp -126.36 159.69 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.243 -0.911 . . . . 0.0 109.89 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.471 ' N ' HG13 ' A' ' 84' ' ' ILE . 37.0 mt-10 -123.13 151.77 41.77 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 121.01 -1.056 . . . . 0.0 111.813 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.642 HG22 ' CB ' ' A' ' 122' ' ' PHE . 0.5 OUTLIER -121.11 168.18 13.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 121.48 -0.762 . . . . 0.0 109.226 179.259 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' ' CG2' ' A' ' 86' ' ' ILE . 56.8 m-20 -131.54 177.28 7.62 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.08 -1.013 . . . . 0.0 109.961 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 1.103 ' HB1' ' CB ' ' A' ' 100' ' ' SER . . . -151.46 -49.96 0.12 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.014 178.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.415 ' O ' ' N ' ' A' ' 92' ' ' GLY . . . -48.53 -47.54 39.11 Favored 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.155 -0.966 . . . . 0.0 111.168 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.412 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.3 mt-10 -48.53 -40.63 27.56 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.813 ' HB3' ' O ' ' A' ' 88' ' ' ALA . . . -53.0 -45.18 67.75 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.923 0.868 . . . . 0.0 108.909 177.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.718 ' N ' ' HB2' ' A' ' 99' ' ' PHE . . . -51.46 -40.4 46.61 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -178.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.412 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.8 mt-10 -64.84 -32.29 73.92 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.476 ' C ' ' CD2' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -70.79 -64.43 0.9 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.51 -0.744 . . . . 0.0 110.048 179.168 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.618 ' H ' HD12 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -107.7 -27.36 10.35 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.191 -0.943 . . . . 0.0 110.575 -179.857 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 97' ' ' LYS . . . 65.26 62.96 4.46 Favored Glycine 0 N--CA 1.497 2.7 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.167 178.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.642 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 19.3 mttt 163.0 -68.34 0.0 OUTLIER Pre-proline 0 N--CA 1.516 2.844 0 O-C-N 121.312 -1.11 . . . . 0.0 111.009 177.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.642 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 55.9 Cg_endo -86.36 6.59 5.37 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 N-CA-C 107.391 -1.811 . . . . 0.0 107.391 176.8 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.718 ' HB2' ' N ' ' A' ' 92' ' ' GLY . 0.1 OUTLIER -52.87 -132.08 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.014 0 CA-C-N 115.004 -0.998 . . . . 0.0 112.874 -179.448 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 1.103 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 40.3 p -6.65 -55.85 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.911 HG12 ' CD1' ' A' ' 105' ' ' LEU . 1.9 t -85.75 -68.78 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -177.34 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.583 ' CB ' ' O ' ' A' ' 98' ' ' PRO . 0.3 OUTLIER -56.83 -30.86 64.17 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 116.929 -1.908 . . . . 0.0 106.21 179.631 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.591 ' HB2' ' HA ' ' A' ' 99' ' ' PHE . 38.9 t70 -66.99 -40.86 87.46 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.214 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.941 HD12 ' N ' ' A' ' 105' ' ' LEU . 3.0 pp -83.27 -41.48 18.28 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 117.98 -1.488 . . . . 0.0 108.913 179.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.941 ' N ' HD12 ' A' ' 104' ' ' LEU . 0.3 OUTLIER -54.04 -16.99 2.24 Favored 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.314 -1.492 . . . . 0.0 110.011 178.673 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.403 ' HB ' ' O ' ' A' ' 102' ' ' TYR . 0.8 OUTLIER -108.74 -27.94 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 179.642 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 103' ' ' ASP . 0.3 OUTLIER -114.12 -2.67 13.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.083 -1.01 . . . . 0.0 110.744 -179.451 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.662 ' O ' HG22 ' A' ' 111' ' ' THR . 4.1 p -81.93 -10.09 12.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.122 -0.986 . . . . 0.0 110.627 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.4 t -43.55 -20.92 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.031 -1.043 . . . . 0.0 110.345 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.591 ' CA ' ' HB ' ' A' ' 41' ' ' VAL . 92.9 p -53.05 -7.81 0.09 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.304 -0.872 . . . . 0.0 112.223 179.286 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.734 ' O ' HG12 ' A' ' 112' ' ' VAL . 0.2 OUTLIER -110.51 -84.79 0.56 Allowed 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.014 -1.474 . . . . 0.0 111.092 -178.752 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.734 HG12 ' O ' ' A' ' 111' ' ' THR . 0.4 OUTLIER 80.06 -14.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.95 -0.468 . . . . 0.0 110.317 -179.239 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -114.95 -75.45 0.63 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.944 ' HB3' HG22 ' A' ' 125' ' ' THR . 11.6 tpt180 -115.24 151.21 34.9 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.353 -1.086 . . . . 0.0 109.531 179.344 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.732 ' HB1' ' CE1' ' A' ' 122' ' ' PHE . . . -165.44 67.99 0.13 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.203 -0.936 . . . . 0.0 110.124 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.511 ' N ' ' O ' ' A' ' 123' ' ' THR . 0.6 OUTLIER -69.21 124.07 22.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.915 . . . . 0.0 109.908 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.465 ' H ' HG22 ' A' ' 117' ' ' THR . 4.3 t -94.68 131.69 40.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 110.356 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.555 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -100.19 45.9 0.97 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.452 -179.98 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.43 -59.2 0.29 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.555 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.6 OUTLIER -115.31 -10.48 12.05 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.947 -0.737 . . . . 0.0 110.3 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -120.38 -168.33 1.61 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.049 -1.032 . . . . 0.0 111.179 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.732 ' CE1' ' HB1' ' A' ' 115' ' ' ALA . 2.2 t80 -150.51 153.37 35.71 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.515 -0.741 . . . . 0.0 110.442 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.552 ' O ' HG22 ' A' ' 123' ' ' THR . 0.8 OUTLIER -142.35 115.38 8.79 Favored 'General case' 0 C--N 1.31 -1.121 0 O-C-N 120.971 -1.081 . . . . 0.0 109.851 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.817 ' CG1' HG23 ' A' ' 84' ' ' ILE . 0.1 OUTLIER -125.03 151.62 30.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.266 -0.896 . . . . 0.0 109.383 179.27 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.944 HG22 ' HB3' ' A' ' 114' ' ' ARG . 6.4 t -136.11 -168.23 2.19 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 110.265 -179.412 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.493 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 19.1 p -78.2 -106.57 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 -179.367 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 28.1 mt-10 -106.37 109.89 21.95 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.058 . . . . 0.0 110.755 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--N 1.305 -1.336 0 O-C-N 121.181 -0.95 . . . . 0.0 110.409 179.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.228 0.537 . . . . 0.0 110.163 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.498 ' OD1' ' HG2' ' A' ' 127' ' ' GLU . 69.4 m-80 -107.03 -41.17 5.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -0.909 . . . . 0.0 110.18 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -39.62 145.83 0.12 Allowed 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.464 -0.773 . . . . 0.0 110.415 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 3.6 m -122.92 171.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.972 . . . . 0.0 110.237 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.69 HG12 HG21 ' A' ' 112' ' ' VAL . 10.8 p -131.52 120.53 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -0.88 . . . . 0.0 110.234 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 1.078 HD12 ' CG1' ' A' ' 84' ' ' ILE . 5.5 tt -73.1 157.77 36.63 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.859 HG13 ' NE1' ' A' ' 77' ' ' TRP . 24.0 t -160.04 116.48 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 121.097 -1.002 . . . . 0.0 110.592 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.874 HD23 ' CG ' ' A' ' 107' ' ' ASN . 2.5 mt -138.02 -169.55 2.59 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.455 ' SD ' ' OD2' ' A' ' 103' ' ' ASP . 2.8 ptt? -106.77 151.02 25.72 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.952 -1.093 . . . . 0.0 109.547 178.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.506 ' HB2' ' HA2' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -44.19 103.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.262 -0.899 . . . . 0.0 111.033 -179.034 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.479 ' O ' ' HB2' ' A' ' 46' ' ' ASP . 1.2 m -86.84 19.4 2.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -0.922 . . . . 0.0 110.286 179.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 2.1 m-20 68.3 -57.24 0.49 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.444 -0.785 . . . . 0.0 111.412 179.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.537 ' O ' HG12 ' A' ' 51' ' ' ILE . 1.6 mm-40 -94.05 31.83 1.59 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.923 -1.11 . . . . 0.0 110.948 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.861 HG22 ' CE2' ' A' ' 76' ' ' TRP . 0.0 OUTLIER -59.97 -78.26 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.201 -0.937 . . . . 0.0 111.084 -178.844 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.546 ' C ' ' O ' ' A' ' 48' ' ' ILE . 6.8 m-20 -36.79 -32.63 0.04 OUTLIER 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 48' ' ' ILE . . . -76.77 -53.41 7.98 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.766 -0.584 . . . . 0.0 109.551 177.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.757 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.47 -50.67 33.43 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 O-C-N 120.943 -1.098 . . . . 0.0 110.089 179.466 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.7 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 32.4 mm -49.88 -40.78 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 119.829 -1.794 . . . . 0.0 108.281 178.288 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.643 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 18.6 tt0 -62.97 -57.74 9.7 Favored 'General case' 0 C--N 1.29 -1.982 0 O-C-N 120.967 -1.083 . . . . 0.0 110.576 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -81.74 -14.51 56.38 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.296 -0.878 . . . . 0.0 111.489 -178.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.913 HG23 HG23 ' A' ' 56' ' ' VAL . 3.7 tp -105.98 -32.35 2.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 CA-C-O 121.563 0.697 . . . . 0.0 110.736 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.913 HG23 HG23 ' A' ' 55' ' ' ILE . 12.0 t -116.34 -43.31 3.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 C-N-CA 119.839 -0.744 . . . . 0.0 112.557 -177.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.783 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -64.32 -41.27 96.89 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.117 -1.614 . . . . 0.0 109.036 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.783 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.0 OUTLIER -85.92 -41.83 14.59 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.61 0.719 . . . . 0.0 109.49 179.323 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.99 -53.0 3.28 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -70.03 -72.11 0.91 Allowed Glycine 0 N--CA 1.49 2.294 0 O-C-N 120.96 -1.318 . . . . 0.0 110.358 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.634 ' HA ' ' CB ' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -45.33 -8.41 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.597 -0.943 . . . . 0.0 113.518 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 60' ' ' GLY . . . -49.81 -65.34 0.58 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.39 -1.443 . . . . 0.0 108.502 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -89.22 -26.95 20.95 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.634 ' CB ' ' HA ' ' A' ' 61' ' ' LYS . 5.3 m-20 -67.6 112.64 10.9 Favored Pre-proline 0 C--N 1.297 -1.676 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.294 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.468 ' O ' ' OG ' ' A' ' 66' ' ' SER . 46.3 Cg_endo -64.59 -41.69 18.64 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 121.839 1.693 . . . . 0.0 111.355 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.638 ' C ' HD12 ' A' ' 67' ' ' ILE . 7.0 m -164.0 104.87 0.9 Allowed 'General case' 0 N--CA 1.484 1.274 0 CA-C-O 123.35 1.548 . . . . 0.0 109.777 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.655 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.312 1.1 mp -106.02 136.42 40.49 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 CA-C-N 113.314 -1.766 . . . . 0.0 110.588 -177.203 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.581 ' CG1' ' HG3' ' A' ' 79' ' ' LYS . 4.4 t -87.42 134.63 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.256 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.648 HG22 HG12 ' A' ' 78' ' ' ILE . 95.8 t -117.36 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 178.116 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.554 ' N ' ' O ' ' A' ' 77' ' ' TRP . 2.9 mm-40 -86.98 113.3 22.63 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.688 -0.633 . . . . 0.0 110.79 -178.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 71' ' ' ASP . 8.3 p-10 -123.97 112.42 17.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.312 179.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.446 ' O ' ' C ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -152.76 150.23 29.18 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.831 -1.168 . . . . 0.0 111.332 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 72' ' ' LYS . . . 35.52 -102.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.818 -0.551 . . . . 0.0 111.036 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.506 ' HA2' ' HB2' ' A' ' 44' ' ' LYS . . . -128.84 37.48 2.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.651 ' CE2' ' CZ2' ' A' ' 77' ' ' TRP . 0.1 OUTLIER -129.77 103.23 6.7 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.698 0.761 . . . . 0.0 109.863 179.54 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.861 ' CE2' HG22 ' A' ' 48' ' ' ILE . 12.5 t90 -96.86 80.95 3.06 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.859 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.6 m0 -103.6 131.3 50.87 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.317 -0.865 . . . . 0.0 112.68 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.682 HD11 ' HE1' ' A' ' 76' ' ' TRP . 2.1 mt -128.14 130.28 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.104 -0.998 . . . . 0.0 109.437 177.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.581 ' HG3' ' CG1' ' A' ' 68' ' ' VAL . 1.9 mtpt -97.86 136.44 38.17 Favored 'General case' 0 C--N 1.295 -1.798 0 C-N-CA 119.748 -0.781 . . . . 0.0 109.779 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.474 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -140.5 140.81 35.37 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 110.003 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -93.91 50.05 1.39 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.165 -0.959 . . . . 0.0 110.302 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.72 -167.89 31.72 Favored Glycine 0 C--N 1.3 -1.46 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.9 129.65 39.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.152 -1.205 . . . . 0.0 110.13 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 1.078 ' CG1' HD12 ' A' ' 40' ' ' LEU . 8.2 tp -120.67 123.97 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.165 -0.96 . . . . 0.0 110.585 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -87.22 161.67 17.89 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.283 -0.886 . . . . 0.0 111.257 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.857 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -161.46 149.01 4.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 O-C-N 121.254 -0.904 . . . . 0.0 110.704 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.857 ' N ' HD13 ' A' ' 86' ' ' ILE . 2.1 m-20 -152.14 171.1 18.43 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.088 -1.008 . . . . 0.0 111.341 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.968 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.24 -37.48 0.13 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.881 -0.728 . . . . 0.0 110.158 177.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.544 ' N ' ' HB3' ' A' ' 100' ' ' SER . . . -39.51 -46.87 1.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.622 -0.674 . . . . 0.0 110.312 -179.267 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.609 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 8.9 mt-10 -65.85 -52.06 53.57 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.813 0.816 . . . . 0.0 109.436 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 95' ' ' LEU . . . -54.25 -30.88 51.89 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.468 -0.77 . . . . 0.0 110.254 179.686 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.523 ' HA2' ' HB3' ' A' ' 99' ' ' PHE . . . -75.38 -56.43 4.68 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.609 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 3.2 pt-20 -50.14 -20.75 1.08 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.255 -1.144 . . . . 0.0 109.706 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 1.015 HD23 ' N ' ' A' ' 95' ' ' LEU . 1.4 tt -86.44 -65.91 0.96 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.861 . . . . 0.0 109.976 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 1.095 HD11 ' CB ' ' A' ' 99' ' ' PHE . 3.4 pp -70.06 -44.62 68.77 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.134 -0.979 . . . . 0.0 110.74 -179.566 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.853 ' N ' HD12 ' A' ' 95' ' ' LEU . . . -149.14 -76.06 0.02 OUTLIER Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.186 -1.483 . . . . 0.0 109.807 179.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.579 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 11.7 mttt 164.68 -63.09 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.917 0 O-C-N 121.843 -0.798 . . . . 0.0 109.989 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.3 Cg_endo -71.87 -18.51 28.07 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.764 1.402 . . . . 0.0 108.945 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 1.095 ' CB ' HD11 ' A' ' 95' ' ' LEU . 3.2 t80 -44.17 -52.09 7.62 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.787 0.803 . . . . 0.0 109.434 179.129 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.968 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 50.6 m -34.16 -58.26 0.46 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.728 0.775 . . . . 0.0 111.856 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.723 HG12 HD11 ' A' ' 105' ' ' LEU . 14.5 t -81.97 -50.43 16.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.453 ' C ' ' O ' ' A' ' 101' ' ' VAL . 4.3 t80 -49.48 -41.22 39.9 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 119.867 -1.77 . . . . 0.0 107.526 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.579 ' OD1' ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -62.73 -43.64 98.27 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 121.602 -0.686 . . . . 0.0 110.146 178.903 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.756 HD12 ' N ' ' A' ' 105' ' ' LEU . 4.1 pp -78.6 -38.9 38.87 Favored 'General case' 0 C--O 1.202 -1.4 0 C-N-CA 117.24 -1.784 . . . . 0.0 109.004 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.756 ' N ' HD12 ' A' ' 104' ' ' LEU . 63.2 mt -53.04 -16.29 1.06 Allowed 'General case' 0 C--N 1.29 -1.99 0 O-C-N 119.074 -2.266 . . . . 0.0 109.35 177.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.415 ' N ' ' C ' ' A' ' 104' ' ' LEU . 0.4 OUTLIER -118.06 -26.67 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.22 -0.925 . . . . 0.0 109.169 179.182 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.874 ' CG ' HD23 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -113.34 -3.8 13.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.375 -0.828 . . . . 0.0 110.26 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.687 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.1 p -60.46 -12.06 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.919 -1.113 . . . . 0.0 109.831 -179.172 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.55 ' O ' HG13 ' A' ' 112' ' ' VAL . 23.5 t -42.59 -22.29 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.429 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 108' ' ' VAL . 6.1 t -44.11 -16.89 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.373 -0.829 . . . . 0.0 110.953 177.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 1.0 HG22 ' CG1' ' A' ' 124' ' ' ILE . 3.0 p -109.22 44.84 1.11 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.648 -1.283 . . . . 0.0 110.677 -178.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.69 HG21 HG12 ' A' ' 39' ' ' VAL . 3.6 m -56.13 -25.63 20.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 110.055 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -96.58 -73.4 1.15 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.517 ' HB3' HG22 ' A' ' 125' ' ' THR . 0.0 OUTLIER -126.55 155.35 42.54 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.383 -1.069 . . . . 0.0 109.804 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.859 ' HB2' ' HB ' ' A' ' 111' ' ' THR . . . -150.81 74.83 1.18 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.026 -1.047 . . . . 0.0 110.981 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.583 ' HB3' HG22 ' A' ' 123' ' ' THR . 4.7 t80 -69.1 101.8 1.51 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.083 -1.011 . . . . 0.0 108.367 178.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.476 ' HA ' ' HB3' ' A' ' 122' ' ' PHE . 3.6 m -79.14 162.9 25.49 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.446 -0.784 . . . . 0.0 111.147 -178.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.836 HD13 ' HE3' ' A' ' 121' ' ' LYS . 0.9 OUTLIER -147.14 39.34 1.0 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.825 -0.547 . . . . 0.0 109.93 -179.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.421 ' H ' HG22 ' A' ' 117' ' ' THR . . . 59.5 -61.07 0.01 OUTLIER Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 179.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.671 ' N ' ' O ' ' A' ' 118' ' ' LEU . 3.3 m -93.34 -16.23 24.89 Favored 'General case' 0 C--N 1.289 -2.033 0 O-C-N 121.914 -0.757 . . . . 0.0 110.473 -179.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.836 ' HE3' HD13 ' A' ' 118' ' ' LEU . 0.0 OUTLIER -159.85 153.86 23.23 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.975 -1.078 . . . . 0.0 111.084 -179.535 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.699 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.4 OUTLIER -134.48 166.38 23.0 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.256 -0.902 . . . . 0.0 109.298 178.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.865 ' C ' HD12 ' A' ' 124' ' ' ILE . 9.2 t -144.11 157.95 44.01 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.958 -1.089 . . . . 0.0 110.461 -178.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 1.0 ' CG1' HG22 ' A' ' 111' ' ' THR . 3.4 mp -121.15 150.27 24.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.383 -0.823 . . . . 0.0 110.307 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.517 HG22 ' HB3' ' A' ' 114' ' ' ARG . 5.3 t -160.47 -163.6 1.11 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.383 -0.823 . . . . 0.0 110.402 -179.568 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER -154.42 -73.28 0.12 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.49 -0.756 . . . . 0.0 109.96 179.723 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.498 ' HG2' ' OD1' ' A' ' 36' ' ' ASN . 0.7 OUTLIER -61.35 111.24 1.68 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.367 -0.833 . . . . 0.0 110.267 179.693 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 127' ' ' GLU . 1.3 mp . . . . . 0 N--CA 1.486 1.328 0 O-C-N 121.456 -0.778 . . . . 0.0 110.623 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.454 ' OG ' ' N ' ' A' ' 36' ' ' ASN . 10.4 p . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.07 0.462 . . . . 0.0 110.157 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.454 ' N ' ' OG ' ' A' ' 35' ' ' SER . 1.6 m-20 -150.9 -82.29 0.1 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.104 -0.997 . . . . 0.0 110.361 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.446 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -34.53 125.49 0.51 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.771 -0.581 . . . . 0.0 111.159 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.426 HG23 ' HB3' ' A' ' 126' ' ' SER . 94.1 t -89.87 135.37 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 110.273 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.658 HG12 HG23 ' A' ' 112' ' ' VAL . 8.2 p -117.5 130.5 72.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.112 -0.993 . . . . 0.0 110.732 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.606 ' HA ' ' OG ' ' A' ' 110' ' ' SER . 25.3 tp -105.9 141.06 37.94 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.936 HG23 ' CB ' ' A' ' 110' ' ' SER . 56.3 t -132.11 134.12 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.316 -1.49 . . . . 0.0 110.909 -178.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.675 HD13 ' CZ3' ' A' ' 76' ' ' TRP . 26.4 mt -140.27 -166.31 2.09 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.551 ' O ' ' CB ' ' A' ' 76' ' ' TRP . 23.5 ptm -101.44 166.59 10.65 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.328 -0.857 . . . . 0.0 110.879 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.505 ' HG2' ' O ' ' A' ' 75' ' ' PHE . 0.0 OUTLIER -65.0 90.57 0.09 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -0.921 . . . . 0.0 111.694 -179.281 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 1.2 t -83.37 8.79 12.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.231 -0.918 . . . . 0.0 109.799 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.546 ' CB ' ' O ' ' A' ' 45' ' ' SER . 3.6 t0 77.16 -71.06 0.12 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.607 -0.683 . . . . 0.0 112.582 178.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.536 ' C ' HD13 ' A' ' 51' ' ' ILE . 3.8 mt-10 -81.74 24.24 0.61 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 120.948 -1.095 . . . . 0.0 111.873 -177.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.846 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -62.19 -63.09 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.874 -1.142 . . . . 0.0 112.323 -179.062 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.459 ' C ' ' O ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -45.85 -35.39 4.44 Favored 'General case' 0 C--N 1.291 -1.946 0 C-N-CA 118.497 -1.281 . . . . 0.0 108.142 178.958 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.466 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -75.25 -51.69 12.69 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.847 -0.533 . . . . 0.0 110.123 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.846 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.5 OUTLIER -72.81 -49.51 39.55 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.009 0 O-C-N 120.6 -1.312 . . . . 0.0 109.752 179.656 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.981 ' CG2' HG22 ' A' ' 69' ' ' VAL . 42.0 mm -46.73 -39.75 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 119.848 -1.783 . . . . 0.0 107.916 177.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.601 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 56.3 tt0 -62.62 -64.17 1.0 Allowed 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.485 179.242 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -80.02 -9.93 59.73 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.212 -0.93 . . . . 0.0 111.51 -178.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.906 HG23 HG23 ' A' ' 56' ' ' VAL . 3.7 tp -106.85 -34.35 2.85 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 121.611 0.719 . . . . 0.0 110.642 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.906 HG23 HG23 ' A' ' 55' ' ' ILE . 9.7 t -116.83 -43.82 3.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 C-N-CA 119.864 -0.734 . . . . 0.0 112.701 -177.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.908 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.1 OUTLIER -55.52 -32.35 62.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.182 -1.574 . . . . 0.0 108.545 -179.849 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.908 ' N ' HD23 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -93.44 -43.33 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.527 -0.733 . . . . 0.0 109.634 179.329 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -73.56 -47.27 22.05 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.582 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.02 -68.22 1.71 Allowed Glycine 0 N--CA 1.49 2.272 0 O-C-N 121.082 -1.246 . . . . 0.0 110.062 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HG3' ' HA ' ' A' ' 66' ' ' SER . 0.0 OUTLIER -60.09 5.92 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.311 -1.111 . . . . 0.0 113.291 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.63 -64.64 0.75 Allowed 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.327 -1.483 . . . . 0.0 108.525 179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.6 ptpt -95.44 -24.72 16.55 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.566 1.174 . . . . 0.0 107.92 177.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.582 ' HB2' ' O ' ' A' ' 60' ' ' GLY . 1.2 m-20 -67.31 145.66 98.62 Favored Pre-proline 0 C--N 1.295 -1.78 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.868 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.462 ' HD2' ' OD1' ' A' ' 64' ' ' ASN . 41.9 Cg_endo -61.62 -47.03 12.25 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 C-N-CA 122.533 2.156 . . . . 0.0 112.164 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.534 ' HA ' ' HG3' ' A' ' 61' ' ' LYS . 0.6 OUTLIER 179.23 112.09 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 123.156 1.455 . . . . 0.0 110.272 -179.793 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.67 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.289 1.1 mp -97.38 155.33 3.62 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.489 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.312 -177.483 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.862 HG13 ' HG3' ' A' ' 79' ' ' LYS . 0.2 OUTLIER -128.89 132.14 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.57 -0.707 . . . . 0.0 110.241 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.981 HG22 ' CG2' ' A' ' 52' ' ' ILE . 16.5 t -78.62 -178.67 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.651 ' H ' HG12 ' A' ' 69' ' ' VAL . 0.8 OUTLIER -160.53 66.39 0.33 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 120.646 -1.283 . . . . 0.0 110.585 -178.747 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -71.63 120.77 17.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 110.24 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -119.67 148.01 43.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.196 -0.94 . . . . 0.0 109.81 179.764 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -60.31 77.61 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.915 . . . . 0.0 110.549 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 133.54 -20.37 4.15 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.697 -1.239 . . . . 0.0 110.302 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.505 ' O ' ' HG2' ' A' ' 44' ' ' LYS . 6.1 m-85 -131.27 176.75 8.02 Favored 'General case' 0 C--N 1.288 -2.097 0 O-C-N 121.703 -0.88 . . . . 0.0 111.612 -179.204 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.766 ' CZ2' HD11 ' A' ' 52' ' ' ILE . 7.4 t90 -141.39 79.11 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.718 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.1 m0 -93.98 162.84 13.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.823 0.82 . . . . 0.0 111.326 -178.622 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.724 HD11 ' NE1' ' A' ' 76' ' ' TRP . 1.2 mp -159.27 138.85 3.48 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.862 ' HG3' HG13 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -106.94 142.14 37.03 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.542 -0.724 . . . . 0.0 110.12 -178.312 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.466 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -138.2 147.26 43.6 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.541 -0.724 . . . . 0.0 110.029 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.29 49.71 0.9 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.024 -1.048 . . . . 0.0 110.218 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 177.99 43.57 Favored Glycine 0 C--N 1.302 -1.356 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -70.61 123.11 21.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.328 -1.101 . . . . 0.0 109.937 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.458 ' CG1' ' N ' ' A' ' 85' ' ' GLU . 15.8 tt -120.3 171.92 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.188 -0.945 . . . . 0.0 110.766 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.522 ' CG ' ' OG1' ' A' ' 123' ' ' THR . 1.3 mt-10 -133.26 158.91 41.73 Favored 'General case' 0 C--N 1.309 -1.171 0 O-C-N 121.299 -0.876 . . . . 0.0 110.966 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 1.005 HD13 ' N ' ' A' ' 87' ' ' ASP . 0.1 OUTLIER -161.51 139.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.589 -0.694 . . . . 0.0 110.502 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 1.005 ' N ' HD13 ' A' ' 86' ' ' ILE . 2.8 m-20 -130.5 -178.51 4.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.244 -0.91 . . . . 0.0 110.679 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.874 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.11 -27.66 0.2 Allowed 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.373 -0.931 . . . . 0.0 111.246 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.644 ' HB2' ' HB ' ' A' ' 120' ' ' THR . . . -43.59 -54.13 5.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.909 -1.119 . . . . 0.0 110.217 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.566 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 4.0 mt-10 -53.58 -46.4 70.31 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.624 -0.83 . . . . 0.0 109.109 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.552 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -66.18 -38.37 87.86 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.436 -0.79 . . . . 0.0 108.99 178.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.651 ' HA2' HD11 ' A' ' 95' ' ' LEU . . . -66.98 -56.83 10.95 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.566 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.1 OUTLIER -57.54 -17.58 14.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.291 -1.123 . . . . 0.0 109.542 179.644 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.832 HD23 ' N ' ' A' ' 95' ' ' LEU . 3.4 tt -80.58 -58.51 3.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.643 -0.661 . . . . 0.0 110.001 -179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.832 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.2 OUTLIER -85.09 -33.26 22.46 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.44 179.48 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.808 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -155.92 -74.59 0.02 OUTLIER Glycine 0 N--CA 1.487 2.055 0 C-N-CA 119.103 -1.522 . . . . 0.0 109.669 179.217 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.58 ' CB ' ' HD3' ' A' ' 98' ' ' PRO . 2.3 mmtp 162.97 -57.56 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.822 -0.81 . . . . 0.0 108.923 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.58 ' HD3' ' CB ' ' A' ' 97' ' ' LYS . 47.7 Cg_endo -75.52 -18.53 17.58 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 124.21 1.637 . . . . 0.0 109.785 179.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.534 ' CZ ' ' CG ' ' A' ' 103' ' ' ASP . 1.1 t80 -51.3 -46.31 62.49 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 119.071 -1.052 . . . . 0.0 108.64 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.874 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 1.3 t -31.7 -68.89 0.08 Allowed 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.974 0.892 . . . . 0.0 110.519 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.792 ' HA ' HD23 ' A' ' 104' ' ' LEU . 1.2 t -72.68 -59.22 3.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.632 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.666 ' N ' HG12 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -44.51 -33.05 1.6 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.467 -1.396 . . . . 0.0 108.712 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.534 ' CG ' ' CZ ' ' A' ' 99' ' ' PHE . 35.2 t70 -64.81 -42.95 94.61 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.792 HD23 ' HA ' ' A' ' 101' ' ' VAL . 1.6 pp -75.27 -41.38 57.36 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.107 -1.437 . . . . 0.0 109.542 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.47 ' N ' ' HG ' ' A' ' 104' ' ' LEU . 52.3 mt -55.15 -16.17 2.87 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 119.86 -1.775 . . . . 0.0 109.904 178.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -95.23 -46.74 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.325 -0.859 . . . . 0.0 110.196 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.551 ' HB2' ' HA ' ' A' ' 42' ' ' LEU . 0.5 OUTLIER -113.27 -4.21 13.74 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.145 -0.972 . . . . 0.0 112.093 -178.711 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.948 ' O ' HG23 ' A' ' 111' ' ' THR . 5.2 p -65.91 -8.8 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.6 -1.312 . . . . 0.0 109.768 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -33.96 -27.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.084 0.468 . . . . 0.0 112.024 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.936 ' CB ' HG23 ' A' ' 41' ' ' VAL . 1.0 OUTLIER -64.52 5.88 0.25 Allowed 'General case' 0 C--N 1.293 -1.864 0 O-C-N 121.135 -0.978 . . . . 0.0 111.949 179.585 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.948 HG23 ' O ' ' A' ' 108' ' ' VAL . 32.2 p -61.93 -8.52 5.21 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.402 -1.436 . . . . 0.0 111.573 -177.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.779 HG12 ' N ' ' A' ' 113' ' ' GLY . 25.5 t 48.66 -92.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.779 ' N ' HG12 ' A' ' 112' ' ' VAL . . . -138.68 -3.8 1.73 Allowed Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.512 -1.327 . . . . 0.0 110.108 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.532 ' HG2' ' CG2' ' A' ' 125' ' ' THR . 1.4 mpt_? -123.95 146.94 48.14 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.046 -1.267 . . . . 0.0 110.661 -179.53 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 123' ' ' THR . . . -169.71 80.06 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.9 m-85 -69.05 89.36 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.258 -0.901 . . . . 0.0 109.06 179.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 122' ' ' PHE . 14.3 t -79.33 151.21 31.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.388 -0.82 . . . . 0.0 111.306 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -133.74 62.67 1.65 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.83 -60.67 0.13 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.644 ' HB ' ' HB2' ' A' ' 89' ' ' ALA . 0.8 OUTLIER -118.21 -34.94 3.95 Favored 'General case' 0 C--N 1.292 -1.921 0 O-C-N 121.964 -0.727 . . . . 0.0 112.004 -179.243 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.567 ' O ' ' N ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -105.0 149.51 25.7 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 120.994 -1.066 . . . . 0.0 111.003 -178.789 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.701 ' CE2' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -136.14 164.08 28.87 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.027 -1.046 . . . . 0.0 110.408 179.501 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.841 ' C ' HD13 ' A' ' 124' ' ' ILE . 0.8 OUTLIER -138.79 149.93 45.52 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.291 -0.881 . . . . 0.0 109.225 -179.684 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.841 HD13 ' C ' ' A' ' 123' ' ' THR . 0.0 OUTLIER -125.24 156.82 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.065 -1.022 . . . . 0.0 110.057 -179.419 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.532 ' CG2' ' HG2' ' A' ' 114' ' ' ARG . 6.3 t -160.78 163.53 32.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.131 -0.981 . . . . 0.0 110.625 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.444 ' HB3' ' O ' ' A' ' 36' ' ' ASN . 0.3 OUTLIER -83.3 -74.38 0.37 Allowed 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.281 -0.887 . . . . 0.0 110.222 179.829 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 128' ' ' LEU . 1.6 mm-40 -81.43 174.5 11.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.343 -0.848 . . . . 0.0 110.469 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' O ' ' O ' ' A' ' 127' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.305 -1.334 0 O-C-N 121.545 -0.722 . . . . 0.0 110.792 -179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.256 0.55 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.476 ' O ' ' OG ' ' A' ' 126' ' ' SER . 52.1 m-20 -157.61 -91.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.317 -0.864 . . . . 0.0 110.239 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.466 ' C ' ' O ' ' A' ' 36' ' ' ASN . . . -37.1 117.61 0.54 Allowed 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.518 -0.739 . . . . 0.0 110.717 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.467 HG13 ' O ' ' A' ' 36' ' ' ASN . 21.2 m -102.41 173.56 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.185 -0.947 . . . . 0.0 109.921 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.602 HG22 ' OG ' ' A' ' 110' ' ' SER . 7.7 p -137.77 145.67 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 111.008 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.587 ' HB2' HD11 ' A' ' 84' ' ' ILE . 10.6 tp -111.67 137.31 49.74 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.064 HG23 ' OG ' ' A' ' 110' ' ' SER . 80.5 t -133.77 124.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 120.664 -1.272 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.95 HD23 ' ND2' ' A' ' 107' ' ' ASN . 16.2 mt -132.84 178.84 6.56 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.632 178.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.446 ' O ' ' HB3' ' A' ' 76' ' ' TRP . 2.2 ppp? -88.64 172.21 9.45 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.139 -0.976 . . . . 0.0 110.142 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.33 83.25 0.25 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.502 ' HB2' HG23 ' A' ' 48' ' ' ILE . 13.7 m -54.17 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.194 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 0.7 OUTLIER -158.64 -83.25 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.407 -0.808 . . . . 0.0 109.964 179.272 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.551 ' HB3' ' HB3' ' A' ' 50' ' ' ALA . 1.5 mt-10 -96.93 38.34 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.35 -0.844 . . . . 0.0 110.064 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.833 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -45.17 -60.72 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.172 -0.955 . . . . 0.0 111.32 -179.083 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 48' ' ' ILE . 3.2 m-20 -47.31 -44.44 23.53 Favored 'General case' 0 C--N 1.282 -2.363 0 C-N-CA 118.372 -1.331 . . . . 0.0 108.622 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB3' ' HB3' ' A' ' 47' ' ' GLU . . . -71.17 -47.04 60.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.559 -0.713 . . . . 0.0 110.854 179.319 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.833 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.8 OUTLIER -74.78 -49.76 28.35 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.062 0 O-C-N 120.649 -1.282 . . . . 0.0 110.069 -179.909 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.762 HD11 ' CZ2' ' A' ' 76' ' ' TRP . 40.7 mm -45.0 -37.53 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.056 -1.652 . . . . 0.0 108.23 177.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.58 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 1.2 tt0 -68.66 -63.18 1.11 Allowed 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.296 -0.878 . . . . 0.0 110.256 179.279 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.11 -10.34 59.33 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.283 -0.885 . . . . 0.0 110.933 -179.322 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.707 HG22 ' HA ' ' A' ' 52' ' ' ILE . 4.0 tp -107.58 -35.43 2.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 CA-C-O 121.575 0.702 . . . . 0.0 110.681 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.644 HG23 HG23 ' A' ' 55' ' ' ILE . 2.1 t -117.75 -44.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.974 -0.69 . . . . 0.0 112.694 -176.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.776 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -56.55 -41.63 77.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.11 -1.619 . . . . 0.0 109.478 -179.363 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.776 ' N ' HD23 ' A' ' 57' ' ' LEU . 3.7 tttt -87.78 -43.98 11.46 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.634 -0.667 . . . . 0.0 110.583 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.17 -41.52 6.58 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.056 -178.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.558 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -68.83 -54.36 15.09 Favored Glycine 0 N--CA 1.492 2.399 0 O-C-N 120.803 -1.41 . . . . 0.0 110.328 -179.143 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.602 ' HA ' ' HB2' ' A' ' 64' ' ' ASN . 0.0 OUTLIER -60.64 8.86 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.45 -1.03 . . . . 0.0 113.248 -179.323 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.603 ' HB1' ' HE3' ' A' ' 63' ' ' LYS . . . -57.19 -67.77 0.29 Allowed 'General case' 0 C--N 1.308 -1.229 0 O-C-N 120.258 -1.526 . . . . 0.0 109.076 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.603 ' HE3' ' HB1' ' A' ' 62' ' ' ALA . 5.4 mmpt? -90.19 -19.53 24.11 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.602 ' HB2' ' HA ' ' A' ' 61' ' ' LYS . 6.3 m-20 -69.34 121.08 80.86 Favored Pre-proline 0 C--N 1.299 -1.588 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.401 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.498 ' HD2' ' HA ' ' A' ' 64' ' ' ASN . 44.9 Cg_endo -64.09 -39.24 32.48 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.884 1.723 . . . . 0.0 111.16 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.688 ' C ' HD12 ' A' ' 67' ' ' ILE . 2.8 m -177.77 111.2 0.07 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 123.012 1.386 . . . . 0.0 109.193 179.418 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.688 HD12 ' C ' ' A' ' 66' ' ' SER 0.299 1.3 mp -107.06 145.48 14.51 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.465 0 CA-C-N 113.823 -1.535 . . . . 0.0 111.673 -176.533 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.579 HG12 ' CG ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.04 142.66 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.931 179.454 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.657 ' CG2' HG21 ' A' ' 52' ' ' ILE . 66.1 t -115.32 100.38 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.125 -0.984 . . . . 0.0 110.154 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 1.1 mm-40 -83.59 124.51 30.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.489 -0.757 . . . . 0.0 109.869 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -123.25 102.47 7.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.15 -0.969 . . . . 0.0 109.587 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -103.97 144.23 31.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.164 -0.96 . . . . 0.0 109.948 -179.704 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.72 83.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.435 -0.79 . . . . 0.0 110.044 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' LYS . . . 132.73 -24.88 3.82 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -125.08 161.63 26.36 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.778 -0.836 . . . . 0.0 110.931 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.762 ' CZ2' HD11 ' A' ' 52' ' ' ILE . 11.8 t90 -135.88 79.46 1.77 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.724 ' NE1' HG13 ' A' ' 41' ' ' VAL . 11.2 m0 -98.79 137.72 36.97 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.495 -0.753 . . . . 0.0 112.433 -177.563 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.556 HD11 ' HE1' ' A' ' 76' ' ' TRP . 1.3 mt -138.29 139.15 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.304 -0.873 . . . . 0.0 109.486 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.579 ' CG ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -109.01 162.28 14.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.188 -0.945 . . . . 0.0 110.582 -179.387 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.439 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -152.31 140.64 20.51 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.97 50.03 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -0.906 . . . . 0.0 109.961 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.53 -138.85 2.6 Favored Glycine 0 C--N 1.301 -1.374 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.29 163.28 23.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.195 -1.179 . . . . 0.0 109.885 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 124' ' ' ILE . 5.7 tp -150.83 161.85 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.099 -1.001 . . . . 0.0 110.307 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.577 ' O ' HD13 ' A' ' 40' ' ' LEU . 2.4 mt-10 -140.18 164.75 29.22 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.229 -0.92 . . . . 0.0 110.384 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.773 ' HB ' ' HB3' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -125.53 165.22 23.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.298 -0.876 . . . . 0.0 109.718 179.62 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.522 ' OD1' ' CG ' ' A' ' 121' ' ' LYS . 9.5 m-20 -149.46 155.29 40.15 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.304 -0.872 . . . . 0.0 110.656 -179.648 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.923 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -146.12 -22.37 0.45 Allowed 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 118.808 -1.157 . . . . 0.0 111.301 177.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.442 ' HA ' ' HE1' ' A' ' 99' ' ' PHE . . . -41.57 -46.48 3.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.667 -1.271 . . . . 0.0 110.624 179.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.492 ' HA ' ' HG3' ' A' ' 93' ' ' GLU . 9.2 tt0 -49.36 -57.76 6.31 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.401 -0.812 . . . . 0.0 109.659 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.708 ' HB3' ' HD1' ' A' ' 99' ' ' PHE . . . -45.55 -30.31 1.43 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.687 -0.633 . . . . 0.0 109.727 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.75 ' N ' ' CD1' ' A' ' 99' ' ' PHE . . . -71.17 -37.83 63.51 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.492 ' HG3' ' HA ' ' A' ' 90' ' ' GLU . 2.3 mt-10 -64.69 -20.19 66.17 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.628 ' HB3' HD23 ' A' ' 95' ' ' LEU . 7.4 tt -84.54 -67.57 0.79 Allowed 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.631 HD11 ' HB3' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -100.77 -23.3 14.63 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.115 -0.99 . . . . 0.0 110.112 179.26 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 92' ' ' GLY . . . 60.1 45.69 95.53 Favored Glycine 0 N--CA 1.5 2.942 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.278 178.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.689 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 13.7 mttt -138.06 -127.43 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.456 0 O-C-N 121.091 -1.241 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.689 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 42.0 Cg_endo -71.61 -4.91 15.96 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 CA-C-N 120.894 1.355 . . . . 0.0 108.605 178.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.767 ' CD1' ' N ' ' A' ' 100' ' ' SER . 2.8 p90 -24.12 -42.55 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 CA-C-O 121.599 0.714 . . . . 0.0 112.032 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.923 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 0.2 OUTLIER -57.94 -54.86 42.18 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 122.901 1.334 . . . . 0.0 109.18 -177.64 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.945 HG12 HD11 ' A' ' 105' ' ' LEU . 6.5 t -94.17 -43.88 13.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 CA-C-N 115.346 -0.843 . . . . 0.0 112.672 -178.135 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.607 ' O ' HD12 ' A' ' 106' ' ' ILE . 37.4 t80 -53.1 -41.12 64.64 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 120.209 -1.557 . . . . 0.0 107.652 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.587 ' CB ' ' O ' ' A' ' 99' ' ' PHE . 11.4 t0 -68.5 -43.13 77.53 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.437 -0.79 . . . . 0.0 109.922 179.152 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.759 HD12 ' N ' ' A' ' 105' ' ' LEU . 2.9 pp -75.25 -40.38 58.99 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 116.756 -1.978 . . . . 0.0 109.046 179.252 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.945 HD11 HG12 ' A' ' 101' ' ' VAL . 23.6 mt -52.82 -20.02 2.93 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.094 -1.629 . . . . 0.0 109.867 178.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.607 HD12 ' O ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -92.09 -44.92 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.267 -0.896 . . . . 0.0 110.629 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.95 ' ND2' HD23 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -114.48 -7.59 12.83 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.021 -1.049 . . . . 0.0 112.243 -178.366 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 104' ' ' LEU . 6.0 p -60.89 -17.64 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.592 -1.317 . . . . 0.0 109.34 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -39.84 -22.78 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.116 -0.634 . . . . 0.0 111.7 -179.231 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 1.064 ' OG ' HG23 ' A' ' 41' ' ' VAL . 0.1 OUTLIER -73.28 9.52 1.26 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.698 -1.251 . . . . 0.0 110.558 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.562 ' O ' ' HB ' ' A' ' 112' ' ' VAL . 1.1 t -61.53 -10.86 8.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.762 -1.212 . . . . 0.0 110.396 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.562 ' HB ' ' O ' ' A' ' 111' ' ' THR . 2.1 t 66.89 -52.73 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.576 -0.702 . . . . 0.0 110.62 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 111' ' ' THR . . . -173.15 -26.87 0.02 OUTLIER Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.516 ' HB2' ' HB2' ' A' ' 128' ' ' LEU . 18.2 ttt180 -138.81 147.74 42.91 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.063 -1.257 . . . . 0.0 111.023 -179.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.631 ' HB1' ' CD2' ' A' ' 122' ' ' PHE . . . -155.76 93.61 1.48 Allowed 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.38 -0.825 . . . . 0.0 110.285 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.551 ' HB3' ' CG2' ' A' ' 123' ' ' THR . 12.2 t80 -69.72 118.88 13.13 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.49 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.2 m -79.55 117.78 20.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.619 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.2 OUTLIER -79.38 49.62 1.01 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.935 179.404 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 67.93 -60.14 0.36 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 108.674 -1.77 . . . . 0.0 108.674 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 118' ' ' LEU . 0.1 OUTLIER -116.01 -10.15 11.63 Favored 'General case' 0 C--N 1.293 -1.875 0 O-C-N 122.001 -0.705 . . . . 0.0 110.382 179.712 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.522 ' CG ' ' OD1' ' A' ' 87' ' ' ASP . 1.7 tttt -121.07 -161.94 0.93 Allowed 'General case' 0 N--CA 1.493 1.685 0 CA-C-O 122.052 0.929 . . . . 0.0 111.397 -179.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.773 ' HB3' ' HB ' ' A' ' 86' ' ' ILE 0.26 0.2 OUTLIER -141.22 150.93 43.31 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.97 -179.105 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.594 ' O ' HG22 ' A' ' 123' ' ' THR . 0.7 OUTLIER -137.4 110.96 8.03 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.982 -1.074 . . . . 0.0 110.001 178.705 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.886 ' HB ' HG23 ' A' ' 84' ' ' ILE . 4.8 mp -113.86 157.28 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 110.174 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 15.3 t -146.96 170.24 17.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.293 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 36' ' ' ASN . 0.2 OUTLIER -91.39 -32.62 15.58 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.307 -0.87 . . . . 0.0 110.684 -179.527 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 128' ' ' LEU . 77.8 mt-10 -84.6 28.81 0.64 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.377 -0.827 . . . . 0.0 110.668 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.516 ' HB2' ' HB2' ' A' ' 114' ' ' ARG . 2.9 pp . . . . . 0 C--N 1.306 -1.301 0 O-C-N 121.092 -1.005 . . . . 0.0 110.672 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 56.9 m . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.235 0.54 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.517 ' HA ' ' OG ' ' A' ' 126' ' ' SER . 26.9 p-10 -118.27 -43.43 2.73 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.332 -0.855 . . . . 0.0 110.38 -179.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.443 ' N ' ' OD1' ' A' ' 36' ' ' ASN . . . -39.74 134.0 1.45 Allowed 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.623 -0.673 . . . . 0.0 110.995 -179.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.18 152.45 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.308 -0.87 . . . . 0.0 109.732 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.937 HG13 ' HB2' ' A' ' 110' ' ' SER . 14.5 p -114.87 136.28 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 111.464 -179.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.646 HD22 HG12 ' A' ' 84' ' ' ILE . 3.8 tp -100.53 146.11 27.49 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 105.911 -1.885 . . . . 0.0 105.911 176.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.007 HG22 ' CD2' ' A' ' 77' ' ' TRP . 2.2 t -139.12 121.45 17.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 O-C-N 120.403 -1.436 . . . . 0.0 111.365 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.953 HD22 ' O ' ' A' ' 41' ' ' VAL . 3.3 mm? -133.42 153.02 51.96 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.294 -0.879 . . . . 0.0 109.212 178.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 12.7 ptm -75.45 153.68 37.47 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.837 -1.164 . . . . 0.0 109.721 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.553 ' CG ' ' HA2' ' A' ' 74' ' ' GLY . 10.0 ptmt -45.16 123.59 4.06 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.032 -1.042 . . . . 0.0 110.859 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.439 ' H ' HD12 ' A' ' 48' ' ' ILE . 12.8 m -100.05 -86.28 0.39 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.209 -0.932 . . . . 0.0 109.592 179.466 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -158.0 -79.11 0.07 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 110.92 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.487 ' C ' HD13 ' A' ' 51' ' ' ILE . 1.4 mt-10 -96.74 39.06 1.18 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.305 -0.872 . . . . 0.0 110.367 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.83 ' HA ' ' CG1' ' A' ' 51' ' ' ILE . 0.0 OUTLIER -53.04 -69.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.117 -0.99 . . . . 0.0 111.586 -178.916 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.503 ' C ' ' O ' ' A' ' 48' ' ' ILE . 4.8 m-20 -41.15 -36.05 0.67 Allowed 'General case' 0 C--N 1.284 -2.267 0 C-N-CA 119.059 -1.057 . . . . 0.0 109.062 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.406 ' O ' ' HB3' ' A' ' 53' ' ' GLU . . . -77.78 -50.22 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.601 -0.687 . . . . 0.0 109.9 178.601 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.83 ' CG1' ' HA ' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -73.31 -50.93 28.0 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.011 0 O-C-N 120.848 -1.157 . . . . 0.0 109.325 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.712 ' HA ' HG22 ' A' ' 55' ' ' ILE . 44.2 mm -47.19 -40.71 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 119.881 -1.762 . . . . 0.0 108.147 177.569 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.617 ' HA ' ' HB3' ' A' ' 57' ' ' LEU . 60.2 tt0 -60.85 -61.58 2.48 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 179.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -84.1 -9.15 58.83 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.201 -0.937 . . . . 0.0 111.669 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.875 HG23 HG23 ' A' ' 56' ' ' VAL . 4.5 tp -106.68 -32.81 2.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.92 0 CA-C-O 121.695 0.759 . . . . 0.0 110.098 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.875 HG23 HG23 ' A' ' 55' ' ' ILE . 7.4 t -116.46 -45.05 3.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 C-N-CA 119.942 -0.703 . . . . 0.0 112.188 -177.626 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.842 HD23 ' N ' ' A' ' 58' ' ' LYS . 0.2 OUTLIER -64.81 -37.67 88.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.339 -1.475 . . . . 0.0 108.557 179.798 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.842 ' N ' HD23 ' A' ' 57' ' ' LEU . 6.6 mtpt -96.86 -42.07 8.13 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.524 -0.735 . . . . 0.0 109.221 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -77.54 -49.84 7.0 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.585 ' O ' ' HB2' ' A' ' 64' ' ' ASN . . . -69.27 -47.86 49.48 Favored Glycine 0 N--CA 1.489 2.178 0 O-C-N 120.973 -1.31 . . . . 0.0 110.136 -179.144 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.641 ' HA ' ' HB2' ' A' ' 64' ' ' ASN . 17.6 ttpp -65.17 9.98 0.09 Allowed 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.624 -0.927 . . . . 0.0 113.124 -179.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -51.67 -62.88 1.35 Allowed 'General case' 0 C--N 1.304 -1.386 0 O-C-N 120.387 -1.446 . . . . 0.0 108.897 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mtmt -101.62 -17.58 16.28 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.641 ' HB2' ' HA ' ' A' ' 61' ' ' LYS . 0.5 OUTLIER -67.96 127.27 93.32 Favored Pre-proline 0 C--N 1.3 -1.544 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.229 -179.165 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -66.22 -49.52 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.321 2.014 . . . . 0.0 111.587 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.44 ' C ' HD12 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -166.97 106.23 0.6 Allowed 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 123.211 1.481 . . . . 0.0 109.489 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.678 ' CD1' ' N ' ' A' ' 67' ' ' ILE 0.318 0.9 OUTLIER -97.1 148.91 5.19 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 CA-C-N 113.47 -1.696 . . . . 0.0 111.836 -176.507 . . . . . . . . 4 4 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.556 HG12 ' CB ' ' A' ' 79' ' ' LYS . 0.3 OUTLIER -107.44 145.44 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.298 -0.876 . . . . 0.0 110.201 179.731 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.698 ' CG1' HG21 ' A' ' 52' ' ' ILE . 99.2 t -121.31 96.7 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.152 -0.968 . . . . 0.0 110.089 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.6 ' HB2' ' HB2' ' A' ' 77' ' ' TRP . 4.3 mm-40 -79.36 134.6 36.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.263 -0.898 . . . . 0.0 110.092 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . 0.469 ' O ' ' OD1' ' A' ' 71' ' ' ASP . 1.1 p30 -143.31 112.24 6.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.179 -0.951 . . . . 0.0 110.017 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.521 ' HG3' ' HB2' ' A' ' 75' ' ' PHE . 0.2 OUTLIER -147.55 -171.45 3.8 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.892 -1.13 . . . . 0.0 111.241 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.465 ' O ' ' C ' ' A' ' 74' ' ' GLY . . . -40.22 110.84 0.16 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.47 -0.769 . . . . 0.0 110.911 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.553 ' HA2' ' CG ' ' A' ' 44' ' ' LYS . . . 36.47 59.62 1.01 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.521 ' HB2' ' HG3' ' A' ' 72' ' ' LYS . 2.5 m-85 -160.75 75.49 0.54 Allowed 'General case' 0 C--N 1.291 -1.961 0 O-C-N 121.849 -0.795 . . . . 0.0 110.039 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.753 ' CE2' HG22 ' A' ' 48' ' ' ILE . 4.1 t90 -82.49 78.34 9.14 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.654 0.74 . . . . 0.0 109.08 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 1.007 ' CD2' HG22 ' A' ' 41' ' ' VAL . 23.2 m0 -98.94 148.27 24.14 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.594 -0.691 . . . . 0.0 111.626 -178.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.595 HG13 ' HA ' ' A' ' 69' ' ' VAL . 1.2 mp -146.65 141.58 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.339 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.556 ' CB ' HG12 ' A' ' 68' ' ' VAL . 0.0 OUTLIER -116.74 141.75 47.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.129 -0.982 . . . . 0.0 110.695 -179.022 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.507 ' HA ' HG13 ' A' ' 67' ' ' ILE . . . -127.07 163.51 23.62 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.385 -0.822 . . . . 0.0 110.008 179.537 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -106.41 47.44 0.88 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.068 -1.02 . . . . 0.0 110.179 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.8 -108.11 0.21 Allowed Glycine 0 C--N 1.299 -1.482 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -126.22 166.14 17.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.458 -1.025 . . . . 0.0 110.091 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.646 HG12 HD22 ' A' ' 40' ' ' LEU . 7.9 tp -143.91 158.61 16.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.121 -0.987 . . . . 0.0 110.524 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.468 ' O ' HG12 ' A' ' 86' ' ' ILE . 34.2 tt0 -122.76 173.8 7.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.261 -0.899 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 1.001 HG21 ' CE2' ' A' ' 122' ' ' PHE . 0.2 OUTLIER -157.62 149.78 9.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 O-C-N 121.148 -0.97 . . . . 0.0 111.007 -179.58 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -138.54 152.21 48.0 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.974 ' HB1' ' HA ' ' A' ' 100' ' ' SER . . . -151.84 -34.84 0.13 Allowed 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.335 -1.346 . . . . 0.0 111.585 178.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.533 ' CB ' ' OG1' ' A' ' 120' ' ' THR . . . -40.91 -45.35 2.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.289 -0.882 . . . . 0.0 110.181 -179.235 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.582 ' HA ' ' HG2' ' A' ' 93' ' ' GLU . 3.8 tt0 -67.86 -52.02 41.52 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 178.792 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.565 ' O ' ' CD1' ' A' ' 95' ' ' LEU . . . -54.8 -41.15 70.23 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 108.965 178.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.522 ' HA2' ' CD1' ' A' ' 95' ' ' LEU . . . -59.49 -55.31 31.35 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.582 ' HG2' ' HA ' ' A' ' 90' ' ' GLU . 0.9 OUTLIER -57.02 -16.94 8.16 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.174 -1.192 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.818 HD23 ' N ' ' A' ' 95' ' ' LEU . 7.4 tt -86.25 -64.27 1.18 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.501 -0.749 . . . . 0.0 111.014 -179.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.818 ' N ' HD23 ' A' ' 94' ' ' LEU . 0.1 OUTLIER -71.36 -37.2 71.66 Favored 'General case' 0 N--CA 1.502 2.168 0 C-N-CA 118.485 -1.286 . . . . 0.0 109.849 -179.706 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.56 ' H ' HD12 ' A' ' 95' ' ' LEU . . . -158.41 -74.43 0.02 OUTLIER Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.545 ' CB ' ' CD ' ' A' ' 98' ' ' PRO . 0.0 OUTLIER 167.53 -63.24 0.0 OUTLIER Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.956 . . . . 0.0 109.52 179.855 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 97' ' ' LYS . 47.9 Cg_endo -72.04 -16.22 28.93 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.476 1.25 . . . . 0.0 109.64 178.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.661 ' CB ' HD13 ' A' ' 95' ' ' LEU . 3.1 t80 -48.87 -48.51 42.09 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 121.074 -1.017 . . . . 0.0 109.171 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.974 ' HA ' ' HB1' ' A' ' 88' ' ' ALA . 3.8 t -32.36 -61.87 0.24 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.752 0.787 . . . . 0.0 110.764 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.86 ' HA ' HD23 ' A' ' 104' ' ' LEU . 19.4 t -82.79 -54.41 9.48 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.822 0 O-C-N 121.183 -0.948 . . . . 0.0 112.793 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.574 ' HA ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -46.56 -29.98 2.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.67 -1.269 . . . . 0.0 108.917 179.911 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.53 ' O ' ' ND2' ' A' ' 107' ' ' ASN . 29.5 t70 -82.17 -37.18 26.53 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.451 -0.78 . . . . 0.0 109.441 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.86 HD23 ' HA ' ' A' ' 101' ' ' VAL . 0.4 OUTLIER -68.75 -21.78 64.35 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.364 179.523 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.748 HD11 ' CG1' ' A' ' 101' ' ' VAL . 4.6 mt -86.75 -27.72 23.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.819 -1.175 . . . . 0.0 110.373 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.441 HG22 ' HA ' ' A' ' 103' ' ' ASP . 0.6 OUTLIER -97.24 -28.52 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 121.134 -0.979 . . . . 0.0 109.956 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.642 ' CG ' HD13 ' A' ' 42' ' ' LEU . 2.5 p30 -87.49 -30.44 20.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.34 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.109 HG22 ' HB ' ' A' ' 111' ' ' THR . 9.9 p -66.3 -0.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 120.61 -1.306 . . . . 0.0 110.9 179.407 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.456 ' C ' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -30.05 -34.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.813 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.937 ' HB2' HG13 ' A' ' 39' ' ' VAL . 82.8 p -84.4 33.66 0.51 Allowed 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.533 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 1.109 ' HB ' HG22 ' A' ' 108' ' ' VAL . 11.5 t -96.46 44.26 1.07 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.26 179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.573 ' CG1' ' N ' ' A' ' 113' ' ' GLY . 0.5 OUTLIER -61.68 -48.66 87.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.542 -0.724 . . . . 0.0 111.015 -178.687 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.573 ' N ' ' CG1' ' A' ' 112' ' ' VAL . . . -57.21 -77.04 0.18 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.531 ' O ' HG13 ' A' ' 124' ' ' ILE . 0.0 OUTLIER -157.72 -169.04 2.72 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.384 -1.068 . . . . 0.0 110.105 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.647 ' HB2' ' OG1' ' A' ' 111' ' ' THR . . . -170.7 84.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.583 ' HB3' HG22 ' A' ' 123' ' ' THR . 4.7 t80 -69.84 105.71 2.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.003 -1.061 . . . . 0.0 108.351 178.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 119' ' ' GLY . 7.6 m -79.03 145.95 33.58 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.299 -0.876 . . . . 0.0 110.915 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.612 ' O ' ' N ' ' A' ' 120' ' ' THR . 0.1 OUTLIER -123.69 50.3 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.587 -0.695 . . . . 0.0 110.282 179.914 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.422 ' H ' HG22 ' A' ' 117' ' ' THR . . . 62.15 -57.26 0.03 OUTLIER Glycine 0 N--CA 1.491 2.326 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 178.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.612 ' N ' ' O ' ' A' ' 118' ' ' LEU . 1.8 t -111.7 -15.18 13.49 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.753 -0.851 . . . . 0.0 111.406 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.538 ' CG ' ' HB3' ' A' ' 118' ' ' LEU . 0.0 OUTLIER -143.57 150.6 39.08 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.758 -1.214 . . . . 0.0 110.77 -179.614 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 1.001 ' CE2' HG21 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -124.68 164.17 20.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.877 -1.139 . . . . 0.0 110.769 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.583 HG22 ' HB3' ' A' ' 116' ' ' TYR . 2.8 t -144.27 131.85 21.09 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.514 -0.741 . . . . 0.0 109.831 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.697 HD12 ' N ' ' A' ' 124' ' ' ILE . 2.0 mp -101.91 162.66 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 110.674 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 114' ' ' ARG . 3.3 t -152.34 -175.3 5.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -0.872 . . . . 0.0 109.806 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 128' ' ' LEU . 19.7 t -108.31 -50.62 3.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.086 . . . . 0.0 110.705 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.429 ' O ' ' C ' ' A' ' 128' ' ' LEU . 1.6 mt-10 -53.54 82.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.586 -0.696 . . . . 0.0 110.686 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.543 ' N ' ' O ' ' A' ' 126' ' ' SER . 1.1 mt . . . . . 0 C--N 1.304 -1.379 0 O-C-N 121.218 -0.927 . . . . 0.0 110.288 -179.976 . . . . . . . . 1 1 . 1 stop_ save_